ID	2.4.1.101
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Gallus gallus   <12>
PR	#2# Mesocricetus auratus   <13>
PR	#3# Drosophila melanogaster   <44,47>
PR	#4# Mus musculus   <47>
PR	#5# Homo sapiens   <11,16,19,21,35,36,39,40,42>
PR	#6# Rattus norvegicus   <2,6,8,14,15,17,26,31,33>
PR	#7# Sus scrofa   <4,7,12,32>
PR	#8# Bos taurus   <5,9,12,29,30>
PR	#9# Oryctolagus cuniculus   <3,10,12,25,43>
PR	#10# Nicotiana tabacum   <20,38>
PR	#11# Arabidopsis thaliana   <20,25,37,41,42>
PR	#12# Xenopus laevis   <23>
PR	#13# Caenorhabditis elegans   <24,47>
PR	#14# Mesocricetus auratus   <12,22>
PR	#15# Acer pseudoplatanus   <1>
PR	#16# Spodoptera frugiperda   <23>
PR	#17# no activity in Saccharomyces cerevisiae   <17>
PR	#18# Phaeodactylum tricornutum   <45>
PR	#19# Trypanosoma brucei brucei   <49>
PR	#20# Cricetulus griseus P70680 SwissProt <22>
PR	#21# Nicotiana benthamiana   <28,50>
PR	#22# Oryctolagus cuniculus P27115  <18,27,34>
PR	#23# Solanum tuberosum Q8VX56  <20>
PR	#24# Nicotiana tabacum Q9ST97 UniProt <46>
PR	#25# Homo sapiens P26572 UniProt <48>

RECOMMENDED_NAME
RN	alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase


SYSTEMATIC_NAME
SN	UDP-N-acetyl-alpha-D-glucosamine:alpha-D-mannosyl-(1->3)-beta-D
	mannosyl-glycoprotein 2-beta-N-acetyl-D-glucosaminyltransferase
	(configuration-inverting)


SYNONYMS
SY	 N-glycosyl-oligosaccharide-glycoprotein
	N-acetylglucosaminyltransferase I
SY	 uridine diphosphoacetylglucosamine-alpha-1,3-mannosylglycoprotein
	beta-1,2-N-acetylglucosaminyltransferase
SY	 acetylglucosaminyltransferase, uridine
	diphosphoacetylglucosamine-alpha-1,3-mannosylglycoprotein beta-1,2-N-
SY	 UDP-N-acetylglucosaminyl:alpha-1,3-D-mannoside-beta-1
	2-N-acetylglucosaminyltransferase I
SY	 UDP-N-acetylglucosaminyl:alpha-3-D-mannoside
	beta-1,2-N-acetylglucosaminyltransferase I
SY	 alpha-1,3-mannosyl-glycoprotein
	beta-1,2-N-acetylglucosaminyltransferase
SY	 UDP-N-acetyl-D-glucosamine:glycoprotein (N-acetyl-D-glucosamine to
	alpha-D-mannosyl-1,3-(R1)-beta-D-mannosyl-R2)
	beta-1,2-N-acetyl-D-glucosaminyltransferase
SY	#11# AtGnTI (#11# Arabidopsis enzyme <42>) <42>
SY	#12# UDP-N-GlcNAc:alpha3-D-mannoside
	beta-1,2-N-acetylglucosaminyltransferase I <23>
SY	#13# GLY-13 (#13# gene name <47>) <24,47>
SY	#13# gly-12 (#13# gene name <47>) <47>
SY	#13# gly-14 (#13# gene name <47>) <47>
SY	#19# UDP-GlcNAc:alpha3-D-mannoside
	beta1-2-N-acetylglucosaminyltransferase I <49>
SY	#19# TbGnTI <49>
SY	#2,6,14,20# GlcNAc-T I <2,13,22>
SY	#21# UDP-GlcNAc:alpha3-D-mannoside
	beta1,2-N-acetylglucosaminyltransferase <28>
SY	#25# Golgi N-glycan branching N-acetylglucosaminyltransferase I <48>
SY	#25# GlcNAcT-I <48>
SY	#3# UDP-GlcNac:alpha3-D-mannoside
	beta1,2-Nacetylglucosaminyltransferase I <44>
SY	#3,4,13# UDP-GlcNAc:alpha3-D-mannoside
	beta1,2-N-acetylglucosaminyltransferase I <47>
SY	#3,4,5,13,25# MGAT1 (#3# gene name <44>) <39,44,47,48>
SY	#3,4,5,9,11,13,19,21# GnTI <28,41,42,43,44,47,49,50>
SY	#5# NT <11>
SY	#5# GlcNAc transferase I <35>
SY	#5# beta-1-2 GlcNAc transferase <36>
SY	#5# GnT1 <36>
SY	#5# HuGnTI (#5# human enzyme <42>) <42>
SY	#5,11# ChGnTI (#5,11# chimeric Arabidopsis-human enzyme <42>) <42>
SY	#5,6,9,10,11,12# GnT-I <14,16,17,18,19,20,21,23,27,33,40>
SY	#5,8,9,10,11,18,21,24# N-acetylglucosaminyltransferase I
	<25,29,30,38,39,40,41,42,43,45,46,50>
SY	#6# N-acetylglucosaminyltransferases I <31>
SY	#6# UDP-N-acetylglucosamine:alpha-3-D-mannoside
	beta-1,2-N-acetylglucosaminyltransferase I <33>
SY	#6,8,13,18,24# GnT I <24,26,29,30,45,46>
SY	#7# pigGnT-I <32>
SY	#8# alpha3-D-mannoside-beta-1,2-N-acetylglucosaminyltransferase I <29>

REACTION
RE	UDP-N-acetyl-alpha-D-glucosamine + Man5GlcNAc2-[protein] = UDP +
	Man5GlcNAc3-[protein] (#9# mechanism <10>; #9,20# active site <18,22>;
	#9# ordered sequential bi bi mechanism <18>; #20# R303 is important for
	enzyme activity, conserved throughout all species <22>; #9# SGC domain
	of SGC superfamily <18>; #9# DxD motif <18>; #20# D212 is the central
	residue of the DxD motif, conserved throughout all species <22>; #9#
	modeling study provides detailed insight into the mechanism of the
	GlcNAc transfer <34>)

REACTION_TYPE
RT	hexosyl group transfer

SOURCE_TISSUE
ST	#1,7# tracheal mucosa <4,7,12>
ST	#1,8# oviduct <12,30>
ST	#11# root <20>
ST	#11# stem <20>
ST	#11# flower <20>
ST	#11,21# leaf <20,42,50>
ST	#12# ovary (#12# isozymes A and B <23>) <23>
ST	#12# kidney (#12# isozyme B, low content of isozyme A <23>) <23>
ST	#12# heart (#12# isozyme B, low content of isozyme A <23>) <23>
ST	#12# muscle (#12# isozymes A and B <23>) <23>
ST	#15# cell suspension culture <1>
ST	#16# SF-21 cell <23>
ST	#2,20# CHO cell (#20# wild-type, Lec1 cells are deficient in enzyme
	activity, mutant Lec1A cells show weak enzyme activity, 2% compared to
	wild-type, and produce complex N-glycans <22>; #2# wild-type and mutant
	F6 and F8 <13>) <13,22>
ST	#5# JURKAT cell <39>
ST	#5# PBMC cell line <39>
ST	#6# testis (#6# two forms of beta 2-N-acetylglucosaminyltransferase I
	in rat testicular and cauda epididymal fluids <26>) <26>
ST	#6# hepatoma cell (#6# diethylnitrosamine- or
	dimethylaminoazobenzene-induced hepatoma, Morris 5123D hepatoma or
	AH-109A, solid or ascitic <6>) <6>
ST	#6# cauda epididymis (#6# two forms of beta
	2-N-acetylglucosaminyltransferase I in rat testicular and epididymal
	fluids <26>) <26>
ST	#6,7,9,12# liver (#12# isozymes A and B <23>) <2,3,6,7,8,10,12,14,15,23>
ST	#8# ovarian follicle (#8# no significant difference between the GnT I
	activities from dominant follicles collected before and after surge of
	luteinizing hormone <29>) <29>
ST	#8# epithelial cell (#8# of oviduct <30>) <30>
ST	#8# colostrum <5,9,12>
ST	#8# oviduct epithelium (#8# BOEC cell <30>) <30>

LOCALIZATION
LO	#11# endoplasmic reticulum membrane <41>
LO	#11,21# Golgi membrane (#21# the enzyme is a Golgi-resident type-II
	membrane protein. The transmembrane domain of enzyme GnTI is the major
	determinant for its cis/medial-Golgi localization, while the stem
	region of GnTI contributes predominately to homomeric and heteromeric
	protein complex formation <50>) <41,42,50>
LO	#2,7# microsome <4,7,13>
LO	#5,6,8,9,15,18# membrane (#8# not <5,9>; #5# membrane-bound recombinant
	chimeras <19>; #6# transferase A <6>) <1,5,6,8,9,10,11,12,19,45>
LO	#5,6,9,10,11,12,15,18,19,24,25# Golgi apparatus (#6# in recombinant
	Saccharomyces cerevisisae <17>; #12# medial enzyme <23>; #5# medial
	Golgi enzyme, exists as high molecular weight complex, which do not
	require the transmembrane domain nor the cytoplasmic tail of the enzyme
	for complex formation <19>; #5# resident type II transmembrane protein
	<11,16>; #11# Golgi-localized N-acetylglucosaminyltransferase I is a
	determinant of osmotic stress tolerance in Arabidopsis thaliana <37>;
	#5# luminal face <35>) <1,8,11,16,17,19,23,35,37,38,43,45,46,48,49>
LO	#6# endoplasmic reticulum (#6# in recombinant Saccharomyces cerevisisae
	<17>) <17>
LO	#6# vacuole (#6# in recombinant Saccharomyces cerevisisae <17>) <17>
LO	#6,11# more (#6# mammalian Golgi retention signal does not function in
	Saccharomyces cerevisiae cells <17>; #11# mesophyll protoplasts are
	created to analyze differences in localization <42>) <17,42>
LO	#6,7,8# cytosol (#6# transferase B, hepatoma <6>) <4,5,6,9>

NATURAL_SUBSTRATE_PRODUCT
NSP	#10# UDP-N-acetylglucosamine + 3-(alpha-D-mannosyl)-beta-D-mannosyl-R =
	UDP +
	3-(2-(N-acetyl-beta-D-glucosaminyl)-alpha-D-mannosyl)-beta-D-mannosyl-R
	{} <38>
NSP	#2,6,8,9,11,13,21# more = ? (#2# enzyme initiates the biosynthesis of
	heparan sulfate <13>; #13# GLY-13 plays an important role in the
	synthesis of N-glycans. Synthesis of paucimannose N-glycans by
	Caenorhabditis elegans requires prior actions of
	UDP-N-acetyl-D-glucosamine:alpha-3-D-mannoside
	beta1,2-N-acetylglucosaminyltransferase I, alpha3,6-mannosidase II and
	a specific membrane-bound beta-N-acetylglucosaminidase <24>; #6,8# the
	enzyme catalyzes the first step in the conversion of oligomannose to
	complex or hybrid N-glycans of glycoproteins <26,29>; #9,11# the enzyme
	is essential for processing of high-mannose to hybrid and complex
	N-glycans <25>; #21# transformant plants that exhibit specific
	reduction of GnTI activity below detection limit, do not exhibit
	significantly altered complex N-glycan structures. Even the
	undetectable residual GnTI activity is sufficient for the synthesis of
	complex N-glycans comparable to wild-type plants <28>) {}
	<13,24,25,26,28,29>
NSP	#2,6,8,9,11,13,21# more = ? (#2# enzyme initiates the biosynthesis of
	heparan sulfate <13>; #13# GLY-13 plays an important role in the
	synthesis of N-glycans. Synthesis of paucimannose N-glycans by
	Caenorhabditis elegans requires prior actions of
	UDP-N-acetyl-D-glucosamine:alpha-3-D-mannoside
	beta1,2-N-acetylglucosaminyltransferase I, alpha3,6-mannosidase II and
	a specific membrane-bound beta-N-acetylglucosaminidase <24>; #6,8# the
	enzyme catalyzes the first step in the conversion of oligomannose to
	complex or hybrid N-glycans of glycoproteins <26,29>; #9,11# the enzyme
	is essential for processing of high-mannose to hybrid and complex
	N-glycans <25>; #21# transformant plants that exhibit specific
	reduction of GnTI activity below detection limit, do not exhibit
	significantly altered complex N-glycan structures. Even the
	undetectable residual GnTI activity is sufficient for the synthesis of
	complex N-glycans comparable to wild-type plants <28>) {}
	<13,24,25,26,28,29>
NSP	#5,6,8,9,12# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(alpha-D-mannosyl-1,3)-alpha-D-mannosyl-1
	6-(alpha-D-mannosyl-1,3)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-1
	4-N-acetyl-D-glucosaminyl-Asn-peptide = UDP +
	alpha-D-mannosyl-1,6-(alpha-D-mannosyl-1,3)-alpha-D-mannosyl-1
	6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-Asn-peptide (#8# stimulates
	galactosyltransferase of bovine milk <9>; #5,6,9,12# key enzyme of
	biosynthesis of complex and hybrid N-glycans <2,10,21,23>)
	<2,9,10,21,23>
NSP	#7,9,19,25# UDP-N-acetyl-D-glucosamine +
	3-(alpha-D-mannosyl)-beta-D-mannosyl-R = UDP +
	3-(2-[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	(#9# GlcNAc transfer catalyzed by GnT-I is the first step in the
	conversion of high mannose oligosaccharides to complex and hybrid
	N-glycan structures <34>) <32,34,48,49>
NSP	#8# UDP-N-acetyl-D-glucosamine + ovalbumin glycopeptide V = UDP +
	ovalbumin glycopeptide IIIA (#8# physiological substrate <5>) <5>

SUBSTRATE_PRODUCT
SP	#1,2,5,6,7,8,9,12,14,15# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(alpha-D-mannosyl-1,3)-alpha-D-mannosyl-1
	6-(alpha-D-mannosyl-1,3)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R
	= UDP +
	alpha-D-mannosyl-1,6-(alpha-D-mannosyl-1,3)-alpha-D-mannosyl-1
	6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-R (#6,7,9,14# substrate specificity
	<2,3,4,10,12>; #6# pyridylaminated oligosaccharide <14>; #7,8,9# R: H
	<3,5,7>; #6,9# essential for activity: unsubstituted equatorial
	hydroxyl on C-4 of beta-linked mannosyl-residue <2,10>; #6,15# R:
	pyridinylamine <1,14>; #8# R: 4-N-acetyl-D-glucosaminyl-Asn-peptide
	<5>; #8# can act on alpha-mannosyl-1,6-beta-mannosyl-terminus if
	alpha-mannosyl-1,3-beta-mannosyl-terminus is not available, appreciable
	higher Km-value <5>; #8# does not act on
	alpha-mannosyl-1,2-alpha-mannosyl-, alpha-mannosyl-1,3-alpha-mannosyl-,
	alpha-mannosyl-1,6-alpha-mannosyl-termini <5>; #8# R:
	(fucose-1,6)-1,4-N-acetyl-D-glucosaminyl-Asn <5>; #6,8,9# R:
	1,4-N-acetyl-D-glucosaminyl-Asn <2,5,6,9,10,15>; #6# an axial
	2-hydroxyl group on the beta-linked mannose of the substrate are
	essential for the enzyme <2>; #7# absolute specificity for terminal
	branched mannosyl residues <4>) |#7,8,9# R: H <3,5,7>; #8# R:
	(fucose-1,6)-1,4-N-acetyl-D-glucosaminyl-Asn <5>; #6,8,9# R:
	1,4-N-acetyl-D-glucosaminyl-Asn <2,5,6,9,10>; #5,6,7# transfers an
	N-acetylglucosamine in beta-1,2-linkage to
	mannosyl-1,3-beta-mannosyl-terminus <2,4,16>; #6# R:
	1,4-N-acetyl-D-glucosaminyl-1,4-N-acetyl-D-glucosaminyl-Asn <15>; #15#
	pyridinylamine <1>| <1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,21,23>
SP	#1,6,7,8,9,12,14,15,16# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1,6)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-R = UDP +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R (#7,8,9# R: H
	<3,5,7,10>; #16# no activity with pyridylaminated substrate <23>; #12#
	recombinant isozyme A and B mutant T223A <23>; #6,12,15# pyridylamine
	<1,14,23>; #9# 1,4-N-acetyl-D-glucosaminyl-Asn <10>; #1,7,8,9,14#
	1,4-N-acetyl-D-glucosaminyl-R <12>; #9#
	synthetic-beta-D-mannosyl-(1,6-anhydro)-derivative acts as substrate,
	too <10>) |#9# R: H <3,10>; #6,15# R: pyridylamine <1,14>|
	<1,3,5,7,10,12,14,23>
SP	#1,6,7,8,9,12,14,15,16# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1,6)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-R = UDP +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R (#7,8,9# R: H
	<3,5,7,10>; #16# no activity with pyridylaminated substrate <23>; #12#
	recombinant isozyme A and B mutant T223A <23>; #6,12,15# pyridylamine
	<1,14,23>; #9# 1,4-N-acetyl-D-glucosaminyl-Asn <10>; #1,7,8,9,14#
	1,4-N-acetyl-D-glucosaminyl-R <12>; #9#
	synthetic-beta-D-mannosyl-(1,6-anhydro)-derivative acts as substrate,
	too <10>) |#9# R: H <3,10>; #6,15# R: pyridylamine <1,14>| {}
	<1,3,5,7,10,12,14,23>
SP	#10# UDP-N-acetylglucosamine + 3-(alpha-D-mannosyl)-beta-D-mannosyl-R =
	UDP +
	3-(2-(N-acetyl-beta-D-glucosaminyl)-alpha-D-mannosyl)-beta-D-mannosyl-R
	{} <38>
SP	#11# UDP-N-acetyl-D-glucosamine +
	Manalpha1,6(Manalpha1,3)Manbeta-1-O-octyl = UDP +
	GlcNAcalpha(1-2)Manalpha(1-6)Manalpha(1-3)Manbeta-1-O-octyl <25>
SP	#13# UDP-N-acetyl-D-glucosamine +
	[Manalpha1,6(Manalpha1,3)Manalpha1,6](Manalpha1,3)Manbeta1,4GlcAcbeta1
	4GlcNAc-R = UDP + ? <24>
SP	#2# UDP-N-acetyl-D-glucosamine +
	GlcUAcbeta1-3Galbeta1-O-naphthalenemethanol = ? (#2# synthetic
	substrate <13>) <13>
SP	#2,6,8,9,11,13,21# more = ? (#6# substrates: dolichol phosphate,
	asialo-bovine submaxillary mucin or galactosylated asialo-bovine
	submaxillary mucin, different specificities of transferase A and B,
	overview <6>; #9# acts on synthetic substrate analogues <10>; #6#
	substrates: free and protein-matrix-bound glycans <8>; #9# no acceptor
	substrates are N-acetyl-D-glucosamine,
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,6)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-1,4-N-acetyl-D-glucosaminyl-Asn <10>; #6#
	specificity for several synthetic acceptor substrate analogues,
	overview <15>; #2# enzyme initiates the biosynthesis of heparan sulfate
	<13>; #13# GLY-13 plays an important role in the synthesis of
	N-glycans. Synthesis of paucimannose N-glycans by Caenorhabditis
	elegans requires prior actions of
	UDP-N-acetyl-D-glucosamine:alpha-3-D-mannoside
	beta1,2-N-acetylglucosaminyltransferase I, alpha3,6-mannosidase II and
	a specific membrane-bound beta-N-acetylglucosaminidase <24>; #6,8# the
	enzyme catalyzes the first step in the conversion of oligomannose to
	complex or hybrid N-glycans of glycoproteins <26,29>; #9,11# the enzyme
	is essential for processing of high-mannose to hybrid and complex
	N-glycans <25>; #21# transformant plants that exhibit specific
	reduction of GnTI activity below detection limit, do not exhibit
	significantly altered complex N-glycan structures. Even the
	undetectable residual GnTI activity is sufficient for the synthesis of
	complex N-glycans comparable to wild-type plants <28>; #9# high-level
	nonempirical calculations describe the mechanism, reaction pathway
	energetics, and structure of the transition state involved in the
	reaction catalyzed by GnT-I <27>; #8# no activity with
	alpha1,6-mannobiose <29>; #8# the GnT I activity in the bovine oviduct
	may contribute to the induction of glycosylation and thereby
	contributing to the provision of the optimal microenvironment for
	fertilization and early development of embryos. Endocrine as well as
	local factors such as luteinizing hormone, vascular endothelial growth
	factor and tumor necrosis factor alpha increase the activity <30>) {}
	<3,5,6,8,9,10,13,15,24,25,26,27,28,29,30>
SP	#2,6,8,9,11,13,21# more = ? (#6# substrates: dolichol phosphate,
	asialo-bovine submaxillary mucin or galactosylated asialo-bovine
	submaxillary mucin, different specificities of transferase A and B,
	overview <6>; #9# acts on synthetic substrate analogues <10>; #6#
	substrates: free and protein-matrix-bound glycans <8>; #9# no acceptor
	substrates are N-acetyl-D-glucosamine,
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,6)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-1,4-N-acetyl-D-glucosaminyl-Asn <10>; #6#
	specificity for several synthetic acceptor substrate analogues,
	overview <15>; #2# enzyme initiates the biosynthesis of heparan sulfate
	<13>; #13# GLY-13 plays an important role in the synthesis of
	N-glycans. Synthesis of paucimannose N-glycans by Caenorhabditis
	elegans requires prior actions of
	UDP-N-acetyl-D-glucosamine:alpha-3-D-mannoside
	beta1,2-N-acetylglucosaminyltransferase I, alpha3,6-mannosidase II and
	a specific membrane-bound beta-N-acetylglucosaminidase <24>; #6,8# the
	enzyme catalyzes the first step in the conversion of oligomannose to
	complex or hybrid N-glycans of glycoproteins <26,29>; #9,11# the enzyme
	is essential for processing of high-mannose to hybrid and complex
	N-glycans <25>; #21# transformant plants that exhibit specific
	reduction of GnTI activity below detection limit, do not exhibit
	significantly altered complex N-glycan structures. Even the
	undetectable residual GnTI activity is sufficient for the synthesis of
	complex N-glycans comparable to wild-type plants <28>; #9# high-level
	nonempirical calculations describe the mechanism, reaction pathway
	energetics, and structure of the transition state involved in the
	reaction catalyzed by GnT-I <27>; #8# no activity with
	alpha1,6-mannobiose <29>; #8# the GnT I activity in the bovine oviduct
	may contribute to the induction of glycosylation and thereby
	contributing to the provision of the optimal microenvironment for
	fertilization and early development of embryos. Endocrine as well as
	local factors such as luteinizing hormone, vascular endothelial growth
	factor and tumor necrosis factor alpha increase the activity <30>) {}
	<3,5,6,8,9,10,13,15,24,25,26,27,28,29,30>
SP	#24# UDP-N-acetyl-D-glucosamine +
	GlcNAcbeta(1-2)Manalpha(1-6)[Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc-pyridylaminoside = UDP +
	GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside (#24# 3.9% activity compared
	to
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside <46>) <46>
SP	#24# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-2)Manalpha(1-3)[Manalpha(1-6)]Manalpha(1-6)[Manalpha(1
	3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside = UDP +
	Manalpha(1-2)Manalpha(1-3)[Manalpha(1-6)]Manalpha(1-6)[GlcNAcbeta(1
	2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside
	(#24# 0.5% activity compared to
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside <46>) <46>
SP	#24# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-3)Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside = UDP +
	GlcNAcbeta(1-2)Manalpha(1-3)Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc
	pyridylaminoside (#24# 0.7% activity compared to
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside <46>) <46>
SP	#24# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside = UDP +
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1
	3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside (#24# 100%
	activity <46>) <46>
SP	#24# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-6)[Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc
	pyridylaminoside = UDP +
	Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc-pyridylaminoside (#24# 6.9% activity compared to
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside <46>) <46>
SP	#24# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-6)[Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1
	3)]GlcNAc-pyridylaminoside = UDP +
	Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1
	4)[Fucalpha(1-3)]GlcNAc-pyridylaminoside (#24# 6.2% activity compared
	to
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside <46>) <46>
SP	#3,4,13# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-3)Manalpha(1-6)[Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc-R = UDP +
	Manalpha(1-3)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-R <47>
SP	#3,4,13# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-R = UDP +
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1
	3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-R <47>
SP	#3,4,13# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-6)[Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-R = UDP +
	Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc-R <47>
SP	#3,5,6,8,9,12,18# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(alpha-D-mannosyl-1,3)-alpha-D-mannosyl-1
	6-(alpha-D-mannosyl-1,3)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-1
	4-N-acetyl-D-glucosaminyl-Asn-peptide = UDP +
	alpha-D-mannosyl-1,6-(alpha-D-mannosyl-1,3)-alpha-D-mannosyl-1
	6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-Asn-peptide (#8# stimulates
	galactosyltransferase of bovine milk <9>; #5,6,9,12# key enzyme of
	biosynthesis of complex and hybrid N-glycans <2,10,21,23>)
	<2,9,10,21,23,44,45>
SP	#5# UDP-N-acetyl-D-glucosamine + fowl plague virus hemagglutinin = UDP
	+ fowl plague virus hemagglutinin with terminal N-acetyl-D-glucosaminyl
	residues (#5# recombinant coexpression of enzyme and substrate in SF9
	insect cells <16>) <16>
SP	#5# UDP-N-acetyl-D-glucosamine + Man5-RNAse B = UDP + RNAse
	B-GlcNAc2-Man5-GlcNAc (#5# wild type hGnT1 and mutants C121A, C121S and
	R120A/C121H transfer GlcNAc from UDP-GlcNAc to the glycoprotein
	acceptor Man5-RNAse B, whereas mutants C121T and C121D are inactive.
	After 1 h, the wild-type MBP-hGnT1(D103) and C121A mutant convert more
	than 50% of RNAse BM5 to RNAse BM5Gn, while the C121S mutant shows less
	than 25% conversion. The wild-type MBP-hGnT1(D103) and both C121A and
	C121S mutants convert RNAse BM5 nearly completely to RNAse BM5Gn
	following overnight incubation. The R120A/C121H mutant is less active
	than the wild-type and the single mutants. It converts more than half
	of the RNAse BM5 into RNAse BM5Gn after 17 h <36>) <36>
SP	#5# UDP-N-acetylglucosamine +
	alpha-D-mannosyl-1,6-(alpha-D-mannosyl-1,3)-alpha-D-mannosyl-1
	6-(alpha-D-mannosyl-1,3)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-1
	4-N-acetyl-D-glucosaminyl-Asn-peptide = UDP +
	alpha-D-mannosyl-1,6-(alpha-D-mannosyl-1,3)-alpha-D-mannosyl-1
	6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-R (#5# regioselective and stereoselective
	addition of beta-1,2-N-acetylglucosamine to a high mannose
	oligosaccharide from yeast, room temperature, 2.7fold excess of
	UDP-N-acetylglucosamine over the oligosaccharide substrate, 20 mM
	HEPES, pH 7.5, 150 mM NaCl, 20 mM MnCl2 <40>) <40>
SP	#5,20# UDP-N-acetyl-D-glucosamine + Man5GlcNAc2 = ? (#5# best substrate
	<21>) <21,22>
SP	#5,6,7# UDP-N-acetyl-D-glucosamine + ovalbumin = ? (#5# best substrate,
	recombinant enzyme expressed in SF9 cells, unmodified and as tagged
	fusion protein <16>; #7# substrate: glycopeptides prepared from
	ovalbumin <4>) <4,6,16,19>
SP	#6# UDP-N-acetyl-D-glucosamine + asialofetuin = ? (#6#
	beta-galactosidase-, beta-N-acetylhexosamidase- and
	alpha-mannosidase-treated asialofetuin, beta-galactosidase- and
	beta-N-acetylhexosamidase-treated asialofetuin <6>) <6>
SP	#6# UDP-N-acetyl-D-glucosamine + beta-galactosidase- and
	beta-N-acetylhexosamidase-treated asialotransferrin = ? <6>
SP	#6# UDP-N-acetyl-D-glucosamine +
	2-deoxy-Manalpha6(Manalpha3)Man-beta-octyl = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	3-O-(4,4-azopentyl)-Manalpha6(Manalpha3)Man-beta-octyl = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	3-O-(4,5-epoxypentyl)-Manalpha6(Manalpha3)Man-beta-octyl = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	3-O-(5-iodoacetamidopentyl)-Manalpha6(Manalpha3)Man-beta-octyl = UDP +
	? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	3-O-pentyl-Manalpha6(Manalpha3)Man-beta-octyl = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	4-O-methyl-Manalpha6(Manalpha3)Man-beta-octyl = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	6-O-methyl-Manalpha6(Manalpha3)Man-beta-octyl = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine + Man3Man-O-beta4-N-acetyl-D-glucosamine
	= UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine + Manalpha(1-6)Man = UDP + ? <26>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Manalpha6(4-deoxy-Manalpha3)Man-beta-octyl = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Manalpha6(4-O-(5-iodoacetamidopentyl)-Manalpha3)Man-beta-octyl = UDP +
	? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Manalpha6(4-O-methyl-Manalpha3)Man-beta-octyl = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine + Manalpha6(Manalpha3)Man-O-beta hexyl =
	UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Manalpha6(Manalpha3)Man-O-beta(8-methoxycarbonyl)octyl = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine + Manalpha6(Manalpha3)Man-O-beta-octyl =
	UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Manalpha6(Manalpha3)Man-O-beta4-N-acetyl-D-glucosamine-beta4(L-fucose
	alpha6)-N-acetyl-D-glucosamine-Asn = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Manalpha6(Manalpha3)Man-O-beta4-N-acetyl-D-glucosamine-beta4-N-acetyl-D
	glucosamine = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Manalpha6(Manalpha3)Man-O-beta4-N-acetyl-D-glucosamine = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosamine-beta2-Manalpha6(Manalpha3)Man-beta4-N-acetyl-D
	glucosamine = UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine + R-Manalpha6(Manalpha3)Man-beta-octyl =
	UDP + ? <31>
SP	#6# UDP-N-acetyl-D-glucosamine +
	[Manalpha(1-6)Manalpha(1-3)Manalpha(1-6)][Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-Asn = UDP + ? <31>
SP	#6,8# UDP-N-acetyl-D-glucosamine + ovalbumin glycopeptide V = UDP +
	ovalbumin glycopeptide IIIA (#6,8# best substrate <5,6>; #8#
	physiological substrate <5>) <5,6>
SP	#6,8# UDP-N-acetyl-D-glucosamine + Manalpha(1-3)Manalpha(1-6)Man = UDP
	+ ? (#8# about 30% of the activity with alpha1,3alpha1,6 mannopentaose
	<29>) <26,29>
SP	#6,8# UDP-N-acetyl-D-glucosamine + Manalpha(1-3)Man = UDP + ? (#8#
	about 15% of the activity with Manalpha(1-3)Manalpha(1-6)Man <29>)
	<26,29>
SP	#7# UDP-N-acetyl-D-glucosamine + glycopeptides prepared from porcine
	IgC = ? <4>
SP	#7,8,9# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,3-beta-D-mannosyl-1,4-N-acetyl-D-glucosamine = UDP +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3-beta-D-mannosyl-1
	4-N-acetyl-D-glucosamine <3,5,7>
SP	#7,8,9# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,3-beta-D-mannosyl-1,4-N-acetyl-D-glucosamine = UDP +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3-beta-D-mannosyl-1
	4-N-acetyl-D-glucosamine {} <3,5,7>
SP	#7,8,9# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetylglucosamine-1,4-(fucose-1
	6)-N-acetyl-glucosamine-Asn-peptide = UDP +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,6)-beta-D-mannosyl-1
	4-N-acetylglucosamine-1,4-(fucose-1,6)-N-acetyl-glucosamine-Asn-peptide
	(#7,9# no activity <3,7>; #8# poor substrate <5>) {} <3,5,7>
SP	#7,8,9# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetylglucosamine-1,4-(fucose-1
	6)-N-acetyl-glucosamine-Asn-peptide = UDP +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,6)-beta-D-mannosyl-1
	4-N-acetylglucosamine-1,4-(fucose-1,6)-N-acetyl-glucosamine-Asn-peptide
	(#7,9# no activity <3,7>; #8# poor substrate <5>) <3,5,7>
SP	#7,9,19,25# UDP-N-acetyl-D-glucosamine +
	3-(alpha-D-mannosyl)-beta-D-mannosyl-R = UDP +
	3-(2-[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	(#9# GlcNAc transfer catalyzed by GnT-I is the first step in the
	conversion of high mannose oligosaccharides to complex and hybrid
	N-glycan structures <34>; #19# enzyme TbGnTI transfers UDP-GlcNAc to
	biantennary Man3GlcNAc2, but not to triantennary Man5GlcNAc2, which is
	the preferred substrate for metazoan enzymes <49>) <32,34,48,49>
SP	#8# UDP-N-acetyl-D-glucosamine + ovalbumin glycopeptide III A-C = ? <5>
SP	#8# UDP-N-acetyl-D-glucosamine + ovalbumin glycopeptide IV = ? <5>
SP	#8# UDP-N-acetyl-D-glucosamine +
	desialo-degalacto-dehexosamine-orosomucoid = ? <9>
SP	#9# UDP-N-acetyl-D-glucosamine + dehexoso-orosomucoid = ? <3>
SP	#9# UDP-N-acetyl-D-glucosamine +
	Manalpha1,6(Manalpha1,3)Manbeta-1-O-octyl = UDP +
	GlcNAc(1-2)Manalpha(1-6)Manalpha(1-3)Manbeta-1-O-octyl <25>
SP	#9,11# UDP-N-acetyl-D-glucosamine + Man5GlcNAc2-glycopeptide = UDP +
	GlcNAc(1-2)Man5GlcNAc2-glycopeptide <25>

KM_VALUE
KM	#12# 1.6 {pyridylaminated Man3GlcNAc2}  (#12# recombinant isozyme A
	<23>) <23>
KM	#15# 0.43
	{N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-pyridinylamine}  <1>
KM	#2# 0.036 {UDP-N-acetyl-D-glucosamine}  <13>
KM	#20# 0.17 {UDP-N-acetyl-D-glucosamine}  (#20# wild-type CHO <22>) <22>
KM	#20# 0.26 {Man5GlcNAc2}  (#20# wild-type CHO <22>) <22>
KM	#20# 5.43 {Man5GlcNAc2}  (#20# mutant Lec1A <22>) <22>
KM	#20# 7.56 {UDP-N-acetyl-D-glucosamine}  (#20# mutant Lec1A <22>) <22>
KM	#24# 0.5
	{Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside}  (#24# recombinant enzyme, pH
	not specified in the publication, at 25°C <46>) <46>
KM	#5# 0.483 {Man5GlcNAc2}  (#5# recombinant fusion protein <21>) <21>
KM	#6# 0.3 {6-O-methyl-Manalpha6(Manalpha3)Man-beta-octyl}  <31>
KM	#6# 0.6 {2-deoxy-Manalpha6(Manalpha3)Man-beta-octyl}  <31>
KM	#6# 1.7 {Manalpha6(Manalpha3)Man-O-beta hexyl}  <31>
KM	#6# 0.4
	{[Manalpha6(Manalpha3)Manalpha6][Manalpha3]Man-beta4-N-acetyl-D
	glucosamine-beta4-N-acetyl-D-glucosamine-Asn}  <31>
KM	#6# 0.4
	{Manalpha6(Manalpha3)Man-O-beta4-N-acetyl-D-glucosamine-beta4(L-fucose
	alpha6)-N-acetyl-D-glucosamine-Asn}  <31>
KM	#6# 0.9 {4-O-methyl-Manalpha6(Manalpha3)Man-beta-octyl}  <31>
KM	#6# 1.4
	{3-O-(5-iodoacetamidopentyl)-Manalpha6(Manalpha3)Man-beta-octyl}  <31>
KM	#6# 1.8
	{Manalpha6(Manalpha3)Man-O-beta4-N-acetyl-D-glucosamine-beta4-N-acetyl
	D-glucosamine}  <31>
KM	#6# 1.8 {3-O-(4,5-epoxypentyl)-Manalpha6(Manalpha3)Man-beta-octyl}  <31>
KM	#6# 1.2 {3-O-(4,4-azopentyl)-Manalpha6(Manalpha3)Man-beta-octyl}  <31>
KM	#6# 1.5 {Manalpha6(Manalpha3)Man-O-beta(8-methoxycarbonyl)octyl}  <31>
KM	#6# 1.9
	{N-acetyl-D-glucosamine-beta2-Manalpha6(Manalpha3)Man-beta4-N-acetyl-D
	glucosamine}  <31>
KM	#6# 0.7 {Manalpha6(Manalpha3)Man-O-beta-octyl}  <31>
KM	#6# 0.046 {UDP-N-acetyl-D-glucosamine}  (#6# recombinant catalytic
	fragment <14>) <14>
KM	#6# 0.33 {ovalbumin glycopeptide V}  (#6# transferase A <6>) <6>
KM	#6# 0.47
	{alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1,6)-alpha-D-mannosyl-1
	3-(alpha-D-mannosyl-1,6)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-1
	4-N-acetylglucosamine}  (#6# recombinant catalytic fragment <14>) <14>
KM	#6# 4.5 {ovalbumin}  (#6# transferase B <6>) <6>
KM	#6# 4.5 {Manalpha6(Manalpha3)Man-O-beta4-N-acetyl-D-glucosamine}  <31>
KM	#6# 2.7 {Manalpha6(Manalpha3)Man-O-beta4-N-acetyl-D-glucosamine}  <31>
KM	#6# 5 {Manalpha6(4-O-(5-iodoacetamidopentyl)-Manalpha3)Man-beta-octyl} 
	<31>
KM	#6# 3.5 {3-O-pentyl-Manalpha6(Manalpha3)Man-beta-octyl}  <31>
KM	#6# 2.6 {Manalpha6(4-O-methyl-Manalpha3)Man-beta-octyl}  <31>
KM	#6# 0.44 {ovalbumin}  (#6# transferase A <6>) <6>
KM	#6# 22 {Manalpha6(4-deoxy-Manalpha3)Man-beta-octyl}  <31>
KM	#6,8,9# -999 {more}  (#9# kinetic study <10>; #6# Km-values for several
	synthetic acceptor substrate analogues, overview <15>; #8# interaction
	with bovine milk galactosyltransferase influences the Km-values <9>;
	#6# elimination of 4-hydroxyl of the alpha-1,3-linked mannose of the
	substrate increases the Km-value 20fold <2>; #6# kinetic data of free
	and protein-matrix-bound acceptor substrates <8>) <2,8,9,10,15,29>
KM	#7# 0.39
	{alpha-D-mannosyl-1,6-(alpha-D-mannosyl-1,3)-alpha-D-mannosyl-1
	6-(alpha-D-mannosyl-1,3)-beta-D-mannosyl-1,4-N-acetyl-D-glucosamine} 
	<7>
KM	#8# 0.1 {UDP-N-acetyl-D-glucosamine}  <5>
KM	#8# 0.2
	{alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1,6)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-R}  (#8# immunoglobulin G glycopeptide <5>)
	<5>
KM	#8# 0.12 {ovalbumin glycopeptide V}  <5>
KM	#8# 10
	{N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R}  (#8# immunoglobulin
	G glycopeptide <5>) <5>
KM	#8# 7.4 {alpha-mannosyl-1,3-beta-mannosyl-1,4-N-acetylglucosamine}  <5>
KM	#9# 0.078 {UDP-N-acetyl-D-glucosamine}  (#9# with
	alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1,6)-alpha-D-mannosyl-1
	3-(alpha-D-mannosyl-1,6)-beta-D-mannosyl-1,4-N-acetyl-D-glucosamine
	<12>) <12>
KM	#9# 0.078
	{alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1,6)-alpha-D-mannosyl-1
	3-(alpha-D-mannosyl-1,6)-beta-D-mannosyl-1,4-N-acetyl-D-glucosamine} 
	<12>
KM	#9# 0.45
	{alpha-D-mannosyl-1,6-(alpha-D-mannosyl-1,3)-alpha-D-mannosyl-1
	6-(alpha-D-mannosyl-1,3)-beta-D-mannosyl-1,4-N-acetyl-D-glucosamine} 
	<3>
KM	#9# 0.25
	{alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1,6)-alpha-D-mannosyl-1
	3-(alpha-D-mannosyl-1,6)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-1
	4-N-acetylglucosamine}  <12>
KM	#9# 2.03
	{alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1,6)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosamine}  <10>
KM	#9# 0.0384 {UDP-N-acetyl-D-glucosamine}  <10>
KM	#9# 0.0384
	{alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1,6)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-R}  <10>

PH_OPTIMUM
PHO	#2# 5-8 (#2# broad optimum <13>) <13>
PHO	#5,25# 6.5 (#25# assay at <48>; #5# recombinant fusion protein <21>)
	<21,48>
PHO	#6# 7 (#6# recombinant catalytic fragment <14>; #6# enzyme from
	epididymal fluid <26>) <14,26>
PHO	#6# 7-7.3 <6>
PHO	#6,8,15# 6 (#6# enzyme from testicular fluid <26>) <1,5,26>
PHO	#8# 5.8 <29>
PHO	#9# 5.6 <10,12>
PHO	#9,12,24# 6.3 (#12# assay at <23>) <3,23,46>

PH_RANGE
PHR	#24# 5-8.5 (#24# activity decreases to less than 15% of the maximum at
	pH values lower than 5.0 and higher than 8.5 <46>) <46>
PHR	#5# 6.5-9 (#5# recombinant fusion protein <21>) <21>
PHR	#9# 5.1-6.9 (#9# about half-maximal activity at pH 5.1 and about 70% of
	maximal activity at pH 6.9 <10>) <10>
PHR	#9# 5.8-6.7 <3>

SPECIFIC_ACTIVITY
SA	#12# 0.6 (#12# recombinant isozyme A <23>) <23>
SA	#2# 2e-07 (#2# wild-type S49 cell <13>) <13>
SA	#2# 8.4e-07 (#2# wild-type CHO cell <13>) <13>
SA	#5# 0.48 (#5# room temperature, 2.7fold excess of
	UDP-N-acetylglucosamine over the oligosaccharide substrate, 20 mM
	HEPES, pH 7.5, 150 mM NaCl, 20 mM MnCl2 <40>) <40>
SA	#5,20# -999.0 (#5# in vivo assay of recombinant enzyme expressed in Sf9
	cells with coexpressed fowl plague virus HA as endogenous substrate
	<16>; #20# wild-type and mutant cell lines <22>) <16,22>
SA	#6# 20.0 (#6# purified enzyme <15>) <15>
SA	#6# 1.5e-05 (#6# transferase A, liver <6>) <6>
SA	#6# 0.00065 (#6# transferase B, hepatoma <6>) <6>
SA	#7# 4.8 (#7# liver <7>) <7>
SA	#7# 3.37 (#7# purified enzyme <4>) <4>
SA	#8# 0.106 (#8# alpha1-acid glycoprotein treated with mild acid,
	beta-galactosidase and beta-N-acetylglucosamidase <5>) <5>
SA	#8# 0.079 (#8#
	alpha-D-mannosyl-1,3-(alpha-D-mannosyl-1,6)-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-R immunoglobulin G glycopeptide <5>) <5>
SA	#9# 19.8 (#9# low-molecular weight form <10>) <10>
SA	#9# 2.51 (#9# purified enzyme <3>) <3>

TEMPERATURE_OPTIMUM
TO	#24# 25 <46>
TO	#5# 40 (#5# recombinant fusion protein <21>) <21>
TO	#6,7,8,9,12,14,15,25# 37 (#6,7,8,9,12,14,15,25# assay at
	<1,3,5,6,7,8,9,10,12,14,23,48>) <1,3,5,6,7,8,9,10,12,14,23,48>

TEMPERATURE_RANGE
TR	#24# 0-45 (#24# the activity decreases with increasing reaction
	temperature and is completely abolished at temperatures higher than
	45°C. On the other hand, substantial GnTI activity is detected at low
	temperatures, even at 0°C (approximately 50% of the maximum) <46>) <46>
TR	#5# 0-70 (#5# recombinant fusion protein <21>) <21>

ACTIVATING_COMPOUND
AC	#2# CHAPS (#2# slight activation <13>) <13>
AC	#2# Zwittergent 3-12 (#2# slight activation <13>) <13>
AC	#2,6,9,14# Triton X-100 (#2,9,14# slight activation <12,13>)
	<6,10,12,13>
AC	#9# more (#9# no activation by 2-mercaptoethanol <10,12>) <10,12>

INHIBITORS
IN	#5# Zn2+ <21>
IN	#5# Ca2+ <21>
IN	#6# Manalpha6(6-O-methyl-Manalpha3)Man-beta-octyl <31>
IN	#6# Manalpha6(6-O-(5-pentanolyl)-Manalpha3)Man-beta-octyl <31>
IN	#6# Manalpha6(6-O-(4-oxopentyl)-Manalpha3)Man-beta-octyl <31>
IN	#6# Manalpha6(6-O-(4,4-azopentyl)-Manalpha3)Man-beta-octyl <31>
IN	#6# [Manalpha6(Manalpha3)][4-O-methyl-Man]-beta4-N-acetyl-D-glucosamine
	<31>
IN	#6# Manalpha6(6-O-(4,5-epoxypentyl)-Manalpha3)Man-beta-octyl <31>
IN	#6#
	alpha-D-Mannosyl-1,3-(alpha-D-mannosyl-1
	6)-4-O-methyl-beta-D-mannosyl-1,4-N-acetyl-D-glucosamine (#6# weak <2>)
	<2>
IN	#6,9# more (#9# high ionic strength, e.g. 0.1 M NaCl <3>; #6# several
	inhibitory synthetic acceptor substrate analogues, overview <15>; #9#
	no inhibitors are CDP, UDPhexanolamine, AMP <10>; #6# strategies for
	inhibitor design based on substrate specificities of the enzyme <15>)
	<3,10,15>
IN	#7# Antibodies to pig liver N-acetylglucosaminyltransferase I <7>
IN	#8,9# EDTA (#8,9# 3 mM <3,5>) <3,5>
IN	#9# UDP <3,10>
IN	#9# TDP <10>
IN	#9# 5-Bromo-UTP <10>
IN	#9#
	alpha-D-mannosyl-1,6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R <10>
IN	#9# 5-Mercury-UDP <10>
IN	#9# UDP-glucose (#9# weak <10>) <10>
IN	#9# UTP (#9# weak <10>) <10>
IN	#9# UMP (#9# weak <10>) <10>
IN	#9# UDP-N-acetylgalactosamine (#9# weak <10>) <10>
IN	#9# 2'-dUDP (#9# weak <10>) <10>
IN	#9# 2'-O-Methyl-UDP (#9# weak <10>) <10>
IN	#9# UDP-N-acetylglucosamine (#9# competitively to UDP <10>) <10>

KI_VALUE
KI	#6# -999 {more}  (#6# several inhibitory synthetic acceptor substrate
	analogues, overview <15>) <15>
KI	#6# 2.6 {Manalpha6(6-O-(4,5-epoxypentyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 1.1 {Manalpha6(6-O-(4,4-azopentyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 0.8 {Manalpha6(6-O-methyl-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 13
	{[Manalpha6(Manalpha3)][4-O-methyl-Man]-beta4-N-acetyl-D-glucosamine} 
	<31>
KI	#6# 10.2 {Manalpha6(6-O-(5-pentanolyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 8.8 {Manalpha6(6-O-(4-oxopentyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#9# 1.8
	{alpha-D-mannosyl-1,6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R}  <10>
KI	#9# 0.034 {UDP-N-acetylglucosamine}  <10>

METALS_IONS
ME	#1,2,5,6,7,8,9,12,14,15,24# Mn2+ (#1,2,5,6,7,8,9,14,15# requirement
	<1,3,4,5,6,7,8,9,10,12,13,14,21>; #9# required for activity <43>; #6# 2
	mM <6>; #9# 25-100 mM <12>; #8# 18-26 mM <5>; #9# binds not
	independently of UDP-N-acetyl-D-glucose <18>; #2# can also use Ca2+
	<13>; #6# 20-80 mM <14>; #8# Co2+, Mn2+ or Mg2+ required, optimal
	concentration is 50 mM <29>; #6# the enzyme in testicular fluid has an
	absolute requirement for either Co2+, or Mn2+, Mg2+ and ca2+. The
	activity is stimulated by the cations in the above order. The enzyme
	from cauda epididymal fluid has an absolute requirement for Mn2+ or
	Ca2+, with Co2+ and Mg2+ being ineffective <26>; #24# maximal activity
	in the presence of 2 mM Mn2+ <46>)
	<1,3,4,5,6,7,8,9,10,12,13,14,18,21,23,26,29,43,46>
ME	#2,6,9,14# Ca2+ (#9# slight activation <3,10,12>; #2# can substitute
	Mn2+ <13>; #6# the enzyme in testicular fluid has an absolute
	requirement for either Co2+, or Mn2+, Mg2+ and ca2+. The activity is
	stimulated by the cations in the above order. The enzyme from cauda
	epididymal fluid has an absolute requirement for Mn2+ or Ca2+, with
	Co2+ and Mg2+ being ineffective <26>) <3,10,12,13,26>
ME	#5,6,8,9# Co2+ (#5# requirement <21>; #9# activation <3,10,12>; #9# 91%
	efficiency <3>; #9# can substitute for Mn2+ with 80% <10>; #8# Co2+,
	Mn2+ or Mg2+ required, Co2+ is most effective <29>; #6# the enzyme in
	testicular fluid has an absolute requirement for either Co2+, or Mn2+,
	Mg2+ and ca2+. The activity is stimulated by the cations in the above
	order. The enzyme from cauda epididymal fluid has an absolute
	requirement for Mn2+ or Ca2+, with Co2+ and Mg2+ being ineffective
	<26>) <3,10,12,21,26,29>
ME	#6,8,9# Mg2+ (#9# activation <3,10,12>; #9# can substitute for Mn2+
	with 40% <10>; #9# 61% efficiency <3>; #8# Co2+, Mn2+ or Mg2+ required
	<29>; #6# the enzyme in testicular fluid has an absolute requirement
	for either Co2+, or Mn2+, Mg2+ and ca2+. The activity is stimulated by
	the cations in the above order. The enzyme from cauda epididymal fluid
	has an absolute requirement for Mn2+ or Ca2+, with Co2+ and Mg2+ being
	ineffective <26>) <3,10,12,26,29>
ME	#9# Zn2+ (#9# activation <3,10,12>; #9# can substitute for Mn2+ with 8%
	<10>; #9# 19% efficiency <3>) <3,10,12>
ME	#9# Fe2+ (#9# activation <3,10,12>; #9# slight <3>; #9# can substitute
	for Mn2+ with 65% efficiency <10>) <3,10,12>
ME	#9# Ni2+ (#9# activation <3,10,12>; #9# can substitute for Mn2+ with
	20% <10>; #9# 34% efficiency <3>) <3,10,12>
ME	#9# Cd2+ (#9# activation <3,10,12>; #9# can substitute for Mn2+ with
	20% <10>; #9# 78% efficiency <3>) <3,10,12>
ME	#9# Ba2+ (#9# no activation <3>; #9# slight activation <10,12>)
	<3,10,12>
ME	#9# Sn2+ (#9# slight activation <10,12>) <10,12>
ME	#9,24# more (#9# no activation by Cu2+ <3,10,12>; #9# no activation by
	Hg2+ <3>; #9# no activation by Sr2+, Pb2+ <10,12>; #24# not stimulated
	by Mg2+, Co2+, Ca2+, Zn2+ and C2+ <46>) <3,10,12,46>

MOLECULAR_WEIGHT
MW	#12# 65000 (#12# x * 65000, recombinant isozyme B, SDS-PAGE <23>) <23>
MW	#18# 56000 (#18# x * 56000, recombinant enzyme, SDS-PAGE <45>) <45>
MW	#25# 53000 (#25# x * 53000, SDS-PAGE <48>) <48>
MW	#5,11# 78000 (#5,11# mass of the fusion protein, free YFP-marker is
	about 27000 Da, SDS-PAGE <42>) <42>
MW	#5,7,9,10,11,12# -999 (#9# 2 domain protein, determination of acceptor
	substrate-, nucleotide sugar- and metal-binding sites <18>; #7# two
	MW-species of pig liver enzyme: major MW 52000 and minor MW 59000,
	SDS-PAGE <7>; #5# enzyme exists as high molecular weight complex, which
	do not require the transmembrane domain nor the cytoplasmic tail of the
	enzyme for complex formation <19>; #10,11# shorter hydrophobic membrane
	anchor domain compared to animal enzymes, amino acid sequences
	alignment <20>; #9# separable by gel filtration <10,12>; #9# two
	MW-species <3,10,12>; #12# type II membrane proteins: short N-terminal
	cytoplasmic tail of 4 amino acid residues, transmembrane domain of 22
	residues, stem region of 81 residue for isozyme A and 77 residues for
	isozyme B, amino acid sequences alignment <23>) <3,7,10,12,18,19,20,23>
MW	#5,9# 50000 (#5# x * 50000, recombinant enzyme, SDS-PAGE <16>; #9# x *
	45000 + x * 50000 + x * 54000, low molecular weight form, SDS-PAGE,
	major band: MW 45000 <10,12>) <10,12,16>
MW	#6# 51000 (#6# x * 51000, recombinant, tagged protein, SDS-PAGE <17>)
	<17>
MW	#6,9# 46000 (#6# x * 46000, recombinant catalytic fragment, SDS-PAGE
	<14>; #9# x * 58000 + x * 46000, SDS-PAGE <3>) <3,14>
MW	#7# 59000 (#7# SDS-PAGE <7>) <7>
MW	#7# 52000 (#7# SDS-PAGE <7>) <7>
MW	#9# 54000 (#9# x * 45000 + x * 50000 + x * 54000, low molecular weight
	form, SDS-PAGE, major band: MW 45000 <10,12>) <10,12>
MW	#9# 58000 (#9# x * 58000 + x * 46000, SDS-PAGE <3>) <3>
MW	#9# 45000 (#9# x * 45000 + x * 50000 + x * 54000, low molecular weight
	form, SDS-PAGE, major band: MW 45000 <10,12>) <10,12>

POSTTRANSLATIONAL_MODIFICATION
PM	#5,10,11# glycoprotein (#10,11# one glycosylation site <20>; #5#
	O-glycosylated <19>; #11# D144N muation in the GnTI of cgl mutant
	lacking GnTI activity is molecular basis of the defect. The mutation
	creates an additional N-glycosylation site, which interferes with the
	proper folding of the enzyme <25>) <19,20,25>
PM	#6# no glycoprotein (#6# recombinant catalytic fragment, no
	glycosylation sites <14>) <14>

SUBUNITS
SU	#21# homodimer (#21# the enzyme has cytoplasmic transmembrane and stem
	regions. The transmembrane domain of enzyme GnTI is the major
	determinant for its cis/medial-Golgi localization, while the stem
	region of GnTI contributes predominately to homomeric and heteromeric
	protein complex formation <50>) <50>
SU	#5,6,9,12,18,25# ? (#25# x * 53000, SDS-PAGE <48>; #18# x * 56000,
	recombinant enzyme, SDS-PAGE <45>; #5# x * 50000, recombinant enzyme,
	SDS-PAGE <16>; #12# x * 65000, recombinant isozyme B, SDS-PAGE <23>;
	#9# x * 45000 + x * 50000 + x * 54000, low molecular weight form,
	SDS-PAGE, major band: MW 45000 <10,12>; #6# x * 46000, recombinant
	catalytic fragment, SDS-PAGE <14>; #6# x * 51000, recombinant, tagged
	protein, SDS-PAGE <17>; #9# x * 58000 + x * 46000, SDS-PAGE <3>)
	<3,10,12,14,16,17,23,45,48>

APPLICATION
AP	#5# molecular biology (#5# production of rare hybrid oligosaccharides
	for biochemical and structural studies, 100% conversion of
	oligosaccharide substrate at room temperature, yield of 42% after
	purification from reaction mixture <40>) <40>
AP	#5,6,10# biotechnology (#5# immobilization of the enzyme as
	maltose-binding fusion protein on an amylose resin for production of
	high-mannose type oligosaccharides <21>; #6# production of glycoprotein
	therapeutics in recombinant Saccharomyces cerevisiae adapted to
	production of hybrid- and complex-type carbohydrates <17>; #10# the
	fusion of the human beta 1,4-galacosyltransferase with the targeting
	domain of Nicotiana N-acetylglucosaminyltransferase I does not increase
	the level of beta 1,4-galactosylation in alfalfa, the expression in
	alfalfa strongly reduces the biosynthesis of Lewis a glycoepitope
	responsible for plant N-glycan immunogenicity in mammals <38>)
	<17,21,38>
AP	#7# medicine (#7# mutant enzyme does not show any activity in an HPLC
	analysis. In the case of pig cell transfectants with pigGnT-I(320),
	cell surface carbohydrate structures are significantly altered and its
	antigenicity to human serum is reduced. pigGnT-I(320) appears to be
	potentially useful in xenotransplantation by remodeling the
	carbohydrate structures on pig cells <32>) <32>

ENGINEERING
EN	#12# T223A (#12# isozyme B, improvement of properties of isozyme B to
	the level of isozyme A <23>) <23>
EN	#20# C907T (#20# point mutation in mutant cell line Lec1A.3E and
	Lec1A.5J, altering interactions important for stabilization of the
	structure, correction of the mutation by site-directed mutagenesis
	restores enzyme activity <22>) <22>
EN	#20# G634A (#20# point mutation in mutant cell line Lec1A.2C, disrution
	of DxD motif responsible for interaction with UDP-GlcNAc and Mn2+,
	correction of the mutation by site-directed mutagenesis restores enzyme
	activity <22>) <22>
EN	#5# D77N (#5# exchange mutation in chimera TfR/GnT1myc, no effect on
	Golgi localization and inclusion into high molecular weight complexes,
	no catalytic activity <19>) <19>
EN	#5# R83S (#5# exchange mutation in chimera TfR/GnT1myc, no effect on
	Golgi localization and inclusion into high molecular weight complexes,
	no catalytic activity <19>) <19>
EN	#5# R85S (#5# exchange mutation in chimera TfR/GnT1myc, no effect on
	Golgi localization and inclusion into high molecular weight complexes,
	no catalytic activity <19>) <19>
EN	#5# C121A (#5# active mutant enzyme. After 1 h, the wild-type
	MBP-hGnT1(D103) and C121A mutant convert more than 50% of Man5-RNAse B
	to RNAse B-GlcNAc2-Man5-GlcNAc <36>) <36>
EN	#5# C121S (#5# active mutant enzyme. After 1 h, the C121S mutant shows
	less than 25% conversion of Man5-RNAse B to RNAse B-GlcNAc2-Man5-GlcNAc
	<36>) <36>
EN	#5# C121T (#5# mutant enzyme shows no transfer of GlcNAc from
	UDP-GlcNAc to the glycoprotein acceptor Man5-RNAse B <36>) <36>
EN	#5# C121D (#5# mutant enzyme shows no transfer of GlcNAc from
	UDP-GlcNAc to the glycoprotein acceptor Man5-RNAse B <36>) <36>
EN	#5# R120A/C121H (#5# active mutant enzyme. The R120A/C121H mutant is
	less active than the wild type and the single mutants. It converts more
	than half of the Man5-RNAse B to RNAse B-GlcNAc2-Man5-GlcNAc <36>) <36>
EN	#5,10,11,20,21,25# more (#20# 1 difference to published sequence with
	accession number U65791: C1340 is A1340 <22>; #11# natural point
	mutation contains mRNA but no enzyme activity <20>; #5# construction of
	chimeric proteins with different portions of the N-terminal ectodomain
	of the enzyme, modification to ectodomain of type II surface membrane
	protein, chimeras are retained in the Golgi apparatus <11>; #5# a
	truncated, soluble enzyme form, consisting of stem region and catalytic
	domain, is accumulated in the Golgi apparatus prior to secretion <19>;
	#10# transient transfection of isolated protoplasts of Arabidopsis
	thaliana defective mutant with cDNA in sense and antisense orientation
	<20>; #10# construction of antisense transgenic plants via
	Agrobacterium tumefaciens transfection of the own gene in antisense
	orientation, regulation analysis <20>; #11# AAA, ER steady-state
	location with little Golgi labelling <41>; #11# AAR, similar
	Golgi-targeting as wild-type <41>; #5,11# Elisa experiments show that
	cgl1-1 mutant of Arabidopsis lacking N-acetylglucosaminyltransferase I
	activity, is fully complemented by YFP-labeled Arabidopsis enzyme
	(similar level of proteins with complex glycans), but only partially
	complemented by human enzyme (lower levels of proteins with complex
	glycans), chimeric enzyme with similar levels compared to wild-type,
	sub-cellular localization of the human enzyme is partly distinct, the
	human enzyme is easily cleaved of its transmembrane anchor <42>; #11#
	RAA, localisation in ER and Golgi membrane, more pronounced labeling in
	the ER <41>; #11# site-directed mutagenesis of single arginine residues
	within cytoplasmic tail are sufficient to promote rapid Golgi targeting
	of Golgi-resident N-acetylglucosaminyltransferase I, an intact ER
	export motif is essential for proper in vivo function, transport is
	COPII-dependent, exchange of the cytoplasmic tail with the
	corresponding part of other plant glycosylation enzymes does not alter
	the Golgi targeting, complementation experiments with cg/1 Arabidopsis
	thaliana lacking an active N-acetylglucosaminyltransferase I <41>; #10#
	the fusion of the human beta 1,4-galactosyltransferase with the
	targeting domain of Nicotiana N-acetylglucosaminyltransferase I does
	not increase the level of beta 1,4-galactosylation in alfalfa <38>;
	#21# construction of a series of chimeric
	N-acetylglucosaminyltransferase I (GnTI) mutants by to investigate the
	contribution of the cytoplasmic, transmembrane, and stem region the
	enzyme for its cis/medial-Golgi localization and for protein-protein
	interaction in the Golgi apparatus. The individual GnTI protein
	domains, i.e. cytoplasmic tail, transmembrane domain and luminal stem
	region, are replaced with those from the well-known trans-Golgi enzyme
	alpha2,6-sialyltransferase and transiently expressed in Nicotiana
	benthamiana. A chimeric GnTI variant with altered sub-Golgi
	localization is not able to complement the GnTI-dependent glycosylation
	defect. Generation of transgenic Arabdiopsis thaliana gntI plants
	expressing the chimeric CTS domai region fused to the catalytic domain
	of Arabidopsis thaliana GnTI enzyme and expression in enzyme
	activity-deficient Nicotiana benthamiana plants under control of the
	endogenous GnTI promoter. The Arabidopsis enzyme chimeric constructs
	can complement the inactive the N-glycan processing defect of tobacco
	mutant plants <50>; #25# GlcNAc and tet-induced Mgat1 increases the
	levels of many metabolites in HeLa cells, and HEK293 cells, tet-induced
	Mgat1 changes in the N-glycan distributions, , N-glycans profiles of
	transgenic HeLa and HEK-293 cells, overview <48>)
	<11,19,20,22,38,41,42,48,50>
EN	#7# G320D (#7# mutant enzyme does not show any activity in an HPLC
	analysis. In the case of pig cell transfectants with pigGnT-I(320),
	cell surface carbohydrate structures are significantly altered and its
	antigenicity to human serum is reduced <32>) <32>
EN	#7# C123R (#7# mutant enzyme does not show any activity in an HPLC
	analysis <32>) <32>
EN	#9# D291N (#9# inactive <43>) <43>
EN	#9# P138L (#9# inactive <43>) <43>
EN	#9# R415K (#9# inactive <43>) <43>
EN	#9# more. (#9# deleting seven C-terminal amino acids of the enzyme
	reduces enzymatic activity by 40% <43>) <43>
EN	#9,11# D144N (#11# D144N muation in the GnTI of cgl mutant lacking GnTI
	activity is molecular basis of the defect. The mutation creates an
	additional N-glycosylation site, which interferes with the proper
	folding of the enzyme <25>; #9# expression of D144N muatant enzyme of
	rabbit in cgl mutant of Arabidopsis thaliana lacking GnTI activity
	(caused by a D144N mutation in GnTI) can partially restore complex
	N-glycan formation <25>) <25>

CLONED
CL	#5# <21>
CL	#5# (functional expression of c-Myc-tagged full length clone and
	chimera TfR/GnT1myc and exchange mutants of the latter in CHO Lec 1
	cells, lacking GnT-1 activity) <19>
CL	#5# (functional expression of unmodified enzyme and as tagged fusion
	protein in Spodoptera frugiperda Sf9 cells via baculovirus infection,
	coexpression of fowl plague virus hemagglutinin HA as endogenous
	substrate for in vivo activity assay) <16>
CL	#5# (cDNA clone, constructed type-II-surface membrane-protein/human
	transferase chimeras are transfected into Madin-Darby canine kidney
	cells) <11>
CL	#5# (human beta-1-2-N-acetylglucosaminyltransferase (hGnT1) lacking the
	first 103 amino acids is expressed as a maltose binding protein (MBP)
	fusion protein in inclusion bodies in Escherichia coli and refolded
	using an oxido-shuffling method. Cloning and expression of
	MBP-hGnT1(D103) and mutant MBP-hGnT1 (D103) enzymes) <36>
CL	#5# (in one construct, the catalytic domain of human GNT I (abbreviated
	as NA) is fused to the MNN9 leader (abbreviated as 15) from
	Saccharomyces cerevisiae to yield construct NA15. In a second
	construct, a fungal codon-optimized form is combined with the same MNN9
	leader to yield construct coNA15. Expression in Aspergillus nidulans
	and Aspergillus niger) <35>
CL	#5# (expression of the histidine-tagged catalytic domain in Escherichia
	coli which is supplemented with mammalian tRNA codons and with
	mutations to improve intracellular disulfide bond formation) <40>
CL	#5# (expression of YFP or CFP fusion enzyme of Arabidopsis and human
	N-acetylglucosaminyltransferase I, and the chimeric enzyme of
	Arabidopsis CTS region and human catalytic domain in mutant cgl1-1
	Arabidopsis (lacking N-acetylglucosaminyltransferase I), transformed by
	Agrobacterium tumefaciens) <42>
CL	#6# (expression of the enzymes catalytic domain in Escherichia coli
	strain BL21, unmodified catalytic domain and His-tagged at the
	C-terminal and at the N-terminal end) <14>
CL	#6# (expression in Saccharomyces cerevisiae, tagged with c-Myc epitope)
	<17>
CL	#6# (the full length GnT-I gene is expressed in Aspergillus oryzae.
	GnT-1 is functionally expressed and N-acetylglusosamine is transferred
	to N-glycan of alpha-amylase in vivo) <33>
CL	#7# <32>
CL	#9# (expression of catalytic fragment in Spodoptera frugiperda Sf9
	cells via baculovirus infection) <18>
CL	#9# (transformation construct contains either the catalytic domain
	(amino acids 106-447) of wild-type enzyme or D144N rabbit NgTI fused to
	the CTS region (amino acids 1-102) of Arabidopsis thaliana GnTI under
	the control of the strong constitutive cauliflower mosaic virus 35S
	promoter) <25>
CL	#9# (expressed in CHO-DUKX-Lec1 cells) <43>
CL	#10# (cloning and DNA sequence determination and analysis) <20>
CL	#10# (Agrobacterium-mediated transformation of alfalfa) <38>
CL	#11# (cloning and DNA sequence determination and analysis) <20>
CL	#11# (expression of the mutant enzyme D144N in insect cells) <25>
CL	#11# (expression of YFP or CFP fusion enzyme of Arabidopsis and human
	N-acetylglucosaminyltransferase I, and the chimeric enzyme of
	Arabidopsis CTS region and human catalytic domain in mutant cgl1-1
	Arabidopsis (lacking N-acetylglucosaminyltransferase I), transformed by
	Agrobacterium tumefaciens) <42>
CL	#11# (PCR-amplification of CTS region (N-terminal cytoplasmic tail,
	transmembrane domain, stem region), fusion to GFP (green fluorescent
	protein), expression of vector in Nicotiana benthamiana mediated by
	Agrobacterium tumefaciens strain UIA143) <41>
CL	#12# (functional expression of isozymes A and B in Spodoptera
	frugiperda Sf21 cells as glutathione-S-transferase fusion proteins via
	baculovirus infection, isozyme B is folded less efficiently) <23>
CL	#12# (cloning of isozymes A and B, 2 separate genes, DNA sequence
	determination and analysis) <23>
CL	#18# (expressed in Chinese hamster ovary Lec1 mutant cells defective in
	endogeneous N-acetylglucosaminyltransferase I) <45>
CL	#19# (gene gene TbGT11, DNA and amino acid sequence determination and
	analysis, gene TbGT11 encodes a Golgi apparatus resident
	UDP-GlcNAc:alpha3-D-mannoside beta1-2-N-acetylglucosaminyltransferaseI
	activity (TbGnTI).overexpression of full-length TbGT11 with a
	C-terminal HA3 epitope tag from a plasmid based on the trypanosome
	expression vector pLEW82) <49>
CL	#21# (transient expression of chimeric enzyme domain mutants in
	Nicotiana benthamiana) <50>
CL	#24# (the enzyme fused to maltose-binding protein is expressed in
	Escherichia coli Rosetta-gami B(DE3) cells) <46>
CL	#25# (recombinant tet-inducible expression of Flag-tagged GlcNAcT-I in
	HeLa and HEK293 cells) <48>
CL	#296# (cloning and DNA sequence determination and analysis) <20>

CRYSTALLIZATION
CR	#9# (catalytic enzyme fragment in presence and absence of
	UDP-N-acetyl-D-glucosamine and Mn2+, hanging drop vapour diffusion
	method, protein 10 mg/ml + 10 mM MES, pH 5.5, + 270 mM KCl + 2 mM
	MnCl2, 10 mM UDP-N-acetyl-D-glucosamine, well-solution: 100 mM
	Tris-HCl, pH 7.9, 15-20% polyethylene glycol , X-ray structure
	determination and analysis) <18>

PURIFICATION
PU	#5# (large scale, recombinant maltose-binding fusion protein) <21>
PU	#5# (one Ni2+-NTA chromatography step is sufficient for oligosaccharide
	synthesis) <40>
PU	#6# <2,15>
PU	#6# (partial) <6>
PU	#6# (recombinant N-terminally His-tagged protein from Escherichia coli)
	<14>
PU	#6# (two forms: transferase A and B, the latter only in hepatoma) <6>
PU	#7# (affinity chromatography) <4>
PU	#7# (liver) <7>
PU	#8# (partial) <5>
PU	#9# <3,12>
PU	#9# (recombinant catalytic fragment from Sf9 insect cells) <18>
PU	#9# (two molecular weight forms separable by gel filtration,
	purification of low-molecular weight form) <10>
PU	#11# (mutant enzyme D144N) <25>
PU	#11# (antibody purification from homogenized transfected Nicotiniana
	benthamiana leaves, resuspended in extraction buffer (PBS, pH 7.2, 1%
	Triton-X-100, protease inhibitor cocktail), centrifugation, supernatant
	incubated with rProtein A-Sepharose, elution by boiling Laemmli sample
	buffer, protein gel blot analysis with specific antibodies) <41>
PU	#12# (recombinant glutathione S-transferase fusion isozymes and mutants
	from insect Sf21 cells) <23>
PU	#24# (amylose resin column chromatography, gel filtration) <46>

GENERAL_STABILITY
GS	#7# (freeze-thawing, solubilized enzyme, unstable to) <4>
GS	#7# (Triton X-100, 0.1%, and albumin, 0.01%, stabilize solubilized
	enzyme) <4>
GS	#7,9# (repeated freeze-thawing, stable to) <3,7>

PH_STABILITY
PHS	#24# 5-10 (#24# the enzymatic activity is maintained after a 90-min
	incubation at pH values 6.0-9.5, but it is mostly abolished at pH
	values 5.0 and 10.0 <46>) <46>

STORAGE_STABILITY
SS	#7# (-20°C, at least 6 months) <7>
SS	#7# (3°C, at least a month) <4>
SS	#8# (4°C, in dilute solution, t1/2: 1 day) <5>
SS	#8# (4°C, in the presence of albumin, at least a month) <5>
SS	#9# (-20°C, 20% glycerol v/v, up to a year) <3>
SS	#9# (4°C, in 20% glycerol, 0.1% Triton X-100, 25 mM MES-buffer, pH
	6.5, 10 mM MnCl2, 1 mM PMSF, 0.1 mM 6-aminocaproic acid and 0.02% NaN3,
	several months) <12>

TEMPERATURE_STABILITY
TS	#24# 25-45 (#24# the activity is stable after a 2 h incubation at a
	temperature lower than 25°C, but it significantly decreases after
	incubation at 35°C and is completely abolished at temperatures higher
	than 45°C <46>) <46>

REFERENCE
RF	<1> Tezuka, K.; Hayashi, M.; Ishihara, H.; Akazawa, T.; Takahashi, N.:
	Studies on synthetic pathway of xylose-containing N-linked
	oligosaccharides deduced from substrate specificities of the processing
	enzymes in sycamore cells (Acer pseudoplatanus L.). Eur. J. Biochem.
	(1992) 203, 401-413. {Pubmed:1531192}
RF	<2> Möller, G.; Reck, F.; Paulsen, H.; Kaur, K.J.; Sarkar, M.;
	Schachter, H.; Brockhausen, I.: Control of glycoprotein synthesis:
	substrate specificity of rat liver UDP-GlcNAc:
	Man-alpha-3R-beta-2-N-acetylglucosaminyltransferase I using synthetic
	substrate analogs. Glycoconj. J. (1992) 9, 180-190. {Pubmed:1422138}
RF	<3> Oppenheimer, C.L.; Hill, R.L.: Purification and characterization of
	a rabbit liver alpha 1-3 mannoside beta 1-2
	N-acetylglucosaminyltransferase. J. Biol. Chem. (1981) 256, 799-804.
	{Pubmed:6450208}
RF	<4> Mendicino, J.; Chandrasekaran, E.V.; Rao Anumula, K.; Davila, M.:
	Isolation and properties of alpha-D-mannose:
	beta-1,2-N-acetylglucosaminyltransferase from trachea mucosa.
	Biochemistry (1981) 20, 967-976. {Pubmed:6452163}
RF	<5> Harpaz, N.; Schachter, H.: Control of glycoprotein synthesis.
	Bovine colostrum UDP-N-acetylglucosamine:alpha-D-mannoside beta
	2-N-acetylglucosaminyltransferase I. Separation from
	UDP-N-acetylglucosamine:alpha-D-mannoside beta
	2-N-acetylglucosaminyltransferase II, partial purification, and
	substrate specificity. J. Biol. Chem. (1980) 255, 4885-4893.
	{Pubmed:6445358}
RF	<6> Miyagi, T.; Tsuiki, S.: Studies on UDP-N-acetylglucosamine:
	alpha-mannoside beta-N-acetylglucosaminyltransferase of rat liver and
	hepatomas. Biochim. Biophys. Acta (1981) 661, 148-157. {Pubmed:6170335}
RF	<7> Oppenheimer, C.L.; Eckhardt, A.E.; Hill, R.L.: The nonidentity of
	porcine N-acetylglucosaminyltransferases I and II. J. Biol. Chem.
	(1981) 256, 11477-11482. {Pubmed:6457827}
RF	<8> Shao, M.C.; Wold, F.: The effect of the protein matrix on glycan
	processing in glycoproteins. Kinetic analysis of three rat liver Golgi
	enzymes. J. Biol. Chem. (1988) 263, 5771-5774. {Pubmed:2965705}
RF	<9> Moscarello, M.A.; Mitranic, M.M.; Vella, G.: Stimulation of bovine
	milk galactosyltransferase activity by bovine colostrum
	N-acetylglucosaminyltransferase I. Biochim. Biophys. Acta (1985) 831,
	192-200. {Pubmed:2931118}
RF	<10> Nishikawa, Y.; Pegg, W.; Paulsen, H.; Schachter, H.: Control of
	glycoprotein synthesis. Purification and characterization of rabbit
	liver UDP-N-acetylglucosamine:alpha-3-D-mannoside
	beta-1,2-N-acetylglucosaminyltransferase I. J. Biol. Chem. (1988) 263,
	8270-8281. {Pubmed:2967294}
RF	<11> Tang, B.L.; Wong, S.H.; Low, S.H.; Hong, W.: The transmembrane
	domain of N-glucosaminyltransferase I contains a Golgi retention
	signal. J. Biol. Chem. (1992) 267, 10122-10126. {Pubmed:1533634}
RF	<12> Schachter, H.; Brockhausen, I.; Hull, E.: High-performance liquid
	chromatography assays for N-acetylglucosaminyltransferases involved in
	N- and O-glycan synthesis. Methods Enzymol. (1989) 179, 351-397.
	{Pubmed:2560125} (review)
RF	<13> Fritz, T.A.; Gabb, M.M.; Wei, G.; Esko, J.D.: Two
	N-acetylglucosaminyltransferases catalyze the biosynthesis of heparan
	sulfate. J. Biol. Chem. (1994) 269, 28809-28814. {Pubmed:7961837}
RF	<14> Nishiu, J.; Kioka, N.; Fukada, T.; Sakai, H.; Komano, T.:
	Characterization of rat N-acetylglucosaminyltransferase I expressed in
	Escherichia coli. Biosci. Biotechnol. Biochem. (1995) 59, 1750-1752.
	{Pubmed:8520118}
RF	<15> Reck, F.; Springer, M.; Meinjohanns, E.; Paulsen, H.; Brockhausen,
	I.; Schachter, H.: Synthetic substrate analogs for UDP-GlcNAc:
	manalpha1-3R beta1-2-N-acetylglucosaminyltransferase I. Substrate
	specificity and inhibitors for the enzyme. Glycoconj. J. (1995) 12,
	747-754. {Pubmed:8748150}
RF	<16> Wagner, R.; Liedtke, S.; Kretzschmar, E.; Geyer, H.G.; Geyer, R.;
	Klenk, H.D.: Elongation of the N-glycans of fowl plague virus
	hemagglutinin expressed in Spodoptera frugiperda (Sf9) cells by
	coexpression of human beta1,2-N-acetylglucosaminyltransferase I.
	Glycobiology (1996) 6, 165-175. {Pubmed:8727789}
RF	<17> Yoshida, S.; Suzuki, M.; Yamano, S.; Takeuchi, M.; Ikenaga, H.;
	Kioka, N.; Sakai, H.; Komano, T.: Expression and characterization of
	rat UDP-N-acetylglucosamine: alpha-3-D-mannoside
	beta-1,2-N-acetylglucosaminyltransferase I in Saccharomyces cerevisiae.
	Glycobiology (1999) 9, 53-58. {Pubmed:9884406}
RF	<18> Unligil, U.M.; Zhou, S.; Yuwaraj, S.; Sarkar, M.; Schachter, H.;
	Rini, J.M.: X-ray crystal structure of rabbit
	N-acetylglucosaminyltransferase I: catalytic mechanism and a new
	protein superfamily. EMBO J. (2000) 19, 5269-5280. {Pubmed:11032794}
RF	<19> Opat, A.S.; Houghton, F.; Gleeson, P.A.: Medial Golgi but not late
	Golgi glycosyltransferases exist as high molecular weight complexes.
	Role of luminal domain in complex formation and localization. J. Biol.
	Chem. (2000) 275, 11836-11845. {Pubmed:10766809}
RF	<20> Wenderoth, I.; Von Schaewen, A.: Isolation and characterization of
	plant N-acetyl glucosaminyltransferase I (GntI) cDNA sequences.
	Functional analyses in the Arabidopsis cgl mutant and in antisense
	plants. Plant Physiol. (2000) 123, 1097-1108. {Pubmed:10889259}
RF	<21> Fujiyama, K.; Ido, Y.; Misaki, R.; Moran, D.G.; Yanagihara, I.;
	Honda, T.; Nishimura, S.I.; Yoshida, T.; Seki, T.: Human
	N-acetylglucosaminyltransferase I. Expression in Escherichia coli as a
	soluble enzyme, and application as an immobilized enzyme for the
	chemoenzymatic synthesis of N-linked oligosaccharides. J. Biosci.
	Bioeng. (2001) 92, 569-574. {Pubmed:16233148}
RF	<22> Chen, W.; Unligil, U.M.; Rini, J.M.; Stanley, P.: Independent
	Lec1A CHO glycosylation mutants arise from point mutations in
	N-acetylglucosaminyltransferase I that reduce affinity for both
	substrates. Molecular consequences based on the crystal structure of
	GlcNAc-TI. Biochemistry (2001) 40, 8765-8772. {Pubmed:11467936}
RF	<23> Mucha, J.; Svoboda, B.; Frohwein, U.; Strasser, R.; Mischinger,
	M.; Schwihla, H.; Altmann, F.; Hane, W.; Schachter, H.; Glossl, J.;
	Mach, L.: Tissues of the clawed frog Xenopus laevis contain two closely
	related forms of UDP-GlcNAc:alpha3-D-mannoside
	beta-1,2-N-acetylglucosaminyltransferase I. Glycobiology (2001) 11,
	769-778. {Pubmed:11555621}
RF	<24> Zhang, W.; Cao, P.; Chen, S.; Spence, A.M.; Zhu, S.; Staudacher,
	E.; Schachter, H.: Synthesis of paucimannose N-glycans by
	Caenorhabditis elegans requires prior actions of
	UDP-N-acetyl-D-glucosamine:alpha-3-D-mannoside
	beta1,2-N-acetylglucosaminyltransferase I, alpha3,6-mannosidase II and
	a specific membrane-bound beta-N-acetylglucosaminidase. Biochem. J.
	(2003) 372, 53-64. {Pubmed:12603202} (c)
RF	<25> Strasser, R.; Stadlmann, J.; Svoboda, B.; Altmann, F.; Glossl, J.;
	Mach, L.: Molecular basis of N-acetylglucosaminyltransferase I
	deficiency in Arabidopsis thaliana plants lacking complex N-glycans.
	Biochem. J. (2005) 387, 385-391. {Pubmed:15537386} (c)
RF	<26> Nozaki, H.; Matsuzawa, T.; Nakamura, T.; Arai, I.; Urashima, T.:
	Are there two forms of beta 2-N-acetylglucosaminyltransferase I in rat
	testicular and epididymal fluids?. Biochim. Biophys. Acta (2003) 1649,
	140-145. {Pubmed:12878032}
RF	<27> Tvaroska, I.; Andre, I.; Carver, J.P.: Catalytic mechanism of the
	inverting N-acetylglucosaminyltransferase I: DFT quantum mechanical
	model of the reaction pathway and determination of the transition state
	structure. Glycobiology (2003) 13, 559-566. {Pubmed:12672701} (c)
RF	<28> Strasser, R.; Altmann, F.; Glossl, J.; Steinkellner, H.: Unaltered
	complex N-glycan profiles in Nicotiana benthamiana despite drastic
	reduction of beta1,2-N-acetylglucosaminyltransferase I activity.
	Glycoconj. J. (2004) 21, 275-282. {Pubmed:15486460} (c)
RF	<29> Nozaki, H.; Miyamoto, A.; Hayashi, K.G.; Matsui, M.; Yoshida, T.;
	Nakamura, T.; Arai, I.; Urashima, T.: N-Acetylglucosaminyltransferase I
	activity in bovine ovarian follicular fluids from dominant and atretic
	follicles. J. Appl. Glycosci. (2004) 51, 315-320. {Pubmed:} (c)
RF	<30> Nozaki, H.; Wijayagunawardane, M.P.; Kodituwakku, S.P.; Yoshida,
	T.; Nakamura, T.; Arai, I.; Urashima, T.; Miyamoto, A.:
	N-acetylglucosaminyltransferase I activity of bovine oviduct epithelial
	cells: stimulation by luteinizing hormone, vascular endothelial growth
	factor and tumor necrosis factor alpha. J. Reprod. Dev. (2005) 51,
	229-234. {Pubmed:15699581} (c)
RF	<31> Schachter, H.; Reck, F.; Paulsen, H.: Use of synthetic
	oligosaccharide substrate analogs to map the active sites of
	N-acetylglucosaminyltransferases I and II. Methods Enzymol. (2003) 363,
	459-475. {Pubmed:14579596} (c)
RF	<32> Matsunami, K.; Miyagawa, S.; Nakagawa, K.; Otsuka, H.; Hideaki,
	O.; Shirakura, R.: Molecular cloning of pigGnT-I and I.2: an
	application to xenotransplantation. Biochem. Biophys. Res. Commun.
	(2006) 343, 677-683. {Pubmed:16563346}
RF	<33> Kasajima, Y.; Yamaguchi, M.; Hirai, N.; Ohmachi, T.; Yoshida, T.:
	In vivo expression of UDP-N-acetylglucosamine: alpha-3-D-Mannoside
	beta-1,2-N-acetylglucosaminyltransferase I (GnT-1) in Aspergillus
	oryzae and effects on the sugar chain of alpha-amylase. Biosci.
	Biotechnol. Biochem. (2006) 70, 2662-2668. {Pubmed:17090929}
RF	<34> Kozmon, S.; Tvaroska, I.: Catalytic mechanism of
	glycosyltransferases: hybrid quantum mechanical/molecular mechanical
	study of the inverting N-acetylglucosaminyltransferase I. J. Am. Chem.
	Soc. (2006) 128, 16921-16927. {Pubmed:17177443}
RF	<35> Kainz, E.; Gallmetzer, A.; Hatzl, C.; Nett, J.H.; Li, H.; Schinko,
	T.; Pachlinger, R.; Berger, H.; Reyes-Dominguez, Y.; Bernreiter, A.;
	Gerngross, T.; Wildt, S.; Strauss, J.: N-glycan modification in
	Aspergillus species. Appl. Environ. Microbiol. (2008) 74, 1076-1086.
	{Pubmed:18083888}
RF	<36> Saribas, A.S.; Johnson, K.; Liu, L.; Bezila, D.; Hakes, D.:
	Refolding of human beta-1-2 GlcNAc transferase (GnT1) and the role of
	its unpaired Cys121. Biochem. Biophys. Res. Commun. (2007) 362,
	381-386. {Pubmed:17716624}
RF	<37> Kang, J.S.; Frank, J.; Kang, C.H.; Kajiura, H.; Vikram, M.; Ueda,
	A.; Kim, S.; Bahk, J.D.; Triplett, B.; Fujiyama, K.; Lee, S.Y.; von
	Schaewen, A.; Koiwa, H.: Salt tolerance of Arabidopsis thaliana
	requires maturation of N-glycosylated proteins in the Golgi apparatus.
	Proc. Natl. Acad. Sci. USA (2008) 105, 5933-5938. {Pubmed:18408158}
RF	<38> Sourrouille, C.; Marquet-Blouin, E.; DAoust, M.A.; Kiefer-Meyer,
	M.C.; Seveno, M.; Pagny-Salehabadi, S.; Bardor, M.; Durambur, G.;
	Lerouge, P.; Vezina, L.; Gomord, V.: Down-regulated expression of
	plant-specific glycoepitopes in alfalfa. Plant Biotechnol. J. (2008) 6,
	702-721. {Pubmed:18498310}
RF	<39> Chen, H.L.; Li, C.F.; Grigorian, A.; Tian, W.; Demetriou, M.: T
	cell receptor signaling co-regulates multiple Golgi genes to enhance
	N-glycan branching. J. Biol. Chem. (2009) 284, 32454-32461.
	{Pubmed:19706602}
RF	<40> Chen, R.; Pawlicki, M.; Hamilton, B.; Tolbert, T.:
	Enzyme-catalyzed synthesis of a hybrid N-linked oligosaccharide using
	N-acetylglucosaminyltransferase I. Adv. Synth. Catal. (2008) 350,
	1689-1695. {Pubmed:}
RF	<41> Schoberer, J.; Vavra, U.; Stadlmann, J.; Hawes, C.; Mach, L.;
	Steinkellner, H.; Strasser, R.: Arginine/lysine residues in the
	cytoplasmic tail promote ER export of plant glycosylation enzymes.
	Traffic (2009) 10, 101-115. {Pubmed:18939950}
RF	<42> Henquet, M.; Heinhuis, B.; Borst, J.; Eigenhuijsen, J.; Schreuder,
	M.; Bosch, D.; van der Krol, A.: Differential effects of human and
	plant N-acetylglucosaminyltransferase I (GnTI) in plants. Transgenic
	Res. (2009) 19, 535-547. {Pubmed:19826906}
RF	<43> Zhong, X.; Cooley, C.; Seth, N.; Juo, Z.S.; Presman, E.; Resendes,
	N.; Kumar, R.; Allen, M.; Mosyak, L.; Stahl, M.; Somers, W.; Kriz, R.:
	Engineering novel Lec1 glycosylation mutants in CHO-DUKX cells:
	molecular insights and effector modulation of
	N-acetylglucosaminyltransferase I. Biotechnol. Bioeng. (2012) 109,
	1723-1734. {Pubmed:22252477}
RF	<44> Schachter, H.; Boulianne, G.: Life is sweet! A novel role for
	N-glycans in Drosophila lifespan. Fly (2011) 5, 18-24. {Pubmed:21057214}
RF	<45> Baiet, B.; Burel, C.; Saint-Jean, B.; Louvet, R.; Menu-Bouaouiche,
	L.; Kiefer-Meyer, M.C.; Mathieu-Rivet, E.; Lefebvre, T.; Castel, H.;
	Carlier, A.; Cadoret, J.P.; Lerouge, P.; Bardor, M.: N-glycans of
	Phaeodactylum tricornutum diatom and functional characterization of its
	N-acetylglucosaminyltransferase I enzyme. J. Biol. Chem. (2011) 286,
	6152-6164. {Pubmed:21169367}
RF	<46> Dohi, K.; Isoyama-Tanaka, J.; Tokuda, T.; Fujiyama, K.:
	Recombinant expression and characterization of
	N-acetylglucosaminyltransferase I derived from Nicotiana tabacum. J.
	Biosci. Bioeng. (2010) 109, 388-391. {Pubmed:20226382}
RF	<47> Schachter, H.: Mgat1-dependent N-glycans are essential for the
	normal development of both vertebrate and invertebrate metazoans.
	Semin. Cell Dev. Biol. (2010) 21, 609-615. {Pubmed:20206280}
RF	<48> Abdel Rahman, A.; Ryczko, M.; Nakano, M.; Pawling, J.; Rodrigues,
	T.; Johswich, A.; Taniguchi, N.; Dennis, J.: Golgi N-glycan branching
	N-acetylglucosaminyltransferases I, V and VI promote nutrient uptake
	and metabolism. Glycobiology (2015) 25, 225-240. {Pubmed:25395405}
RF	<49> Damerow, M.; Rodrigues, J.A.; Wu, D.; Guether, M.L.; Mehlert, A.;
	Ferguson, M.A.: Identification and functional characterization of a
	highly divergent N-acetylglucosaminyltransferase I (TbGnTI) in
	Trypanosoma brucei. J. Biol. Chem. (2014) 289, 9328-9339.
	{Pubmed:24550396}
RF	<50> Schoberer, J.; Liebminger, E.; Vavra, U.; Veit, C.; Castilho, A.;
	Dicker, M.; Maresch, D.; Altmann, F.; Hawes, C.; Botchway, S.;
	Strasser, R.: The transmembrane domain of
	N-acetylglucosaminyltransferase I is the key determinant for its Golgi
	subcompartmentation. Plant J. (2014) 80, 809-822. {Pubmed:25230686}

ACTIVATING_COMPOUND
AC	#2# CHAPS (#2# slight activation <13>) <13>
AC	#2# Zwittergent 3-12 (#2# slight activation <13>) <13>
AC	#2,6,9,14# Triton X-100 (#2,9,14# slight activation <12,13>)
	<6,10,12,13>
AC	#9# more (#9# no activation by 2-mercaptoethanol <10,12>) <10,12>

KI_VALUE
KI	#6# -999 {more}  (#6# several inhibitory synthetic acceptor substrate
	analogues, overview <15>) <15>
KI	#6# 2.6 {Manalpha6(6-O-(4,5-epoxypentyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 1.1 {Manalpha6(6-O-(4,4-azopentyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 0.8 {Manalpha6(6-O-methyl-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 13
	{[Manalpha6(Manalpha3)][4-O-methyl-Man]-beta4-N-acetyl-D-glucosamine} 
	<31>
KI	#6# 10.2 {Manalpha6(6-O-(5-pentanolyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 8.8 {Manalpha6(6-O-(4-oxopentyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#9# 1.8
	{alpha-D-mannosyl-1,6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R}  <10>
KI	#9# 0.034 {UDP-N-acetylglucosamine}  <10>

KI_VALUE
KI	#6# -999 {more}  (#6# several inhibitory synthetic acceptor substrate
	analogues, overview <15>) <15>
KI	#6# 2.6 {Manalpha6(6-O-(4,5-epoxypentyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 1.1 {Manalpha6(6-O-(4,4-azopentyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 0.8 {Manalpha6(6-O-methyl-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 13
	{[Manalpha6(Manalpha3)][4-O-methyl-Man]-beta4-N-acetyl-D-glucosamine} 
	<31>
KI	#6# 10.2 {Manalpha6(6-O-(5-pentanolyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#6# 8.8 {Manalpha6(6-O-(4-oxopentyl)-Manalpha3)Man-beta-octyl}  <31>
KI	#9# 1.8
	{alpha-D-mannosyl-1,6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R}  <10>
KI	#9# 0.034 {UDP-N-acetylglucosamine}  <10>

EXPRESSION
EXP	#5# down (#5# limited enzyme expression after anti-CD3 stimulation
	<39>) <39>
EXP	#5,11# more (#11# human fusion enzyme expression is about 5fold higher
	in Arabidopsis cgl1-1 mutant than Arabidopsis and chimeric enzyme
	expression but lower catalytic activity in the plant and partly
	distinct sub-cellular localization <42>; #5# human fusion enzyme
	expression is about 5fold higher in Arabidopsis than Arabidopsis enzyme
	and chimeric enzyme expression but catalytic activity in the plant is
	lower and shows partly distinct sub-cellular localization <42>) <42>

///
ID	2.4.1.143
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Gallus gallus   (#1# catalytic subunit ilvG <5>) <5>
PR	#2# Vigna radiata var. radiata   (#2# fragment CYP153A8 <11>) <11>
PR	#3# Drosophila melanogaster   <22,30>
PR	#4# Mus musculus   <17,32>
PR	#5# Homo sapiens   <13,14,15,16,23,24,26,28,31,33,34>
PR	#6# Rattus norvegicus   <4,8,9,14,20,21>
PR	#7# Sus scrofa   <3,19>
PR	#8# Bos taurus   <2,10>
PR	#9# Bombyx mori   <7>
PR	#10# Oryctolagus cuniculus   <18>
PR	#11# Arabidopsis thaliana   <12>
PR	#12# Caenorhabditis elegans   <29>
PR	#13# Mesocricetus auratus   <5>
PR	#14# Acer pseudoplatanus   <1>
PR	#15# Oncorhynchus mykiss   <6>
PR	#16# Spodoptera frugiperda   <7,35>
PR	#17# Mamestra brassicae   <7>
PR	#18# Xenopus laevis Q7ZZX7 SwissProt <27>
PR	#19# Rattus norvegicus Q09326 SwissProt <25>

RECOMMENDED_NAME
RN	alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase


SYSTEMATIC_NAME
SN	UDP-N-acetyl-alpha-D-glucosamine:alpha-D-mannosyl-(1->6)-beta-D
	mannosyl-glycoprotein 2-beta-N-acetyl-D-glucosaminyltransferase
	(configuration-inverting)


SYNONYMS
SY	 N-glycosyl-oligosaccharide-glycoprotein
	N-acetylglucosaminyltransferase II
SY	 acetylglucosaminyltransferase II
SY	 uridine diphosphoacetylglucosamine-mannoside
	alpha1->6-acetylglucosaminyltransferase
SY	 uridine diphosphoacetylglucosamine-alpha-1,6-mannosylglycoprotein
	beta-1-2-N-acetylglucosaminyltransferase
SY	 uridine diphosphoacetylglucosamine-alpha-D-mannoside
	beta1-2-acetylglucosaminyltransferase
SY	 UDP-GlcNAc:mannoside alpha1-6 acetylglucosaminyltransferase
SY	 alpha-1,6-mannosylglycoprotein beta-1-2-N-acetylglucosaminyltransferase
SY	 alpha-1,6-mannosyl-glycoprotein
	beta-1,2-N-acetylglucosaminyltransferase
SY	#12,16# GnT-II <29,35>
SY	#18# UDP-GlcNAc:alpha6-D-mannoside
	beta1,2-N-acetylglucosaminyltransferase II <27>
SY	#18# Gnt II-A <27>
SY	#18# Gnt II-B <27>
SY	#3# N-acetylglucosaminyltransferase-II <30>
SY	#3# TTV/DEXT1 <30>
SY	#3,4,5# Mgat2 <22,32,34>
SY	#3,4,5,16# N-acetylglucosaminyltransferase II <22,23,31,32,33,34,35>
SY	#3,5# GlcNAcT-II <24,30>
SY	#5# N-acetylglucosaminyltransferases II <26>
SY	#5# GlcNAc-T II <26>
SY	#5# GlcNAcTase-II <23>
SY	#5,19# GnT II <25,33>

REACTION
RE	UDP-N-acetyl-alpha-D-glucosamine +
	beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man
	(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc-N-Asn-[protein] = UDP +
	beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D
	Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc-N-Asn
	[protein]

REACTION_TYPE
RT	hexosyl group transfer

SOURCE_TISSUE
ST	#1# oviduct <5>
ST	#13,15,18# ovary <5,6,27>
ST	#13,18# kidney (#13# baby hamster <5>) <5,27>
ST	#14# cell suspension culture <1>
ST	#18# heart <27>
ST	#18# spleen <27>
ST	#18# lung <27>
ST	#18# muscle <27>
ST	#2# seedling <11>
ST	#3# embryo (#3# gene is expressed in the early stages of development
	mainly in the nervous system <22>) <22>
ST	#3,7# brain (#3# gene is expressed mainly but not exclusively in <22>)
	<19,22>
ST	#5# HEL cell <23>
ST	#5# Hep-G2 cell <23>
ST	#5# JURKAT cell <34>
ST	#5# HL-60 cell <23>
ST	#5# KU-812 cell <23>
ST	#5# HMCB cell <23>
ST	#5# PBMC cell line <34>
ST	#5# HeLa-S3 cell <23>
ST	#5# T-24 cell <23>
ST	#5# THP-1 cell <23>
ST	#5# A-549 cell <23>
ST	#5# BeWo cell <23>
ST	#5# MOLT-4 cell <23>
ST	#5# BALL-1 cell <23>
ST	#5# CACO-2 cell <23>
ST	#5# YMB-1 cell <23>
ST	#5# HuO-3N1 cell <23>
ST	#5# EoL-1 cell <23>
ST	#5# OS-RC-2 cell <23>
ST	#5# NAMALWA cell <23>
ST	#5,18# skin (#5# reduction of N-acetylglucosaminyltransferase II in
	hyperkeratotic skin of ichthyosis patients <31>) <27,31>
ST	#6,7,18# liver <3,4,8,9,19,20,21,27>
ST	#7# tracheal mucosa <3>
ST	#8# colostrum <2,10>

LOCALIZATION
LO	#1,2,6,13,18# membrane (#18# enzyme exhibits a type II transmembrane
	protein topology with a putative N-terminal cytoplasmic tail of 9 amino
	acids followed by transmembrane domain of 18 residues, and a C-terminal
	luminal domain of 405 residues <27>) <4,5,9,11,27>
LO	#2,7# microsome <3,11>
LO	#5,6,11,14,16# Golgi apparatus (#11# type II transmembrane topology
	<12>) <1,4,12,13,15,16,21,35>

NATURAL_SUBSTRATE_PRODUCT
NSP	#18# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl
	1,2-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-R (#18# the enzyme catalyzes an
	essential step in the biosynthetic pathway leading from high mannose to
	complex N-linked oligosaccharides <27>) <27>
NSP	#3# more = ? (#3# the gene is alternatively spliced and
	developmmentally regulated <22>; #3# the enzyme is required for the
	chain initiation and elongation of the heparan sulfate backbone <30>)
	{} <22,30>
NSP	#6# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetylglucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetylglucosaminyl-R (#6# essential for
	biosynthesis of complex N-linked oligosaccharides <9>) <9>

SUBSTRATE_PRODUCT
SP	#1,2,4,5,6,7,8,9,10,11,13,14,15,16,17# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-1,4-N-acetylglucosaminyl-R =
	UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetylglucosaminyl-R (#6# R represents the
	remainder of the N-oligosaccharide core (n fucose), R: H or
	1,4-(+/-)-fucose-1,6-N-acetylglucosaminyl-1-N-asparagine <9>; #2# best
	acceptor, high specificity <11>; #14# or
	1,4-(+/-)-fucose-1,6-N-acetylglucosamine-pyridinylamine (with or
	without xylose in 1,2-beta-linkage to the beta-mannosyl residue) <1>;
	#6# acceptors are free and protein-matrix-bound glycans <4>; #2#
	UDP-N-acetyl-D-glucosamine cannot be replaced by
	UDP-N-acetylgalactosamine, UDPgalactose, UDPxylose, UDPglucose or
	GDPfucose <11>; #2# no acceptor substrates: overview <11>)
	<1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21>
SP	#10# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-O-octyl <18>
SP	#10# UDP-N-acetyl-D-glucosamine +
	3-O-methyl-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-(3-O-methyl-alpha-D-mannosyl)-1
	6-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-O-octyl <18>
SP	#10# UDP-N-acetyl-D-glucosamine +
	6-O-methyl-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-(6-O-methyl-alpha-D-mannosyl)-1
	6-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-O-octyl <18>
SP	#16# UDP-N-acetyl-D-glucosamine +
	Manalpha(1->6)[GlcNAcbeta(1->2)-Manbeta(1->3)]Manbeta(1->4)GlcNAcbeta(1
	>4)GlcNAcbeta-2-pyridyl-aminoside = ? (#16# the enzyme can transfer a
	second N-acetylglucosamine residue to the product of the first
	transferase reaction but in an extremely slow reaction that is unlikely
	to be biologically relevant <35>) <35>
SP	#18# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl
	1,2-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-R (#18# the enzyme catalyzes an
	essential step in the biosynthetic pathway leading from high mannose to
	complex N-linked oligosaccharides <27>) <27>
SP	#3,16# more = ? (#3# the gene is alternatively spliced and
	developmmentally regulated <22>; #3# the enzyme is required for the
	chain initiation and elongation of the heparan sulfate backbone <30>;
	#16# the enzyme cannot use Man3GlcNAc2 and
	Manalpha(1->6)[Manbeta(1->3)]Manbeta(1->4)GlcNAcbeta(1->4)GlcNAcbeta-2
	pyridyl-aminoside as substrate <35>) {} <22,30,35>
SP	#4# UDP-N-acetyl-D-glucosamine + betaGlc-O(CH2)7CH3 = ? <32>
SP	#5# UDP-N-acetyl-D-glucosamine +
	3-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl = UDP
	+
	GlcNAcbeta(1-2)3-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta-octyl <28>
SP	#5# UDP-N-acetyl-D-glucosamine +
	3-O-methyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl =
	UDP +
	GlcNAcbeta(1-2)3-O-methyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta-octyl <28>
SP	#5# UDP-N-acetyl-D-glucosamine +
	4-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl = UDP
	+
	GlcNAcbeta(1-2)4-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta-octyl <28>
SP	#5# UDP-N-acetyl-D-glucosamine +
	4-O-methyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl =
	UDP +
	GlcNAcbeta(1-2)4-O-methyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta-octyl <28>
SP	#5# UDP-N-acetyl-D-glucosamine +
	6-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl = UDP
	+
	GlcNAcbeta(1-2)6-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta-octyl <28>
SP	#5# UDP-N-acetyl-D-glucosamine +
	6-O-methyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl =
	UDP +
	GlcNAcbeta(1-2)6-O-methyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta-octyl <28>
SP	#5# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-6)(GlcNAcbeta(1-2)-6-deoxy-Manalpha(1-3))Manbeta-octyl = UDP
	+
	GlcNAcbeta(1-2)Manalpha(1-6)(GlcNAcbeta(1-2)-6-deoxy-Manalpha(1
	3))Manbeta-octyl <28>
SP	#5# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-6)(GlcNAcbeta(1-2)4-O-methyl-Manalpha(1-3))Manbeta-octyl =
	UDP +
	GlcNAcbeta(1-2)Manalpha(1-6)(GlcNAcbeta(1-2)4-O-methyl-Manalpha(1
	3))Manbeta-octyl <28>
SP	#5# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))-4-deoxy-Manbeta-octyl = UDP
	+
	GlcNAcbeta(1-2)Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))-4-deoxy
	Manbeta-octyl <28>
SP	#5# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-2-aminopyridine = UDP +
	N-acetyl-beta-D-glucosaminyl
	1,2-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-2-aminopyridine <33>
SP	#5,18# UDP-N-acetyl-D-glucosamine +
	Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl = UDP +
	GlcNAcbeta(1-2)Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl
	<27,28>
SP	#6# UDP-N-acetyl-D-glucosamine + dideoxytetrasaccharide = UDP +
	dideoxypentasaccharide <8>
SP	#6# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetylglucosaminyl-R <20>
SP	#6# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-6-deoxy-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6-(N-acetyl-beta-D-glucosaminyl-1,2-6-deoxy-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-O-octyl <20>
SP	#6# UDP-N-acetyl-D-glucosamine +
	alpha-D-mannosyl-1,6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetylglucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetylglucosaminyl-R (#6# essential for
	biosynthesis of complex N-linked oligosaccharides <9>) <9>
SP	#6,10# UDP-N-acetyl-D-glucosamine +
	4-O-methyl-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-(4-O-methyl-alpha-D-mannosyl)-1
	6-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-O-octyl <18,20>

KM_VALUE
KM	#13# 0.19
	{alpha-D-mannosyl-1,6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetylglucosaminyl-R}  (#13# pH 6.5, 37°C
	<5>) <5>
KM	#13# 0.96 {UDP-N-acetylglucosamine}  (#13# pH 6.5, 37°C <5>) <5>
KM	#15# 0.23 {UDP-N-acetylglucosamine}  (#15# pH 6.5, 37°C <6>) <6>
KM	#2# 0.018 {UDP-N-acetylglucosamine}  (#2# pH 6.5 <11>) <11>
KM	#2# 0.0166
	{alpha-D-mannosyl-1,6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetylglucosaminyl-R}  (#2# pH 6.5 <11>) <11>
KM	#5# 0.16
	{Manalpha(1-6)(GlcNAcbeta(1-2)4-O-methyl-Manalpha(1-3))Manbeta-octyl} 
	<28>
KM	#5# 0.26
	{3-O-methyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl} 
	<28>
KM	#5# 0.26
	{4-O-methyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl} 
	<28>
KM	#5# 0.55
	{Manalpha(1-6)(GlcNAcbeta(1-2)-6-deoxy-Manalpha(1-3))Manbeta-octyl} 
	<28>
KM	#5# 0.2
	{6-O-methyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl} 
	<28>
KM	#5# 0.25
	{6-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl}  <28>
KM	#5# 0.22
	{4-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl}  <28>
KM	#5# 0.13 {Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl} 
	<28>
KM	#5# 3.7
	{3-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta-octyl}  <28>
KM	#5# 0.48
	{Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))-4-deoxy-Manbeta-octyl} 
	<28>
KM	#6# 0.16
	{4-O-methyl-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl}  (#6# 37°C <20>) <20>
KM	#6# 0.55
	{alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-6-deoxy-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl}  (#6# 37°C
	<20>) <20>
KM	#6# 0.13
	{alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl}  (#6# 37°C <20>) <20>
KM	#8# 0.1
	{alpha-D-mannosyl-1,6-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-1,4-N-acetylglucosaminyl-R}  (#8# 37°C <2>) <2>

PH_OPTIMUM
PHO	#15# 5-8 <6>
PHO	#16# 6.7 <35>
PHO	#2# 6.5-7 <11>
PHO	#7,13# 6-6.5 <3,5>

PH_RANGE
PHR	#16# 6.7-8.1 (#16# the enzyme has an optimum pH of 6.7, with a broad
	shoulder of high activity from pH 7.1 to 8.1 <35>) <35>

SPECIFIC_ACTIVITY
SA	#2# 9.3 <11>
SA	#5# 20.0 <13>
SA	#6# 7.8 (#6#
	alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl as substrate <20>) <20>
SA	#6# 21.4 (#6#
	5-deoxy-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl as substrate <20>) <20>
SA	#6# 11.2 (#6#
	4-O-methyl-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl as substrate <20>) <20>
SA	#6# 27.5 <9>

TEMPERATURE_OPTIMUM
TO	#1,6,7,8,13# 37 (#1,6,7,8,13# assay at <2,3,4,5,9>) <2,3,4,5,9>
TO	#6# 30 (#6# assay at <8>) <8>

ACTIVATING_COMPOUND
AC	#15# CHAPS <6>
AC	#15# Zwittergent 3-12 <6>
AC	#2,15# Triton X-100 (#2# activation, 0.1% <11>) <6,11>

INHIBITORS
IN	#10#
	O-(5-iodoacetamido)pentyl-alpha-D-mannosyl-1
	6-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-beta-D-mannosyl-O-octyl (#10# irreversible inhibition <18>) <18>
IN	#10#
	2-deoxy-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl (#10# reversible
	inhibition <18>) <18>
IN	#10#
	O-(5-amino)pentyl-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl (#10# reversible
	inhibition <18>) <18>
IN	#10#
	O-pentyl-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl (#10# reversible
	inhibition <18>) <18>
IN	#5# 2-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl
	<28>
IN	#5#
	3-O-pentyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl
	<28>
IN	#5#
	3-O-(5-aminopentyl)-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta
	octyl <28>
IN	#5#
	3-O-(4
	4-azopentyl)-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl
	<28>
IN	#5# GlcNAcbeta(1-2)Manalpha(1-3)Man-beta-octyl <28>
IN	#6#
	6-deoxy-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl <20>
IN	#6#
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-beta-D-mannosyl-octyl <20>
IN	#6# 5-Hg-UDP (#6# reversible <9>) <9>
IN	#6# 5-Hg-UDP-N-acetylglucosamine (#6# reversible <9>) <9>
IN	#6,10#
	O-(4,4-azo)pentyl-alpha-D-mannosyl-1,6-(N-acetyl-beta-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,3)-beta-D-mannosyl-O-octyl (#10# irreversible
	inhibition <18>) <18,20>
IN	#7,16# EDTA (#16# complete inhibition in the presence of EDTA <35>)
	<3,35>

KI_VALUE
KI	#5# 0.13
	{2-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl} 
	<28>
KI	#5# 1
	{3-O-(4
	4-azopentyl)-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl}
	 <28>
KI	#5# 0.9 {GlcNAcbeta(1-2)Manalpha(1-3)Man-beta-octyl}  <28>
KI	#5# 2.5
	{3-O-(5-aminopentyl)-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man
	beta-octyl}  <28>
KI	#5# 2.4
	{3-O-pentyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl} 
	<28>

METALS_IONS
ME	#2# Cd2+ (#2# activation, can replace Mn2+ to some extent, 0.5-1 mM
	<11>) <11>
ME	#2,13,15,16# Mn2+ (#2,13# requirement <5,11>; #16# required for
	activity <35>; #13# 10-15 mM <5>; #2# 2-3 mM <11>) <5,6,11,35>
ME	#2,15# more (#2# Ca2+, Co2+, Cu2+, Hg2+, Mg2+ or Zn2+ cannot replace
	Mn2+, at 1 or 2.5 mM each <11>; #15# Ca2+, Co2+, Cu2+ and Mg2+ cannot
	replace Mn2+ <6>) <6,11>

MOLECULAR_WEIGHT
MW	#5# 52000 (#5# SDS-PAGE <33>) <33>
MW	#5# 56000 (#5# gel filtration, fusion protein <13>) <13>
MW	#6# -999 (#6# rat enzyme in crude extract exists in 2 forms,
	high-molecular weight form: above MW 200000, low-molecular weight form:
	MW 43000-48000, gel filtration <9>) <9>
MW	#6# 43000 (#6# x * 43000, x * 48000, SDS-PAGE, one or both of these
	bands represent the enzyme <9>) <9>
MW	#6# 42000 (#6# x * 42000, SDS-PAGE <20,21>) <20,21>
MW	#6# 48000 (#6# x * 43000, x * 48000, SDS-PAGE, one or both of these
	bands represent the enzyme <9>) <9>
MW	#7# 51100 (#7# calculated from nucleotide sequence <19>) <19>

POSTTRANSLATIONAL_MODIFICATION
PM	#18# glycoprotein (#18# N-linked oligosaccharides <27>) <27>

SUBUNITS
SU	#6# ? (#6# x * 42000, SDS-PAGE <20,21>; #6# x * 43000, x * 48000,
	SDS-PAGE, one or both of these bands represent the enzyme <9>) <9,20,21>

APPLICATION
AP	#5# synthesis (#5# the baculoviris-host system constitutively
	expressing beta-1,4-galactosyltransferase and
	beta-1,2-N-acetylglucosaminyltransferase II can be used to produce a
	recombinant glycoprotein with fully galactosylated, biantennary
	N-glycans <24>) <24>

CLONED
CL	#5# <26>
CL	#5# (expression as fusion protein vHis-GlcNAc-TII in Spodoptera
	frugiperda Sf-9 cells) <13>
CL	#5# (a transformed insect cell line (Tn5beta4GalT) constitutively
	expresses a mammalian beta-1,4-galactosyltransferase and human
	beta-1,2-N-acetylglucosaminyltransferase II under the control of an
	immediate-early promoter. The baculovirus-host system can be used to
	produce a recombinant glycoprotein with fully galactosylated,
	biantennary N-glycans) <24>
CL	#5# (expressed in Spodoptera frugiperda and Trichoplusia ni cells by
	using a baculovirus expression vector) <33>
CL	#6# (transient expression in COS-7 cells, linked in frame to a cDNA
	segment encoding the cleavable signal sequence of the human IL-2
	receptor) <21>
CL	#7# (expression in Escherichia coli) <19>
CL	#11# (expression in Spodoptera frugiperda Sf-9 cells) <12>
CL	#18# (heterologous expression in insect cells) <27>
CL	#19# (construction of a Gnt II-expressing alg3 mutant strain of Pichia
	pastoris. Engineering of an artificial glycosylation pathway in Pichia
	pastoris blocked in dolichol oligosaccharide assembly) <25>

PURIFICATION
PU	#2# (solubilized with Triton X-100) <11>
PU	#5# <13>
PU	#5# (IgG Sepharose resin column chromatography) <33>
PU	#6# <21>
PU	#6# (solubilized with Triton X-100/NaCl, enzyme in crude extract exists
	in 2 molecular weight forms: purification of low-molecular weight form,
	affinity chromatography on
	Hg-UDP-N-acetylglucosamine-thiopropyl-Sepharose) <9>
PU	#18# <27>

GENERAL_STABILITY
GS	#13# (bovine serum albumin stabilizes during purification) <5>
GS	#6# (Triton X-100 stabilizes) <9>
GS	#7# (acetone precipitation, unstable to) <3>

STORAGE_STABILITY
SS	#2# (0°C, at least 1 week) <11>
SS	#2# (-20°C, several weeks in 20% glycerol, 0.0005 mM DTT and 0.1%
	Triton X-100) <11>
SS	#6# (4°C, at least 6 months in 20% glycerol, 10 mM EDTA and 0.1%
	Triton X-100) <9>

REFERENCE
RF	<1> Tezuka, K.; Hayashi, M.; Ishihara, H.; Akazawa, T.; Takahashi, N.:
	Studies on synthetic pathway of xylose-containing N-linked
	oligosaccharides deduced from substrate specificities of the processing
	enzymes in sycamore cells (Acer pseudoplatanus L.). Eur. J. Biochem.
	(1992) 203, 401-413. {Pubmed:1531192}
RF	<2> Harpaz, N.; Schachter, H.: Control of glycoprotein synthesis.
	Bovine colostrum UDP-N-acetylglucosamine:alpha-D-mannoside beta
	2-N-acetylglucosaminyltransferase I. Separation from
	UDP-N-acetylglucosamine:alpha-D-mannoside beta
	2-N-acetylglucosaminyltransferase II, partial purification, and
	substrate specificity. J. Biol. Chem. (1980) 255, 4885-4893.
	{Pubmed:6445358}
RF	<3> Oppenheimer, C.L.; Eckhardt, A.E.; Hill, R.L.: The nonidentity of
	porcine N-acetylglucosaminyltransferases I and II. J. Biol. Chem.
	(1981) 256, 11477-11482. {Pubmed:6457827}
RF	<4> Shao, M.C.; Wold, F.: The effect of the protein matrix on glycan
	processing in glycoproteins. Kinetic analysis of three rat liver Golgi
	enzymes. J. Biol. Chem. (1988) 263, 5771-5774. {Pubmed:2965705}
RF	<5> Schachter, H.; Brockhausen, I.; Hull, E.: High-performance liquid
	chromatography assays for N-acetylglucosaminyltransferases involved in
	N- and O-glycan synthesis. Methods Enzymol. (1989) 179, 351-397.
	{Pubmed:2560125} (review)
RF	<6> Fritz, T.A.; Gabb, M.M.; Wei, G.; Esko, J.D.: Two
	N-acetylglucosaminyltransferases catalyze the biosynthesis of heparan
	sulfate. J. Biol. Chem. (1994) 269, 28809-28814. {Pubmed:7961837}
RF	<7> Altmann, F.; Kornfeld, G.; Dalik, T.; Staudacher, E.; Glossl, J.:
	Processing of asparagine-linked oligosaccharides in insect cells.
	N-acetylglucosaminyltransferase I and II activities in cultured
	lepidopteran cells. Glycobiology (1993) 3, 619-625. {Pubmed:8130393}
RF	<8> Alton, G.; Srivastava, G.; Kaur, K.J.; Hindsgaul, O.: Use of
	N-acetylglucosaminyltransferases I and II in the synthesis of a
	dideoxypentasaccharide. Bioorg. Med. Chem. (1994) 2, 675-680.
	{Pubmed:7858975}
RF	<9> Bendiak, B.; Schachter, H.: Control of glycoprotein synthesis.
	Purification of UDP-N-acetylglucosamine:alpha-D-mannoside beta 1-2
	N-acetylglucosaminyltransferase II from rat liver. J. Biol. Chem.
	(1987) 262, 5775-5783. {Pubmed:2952644}
RF	<10> Rogers, G.N.; Paulsen, J.C.; Daniels, R.S.; Skehel, J.J.; Wilson,
	I.A.; Wiley, D.C.: Single amino acid substitutions in influenza
	haemagglutinin change receptor binding specificity. Nature (1983) 304,
	76-78. {Pubmed:6191220}
RF	<11> Szumilo, T.; Kaushal, G.P.; Elbein, A.D.: Purification and
	properties of the glycoprotein processing
	N-acetylglucosaminyltransferase II from plants. Biochemistry (1987) 26,
	5498-5505. {Pubmed:2960375}
RF	<12> Strasser, R.; Steinkellner, H.; Boren, M.; Altmann, F.; Mach, L.;
	GlÖssl, J.; Mucha, J.: Molecular cloning of cDNA encoding
	N-acetylglucosaminyltransferase II from Arabidopsis thaliana.
	Glycoconj. J. (2000) 16, 787-791. {Pubmed:11229321}
RF	<13> Tan, J.; D'Agostaro, G.A.F.; Bendiak, B.; Reck, F.; Sarkar, M.;
	Squire, J.A.; Leong, P.; Schachter, H.: The human
	UDP-N-acetylglucosamine:alpha-6-D-mannoside-beta-1
	2-N-acetylglucosaminyltransferase II gene (MGAT2). Cloning of genomic
	DNA, localization to chromosome 14q21, expression in insect cells and
	purification of the recombinant protein. Eur. J. Biochem. (1995) 231,
	317-328. {Pubmed:7635144}
RF	<14> Schachter, H.; Chen, S.H.; Zhou, S.; Tan, J.; Yip, B.; Sarkar, M.;
	Spence, A.: Structure and function of the genes encoding
	N-acetylglucosaminyltransferases which initiate N-glycan antennae.
	Biochem. Soc. Trans. (1997) 25, 875-880. {Pubmed:9388565}
RF	<15> Chen, S.H.; Zhou, S.; Tan, J.; Schachter, H.: Transcriptional
	regulation of the human UDP-GlcNAc: alpha-6lpha-D-mannoside
	beta-1-2-N-acetylglucosaminyltransferase II gene (MGAT2) which controls
	complex N-glycan synthesis. Glycoconj. J. (1998) 15, 301-308.
	{Pubmed:9579808}
RF	<16> Zhang, W.; Revers, L.; Pierce, M.; Schachter, H.: Regulation of
	expression of the human beta-1,2-N-acetylglucosaminyltransferase II
	gene (MGAT2) by Ets transcription factors. Biochem. J. (2000) 347,
	511-518. {Pubmed:10749681}
RF	<17> Wang, Y.; Schachter, H.; Marth, J.D.: Mice with a homozygous
	deletion of the Mgat2 gene encoding
	UDP-N-acetylglucosamine:alpha-6-D-mannoside
	beta1,2-N-acetylglucosaminyltransferase II: a model for congenital
	disorder of glycosylation type IIa. Biochim. Biophys. Acta (2002) 1573,
	301-311. {Pubmed:12417412}
RF	<18> Reck, F.; Springer, M.; Paulsen, H.; Brockhausen, I.; Sarkar, M.;
	Schachter, H.: Synthesis of tetrasaccharide analogs of the N-glycan
	substrate of beta-(1->2)-N-acetylglucosaminyltransferase II using
	trisaccharide precursors and recombinant
	beta-(1->2)-N-acetylglucosaminyltransferase I. Carbohydr. Res. (1994)
	259, 93-101. {Pubmed:8039192}
RF	<19> Leeb, T.; Kriegesmann, B.; Baumgartner, B.G.; Klett, C.; Yerle,
	M.; Hameister, H.; Brenig, B.: Molecular cloning of the porcine
	beta-1,2-N-acetylglucosaminyltransferase II gene and assignment to
	chromosome 1q23-q27. Biochim. Biophys. Acta (1997) 1336, 361-366.
	{Pubmed:9367162}
RF	<20> Reck, F.; Meinjohanns, E.; Springer, M.; Wilkens, R.; Van Dorst,
	J.A.; Paulsen, H.; Moller, G.; Brockhausen, I.; Schachter, H.:
	Synthetic substrate analogues for UDP-GlcNAc: Man alpha 1-6R
	beta(1-2)-N-acetylglucosaminyltransferase II. Substrate specificity and
	inhibitors for the enzyme. Glycoconj. J. (1994) 11, 210-216.
	{Pubmed:7841796}
RF	<21> D'Agostaro, G.A.F.; Zingoni, A.; Moritz, R.L.; Simpson, R.J.;
	Schachter, H.; Bendiak, B.: Molecular cloning and expression of cDNA
	encoding the rat UDP-N-acetylglucosamine:alpha-6-D-mannoside
	beta-1,2-N-acetylglucosaminyltransferase II. J. Biol. Chem. (1995) 270,
	15211-15221. {Pubmed:7797505}
RF	<22> Tsitilou, S.G.; Grammenoudi, S.: Evidence for alternative splicing
	and developmental regulation of the Drosophila melanogaster Mgat2
	(N-acetylglucosaminyltransferase II) gene. Biochem. Biophys. Res.
	Commun. (2003) 312, 1372-1376. {Pubmed:14652025} (c)
RF	<23> Takamatsu, S.; Inoue, N.; Katsumata, T.; Nakamura, K.;
	Fujibayashi, Y.; Takeuchi, M.: The relationship between the
	branch-forming glycosyltransferases and cell surface sugar chain
	structures. Biochemistry (2005) 44, 6343-6349. {Pubmed:15835923}
RF	<24> Tomiya, N.; Howe, D.; Aumiller, J.J.; Pathak, M.; Park, J.;
	Palter, K.B.; Jarvis, D.L.; Betenbaugh, M.J.; Lee, Y.C.: Complex-type
	biantennary N-glycans of recombinant human transferrin from
	Trichoplusia ni insect cells expressing mammalian
	beta-1,4-galactosyltransferase and
	beta-1,2-N-acetylglucosaminyltransferase II. Glycobiology (2003) 13,
	23-34. {Pubmed:12634321} (c)
RF	<25> Bobrowicz, P.; Davidson, R.C.; Li, H.; Potgieter, T.I.; Nett,
	J.H.; Hamilton, S.R.; Stadheim, T.A.; Miele, R.G.; Bobrowicz, B.;
	Mitchell, T.; Rausch, S.; Renfer, E.; Wildt, S.: Engineering of an
	artificial glycosylation pathway blocked in core oligosaccharide
	assembly in the yeast Pichia pastoris: Production of complex humanized
	glycoproteins with terminal galactose. Glycobiology (2004) 14, 757-766.
	{Pubmed:15190003} (c)
RF	<26> Schachter, H.: The joys of HexNAc. The synthesis and function of
	N- and O-glycan branches. Glycoconj. J. (2000) 17, 465-483.
	{Pubmed:11421343}
RF	<27> Mucha, J.; Svoboda, B.; Kappel, S.; Strasser, R.; Bencur, P.;
	Froehwein, U.; Schachter, H.; Mach, L.; Gloessl, J.: Two closely
	related forms of UDP-GlcNAc:alpha6-D-mannoside
	beta1,2-N-acetylglucosaminyltransferase II occur in the clawed frog
	Xenopus laevis. Glycoconj. J. (2003) 19, 187-195. {Pubmed:12815230} (c)
RF	<28> Schachter, H.; Reck, F.; Paulsen, H.: Use of synthetic
	oligosaccharide substrate analogs to map the active sites of
	N-acetylglucosaminyltransferases I and II. Methods Enzymol. (2003) 363,
	459-475. {Pubmed:14579596} (c)
RF	<29> Hanneman, A.J.; Rosa, J.C.; Ashline, D.; Reinhold, V.N.: Isomer
	and glycomer complexities of core GlcNAcs in Caenorhabditis elegans.
	Glycobiology (2006) 16, 874-890. {Pubmed:16769777}
RF	<30> Izumikawa, T.; Egusa, N.; Taniguchi, F.; Sugahara, K.; Kitagawa,
	H.: Heparan sulfate polymerization in Drosophila. J. Biol. Chem. (2006)
	281, 1929-1934. {Pubmed:16303756}
RF	<31> Ito, H.; Akiyama, M.; Nakagawa, H.; Uematsu, R.; Deguchi, K.;
	McMillan, J.R.; Nishimura, S.; Shimizu, H.: N-Linked neutral
	oligosaccharides in the stratum corneum of normal and ichthyotic skin.
	Arch. Dermatol. Res. (2007) 298, 403-407. {Pubmed:17021764}
RF	<32> Lee, S.; Grigorian, A.; Pawling, J.; Chen, I.; Gao, G.; Mozaffar,
	T.; McKerlie, C.; Demetriou, M.: N-Glycan processing deficiency
	promotes spontaneous inflammatory demyelination and neurodegeneration.
	J. Biol. Chem. (2007) 282, 33725-33734. {Pubmed:17855338}
RF	<33> Kim, N.Y.; Kim, H.G.; Kim, Y.H.; Chung, I.S.; Yang, J.M.:
	Expression and characterization of human
	N-acetylglucosaminyltransferases and alpha2,3-sialyltransferase in
	insect cells for in vitro glycosylation of recombinant erythropoietin.
	J. Microbiol. Biotechnol. (2008) 18, 383-391. {Pubmed:18309288}
RF	<34> Chen, H.L.; Li, C.F.; Grigorian, A.; Tian, W.; Demetriou, M.: T
	cell receptor signaling co-regulates multiple Golgi genes to enhance
	N-glycan branching. J. Biol. Chem. (2009) 284, 32454-32461.
	{Pubmed:19706602}
RF	<35> Geisler, C.; Jarvis, D.L.: Substrate specificities and
	intracellular distributions of three N-glycan processing enzymes
	functioning at a key branch point in the insect N-glycosylation
	pathway. J. Biol. Chem. (2012) 287, 7084-7097. {Pubmed:22238347}

ACTIVATING_COMPOUND
AC	#15# CHAPS <6>
AC	#15# Zwittergent 3-12 <6>
AC	#2,15# Triton X-100 (#2# activation, 0.1% <11>) <6,11>

KI_VALUE
KI	#5# 0.13
	{2-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl} 
	<28>
KI	#5# 1
	{3-O-(4
	4-azopentyl)-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl}
	 <28>
KI	#5# 0.9 {GlcNAcbeta(1-2)Manalpha(1-3)Man-beta-octyl}  <28>
KI	#5# 2.5
	{3-O-(5-aminopentyl)-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man
	beta-octyl}  <28>
KI	#5# 2.4
	{3-O-pentyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl} 
	<28>

KI_VALUE
KI	#5# 0.13
	{2-deoxy-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl} 
	<28>
KI	#5# 1
	{3-O-(4
	4-azopentyl)-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl}
	 <28>
KI	#5# 0.9 {GlcNAcbeta(1-2)Manalpha(1-3)Man-beta-octyl}  <28>
KI	#5# 2.5
	{3-O-(5-aminopentyl)-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man
	beta-octyl}  <28>
KI	#5# 2.4
	{3-O-pentyl-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Man-beta-octyl} 
	<28>

EXPRESSION
EXP	#5# down (#5# limited enzyme expression after anti-CD3 stimulation
	<34>) <34>

///
ID	2.4.1.144
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Gallus gallus   <1,3,11,16>
PR	#2# Cricetulus griseus   <1,4>
PR	#3# Mus musculus   <11,28,32,42,46>
PR	#4# Homo sapiens  
	<1,4,5,6,8,10,11,12,14,15,16,17,18,20,21,22,23,24,27,29,30,34,35,36,38
	39,40,42,43,45,46,47,48>
PR	#5# Rattus norvegicus   <1,2,7,11,13,16,17,19,25,26,31,33,37,41,44>
PR	#6# Mesocricetus auratus   <9>
PR	#7# no activity in Mus musculus   <8>
PR	#8# Rattus norvegicus Q02527 SwissProt <4,11,16>
PR	#9# Homo sapiens Q09327 UniProt <43,49,50,51>

RECOMMENDED_NAME
RN	beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase


SYSTEMATIC_NAME
SN	UDP-N-acetyl-alpha-D-glucosamine:beta-D-mannosyl-glycoprotein
	4-beta-N-acetyl-D-glucosaminyltransferase (configuration-inverting)


SYNONYMS
SY	 N-glycosyl-oligosaccharide-glycoprotein
	N-acetylglucosaminyltransferase III
SY	 uridine diphosphoacetylglucosamine-glycopeptide
	beta4-acetylglucosaminyltransferase III
SY	 acetylglucosaminyltransferase, uridine
	diphosphoacetylglucosamine-glycopeptide beta4-, III
SY	 beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase
SY	#1,3,4,5,8# beta1,4-N-acetylglucosaminyltransferase III
	<13,16,17,25,26,31,32,40,41,44>
SY	#1,3,4,5,8,9# GnT-III
	<4,5,6,7,8,10,11,12,13,14,16,17,25,29,31,34,35,36,37,38,39,40,41,42,43
	44,45,46,47,48,49,50,51>
SY	#3,4,9# N-acetylglucosaminyltransferase III
	<27,28,29,34,35,36,38,39,42,43,45,46,50,51>
SY	#4# N-acetyl-glucosaminyltransferase III <14>
SY	#4# beta-D-mannoside beta-1,4-N-acetylglucosaminyltransferase <14>
SY	#4# uridine diphosphate (UDP)-N-acetylglucosamin/beta-D-mannoside
	beta-1,4-N-acetylglucosaminyltransferase III <15>
SY	#4# GlcNAc-transferase-III <15>
SY	#4# GlcNAcTase-III <18>
SY	#4# (GnT)-III <27>
SY	#4# MGAT3 (#4# gene name <48>) <38,48>
SY	#4# N-acetylglucosaminyltransferase-III <43,47,48>
SY	#5# beta(1,4)-N-acetylglucosaminyltransferase III <33>
SY	#5# beta-1,4-N-acetylglucosaminyltransferase III <37>
SY	#5,6# GnTIII <9,33>
SY	#9# Golgi beta-1,4-mannosyl-glycoprotein
	4-beta-N-acetylglucosaminyltransferase III <49>

REACTION
RE	UDP-N-acetyl-alpha-D-glucosamine +
	beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D
	Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc-N-Asn
	[protein] = UDP +
	beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D
	Man-(1->6)]-[beta-D-GlcNAc-(1->4)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1
	>4)-beta-D-GlcNAc-N-Asn-[protein] (#5# sequential, random or partially
	random mechanism <16>)

REACTION_TYPE
RT	hexosyl group transfer

SOURCE_TISSUE
ST	#1# oviduct <1,3,11,16>
ST	#1,4,5# liver (#4,5# very low amount <11,15,16>; #4# high levels in
	fetal liver, but not in adult liver <11>; #1# preneoplastic hepatic
	nodules <1>) <1,2,11,15,16>
ST	#2# CHO cell (#2# LEC10 ovary cell line <1>; #2# ricin resistant mutant
	<1>) <1,4>
ST	#3# GE11 cell <28>
ST	#3# GE-11 cell <46>
ST	#3,4,5,6# brain (#6# cells forming normal prion protein PrPC with
	normal enzyme activity, and pathogenic prion protein PrPSc with reduced
	enzyme activity <9>) <2,9,11,16>
ST	#3,4,5,8# kidney <2,4,11,16>
ST	#3,4,5,9# hepatoma cell (#3# low activity <11>; #5# primary, about
	100fold increased activity compared to normal liver tissue <11>; #4#
	7721 cells, activity during cell-cycle <14>) <1,2,11,12,14,15,51>
ST	#3,9# melanoma cell <32,49>
ST	#4# HeLa cell <4,40>
ST	#4# HEL cell <18>
ST	#4# placenta <22>
ST	#4# bone marrow <6>
ST	#4# hepatoma cell line (#4# 7721 cell <14>) <14>
ST	#4# MCF-7 cell <38>
ST	#4# Hep-G2 cell (#4# hepatoma cell line <15>) <15>
ST	#4# HL-60 cell <18>
ST	#4# myeloma cell (#4# multiple myeloma <6>) <6>
ST	#4# KU-812 cell <18>
ST	#4# leukemia cell (#4# from patients with chronic lymphocytic leukemia
	CLL or acute lymphoblastic leukemia ALL <6>) <6,11>
ST	#4# HMCB cell <18>
ST	#4# BeWo cell <18>
ST	#4# MOLT-4 cell <18>
ST	#4# BALL-1 cell <18>
ST	#4# CACO-2 cell <18>
ST	#4# colonic cancer cell line (#4# DLD-1/DELTAalpha cells lacking
	alpha-catenin expression <34>) <34>
ST	#4# peripheral blood <6>
ST	#4# chronic myeloid leukemia cell (#4# chronic myelogenous leukemia
	granulocyte cell lines, e.g. clone KU812 and subclone KU812F <6>) <6>
ST	#4# HB611 cell (#4# hepatoblastoma cell line, derived from Huh6 by
	transfection of 3 copies of hepatitis B virus genome, decreased
	transcription level <5,8,11>) <5,8,11>
ST	#4# Hep-3B cell (#4# hepatoma cell line <15>) <15>
ST	#4# Huh-6 cell (#4# hepatoblastoma cell line <5,8,17>) <5,8,17>
ST	#4# lymphoid cell line <1>
ST	#4# myeloid cell line <1>
ST	#4# MCF-10A cell <46>
ST	#4# JEG-3 cell <22>
ST	#4# EoL-1 cell <18>
ST	#4# MDA-MB-435 cell <38>
ST	#4# CHP-134 cell <29>
ST	#4# DLD-1/alpha-cat cell <45>
ST	#4,5# more (#5# tissue distribution <2>; #4# multiple promotors allow
	tissue-specific expression <16>; #4# three choriocarcinoma cell lines
	<22>; #4# MCF-7/AZ cell <38>) <2,16,22,38>
ST	#4,5# hepatocyte (#4# primary <15>; #4,5# very low amount <11,15>; #4#
	different expression level in fetal and adult hepatocytes <15>) <11,15>
ST	#4,5# serum <2,20>
ST	#4,9# MKN-45 cell <43>
ST	#4,9# HEK-293T cell <47,51>
ST	#4,9# gastric carcinoma cell <43>
ST	#5# hepatoma ascites cell (#5# about 100fold increased activity
	compared to normal liver tissue <11>) <11>
ST	#9# epithelium <43>
ST	#9# HeLa-S3 cell <51>
ST	#9# ovarian cancer cell <51>
ST	#9# glioma cell <51>
ST	#9# MDA-MB-231 cell <51>

LOCALIZATION
LO	#1# microsome <1,3>
LO	#1,2,4,5,8# membrane <1,3,4,11,15,16>
LO	#4# cytosol (#4# minor fraction <15>) <15>
LO	#4,5,9# Golgi apparatus (#5# deglycosylated mutants are not localized
	in the Golgi apparatus <7,16>; #5# wild-type <7>; #4# functional
	localization of enzyme is regulated by caveolin-1 <23>)
	<7,11,14,16,23,49>
LO	#5# endoplasmic reticulum (#5# tunicamycin-treated and
	castanospermine-treated enzyme, not native enzyme <7>) <7>

NATURAL_SUBSTRATE_PRODUCT
NSP	#1,2,3,4,5,8# UDP-N-acetyl-D-glucosamine +
	(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-(N-acetyl-beta-D-glucosaminyl-1,4)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#4,5,8# key regulatory role in
	N-glycan biosynthesis, responsible for cancer-associated alterations
	<16>; #4,5# important role in carcinogenesis and cancer metastasis
	<16>; #3,4,5,8# key enzyme in the biosynthesis of N-glycans since it
	inhibits the other involved glycosyltransferases by adding the
	GlcNAc-residue in an beta-1,4- linkage <11,16>; #3# enzyme plays an
	important role in the progression of preneoplastic foci to primary
	hepatoma <11>; #1,2,3,4,5,8# R represents the remainder of the
	N-oligosaccharide core (+/-fucose), essential for biosynthesis of
	complex N-linked oligosaccharides <1,3,11,16>; #4,5# numerous target
	proteins, multifacial glycosyltransferase <11,16>) {} <1,3,5,11,16>
NSP	#1,2,3,4,5,8# UDP-N-acetyl-D-glucosamine +
	(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-(N-acetyl-beta-D-glucosaminyl-1,4)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#4,5,8# key regulatory role in
	N-glycan biosynthesis, responsible for cancer-associated alterations
	<16>; #4,5# important role in carcinogenesis and cancer metastasis
	<16>; #3,4,5,8# key enzyme in the biosynthesis of N-glycans since it
	inhibits the other involved glycosyltransferases by adding the
	GlcNAc-residue in an beta-1,4- linkage <11,16>; #3# enzyme plays an
	important role in the progression of preneoplastic foci to primary
	hepatoma <11>; #1,2,3,4,5,8# R represents the remainder of the
	N-oligosaccharide core (+/-fucose), essential for biosynthesis of
	complex N-linked oligosaccharides <1,3,11,16>; #4,5# numerous target
	proteins, multifacial glycosyltransferase <11,16>) {ir} <1,3,5,11,16>
NSP	#1,2,3,4,5,8# UDP-N-acetyl-D-glucosamine +
	(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-(N-acetyl-beta-D-glucosaminyl-1,4)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#4,5,8# key regulatory role in
	N-glycan biosynthesis, responsible for cancer-associated alterations
	<16>; #4,5# important role in carcinogenesis and cancer metastasis
	<16>; #3,4,5,8# key enzyme in the biosynthesis of N-glycans since it
	inhibits the other involved glycosyltransferases by adding the
	GlcNAc-residue in an beta-1,4- linkage <11,16>; #3# enzyme plays an
	important role in the progression of preneoplastic foci to primary
	hepatoma <11>; #1,2,3,4,5,8# R represents the remainder of the
	N-oligosaccharide core (+/-fucose), essential for biosynthesis of
	complex N-linked oligosaccharides <1,3,11,16>; #4,5# numerous target
	proteins, multifacial glycosyltransferase <11,16>) <1,3,5,11,16>
NSP	#3,4,5,6,9# more = ? (#4# the biantennary structure of a core mannose
	is twisted in presence of bisecting GlcNAc, probably responsible for
	the substrate inaccessibility to N-acetylglucosamine transferase V to
	form the beta-1,6 structure <11>; #6# in brain cells with
	down-regulated enzyme activity, normal prion proteins PrPC get
	conversed to pathogenic prion protein PrPSc due to a lower amount of
	glycans with bisecting N-acetylglucosamine residues <9>; #4,5#
	biosynthetic pathway of the core structures of Asn-linked sugar chains,
	overview <16>; #4# key enzyme that inhibits the extension of N-glycans
	by introducing a bisecting N-acetylglucosamine residue, modification of
	N-glycans by the enzyme affects a number of intracellular signalling
	pathways <10,11>; #5# beta1,4-N-acetylglucosaminyltransferase III
	potentiates beta1 integrin-mediated neuritogenesis induced by serum
	deprivation in Neuro2a cells <26>; #3# cell-cell interaction-dependent
	regulation of N-acetylglucosaminyltransferase III and the bisected
	N-glycans in GE11 epithelial cells <28>; #4#
	N-acetylglucosaminyltransferase III expression is regulated by
	cell-cell adhesion via the E-cadherin-catenin-actin complex <34>; #9#
	N-acetylglucosaminyltransferase III is a glycosyltransferase which
	produces bisected N-glycans by transferring GlcNAc to the 4-position of
	core mannose <50>; #9# the MCAM glycoprotein, which is a biomarker of
	cutaneous melanoma, as a potential target for overexpressed
	glycosyltransferases <49>) {} <9,10,11,16,26,28,34,49,50>
NSP	#3,4,5,6,9# more = ? (#4# the biantennary structure of a core mannose
	is twisted in presence of bisecting GlcNAc, probably responsible for
	the substrate inaccessibility to N-acetylglucosamine transferase V to
	form the beta-1,6 structure <11>; #6# in brain cells with
	down-regulated enzyme activity, normal prion proteins PrPC get
	conversed to pathogenic prion protein PrPSc due to a lower amount of
	glycans with bisecting N-acetylglucosamine residues <9>; #4,5#
	biosynthetic pathway of the core structures of Asn-linked sugar chains,
	overview <16>; #4# key enzyme that inhibits the extension of N-glycans
	by introducing a bisecting N-acetylglucosamine residue, modification of
	N-glycans by the enzyme affects a number of intracellular signalling
	pathways <10,11>; #5# beta1,4-N-acetylglucosaminyltransferase III
	potentiates beta1 integrin-mediated neuritogenesis induced by serum
	deprivation in Neuro2a cells <26>; #3# cell-cell interaction-dependent
	regulation of N-acetylglucosaminyltransferase III and the bisected
	N-glycans in GE11 epithelial cells <28>; #4#
	N-acetylglucosaminyltransferase III expression is regulated by
	cell-cell adhesion via the E-cadherin-catenin-actin complex <34>; #9#
	N-acetylglucosaminyltransferase III is a glycosyltransferase which
	produces bisected N-glycans by transferring GlcNAc to the 4-position of
	core mannose <50>; #9# the MCAM glycoprotein, which is a biomarker of
	cutaneous melanoma, as a potential target for overexpressed
	glycosyltransferases <49>) {} <9,10,11,16,26,28,34,49,50>
NSP	#4# UDP-N-acetyl-D-glucosamine + E-cadherin = UDP + E-cadherin with
	bisecting N-acetyl-D-glucosamine (#4# recombinant enzyme expressed in
	murine lung melanoma cells <11,16>) {} <11,16>
NSP	#4,9# UDP-N-acetyl-D-glucosamine + beta-D-mannosyl-R = UDP +
	4-(N-acetyl-beta-D-glucosaminyl)-beta-D-mannosyl-R (#4# GnT-III
	catalyzes the formation of a bisecting GlcNAc structure in N-glycans,
	resulting in the suppression of metastasis. The priority of GnT-III for
	the modification of the integrin alpha3 subunit may be an explanation
	for why GnT-III inhibits GnT-V-induced cell migration. TGnT-III and
	GnT-V can competitively modify the same target glycoprotein and
	furthermore positively or negatively regulate its biological functions
	<29>) <29,43,49>

SUBSTRATE_PRODUCT
SP	#1# UDP-N-acetyl-D-glucosamine +
	GlcNAc-beta-1,2-Man-alpha-1,6-(GlcNAc-beta-1,2-Man-alpha-1
	3)-Man-beta-1,4-GlcNAc-beta-1,4-(Fuc-alpha-1,6)-GlcNAc-Asn = UDP +
	GlcNAc-beta-1,2-Man-alpha-1,6-(GlcNAc-beta-1,2-Man-alpha-1
	3)(GlcNAc-beta-1,4)-Man-beta-1,4-GlcNAc-beta-1,4-(Fuc-alpha-1
	6)-GlcNAc-Asn |#1# incorporates a N-acetylglucosamine residue in
	beta-1,4-linkage to beta-linked mannosyl, i.e. bisecting
	N-acetylglucosamine, both terminal beta-1,2-linked N-acetylglucosamine
	residues required for maximum activity, removal of one or both of them
	reduces activity by 85 or 93%, respectively <3>| {ir} <3>
SP	#1,2,3,4,5,6,8# UDP-N-acetyl-D-glucosamine +
	(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-(N-acetyl-beta-D-glucosaminyl-1,4)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#1,4,5# substrate specificity <1,16>;
	#4,5# pyridylaminated biantennary sugar chain <2,13,15>; #4,5#
	structural requirements, stereochemistry <16>; #1,4,5# beta1,2-GlcNAc
	linked to alpha1,3-Man is required for activity, beta1,2-GlcNAc linked
	to alpha1,6-Man is not required <16>; #1,4,5# any agalacto form of the
	bi-, tri- and tetraantennary sugar chains is capable of serving as ana
	cceptor substrate <16>; #2,4,5# beta1,4-galactosylation of
	N-acetylglucosaminyl-1,2-alpha-mannosyl-1,3-beta-mannosyl moiety
	prevents transferase III action <1,16>; #2,3,4,5# R represents the
	remainder of the N-oligosaccharide core, (+/-)-fucose, favourite
	substrate <1,11,16>; #5# absolute requirement for the conserved
	residues Asp321 and Asp323 as part of a D-X-D motif <17>; #4,5,8# key
	regulatory role in N-glycan biosynthesis, responsible for
	cancer-associated alterations <16>; #4,5# important role in
	carcinogenesis and cancer metastasis <16>; #3,4,5,8# key enzyme in the
	biosynthesis of N-glycans since it inhibits the other involved
	glycosyltransferases by adding the GlcNAc-residue in an beta-1,4-
	linkage <11,16>; #3# enzyme plays an important role in the progression
	of preneoplastic foci to primary hepatoma <11>; #1,2,3,4,5,8# R
	represents the remainder of the N-oligosaccharide core (+/-fucose),
	essential for biosynthesis of complex N-linked oligosaccharides
	<1,3,11,16>; #4,5# numerous target proteins, multifacial
	glycosyltransferase <11,16>) |#1,2,3,4,5,6,8# incorporates a
	N-acetylglucosamine residue in beta-1,4-linkage to beta-linked
	mannosyl, i.e. bisecting N-acetylglucosamine <1,3,4,5,8,9,11,14,16,17>|
	{} <1,2,3,4,5,6,7,8,9,11,13,14,15,16,17>
SP	#1,2,3,4,5,6,8# UDP-N-acetyl-D-glucosamine +
	(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-(N-acetyl-beta-D-glucosaminyl-1,4)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#1,4,5# substrate specificity <1,16>;
	#4,5# pyridylaminated biantennary sugar chain <2,13,15>; #4,5#
	structural requirements, stereochemistry <16>; #1,4,5# beta1,2-GlcNAc
	linked to alpha1,3-Man is required for activity, beta1,2-GlcNAc linked
	to alpha1,6-Man is not required <16>; #1,4,5# any agalacto form of the
	bi-, tri- and tetraantennary sugar chains is capable of serving as ana
	cceptor substrate <16>; #2,4,5# beta1,4-galactosylation of
	N-acetylglucosaminyl-1,2-alpha-mannosyl-1,3-beta-mannosyl moiety
	prevents transferase III action <1,16>; #2,3,4,5# R represents the
	remainder of the N-oligosaccharide core, (+/-)-fucose, favourite
	substrate <1,11,16>; #5# absolute requirement for the conserved
	residues Asp321 and Asp323 as part of a D-X-D motif <17>; #4,5,8# key
	regulatory role in N-glycan biosynthesis, responsible for
	cancer-associated alterations <16>; #4,5# important role in
	carcinogenesis and cancer metastasis <16>; #3,4,5,8# key enzyme in the
	biosynthesis of N-glycans since it inhibits the other involved
	glycosyltransferases by adding the GlcNAc-residue in an beta-1,4-
	linkage <11,16>; #3# enzyme plays an important role in the progression
	of preneoplastic foci to primary hepatoma <11>; #1,2,3,4,5,8# R
	represents the remainder of the N-oligosaccharide core (+/-fucose),
	essential for biosynthesis of complex N-linked oligosaccharides
	<1,3,11,16>; #4,5# numerous target proteins, multifacial
	glycosyltransferase <11,16>) |#1,2,3,4,5,6,8# incorporates a
	N-acetylglucosamine residue in beta-1,4-linkage to beta-linked
	mannosyl, i.e. bisecting N-acetylglucosamine <1,3,4,5,8,9,11,14,16,17>|
	{ir} <1,2,3,4,5,6,7,8,9,11,13,14,15,16,17>
SP	#1,2,3,4,5,6,8# UDP-N-acetyl-D-glucosamine +
	(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-(N-acetyl-beta-D-glucosaminyl-1,4)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#1,4,5# substrate specificity <1,16>;
	#4,5# pyridylaminated biantennary sugar chain <2,13,15>; #4,5#
	structural requirements, stereochemistry <16>; #1,4,5# beta1,2-GlcNAc
	linked to alpha1,3-Man is required for activity, beta1,2-GlcNAc linked
	to alpha1,6-Man is not required <16>; #1,4,5# any agalacto form of the
	bi-, tri- and tetraantennary sugar chains is capable of serving as ana
	cceptor substrate <16>; #2,4,5# beta1,4-galactosylation of
	N-acetylglucosaminyl-1,2-alpha-mannosyl-1,3-beta-mannosyl moiety
	prevents transferase III action <1,16>; #2,3,4,5# R represents the
	remainder of the N-oligosaccharide core, (+/-)-fucose, favourite
	substrate <1,11,16>; #5# absolute requirement for the conserved
	residues Asp321 and Asp323 as part of a D-X-D motif <17>; #4,5,8# key
	regulatory role in N-glycan biosynthesis, responsible for
	cancer-associated alterations <16>; #4,5# important role in
	carcinogenesis and cancer metastasis <16>; #3,4,5,8# key enzyme in the
	biosynthesis of N-glycans since it inhibits the other involved
	glycosyltransferases by adding the GlcNAc-residue in an beta-1,4-
	linkage <11,16>; #3# enzyme plays an important role in the progression
	of preneoplastic foci to primary hepatoma <11>; #1,2,3,4,5,8# R
	represents the remainder of the N-oligosaccharide core (+/-fucose),
	essential for biosynthesis of complex N-linked oligosaccharides
	<1,3,11,16>; #4,5# numerous target proteins, multifacial
	glycosyltransferase <11,16>) |#1,2,3,4,5,6,8# incorporates a
	N-acetylglucosamine residue in beta-1,4-linkage to beta-linked
	mannosyl, i.e. bisecting N-acetylglucosamine <1,3,4,5,8,9,11,14,16,17>|
	<1,2,3,4,5,6,7,8,9,11,13,14,15,16,17>
SP	#3,4# UDP-N-acetyl-D-glucosamine +
	GlcNAcbeta(1->2)Manalpha(1->6)(GlcNAcbeta(1->2)Manbeta(1->3)Manbeta(1
	>4)GlcNAcbeta(1->4)GlcNAc-NH(CH2)4NH(2-pyridyl) = ? <45,46>
SP	#3,4,5,6,9# more = ? (#5# UDP-galactose is no substrate <13,16>; #5#
	ADP-, CDP-, GDP-, and TDP-glucose are no donor substrates <13>; #5#
	specificity towards the sugar moiety of the donor substrate appears to
	be critically determined during the catalytic process but not during
	binding to the enzyme in ground state <16>; #4# the biantennary
	structure of a core mannose is twisted in presence of bisecting GlcNAc,
	probably responsible for the substrate inaccessibility to
	N-acetylglucosamine transferase V to form the beta-1,6 structure <11>;
	#6# in brain cells with down-regulated enzyme activity, normal prion
	proteins PrPC get conversed to pathogenic prion protein PrPSc due to a
	lower amount of glycans with bisecting N-acetylglucosamine residues
	<9>; #4,5# biosynthetic pathway of the core structures of Asn-linked
	sugar chains, overview <16>; #4# key enzyme that inhibits the extension
	of N-glycans by introducing a bisecting N-acetylglucosamine residue,
	modification of N-glycans by the enzyme affects a number of
	intracellular signalling pathways <10,11>; #5#
	beta1,4-N-acetylglucosaminyltransferase III potentiates beta1
	integrin-mediated neuritogenesis induced by serum deprivation in
	Neuro2a cells <26>; #3# cell-cell interaction-dependent regulation of
	N-acetylglucosaminyltransferase III and the bisected N-glycans in GE11
	epithelial cells <28>; #4# N-acetylglucosaminyltransferase III
	expression is regulated by cell-cell adhesion via the
	E-cadherin-catenin-actin complex <34>; #5# expression of GnTIII leads
	to a high proportion of N-glycans of the complex type, modified with
	the bisecting GlcNAc (median value 37%, q1, 33%, q3, 39%) and a strong
	reduction of paucimannosidic type N-glycans (median value 2%, q1, 1%,
	q3.2%) that are abundant in secreted proteins of tobacco BY-2 cells.
	Native GnTIII expression, the coexpression of Arabidopsis thaliana
	ManII leads to an increase in the proportion of complex bisected
	N-glycan structures, whereas the expression of native human ManII does
	not significantly increase these structures. In the case of chimeric
	GnTIIIA.th. and chimeric ManIIA.th. expression, reduction in hybrid
	bisected structures. No viable cultures expressing GnTIIIA.th. and A.
	thaliana ManII. Plant-specific core fucosylation and xylosylation can
	be greatly reduced, with up to 59% of N-glycans on endogenous secreted
	protein lacking the plant-specific modifications <41>; #4# GnT-III
	selectively modifies N-glycosylation site-4 on the integrin alpha5
	subunit (S-3,4,5), which down-regulates its biological functions <40>;
	#4# N-glycosylation of laminin-332, GnT-III down-regulates activities
	of laminin-332 <39>; #4# the enzyme catalyzes the transfer of
	N-acetylglucosamine in a beta1,4 linkage to mannose on N-glycans
	forming a bisecting N-acetylglucosamine structure <48>; #4# the enzyme
	introduces a N-acetylglucosamine in a beta1,4-linkage to the mannose
	residue located at the base of the trimannosyl core (bisecting
	N-acetylglucosamine) in N-glycans <47>; #9#
	N-acetylglucosaminyltransferase III is a glycosyltransferase which
	produces bisected N-glycans by transferring GlcNAc to the 4-position of
	core mannose <50>; #9# the MCAM glycoprotein, which is a biomarker of
	cutaneous melanoma, as a potential target for overexpressed
	glycosyltransferases <49>) {}
	<9,10,11,13,16,26,28,34,39,40,41,47,48,49,50>
SP	#3,4,5,6,9# more = ? (#5# UDP-galactose is no substrate <13,16>; #5#
	ADP-, CDP-, GDP-, and TDP-glucose are no donor substrates <13>; #5#
	specificity towards the sugar moiety of the donor substrate appears to
	be critically determined during the catalytic process but not during
	binding to the enzyme in ground state <16>; #4# the biantennary
	structure of a core mannose is twisted in presence of bisecting GlcNAc,
	probably responsible for the substrate inaccessibility to
	N-acetylglucosamine transferase V to form the beta-1,6 structure <11>;
	#6# in brain cells with down-regulated enzyme activity, normal prion
	proteins PrPC get conversed to pathogenic prion protein PrPSc due to a
	lower amount of glycans with bisecting N-acetylglucosamine residues
	<9>; #4,5# biosynthetic pathway of the core structures of Asn-linked
	sugar chains, overview <16>; #4# key enzyme that inhibits the extension
	of N-glycans by introducing a bisecting N-acetylglucosamine residue,
	modification of N-glycans by the enzyme affects a number of
	intracellular signalling pathways <10,11>; #5#
	beta1,4-N-acetylglucosaminyltransferase III potentiates beta1
	integrin-mediated neuritogenesis induced by serum deprivation in
	Neuro2a cells <26>; #3# cell-cell interaction-dependent regulation of
	N-acetylglucosaminyltransferase III and the bisected N-glycans in GE11
	epithelial cells <28>; #4# N-acetylglucosaminyltransferase III
	expression is regulated by cell-cell adhesion via the
	E-cadherin-catenin-actin complex <34>; #5# expression of GnTIII leads
	to a high proportion of N-glycans of the complex type, modified with
	the bisecting GlcNAc (median value 37%, q1, 33%, q3, 39%) and a strong
	reduction of paucimannosidic type N-glycans (median value 2%, q1, 1%,
	q3.2%) that are abundant in secreted proteins of tobacco BY-2 cells.
	Native GnTIII expression, the coexpression of Arabidopsis thaliana
	ManII leads to an increase in the proportion of complex bisected
	N-glycan structures, whereas the expression of native human ManII does
	not significantly increase these structures. In the case of chimeric
	GnTIIIA.th. and chimeric ManIIA.th. expression, reduction in hybrid
	bisected structures. No viable cultures expressing GnTIIIA.th. and A.
	thaliana ManII. Plant-specific core fucosylation and xylosylation can
	be greatly reduced, with up to 59% of N-glycans on endogenous secreted
	protein lacking the plant-specific modifications <41>; #4# GnT-III
	selectively modifies N-glycosylation site-4 on the integrin alpha5
	subunit (S-3,4,5), which down-regulates its biological functions <40>;
	#4# N-glycosylation of laminin-332, GnT-III down-regulates activities
	of laminin-332 <39>; #4# the enzyme catalyzes the transfer of
	N-acetylglucosamine in a beta1,4 linkage to mannose on N-glycans
	forming a bisecting N-acetylglucosamine structure <48>; #4# the enzyme
	introduces a N-acetylglucosamine in a beta1,4-linkage to the mannose
	residue located at the base of the trimannosyl core (bisecting
	N-acetylglucosamine) in N-glycans <47>; #9#
	N-acetylglucosaminyltransferase III is a glycosyltransferase which
	produces bisected N-glycans by transferring GlcNAc to the 4-position of
	core mannose <50>; #9# the MCAM glycoprotein, which is a biomarker of
	cutaneous melanoma, as a potential target for overexpressed
	glycosyltransferases <49>) {}
	<9,10,11,13,16,26,28,34,39,40,41,47,48,49,50>
SP	#4# UDP-N-acetyl-D-glucosamine +
	(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-N-acetyl-D-glucosaminyl-2-aminopyridine
	= UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-(N-acetyl-beta-D-glucosaminyl-1,4)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-N-acetyl-D-glucosaminyl-2-aminopyridine
	{ir} <6>
SP	#4# UDP-N-acetyl-D-glucosamine + E-cadherin = UDP + E-cadherin with
	bisecting N-acetyl-D-glucosamine (#4# recombinant enzyme expressed in
	murine lung melanoma cells <11,16>) {} <11,16>
SP	#4# UDP-D-glucose +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-(beta-D-glucosyl-1,4)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R <35,36>
SP	#4,5# UDP-D-glucose +
	(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-(beta-D-glucosyl-1,4)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#5# pyridylaminated biantennary sugar
	chain <13>; #5# 0.2% activity compared to donor substrate
	UDP-N-acetyl-D-glucosamine <13,16>) <13,16,42>
SP	#4,9# UDP-N-acetyl-D-glucosamine + beta-D-mannosyl-R = UDP +
	4-(N-acetyl-beta-D-glucosaminyl)-beta-D-mannosyl-R (#4# GnT-III
	catalyzes the formation of a bisecting GlcNAc structure in N-glycans,
	resulting in the suppression of metastasis. The priority of GnT-III for
	the modification of the integrin alpha3 subunit may be an explanation
	for why GnT-III inhibits GnT-V-induced cell migration. TGnT-III and
	GnT-V can competitively modify the same target glycoprotein and
	furthermore positively or negatively regulate its biological functions
	<29>) <29,43,49>
SP	#5# UDP-N-acetyl-D-glucosamine +
	GlcNAc-beta-1,2-Man-alpha-1,6-(GlcNAc-beta-1,2-Man-alpha-1
	3)-Man-beta-1,4-GlcNAc-beta-1,4-GlcNAc-2-aminopyridine = UDP +
	GlcNAc-beta-1,2-Man-alpha-1,6-(GlcNAc-beta-1,2-Man-alpha-1
	3)(GlcNAc-beta-1,4)-Man-beta-1,4-GlcNAc-beta-1,4-GlcNAc-2-aminopyridine
	<7>
SP	#5# UDP-N-acetyl-D-glucosamine + gamma-glutamyltranspeptidase = UDP +
	gamma-glutamyltranspeptidase with bisecting N-acetyl-D-glucosamine <11>
SP	#5# UDP-N-acetyl-D-glucosamine + transferrin = UDP + transferrin with
	bisecting N-acetyl-D-glucosamine <16>
SP	#5# UDP-N-acetyl-D-galactosamine +
	(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-(N-acetyl-beta-D-galactosaminyl-1,4)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#5# pyridylaminated biantennary sugar
	chain <13>; #5# 0.1% activity compared to donor substrate
	UDP-N-acetyl-D-glucosamine <13,16>) <13,16>
SP	#5# UDP +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-(beta-D-glucosyl-1,4)-beta-D-mannosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R = UDP-D-glucose +
	N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R (#5# GnT-III
	catalyzes the removal of the bisecting GlcNAc from the bisected
	oligosaccharide, producing the corresponding nonbisected sugar chain
	<37>) {r} <37>
SP	#9# UDP-N-acetyl-D-glucosamine + GnGnbi-PA = UDP +
	4-(N-acetyl-beta-D-glucosaminyl)-GnGnbi-PA (#9# the bi-branched
	N-glycan carrying a pyridylamino (PA) group at the reducing terminus
	(GnGnbi-PA) serves as a typical acceptor substrate and UDP-GlcNAc as a
	donor substrate <50>) <50>

KM_VALUE
KM	#1# 0.23
	{(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3)-(N-acetyl-beta-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6)-beta-D-mannosyl-1,4-N-acetyl-beta-D-glucosaminyl-R}  <1,3>
KM	#1# 1.1 {UDP-N-acetyl-D-glucosamine}  <1,3>
KM	#4# -999 {more}  (#4# solid-phase enzyme-linked immunosorbent sandwich
	assay for enzyme activity <20>) <20>
KM	#4# 4.7 {UDP-N-acetyl-D-glucosamine}  (#4# Hep3B cells <15>) <15>
KM	#4# 6.8 {UDP-N-acetyl-D-glucosamine}  (#4# HepG2 cells <15>) <15>
KM	#4# 1.1 {pyridylaminated acceptor substrate}  (#4# Hep3B cells <15>)
	<15>
KM	#4# 3.4 {pyridylaminated acceptor substrate}  (#4# HepG2 cells <15>)
	<15>
KM	#5# 0.021 {pyridylaminated acceptor substrate}  (#5# recombinant enzyme
	<13>; #5# with UDP-GlcNAc as donor substrate <13>) <13>
KM	#5# 1 {UDP-D-glucose}  (#5# recombinant enzyme <13,16>) <13,16>
KM	#5# 0.023 {pyridylaminated acceptor substrate}  (#5# recombinant enzyme
	<13>; #5# with UDP-Glc as donor substrate <13>) <13>
KM	#5# 0.19 {pyridylaminated acceptor substrate}  <2>
KM	#5# 3.1 {UDP-N-acetyl-D-glucosamine}  (#5# + pyridylaminated acceptor
	substrate <2>) <2>
KM	#5# 0.024 {pyridylaminated acceptor substrate}  (#5# recombinant enzyme
	<13>; #5# with UDP-GalNAc as donor substrate <13>) <13>
KM	#5# 0.42 {UDP-N-acetyl-D-glucosamine}  (#5# recombinant enzyme <13,16>)
	<13,16>
KM	#5# 3.6 {UDP-N-acetyl-D-galactosamine}  (#5# recombinant enzyme
	<13,16>) <13,16>

PH_OPTIMUM
PHO	#1# 7 <3>
PHO	#1# 6-7 <1>
PHO	#4# 6.5 (#4# Hep3B cells <15>) <15>
PHO	#4,5# 6.3 (#4,5# assay at <6,14,17>) <2,6,14,17>
PHO	#4,9# 6 (#9# assay at <49>; #4# HepG2 cells <15>) <15,49>

SPECIFIC_ACTIVITY
SA	#1# 8.3e-05 <3>
SA	#4# -999.0 (#4# transcript amount is not correlated to enzyme activity
	<6>; #4# activity and expression level in various leukemic cells <6>)
	<6>
SA	#4# 2.4e-05 (#4# Hep3B cells <15>) <15>
SA	#4# 1.2e-05 (#4# purified enzyme <12>) <12>
SA	#4# 4e-07 (#4# HB611 cells treated with interferon-alpha-2a <5>) <5>
SA	#4# 1.8e-05 (#4# HepG2 cells <15>) <15>
SA	#4# 1e-07 (#4# HB611 cells <5,8>) <5,8>
SA	#4# 2.1e-06 (#4# Huh6 cells treated with interferon-alpha-2a <5>) <5>
SA	#4# 4e-06 (#4# about, hepatoma cell line 7721, all-trans retinoic acid
	treated <14>) <14>
SA	#4# 2.5e-06 (#4# hepatoma cell line 7721 <14>) <14>
SA	#4# 2.2e-08 (#4# hepatoma cells <12>) <12>
SA	#4# 1.3e-07 (#4# normal liver <15>) <15>
SA	#4# 2.3e-06 (#4# Huh6 cells <5,8>) <5,8>
SA	#4# 9.6e-06 (#4# fetal primary hepatocytes <15>) <15>
SA	#4# 1.24e-05 (#4# hepatic carcinoma cells <15>) <15>
SA	#5# 0.02 (#5# purified recombinant enzyme <13>) <13>
SA	#5# 1.7e-05 (#5# wild-type and mutant D329A <17>) <17>
SA	#8# 5.52 (#8# purified enzyme <4>) <4>
SA	#8# 6e-05 (#8# recombinant enzyme in COS-1 cells <4>) <4>
SA	#8# 9e-07 (#8# recombinant enzyme in HeLa cells <4>) <4>

TEMPERATURE_OPTIMUM
TO	#4# 40 (#4# HepG2 cells <15>) <15>
TO	#4# 43 (#4# Hep3B cells <15>) <15>
TO	#4,5# 37 (#4,5# assay at <6,7,14>) <6,7,14>
TO	#9# 30 (#9# assay at <49>) <49>

ACTIVATING_COMPOUND
AC	#1,4,5,8# Triton X-100 (#1,8# activation, about 8fold at 0.13-1.3% v/v
	<1,3,4>) <1,3,4,6,14,15,17>
AC	#4# all-trans retinoic acid (#4# activation <14>) <14>
AC	#4# forskolin (#4# induction of the enzyme in hepatoma cells <11>) <11>
AC	#4# tunicamycin (#4# increase in activity, HepG2 and Hep3B cells <15>)
	<15>
AC	#4# deoxymannojirimycin (#4# increase in activity, HepG2 and Hep3B
	cells <15>) <15>
AC	#4# more (#4# not affected by swainsonine <15>; #4# interferon-alpha-2a
	leads to an increase in enzyme activity in hepatitis B virus infected
	cells due to reduction of virus expression <5>; #4# not affected by
	cAMP <14>) <5,14,15>

INHIBITORS
IN	#4# EDTA <8>
IN	#4# inactive rat mutant D323A enzyme (#4# acts as an inhibitor of
	endogenous enzyme activity when expressed in human Huh6 cells <17>) <17>
IN	#4# hepatitis B virus (#4# selective suppression of enzyme activity on
	transcription level in transfected cells, e.g. cell line Hb611 <5>) <5>
IN	#4,9# more (#4# transgenic expression of the enzyme in hepatitis B
	virus infected cells suppress the virus expression, cell line HB611
	<8,11>; #9# systematic synthesis of four N-glycan units, the branching
	parts of the bisected and non-bisected N-glycans, from a common core
	trimannose, giving bisected tetra- and hexasaccharides as well as
	non-bisected tri- and pentasaccharides, and evaluation as enzyme
	inhibitors, overview. The competitive GnT-III inhibition assay using
	the synthetic substrates reveals a vital role for the
	Manbeta(1-4)GlcNAc moiety, GlcNAc at the alpha1,3-branch is also
	involved in the interaction. Competitive inhibition, overview <50>)
	<8,11,50>
IN	#5# ADP <13>
IN	#5# UDP <13>
IN	#5# GDP <13>
IN	#5# CDP <13>
IN	#5# N-acetyl-D-glucosamine <13>
IN	#5# TDP <13>
IN	#5# alpha-N-acetyl-D-glucosamine-1-phosphate <13>
IN	#5# ADP-glucose (#5# competitive against UDP-N-acetyl-D-glucosamine
	<13>) <13>
IN	#5# GDP-glucose (#5# competitive against UDP-N-acetyl-D-glucosamine
	<13>) <13>
IN	#5# TDP-glucose (#5# competitive against UDP-N-acetyl-D-glucosamine
	<13>) <13>
IN	#5# CDP-glucose (#5# competitive against UDP-N-acetyl-D-glucosamine
	<13>) <13>
IN	#5# tunicamycin (#5# completely abolishes the enzyme activity due to
	deglycosylation of the enzyme, not localized in the Golgi apparatus
	<7>) <7>
IN	#5# castanospermine (#5# activity is not affected, but the enzyme is
	not localized in the Golgi apparatus <7>) <7>
IN	#9# methyl
	3
	6-di-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl-2-O-alpha-D
	mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl)-alpha-D
	mannopyranoside <50>
IN	#9# methyl
	3
	6-di-O-(alpha-D-mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D
	glucopyranosyl)-alpha-D-mannopyranoside <50>
IN	#9# methyl
	3
	6-di-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl-2-O-alpha-D
	mannopyranosyl)-alpha-D-mannopyranoside <50>
IN	#9# methyl 3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside
	<50>

KI_VALUE
KI	#5# 1 {GDP-glucose}  (#5# recombinant enzyme <13>) <13>
KI	#5# 3.9 {CDP-glucose}  (#5# recombinant enzyme <13>) <13>
KI	#5# 0.75 {ADP-glucose}  (#5# recombinant enzyme <13>) <13>
KI	#9# 1.5 {methyl
	3
	6-di-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl-2-O-alpha-D
	mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl)-alpha-D
	mannopyranoside}  (#9# pH and temperature not specified in the
	publication, versus UDP-N-acetyl-D-glucosamine <50>) <50>
KI	#9# 1.4 {methyl
	3
	6-di-O-(alpha-D-mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D
	glucopyranosyl)-alpha-D-mannopyranoside}  (#9# pH and temperature not
	specified in the publication, versus UDP-N-acetyl-D-glucosamine <50>)
	<50>
KI	#9# 1.2 {methyl
	3
	6-di-O-(alpha-D-mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D
	glucopyranosyl)-alpha-D-mannopyranoside}  (#9# pH and temperature not
	specified in the publication, versus GnGnbi-PA <50>) <50>
KI	#9# 14 {methyl
	3
	6-di-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl-2-O-alpha-D
	mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl)-alpha-D
	mannopyranoside}  (#9# pH and temperature not specified in the
	publication, versus GnGnbi-PA <50>) <50>

METALS_IONS
ME	#1,4,5,9# Mn2+ (#9# required <49>; #5# Asp321 and Asp323 are absolutely
	required for the coordination of Mn2+ during enzyme reaction <17>; #4#
	HepG2 cells: maximal at 12 mM, Hep3B cells: maximal at 15 mM <15>;
	#1,5# broad optimum at 12 mM <1,2,3>) <1,2,3,6,14,15,16,17,49>

MOLECULAR_WEIGHT
MW	#3,4,8# 62000 (#8# x * 62000 + x * 52000, SDS-PAGE <4>; #3,4# x *
	62000, two major bands migrate at 62000 and 52000 Da, SDS-PAGE <46>)
	<4,46>
MW	#3,4,8# 52000 (#8# x * 62000 + x * 52000, SDS-PAGE <4>; #3,4# x *
	52000, two major bands migrate at 62000 and 52000 Da, SDS-PAGE <46>)
	<4,46>
MW	#4# 110000 (#4# about, PAGE <12>) <12>
MW	#4# 63000 (#4# 1 * 63000 + 1 * 53000, SDS-PAGE <12>) <12>
MW	#4# 53000 (#4# 1 * 63000 + 1 * 53000, SDS-PAGE <12>) <12>
MW	#5# 50000 (#5# x * 60000 + x * 50000, SDS-PAGE <13>) <13>
MW	#5# 60000 (#5# x * 60000 + x * 50000, SDS-PAGE <13>) <13>
MW	#5# 68100 (#5# x * 68100, wild-type enzyme, SDS-PAGE <7>) <7>
MW	#8# -999 (#8# amino acid and DNA sequence <4,16>; #8# type II
	transmembrane protein <4,16>) <4,16>

POSTTRANSLATIONAL_MODIFICATION
PM	#5,8# glycoprotein (#8# enzyme binds to concanavalin A <4>; #8# enzyme
	contains 3 putative N-glycosylation sites <4>; #5# requires core
	glycosylation but not glucose trimming <7>; #5# 3 N-glycosylation
	sites: Asn243, Asn261, Asn399, essential for activity,
	tunicamycin-treated enzyme, which is not glycosylated, shows no
	activity <7,16,17>) <4,7,16,17>

SUBUNITS
SU	#3,4,5,8# ? (#5# x * 60000 + x * 50000, SDS-PAGE <13>; #8# x * 62000 +
	x * 52000, SDS-PAGE <4>; #5# x * 68100, wild-type enzyme, SDS-PAGE <7>;
	#3,4# x * 52000, two major bands migrate at 62000 and 52000 Da,
	SDS-PAGE <46>; #3,4# x * 62000, two major bands migrate at 62000 and
	52000 Da, SDS-PAGE <46>) <4,7,13,46>
SU	#4# dimer (#4# 1 * 63000 + 1 * 53000, SDS-PAGE <12>) <12>

APPLICATION
AP	#4,5# medicine (#4# enzyme activity in extrahepatic bile duct carcinoma
	is increased 3fold compared to mean enzyme activity values, resulting
	in increased bisecting-GlcNAc on the glycans of glycoproteins in cancer
	tissues and a 201 kDa bile glycoprotein <21>; #4# enzyme activity is
	elevated in serum of 60 out of 86 patients with liver cirrhosis, and of
	86 out of 91 patients with chronic hepatitis <20>; #4# enzyme activity
	is elevated in three choriocarcinoma cell lines compared to normal
	placenta. Activity in JEG-3 cells is 27 times higher than normal <22>;
	#5# apart from GnT-III overexpression, engineering of GnT-III
	localization is a versatile tool to modulate the biological activities
	of antibodies relevant for their therapeutic application <25>; #4# the
	majority of N-glycans of a recombinant antibody produced in Nicotiana
	tabacum expressing GnT-III is bisected and devoid of paucimannosidic
	structures. This might improve the efficacy of therapeutic antibodies
	produced in the transgenic plants <27>) <20,21,22,25,27>
AP	#4,5# synthesis (#4# overexpression of enzyme in human hepatoma cells
	fails to reduce branch formation of N-glycans, coexpression of
	caveolin-1 leads to a dramatic decrease in the extent of branching with
	no enhancement of enzyme activity <23>; #5# RC12 cells,
	apheochromocytoma cell line, transfected with enzyme gene, result in
	suppression of neurite outgrowth induced by costimulation of epidermal
	growth factor and integrins. Epidermal growth factor receptor-mediated
	ERK-activation is blocked in transfectants. Epidermal growth factor
	receptor of transfectants is modified by bisecting GlcNAc in its
	N-glycan structures <19>; #4# transfection of mouse aorta endothelial
	cells with enzyme results in reduction of their susceptibility to
	complement-mediated cell lysis by normal human serum and suppresses the
	antigenicity of cells to human natural antibodies. Reactivity of
	glycoproteins of transfectants to normal human serum and GSIB4 lectin
	is reduced <24>; #4# introduction of human
	N-acetylglucosaminyltransferase gene into tobacco plants leads to
	highly efficient synthesis of bisected N-glycans. The majority of
	N-glycans of an antibody produced in a plant expressing GnT-III is also
	bisected. This might improve the efficacy of therapeutic antibodies
	produced in this type of transgenic plant <27>) <19,23,24,27>

ENGINEERING
EN	#5# D321A (#5# inactive <44>; #5# site-directed mutagenesis, expression
	level in COS-1 cells similar to wild-type, but no remaining catalytic
	activity <17>) <17,44>
EN	#5# D323A (#5# site-directed mutagenesis, expression level in COS-1
	cells similar to wild-type, but no remaining catalytic activity <17>;
	#5# expression of a catalytically inactive D232A mutant in human
	hepatoblastoma cell line Huh6, leading to suppression of the endogenous
	enzyme activity, but not to a significant decrease in the expression
	level of the endogenous enzyme <17>) <17>
EN	#5# D329A (#5# site-directed mutagenesis, unaltered compared to
	wild-type <17>) <17>
EN	#5# N243Q (#5# site-directed mutagenesis of 1 N-glycosylation site,
	40-50% activity compared to the wild-type, slightly increased Km-value
	for the donor substrate <7>) <7,16>
EN	#5# N261Q (#5# site-directed mutagenesis of 1 N-glycosylation site,
	40-50% activity compared to the wild-type, slightly increased Km-value
	for the donor substrate <7>) <7,16>
EN	#5# N399Q (#5# site-directed mutagenesis of 1 N-glycosylation site,
	70-80% activity compared to the wild-type <7>) <7,16>
EN	#5# N243Q/N261Q (#5# site-directed mutagenesis of 2 N-glycosylation
	sites, 10% activity compared to the wild-type <7>) <7,16>
EN	#5# N243Q/N399Q (#5# site-directed mutagenesis of 2 N-glycosylation
	sites, highly reduced activity <7>) <7,16>
EN	#5# N261Q/N399Q (#5# site-directed mutagenesis of 2 N-glycosylation
	sites, highly reduced activity <7>) <7,16>
EN	#5# N243Q/N261Q/N399Q (#5# site-directed mutagenesis of all
	N-glycosylation sites, no remaining activity <7>) <7,16>
EN	#9# more (#9# GnT-III overexpression does not affect cell morphology.
	Gastric cells overexpressing GnT-III appears to exhibit a more focused
	immunolocalization at cell-cell borders than control cells. In GnT-III
	transfected cells there is a well-localized continuous staining of
	E-cadherin at the cell membrane that correlates with F-actin staining,
	suggesting co-localization, GnT-III overexpression prevents
	clathrin-dependent E-cadherin endocytosis, phenotype, overview <43>;
	#9# overexpression of GnT-III significantly inhibits
	alpha2,3-sialylation but not alpha2,6-sialylation. The migratory
	ability of cells, HeLa-S3, CHO-K1 and Pro-5, without or with a low
	level of alpha2,6-sialylation is consistently suppressed after
	overexpression of GnT-III, while in alpha2,6-hypersialylated MDA-MB-231
	and MKN-45 cells little effects are observed. Phenotypes, detailed
	overview <51>) <43,51>

CLONED
CL	#3# (GnT-III transfection into highly pigmented, highly metastatic
	macrophage-melanoma fusion hybrids results in the suppression of both
	melanogenesis and motility. The effects of GnT-III appear to occur
	through inhibition of GnT-V action) <32>
CL	#4# (cloning of cDNA by RT-PCR) <15>
CL	#4# (expression of mutant aglycosyl-enzyme, lacking the first 23 amino
	acid residues, in Escherichia coli) <12>
CL	#4# (overexpression in HeLa cells, leading to suppression of
	H2O2-induced activation of PKCdelta-JNK1 signalling pathway resulting
	in inhibition of apoptosis) <10>
CL	#4# (expression in erythroleukemia cell line K562, leading to increased
	resistance to lysis by natural killer cells and enhanced spleen
	colonization ability) <11,16>
CL	#4# (overexpression in murine lung melanoma cell line B16-hm, leading
	to suppression of the formation of beta-1,6-tri- and tetraantennary
	N-linked oligosaccharides by inhibiting the responsible enzymes, e.g.
	N-acetylglucosamine transferase V, EC 2.4.1.155, decrease of the
	metastatic potential of B16-hm melanoma in vivo, changed phenotype)
	<8,11,16>
CL	#4# (heterozygous alpha 1,3-galactosyltransferase gene knockout pigs
	produced with transgenic pig fetal cells expressing both human
	decay-accelerating factor and N-acetylglucosaminyltransferase III) <30>
CL	#4# (introduction of human N-acetylglucosaminyltransferase (GnT)-III
	gene into Nicotiana tabacum leads to highly efficient synthesis of
	bisected N-glycans) <27>
CL	#4# (introduction of human N-acetylglucosaminyltransferase gene into
	tobacco plants leads to highly efficient synthesis of bisected
	N-glycans. The majority of N-glycans of an antibody produced in a plant
	expressing GnT-III is also bisected. This might improve the efficacy of
	therapeutic antibodies produced in this type of transgenic plant) <27>
CL	#4# (amplified for cloning into pENTR-D-Topo vector, cloned gene
	inserted into the virus expression vector, pBABE-puro. GnT-III and
	GnT-V constructs transfected into Phoenix-Ampho cells) <40>
CL	#4# (expressed in transgenic mice) <42>
CL	#4# (GnT-III overexpressed in MKN45 cells) <39>
CL	#4# (highly metastatic melanoma B16 cells transfected with GnT-III and
	then injected into syngeneic mice via the tail vein) <35>
CL	#5# <25>
CL	#5# (expression of wild-type and mutants in COS-1 cells) <7,16,17>
CL	#5# (expression of a catalytically inactive D232A mutant in human
	hepatoblastoma cell line Huh6, leading to suppression of the endogenous
	enzyme activity, but not to a significant decrease in the expression
	level of the endogenous enzyme) <17>
CL	#5# (expression of soluble His-tagged protein in Spodoptera frugiperda
	Sf 21 insect cells via baculovirus infection, secretion into the
	medium) <13,16>
CL	#5# (construction of transgenic mice, disruption of certain functions
	of apolipoprotein B leading to generation of a aftty liver) <11,16>
CL	#5# (overexpression in rat pheochromocytoma cell line PC-12,
	glycoproteins contain elevated levels of bisecting GlcNAc, abolished
	cell differentiation) <11>
CL	#5# (GnT-III stable expressing cell lines of Neuro-2a mouse
	neuroblastoma cells and B16 mouse melanoma cells are established.
	Overexpression of GnT-III up-regulates adenylyl cyclases activity in
	Neuro-2a mouse neuroblastoma cells and B16 mouse melanoma cells) <31>
CL	#5# (rat GnTIII is expressed either with its native localization domain
	(GnTIII) or with the cytoplasmic tail, transmembrane domain and stem
	region (CTS) of Arabidopsis thaliana mannosidase II. N-Glycans of
	plants expressing rat GnTIII contain three major glycan structures of
	complex bisected, complex, or hybrid bisected type, accounting for
	70%-85% of the total N-glycans. Expression of rat
	beta(1,4)-N-acetylglucosaminyltransferase III in Nicotiana tabacum
	remodels the plant-specific N-glycosylation) <33>
CL	#5# (construction of genes for expression of native rat GnTIII, human
	ManII, Arabidopsis thaliana ManII and for the expression of the
	catalytic domains of rat GnTIII and human ManII fused to the N-terminal
	region of Arabidopsis thaliana ManII. Binary plasmids for high-level
	expression of rat GnTIII (pAX67), chimeric rat GnTIIIA.th. (replaced
	native localization domain with the cytoplasmic tail, transmembrane,
	and stem region of Arabidopsis thaliana mannosidase II) (pAX70),
	co-expression of rat GnTIII together with human ManII (pAX73) or
	Arabidopsis thaliana ManII (pAX100), co-expression of GnTIIIA.th.
	together with ManIIA.th. (pAX74), and co-expression of GnTIIIA.th. and
	Arabidopsis thaliana ManII (pAX101). Expression of the transgenes is
	driven by a chimeric promoter assembled from regulatory elements from
	mannopine and octopine synthase genes. Expression cassettes comprising
	the CaMV 35S promoter, GnTIII or ManII and the nos pA, being pSK103
	(ManII), pSK124 (ManII-Arabidopsis thaliana), pAX63 (GnTIII-Arabidopsis
	thaliana) and pAX68 (GnTIII) serve as starting point for further
	expression constructs. The cassette comprising the CaMV 35 promoter,
	plant relocalized GnTIII and polyadenylation signal is excised from
	pAX68 using SbfI, EcoRI and inserted into pAX36 generating pAX90. The
	construct comprising the rat GnTIII obtained by replacing the XbaI,
	AflII fragment from pAX90 with the fragment isolated from pAX63,
	generating pAX91. Mutated fragment from pCLF40 inserted into pAX69
	using AvaI, StuI, generating pAX104. The binary expression plasmids for
	inactive GnTIII and GnTIIIA.th. under the control of the UAS123mas
	promoter generated by replacing the StuI, EcoRI fragment from pAX104
	with that in pAX67 (generating pAX105) and pAX70 (generating pAX106),
	respectively. The mutated fragment from pCLF40 inserted into pAX91
	using Eam1105I, StuI, generating the expression plasmid for inactive
	GnTIII under the control of the CaMV 35S promoter (pAX108). The
	exchange of the fragment containing the Arabidopsis thaliana Golgi
	localization domain from pAX90 in pAX108 using SbfI, StuI yields an
	expression plasmid for inactive GnTIIIA.th. under the control of the
	CaMV 35S promoter. Plasmids transferred into Agrobacterium tumefaciens
	LBA4404 for transformation into tobacco BY-2 cells) <41>
CL	#5# (Sf21 cells infected with recombinant baculovirus encoding GnT-III)
	<37>
CL	#5# (expressed in Spodoptera frugiperda Sf21 cells) <44>
CL	#8# <16>
CL	#8# (cloning from genetic library, DNA sequence determination,
	functional overexpression in COS-1 or HeLa-cells, transient
	transfection) <4>
CL	#9# (enzyme overexpression in HeLa-S3, CHO-K1, Pro-5, and MDA-MB-231
	cells using vector CSIV-TRE-RfA-CMV-KT, cloning in HEK-293T cells) <51>
CL	#9# (gene MGAT3, quantitative real-time PCR enzyme expression analysis)
	<43>
CL	#9# (gene MGAT3, real-time RT-PCR enzyme expression analysis,
	establishing of human melanoma cell line WM-266-4 with induced stable
	overexpression of GnT-III, the cells show increased amounts of bisected
	and beta1-6 branched N-glycans on melanoma cell adhesion molecule
	MCAM/MUC18, but do not display significant differences in viability and
	capabilities to migrate through an endothelial layer, coexpression with
	MGAT5 gene, EC 2.4.1.155) <49>

PURIFICATION
PU	#4# (recombinant mutant enzyme from E. coli) <12>
PU	#4# (wild-type, diethyl(2-hydroxypropyl)aminoethyl-Sepharose and
	immunoaffinity chromatography) <12>
PU	#5# <16>
PU	#5# (recombinant His-tagged protein from medium of Spodoptera
	frugiperda Sf 21 cell culture) <13>
PU	#5# (by nickel-chelating affinity chromatography) <37>
PU	#8# <11>
PU	#8# (primary structure) <4,16>

STORAGE_STABILITY
SS	#1# (-20°C, chicken oviduct microsomal preparation, several months in
	detergent-free buffer) <1>

REFERENCE
RF	<1> Schachter, H.; Brockhausen, I.; Hull, E.: High-performance liquid
	chromatography assays for N-acetylglucosaminyltransferases involved in
	N- and O-glycan synthesis. Methods Enzymol. (1989) 179, 351-397.
	{Pubmed:2560125} (review)
RF	<2> Taniguchi, N.; Nishikawa, A.; Fujii, S.; Gu, J.:
	Glycosyltransferase assays using pyridylaminated acceptors:
	N-acetylglucosaminyltransferase III, IV, and V. Methods Enzymol. (1989)
	179, 397-408. {Pubmed:2533651}
RF	<3> Narasimhan, S.: Control of glycoprotein synthesis.
	UDP-GlcNAc:glycopeptide beta 4-N-acetylglucosaminyltransferase III, an
	enzyme in hen oviduct which adds GlcNAc in beta 1-4 linkage to the
	beta-linked mannose of the trimannosyl core of N-glycosyl
	oligosaccharides. J. Biol. Chem. (1982) 257, 10235-10242.
	{Pubmed:6213618}
RF	<4> Nishikawa, A.; Ihara, Y.; Hatakeyama, M.; Kangawa, K.; Taniguchi,
	N.: Purification, cDNA cloning, and expression of
	UDP-N-acetylglucosamine: beta-D-mannoside
	beta-1,4N-acetylglucosaminyltransferase III from rat kidney. J. Biol.
	Chem. (1992) 267, 18199-18204. {Pubmed:1325461}
RF	<5> Miyoshi, E.; Nishikawa, A.; Ihara, Y.; Hayashi, N.; Fusamoto, H.;
	Kamada, T.; Taniguchi, N.: Selective suppression of
	N-acetylglucosaminyltransferase III activity in a human hepatoblastoma
	cell line transfected with hepatitis B virus. Cancer Res. (1994) 54,
	1854-1858. {Pubmed:8137300}
RF	<6> Yoshimura, M.; Nishikawa, A.; Ihara, Y.; Nishiura, T.; Nakao, H.;
	Kanayama, Y.; Matuzawa, Y.; Taniguchi, N.: High expression of
	UDP-N-acetylglucosamine:beta-D mannoside
	beta-1,4-N-acetylglucosaminyltransferase III (GnT-III) in chronic
	myelogenous leukemia in blast crisis. Int. J. Cancer (1995) 60,
	443-449. {Pubmed:7829256}
RF	<7> Nagai, K.; Ihara, Y.; Wada, Y.; Taniguchi, N.: N-Glycosylation is
	requisite for the enzyme activity and Golgi retention of
	N-acetylglucosaminyltransferase III. Glycobiology (1997) 7, 769-776.
	{Pubmed:9376679}
RF	<8> Taniguchi, N.; Yoshimura, M.; Miyoshi, E.; Ihara, Y.; Nishikawa,
	A.; Kang, R.; Ikeda, Y.: Gene expression and regulation of
	N-acetylglucosaminyltransferases III and V in cancer tissues. Adv.
	Enzyme Regul. (1998) 38, 223-232. {Pubmed:9762355}
RF	<9> Rudd, P.M.; Endo, T.; Colominas, C.; Groth, D.; Wheeler, S.F.;
	Harvey, D.J.; Wormald, M.R.; Serban, H.; Prusiner, S.B.; Kobata, A.;
	Dwek, R.A.: Glycosylation differences between the normal and pathogenic
	prion protein isoforms. Proc. Natl. Acad. Sci. USA (1999) 96,
	13044-13049. {Pubmed:10557270}
RF	<10> Shibukawa, Y.; Takahashi, M.; Laffont, I.; Honke, K.; Taniguchi,
	N.: Down-regulation of hydrogen peroxide-induced PKCdelta activation in
	N-acetylglucosaminyltransferase III-transfected HeLaS3 cells. J. Biol.
	Chem. (2003) 278, 3197-3203. {Pubmed:12427758}
RF	<11> Taniguchi, N.; Miyoshi, E.; Ko, J.H.; Ikeda, Y.; Ihara, Y.:
	Implication of N-acetylglucosaminyltransferases III and V in cancer:
	gene regulation and signaling mechanism. Biochim. Biophys. Acta (1999)
	1455, 287-300. {Pubmed:10571019} (review)
RF	<12> Song, E.Y.; Kim, K.A.; Kim, Y.D.; Kwon, D.H.; Lee, H.S.; Kim,
	C.H.; Chung, T.W.; Byun, S.M.: A simplified procedure for the
	purification of human N-acetylglucosaminyltransferase-III from human
	hepatocellular carcinoma tissues. Biotechnol. Lett. (2000) 22, 201-204.
	{Pubmed:}
RF	<13> Ikeda, Y.; Koyota, S.; Ihara, H.; Yamaguchi, Y.; Korekane, H.;
	Tsuda, T.; Sasai, K.; Taniguchi, N.: Kinetic basis for the donor
	nucleotide-sugar specificity of beta1,4-N-acetylglucosaminyltransferase
	III. J. Biochem. (2000) 128, 609-619. {Pubmed:11011143}
RF	<14> Guo, H.B.; Jiang, A.L.; Ju, T.Z.; Chen, H.L.: Opposing changes in
	N-acetylglucosaminyltransferase-V and -III during the cell cycle and
	all-trans retinoic acid treatment of hepatocarcinoma cell line.
	Biochim. Biophys. Acta (2000) 1495, 297-307. {Pubmed:10699467}
RF	<15> Song, E.Y.; Kang, S.K.; Lee, Y.C.; Park, Y.G.; Chung, T.H.; Kwon,
	D.H.; Byun, S.M.; Kim, C.H.: Expression of bisecting
	N-acetylglucosaminyltransferase-III in human hepatocarcinoma tissues,
	fetal liver tissues, and hepatoma cell lines of Hep3B and HepG2. Cancer
	Invest. (2001) 19, 799-807. {Pubmed:11768033}
RF	<16> Ikeda, Y.; Taniguchi, N.: Enzymatic properties and biological
	functions of beta1,4-N-acetylglucosaminyltransferase III. Trends
	Glycosci. Glycotechnol. (2001) 13, 167-176. {Pubmed:} (review)
RF	<17> Ihara, H.; Ikeda, Y.; Koyota, S.; Endo, T.; Honke, K.; Taniguchi,
	N.: A catalytically inactive beta1,4-N-acetylglucosaminyltransferase
	III (GnT-III) behaves as a dominant negative GnT-III inhibitor. Eur. J.
	Biochem. (2002) 269, 193-201. {Pubmed:11784313}
RF	<18> Takamatsu, S.; Inoue, N.; Katsumata, T.; Nakamura, K.;
	Fujibayashi, Y.; Takeuchi, M.: The relationship between the
	branch-forming glycosyltransferases and cell surface sugar chain
	structures. Biochemistry (2005) 44, 6343-6349. {Pubmed:15835923}
RF	<19> Gu, J.; Zhao, Y.; Isaji, T.; Shibukawa, Y.; Ihara, H.; Takahashi,
	M.; Ikeda, Y.; Miyoshi, E.; Honke, K.; Taniguchi, N.:
	beta1,4-N-Acetylglucosaminyltransferase III down-regulates neurite
	outgrowth induced by costimulation of epidermal growth factor and
	integrins through the Ras/ERK signaling pathway in PC12 cells.
	Glycobiology (2004) 14, 177-186. {Pubmed:14576170}
RF	<20> Song, E.Y.; Kim, K.S.; Kim, K.A.; Kim, Y.D.; Kwon, D.H.; Byun,
	S.M.; Kim, H.J.; Chung, T.W.; Choe, Y.K.; Chung, T.W.; Kim, C.H.:
	Determination of
	UDP-N-acetylglucosamine:beta-D-mannoside-1
	4-N-acetylglucosaminyltransferase-III in patients sera with chronic
	hepatitis and liver cirrhosis using a monoclonal antibody. Glycoconj.
	J. (2003) 19, 415-421. {Pubmed:14707488}
RF	<21> Jin, X.L.; Liu, H.B.; Zhang, Y.; Wang, B.S.; Chen, H.L.:
	Alteration in N -acetylglucosaminyltransferase activities and glycan
	structure in tissue and bile glycoproteins from extrahepatic bile duct
	carcinoma. Glycoconj. J. (2004) 20, 399-406. {Pubmed:15238704}
RF	<22> Takamatsu, S.; Katsumata, T.; Inoue, N.; Watanabe, T.;
	Fujibayashi, Y.; Takeuchi, M.: Abnormal biantennary sugar chains are
	expressed in human chorionic gonadotropin produced in the
	choriocarcinoma cell line, JEG-3. Glycoconj. J. (2004) 20, 473-481.
	{Pubmed:15316280}
RF	<23> Sasai, K.; Ikeda, Y.; Ihara, H.; Honke, K.; Taniguchi, N.:
	Caveolin-1 regulates the functional localization of
	N-acetylglucosaminyltransferase III within the Golgi apparatus. J.
	Biol. Chem. (2003) 278, 25295-25301. {Pubmed:12716887}
RF	<24> Chung, T.W.; Kim, K.S.; Kim, C.H.: Reduction of the
	Gal-alpha1,3-Gal epitope of mouse endothelial cells by transfection
	with the N-acetylglucosaminyltransferase III gene. Mol. Cells (2003)
	16, 368-376. {Pubmed:14744028}
RF	<25> Ferrara, C.; Bruenker, P.; Suter, T.; Moser, S.; Puentener, U.;
	Umana, P.: Modulation of therapeutic antibody effector functions by
	glycosylation engineering: influence of Golgi enzyme localization
	domain and co-expression of heterologous
	beta1,4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase
	II. Biotechnol. Bioeng. (2006) 93, 851-861. {Pubmed:16435400}
RF	<26> Shigeta, M.; Shibukawa, Y.; Ihara, H.; Miyoshi, E.; Taniguchi, N.;
	Gu, J.: beta1,4-N-Acetylglucosaminyltransferase III potentiates beta1
	integrin-mediated neuritogenesis induced by serum deprivation in
	Neuro2a cells. Glycobiology (2006) 16, 564-571. {Pubmed:16531477}
RF	<27> Rouwendal, G.J.; Wuhrer, M.; Florack, D.E.; Koeleman, C.A.;
	Deelder, A.M.; Bakker, H.; Stoopen, G.M.; van Die, I.; Helsper, J.P.;
	Hokke, C.H.; Bosch, D.: Efficient introduction of a bisecting GlcNAc
	residue in tobacco N-glycans by expression of the gene encoding human
	N-acetylglucosaminyltransferase III. Glycobiology (2007) 17, 334-344.
	{Pubmed:17179169}
RF	<28> Iijima, J.; Zhao, Y.; Isaji, T.; Kameyama, A.; Nakaya, S.; Wang,
	X.; Ihara, H.; Cheng, X.; Nakagawa, T.; Miyoshi, E.; Kondo, A.;
	Narimatsu, H.; Taniguchi, N.; Gu, J.: Cell-cell interaction-dependent
	regulation of N-acetylglucosaminyltransferase III and the bisected
	N-glycans in GE11 epithelial cells. Involvement of E-cadherin-mediated
	cell adhesion. J. Biol. Chem. (2006) 281, 13038-13046. {Pubmed:16537539}
RF	<29> Zhao, Y.; Nakagawa, T.; Itoh, S.; Inamori, K.; Isaji, T.; Kariya,
	Y.; Kondo, A.; Miyoshi, E.; Miyazaki, K.; Kawasaki, N.; Taniguchi, N.;
	Gu, J.: N-acetylglucosaminyltransferase III antagonizes the effect of
	N-acetylglucosaminyltransferase V on alpha3beta1 integrin-mediated cell
	migration. J. Biol. Chem. (2006) 281, 32122-32130. {Pubmed:16940045}
RF	<30> Takahagi, Y.; Fujimura, T.; Miyagawa, S.; Nagashima, H.;
	Shigehisa, T.; Shirakura, R.; Murakami, H.: Production of alpha
	1,3-galactosyltransferase gene knockout pigs expressing both human
	decay-accelerating factor and N-acetylglucosaminyltransferase III. Mol.
	Reprod. Dev. (2005) 71, 331-338. {Pubmed:15806557}
RF	<31> Li, W.; Takahashi, M.; Shibukawa, Y.; Yokoe, S.; Gu, J.; Miyoshi,
	E.; Honke, K.; Ikeda, Y.; Taniguchi, N.: Introduction of bisecting
	GlcNAc in N-glycans of adenylyl cyclase III enhances its activity.
	Glycobiology (2007) 17, 655-662. {Pubmed:17324955}
RF	<32> Chakraborty, A.K.; Pawelek, J.: beta1,6-Branched oligosaccharides
	regulate melanin content and motility in macrophage-melanoma fusion
	hybrids. Melanoma Res. (2007) 17, 9-16. {Pubmed:17235237}
RF	<33> Frey, A.D.; Karg, S.R.; Kallio, P.T.: Expression of rat
	beta(1,4)-N-acetylglucosaminyltransferase III in Nicotiana tabacum
	remodels the plant-specific N-glycosylation. Plant Biotechnol. J.
	(2009) 7, 33-48. {Pubmed:18778316}
RF	<34> Akama, R.; Sato, Y.; Kariya, Y.; Isaji, T.; Fukuda, T.; Lu, L.;
	Taniguchi, N.; Ozawa, M.; Gu, J.: N-acetylglucosaminyltransferase III
	expression is regulated by cell-cell adhesion via the
	E-cadherin-catenin-actin complex. Proteomics (2008) 8, 3221-3228.
	{Pubmed:18690644}
RF	<35> Gu, J.; Isaji, T.; Sato, Y.; Kariya, Y.; Fukuda, T.: Importance of
	N-glycosylation on alpha5beta1 integrin for its biological functions.
	Biol. Pharm. Bull. (2009) 32, 780-785. {Pubmed:19420742} (review)
RF	<36> Gu, J.; Taniguchi, N.: Potential of N-glycan in cell adhesion and
	migration as either a positive or negative regulator. Cell Adh. Migr.
	(2008) 2, 243-245. {Pubmed:19262156}
RF	<37> Okada, T.; Ihara, H.; Ito, R.; Taniguchi, N.; Ikeda, Y.:
	Bidirectional N-acetylglucosamine transfer mediated by
	beta-1,4-N-acetylglucosaminyltransferase III. Glycobiology (2009) 19,
	368-374. {Pubmed:19095698}
RF	<38> Pinho, S.S.; Reis, C.A.; Paredes, J.; Magalhaes, A.M.; Ferreira,
	A.C.; Figueiredo, J.; Xiaogang, W.; Carneiro, F.; Gaertner, F.; Seruca,
	R.: The role of N-acetylglucosaminyltransferase III and V in the
	post-transcriptional modifications of E-cadherin. Hum. Mol. Genet.
	(2009) 18, 2599-2608. {Pubmed:19403558}
RF	<39> Kariya, Y.; Kato, R.; Itoh, S.; Fukuda, T.; Shibukawa, Y.; Sanzen,
	N.; Sekiguchi, K.; Wada, Y.; Kawasaki, N.; Gu, J.: N-Glycosylation of
	laminin-332 regulates its biological functions. A novel function of the
	bisecting GlcNAc. J. Biol. Chem. (2008) 283, 33036-33045.
	{Pubmed:18812317}
RF	<40> Sato, Y.; Isaji, T.; Tajiri, M.; Yoshida-Yamamoto, S.; Yoshinaka,
	T.; Somehara, T.; Fukuda, T.; Wada, Y.; Gu, J.: An N-glycosylation site
	on the beta-propeller domain of the integrin alpha5 subunit plays key
	roles in both its function and site-specific modification by
	beta1,4-N-acetylglucosaminyltransferase III. J. Biol. Chem. (2009) 284,
	11873-11881. {Pubmed:19276077}
RF	<41> Karg, S.R.; Frey, A.D.; Kallio, P.T.: Reduction of N-linked xylose
	and fucose by expression of rat beta1,4-N-acetylglucosaminyltransferase
	III in tobacco BY-2 cells depends on Golgi enzyme localization domain
	and genetic elements used for expression. J. Biotechnol. (2010) 146,
	54-65. {Pubmed:20083147}
RF	<42> Gu, J.; Sato, Y.; Kariya, Y.; Isaji, T.; Taniguchi, N.; Fukuda,
	T.: A mutual regulation between cell-cell adhesion and N-glycosylation:
	implication of the bisecting GlcNAc for biological functions. J.
	Proteome Res. (2009) 8, 431-435. {Pubmed:19053837}
RF	<43> Pinho, S.S.; Figueiredo, J.; Cabral, J.; Carvalho, S.; Dourado,
	J.; Magalhaes, A.; Gaertner, F.; Mendonca, A.M.; Isaji, T.; Gu, J.;
	Carneiro, F.; Seruca, R.; Taniguchi, N.; Reis, C.A.: E-cadherin and
	adherens-junctions stability in gastric carcinoma: Functional
	implications of glycosyltransferases involving N-glycan branching
	biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim.
	Biophys. Acta (2012) 1830, 2690-2700. {Pubmed:23671930}
RF	<44> Okada, T.; Ihara, H.; Ito, R.; Nakano, M.; Matsumoto, K.;
	Yamaguchi, Y.; Taniguchi, N.; Ikeda, Y.: N-Glycosylation engineering of
	lepidopteran insect cells by the introduction of the
	beta1,4-N-acetylglucosaminyltransferase III gene. Glycobiology (2010)
	20, 1147-1159. {Pubmed:20554946}
RF	<45> Xu, Q.; Akama, R.; Isaji, T.; Lu, Y.; Hashimoto, H.; Kariya, Y.;
	Fukuda, T.; Du, Y.; Gu, J.: Wnt/beta-catenin signaling down-regulates
	N-acetylglucosaminyltransferase III expression: the implications of two
	mutually exclusive pathways for regulation. J. Biol. Chem. (2011) 286,
	4310-4318. {Pubmed:21115490}
RF	<46> Xu, Q.; Isaji, T.; Lu, Y.; Gu, W.; Kondo, M.; Fukuda, T.; Du, Y.;
	Gu, J.: Roles of N-acetylglucosaminyltransferase III in
	epithelial-to-mesenchymal transition induced by transforming growth
	factor beta1 (TGF-beta1) in epithelial cell lines. J. Biol. Chem.
	(2012) 287, 16563-16574. {Pubmed:22451656}
RF	<47> Reinke, S.; Bayer, M.; Berger, M.; Blanchard, V.; Hinderlich, S.:
	Analysis of cell surface N-glycosylation of the human embryonic kidney
	293T cell line. J. Carbohydr. Chem. (2011) 30, 218-232. {Pubmed:}
RF	<48> Pinho, S.S.; Oliveira, P.; Cabral, J.; Carvalho, S.; Huntsman, D.;
	Gaertner, F.; Seruca, R.; Reis, C.A.; Oliveira, C.: Loss and recovery
	of Mgat3 and GnT-III mediated E-cadherin N-glycosylation is a mechanism
	involved in epithelial-mesenchymal-epithelial transitions. PLoS ONE
	(2012) 7, e33191. {Pubmed:22427986}
RF	<49> Bubka, M.; Link-Lenczowski, P.; Janik, M.; Pochec, E.; Litynska,
	A.: Overexpression of N-acetylglucosaminyltransferases III and V in
	human melanoma cells. Implications for MCAM N-glycosylation. Biochimie
	(2014) 103, 37-49. {Pubmed:24726881}
RF	<50> Hanashima, S.; Korekane, H.; Taniguchi, N.; Yamaguchi, Y.:
	Synthesis of N-glycan units for assessment of substrate structural
	requirements of N-acetylglucosaminyltransferase III. Bioorg. Med. Chem.
	Lett. (2014) 24, 4533-4537. {Pubmed:25139566}
RF	<51> Lu, J.; Isaji, T.; Im, S.; Fukuda, T.; Kameyama, A.; Gu, J.:
	Expression of N-acetylglucosaminyltransferase III suppresses
	alpha2,3-sialylation, and its distinctive functions in cell migration
	are attributed to alpha2,6-sialylation levels. J. Biol. Chem. (2016)
	291, 5708-5720. {Pubmed:26801611}

ACTIVATING_COMPOUND
AC	#1,4,5,8# Triton X-100 (#1,8# activation, about 8fold at 0.13-1.3% v/v
	<1,3,4>) <1,3,4,6,14,15,17>
AC	#4# all-trans retinoic acid (#4# activation <14>) <14>
AC	#4# forskolin (#4# induction of the enzyme in hepatoma cells <11>) <11>
AC	#4# tunicamycin (#4# increase in activity, HepG2 and Hep3B cells <15>)
	<15>
AC	#4# deoxymannojirimycin (#4# increase in activity, HepG2 and Hep3B
	cells <15>) <15>
AC	#4# more (#4# not affected by swainsonine <15>; #4# interferon-alpha-2a
	leads to an increase in enzyme activity in hepatitis B virus infected
	cells due to reduction of virus expression <5>; #4# not affected by
	cAMP <14>) <5,14,15>

KI_VALUE
KI	#5# 1 {GDP-glucose}  (#5# recombinant enzyme <13>) <13>
KI	#5# 3.9 {CDP-glucose}  (#5# recombinant enzyme <13>) <13>
KI	#5# 0.75 {ADP-glucose}  (#5# recombinant enzyme <13>) <13>
KI	#9# 1.5 {methyl
	3
	6-di-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl-2-O-alpha-D
	mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl)-alpha-D
	mannopyranoside}  (#9# pH and temperature not specified in the
	publication, versus UDP-N-acetyl-D-glucosamine <50>) <50>
KI	#9# 1.4 {methyl
	3
	6-di-O-(alpha-D-mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D
	glucopyranosyl)-alpha-D-mannopyranoside}  (#9# pH and temperature not
	specified in the publication, versus UDP-N-acetyl-D-glucosamine <50>)
	<50>
KI	#9# 1.2 {methyl
	3
	6-di-O-(alpha-D-mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D
	glucopyranosyl)-alpha-D-mannopyranoside}  (#9# pH and temperature not
	specified in the publication, versus GnGnbi-PA <50>) <50>
KI	#9# 14 {methyl
	3
	6-di-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl-2-O-alpha-D
	mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl)-alpha-D
	mannopyranoside}  (#9# pH and temperature not specified in the
	publication, versus GnGnbi-PA <50>) <50>

KI_VALUE
KI	#5# 1 {GDP-glucose}  (#5# recombinant enzyme <13>) <13>
KI	#5# 3.9 {CDP-glucose}  (#5# recombinant enzyme <13>) <13>
KI	#5# 0.75 {ADP-glucose}  (#5# recombinant enzyme <13>) <13>
KI	#9# 1.5 {methyl
	3
	6-di-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl-2-O-alpha-D
	mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl)-alpha-D
	mannopyranoside}  (#9# pH and temperature not specified in the
	publication, versus UDP-N-acetyl-D-glucosamine <50>) <50>
KI	#9# 1.4 {methyl
	3
	6-di-O-(alpha-D-mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D
	glucopyranosyl)-alpha-D-mannopyranoside}  (#9# pH and temperature not
	specified in the publication, versus UDP-N-acetyl-D-glucosamine <50>)
	<50>
KI	#9# 1.2 {methyl
	3
	6-di-O-(alpha-D-mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D
	glucopyranosyl)-alpha-D-mannopyranoside}  (#9# pH and temperature not
	specified in the publication, versus GnGnbi-PA <50>) <50>
KI	#9# 14 {methyl
	3
	6-di-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl-2-O-alpha-D
	mannopyranosyl)-4-O-(2-deoxy-2-acetamide-beta-D-glucopyranosyl)-alpha-D
	mannopyranoside}  (#9# pH and temperature not specified in the
	publication, versus GnGnbi-PA <50>) <50>

EXPRESSION
EXP	#3,4# down (#4# downregulation of GnT-III expression in MDA-MB-231
	cells, an E-cadherin-deficient cell line, the MDCK cell, in which
	GnTIII expression is undetectable, and fibroblasts, which lack
	E-cadherin <42>; #4# GnT-III knockdown in MCF-7/AZ cells through siRNA
	<38>; #4# in MDA-MB231 cells, an E-cadherin-deficient cell line,
	GnT-III expression is undetectable <35>; #4# knockdown of GnT-III,
	de-localization of E-cadherin and cytoplasmic accumulation,
	modification of N-glycosylation in E-cadherin <38>; #4# during
	epithelial-mesenchymal-transition, enzyme expression is dramatically
	decreased and later recoveres when cells return to an epithelial-like
	phenotype <48>; #4# stimulation of the Wnt signaling pathway by the
	addition of exogenous Wnt3a or SB415286 consistently and significantly
	inhibits enzyme expression <45>; #3,4# the expression levels of GnT-III
	are suppressed about 25fold in transforming growth factor-beta-treated
	cells (5 ng/ml) <46>) <35,38,42,45,46,48>
EXP	#4# up (#4# E-cadherin-mediated cell-cell interaction upregulates
	GnT-III expression, suggesting that regulation of GnT-III and
	E-cadherin expression may exist as a positive feedback loop <36>; #4#
	E-cadherin-mediated cell-cell interaction upregulates GnT-III
	expression. Significant upregulation of GnT-III expression in
	epithelial cells that express basal levels of E-cadherin and GnT-III
	<35>; #4# increase of enzyme expression by wild-type E-cadherin <38>;
	#4# significant up-regulation of GnT-III expression in epithelial cells
	that express basal levels of E-cadherin and GnT-III. Expression levels
	of GnT-III and its products, the bisected N-glycans, are up-regulated
	by cell-cell interaction via the E-cadherin-catenin-actin complex.
	GnT-III expression is significantly up-regulated in cells cultured
	under dense conditions. Modest increase in GnT-III expression under
	dense culture conditions in alpha-catenin-deficient DLD-1 cells as well
	as in E-cadherin-deficient MDA-MB-231 cells. Mutual regulation of
	GnT-III expression and E-cadherin-mediated cell-cell interaction exists
	as a positive-feedback loop <42>; #4# wild-type E-cadherin regulates
	MGAT3 gene transcription resulting in increased GnT-III expression.
	GnT-III mRNA transcription levels in MDA-MB-435 cells transfected with
	E-cadherin wild-type are ca. 2fold higher than those in MDA-MB-435 mock
	cells <38>; #4# shRNA knockdown of beta-catenin results in a dramatic
	increase in enzyme expression <45>) <35,36,38,42,45>

///
ID	2.4.1.145
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Gallus gallus   <1,2>
PR	#2# Mus musculus   <18,19>
PR	#3# Homo sapiens   <5,8,10,11,12,13,15,16,20,21>
PR	#4# Rattus norvegicus   <3>
PR	#5# Bos taurus   <21>
PR	#6# Bos taurus O77836 SwissProt <4,6>
PR	#7# Homo sapiens Q9UQ53 SwissProt <7,14,17>
PR	#8# Homo sapiens Q9UM21 SwissProt <9,14,17,22>
PR	#8# Homo sapiens Q9UM21 UniProt <9,14,17,22>

RECOMMENDED_NAME
RN	alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase


SYSTEMATIC_NAME
SN	UDP-N-acetyl-alpha-D-glucosamine:N-acetyl-beta-D-glucosaminyl-(1->2)
	alpha-D-mannosyl-(1->3)-beta-D-mannosyl-glycoprotein
	4-beta-N-acetyl-D-glucosaminyltransferase (configuration-inverting)


SYNONYMS
SY	 N-glycosyl-oligosaccharide-glycoprotein
	N-acetylglucosaminyltransferase IV
SY	 beta-acetylglucosaminyltransferase IV
SY	 uridine diphosphoacetylglucosamine-glycopeptide
	beta4-acetylglucosaminyltransferase IV
SY	 alpha-1,3-mannosylglycoprotein beta-1,4-N-acetylglucosaminyltransferase
SY	#2,3,5,8# GnT-IVa (#2# isozyme <18>; #3# isoform <20>; #5# iozyme <21>)
	<14,18,19,20,21,22>
SY	#2,3,7# N-acetylglucosaminyltransferase-IVb (#2# isozyme <18>)
	<14,15,18>
SY	#2,3,7# GnT-IVb (#2# isozyme <18>; #3# isoform <20>; #3# iozyme <21>)
	<14,15,18,20,21>
SY	#2,3,8# N-acetylglucosaminyltransferase-IVa (#2# isozyme <18>)
	<14,15,18,19>
SY	#2,5# Mgat4a (#2,5# gene name <19,21>) <19,21>
SY	#3# N-acetylglucosaminyltransferase IV <16>
SY	#3# GlcNAcTase-IV <11>
SY	#3# GnTIVa <15>
SY	#3# GnT IV <16>
SY	#3# alpha1,3-mannosyl-beta1,4-N-acetylglucosaminyltransferase IV <20>
SY	#3# Mgat4b (#3# gene name <21>) <21>
SY	#3,5# N-acetylglucosaminyltransferase-IV <11,21>
SY	#7# (GnT)-IVb <17>
SY	#8# (GnT)-IVa <17>
SY	#8# N-acetylglucosaminyltransferase IVa <22>

REACTION
RE	UDP-N-acetyl-alpha-D-glucosamine +
	beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D
	Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc-N-Asn
	[protein] = UDP +
	beta-D-GlcNAc-(1->2)-[beta-D-GlcNAc-(1->4)]-alpha-D-Man-(1->3)-[beta-D
	GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1
	>4)-beta-D-GlcNAc-N-Asn-[protein]

REACTION_TYPE
RT	hexosyl group transfer

SOURCE_TISSUE
ST	#1# oviduct <1,2>
ST	#2# liver <18>
ST	#2# ovary <18>
ST	#2# uterus <18>
ST	#2# heart <18>
ST	#2# stomach <18>
ST	#2# brain <18>
ST	#2# lung <18>
ST	#2# muscle <18>
ST	#2# adrenal gland <18>
ST	#2# testis <18>
ST	#2# bone marrow <18>
ST	#2# colon <18>
ST	#2# thymus <18>
ST	#2# hepatoma cell <19>
ST	#2# lymph node <18>
ST	#2# Hca-F cell <19>
ST	#2# HEPA 1-6 cell <19>
ST	#2,3# pancreas <8,18>
ST	#2,3# kidney <5,18>
ST	#2,3# more (#3# three choriocarcinoma cell lines <13>; #2# in wild type
	mice, GnT-IVa expression is restricted to gastrointestinal tissues,
	whereas GnT-IVb is broadly expressed among organs <18>; #3# isoform
	GnT-IVb is ubiquitously and constitutively expressed among tissues
	<21>) <13,18,21>
ST	#2,4# spleen <3,18>
ST	#2,4,6# small intestine <3,4,18>
ST	#3# placenta <13>
ST	#3# KU-812 cell (#3# low activity <11>) <11>
ST	#3# HMCB cell (#3# low activity <11>) <11>
ST	#3# chorion <10>
ST	#3# HeLa-S3 cell (#3# low activity <11>) <11>
ST	#3# THP-1 cell <11>
ST	#3# A-549 cell (#3# low activity <11>) <11>
ST	#3# BeWo cell (#3# high activity <11>) <11>
ST	#3# MOLT-4 cell (#3# high activity <11>) <11>
ST	#3# BALL-1 cell <11>
ST	#3# CACO-2 cell (#3# high activity <11>) <11>
ST	#3# JEG-3 cell <13>
ST	#3# HuO-3N1 cell (#3# low activity <11>) <11>
ST	#3# EoL-1 cell (#3# low activity <11>) <11>
ST	#3# OS-RC-2 cell <11>
ST	#3# NAMALWA cell <11>
ST	#3,5# choriocarcinoma cell <21>
ST	#3,8# Hep-G2 cell (#3# high activity <11>) <11,22>
ST	#5# leukocyte (#5# isoform GnT-IVa is highly restricted in
	gastrointestinal organs and peripheral blood leukocytes <21>) <21>
ST	#5# gastrointestinal tract (#5# isoform GnT-IVa is highly restricted in
	gastrointestinal organs and peripheral blood leukocytes <21>) <21>
ST	#5# peripheral blood <21>
ST	#7,8# pancreatic cancer cell line (#8# Panc-1, PCI6, MIA PaCa-2, and
	BxPC3. Down-regulation of GnT-IVa in pancreatic cancer cells is due to
	an epigenetic abnormality in the gene. When pancreatic cancer cells are
	treated with 5-aza-C or butyrate, the expression of GnT-IVa is
	dramatically increased <14>; #7# Panc-1, PCI6, MIA PaCa-2, and BxPC3.
	Expression of GnT-IVb is increased in pancreatic cancer, compared to
	normal pancreatic tissues <14>) <14>
ST	#7,8# hepatoma HLE cell (#8# in epirubicin-resistant HLE cells, GnT-IVa
	expression is decreased <17>; #7# in epirubicin-resistant HLE cells,
	GnT-IVb expression is increased <17>) <17>
ST	#8# hepatocellular carcinoma cell (#8# high expression of GnT-IVa,
	profiles and structures of the cell-surface N-glycan of hepatocellular
	carcinoma cells, high levels of NA3Fb, a core-alpha-1,6-fucosylated
	triantennary glycan, overview <22>) <22>

LOCALIZATION
LO	#1# membrane <1,2>

NATURAL_SUBSTRATE_PRODUCT
NSP	#1,3# UDP-N-acetyl-D-glucosamine +
	3-(2-[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	= UDP +
	3-(2
	4-bis[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	(#3# GnT-IVa is primarily responsible for the biosynthesis of
	complex-type N-glycans <15>; #3# GnT-IVb might contribute to the basal
	GnT-IV activity in cells <15>; #3# the enzyme is involved in the branch
	formation of Asn-linked sugar chains <11>) {} <2,11,15>
NSP	#1,3# UDP-N-acetyl-D-glucosamine +
	3-(2-[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	= UDP +
	3-(2
	4-bis[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	(#3# GnT-IVa is primarily responsible for the biosynthesis of
	complex-type N-glycans <15>; #3# GnT-IVb might contribute to the basal
	GnT-IV activity in cells <15>; #3# the enzyme is involved in the branch
	formation of Asn-linked sugar chains <11>) <2,11,15>

SUBSTRATE_PRODUCT
SP	#1,3,4,6,7,8# UDP-N-acetyl-D-glucosamine +
	3-(2-[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	= UDP +
	3-(2
	4-bis[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	(#1,6# maximal activity requires the presence of both terminal
	beta-1,2-linked N-acetylglucosamine residues in the substrate <2,4>;
	#4# pyridylaminated sugar chain <3>; #1# R represents the remainder of
	the N-oligosaccharide in the glycoprotein acceptor, the enzyme adds
	N-cetylglucosamine in beta-1,4-linkage to the alpha-1,3-linked mannosyl
	residues of the trimannosyl core of N-glycosyloligosaccharides <2>; #3#
	GnT-IVa is primarily responsible for the biosynthesis of complex-type
	N-glycans <15>; #3# GnT-IVb might contribute to the basal GnT-IV
	activity in cells <15>; #3# the enzyme is involved in the branch
	formation of Asn-linked sugar chains <11>) {}
	<1,2,3,4,5,6,7,8,9,10,11,15>
SP	#1,3,4,6,7,8# UDP-N-acetyl-D-glucosamine +
	3-(2-[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	= UDP +
	3-(2
	4-bis[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	(#1,6# maximal activity requires the presence of both terminal
	beta-1,2-linked N-acetylglucosamine residues in the substrate <2,4>;
	#4# pyridylaminated sugar chain <3>; #1# R represents the remainder of
	the N-oligosaccharide in the glycoprotein acceptor, the enzyme adds
	N-cetylglucosamine in beta-1,4-linkage to the alpha-1,3-linked mannosyl
	residues of the trimannosyl core of N-glycosyloligosaccharides <2>; #3#
	GnT-IVa is primarily responsible for the biosynthesis of complex-type
	N-glycans <15>; #3# GnT-IVb might contribute to the basal GnT-IV
	activity in cells <15>; #3# the enzyme is involved in the branch
	formation of Asn-linked sugar chains <11>) <1,2,3,4,5,6,7,8,9,10,11,15>
SP	#2# UDP-N-acetyl-D-glucosamine +
	GlcNAcbeta1-2Manalpha1-6(GlcNAcbeta1-2Manalpha1-3)Manbeta1-4GlcNAcbeta1
	4GlcNAc-2-aminopyridine = ? (#2# isozyme GnT-IVb has about 30% activity
	of isozyme GnT-IVa <18>) <18>
SP	#3# UDP-N-acetyl-D-glucosamine +
	GlcNAcbeta1-2(GlcNAcbeta1-6)Manalpha1-6(GlcNAcbeta1-2Manalpha1
	3)Manbeta1-4GlcNAcbeta1-4GlcNAc-2-aminopyridine = ? (#3#
	N-acetylglucosaminyltransferase-IVa <15>; #3#
	N-acetylglucosaminyltransferase-IVb <15>) <15>
SP	#3# UDP-N-acetyl-D-glucosamine +
	GlcNAcbeta1-2Manalpha1-3(GlcNAcbeta1-2Manalpha1-6)Manbeta1-4GlcNAcbeta1
	4GlcNAc-2-aminopyridine = ? (#3# N-acetylglucosaminyltransferase-IVa
	<15>; #3# N-acetylglucosaminyltransferase-IVb <15>) <15>
SP	#3# UDP-N-acetyl-D-glucosamine +
	GlcNAcbeta1-2Manalpha1-3(Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc-2
	aminopyridine = ? (#3# N-acetylglucosaminyltransferase-IVa <15>; #3#
	N-acetylglucosaminyltransferase-IVb <15>) <15>
SP	#3# UDP-N-acetyl-D-glucosamine +
	GlcNAcbeta1-2Manalpha1-3(GlcNAcbeta1-2Manalpha1-6)Manbeta1-4GlcNAcbeta1
	4GlcNAc-2-aminopyridine = UDP + ? <16>
SP	#3# UDP-N-acetyl-D-glucosamine + biantennary N-glycan = ? (#3# the
	enzyme transfers a N-acetyl-D-glucosamine from
	UDP-N-acetyl-D-glucosamine to the biantennary oligosaccharide and
	produces triantennary N-glycans with a beta1,4-N-acetyl-D-glucosamine
	on the alpha1,3-Man arm <20>) <20>

KM_VALUE
KM	#3# 10.5
	{GlcNAcbeta1-2Manalpha1-3(Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc-2
	aminopyridine}  (#3# 37°C, pH 7.5, recombinant full-length
	N-acetylglucosaminyltransferase-IVb <15>) <15>
KM	#3# 0.118 {UDP-N-acetyl-D-glucosamine}  (#3# 37°C, pH 7.5, recombinant
	full-length N-acetylglucosaminyltransferase-IVa <15>) <15>
KM	#3# 3.19
	{GlcNAcbeta1-2Manalpha1-3(Manalpha1-6)Manbeta1-4GlcNAcbeta1-4GlcNAc-2
	aminopyridine}  (#3# 37°C, pH 7.5, recombinant full-length
	N-acetylglucosaminyltransferase-IVa <15>) <15>
KM	#3# 3.35
	{GlcNAcbeta1-2(GlcNAcbeta1-6)Manalpha1-6(GlcNAcbeta1-2Manalpha1
	3)Manbeta1-4GlcNAcbeta1-4GlcNAc-2-aminopyridine}  (#3# 37°C, pH 7.5,
	recombinant full-length N-acetylglucosaminyltransferase-IVb <15>) <15>
KM	#3# 1.04
	{GlcNAcbeta1-2Man1-3(GlcNAcbeta1-2Manalpha1-6)Manbeta1-4GlcNAcbeta1
	4GlcNAc-2-aminopyridine}  (#3# 37°C, pH 7.5, recombinant soluble human
	flag-GnTIVa <15>) <15>
KM	#3# 0.242 {UDP-N-acetyl-D-glucosamine}  (#3# 37°C, pH 7.5, recombinant
	full-length N-acetylglucosaminyltransferase-IVb <15>) <15>
KM	#3# 0.358 {UDP-N-acetyl-D-glucosamine}  (#3# 37°C, pH 7.5, recombinant
	soluble human flag-GnTIVa <15>) <15>
KM	#3# 0.341 {UDP-N-acetyl-D-glucosamine}  (#3# 37°C, pH 7.5, recombinant
	soluble human flag-GnTIVa <15>) <15>
KM	#3# 0.532
	{GlcNAcbeta1-2(GlcNAcbeta1-6)Manalpha1-6(GlcNAcbeta1-2Manalpha1
	3)Manbeta1-4GlcNAcbeta1-4GlcNAc-2-aminopyridine}  (#3# 37°C, pH 7.5,
	recombinant full-length N-acetylglucosaminyltransferase-IVa <15>) <15>
KM	#3# 5.72
	{GlcNAcbeta1-2Manalpha1-3(GlcNAcbeta1-2Manalpha1-6)Manbeta1
	4GlcNAcbeta1-4GlcNAc-2-aminopyridine}  (#3# 37°C, pH 7.5, recombinant
	full-length N-acetylglucosaminyltransferase-IVb <15>) <15>
KM	#3# 6.94
	{GlcNAcbeta1-2Man1-3(GlcNAcbeta1-2Manalpha1-6)Manbeta1-4GlcNAcbeta1
	4GlcNAc-2-aminopyridine}  (#3# 37°C, pH 7.5, recombinant soluble human
	flag-GnTIVa <15>) <15>
KM	#3# 0.971
	{GlcNAcbeta1-2Manalpha1-3(GlcNAcbeta1-2Manalpha1-6)Manbeta1
	4GlcNAcbeta1-4GlcNAc-2-aminopyridine}  (#3# 37°C, pH 7.5, recombinant
	full-length N-acetylglucosaminyltransferase-IVa <15>) <15>
KM	#4# 8.3 {UDP-N-acetylglucosamine}  (#4# pyridylaminated acceptor
	substrate <3>) <3>
KM	#4# 3.4 {pyridylaminated acceptor substrate}  <3>

PH_OPTIMUM
PHO	#1# 7 (#1# in presence of 0.625% Triton X-100 <2>) <2>
PHO	#4,6# 7.3 <3,4>

PH_RANGE
PHR	#1# 6.5-7.5 (#1# depends on Triton X-100 concentration <2>) <2>
PHR	#6# 7-8 <4>

SPECIFIC_ACTIVITY
SA	#1,3,7# -999.0 (#3# comparison between normal and malignant chorionic
	cells <10>; #3# comparison between normal and malignant pancreatic
	cells <8>; #1# activities for different glycopeptides as acceptors <2>;
	#7# differences between isozymes expressed in COS7 cells <7>; #3#
	comparison between normal and malignant kidney cortex cells <5>)
	<2,5,7,8,10>
SA	#6# 1.65 <4>

TEMPERATURE_OPTIMUM
TO	#1,4# 37 (#1,4# assay at <1,2,3>) <1,2,3>

ACTIVATING_COMPOUND
AC	#1# Triton X-100 (#1# maximum activation at 0.125% <2>) <2>

INHIBITORS
IN	#6# Cu2+ <4>
IN	#6# EDTA <4>
IN	#6# UDP <4>
IN	#6# Mn2+ (#6# at high concentration <4>) <4>
IN	#6# more (#6# sugar nucleotides having the UDP moiety inhibit activity
	to different extent <4>) <4>

METALS_IONS
ME	#1,4,6# Mn2+ <1,3,4>
ME	#6# Mg2+ <4>
ME	#6# Co2+ <4>

MOLECULAR_WEIGHT
MW	#3# 66000 (#3# SDS-PAGE <16>) <16>
MW	#6# 58000 (#6# deduced from SDS-PAGE and gel filtration results <4>) <4>
MW	#6# 61610 (#6# deduced from cDNA sequence <6>) <6>
MW	#7# 63200 (#7# isozyme b, deduced from cDNA sequence <7>) <7>

POSTTRANSLATIONAL_MODIFICATION
PM	#6# glycoprotein (#6# Asn-linked sugar chains <4,6>) <4,6>

SUBUNITS
SU	#6# monomer (#6# 1 * 58000, SDS-PAGE <4>) <4>

APPLICATION
AP	#3# medicine (#3# enzyme activity in tissue from patients with
	extrahepatic bile duct carcinoma remains unchanged <12>; #3# enzyme
	activity is elevated in three choriocarcinoma cell lines compared to
	normal placenta. Activity in JEG-3 cells is 29 times higher than normal
	<13>) <12,13>
AP	#3# synthesis (#3# it is necessary to select appropriate host cell
	lines according to their glycosyltransferases activity balance to
	produce glycoproteins with an objective sugar chain structure. The
	descibed method of grouping cell lines according to their
	glycosyltransferases activity balance is useful to select appropriate
	host cells <11>) <11>

ENGINEERING
EN	#8# more (#8# knockdown of GnT-IVa in 1668 cells and HepG2 cells by
	transfection with GnT-IVa shRNA. The level of NA3Fb decreases and M8
	increases in knockdown GnT-IVa/1668 cells compared with GnT-IVa/NC
	after 48 h transfection. The scratch healing rates of the GnT-IVa/1668
	group decreases more than the GnT-IVa/NC group. High expression of
	GnT-IVa leads to a higher level of NA3Fb in the HCC cell surface, and
	the downregulation of GnT-IVa may modulate cell invasion and migration
	through NA3Fb glycan <22>) <22>

CLONED
CL	#3# (recombinant full-length enzyme and soluble truncated form tagged
	with FLAG sequence at the N-terminus. expressed in COS7 cells,
	N-acetylglucosaminyltransferase-IVa) <15>
CL	#3# (recombinant full-length enzyme and soluble truncated form tagged
	with FLAG sequence at the N-terminus. expressed in COS7 cells,
	N-acetylglucosaminyltransferase-IVb) <15>
CL	#3# (expressed in Nicotiana benthamiana) <20>
CL	#3# (expressed in Spodoptera frugiperda and Trichoplusia ni cells by
	using a baculovirus expression vector) <16>
CL	#6# (expression in COS-7 cells) <6>
CL	#7# (expression of the isozyme b in COS7 cells) <7>
CL	#8# (expression in COS7 cells) <9>
CL	#8# (gene MGAT4A, expression analysis) <22>

PURIFICATION
PU	#1# (partial) <1,2>
PU	#3# (IgG Sepharose resin column chromatography) <16>
PU	#6# (Q-Sepharose and Cu2+ Sepharose chromatography, followed by
	UDP-hexanolamine-agarose affinity chomatography) <4>

STORAGE_STABILITY
SS	#1# (-20°C, crude microsomal preparation, several months in
	detergent-free buffer) <1>

REFERENCE
RF	<1> Schachter, H.; Brockhausen, I.; Hull, E.: High-performance liquid
	chromatography assays for N-acetylglucosaminyltransferases involved in
	N- and O-glycan synthesis. Methods Enzymol. (1989) 179, 351-397.
	{Pubmed:2560125} (review)
RF	<2> Gleeson, P.A.; Schachter, H.: Control of glycoprotein synthesis. J.
	Biol. Chem. (1983) 258, 6162-6173. {Pubmed:6222042}
RF	<3> Taniguchi, N.; Nishikawa, A.; Fujii, S.; Gu, J.:
	Glycosyltransferase assays using pyridylaminated acceptors:
	N-acetylglucosaminyltransferase III, IV, and V. Methods Enzymol. (1989)
	179, 397-408. {Pubmed:2533651}
RF	<4> Oguri, S.; Minowa, M.T.; Ihara, Y.; Taniguchi, N.; Ikenaga, H.;
	Takeuchi, M.: Purification and characterization of
	UDP-N-acetylglucosamine: alpha1,3-D-mannoside
	beta1,4-N-acetylglucosaminyltransferase
	(N-acetylglucosaminyltransferase-IV) from bovine small intestine. J.
	Biol. Chem. (1997) 272, 22721-22727. {Pubmed:9278430}
RF	<5> Zhu, T.Y.; Chen, H.L.; Gu, J.X.; Zhang, Y.F.; Zhang, Y.K.; Zhang,
	R.A.: Changes in N-acetylglucosaminyltransferase III, IV, and V in
	renal cell carcinoma. J. Cancer Res. Clin. Oncol. (1997) 123, 296-299.
	{Pubmed:9201254}
RF	<6> Minowa, M.T.; Oguri, S.; Yoshida, A.; Hara, T.; Iwamatsu, A.;
	Ikenaga, H.; Takeuchi, M.: cDNA cloning and expression of bovine
	UDP-N-acetylglucosamine: alpha1,3-D-mannoside
	beta1,4-N-acetylglucosaminyltransferase IV. J. Biol. Chem. (1998) 273,
	11556-11562. {Pubmed:9565571}
RF	<7> Yoshida, A.; Minowa, M.T.; Takamatsu, S.; Hara, T.; Ikenaga, H.;
	Takeuchi, M.: A novel second isoenzyme of the human
	UDP-N-acetylglucosamine:alpha1,3-D-mannoside
	beta1,4-N-acetylglucosaminyltransferase family: cDNA cloning,
	expression, and chromosomal assignment. Glycoconjugate J. (1998) 15,
	1115-1123. {Pubmed:10372966}
RF	<8> Nan, B.C.; Shao, D.M.; Chen, H.L.; Huang, Y.; Gu, J.X.; Zhang,
	Y.B.; Wu, Z.G.: Alteration of N-acetylglucosaminyltransferases in
	pancreatic carcinoma. Glycoconjugate J. (1998) 15, 1033-1037.
	{Pubmed:10211708}
RF	<9> Yoshida, A.; Minowa, M.T.; Takamatsu, S.; Hara, T.; Oguri, S.;
	Ikenaga, H.; Takeuchi, M.: Tissue specific expression and chromosomal
	mapping of a human UDP-N-acetylglucosamine:alpha1,3-D-mannoside
	beta1,4-N-acetylglucosaminyltransferase. Glycobiology (1999) 9,
	303-310. {Pubmed:10024668}
RF	<10> Takamatsu, S.; Oguri, S.; Minowa, M.T.; Yoshida, A.; Nakamura, K.;
	Takeuchi, M.; Kobata, A.: Unusually high expression of
	N-acetylglucosaminyltransferase-IVa in human choriocarcinoma cell
	lines: a possible enzymatic basis of the formation of abnormal
	biantennary sugar chain. Cancer Res. (1999) 59, 3949-3953.
	{Pubmed:10463590}
RF	<11> Takamatsu, S.; Inoue, N.; Katsumata, T.; Nakamura, K.;
	Fujibayashi, Y.; Takeuchi, M.: The relationship between the
	branch-forming glycosyltransferases and cell surface sugar chain
	structures. Biochemistry (2005) 44, 6343-6349. {Pubmed:15835923}
RF	<12> Jin, X.L.; Liu, H.B.; Zhang, Y.; Wang, B.S.; Chen, H.L.:
	Alteration in N -acetylglucosaminyltransferase activities and glycan
	structure in tissue and bile glycoproteins from extrahepatic bile duct
	carcinoma. Glycoconj. J. (2004) 20, 399-406. {Pubmed:15238704}
RF	<13> Takamatsu, S.; Katsumata, T.; Inoue, N.; Watanabe, T.;
	Fujibayashi, Y.; Takeuchi, M.: Abnormal biantennary sugar chains are
	expressed in human chorionic gonadotropin produced in the
	choriocarcinoma cell line, JEG-3. Glycoconj. J. (2004) 20, 473-481.
	{Pubmed:15316280}
RF	<14> Ide, Y.; Miyoshi, E.; Nakagawa, T.; Gu, J.; Tanemura, M.; Nishida,
	T.; Ito, T.; Yamamoto, H.; Kozutsumi, Y.; Taniguchi, N.: Aberrant
	expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and
	b) in pancreatic cancer. Biochem. Biophys. Res. Commun. (2006) 341,
	478-482. {Pubmed:16434023}
RF	<15> Oguri, S.; Yoshida, A.; Minowa, M.T.; Takeuchi, M.: Kinetic
	properties and substrate specificities of two recombinant human
	N-acetylglucosaminyltransferase-IV isozymes. Glycoconj. J. (2006) 23,
	473-480. {Pubmed:17006639}
RF	<16> Kim, N.Y.; Kim, H.G.; Kim, Y.H.; Chung, I.S.; Yang, J.M.:
	Expression and characterization of human
	N-acetylglucosaminyltransferases and alpha2,3-sialyltransferase in
	insect cells for in vitro glycosylation of recombinant erythropoietin.
	J. Microbiol. Biotechnol. (2008) 18, 383-391. {Pubmed:18309288}
RF	<17> Kudo, T.; Nakagawa, H.; Takahashi, M.; Hamaguchi, J.; Kamiyama,
	N.; Yokoo, H.; Nakanishi, K.; Nakagawa, T.; Kamiyama, T.; Deguchi, K.;
	Nishimura, S.; Todo, S.: N-glycan alterations are associated with drug
	resistance in human hepatocellular carcinoma. Mol. Cancer (2007) 6, 32.
	{Pubmed:17488527}
RF	<18> Takamatsu, S.; Antonopoulos, A.; Ohtsubo, K.; Ditto, D.; Chiba,
	Y.; Le, D.T.; Morris, H.R.; Haslam, S.M.; Dell, A.; Marth, J.D.;
	Taniguchi, N.: Physiological and glycomic characterization of
	N-acetylglucosaminyltransferase-IVa and -IVb double deficient mice.
	Glycobiology (2010) 20, 485-497. {Pubmed:20015870}
RF	<19> Fan, J.; Wang, S.; Yu, S.; He, J.; Zheng, W.; Zhang, J.:
	N-acetylglucosaminyltransferase IVa regulates metastatic potential of
	mouse hepatocarcinoma cells through glycosylation of CD147. Glycoconj.
	J. (2012) 29, 323-334. {Pubmed:22736280}
RF	<20> Nagels, B.; Van Damme, E.J.; Pabst, M.; Callewaert, N.; Weterings,
	K.: Production of complex multiantennary N-glycans in Nicotiana
	benthamiana plants. Plant Physiol. (2011) 155, 1103-1112.
	{Pubmed:21233332}
RF	<21> Ohtsubo, K.: Biological significance of
	N-acetylglucosaminyltransferase-IV-mediated protein glycosylation on
	the homeostasis of cellular physiological functions. Trends Glycosci.
	Glycotechnol. (2011) 23, 103-105. {Pubmed:}
RF	<22> Nie, H.; Liu, X.; Zhang, Y.; Li, T.; Zhan, C.; Huo, W.; He, A.;
	Yao, Y.; Jin, Y.; Qu, Y.; Sun, X.L.; Li, Y.: Specific N-glycans of
	hepatocellular carcinoma cell surface and the abnormal increase of
	core-alpha-1,6-fucosylated triantennary Glycan via
	N-acetylglucosaminyltransferases-IVa regulation. Sci. Rep. (2015) 5,
	16007. {Pubmed:26537865}

ACTIVATING_COMPOUND
AC	#1# Triton X-100 (#1# maximum activation at 0.125% <2>) <2>

EXPRESSION
EXP	#5# up (#5# Mgat4a expression is induced under hypoxic conditions.
	Isoform GnT-IVa expression is aberrantly up-regulated in some type of
	tumor cells <21>) <21>
EXP	#5# down (#5# Mgat4a expression levels are significantly reduced in the
	pancreatic beta cells of type 2 diabetes patients <21>) <21>

///
ID	2.4.1.149
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Cricetulus griseus   <12>
PR	#2# Mus musculus   <13,15>
PR	#3# Homo sapiens   <2,3,4,7,11,14,16,17>
PR	#4# Rattus norvegicus   <1,5,8>
PR	#5# Bos taurus   <6>
PR	#6# Helicobacter pylori   <18>
PR	#7# Mus musculus Q8K0J2 SwissProt <9>
PR	#8# Homo sapiens Q8NFL0 SwissProt <9>
PR	#9# Homo sapiens O43505  <10>

RECOMMENDED_NAME
RN	N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase


SYSTEMATIC_NAME
SN	UDP-N-acetyl-alpha-D-glucosamine:beta-D-galactosyl-(1->4)-N-acetyl-beta
	D-glucosaminyl-R 3-beta N-acetylglucosaminyltransferase
	(configuration-inverting)


SYNONYMS
SY	 GnT-I
SY	 IGnT
SY	 acetylglucosaminyltransferase, uridine
	diphosphoacetylglucosamine-acetyllactosaminide beta1-->3-
SY	 uridine diphosphoacetylglucosamine-acetyllactosaminide
	beta1-->3-acetylglucosaminyltransferase
SY	 poly-N-acetyllactosamine extension enzyme
SY	 Galbeta1-->4GlcNAc-R beta1-->3 N-acetylglucosaminyltransferase
SY	 UDP-GlcNAc:GalR, beta-D-3-N-acetylglucosaminyltransferase
SY	 N-acetyllactosamine beta(1-3)N-acetylglucosaminyltransferase
SY	 UDP-GlcNAc:Galbeta1-->4GlcNAcbeta-Rbeta1-->3-N
	acetylglucosaminyltransferase
SY	 UDP-GlcNAc:Galbeta1-4Glc(NAc) beta-1,3-N-acetylglucosaminyltransferase
SY	 i-GlcNAc transferase
SY	 i-GlcNAcT
SY	#2# beta1-3 N-acetylglucosaminyltransferase-1 <15>
SY	#2,3# B3gnt1 <15,16>
SY	#3# beta3Gn-T7 <14>
SY	#3# beta1,3-N-acetylglucosaminyltransferase-7 <14>
SY	#3# beta-1,3-N-acetylglucosaminyltransferase 1 <16>
SY	#3# UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 <16>
SY	#3# beta3-N-acetylglucosaminyltransferase 1 <17>
SY	#3# beta3GnT1 <17>
SY	#6# beta1,3-N-acetylglucosaminyltransferase <18>
SY	#6# beta3GlcNAcT <18>
SY	#6# JHP1032 <18>
SY	#7# beta3GnT7 <9>

REACTION
RE	UDP-N-acetyl-alpha-D-glucosamine +
	beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl
	beta-D-glucosaminyl-R

REACTION_TYPE
RT	hexosyl group transfer

SOURCE_TISSUE
ST	#1# CHO cell (#1# Pro-5 and Lec2 CHO cells <12>) <12>
ST	#2# P-1798 cell (#2# lymphoma cell line <13>) <13>
ST	#3# HeLa cell <16>
ST	#3# brain (#3# highly expressed in fetal and adult brain <10>) <10>
ST	#3# more (#3# enzyme is undetectable in normal colonic epithelial
	cells, but is greatly enhanced both during fetal development and in
	colonic adenocarcinomas <4>; #3# enzyme is expressed ubiquitously in
	various adult tissues <10>) <4,10>
ST	#3# MCF-7 cell <17>
ST	#3# MDA-MB-231 cell <17>
ST	#3# DU-145 cell <17>
ST	#3# PC-3 cell <17>
ST	#3# SW-1116 cell (#3# colonic carcinoma cell line <10>) <10>
ST	#3# SW-403 cell (#3# colonic adenocarcinoma cell line <4>) <4>
ST	#3# WM-266-4 cell (#3# human melanoma cell line <10>) <10>
ST	#3# LNCaP cell <17>
ST	#3# MDA-MB-435 cell <17>
ST	#3# PC-3H cell <17>
ST	#3,5# serum (#3# normal blood group 0 serum <3>; #5# newborn calf serum
	<6>) <2,3,6,11>
ST	#3,7# kidney (#7# moderate expression of beta3GnT7 <9>; #3# highly
	expressed in fetal kidney <10>) <9,10>
ST	#4# Novikoff ascites tumor cell (#4# strain N1S1-67 <1,5>) <1,5>
ST	#4# PC-12 cell (#4# pheochromacytoma cells, nerve growth factor
	stimulated cells with reduced GnT-i activity compared to unstimulated
	cells <8>) <8>
ST	#4# PC-12D cell (#4# new subline of pheochromacytoma cells PC-12, low
	GnT-i activity <8>) <8>
ST	#7# placenta (#7# beta3GnT7 is most strongly expressed in the placenta
	at the later stages of gestation and in colon <9>) <9>
ST	#7# heart (#7# very weak expression of beta3GnT7 <9>) <9>
ST	#7# stomach (#7# moderate expression of beta3GnT7 <9>) <9>
ST	#7# cerebellum (#7# very weak expression of beta3GnT7 <9>) <9>
ST	#7# lung (#7# moderate expression of beta3GnT7 <9>) <9>
ST	#7# testis (#7# very weak expression of beta3GnT7 <9>) <9>
ST	#7# small intestine (#7# moderate expression of beta3GnT7 <9>) <9>
ST	#7# colon (#7# beta3GnT7 is most strongly expressed in the placenta and
	colon <9>) <9>
ST	#7# FM3A cell (#7# breast cancer cell line, higher expression of
	beta3GnT7 in cancer cell lines with low degrees of invasiveness <9>) <9>
ST	#7# cerebrum (#7# very weak expression of beta3GnT7 <9>) <9>
ST	#7# KLN205 cell (#7# KLN205-MUC1, lung cancer cell line, higher
	expression of beta3GnT7 in cancer cell lines with low degrees of
	invasiveness <9>) <9>

LOCALIZATION
LO	#2,3# membrane (#3# membrane-bound <4>; #3# type II membrane protein
	topology, longest transmembrane domain among glycosyltransferases
	cloned so far <10>) <4,10,13>
LO	#3# soluble <3,7>
LO	#3# Golgi apparatus (#3# stem region and large catalytic domain reside
	presumably in the Golgi lumen <10>; #3# B3GNT1 and B4GALT1 colocalize
	and interact with each other in the trans-Golgi <16>) <10,16>

NATURAL_SUBSTRATE_PRODUCT
NSP	#1,3,4,5# UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine = ?
	(#5# involved in the initiation and extension of
	poly-N-acetyllactosamine biosynthesis, may act as a key enzyme <6>; #3#
	enzyme is capable of elongation of polylactosamine i-chains <11>; #4#
	biosynthesis of poly-N-acetyllactosamine chains on N-linked
	oligosaccharides, catalyzes a rate-limiting reaction in the expression
	of poly-N-acetyllactosamine chains, especially in pheochromocytoma
	cells <8>; #3# poly-N-acetyllactosamine biosynthesis, polylactosamine
	extension occurs on both beta1,2- and beta1,6-branches of complex
	N-type glycans <7>; #1# synthesis of N-acetyllactosamine repeats in
	Asn-linked oligosaccharides is enhanced by an increase of enzyme <12>)
	{} <5,6,7,8,10,11,12>
NSP	#2,3,7# more = ? (#3# biosynthesis of lacto-series core chains, enzyme
	is activated in association with oncogenesis in colonic epithelia <4>;
	#7# beta3GnT7 may play a role in preventing cells from migrating out of
	the original tissues and invading surrounding tissues <9>; #3# the
	enzyme together with N-acetyllactosamine synthase, EC 2.4.1.90,
	catalyzes formation of linear glycans containing alternating
	beta-3-O-substituted residues of D-galactose and beta-4-O-substituted
	residues of N-acetyl-D-glucosamine, structures are present among others
	in glycosphingolipids or H-II type, polyglycosylceramides and
	polyglycosylpeptides, e.g. erythroglycan <2>; #2# biosynthesis of Ii
	core glycosphingolipids <13>; #3# enzyme is in volved in biosynthesis
	of keratan sulfate, overview, enzyme is an anti-migration factor for a
	lung cancer cell line <14>; #2# B3gnt1 null females are fertile, the
	B3gnt1 null males are not able to sire litters at the expected rate
	when mated to either wild type or B3gnt1-null females <15>) {}
	<2,4,9,13,14,15>
NSP	#2,3,7# more = ? (#3# biosynthesis of lacto-series core chains, enzyme
	is activated in association with oncogenesis in colonic epithelia <4>;
	#7# beta3GnT7 may play a role in preventing cells from migrating out of
	the original tissues and invading surrounding tissues <9>; #3# the
	enzyme together with N-acetyllactosamine synthase, EC 2.4.1.90,
	catalyzes formation of linear glycans containing alternating
	beta-3-O-substituted residues of D-galactose and beta-4-O-substituted
	residues of N-acetyl-D-glucosamine, structures are present among others
	in glycosphingolipids or H-II type, polyglycosylceramides and
	polyglycosylpeptides, e.g. erythroglycan <2>; #2# biosynthesis of Ii
	core glycosphingolipids <13>; #3# enzyme is in volved in biosynthesis
	of keratan sulfate, overview, enzyme is an anti-migration factor for a
	lung cancer cell line <14>; #2# B3gnt1 null females are fertile, the
	B3gnt1 null males are not able to sire litters at the expected rate
	when mated to either wild type or B3gnt1-null females <15>) {}
	<2,4,9,13,14,15>
NSP	#3,4# UDP-N-acetyl-D-glucosamine +
	beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1
	4-N-acetyl-D-glucosaminyl-R (#4# might function in the biosynthesis of
	cell surface polylactosaminoglycans on Novikoff cells and blood group i
	antigenic structures, enzyme controls the synthesis of linear chain
	types by adding a N-acetylglucosaminyl residue to a
	Galbeta(1-4)GlcNAc-R primer structure present on glycoprotein or
	glycolipid yielding a GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R sequence <1>;
	#3# involved in the biosynthesis of blood group precursors, enzyme
	might control the biosynthesis of the linear carbohydrate chain by
	adding a N-acetylglucosaminyl residue to a Galbeta(1-4)GlcNAc-R
	structure present on oligosaccharides, glycosylceramides and
	glycoproteins <3>; #3# enzyme is essential for the formation of
	poly-N-acetyllactosamines and the i-antigen, responsible for the
	formation of GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R structure and
	poly-N-acetyllactosamine extension <10>; #4# enzyme functions in both
	the initiation and elongation of linear i-active polylactosaminoglycan
	chains of N-glycoproteins and possibly other glycoconjugates <5>)
	<1,3,5,10>
NSP	#3,4# UDP-N-acetyl-D-glucosamine +
	beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1
	4-N-acetyl-D-glucosaminyl-R (#4# might function in the biosynthesis of
	cell surface polylactosaminoglycans on Novikoff cells and blood group i
	antigenic structures, enzyme controls the synthesis of linear chain
	types by adding a N-acetylglucosaminyl residue to a
	Galbeta(1-4)GlcNAc-R primer structure present on glycoprotein or
	glycolipid yielding a GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R sequence <1>;
	#3# involved in the biosynthesis of blood group precursors, enzyme
	might control the biosynthesis of the linear carbohydrate chain by
	adding a N-acetylglucosaminyl residue to a Galbeta(1-4)GlcNAc-R
	structure present on oligosaccharides, glycosylceramides and
	glycoproteins <3>; #3# enzyme is essential for the formation of
	poly-N-acetyllactosamines and the i-antigen, responsible for the
	formation of GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R structure and
	poly-N-acetyllactosamine extension <10>; #4# enzyme functions in both
	the initiation and elongation of linear i-active polylactosaminoglycan
	chains of N-glycoproteins and possibly other glycoconjugates <5>) {}
	<1,3,5,10>
NSP	#3,5# UDP-N-acetyl-D-glucosamine + N-glycan = ? (#3# polylactosamine
	extension occurs on both beta1,2- and beta1,6-branches of complex
	N-type glycans <7>; #5# physiological acceptors: N-glycans, O-glycans,
	glycolipids and keratan sulfates <6>) {} <6,7>
NSP	#5# UDP-N-acetyl-D-glucosamine + O-glycan = ? (#5# physiological
	acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates <6>)
	{} <6>
NSP	#5# UDP-N-acetyl-D-glucosamine + glycolipid = ? (#5# physiological
	acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates <6>)
	{} <6>
NSP	#5# UDP-N-acetyl-D-glucosamine + keratan sulfate = ? (#5# physiological
	acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates <6>)
	{} <6>

SUBSTRATE_PRODUCT
SP	#1,3,4,5# UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine = ?
	(#5# involved in the initiation and extension of
	poly-N-acetyllactosamine biosynthesis, may act as a key enzyme <6>; #3#
	enzyme is capable of elongation of polylactosamine i-chains <11>; #4#
	biosynthesis of poly-N-acetyllactosamine chains on N-linked
	oligosaccharides, catalyzes a rate-limiting reaction in the expression
	of poly-N-acetyllactosamine chains, especially in pheochromocytoma
	cells <8>; #3# poly-N-acetyllactosamine biosynthesis, polylactosamine
	extension occurs on both beta1,2- and beta1,6-branches of complex
	N-type glycans <7>; #1# synthesis of N-acetyllactosamine repeats in
	Asn-linked oligosaccharides is enhanced by an increase of enzyme <12>)
	{} <5,6,7,8,10,11,12>
SP	#1,3,4,5# UDP-N-acetylglucosamine + N-acetyllactosamine = UDP +
	GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc (#3# more physiological acceptor than
	lactose <2>; #3,4# more effective acceptor than lactose <3,5>; #5#
	transfer of one GlcNAc to position C-3 of the terminal Gal residue of
	lactose or N-acetyllactosamine in the beta linkage <6>) <2,3,5,6,12,17>
SP	#2# UDP-N-acetyl-D-glucosamine + lactosylceramide = ? (#2# 15% of the
	activity with neolactotetraosylceramide <13>) <13>
SP	#2# UDP-N-acetyl-D-glucosamine +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1
	3-beta-D-galactosyl-1,4-beta-D-glucosylceramide = UDP +
	N-acetyl-D-glucosaminyl-1,3-beta-D-galactosyl-1
	4-N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1
	4-beta-D-glucosylceramide (#2# i.e. neolactotetraosylceramide,
	GlcNAcT-2, synthesis in vitro of Ii core glycosphingolipids <13>) <13>
SP	#2# UDP-N-acetyl-D-glucosamine + asialo alpha1-acid glycoprotein = ?
	(#2# sialic acid depleted alpha1-acid glycoprotein, 30% of the activity
	with neolactotetraosylceramide <13>) <13>
SP	#2,3,4,5,6,7# more = ? (#3# no acceptors: melibiose, gentiobiose,
	galactose, glucose, N-acetylgalactosamine, N-acetylglucosamine <3>; #4#
	asialo-serum glycoproteins are much more effective than O-glycoproteins
	as acceptors, overview over oligosaccharide substrates <5>; #3#
	transfer of GlcNAc occurs mainly to type 2 chain nonfucosylated
	structures, elongation of type 1 chain structure Lc4 is also
	detectable, no transfer to any fucosylated derivative of either type 1
	or 2 chains, transfer of GlcNAc to a terminal Gal residue on a
	lacto-series core chain <4>; #5# terminal Galbeta(1-4)Glc(NAc)
	sequences, i.e. type II chains, are preferred substrates, no
	substrates: terminal Galbeta(1-3)GlcNAc sequences, i.e. type I chains,
	Lewis X trisaccharides, i.e. Galbeta(1-4)(Fucalpha(1-3))GlcNAc,
	monosaccharides, e.g. galactose, asialo-bovine submaxillary mucin that
	contains GalNAcalpha1-Ser/Thr and Galbeta(1-3)GalNAcalpha1-Ser/Thr <6>;
	#3# no acceptor: Galbeta(1-3)GlcNAcbeta(1-3)Galbeta(1-4)Glc <10>; #3#
	biosynthesis of lacto-series core chains, enzyme is activated in
	association with oncogenesis in colonic epithelia <4>; #7# beta3GnT7
	may play a role in preventing cells from migrating out of the original
	tissues and invading surrounding tissues <9>; #3# the enzyme together
	with N-acetyllactosamine synthase, EC 2.4.1.90, catalyzes formation of
	linear glycans containing alternating beta-3-O-substituted residues of
	D-galactose and beta-4-O-substituted residues of
	N-acetyl-D-glucosamine, structures are present among others in
	glycosphingolipids or H-II type, polyglycosylceramides and
	polyglycosylpeptides, e.g. erythroglycan <2>; #2# biosynthesis of Ii
	core glycosphingolipids <13>; #3# enzyme is in volved in biosynthesis
	of keratan sulfate, overview, enzyme is an anti-migration factor for a
	lung cancer cell line <14>; #3# substrate specificity, enzyme acts
	efficiently on keratan sulfate-related glycans, while lacto-N-tetraose
	and lacto-N-neo-tetraose are poor substrates, overview, product
	analysis <14>; #2# B3gnt1 null females are fertile, the B3gnt1 null
	males are not able to sire litters at the expected rate when mated to
	either wild type or B3gnt1-null females <15>; #6# the enzyme shows no
	activity on a terminal Gal with Neu5Acalpha(2->6) substitution.
	Terminal galactose with alpha-linkage, Galalpha(1->3)Gal or
	Galalpha(1->4)Gal is not an acceptor substrate for the enzyme <18>) {}
	<2,3,4,5,6,9,10,13,14,15,18>
SP	#2,3,4,5,6,7# more = ? (#3# no acceptors: melibiose, gentiobiose,
	galactose, glucose, N-acetylgalactosamine, N-acetylglucosamine <3>; #4#
	asialo-serum glycoproteins are much more effective than O-glycoproteins
	as acceptors, overview over oligosaccharide substrates <5>; #3#
	transfer of GlcNAc occurs mainly to type 2 chain nonfucosylated
	structures, elongation of type 1 chain structure Lc4 is also
	detectable, no transfer to any fucosylated derivative of either type 1
	or 2 chains, transfer of GlcNAc to a terminal Gal residue on a
	lacto-series core chain <4>; #5# terminal Galbeta(1-4)Glc(NAc)
	sequences, i.e. type II chains, are preferred substrates, no
	substrates: terminal Galbeta(1-3)GlcNAc sequences, i.e. type I chains,
	Lewis X trisaccharides, i.e. Galbeta(1-4)(Fucalpha(1-3))GlcNAc,
	monosaccharides, e.g. galactose, asialo-bovine submaxillary mucin that
	contains GalNAcalpha1-Ser/Thr and Galbeta(1-3)GalNAcalpha1-Ser/Thr <6>;
	#3# no acceptor: Galbeta(1-3)GlcNAcbeta(1-3)Galbeta(1-4)Glc <10>; #3#
	biosynthesis of lacto-series core chains, enzyme is activated in
	association with oncogenesis in colonic epithelia <4>; #7# beta3GnT7
	may play a role in preventing cells from migrating out of the original
	tissues and invading surrounding tissues <9>; #3# the enzyme together
	with N-acetyllactosamine synthase, EC 2.4.1.90, catalyzes formation of
	linear glycans containing alternating beta-3-O-substituted residues of
	D-galactose and beta-4-O-substituted residues of
	N-acetyl-D-glucosamine, structures are present among others in
	glycosphingolipids or H-II type, polyglycosylceramides and
	polyglycosylpeptides, e.g. erythroglycan <2>; #2# biosynthesis of Ii
	core glycosphingolipids <13>; #3# enzyme is in volved in biosynthesis
	of keratan sulfate, overview, enzyme is an anti-migration factor for a
	lung cancer cell line <14>; #3# substrate specificity, enzyme acts
	efficiently on keratan sulfate-related glycans, while lacto-N-tetraose
	and lacto-N-neo-tetraose are poor substrates, overview, product
	analysis <14>; #2# B3gnt1 null females are fertile, the B3gnt1 null
	males are not able to sire litters at the expected rate when mated to
	either wild type or B3gnt1-null females <15>; #6# the enzyme shows no
	activity on a terminal Gal with Neu5Acalpha(2->6) substitution.
	Terminal galactose with alpha-linkage, Galalpha(1->3)Gal or
	Galalpha(1->4)Gal is not an acceptor substrate for the enzyme <18>) {}
	<2,3,4,5,6,9,10,13,14,15,18>
SP	#3# UDP-N-acetyl-D-glucosamine +
	Galbeta(1-4)GlcNAcbeta(1-6)(Galbeta(1-4)GlcNAcbeta(1-2))Manalpha(1
	6)Manbeta-octyl = ? (#3# regioselectivity of enzyme, favored site of
	GlcNAc addition is the lower beta1,2-branch over the beta1,6-branch by
	a 3:1 ratio resulting in a mixture of heptasaccharides <7>) <7>
SP	#3# UDP-N-acetyl-D-glucosamine + Galbeta(1-4)GlcNAcbeta-p-nitrophenol =
	UDP + GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta-p-nitrophenol <7>
SP	#3# UDP-N-acetyl-D-glucosamine + GalNAcbeta(1-4)GlcNAcbeta1-OR = UDP +
	GlcNAcbeta(1-3)GalNAcbeta(1-4)GlcNAcbeta1-OR (#3# i.e.
	N,N’-diacetyllactosediamine-OR <11>) |#3# only 12.5% of the substrate
	is converted into the product, which is unusually resistant towards
	jackbean beta-N-acetylhexosaminidase <11>| <11>
SP	#3# UDP-N-acetyl-D-glucosamine +
	GalNAcbeta(1-4)GlcNAcbeta(1-3)Galbeta1-OMe = UDP +
	GlcNAcbeta(1-3)GalNAcbeta(1-4)GlcNAcbeta(1-3)Galbeta1-OMe <11>
SP	#3# UDP-N-acetyl-D-glucosamine + GalNAcbeta(1-4)GlcNAcbeta1-OMe = UDP +
	GlcNAcbeta(1-3)GalNAcbeta(1-4)GlcNAcbeta1-OMe <11>
SP	#3# UDP-N-acetyl-D-glucosamine +
	GalNAcbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc = UDP +
	GlcNAcbeta(1-3)GalNAcbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc |#3#
	mixture of the pentasaccharide product, 27 mol%, and the unreacted
	tetrasaccharide, 73 mol% <11>| <11>
SP	#3# UDP-N-acetylglucosamine + lactosylceramide = ? (#3#
	lactosylceramide from human erythrocytes <4>) <4>
SP	#3# UDP-N-acetylglucosamine + lactoneotetraosylceramide = ? (#3#
	lactoneotetraosylceramide from bovine erythrocytes, higher rate than
	with lactonorhexaosylceramide, efficiency decreases with growing
	acceptor chain length <4>) <4>
SP	#3# UDP-N-acetylglucosamine + lactonorhexaosylceramide = ? (#3#
	lactonorhexaosylceramide from bovine erythrocytes, lower rate than with
	lactoneotetraosylceramide, efficiency decreases with growing acceptor
	chain length <4>) <4>
SP	#3# UDP-N-acetylglucosamine + lactotetraosylceramide = ? (#3#
	lactotetraosylceramide from human meconium, poor substrate <4>) <4>
SP	#3# UDP-N-acetyl-D-glucosamine +
	Galbeta1,4(SO3-,6)-GlcNAcbeta1,3(SO3-,6)-Galbeta1,4(SO3-,6)-GlcNAc =
	UDP +
	GlcNAcbeta1,3-Galbeta1,4(SO3-,6)-GlcNAcbeta1,3(SO3-,6)-Galbeta1,4(SO3-
	6)-GlcNAc (#3# i.e. L2L4, 72% activity compared to L2L2 <14>) {} <14>
SP	#3# UDP-N-acetyl-D-glucosamine +
	Galbeta1,4(SO3-,6)-GlcNAcbeta1,3-Galbeta1,4(SO3-,6)-GlcNAc = UDP +
	GlcNAcbeta1,3-Galbeta1,4(SO3-,6)GlcNAcbeta1,3-Galbeta1,4(SO3-,6)-GlcNAc
	(#3# i.e. L2L2, a 6-O-sulfated keratan sulfate, best substrate <14>)
	<14>
SP	#3# UDP-N-acetyl-D-glucosamine +
	Galbeta1,4(SO3-,6)-GlcNAcbeta1,3-Galbeta1,4(SO3-,6)-GlcNAc = UDP +
	GlcNAcbeta1,3-Galbeta1,4(SO3-,6)GlcNAcbeta1,3Galbeta1,4(SO3-,6)-GlcNAc
	(#3# i.e. L2L2, a 6-O-sulfated keratan sulfate, best substrate <14>)
	<14>
SP	#3# UDP-N-acetyl-D-glucosamine + poly-N-acetyllactosamine = UDP +
	GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc (#3# poly-N-acetyllactosamine is
	biosynthesized by the alternating addition of N-acetyl-D-glucosamine by
	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase and Gal by
	UDP-Gal:betaGlcNAc beta-1,4-galactosyltransferase <16>) <16>
SP	#3,4# UDP-N-acetyl-D-glucosamine +
	beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1
	4-N-acetyl-D-glucosaminyl-R (#4# acts on
	beta-galactosyl-1,4-N-acetylglucosaminyl termini on asialo-alpha1-acid
	glycoproteins and other glycoproteins and oligosaccharides, GlcNAc
	residues are introduced to position C-3 of the terminal galactose of
	the glycoprotein <1>; #4# highly specific for acceptor oligosaccharides
	and glycoproteins carrying a terminal Galbeta(1-4)GlcNAcbeta1-R unit,
	catalyzes the formation of GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta-R
	sequence, Galbeta(1-4)GlcNAcbeta(1-2)(Galbeta(1-4)GlcNAcbeta(1-6))Man
	pentasaccharide in the acceptor structure is a requirement for optimal
	activity, branch specificity, branches of this pentasaccharide
	structure, when contained in tri- and tetraantennary oligosaccharides,
	are highly preferred over other branches for attachment of the 1st and
	2nd mol of GlcNAc into the acceptor molecule, enzyme also shows
	activity towards oligosaccharides related to blood group I- and
	i-active polylactosaminoglycans <5>; #3# iGnT has a unique
	characteristic in binding to acceptor substrates, preferentially adding
	poly-N-acetyllactosamine to membrane glycoproteins <10>; #4# might
	function in the biosynthesis of cell surface polylactosaminoglycans on
	Novikoff cells and blood group i antigenic structures, enzyme controls
	the synthesis of linear chain types by adding a N-acetylglucosaminyl
	residue to a Galbeta(1-4)GlcNAc-R primer structure present on
	glycoprotein or glycolipid yielding a
	GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R sequence <1>; #3# involved in the
	biosynthesis of blood group precursors, enzyme might control the
	biosynthesis of the linear carbohydrate chain by adding a
	N-acetylglucosaminyl residue to a Galbeta(1-4)GlcNAc-R structure
	present on oligosaccharides, glycosylceramides and glycoproteins <3>;
	#3# enzyme is essential for the formation of poly-N-acetyllactosamines
	and the i-antigen, responsible for the formation of
	GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R structure and
	poly-N-acetyllactosamine extension <10>; #4# enzyme functions in both
	the initiation and elongation of linear i-active polylactosaminoglycan
	chains of N-glycoproteins and possibly other glycoconjugates <5>; #3#
	B3GNT1 displays an in vitro preference for the GlcNAcbeta1->2Man branch
	<16>) <1,2,3,5,10,11,16>
SP	#3,4# UDP-N-acetyl-D-glucosamine +
	beta-D-galactosyl-1,4-N-acetyl-D-glucosaminyl-R = UDP +
	N-acetyl-beta-D-glucosaminyl-1,3-beta-D-galactosyl-1
	4-N-acetyl-D-glucosaminyl-R (#4# acts on
	beta-galactosyl-1,4-N-acetylglucosaminyl termini on asialo-alpha1-acid
	glycoproteins and other glycoproteins and oligosaccharides, GlcNAc
	residues are introduced to position C-3 of the terminal galactose of
	the glycoprotein <1>; #4# highly specific for acceptor oligosaccharides
	and glycoproteins carrying a terminal Galbeta(1-4)GlcNAcbeta1-R unit,
	catalyzes the formation of GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta-R
	sequence, Galbeta(1-4)GlcNAcbeta(1-2)(Galbeta(1-4)GlcNAcbeta(1-6))Man
	pentasaccharide in the acceptor structure is a requirement for optimal
	activity, branch specificity, branches of this pentasaccharide
	structure, when contained in tri- and tetraantennary oligosaccharides,
	are highly preferred over other branches for attachment of the 1st and
	2nd mol of GlcNAc into the acceptor molecule, enzyme also shows
	activity towards oligosaccharides related to blood group I- and
	i-active polylactosaminoglycans <5>; #3# iGnT has a unique
	characteristic in binding to acceptor substrates, preferentially adding
	poly-N-acetyllactosamine to membrane glycoproteins <10>; #4# might
	function in the biosynthesis of cell surface polylactosaminoglycans on
	Novikoff cells and blood group i antigenic structures, enzyme controls
	the synthesis of linear chain types by adding a N-acetylglucosaminyl
	residue to a Galbeta(1-4)GlcNAc-R primer structure present on
	glycoprotein or glycolipid yielding a
	GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R sequence <1>; #3# involved in the
	biosynthesis of blood group precursors, enzyme might control the
	biosynthesis of the linear carbohydrate chain by adding a
	N-acetylglucosaminyl residue to a Galbeta(1-4)GlcNAc-R structure
	present on oligosaccharides, glycosylceramides and glycoproteins <3>;
	#3# enzyme is essential for the formation of poly-N-acetyllactosamines
	and the i-antigen, responsible for the formation of
	GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc-R structure and
	poly-N-acetyllactosamine extension <10>; #4# enzyme functions in both
	the initiation and elongation of linear i-active polylactosaminoglycan
	chains of N-glycoproteins and possibly other glycoconjugates <5>; #3#
	B3GNT1 displays an in vitro preference for the GlcNAcbeta1->2Man branch
	<16>) {} <1,2,3,5,10,11,16>
SP	#3,4,5# UDP-N-acetylglucosamine + asialo-alpha1-acid glycoprotein = UDP
	+ N-acetylglucosaminylated asialo-alpha1-acid glycoprotein (#5# best
	acceptor among the glycoproteins that contain Galbeta(1-4)GlcNAc <6>;
	#4# GlcNAc residues are introduced to position C-3 of the terminal
	galactose of the glycoprotein, relative high activity towards
	asialo-alpha1-acid glycoprotein in Novikoff ascites tumor cells <1>;
	#4# much more effective than asialo-transferrin and asialo-fetuin,
	asialo-alpha1-acid glycoprotein from human plasma Cohn fraction V,
	transfer of GlcNAc to a terminal Gal in a beta1,3-linkage <5>)
	<1,5,6,10>
SP	#3,4,5# UDP-N-acetylglucosamine + lactose = UDP +
	GlcNAcbeta(1-3)Galbeta(1-4)Glc (#3# less physiological acceptor than
	N-acetyllactosamine <2>; #3# less effective acceptor than
	N-acetyllactosamine <3>; #4# 70% of activity with N-acetyllactosamine
	<5>; #5# transfer of one GlcNAc to position C-3 of the terminal Gal
	residue of lactose or N-acetyllactosamine in the beta linkage, 51% of
	activity with N-acetyllactosamine <6>) <2,3,5,6>
SP	#3,5# UDP-N-acetyl-D-glucosamine +
	Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc = UDP +
	GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc (#5# i.e.
	lacto-N-neotetraose, 117% of activity with N-acetyllactosamine <6>)
	<6,10>
SP	#3,5# UDP-N-acetyl-D-glucosamine + N-glycan = ? (#3# polylactosamine
	extension occurs on both beta1,2- and beta1,6-branches of complex
	N-type glycans <7>; #5# physiological acceptors: N-glycans, O-glycans,
	glycolipids and keratan sulfates <6>) {} <6,7>
SP	#4# UDP-N-acetylglucosamine + porcine submaxillary asialo-afuco-mucin =
	UDP + N-acetylglucosaminylated porcine submaxillary asialo-afuco-mucin
	(#4# very poor substrate <5>; #4# poor acceptor, Galbeta(1-3)GalNAc as
	terminal acceptor structure <1>) <1,5>
SP	#4# UDP-N-acetylglucosamine + asialo-transferrin = UDP +
	N-acetylglucosaminylated asialo-transferrin (#4# much less effective
	than asialo-alpha1-acid glycoprotein, transfer of GlcNAc to a terminal
	Gal in a beta1,3-linkage <5>) <5>
SP	#4# UDP-N-acetylglucosamine + asialo-fetuin = UDP +
	N-acetylglucosaminylated asialo-fetuin (#4# much less effective than
	asialo-alpha1-acid glycoprotein, transfer of GlcNAc to a terminal Gal
	in a beta1,3-linkage <5>) <5>
SP	#4# UDP-N-acetyl-D-glucosamine +
	Galbeta(1-4)GlcNAcbeta(1-4)GlcNAc-2-aminopyridine = UDP +
	GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta(1-4)GlcNAc-2-aminopyridine <8>
SP	#5# UDP-N-acetyl-D-glucosamine + O-glycan = ? (#5# physiological
	acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates <6>)
	{} <6>
SP	#5# UDP-N-acetyl-D-glucosamine + glycolipid = ? (#5# physiological
	acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates <6>)
	{} <6>
SP	#5# UDP-N-acetyl-D-glucosamine + keratan sulfate = ? (#5# physiological
	acceptors: N-glycans, O-glycans, glycolipids and keratan sulfates <6>)
	{} <6>
SP	#6#
	Galbeta(1->4)GlcNAcbeta(1->3)[Galbeta(1->4)GlcNAcbeta(1->6)]GalNAcalpha
	OCH(CH3)CH(NH2)CO2H = UDP +
	GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)[Galbeta(1->4)GlcNAcbeta(1
	>6)]GalNAcalpha-OCH(CH3)CH(NH2)CO2H (#6# 115% activity compared to
	Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Fucalpha(1->2)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 = UDP +
	GlcNAcbeta(1->3)[Fucalpha(1->2)]Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 (#6#
	32% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Galbeta(1->3)GalNAcalpha-OCH(CH3)CH(NH2)CO2H = UDP +
	GlcNAcbeta(1->3)Galbeta(1->3)GalNAcalpha-OCH(CH3)CH(NH2)CO2H (#6# 48%
	activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine + Galbeta(1->3)GalNAcbeta-O(CH2)2NH2 =
	UDP + GlcNAcbeta(1->3)Galbeta(1->3)GalNAcbeta-O(CH2)2NH2 (#6# 76%
	activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine + Galbeta(1->3)GalNAcbeta-pNP = UDP +
	GlcNAcbeta(1->3)Galbeta(1->3)GalNAcbeta-pNP (#6# poor acceptor, 23%
	activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine + Galbeta(1->3)GlcNAcbeta-O(CH2)3N3 =
	UDP + GlcNAcbeta(1->3)Galbeta(1->3)GlcNAcbeta-O(CH2)3N3 (#6# 48%
	activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Galbeta(1->3)[Galbeta(1->4)GlcNAcbeta(1->6)]GalNAcalpha
	OCH(CH3)CH(NH2)CO2H = UDP +
	GlcNAcbeta(1->3)Galbeta(1->3)[Galbeta(1->4)GlcNAcbeta(1->6)]GalNAcalpha
	OCH(CH3)CH(NH2)CO2H (#6# 101% activity compared to
	Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Galbeta(1->3)[GlcNAcbeta(1->6)]GalNAcalpha-OCH(CH3)CH(NH2)CO2H = UDP +
	GlcNAcbeta(1->3)Galbeta(1->3)[GlcNAcbeta(1->6)]GalNAcalpha
	OCH(CH3)CH(NH2)CO2H (#6# 28% activity compared to
	Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine + Galbeta(1->4)Glcbeta-O(CH2)3N3 = UDP +
	GlcNAcbeta(1->3)Galbeta(1->4)Glcbeta-O(CH2)3N3 (#6# 65% activity
	compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1
	>4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 = UDP +
	GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1
	>3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 (#6#
	107% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1
	>4)GlcNAcbeta-O(CH2)3N3 = UDP +
	GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1
	>3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 (#6# 101% activity compared to
	Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 = UDP +
	GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta
	O(CH2)3N3 (#6# 90% activity compared to
	Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Galbeta(1->4)GlcNAcbeta(1->3)GalNAcalpha-OCH(CH3)CH(NH2)CO2H = UDP +
	GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->3)GalNAcalpha
	OCH(CH3)CH(NH2)CO2H (#6# 57% activity compared to
	Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Galbeta(1->4)GlcNAcbeta(1->6)GalNAcalpha-OCH(CH3)CH(NH2)CO2H = UDP +
	GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->6)GalNAcalpha
	OCH(CH3)CH(NH2)CO2H (#6# 101% activity compared to
	Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Galbeta(1->4)GlcNAcbeta(1->6)[GlcNAcbeta(1->4)]Galbeta(1->4)GlcNAcbeta
	pNP = UDP +
	GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta(1->6)[GlcNAcbeta(1
	>4)]Galbeta(1->4)GlcNAcbeta-pNP (#6# 104% activity compared to
	Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine + Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 =
	UDP + GlcNAcbeta(1->3)Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 (#6# 100%
	activity <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine + Galbeta(1->4)GlcNAc = UDP +
	GlcNAcbeta(1->3)Galbeta(1->4)GlcNAc (#6# 73% activity compared to
	Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>
SP	#6# UDP-N-acetyl-D-glucosamine +
	Galbeta(1->4)[Fucalpha(1->3)]GlcNAcbeta-O(CH2)3N3 = UDP +
	GlcNAcbeta(1->3)Galbeta(1->4)[Fucalpha(1->3)]GlcNAcbeta-O(CH2)3N3 (#6#
	26% activity compared to Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 <18>) <18>

KM_VALUE
KM	#2# 0.09 {neolactotetraosylceramide}  <13>
KM	#2# 2.5 {UDP-N-acetyl-D-glucosamine}  (#2# membrane-bound enzyme <13>)
	<13>
KM	#2# 0.33 {UDP-N-acetyl-D-glucosamine}  (#2# solubilized enzyme <13>)
	<13>
KM	#3# 0.17 {UDP-N-acetyl-D-glucosamine}  (#3# lactosylceramide as
	acceptor <4>) <4>
KM	#3# 0.133 {UDP-N-acetyl-D-glucosamine}  (#3# lactose as acceptor <3>)
	<3>
KM	#3# 7 {N-acetyllactosamine}  <3>
KM	#3# 0.19 {lactoneotetraosylceramide}  <4>
KM	#3# 0.19 {lactonorhexaosylceramide}  <4>
KM	#3# 0.36 {Galbeta1,4(SO3-,6)-GlcNAcbeta1,3-Galbeta1,4(SO3-,6)-GlcNAc} 
	(#3# recombinant enzyme, pH 7.2, 37°C <14>) <14>
KM	#3# 29.8 {lactose}  <3>
KM	#4# -999 {more}  <5>
KM	#4# 0.6 {asialo-alpha1-acid glycoprotein}  <5>
KM	#4# 1 {Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)GlcNAc}  <5>
KM	#4# 0.9 {Galbeta(1-4)GlcNAcbeta(1-4)GlcNAc-2-aminopyridine}  (#4#
	PC-12D cells <8>) <8>
KM	#4# 2.2 {N-acetyllactosamine}  <5>
KM	#4# 8 {UDP-N-acetyl-D-glucosamine}  (#4# PC-12 and PC-12D cells <8>) <8>
KM	#4# 0.44 {Galbeta(1-4)GlcNAcbeta(1-4)GlcNAc-2-aminopyridine}  (#4#
	PC-12 cells <8>) <8>
KM	#4# 5.2 {lactose}  <5>
KM	#5# 18.2 {lactose}  <6>
KM	#5# 0.129 {UDP-N-acetyl-D-glucosamine}  <6>
KM	#5# 19.6 {N-acetyllactosamine}  <6>
KM	#6# 1.487 {UDP-N-acetyl-D-glucosamine}  (#6# using
	Galbeta(1->4)GlcNAcbeta-O(CH2)3N3 as acceptor, in cacodylate buffer
	(100 mM, pH 7.5), at 37°C <18>) <18>
KM	#6# 15.97 {UDP-N-acetyl-D-glucosamine}  (#6# using
	Galbeta(1->3)GlcNAcbeta-O(CH2)3N3 as acceptor, in cacodylate buffer
	(100 mM, pH 7.5), at 37°C <18>) <18>
KM	#6# 2.082 {UDP-N-acetyl-D-glucosamine}  (#6# using
	Galbeta(1->3)GalNAcalpha-OCH(CH3)CH(NH2)CO2H as acceptor, in cacodylate
	buffer (100 mM, pH 7.5), at 37°C <18>) <18>
KM	#6# 1.445 {UDP-N-acetyl-D-glucosamine}  (#6# using
	Galbeta(1->3)[GlcNAcbeta(1->6)]GalNAcalpha-OCH(CH3)CH(NH2)CO2H as
	acceptor, in cacodylate buffer (100 mM, pH 7.5), at 37°C <18>) <18>

PH_OPTIMUM
PHO	#2# 7-8 <13>
PHO	#3# 6.5-7 <14>
PHO	#3# 7-7.2 (#3# highest activity, with Hepes buffer <4>) <4>
PHO	#3# 6.8-7.8 (#3# broad <2>) <2>
PHO	#3# 5.8-7.5 (#3# broad <4>) <4>
PHO	#4# 6.5-8 <1>
PHO	#4# 6.8-7.2 (#4# asialo-alpha1-acid glycoprotein as acceptor <5>) <5>
PHO	#5# 7 (#5# broad pH-optimum around pH 7 <6>) <6>
PHO	#7# -999 (#7# pI: 8.7 <9>) <9>

PH_RANGE
PHR	#5# 6-7.5 (#5# substantial reaction in the range, 65% of activity at pH
	7 <6>) <6>

SPECIFIC_ACTIVITY
SA	#4# -999.0 <8>
SA	#4# 0.00153 <5>
SA	#5# 0.118 <6>

TEMPERATURE_OPTIMUM
TO	#3,4,5# 37 (#3,4,5# assay at <1,2,3,4,5,6,7,8,10,14>)
	<1,2,3,4,5,6,7,8,10,14>
TO	#5# 42 (#5# 112% of activity compared with that at 37°C <6>) <6>

ACTIVATING_COMPOUND
AC	#2# detergent (#2# activates, reaction rate is optimal at
	detergent:protein ratio of 1.6 in Triton CF-54 or X-100, 1:3 in Nonidet
	P-40 <13>) <13>
AC	#2# Nonidet P-40 (#2# reaction rate is optimal at detergent:protein
	ratio of 1:3 <13>) <13>
AC	#2,3# Triton CF-54 (#3# activates solubilized enzyme, activity is
	optimal when assayed in the presence of a final concentration of 0.3%
	<4>; #2# reaction rate is optimal at detergent:protein ratio of 1:6
	<13>) <4,13>
AC	#2,3# Triton X-100 (#3# activates solubilized enzyme <4>; #2# reaction
	rate is optimal at detergent:protein ratio of 1:6 <13>) <4,13>
AC	#3# ATP (#3# omitting ATP from reaction mixture decreases activity by
	87% <3>) <3>
AC	#3# deoxycholate (#3# activates solubilized enzyme <4>) <4>
AC	#3# CHAPSO (#3# activates solubilized enzyme <4>) <4>
AC	#3# G-3634-A (#3# activates solubilized enzyme <4>) <4>
AC	#3# more (#3# not activated by Triton X-100 <3>; #3# CDPcholine
	stimulates by protecting UDP-GlcNAc from hydrolysis by endogenous
	enzymes <4>) <3,4>

INHIBITORS
IN	#2,3,4# EDTA (#4# strong <5>; #3# 10 mM, complete inhibition <4>; #3#
	slightly, 12% inhibition at 10 mM <14>) <1,4,5,13,14>
IN	#4# CaCl2 (#4# weak <5>) <1,5>
IN	#4# ZnCl2 (#4# strong <5>) <1,5>
IN	#4# NiCl2 <5>
IN	#4# CdCl2 <5>
IN	#4# FeCl2 <5>
IN	#4# more (#4# nerve growth factor stimulated PC-12 cells with reduced
	GnT-i activity compared to unstimulated cells, no effect in PC-12D
	cells <8>) <8>
IN	#5# 2-mercaptoethanol <6>
IN	#5# SDS <6>
IN	#5# CH3CN <6>
IN	#5# UDP (#5# 1 mM, 70% inhibition <6>) <6>
IN	#5# N-acetyllactosamine (#5# strong product inhibition <6>) <6>
IN	#5# 4-Thiouridine diphosphate (#5# inhibits in a
	concentration-dependent manner <6>) <6>

METALS_IONS
ME	#2,3# Ca2+ (#2# activates, 48% as effective as Mn2+ <13>; #3# about one
	third of the activity compared to Mn2+, recombinant enzyme <14>) <13,14>
ME	#2,3,4,5# more (#3# not activated by Mg2+ or Ca2+ <3>; #5# enzyme
	possesses 2 distinct metal binding sites, not activated by Ca2+, Mg2+,
	Zn2+, Fe2+, Cu2+, Ni2+, K+, Na+ <6>; #4# absolute requirement for
	divalent cations, not stimulated by Mg2+ <5>; #2# not activated by
	Mg2+, Zn2+, Cu2+ or Cd2+ <13>) <3,5,6,13>
ME	#2,3,4,5# Mn2+ (#3# requirement <2>; #3,5# strict requirement <4,6>;
	#5# optimum concentration: 2-15 mM, cooperative activating effects by
	combination of Mn2+ at a low concentration and Mg2+ or Ca2+ <6>; #4#
	MnCl2 stimulates 2.5fold, optimal concentration: 20 mM <5>; #4# MnCl2:
	10-25 mM for optimal activity required <1>; #3# essential for activity,
	neither Mg2+ nor Ca2+ can substitute for Mn2+ <3>; #2# requirement, Km:
	1.25 mM, Mn2+ cannot be replaced by Mg2+, Zn2+, Cu2+ or Cd2+ <13>; #3#
	required for activity, recombinant enzyme <14>) <1,2,3,4,5,6,13,14>
ME	#2,5# Co2+ (#5# slightly stimulates, 12.8% as effective as Mn2+ at 10
	mM <6>; #2# activates, 52% as effective as Mn2+ <13>) <6,13>
ME	#3,4# Mg2+ (#4# MgCl2 slightly stimulates <1>; #3# about one third of
	the activity compared to Mn2+, recombinant enzyme <14>) <1,14>
ME	#4# Cd2+ (#4# CdCl2 slightly stimulates <1>) <1>

MOLECULAR_WEIGHT
MW	#3# 47125 (#3# x * 47125, calculated from the amino acid sequence,
	mature N-glycosylated iGnT: may be approximately 53 kDa <10>) <10>
MW	#5# 70000 (#5# 1 * 70000, SDS-PAGE <6>) <6>
MW	#5# 90000 (#5# gel filtration <6>) <6>
MW	#7# 45000 (#7# x * 45000, calculated from the amino acid sequence <9>)
	<9>

POSTTRANSLATIONAL_MODIFICATION
PM	#3,4,5# glycoprotein (#3# 2 potential N-glycosylation sites <10>)
	<5,6,10>

SUBUNITS
SU	#3,7# ? (#7# x * 45000, calculated from the amino acid sequence <9>;
	#3# x * 47125, calculated from the amino acid sequence, mature
	N-glycosylated iGnT: may be approximately 53 kDa <10>) <9,10>
SU	#5# monomer (#5# 1 * 70000, SDS-PAGE <6>) <6>

APPLICATION
AP	#7# medicine (#7# enzyme may be used as diagnostic marker of human
	cancer or as target molecule for the development of a new therapy <9>)
	<9>

CLONED
CL	#3# (plasmid cDNA encoding the catalytic domain of i-GlcNAcT, amino
	acids 53-415, is expressed in COS-1 cells) <7>
CL	#3# (cDNA from melanoma and colonic cancer cells is cloned and
	overexpressed in human Burkitt lymphoma Namalwa KJM-1 cells
	overexpressing the i-antigen, nucleotide and amino acid sequence of the
	415-amino acids protein, cDNA fragment encoding the stem region plus
	putative catalytic domain of iGnT fused to protein A is expressed in
	COS-1 cells) <10>
CL	#3# (expression in COS-7 cells, localization in membranes) <14>
CL	#7# (cDNA from placenta encoding beta3GnT7 is cloned and partially
	characterized, open reading frame encodes a 397-amino acids protein) <9>
CL	#8# (human ortholog to mouse enzyme beta3GnT7 has the chromosomal locus
	2q37.1) <9>

PURIFICATION
PU	#4# (partial, 178fold, from Novikoff tumor cell ascites fluid) <5>
PU	#5# (125000fold) <6>

STORAGE_STABILITY
SS	#4# (0-4°C, lyophilized enzyme form, over 6 months, stable) <5>
SS	#5# (4°C, purified enzyme, at least 2 weeks, stable) <6>

TEMPERATURE_STABILITY
TS	#5# 42 (#5# 112% of activity compared with that at 37°C <6>) <6>
TS	#5# 50 (#5# 10% of activity compared with that at 37°C <6>) <6>
TS	#5# 55 (#5# 2% of activity compared with that at 37°C <6>) <6>
TS	#5# 20 (#5# 28% of activity compared with that at 37°C <6>) <6>
TS	#5# 30 (#5# 63% of activity compared with that at 37°C <6>) <6>
TS	#5# 45 (#5# 88% of activity compared with that at 37°C <6>) <6>
TS	#5# 4 (#5# 4% of activity compared with that at 37°C <6>) <6>
TS	#5# 12 (#5# 9% of activity compared with that at 37°C <6>) <6>

REFERENCE
RF	<1> Van den Eijnden, D.H.; Winterwerp, H.; Smeeman, P.; Schiphorst,
	W.E.C.M.: Novikoff ascites tumor cells contain N-acetyllactosaminide
	beta 1-3 and beta 1-6 N-acetylglucosaminyltransferase activity. J.
	Biol. Chem. (1983) 258, 3435-3437. {Pubmed:6219989}
RF	<2> Zielenski, J.; Koscielak, J.: The occurrence of two novel
	N-acetylglucosaminyltransferase activities in human serum. FEBS Lett.
	(1983) 158, 164-168. {Pubmed:6222918}
RF	<3> Hosomi, O.; Takeya, A.; Kogure, T.: Human serum contains
	N-acetyllactosamine: beta 1-3 N-acetylglucosaminyltransferase activity.
	J. Biochem. (1984) 95, 1655-1659. {Pubmed:6236210}
RF	<4> Holmes, E.H.: Characterization of a beta
	1-->3-N-acetylglucosaminyltransferase associated with synthesis of type
	1 and type 2 lacto-series tumor-associated antigens from the human
	colonic adenocarcinoma cell line SW403. Arch. Biochem. Biophys. (1988)
	260, 461-468. {Pubmed:2963590}
RF	<5> van den Eijnden, D.H.; Koenderman, A.H.L.; Schiphorst, W.E.C.M.:
	Biosynthesis of blood group i-active polylactosaminoglycans. Partial
	purification and properties of an UDP-GlcNAc:N-acetyllactosaminide beta
	1-->3-N-acetylglucosaminyltransferase from Novikoff tumor cell ascites
	fluid. J. Biol. Chem. (1988) 263, 12461-12471. {Pubmed:2970459}
RF	<6> Kawashima, H.; Yamamoto, K.; Osawa, T.; Irimura, T.: Purification
	and characterization of UDP-GlcNAc:Galbeta
	1-4Glc(NAc)beta-1,3-N-acetylglucosaminyltransferase
	(poly-N-acetyllactosamine extension enzyme) from calf serum. J. Biol.
	Chem. (1993) 268, 27118-27126. {Pubmed:8262950}
RF	<7> McAuliffe, J.C.; Ujita, M.; Fukuda, M.; Hindsgaul, O.: Synthesis of
	selectively radiolabeled hexasaccharides for the determination of
	enzymatic regioselectivity. Glycoconjugate J. (1999) 16, 767-772.
	{Pubmed:11133016}
RF	<8> Fukuzumi, M.; Maruyama, S.; Sano, M.; Fukui, S.: Comparison of the
	expression of cell surface poly-N-acetyllactosamine-type
	oligosaccharides in PC12 cells with those in its variant PC12D.
	Glycobiology (2001) 11, 481-494. {Pubmed:11445553}
RF	<9> Kataoka, K.; Huh, N.h.: A novel
	beta1,3-N-acetylglucosaminyltransferase involved in invasion of cancer
	cells as assayed in vitro. Biochem. Biophys. Res. Commun. (2002) 294,
	843-848. {Pubmed:12061784}
RF	<10> Sasaki, K.; Kurata-Miura, K.; Ujita, M.; Angata, K.; Nakagawa, S.;
	Sekine, S.; Nishi, T.; Fukuda, M.: Expression cloning of cDNA encoding
	a human beta-1,3-N-acetylglucosaminyltransferase that is essential for
	poly-N-acetyllactosamine synthesis. Proc. Natl. Acad. Sci. USA (1997)
	94, 14294-14299. {Pubmed:9405606}
RF	<11> Salo, H.; Aitio, O.; Ilves, K.; Bencomo, E.; Toivonen, S.;
	Penttilä, L.; Niemelä, R.; Salminen, H.; Grabenhorst, E.; Renkonen,
	R.; Renkonen, O.: Several polylactosamine-modifying
	glycosyltransferases also use internal GalNAcbeta1-4GlcNAc units of
	synthetic saccharides as acceptors. Glycobiology (2002) 12, 217-228.
	{Pubmed:11971866}
RF	<12> Hummel, M.; Hedrich, H.C.; Hasilik, A.: Elongation of
	N-acetyllactosamine repeats in diantennary oligosaccharides. Eur. J.
	Biochem. (1997) 245, 428-433. {Pubmed:9151975}
RF	<13> Basu, M.; Basu, S.: Biosynthesis in vitro of Ii core
	glycosphingolipids from neolactotetraosylceramide by beta1-3- and
	beta1-6-N-acetylglucosaminyltransferases from mouse T-lymphoma. J.
	Biol. Chem. (1984) 259, 12557-12562. {Pubmed:6238026}
RF	<14> Seko, A.; Yamashita, K.: beta1,3-N-Acetylglucosaminyltransferase-7
	(beta3Gn-T7) acts efficiently on keratan sulfate-related glycans. FEBS
	Lett. (2004) 556, 216-220. {Pubmed:14706853}
RF	<15> Biellmann, F.; Henion, T.R.; Burki, K.; Hennet, T.: Impaired
	sexual behavior in male mice deficient for the beta 1-3
	N-acetylglucosaminyltransferase-I gene. Mol. Reprod. Dev. (2008) 75,
	699-706. {Pubmed:18008318}
RF	<16> Lee, P.L.; Kohler, J.J.; Pfeffer, S.R.: Association of
	beta-1,3-N-acetylglucosaminyltransferase 1 and
	beta-1,4-galactosyltransferase 1, trans-Golgi enzymes involved in
	coupled poly-N-acetyllactosamine synthesis. Glycobiology (2009) 19,
	655-664. {Pubmed:19261593}
RF	<17> Bao, X.; Kobayashi, M.; Hatakeyama, S.; Angata, K.; Gullberg, D.;
	Nakayama, J.; Fukuda, M.; Fukuda, M.: Tumor suppressor function of
	laminin-binding alpha-dystroglycan requires a distinct
	beta3-N-acetylglucosaminyltransferase. Proc. Natl. Acad. Sci. USA
	(2009) 106, 12109-12114. {Pubmed:19587235}
RF	<18> Peng, W.; Pranskevich, J.; Nycholat, C.; Gilbert, M.; Wakarchuk,
	W.; Paulson, J.C.; Razi, N.: Helicobacter pylori
	beta1,3-N-acetylglucosaminyltransferase for versatile synthesis of type
	1 and type 2 poly-LacNAcs on N-linked, O-linked and I-antigen glycans.
	Glycobiology (2012) 22, 1453-1464. {Pubmed:22786570}

ACTIVATING_COMPOUND
AC	#2# detergent (#2# activates, reaction rate is optimal at
	detergent:protein ratio of 1.6 in Triton CF-54 or X-100, 1:3 in Nonidet
	P-40 <13>) <13>
AC	#2# Nonidet P-40 (#2# reaction rate is optimal at detergent:protein
	ratio of 1:3 <13>) <13>
AC	#2,3# Triton CF-54 (#3# activates solubilized enzyme, activity is
	optimal when assayed in the presence of a final concentration of 0.3%
	<4>; #2# reaction rate is optimal at detergent:protein ratio of 1:6
	<13>) <4,13>
AC	#2,3# Triton X-100 (#3# activates solubilized enzyme <4>; #2# reaction
	rate is optimal at detergent:protein ratio of 1:6 <13>) <4,13>
AC	#3# ATP (#3# omitting ATP from reaction mixture decreases activity by
	87% <3>) <3>
AC	#3# deoxycholate (#3# activates solubilized enzyme <4>) <4>
AC	#3# CHAPSO (#3# activates solubilized enzyme <4>) <4>
AC	#3# G-3634-A (#3# activates solubilized enzyme <4>) <4>
AC	#3# more (#3# not activated by Triton X-100 <3>; #3# CDPcholine
	stimulates by protecting UDP-GlcNAc from hydrolysis by endogenous
	enzymes <4>) <3,4>

EXPRESSION
EXP	#3# up (#3# forced expression of beta3GnT1 in aggressive cancer cells
	restores the laminin-binding glycans and decreased tumor formation
	<17>) <17>
EXP	#3# down (#3# the decrease of laminin-binding glycans and consequent
	increased cell migration are associated with the decreased expression
	of beta3-N-acetylglucosaminyltransferase-1 <17>) <17>

///
ID	2.4.1.155
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Gallus gallus   <1>
PR	#2# Mus musculus   <1,3,9,11,30,36,39,40,42,43,54,55,57,59>
PR	#3# Homo sapiens  
	<1,4,12,13,14,15,16,17,18,20,21,22,23,24,25,26,27,28,29,31,32,33,34,35
	37,38,41,44,45,46,47,48,49,50,51,52,56,58,60,64>
PR	#4# Rattus norvegicus   <2,8>
PR	#5# Mesocricetus auratus   (#5# isoform Gal1 <5>) <1,5,6,7,10>
PR	#6# Homo sapiens Q09328 Swissprot <19,53,61,62,63,65,66>
PR	#6# Homo sapiens Q09328 UniProt <19,53,61,62,63,65,66>
PR	#7# Cricetulus griseus P97259 UniProt <67>
PR	#8# Rattus norvegicus Q08834 UniProt <67>

RECOMMENDED_NAME
RN	alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferase


SYSTEMATIC_NAME
SN	UDP-N-acetyl-alpha-D-glucosamine:N-acetyl-beta-D-glucosaminyl-(1->2)
	alpha-D-mannosyl-(1->6)-beta-D-mannosyl-glycoprotein
	6-beta-N-acetyl-D-glucosaminyltransferase (configuration-inverting)


SYNONYMS
SY	 alpha-mannoside beta-1,6-N-acetylglucosaminyltransferase
SY	 acetylglucosaminyltransferase, uridine
	diphosphoacetylglucosamine-alpha-mannoside
	beta1-6-UDP-N-acetylglucosamine:alpha-mannoside-beta1,6
	N-acetylglucosaminyltransferase
SY	 alpha-1,3(6)-mannosylglycoprotein
	beta-1,6-N-acetylglucosaminyltransferase
SY	#2# beta1,6-N-acetylglucosaminyltransferase-V <30>
SY	#2# beta1,6-N-acetylglucosaminyltransferase V <36,39>
SY	#2# N-acetylglucosaminyltransferase Va <42>
SY	#2# beta N-acetylglucosaminyltransferase V <43>
SY	#2# Golgi UCD-GlcNAc:N-acetylglucosaminyltransferase 5 <43>
SY	#2,3# glycosyltransferase <30,38>
SY	#2,3# N-acetylglucosaminyltransferase-V <32,37,55,60>
SY	#2,3# GnT-Va <38,42,44>
SY	#2,3,6# GnT-V
	<22,23,24,25,26,28,29,30,32,33,34,35,37,38,39,40,41,45,46,47,49,50,51
	52,53,54,55,56,57,58,59,60,61,64,66>
SY	#2,3,6,7,8# Mgat5 (#2,3,6,7,8# gene name <54,55,60,63,65,67>)
	<19,31,34,36,40,43,47,48,54,55,60,63,65,66,67>
SY	#2,3,6,7,8# N-acetylglucosaminyltransferase V
	<22,23,25,28,31,33,34,35,40,41,45,46,47,48,50,51,52,53,54,56,57,58,59
	61,64,65,66,67>
SY	#3# GlcNAcTase-V <16>
SY	#3# UDP-N-acetylglucosamine:a-mannoside
	beta-1,6-N-acetylglucosaminyltransferase <26>
SY	#3# alpha-1,6-mannosyl-glycoprotein
	6-beta-N-acetylglucosaminyltransferase <31>
SY	#3# beta1,6-N-acetylglucosaminyltransferase <31>
SY	#3# N-acetylglucosaminyltransferase-Va <38>
SY	#3# N-acetylglucosaminyltransferase-Vb <45>
SY	#3# GnT-IX <45>
SY	#3# N-acetylglucsaminyltransferase V <49>
SY	#3,6# GnT-VB <19,45>
SY	#6# Golgi beta-1,4-mannosyl-glycoprotein
	4-beta-N-acetylglucosaminyltransferase V <62>
SY	#6# GnT-IV <62>
SY	#6# beta1, 6-N-acetylglucosaminyltransferase V <63>
SY	#7,8# GlcNAcT-V <67>
SY	#7,8# Glc-NAcT-V <67>

REACTION
RE	UDP-N-acetyl-alpha-D-glucosamine +
	beta-D-GlcNAc-(1->2)-[beta-D-GlcNAc-(1->4)]-alpha-D-Man-(1->3)-[beta-D
	GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1
	>4)-beta-D-GlcNAc-N-Asn-[protein] = UDP +
	beta-D-GlcNAc-(1->2)-[beta-D-GlcNAc-(1->4)]-alpha-D-Man-(1->3)-[beta-D
	GlcNAc-(1->2)-[beta-D-GlcNAc-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1
	>4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc-N-Asn-[protein] (#5# mechanism
	<6>)

REACTION_TYPE
RT	hexosyl group transfer

SOURCE_TISSUE
ST	#1# oviduct <1>
ST	#2# embryo <9>
ST	#2# fibroblast <36>
ST	#2# heart <42>
ST	#2# muscle <36>
ST	#2# cell culture <1>
ST	#2# central nervous system (#2# of the embryo <9>) <9>
ST	#2# intestine <42>
ST	#2# skin (#2# of the embryo <9>) <9,54,55>
ST	#2# embryonic fibroblast cell line <42>
ST	#2# gonad (#2# of the adult <9>) <9>
ST	#2# keratinocyte <55>
ST	#2# BW-5147 cell <1,3>
ST	#2# respiratory epithelium (#2# of the embryo <9>) <9>
ST	#2# satellite cell <36>
ST	#2# MEF cell <36,42>
ST	#2# 95-H1 cell (#2# melanotic hybrid cell <30,39>) <30,39>
ST	#2# 94-H48 cell (#2# melanotic hybrid cell <30>) <30>
ST	#2# 4TO7 cell (#2# mouse mammary tumor cell line <40>) <40>
ST	#2# Mv1Lu cell <54>
ST	#2,3# liver <21,31,42,54>
ST	#2,4# spleen <2,42>
ST	#2,4# brain <2,9,42,59>
ST	#2,4# small intestine (#2# of the embryo <9>) <2,9>
ST	#2,4,5# kidney (#2# of the embryo <9>) <1,5,6,7,8,9,42>
ST	#2,6# melanoma cell (#2# parental mouse melanoma cell S91 6neo <30,39>)
	<30,39,62>
ST	#3# HEL cell <16>
ST	#3# placenta (#3# localized in the trophoblast layer. Both protein
	expression and the enzyme activity of GnT-V in first trimester
	placentas are higher than those at term. These results suggest that
	GnT-V would contribute to placentation in the early phase of pregnancy,
	possibly regulating the process of invasion of trophoblast cells <22>)
	<22,35>
ST	#3# hepatocyte (#3# primary <21>) <21,50>
ST	#3# MCF-7 cell <47>
ST	#3# hepatoma cell <29>
ST	#3# gastric mucosa <52>
ST	#3# JURKAT cell <48>
ST	#3# monocyte <58>
ST	#3# HL-60 cell <16>
ST	#3# KU-812 cell <16>
ST	#3# HMCB cell <16>
ST	#3# PBMC cell line <48>
ST	#3# HeLa-S3 cell <16>
ST	#3# gastric epithelium <52>
ST	#3# fibrosarcoma cell line <44>
ST	#3# neuroblastoma cell (#3# higher expression of GnT-V is correlated
	with a favorable prognosis for neuroblastoma patients. GnT-V may cause
	these tumors to regress by increasing their susceptibility to apoptosis
	<25>) <25>
ST	#3# T-24 cell <16>
ST	#3# THP-1 cell <16,58>
ST	#3# breast cancer cell <38>
ST	#3# colonic adenocarcinoma cell <60>
ST	#3# A-549 cell <16>
ST	#3# LoVo cell <49>
ST	#3# BeWo cell <16>
ST	#3# MOLT-4 cell <16>
ST	#3# BALL-1 cell <16>
ST	#3# CACO-2 cell <16>
ST	#3# gastric cancer cell <52>
ST	#3# colonic cancer cell line <12>
ST	#3# DU-145 cell <31>
ST	#3# PC-3 cell <31>
ST	#3# endometrioid carcinoma cell (#3# endometrial endometrioid
	adenocarcinoma cell <33>) <33>
ST	#3# small cell lung cancer cell <64>
ST	#3# germ cell (#3# testicular germ cell <37>) <37>
ST	#3# choriocarcinoma cell <33>
ST	#3# JAR cell <33,35>
ST	#3# Hep-3B cell <12,21>
ST	#3# myeloid cell line <1>
ST	#3# follicular thyroid cancer cell (#3# oberserved in 10/23 cases <26>)
	<26>
ST	#3# LNCaP cell <31>
ST	#3# YMB-1 cell <16>
ST	#3# HuO-3N1 cell <16>
ST	#3# EoL-1 cell <16>
ST	#3# OS-RC-2 cell <16>
ST	#3# H-7721 cell <23,50>
ST	#3# MDA-MB-435 cell <47>
ST	#3# breast epithelium <38>
ST	#3# papillary thyroid cancer cell (#3# observed in 66/68 cases <26>)
	<26>
ST	#3# NAMALWA cell <16>
ST	#3# MIA PaCa-2 cell <24>
ST	#3# anaplastic thyroid cancer cell (#3# observed in 6/28 cases <26>)
	<26>
ST	#3# SMMC-7721 cell <49>
ST	#3# ovary adenocarcinoma cell line <51>
ST	#3# extravillous trophoblast <35>
ST	#3# CA-HPV-10 cell <31>
ST	#3# PZ-HPV-7 cell <31>
ST	#3# PC-J cell <31>
ST	#3# HTR-8/Svneo cell <35>
ST	#3# uterine smooth muscle cell line (#3# UtSMC, CC-2562 <33>) <33>
ST	#3# seminoma cell <37>
ST	#3# epithelial ovarian cancer cell <51>
ST	#3# H-1688 cell <64>
ST	#3# H-146 cell <64>
ST	#3,4# lung (#3# QC, small lung cancer cell line <4>) <2,4>
ST	#3,4# testis <2,37>
ST	#3,6# more (#3# macrophage fusion hybrids with Cloudman S91 mouse
	melanoma cells <18>; #3# not expressed in normal thyroid tissue <26>;
	#6# quantitative enzyme expression analysis in cancer cells, overview
	<61>) <18,26,61>
ST	#3,6# Hep-G2 cell (#6# the cells show lower enzyme activity <65>)
	<16,21,32,56,61,65>
ST	#3,6# MDA-MB-231 cell <44,61>
ST	#3,6# MKN-45 cell <46,53,61>
ST	#3,6# Huh-7 cell (#6# the cells show lower enzyme activity <65>) <32,65>
ST	#3,6# hepatocellular carcinoma cell <56,65>
ST	#3,6# WiDr cell <41,46,60,61>
ST	#5# BHK-21 cell (#5# native BHK-21/c13 cells, cells transformed with
	Rous sarcoma virus, i.e. RS-BHK-cells, and lectin-resistant cell-lines
	LP 1.6 and 3.3 <5>) <5>
ST	#6# HeLa cell <61>
ST	#6# stomach (#6# non-tumor tissue shows strong expression of MGAT5,
	immunohistochemic analysis <63>) <63>
ST	#6# epithelium <53>
ST	#6# colon <61>
ST	#6# gastric adenocarcinoma cell (#6# immunohistochemic analysis of 313
	clinical samples, overview <63>) <63>
ST	#6# Colo-205 cell <61>
ST	#6# colon cancer cell <61>
ST	#6# gastric carcinoma cell <53>
ST	#7# CHO cell <67>
ST	#7# CHO-Lec4 cell <67>

LOCALIZATION
LO	#2,3,6,7,8# Golgi apparatus <24,39,60,61,62,63,64,67>
LO	#2,4,5# membrane <3,5,6,7,8>
LO	#3# cytoplasm (#3# cytoplasm of extravillous trophoblast in the
	anchoring villi <35>) <35,49,51>
LO	#3# soluble (#3# fusion with signal peptide from baculoviral protein to
	permit secretion into medium <15>) <4,13,15>
LO	#5# microsome <5>

NATURAL_SUBSTRATE_PRODUCT
NSP	#1,2,3,5# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R = UDP +
	N-acetyl-D-glucosaminyl-1,2-(N-acetyl-D-glucosaminyl-1,6)-1
	2-alpha-D-mannosyl-1,3(6)-(N-acetyl-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,6(3))-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-R (#1,2,3,5# enzyme requires prior action of
	N-acetylglucosaminyltransferase II which requires prior action of
	N-acetylglucosaminyltransferase I <1>; #3# promotes angiogenesis in
	vitro and in vivo at physiological concentrations <13>; #2,3,5#
	involved in biosynthesis of branched N-glycopeptides <3,4,5>; #5#
	biosynthesis of cell-surface ASSN-linked oligosaccharides <10>)
	<1,3,4,5,10,13,54>
NSP	#1,2,3,5# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R = UDP +
	N-acetyl-D-glucosaminyl-1,2-(N-acetyl-D-glucosaminyl-1,6)-1
	2-alpha-D-mannosyl-1,3(6)-(N-acetyl-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,6(3))-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-R (#1,2,3,5# enzyme requires prior action of
	N-acetylglucosaminyltransferase II which requires prior action of
	N-acetylglucosaminyltransferase I <1>; #3# promotes angiogenesis in
	vitro and in vivo at physiological concentrations <13>; #2,3,5#
	involved in biosynthesis of branched N-glycopeptides <3,4,5>; #5#
	biosynthesis of cell-surface ASSN-linked oligosaccharides <10>) {}
	<1,3,4,5,10,13,54>
NSP	#2# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-L-Asn = UDP +
	N-acetyl-D-glucosaminyl-1,2-(N-acetyl-D-glucosaminyl-1,6)-1
	2-alpha-D-mannosyl-1,3(6)-(N-acetyl-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,6(3))-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-L-Asn <59>
NSP	#2,3,6# more = ? (#3# down regulation of
	N-acetylglucosaminyltransferase V facilitates all-transretinoic acid to
	induce apoptosis of human hepatocarcinoma cells <29>; #3# GnT-V is
	cleaved at the transmembrane region by gamma-secretase, and this might
	control tumor angiogenesis <24>; #3# N-acetylglucosaminyltransferase V
	is a key enzyme in the formation of branching of asparagine-linked
	oligosaccharides and is strongly linked to tumor invasion and
	metastasis. Blocking of GnT-V expression impairs functions of
	chaperones and N-glycan-synthesizing enzymes, which causes unfolded
	protein response in vivo <23>; #2# GnT-V can partially compensate for
	GnT-Vb(IX) activity in vivo <59>; #6# the MCAM glycoprotein, which is a
	biomarker of cutaneous melanoma, as a potential target for
	overexpressed glycosyltransferases <62>) {} <23,24,29,59,62>
NSP	#2,3,6# more = ? (#3# down regulation of
	N-acetylglucosaminyltransferase V facilitates all-transretinoic acid to
	induce apoptosis of human hepatocarcinoma cells <29>; #3# GnT-V is
	cleaved at the transmembrane region by gamma-secretase, and this might
	control tumor angiogenesis <24>; #3# N-acetylglucosaminyltransferase V
	is a key enzyme in the formation of branching of asparagine-linked
	oligosaccharides and is strongly linked to tumor invasion and
	metastasis. Blocking of GnT-V expression impairs functions of
	chaperones and N-glycan-synthesizing enzymes, which causes unfolded
	protein response in vivo <23>; #2# GnT-V can partially compensate for
	GnT-Vb(IX) activity in vivo <59>; #6# the MCAM glycoprotein, which is a
	biomarker of cutaneous melanoma, as a potential target for
	overexpressed glycosyltransferases <62>) {} <23,24,29,59,62>
NSP	#2,3,6# UDP-N-acetyl-D-glucosamine +
	6-(2-[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	= UDP +
	6-(2
	6-bis[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	(#3# catalyzes the formation of beta-1-6 GlcNAc branches on
	asparagine-linked oligosaccharides, which is directly linked to
	tumorigenesis <26>; #3# GnTIII competes with GnT-V for the modification
	of integrin alpha3 subunit in living cells. This competition results in
	the inhibition of alpha3beta1 integrin-mediated cell migration induced
	by GnT-V <27>) <26,27,30,31,32,33,34,35,36,37,38,39,40,41,53,62,66>
NSP	#3# UDP-N-acetyl-D-glucosamine + epidermal growth factor receptor = UDP
	+ N-acetylglucosamine-beta-1,6-mannose-alpha-1,3-branch of epidermal
	growth factor receptor <17>

SUBSTRATE_PRODUCT
SP	#1,2,3,4,5# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R = UDP +
	N-acetyl-D-glucosaminyl-1,2-(N-acetyl-D-glucosaminyl-1,6)-1
	2-alpha-D-mannosyl-1,3(6)-(N-acetyl-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,6(3))-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-R (#3# best substrates are bi- and
	tri-antennary acceptors <4>; #3# most active towards biantennary sugars
	<12>; #2# glycopeptides with sialic acid <3>; #3# enzyme also uses
	bisected oligosaccharides <14>; #2,3# glycopeptides with sialic acid or
	galactose at non-reducing terminal <3,4>; #3# specificity study with
	various pyridylaminated sugar chains <4>; #2# transfers
	N-acetylglucosamine to C-6 of alpha-linked mannose residue with
	inversion of configuration at its anomeric center <3>; #4,5# synthetic
	acceptor substrates <2,5>; #2,3# acceptor substrates are only branched
	mannose glycopeptides with non-reducing N-acetylglucosamine terminal
	residues <3,4>; #2# acceptors are bi-antennary Asn-linked asialo-or
	agalacto-oligosaccharides containing N-acetylglucosamine at the
	non-reducing terminal <3>; #1,2,3,5# no substrates are bisected
	N-glycans <1>; #1,2,3,5# enzyme requires prior action of
	N-acetylglucosaminyltransferase II which requires prior action of
	N-acetylglucosaminyltransferase I <1>; #3# promotes angiogenesis in
	vitro and in vivo at physiological concentrations <13>; #2,3,5#
	involved in biosynthesis of branched N-glycopeptides <3,4,5>; #5#
	biosynthesis of cell-surface ASSN-linked oligosaccharides <10>)
	<1,2,3,4,5,6,7,8,10,12,13,14,15,54,56>
SP	#1,2,3,4,5# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R = UDP +
	N-acetyl-D-glucosaminyl-1,2-(N-acetyl-D-glucosaminyl-1,6)-1
	2-alpha-D-mannosyl-1,3(6)-(N-acetyl-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,6(3))-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-R (#3# best substrates are bi- and
	tri-antennary acceptors <4>; #3# most active towards biantennary sugars
	<12>; #2# glycopeptides with sialic acid <3>; #3# enzyme also uses
	bisected oligosaccharides <14>; #2,3# glycopeptides with sialic acid or
	galactose at non-reducing terminal <3,4>; #3# specificity study with
	various pyridylaminated sugar chains <4>; #2# transfers
	N-acetylglucosamine to C-6 of alpha-linked mannose residue with
	inversion of configuration at its anomeric center <3>; #4,5# synthetic
	acceptor substrates <2,5>; #2,3# acceptor substrates are only branched
	mannose glycopeptides with non-reducing N-acetylglucosamine terminal
	residues <3,4>; #2# acceptors are bi-antennary Asn-linked asialo-or
	agalacto-oligosaccharides containing N-acetylglucosamine at the
	non-reducing terminal <3>; #1,2,3,5# no substrates are bisected
	N-glycans <1>; #1,2,3,5# enzyme requires prior action of
	N-acetylglucosaminyltransferase II which requires prior action of
	N-acetylglucosaminyltransferase I <1>; #3# promotes angiogenesis in
	vitro and in vivo at physiological concentrations <13>; #2,3,5#
	involved in biosynthesis of branched N-glycopeptides <3,4,5>; #5#
	biosynthesis of cell-surface ASSN-linked oligosaccharides <10>) {}
	<1,2,3,4,5,6,7,8,10,12,13,14,15,54,56>
SP	#2# lysosomal-associated membrane protein-1 +
	UDP-N-acetyl-D-glucosamine = ? (#2# LAMP-1 <30>) <30>
SP	#2# lysosome-associated membrane protein-1 + UDP-N-acetyl-D-glucosamine
	= ? (#2# LAMP-1 <39>) <39>
SP	#2# tyrosinase + UDP-N-acetyl-D-glucosamine = ? <30,39>
SP	#2# tyrosinase-related protein-1 + UDP-N-acetyl-D-glucosamine = ? (#2#
	TYRP-1 <30>) <30>
SP	#2# tyrosinase-related protein-2 + UDP-N-acetyl-D-glucosamine = ? (#2#
	TYRP-2 <30>) <30>
SP	#2# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-L-Asn = UDP +
	N-acetyl-D-glucosaminyl-1,2-(N-acetyl-D-glucosaminyl-1,6)-1
	2-alpha-D-mannosyl-1,3(6)-(N-acetyl-D-glucosaminyl-1
	2-alpha-D-mannosyl-1,6(3))-beta-D-mannosyl-1
	4-N-acetyl-D-glucosaminyl-L-Asn <59>
SP	#2,3,6# more = ? (#3# ADP-glucose, CDP-glucose and GDP-glucose do not
	act as glycosyl donor <15>; #6# synthesis of N-linked
	beta(1,6)-branched glykans <19>; #3# down regulation of
	N-acetylglucosaminyltransferase V facilitates all-transretinoic acid to
	induce apoptosis of human hepatocarcinoma cells <29>; #3# GnT-V is
	cleaved at the transmembrane region by gamma-secretase, and this might
	control tumor angiogenesis <24>; #3# N-acetylglucosaminyltransferase V
	is a key enzyme in the formation of branching of asparagine-linked
	oligosaccharides and is strongly linked to tumor invasion and
	metastasis. Blocking of GnT-V expression impairs functions of
	chaperones and N-glycan-synthesizing enzymes, which causes unfolded
	protein response in vivo <23>; #3# NMR structural characterization of
	substrates bound to N-acetylglucosaminyltransferase V <28>; #2# GnT-V
	can partially compensate for GnT-Vb(IX) activity in vivo <59>; #6# the
	MCAM glycoprotein, which is a biomarker of cutaneous melanoma, as a
	potential target for overexpressed glycosyltransferases <62>) {}
	<15,19,23,24,28,29,59,62>
SP	#2,3,6# more = ? (#3# ADP-glucose, CDP-glucose and GDP-glucose do not
	act as glycosyl donor <15>; #6# synthesis of N-linked
	beta(1,6)-branched glykans <19>; #3# down regulation of
	N-acetylglucosaminyltransferase V facilitates all-transretinoic acid to
	induce apoptosis of human hepatocarcinoma cells <29>; #3# GnT-V is
	cleaved at the transmembrane region by gamma-secretase, and this might
	control tumor angiogenesis <24>; #3# N-acetylglucosaminyltransferase V
	is a key enzyme in the formation of branching of asparagine-linked
	oligosaccharides and is strongly linked to tumor invasion and
	metastasis. Blocking of GnT-V expression impairs functions of
	chaperones and N-glycan-synthesizing enzymes, which causes unfolded
	protein response in vivo <23>; #3# NMR structural characterization of
	substrates bound to N-acetylglucosaminyltransferase V <28>; #2# GnT-V
	can partially compensate for GnT-Vb(IX) activity in vivo <59>; #6# the
	MCAM glycoprotein, which is a biomarker of cutaneous melanoma, as a
	potential target for overexpressed glycosyltransferases <62>) {}
	<15,19,23,24,28,29,59,62>
SP	#2,3,6# UDP-N-acetyl-D-glucosamine +
	6-(2-[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	= UDP +
	6-(2
	6-bis[N-acetyl-beta-D-glucosaminyl]-alpha-D-mannosyl)-beta-D-mannosyl-R
	(#3# catalyzes the formation of beta-1-6 GlcNAc branches on
	asparagine-linked oligosaccharides, which is directly linked to
	tumorigenesis <26>; #3# GnTIII competes with GnT-V for the modification
	of integrin alpha3 subunit in living cells. This competition results in
	the inhibition of alpha3beta1 integrin-mediated cell migration induced
	by GnT-V <27>) <26,27,30,31,32,33,34,35,36,37,38,39,40,41,53,62,66>
SP	#2,5# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-mannosyl-1,6-beta-glucosyl-O-R = UDP
	+
	N-acetyl-D-glucosaminyl-1,6-(N-acetyl-D-glucosaminyl-1
	2)-alpha-mannosyl-1,6-beta-D-glucosyl-O-R (#5# best substrate <6>;
	#2,5# R: hydrophobic group, e.g. (CH2)7-CH3 or (CH2)8-COOCH3 <1>; #5#
	R: hydrophobic group, e.g. (CH2)7-CH3 <6,7>) <1,6,7>
SP	#2,5# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-mannosyl-1,6-beta-mannosyl-O-R = UDP
	+
	N-acetyl-D-glucosaminyl-1,6-(N-acetyl-D-glucosaminyl-1
	2)-alpha-mannosyl-1,6-beta-D-mannosyl-O-R (#2,5# R: hydrophobic group,
	e.g. (CH2)8-COOCH3 <1>) <1>
SP	#3# TDP-glucose +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R = TDP + ? <15>
SP	#3# UDP-glucose +
	N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R = UDP + ? <15>
SP	#3# UDP-N-acetyl-D-glucosamine + epidermal growth factor receptor = UDP
	+ N-acetylglucosamine-beta-1,6-mannose-alpha-1,3-branch of epidermal
	growth factor receptor <17>
SP	#3# UDP-GlcNAc +
	GlcNAc-beta(1-2)Man-alpha(1-3)(GlcNAc-beta(1-2)Man-alpha(1-4))Man
	beta(1-4)GlcNAc-2-amino pyridine = ? <21>
SP	#3# alpha-1-antitrypsin precursor + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# angiotensinogen preproprotein + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# beta-N-acetylhexosaminidase A + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# cathepsin D preproprotein + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# cathepsin X precursor + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# DDR1 variant protein + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# dipeptidyl peptidase 7 preproprotein + UDP-N-acetyl-D-glucosamine =
	? (#3# identified target protein for GnT-V in human colon cancer cell
	WiDr <41>) <41>
SP	#3# discoidin receptor tyrosine kinase + UDP-N-acetyl-D-glucosamine = ?
	(#3# identified target protein for GnT-V in human colon cancer cell
	WiDr <41>) <41>
SP	#3# dystroglycan 1 precursor + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# galectin 3 binding protein + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# granulin isoform 1 precursor + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# heat shock protein 70 kDa protein 8 isoform 1 +
	UDP-N-acetyl-D-glucosamine = ? (#3# identified target protein for GnT-V
	in human colon cancer cell WiDr <41>) <41>
SP	#3# heat shock protein gp96 precursor + UDP-N-acetyl-D-glucosamine = ?
	(#3# identified target protein for GnT-V in human colon cancer cell
	WiDr <41>) <41>
SP	#3# heparan sulfate proteoglycan perlecan + UDP-N-acetyl-D-glucosamine
	= ? (#3# identified target protein for GnT-V in human colon cancer cell
	WiDr <41>) <41>
SP	#3# hexosaminidase B preproprotein + UDP-N-acetyl-D-glucosamine = ?
	(#3# identified target protein for GnT-V in human colon cancer cell
	WiDr <41>) <41>
SP	#3# human Fc binding protein + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# Ig kappa chain V-III + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# laminin gamma1 precursor + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# legumain preproprotein + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# met proto-oncogene + UDP-N-acetyl-D-glucosamine = ? (#3# identified
	target protein for GnT-V in human colon cancer cell WiDr <41>) <41>
SP	#3# N-acetylgalactosamine-6-sulfatase + UDP-N-acetyl-D-glucosamine = ?
	(#3# identified target protein for GnT-V in human colon cancer cell
	WiDr <41>) <41>
SP	#3# N-acetylglucosamine-6-sulfatase + UDP-N-acetyl-D-glucosamine = ?
	(#3# identified target protein for GnT-V in human colon cancer cell
	WiDr <41>) <41>
SP	#3# prosaposin + UDP-N-acetyl-D-glucosamine = ? (#3# identified target
	protein for GnT-V in human colon cancer cell WiDr <41>) <41>
SP	#3# protective protein for beta-galactosidase +
	UDP-N-acetyl-D-glucosamine = ? (#3# identified target protein for GnT-V
	in human colon cancer cell WiDr <41>) <41>
SP	#3# protein tyrosine phosphatase kappa + UDP-N-acetyl-D-glucosamine = ?
	(#3# identified target protein for GnT-V in human colon cancer cell
	WiDr <41>) <41>
SP	#3# protein-tyrosine kinase-related receptor PTK7 +
	UDP-N-acetyl-D-glucosamine = ? (#3# identified target protein for GnT-V
	in human colon cancer cell WiDr <41>) <41>
SP	#3# ribonuclease T2 precursor + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# tissue inhibitor of metalloproteinase-1 +
	UDP-N-acetyl-D-glucosamine = ? (#3# identified target protein for GnT-V
	in human colon cancer cell WiDr <41>) <41>
SP	#3# tumor-associated calcium signal transducer 1 +
	UDP-N-acetyl-D-glucosamine = ? (#3# identified target protein for GnT-V
	in human colon cancer cell WiDr <41>) <41>
SP	#3# Zn-alpha-2-glycoprotein + UDP-N-acetyl-D-glucosamine = ? (#3#
	identified target protein for GnT-V in human colon cancer cell WiDr
	<41>) <41>
SP	#3# UDP-N-acetyl-D-glucosamine +
	Ac-Val-Glu-Pro-(GlcNAcbeta(1-2)Manalpha1-O-)Thr-Ala-Val-NH2 = UDP +
	Ac-Val-Glu-Pro-(GlcNAcbeta(1-2)[GlcNAcbeta(1-6)]Manalpha1-O-)Thr-Ala
	Val-NH2 <45>
SP	#3# UDP-N-acetyl-D-glucosamine +
	GlcNAcbeta(1-2)Manalpha(1-2)Glc-O-octyl = UDP +
	GlcNAcbeta(1-2)[GlcNAcbeta(1-6)]Manalpha(1-2)Glc-O-octyl <45>
SP	#3# UDP-N-acetyl-D-glucosamine +
	GlcNAcbeta(1-2)Manalpha(1-3)[GlcNAcbeta(1-2)Manalpha(1-6)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc = UDP +
	GlcNAcbeta(1-2)[GlcNAcbeta(1-6)]Manalpha(1-3)[GlcNACbeta(1-2)Manalpha(1
	6)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc <45>
SP	#3# UDP-N-acetyl-D-glucosamine + GlcNAcbeta(1-2)Manalpha1-O-benzyl =
	UDP + GlcNAcbeta(1-2)[GlcNAcbeta(1-6)]Manalpha1-O-benzyl <45>
SP	#3# UDP-N-acetyl-D-glucosamine +
	[GlcNAcbeta(1-2)][GlcNAcbeta(1-6)]Manalpha(1-3)[GlcNAcbeta(1
	2)Manalpha(1-6)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc = UDP +
	[GlcNAcbeta(1-2)][GlcNAcbeta(1-6)]Manalpha(1-3)[[GlcNAcbeta(1
	2)][GlcNAcbeta(1-6)]Manalpha(1-6)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc <45>
SP	#4# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-mannosyl-1
	6-beta-mannosyl-O-(CH2)8COOCH3 = UDP +
	N-acetyl-D-glucosaminyl-1,6-(N-acetyl-D-glucosaminyl-1
	2)-alpha-mannosyl-1,6-beta-D-mannosyl-O-(CH2)8COOCH3 <8>
SP	#5# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,2-alpha-4-deoxy-mannosyl-1
	6-beta-glucosyl-O-(CH2)7-CH3 = UDP +
	N-acetyl-D-glucosaminyl-1,6-(N-acetyl-D-glucosaminyl-1
	2)-alpha-4-deoxy-mannosyl-1,6-beta-D-mannosyl-O-(CH2)7-CH3 (#5# good
	substrate <6>) {} <6>
SP	#5# UDP-N-acetyl-D-glucosamine +
	N-acetyl-D-glucosaminyl-1,6-beta-glucosaminyl-O-(CH2)7-CH3 = UDP + ?
	<10>
SP	#7,8# UDP-N-acetyl-D-glucosamine + octyl
	6-O-[2-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-alpha-D
	mannopyranosyl]-beta-D-glucopyranoside = UDP + ? (#7,8# a synthetic
	trisaccharide acceptor <67>) <67>

KM_VALUE
KM	#3# 0.05 {Ac-Val-Glu-Pro-(GlcNAcbeta(1-2)Manalpha1-O-)Thr-Ala-Val-NH2} 
	<45>
KM	#3# 0.133 {pyridylaminated biantennary acceptor substrates}  <4>
KM	#3# 0.18
	{N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R}  <14>
KM	#3# 4.6 {UDP-N-acetylglucosamine}  (#3# BVVdelta73 mutant <15>) <15>
KM	#3# 2.4
	{GlcNAc-beta(1-2)Man-alpha(1-3)(GlcNAc-beta(1-2)Man-alpha(1-4))Man
	beta(1-4)GlcNAc-2-amino pyridine}  (#3# Hep3B cell, pH 7.0, 37°C <21>)
	<21>
KM	#3# 0.23
	{N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R}  (#3# with
	UDP-glucose <15>) <15>
KM	#3# 0.15
	{N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R}  (#3# with
	UDP-N-acetylglucosamine <15>) <15>
KM	#3# 0.56 {UDP-N-acetyl-D-glucosamine}  <45>
KM	#3# 4 {UDP-N-acetylglucosamine}  (#3# BVVdelta188 mutant <15>) <15>
KM	#3# 5.8 {UDP-GlcNAc}  (#3# Hep2G cell, pH 7.0, 37°C <21>) <21>
KM	#3# 5.8 {UDP-N-acetylglucosamine}  <12>
KM	#3# 0.13
	{N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	3(6)-(N-acetyl-D-glucosaminyl-1,2-alpha-D-mannosyl-1
	6(3))-beta-D-mannosyl-1,4-N-acetyl-D-glucosaminyl-R}  (#3# with
	TDP-glucose <15>) <15>
KM	#3# 4.5 {UDP-GlcNAc}  (#3# Hep3B cell, pH 7.0, 37°C <21>) <21>
KM	#3# 0.53 {GlcNAcbeta(1-2)Manalpha(1-2)Glc-O-octyl}  <45>
KM	#3# 3.5 {UDP-N-acetylglucosamine}  <4>
KM	#3# 0.61 {GlcNAcbeta(1-2)Manalpha1-O-benzyl}  <45>
KM	#3# 2.9 {UDP-glucose}  <15>
KM	#3# 2.9 {TDP-glucose}  <15>
KM	#3# 6 {UDP-N-acetylglucosamine}  <14>
KM	#3# 0.88 {GlcNAcbeta(1-2)Manalpha1-O-benzyl}  <45>
KM	#3# 1.28
	{GlcNAc-beta(1-2)Man-alpha(1-3)(GlcNAc-beta(1-2)Man-alpha(1-4))Man
	beta(1-4)GlcNAc-2-amino pyridine}  (#3# Hep2G cell, pH 7.0, 37°C <21>)
	<21>
KM	#3# 1.11 {Ac-Val-Glu-Pro-(GlcNAcbeta(1-2)Manalpha1-O-)Thr-Ala-Val-NH2} 
	<45>
KM	#3# 1.82 {GlcNAcbeta(1-2)Manalpha(1-2)Glc-O-octyl}  <45>
KM	#3# 1.62 {UDP-N-acetyl-D-glucosamine}  <45>
KM	#4# 11 {UDP-N-acetylglucosamine}  <8>
KM	#4# 0.087
	{N-acetyl-D-glucosaminyl-1,2-alpha-mannosyl-1
	6-beta-mannosyl-O-(CH2)8COOCH3}  <8>
KM	#4# 7.6 {UDP-N-acetylglucosamine}  (#4# + pyridylaminated acceptor
	substrate <2>) <2>
KM	#5# -999 {more}  (#5# kinetic study <6>) <6>
KM	#5# 0.18
	{N-acetyl-D-glucosaminyl-1,2-alpha-mannosyl-1
	6-beta-mannosyl-O-(CH2)-COOCH3}  <1>
KM	#5# 0.023
	{N-acetyl-D-glucosaminyl-1,2-alpha-mannosyl-1
	6-beta-glucosyl-O-(CH2)7-CH3}  <6>
KM	#5# 0.25 {N-acetyl-D-glucosamine}  <1>
KM	#5# 1.4 {UDP-N-acetylgucosamine}  (#5# cosubstrate:
	N-acetyl-D-glucosaminyl-1,2-alpha-4-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3 <6>) <6>
KM	#5# 0.036
	{N-acetyl-D-glucosaminyl-1,2-alpha-mannosyl-1
	6-beta-glucosyl-O-(CH2)7-CH3}  <6>
KM	#5# 1.1-1.2 {UDP-N-acetylglucosamine}  (#5# cosubstrate:
	N-acetyl-D-glucosaminyl-1,2-alpha-mannosyl-1
	6-beta-glucosyl-O-(CH2)7-CH3 <6>) <5,6>
KM	#5# 0.074
	{N-acetyl-D-glucosaminyl-1,2-alpha-4-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3}  <6>
KM	#5# 0.66-0.7 {UDP-N-acetylgucosamine}  (#5# cosubstrate:
	N-acetyl-D-glucosaminyl-1,2-alpha-6-deoxy- (or-4-O-methyl-)
	mannosyl-1,6-beta-D-glucosyl-O-(CH2)7-CH3 <6>) <6>

PH_OPTIMUM
PHO	#2# 6-6.7 <11>
PHO	#3# 8 <45>
PHO	#3,6,7,8# 6.5 (#6,7,8# assay at <66,67>) <12,21,66,67>
PHO	#4# 6.3 <2>
PHO	#4# 6.5-7 <8>
PHO	#5,6# 6 (#5# around <1>; #6# assay at <62>) <1,62>

PH_RANGE
PHR	#3# 6.5-7 <45>
PHR	#4# 6.25 <2>

SPECIFIC_ACTIVITY
SA	#2# 1e-06 (#2# spleen, wild-type mice <42>) <42>
SA	#2# 1.2e-06 (#2# liver, wild-type mice <42>) <42>
SA	#2# 0.0015 <11>
SA	#2# 0.03 (#2# Q39-740 mutant <11>) <11>
SA	#2# 3e-08 (#2# heart, wild-type mice <42>) <42>
SA	#2# 6e-07 (#2# brain, wild-type mice <42>) <42>
SA	#2# 2.75e-06 (#2# intestine, wild-type mice <42>) <42>
SA	#2# 1.33e-06 (#2# kidney, wild-type mice <42>) <42>
SA	#2,5# -999.0 (#2# no activity in GnT-Va knockout mice <42>) <3,5,42>
SA	#3# 0.139 <4>
SA	#3# 110.0 <12>
SA	#3# 0.004 (#3# BVVDELTA188 mutant <15>) <15>
SA	#3# 0.0036 (#3# BVVDELTA73 mutant <15>) <15>
SA	#4# 1.22 <8>

TEMPERATURE_OPTIMUM
TO	#1,2,3,4,5,6,7,8# 37 (#1,2,3,4,5,6,7,8# assay at <1,2,3,5,6,7,66,67>)
	<1,2,3,5,6,7,45,66,67>
TO	#2# 42 (#2# 2fold increase as compared to 37°C <11>) <11>
TO	#3# 50 <12,21>
TO	#6# 30 (#6# assay at <62>) <62>

ACTIVATING_COMPOUND
AC	#3,4# NaCl (#4# stabilizes and enhances activity, 0.2 M <8>; #3# up to
	0.2 M, increase in enzyme activity <45>) <8,45>
AC	#4# Triton X-100 (#4# activation, 1.0-1.5% <8>) <8>
AC	#4# Immunoglobulin G (#4# activation and stabilization, 0.5 mg/ml <8>)
	<8>
AC	#4# glycerol (#4# activation and stabilization, 20% <8>) <8>

INHIBITORS
IN	#2# beta1,4-N-acetylglucosaminyltransferase-III (#2# competitive
	inhibitor <30>) <30>
IN	#2# beta1,6-N-acetylglucosaminyltransferase III (#2# GnT-III,
	competitive inhibitor <39>) <39>
IN	#2,3# siRNA (#2# three RNAi sequences are designed, based on the mouse
	GnT-V cDNA sequence <40>) <35,40>
IN	#2,3,4# more (#2,4# no inhibitor: EDTA <3,8>; #3# 20% of maximal
	activity in absence of any 2+ cation <45>) <3,8,45>
IN	#3# antisense GnT-V <32>
IN	#3# TDP-N-acetylglucosamine (#3# 20 mM <12>) <12>
IN	#3# ADP-N-acetylglucosamine (#3# 20 mM <12>) <12>
IN	#3# CDP-N-acetylglucosamine (#3# 20 mM <12>) <12>
IN	#3# GDP-N-acetylglucosamine (#3# 20 mM <12>) <12>
IN	#3# Ca2+ (#3# 20% of maximal activity <45>; #3# 35% of maximal activity
	<45>) <45>
IN	#3# Fe3+ (#3# 1 mM inhibits <12>) <12>
IN	#3# N-bromosuccinimide (#3# 1 mM inhibits <12>) <12>
IN	#3# PC-MGAT5si (#3# a MGAT5 knock-down vector is used for animal
	studies in mice <31>) <31>
IN	#3# Zn2+ (#3# 10% of maximal activity <45>) <45>
IN	#3# EDTA (#3# 10% of maximal activity in absence of any cation and in
	presence in EDTA <45>) <45>
IN	#3# Fe2+ (#3# 15% of maximal activity <45>) <45>
IN	#3# Ni2+ (#3# 15% of maximal activity <45>) <45>
IN	#3# Cu2+ (#3# 30% of maximal activity <45>) <45>
IN	#3# Ba2+ (#3# 30% of maximal activity <45>) <45>
IN	#3# Mg2+ (#3# 50% of maximal activity <45>) <45>
IN	#3# NaCl (#3# more than 0.2 M, decrease in enzyme acitivty <45>; #3#
	more than 50 mM, decrease in enzyme acitivty <45>) <45>
IN	#4#
	N-Acetyl-D-glucosaminyl-1,2-alpha-6-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)8-COOCH3 <8>
IN	#5#
	N-Acetyl-D-glucosaminyl-1,2-alpha-6-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3 (#5# competitive <7>; #5# kinetics <6>)
	<5,6,7>
IN	#5#
	N-Acetyl-D-glucosaminyl-1,2-alpha-4-O-methyl-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3 <6>

KI_VALUE
KI	#4# 0.141
	{N-Acetyl-D-glucosaminyl-1,2-alpha-6-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)8-COOCH3}  <8>
KI	#5# 0.014
	{N-Acetyl-D-glucosaminyl-1,2-alpha-4-O-methyl-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3}  <6>
KI	#5# 0.063
	{N-Acetyl-D-glucosaminyl-1,2-alpha-6-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3}  <6,7>
KI	#5# 0.06-0.077
	{N-Acetyl-D-glucosaminyl-1,2-alpha-6-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3}  <5>

METALS_IONS
ME	#1,2,3,4,5# more (#1,2,3,4,5# no requirement for Mn2+ <1,2,3,4,5,8>;
	#4# no requirement for Mn2+, Mg2+, Ca2+ <8>) <1,2,3,4,5,8>
ME	#3,6# Mn2+ (#6# required <62>; #3# 1 mM stimulates <12>; #3# 10mM,
	4-fold stimulated enzyme activity <45>; #3# decrease in enzyme activity
	<45>) <12,45,62>
ME	#4# NaCl (#4# activation, 0.2 M <8>) <8>
ME	#6# MnCl2 (#6# up to 3fold stimulation <19>) <19>

MOLECULAR_WEIGHT
MW	#3# 70000 (#3# SDS-PAGE, BVVdelta188 <15>) <15>
MW	#3# 100000 (#3# determined by SDS-PAGE and Western Blot analysis <35>)
	<35>
MW	#3# 110000 (#3# Western blot <51>; #3# determined by Western blot
	analysis <33>) <33,51>
MW	#3# 65000 (#3# native PAGE <12>) <12>
MW	#3# 85000 (#3# SDS-PAGE, BVVdelta73 <15>) <15>
MW	#3# 73000 (#3# HPLC-gel filtration <4>) <4>
MW	#3# 67000 (#3# SDS-PAGE <12>) <12>
MW	#3# 84570 (#3# determined by SDS-PAGE and Western Blot analysis <34>)
	<34>
MW	#4# 75000 (#4# SDS-PAGE, 2 bands: 69000 and 75000 <8>) <8>
MW	#4# 69000 (#4# SDS-PAGE, 2 bands: 69000 and 75000 <8>) <8>

POSTTRANSLATIONAL_MODIFICATION
PM	#3# glycoprotein (#3# amino acids N334, N433 and N447 are glycosylated.
	N334 contains a biantennary structure with one or two terminating
	sialic acids. N433 and N447 contain structures that range from
	biantennary with two sialic acids to tetraantennary terminating with
	four sialic acids <20>) <12,20,33>
PM	#3# proteolytic modification (#3# Golgi-resident GnT-V is cleaved
	mainly in the transmembrane region by gamma-secretase, followed by its
	secretion <24>) <24>

SUBUNITS
SU	#3# monomer (#3# 1 * 73000, SDS-PAGE <4>) <4>
SU	#4# More (#4# rat kidney enzyme appears as doublet of MW 69000 and
	75000 on SDS-PAGE <8>) <8>

APPLICATION
AP	#2,3# medicine (#3# link between elevated expression of enzyme and
	malignant transformation, macrophage fusion hybrids with Cloudman S91
	mouse melanoma cells are highly metastatic in vivo, motile in vitro and
	express macrophage-associated traits of increased enzyme activity,
	beta1,6-branching and polylactosamine content <18>; #3# a selective
	inhibitor for this GnT-V secretion, a gamma-secretase inhibitor, could
	provide a useful strategy for the inhibition of tumor angiogenesis and
	progression <24>; #3# GnT-V is a potential target for tumor treatment
	<23>; #3# higher expression of GnT-V is correlated with a favorable
	prognosis for neuroblastoma patients. GnT-V may cause these tumors to
	regress by increasing their susceptibility to apoptosis <25>; #3#
	prognosis of thyroid carcinoma after surgery is not correlated with the
	expression GnT-V because the levels of expression is quite low in
	anaplastic (undifferentiated) carcinomas <26>; #3# a simple
	glycoproteomic strategy to identify the glycoproteins from breast
	tissue that bind to the lectin L-phytohemagglutinin is developed <38>;
	#2# conditional expression of beta1,6GlcNAc-branched N-glycans in
	postnatal tissues promotes anabolic metabolism and tissue renewal by
	adapting cellular sensitivities to growth and arrest cues <36>; #2#
	GnT-III transfection into highly pigmented, highly metastatic
	macrophage-melanoma fusion hybrids resulted in the suppression of both
	melanogenesis and motility <30>; #3# GnT-V and beta1-6 branching
	N-linked oligosaccharide expressions are downregulated during
	carcinogenesis and progression of human testicular germ cell tumors,
	GnT-V may be a promising recurrence predictor for stage I
	non-seminomatous germ cell tumors <37>; #3# high GnT-V expression is
	correlated with impaired clinical outcome in endometrial cancer
	patients, GnT-V is an independent prognostic factor for
	progression-free survival <33>; #3# knowledge of the biological
	behavior of metalloproteinases and tissue inhibitor of
	metalloproteinases and the roles in various diseases have an eventual
	goal of therapeutic uses and clinical trials of anti-cancer agents
	<41>; #3# MGAT5 is important in the metastasis of prostate cancer <31>;
	#3# the study demonstrates the effect of down-regulating GnT-V on
	glucose uptake and provides a new mechanistic link between GnT-V and
	GLUT1, since ER stress may cause apoptosis of tumor cells, selective
	modulation of GLUT1 may be a useful pro-apoptotic strategy for liver or
	other cancers <32>; #3# GnT-V expression correlated with a poor
	prognosis in gastric cancer patients due to metastases <52>; #3#
	possible decrease of human hepatoma SMMC-7721 cell adhesion <49>; #3#
	enzyme expression is positively related with malignancy in HCC. The
	enzyme is both a differentiation marker and a potential target for the
	treatment of hepatocellular carcinoma <56>; #3# the enzyme is a
	potential therapeutic target for vascular inflammatory conditions <58>)
	<18,23,24,25,26,30,31,32,33,36,37,38,41,49,52,56,58>
AP	#3# pharmacology (#3# the work is a step toward intriguing innovative
	therapeutic strategies for trials currently in consider with
	glycosyltransferase in neurodegenerative disorders <34>) <34>
AP	#3# biotechnology (#3# transfection of sense cDNA of enzyme results in
	increase in the N-acetylglucosamine-beta1,6-mannose-alpha1,3-branch of
	epidermal growth factor receptor. Transfection with antisense CDNA of
	enzyme rsults in reverse reaction. Altered expression of enzyme will
	change the glycan structure and function of epidermal growth factor
	receptor, which may modify downstream signal transduction <17>) <17>
AP	#3# more (#3# an elevation of enzyme Gnt-V activity leads to
	radiosensitivity and migration of small cell lung cancer cells by
	inducing epithelial-mesenchymal transition, EMT, thereby highlighting
	Gnt-V as a potential therapeutic target for the prevention of
	EMT-associated tumour radioresistance and migration <64>) <64>
AP	#6# diagnostics (#6# the enzyme is useful as diagnostic marker for
	gastric adenocarcinomas: low intratumoral MGAT5 density is associated
	with poor differentiation, N classification, TNM stage, and Kiel stage,
	and is an independent prognosticator for poor overall survival. The
	combination of intratumoral MGAT5 expression and TNM or Kiel staging
	systems has a better predictive power for overall survival. Applying
	the prognostic value of intratumoral MGAT5 density to TNM stage III+IV
	and Kiel stage IIIB+IV groups shows a better risk stratification for
	overall survival in patients with late-stage gastric cancer, overview
	<63>) <63>

ENGINEERING
EN	#2,3,6,7# more (#2# Mgat5 knockout mice, change in depression-like
	behaviour, decrease in immobility duration in tests of depression, no
	response to antidepressant treatment, altered social behavior in males
	<43>; #2# N-acetylglucosaminyltransferase Va knockout mice, aberrant
	expression of several N-glycan structures, decrease in tumor
	progression <42>; #3# overexpression of GnT-V, change in glycosylation
	of receptor protein tyrosine phosphatase kappa, decrease of cell
	calcium-independent adhesion, increase of tyrosine phosphorylation
	level of beta-catenin <49>; #6# enzyme downregulation in cancer cells
	by specific shRNA expression <61>; #6# generation of a stable BEL7404
	Tet-on-Mgat5 cell line in which human Mgat5 can be specifically induced
	by doxycycline to explore functional alterations after Mgat5
	overexpression <65>; #7# generation of cell line Lec4A lacking
	N-acetylglucosaminyltransferase V activity and protein in the Golgi
	apparatus <67>; #6# GlcNAc and tet-induced Mgat5 increases the levels
	of many metabolites in HeLa cells, and HEK293 cells, and tet-induced
	Mgat5 changes in the N-glycan distributions, N-glycans profiles of
	transgenic HeLa and HEK-293 cells, overview. Tet-inducible Mgat5
	enhances amino acid uptake and growth in nutrient-poor conditions and
	complex-type N-glycan branching in HEK293 Mgat5 clones. Up-regulation
	of Mgat5 in HEK293 cells stimulates amino acid uptake and increases
	metabolite levels under low Gln/Glc culture conditions <66>; #6# GnT-V
	overexpression induces an aberrant E-cadherin cellular localization and
	alters cell morphology, GnT-V increases the stability of the
	cadherin/catenin complex, GnT-V leads to a reduced intercellular
	adhesion of gastric cells, phenotype, overview <53>; #3# silencing of
	the enzyme by expression of short hairpin RNAs specific to Gnt-V in
	small cell lung cancer cell lines H1688 and H146 <64>)
	<42,43,49,53,61,64,65,66,67>
EN	#3# V375L (#3# increased specific activity <12>) <12>
EN	#3# T555R (#3# increased specific activity <12>) <12>
EN	#3# A592G (#3# increased specific activity <12>) <12>
EN	#6# L188R (#6# site-directed mutagenesis, inactive mutant <65>) <65>

CLONED
CL	#2# (wild type enzyme and several N- and C-terminal deletions, fusion
	to protein A from Staphylococcus aurus) <11>
CL	#3# (fusion with signal peptide from baculoviral protein to permit
	secretion into medium, BVVdelta73 and BVV delta188) <15>
CL	#3# (transfection in HEK-293 cells) <45>
CL	#3# (MKN45 cells are transfected with GnT-III, GnT-V, or both,
	respectively) <27>
CL	#3# (a recombinant vector MGAT5-pCXNneo is constructed for transfection
	of WiDr cells) <41>
CL	#3# (into the pcDNA3 vector for transfection of rat pheochromocytoma
	cells, PC12) <34>
CL	#3# (into the pGEM-Teasy vector and subcloned into the pcDNA3
	expression vector) <31>
CL	#3# (transfection into 7721 cells) <50>
CL	#6# (gene MGAT5, quantitative real-time PCR enzyme expression analysis)
	<53,61>
CL	#6# (gene MGAT5, real-time RT-PCR enzyme expression analysis,
	establishing of human melanoma cell line WM-266-4 with induced stable
	overexpression of GnT-V, the cells show ncreased amounts of bisected
	and beta1-6 branched N-glycans on melanoma cell adhesion molecule
	MCAM/MUC18, but do not display significant differences in viability and
	capabilities to migrate through an endothelial layer, coexpression with
	MGAT3 gene, EC 2.4.1.144) <62>
CL	#6# (gene MGAT5, recombinant tet-inducible expression of Flag-tagged
	GlcNAcT-V in HeLa and HEK293 cells. Tet-induced Mgat5 HEK293 cells
	display a 2fold increase in tri-antennary and a 2fold increase in
	tetraantennary N-glycans) <66>
CL	#6# (Huh7 and HepG2 cells are transiently transfected by both Mgat5
	expression vector plasmid and empty vector plasmid as a control) <65>
CL	#8# (gene MGAT5, overexpression in CHO cells and Lec4 cells from
	Cricetulus griseus) <67>

PURIFICATION
PU	#2# <11>
PU	#3# <12,14,15,24>
PU	#3# (partial) <4>
PU	#3# (GnT-Vdelta73, GnT-Vdelta233, GnT-Vdelta436 and GnT-Vdelta188) <13>
PU	#3# (nickel column chromatography) <45>
PU	#4# <8>
PU	#5# (partial) <6,7>

GENERAL_STABILITY
GS	#4# (glycerol, 20%, stabilizes and enhances activity) <8>
GS	#4# (immunoglobulin G, 0.5 mg/ml, stabilizes and enhances activity) <8>
GS	#4# (NaCl, 0.2 M, stabilizes and enhances activity) <8>

PH_STABILITY
PHS	#3# 4.5-10.5 (#3# stable for 24 h at 4°C <12>) <12>

STORAGE_STABILITY
SS	#2# (-20°C stable for 2 months) <11>
SS	#4# (4°C, several months in 20% glycerol) <8>

TEMPERATURE_STABILITY
TS	#2# 4 (#2# stable for 2 months <11>) <11>

REFERENCE
RF	<1> Schachter, H.; Brockhausen, I.; Hull, E.: High-performance liquid
	chromatography assays for N-acetylglucosaminyltransferases involved in
	N- and O-glycan synthesis. Methods Enzymol. (1989) 179, 351-397.
	{Pubmed:2560125} (review)
RF	<2> Taniguchi, N.; Nishikawa, A.; Fujii, S.; Gu, J.:
	Glycosyltransferase assays using pyridylaminated acceptors:
	N-acetylglucosaminyltransferase III, IV, and V. Methods Enzymol. (1989)
	179, 397-408. {Pubmed:2533651}
RF	<3> Cummings, R.D.; Trowbridge, I.S.; Kornfeld, S.: A mouse lymphoma
	cell line resistant to the leukoagglutinating lectin from Phaseolus
	vulgaris is deficient in UDP-GlcNAc: alpha-D-mannoside beta 1,6
	N-acetylglucosaminyltransferase. J. Biol. Chem. (1982) 257,
	13421-13427. {Pubmed:6216250}
RF	<4> Gu, J.; Nishikawa, A.; Tsuruoka, N.; Ohno, M.; Yamaguchi, N.;
	Kangawa, K.; Taniguchi, N.: Purification and characterization of
	UDP-N-acetylglucosamine: alpha-6-D-mannoside beta
	1-6N-acetylglucosaminyltransferase (N-acetylglucosaminyltransferase V)
	from a human lung cancer cell line. J. Biochem. (1993) 113, 614-619.
	{Pubmed:8393437}
RF	<5> Palcic, M.M.; Ripka, J.; Kaur, K.J.; Shoreibah, M.; Hindsgaul, O.;
	Pierce, M.: Regulation of N-acetylglucosaminyltransferase V activity.
	Kinetic comparisons of parental, Rous sarcoma virus-transformed BHK,
	and L-phytohemagglutinin-resistant BHK cells using synthetic substrates
	and an inhibitory substrate analog. J. Biol. Chem. (1990) 265,
	6759-6769. {Pubmed:2157709}
RF	<6> Khan, S.H.; Crawley, S.C.; Kanie, O.; Hindsgaul, O.: A
	trisaccharide acceptor analog for N-acetylglucosaminyltransferase V
	which binds to the enzyme but sterically precludes the transfer
	reaction. J. Biol. Chem. (1993) 268, 2468-2473. {Pubmed:8428922}
RF	<7> Hindsgaul, O.; Kaur, K.J.; Srivastava, G.; Blaszcyk-Thurin, M.;
	Crawley, S.C.; Heerze, L.D.; Palcic, M.M.: Evaluation of deoxygenated
	oligosaccharide acceptor analogs as specific inhibitors of
	glycosyltransferases. J. Biol. Chem. (1991) 266, 17858-17862.
	{Pubmed:1917926}
RF	<8> Shoreibah, M.; Hindsgaul, O.; Pierce, M.: Purification and
	characterization of rat kidney UDP-N-acetylglucosamine:
	alpha-6-D-mannoside beta-1,6-N-acetylglucosaminyltransferase. J. Biol.
	Chem. (1992) 267, 2920-2927. {Pubmed:1531335}
RF	<9> Granovsky, M.; Fode, C.; Warren, C.E.; Campbell, R.M.; Marth, J.D.;
	Pierce, M.; Fregien, N.; Dennis, J.W.: GlcNAc-transferase V and core 2
	GlcNAc-transferase expression in the developing mouse embryo.
	Glycobiology (1995) 5, 797-806. {Pubmed:8720078}
RF	<10> Khan, S.H.; Duus, J.O.; Crawley, S.C.; Palcic, M.M.; Hindsgaul,
	O.: Acceptor-substrate recognition by
	N-acetylglucosaminyltransferase-V: role of the mannose residue in
	beta-DGlcNAc(1->2)alpha-DMan(1->6)beta-DGlcOR. Tetrahedron (1994) 5,
	2415-2435. {Pubmed:}
RF	<11> Korczak, B.; Le, T.; Elowe, S.; Datti, A.; Dennis, J.W.: Minimal
	catalytic domain of N-acetylglucosaminyltransferase V. Glycobiology
	(2000) 10, 595-599. {Pubmed:10814701}
RF	<12> Park, C.; Jin, U.H.; Lee, Y.C.; Cho, T.J.; Kim, C.H.:
	Characterization of UDP-N-acetylglucosamine:alpha-6-D-mannoside
	beta-1,6-N-Acetylglucosaminyltransferase V from a Human Hepatoma Cell
	Line Hep3B. Arch. Biochem. Biophys. (1999) 367, 281-288.
	{Pubmed:10395745}
RF	<13> Saito, T.; Miyoshi, E.; Sasai, K.; Nakano, N.; Eguchi, H.; Honke,
	K.; Taniguchi, N.: A secreted type of beta
	1,6-N-acetylglucosaminyltransferase V (GnT-V) induces tumor
	angiogenesis without mediation of glycosylation: a novel function of
	GnT-V distinct from the original glycosyltransferase activity. J. Biol.
	Chem. (2002) 277, 17002-17008. {Pubmed:11872751}
RF	<14> Sasai, K.; Ikeda, Y.; Eguchi, H.; Tsuda, T.; Honke, K.; Taniguchi,
	N.: The action of N-acetylglucosaminyltransferase-V is prevented by the
	bisecting GlcNAc residue at the catalytic step. FEBS Lett. (2002) 522,
	151-155. {Pubmed:12095636}
RF	<15> Sasai, K.; Ikeda, Y.; Fujii, T.; Tsuda, T.; Taniguchi, N.:
	UDP-GlcNAc concentration is an important factor in the biosynthesis of
	beta1,6-branched oligosaccharides: Regulation based on the kinetic
	properties of N-acetylglucosaminyltransferase V. Glycobiology (2002)
	12, 119-127. {Pubmed:11886845}
RF	<16> Takamatsu, S.; Inoue, N.; Katsumata, T.; Nakamura, K.;
	Fujibayashi, Y.; Takeuchi, M.: The relationship between the
	branch-forming glycosyltransferases and cell surface sugar chain
	structures. Biochemistry (2005) 44, 6343-6349. {Pubmed:15835923}
RF	<17> Guo, P.; Wang, Q.Y.; Guo, H.B.; Shen, Z.H.; Chen, H.L.:
	N-acetylglucosaminyltransferase V modifies the signaling pathway of
	epidermal growth factor receptor. Cell. Mol. Life Sci. (2004) 61,
	1795-1804. {Pubmed:15241555}
RF	<18> Chakraborty, A.K.; Pawelek, J.M.: GnT-V, macrophage and cancer
	metastasis: a common link. Clin. Exp. Metastasis (2003) 20, 365-373.
	{Pubmed:12856724}
RF	<19> Kaneko, M.; Alvarez-Manilla, G.; Kamar, M.; Lee, I.; Lee, J.K.;
	Troupe, K.; Zhang, W.; Osawa, M.; Pierce, M.: A novel
	beta(1,6)-N-acetylglucosaminyltransferase V (GnT-VB)(1). FEBS Lett.
	(2003) 554, 515-519. {Pubmed:14623122}
RF	<20> Kamar, M.; Alvarez-Manilla, G.; Abney, T.; Azadi, P.; Kumar Kolli,
	V.S.; Orlando, R.; Pierce, M.: Analysis of the site-specific
	N-glycosylation of beta1,6 N-acetylglucosaminyltransferase V.
	Glycobiology (2004) 14, 583-592. {Pubmed:15084511}
RF	<21> Dawson, G.; Moskal, J.R.; Dawson, S.A.: Transfection of 2,6 and
	2,3-sialyltransferase genes and GlcNAc-transferase genes into human
	glioma cell line U-373 MG affects glycoconjugate expression and
	enhances cell death. J. Neurochem. (2004) 89, 1436-1444.
	{Pubmed:15189346}
RF	<22> Tomiie, M.; Isaka, S.; Miyoshi, E.; Taniguchi, N.; Kimura, T.;
	Ogita, K.; Tsutsui, T.; Shimoya, K.; Nakagawa, T.; Kondo, A.; Koyama,
	M.; Murata, Y.: Elevated expression of N-acetylglucosaminyltransferase
	V in first trimester human placenta. Biochem. Biophys. Res. Commun.
	(2005) 330, 999-1004. {Pubmed:15809094}
RF	<23> Fang, H.; Huang, W.; Xu, Y.Y.; Shen, Z.H.; Wu, C.Q.; Qiao, S.Y.;
	Xu, Y.; Yu, L.; Chen, H.L.: Blocking of N-acetylglucosaminyltransferase
	V induces cellular endoplasmic reticulum stress in human
	hepatocarcinoma 7721 cells. Cell Res. (2006) 16, 82-92.
	{Pubmed:16467879}
RF	<24> Nakahara, S.; Saito, T.; Kondo, N.; Moriwaki, K.; Noda, K.; Ihara,
	S.; Takahashi, M.; Ide, Y.; Gu, J.; Inohara, H.; Katayama, T.; Tohyama,
	M.; Kubo, T.; Taniguchi, N.; Miyoshi, E.: A secreted type of beta1,6
	N-acetylglucosaminyltransferase V (GnT-V), a novel angiogenesis
	inducer, is regulated by gamma-secretase. FASEB J. (2006) 20,
	2451-2459. {Pubmed:17142794}
RF	<25> Inamori, K.; Gu, J.; Ohira, M.; Kawasaki, A.; Nakamura, Y.;
	Nakagawa, T.; Kondo, A.; Miyoshi, E.; Nakagawara, A.; Taniguchi, N.:
	High expression of N-acetylglucosaminyltransferase V in favorable
	neuroblastomas: Involvement of its effect on apoptosis. FEBS Lett.
	(2006) 580, 627-632. {Pubmed:16406367}
RF	<26> Ito, Y.; Akinaga, A.; Yamanaka, K.; Nakagawa, T.; Kondo, A.;
	Dickson, R.B.; Lin, C.Y.; Miyauchi, A.; Taniguchi, N.; Miyoshi, E.:
	Co-expression of matriptase and N-acetylglucosaminyltransferase V in
	thyroid cancer tissues - its possible role in prolonged stability in
	vivo by aberrant glycosylation. Glycobiology (2006) 16, 368-374.
	{Pubmed:16464868}
RF	<27> Zhao, Y.; Nakagawa, T.; Itoh, S.; Inamori, K.; Isaji, T.; Kariya,
	Y.; Kondo, A.; Miyoshi, E.; Miyazaki, K.; Kawasaki, N.; Taniguchi, N.;
	Gu, J.: N-acetylglucosaminyltransferase III antagonizes the effect of
	N-acetylglucosaminyltransferase V on alpha3beta1 integrin-mediated cell
	migration. J. Biol. Chem. (2006) 281, 32122-32130. {Pubmed:16940045}
RF	<28> Macnaughtan, M.A.; Kamar, M.; Alvarez-Manilla, G.; Venot, A.;
	Glushka, J.; Pierce, J.M.; Prestegard, J.H.: NMR structural
	characterization of substrates bound to N-acetylglucosaminyltransferase
	V. J. Mol. Biol. (2007) 366, 1266-1281. {Pubmed:17204285}
RF	<29> Guo, P.; Chen, H.J.; Wang, Q.Y.; Chen, H.L.: Down regulation of
	N-acetylglucosaminyltransferase V facilitates all-transretinoic acid to
	induce apoptosis of human hepatocarcinoma cells. Mol. Cell. Biochem.
	(2006) 284, 103-110. {Pubmed:16411021}
RF	<30> Chakraborty, A.K.; Pawelek, J.: beta1,6-Branched oligosaccharides
	regulate melanin content and motility in macrophage-melanoma fusion
	hybrids. Melanoma Res. (2007) 17, 9-16. {Pubmed:17235237}
RF	<31> Tsui, K.H.; Chang, P.L.; Feng, T.H.; Chung, L.C.; Sung, H.C.;
	Juang, H.H.: Evaluating the function of matriptase and
	N-acetylglucosaminyltransferase V in prostate cancer metastasis.
	Anticancer Res. (2008) 28, 1993-1999. {Pubmed:18649738}
RF	<32> Li, J.; Wang, X.M.; Wang, Q.; Yang, M.; Feng, X.C.; Shen, Z.H.:
	Down-regulation of N-acetylglucosaminyltransferase-V induces ER stress
	by changing glycosylation and function of GLUT1. Arch. Biochem.
	Biophys. (2007) 463, 102-109. {Pubmed:17451637}
RF	<33> Yamamoto, E.; Ino, K.; Miyoshi, E.; Shibata, K.; Takahashi, N.;
	Kajiyama, H.; Nawa, A.; Nomura, S.; Nagasaka, T.; Kikkawa, F.:
	Expression of N-acetylglucosaminyltransferase V in endometrial cancer
	correlates with poor prognosis. Br. J. Cancer (2007) 97, 1538-1544.
	{Pubmed:17971775}
RF	<34> Yang, X.; Li, J.; Geng, M.: N-acetylglucosaminyltransferase V
	modifies TrKA protein, regulates the receptor function. Cell. Mol.
	Neurobiol. (2008) 28, 663-670. {Pubmed:18343992}
RF	<35> Yamamoto, E.; Ino, K.; Miyoshi, E.; Inamori, K.I.; Abe, A.;
	Sumigama, S.; Iwase, A.; Kajiyama, H.; Shibata, K.; Nawa, A.; Kikkawa,
	F.: N-acetylglucosaminyltransferase V regulates extravillous
	trophoblast invasion through glycosylation of alpha5beta1 integrin.
	Endocrinology (2009) 150, 990-999. {Pubmed:18845630}
RF	<36> Cheung, P.; Pawling, J.; Partridge, E.A.; Sukhu, B.; Grynpas, M.;
	Dennis, J.W.: Metabolic homeostasis and tissue renewal are dependent on
	beta1,6GlcNAc-branched N-glycans. Glycobiology (2007) 17, 828-837.
	{Pubmed:17483135}
RF	<37> Kyan, A.; Kamimura, N.; Hagisawa, S.; Hatakeyama, S.; Koie, T.;
	Yoneyama, T.; Arai, Y.; Nakagawa, H.; Nishimura, S.; Miyoshi, E.;
	Hashimoto, Y.; Ohyama, C.: Positive expressions of
	N-acetylglucosaminyltransferase-V (GnT-V) and beta1-6 branching
	N-linked oligosaccharides in human testicular germ cells diminish
	during malignant transformation and progression. Int. J. Oncol. (2008)
	32, 129-134. {Pubmed:18097551}
RF	<38> Abbott, K.L.; Aoki, K.; Lim, J.M.; Porterfield, M.; Johnson, R.;
	ORegan, R.M.; Wells, L.; Tiemeyer, M.; Pierce, M.: Targeted
	glycoproteomic identification of biomarkers for human breast carcinoma.
	J. Proteome Res. (2008) 7, 1470-1480. {Pubmed:18271524}
RF	<39> Chakraborty, D.; Chakraborty, A.K.: Evidence for tyrosinase as a
	beta1,6 branch containing glycoprotein: substrate of GnT-V. Life Sci.
	(2008) 83, 260-263. {Pubmed:18655794}
RF	<40> Zhao, Y.; Li, J.; Xing, Y.; Wang, J.; Lu, C.; Xin, X.; Geng, M.:
	N-acetylglucosaminyltransferase V mediates cell migration and invasion
	of mouse mammary tumor cells 4TO7 via RhoA and Rac1 signaling pathway.
	Mol. Cell. Biochem. (2008) 309, 199-208. {Pubmed:18060576}
RF	<41> Kim, Y.S.; Hwang, S.Y.; Kang, H.Y.; Sohn, H.; Oh, S.; Kim, J.Y.;
	Yoo, J.S.; Kim, Y.H.; Kim, C.H.; Jeon, J.H.; Lee, J.M.; Kang, H.A.;
	Miyoshi, E.; Taniguchi, N.; Yoo, H.S.; Ko, J.H.: Functional proteomics
	study reveals that N-acetylglucosaminyltransferase V reinforces the
	invasive/metastatic potential of colon cancer through aberrant
	glycosylation on tissue inhibitor of metalloproteinase-1. Mol. Cell.
	Proteomics (2008) 7, 1-14. {Pubmed:17878270}
RF	<42> Guo, H.B.; Nairn, A.; Harris, K.; Randolph, M.; Alvarez-Manilla,
	G.; Moremen, K.; Pierce, M.: Loss of expression of
	N-acetylglucosaminyltransferase Va results in altered gene expression
	of glycosyltransferases and galectins. FEBS Lett. (2008) 582, 527-535.
	{Pubmed:18230362}
RF	<43> Soleimani, L.; Roder, J.; Dennis, J.; Lipina, T.: Beta
	N-acetylglucosaminyltransferase V (Mgat5) deficiency reduces the
	depression-like phenotype in mice. Genes Brain Behav. (2008) 7,
	334-343. {Pubmed:17883406}
RF	<44> Guo, H.B.; Johnson, H.; Randolph, M.; Lee, I.; Pierce, M.:
	Knockdown of GnT-Va expression inhibits ligand-induced downregulation
	of the epidermal growth factor receptor and intracellular signaling by
	inhibiting receptor endocytosis. Glycobiology (2009) 19, 547-559.
	{Pubmed:19225046}
RF	<45> Alvarez-Manilla, G.; Troupe, K.; Fleming, M.; Martinez-Uribe, E.;
	Pierce, M.: Comparison of the substrate specificities and catalytic
	properties of the sister N-acetylglucosaminyltransferases, GnT-V and
	GnT-Vb (IX). Glycobiology (2010) 20, 166-174. {Pubmed:19846580}
RF	<46> Kasuya, T.; Jung, J.; Kadoya, H.; Matsuzaki, T.; Tatemastu, K.;
	Okajima, T.; Miyoshi, E.; Tanizawa, K.; Kuroda, S.: In vivo delivery of
	bio-nanocapsules displaying L4-PHA isolectin to malignant tumors
	overexpressing N-acetylglucosaminyltransferase V. Hum. Gene Ther.
	(2008) 19, 887-895. {Pubmed:18717644}
RF	<47> Pinho, S.S.; Reis, C.A.; Paredes, J.; Magalhaes, A.M.; Ferreira,
	A.C.; Figueiredo, J.; Xiaogang, W.; Carneiro, F.; Gaertner, F.; Seruca,
	R.: The role of N-acetylglucosaminyltransferase III and V in the
	post-transcriptional modifications of E-cadherin. Hum. Mol. Genet.
	(2009) 18, 2599-2608. {Pubmed:19403558}
RF	<48> Chen, H.L.; Li, C.F.; Grigorian, A.; Tian, W.; Demetriou, M.: T
	cell receptor signaling co-regulates multiple Golgi genes to enhance
	N-glycan branching. J. Biol. Chem. (2009) 284, 32454-32461.
	{Pubmed:19706602}
RF	<49> Wang, C.; Li, Z.; Yang, Z.; Zhao, H.; Yang, Y.; Chen, K.; Cai, X.;
	Wang, L.; Shi, Y.; Qiu, S.; Fan, J.; Zha, X.: The effect of receptor
	protein tyrosine phosphatase kappa on the change of cell adhesion and
	proliferation induced by N-acetylglucosaminyltransferase V. J. Cell.
	Biochem. (2010) 109, 113-123. {Pubmed:19911372}
RF	<50> Xu, Y.Y.; Guan, D.Y.; Yang, M.; Wang, H.; Shen, Z.H.:
	All-trans-retinoic acid intensifies endoplasmic reticulum stress in
	N-acetylglucosaminyltransferase V repressed human hepatocarcinoma cells
	by perturbing homocysteine metabolism. J. Cell. Biochem. (2010) 109,
	468-477. {Pubmed:19960509}
RF	<51> Takahashi, N.; Yamamoto, E.; Ino, K.; Miyoshi, E.; Nagasaka, T.;
	Kajiyama, H.; Shibata, K.; Nawa, A.; Kikkawa, F.: High expression of
	N-acetylglucosaminyltransferase V in mucinous tumors of the ovary.
	Oncol. Rep. (2009) 22, 1027-1032. {Pubmed:19787216}
RF	<52> Tian, H.; Miyoshi, E.; Kawaguchi, N.; Shaker, M.; Ito, Y.;
	Taniguchi, N.; Tsujimoto, M.; Matsuura, N.: The implication of
	N-acetylglucosaminyltransferase V expression in gastric cancer.
	Pathobiology (2008) 75, 288-294. {Pubmed:18931531}
RF	<53> Pinho, S.S.; Figueiredo, J.; Cabral, J.; Carvalho, S.; Dourado,
	J.; Magalhaes, A.; Gaertner, F.; Mendonca, A.M.; Isaji, T.; Gu, J.;
	Carneiro, F.; Seruca, R.; Taniguchi, N.; Reis, C.A.: E-cadherin and
	adherens-junctions stability in gastric carcinoma: Functional
	implications of glycosyltransferases involving N-glycan branching
	biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim.
	Biophys. Acta (2012) 1830, 2690-2700. {Pubmed:23671930}
RF	<54> Miyoshi, E.; Terao, M.; Kamada, Y.: Physiological roles of
	N-acetylglucosaminyltransferase V (GnT-V) in mice. BMB Rep. (2012) 45,
	554-559. {Pubmed:23101508}
RF	<55> Kimura, A.; Terao, M.; Kato, A.; Hanafusa, T.; Murota, H.;
	Katayama, I.; Miyoshi, E.: Upregulation of
	N-acetylglucosaminyltransferase-V by heparin-binding EGF-like growth
	factor induces keratinocyte proliferation and epidermal hyperplasia.
	Exp. Dermatol. (2012) 21, 515-519. {Pubmed:22716246}
RF	<56> Wei, T.; Liu, Q.; He, F.; Zhu, W.; Hu, L.; Guo, L.; Zhang, J.: The
	role of N-acetylglucosaminyltransferases V in the malignancy of human
	hepatocellular carcinoma. Exp. Mol. Pathol. (2012) 93, 8-17.
	{Pubmed:22537550}
RF	<57> Kamada, Y.; Mori, K.; Matsumoto, H.; Kiso, S.; Yoshida, Y.;
	Shinzaki, S.; Hiramatsu, N.; Ishii, M.; Moriwaki, K.; Kawada, N.;
	Takehara, T.; Miyoshi, E.: N-Acetylglucosaminyltransferase V regulates
	TGF-beta response in hepatic stellate cells and the progression of
	steatohepatitis. Glycobiology (2012) 22, 778-787. {Pubmed:22294551}
RF	<58> Yang, H.M.; Yu, C.; Yang, Z.: N-Acetylglucosaminyltransferase V
	negatively regulates integrin alpha5beta1-mediated monocyte adhesion
	and transmigration through vascular endothelium. Int. J. Oncol. (2012)
	41, 589-598. {Pubmed:22614033}
RF	<59> Lee, J.K.; Matthews, R.T.; Lim, J.M.; Swanier, K.; Wells, L.;
	Pierce, J.M.: Developmental expression of the neuron-specific
	N-acetylglucosaminyltransferase Vb (GnT-Vb/IX) and identification of
	its in vivo glycan products in comparison with those of its paralog,
	GnT-V. J. Biol. Chem. (2012) 287, 28526-28536. {Pubmed:22715095}
RF	<60> Kim, Y.S.; Ahn, Y.H.; Song, K.J.; Kang, J.G.; Lee, J.H.; Jeon,
	S.K.; Kim, H.C.; Yoo, J.S.; Ko, J.H.: Overexpression and
	beta-1,6-N-acetylglucosaminylation-initiated aberrant glycosylation of
	TIMP-1: a double whammy strategy in colon cancer progression. J. Biol.
	Chem. (2012) 287, 32467-32478. {Pubmed:22859303}
RF	<61> Lee, J.H.; Kang, J.G.; Song, K.J.; Jeon, S.K.; Oh, S.; Kim, Y.S.;
	Ko, J.H.: N-Acetylglucosaminyltransferase V triggers overexpression of
	MT1-MMP and reinforces the invasive/metastatic potential of cancer
	cells. Biochem. Biophys. Res. Commun. (2013) 431, 658-663.
	{Pubmed:23357422}
RF	<62> Bubka, M.; Link-Lenczowski, P.; Janik, M.; Pochec, E.; Litynska,
	A.: Overexpression of N-acetylglucosaminyltransferases III and V in
	human melanoma cells. Implications for MCAM N-glycosylation. Biochimie
	(2014) 103, 37-49. {Pubmed:24726881}
RF	<63> Wang, X.; He, H.; Zhang, H.; Chen, W.; Ji, Y.; Tang, Z.; Fang, Y.;
	Wang, C.; Liu, F.; Shen, Z.; Qin, J.; Zhu, Y.; Liu, H.; Xu, J.; Gu, J.;
	Qin, X.; Sun, Y.: Clinical and prognostic implications of
	beta1,6-N-acetylglucosaminyltransferase V in patients with gastric
	cancer. Cancer Sci. (2013) 104, 185-193. {Pubmed:23107376}
RF	<64> Huang, C.; Huang, M.; Chen, W.; Zhu, W.; Meng, H.; Guo, L.; Wei,
	T.; Zhang, J.: N-acetylglucosaminyltransferase V modulates
	radiosensitivity and migration of small cell lung cancer through
	epithelial-mesenchymal transition. FEBS J. (2015) 282, 4295-4306.
	{Pubmed:26293457}
RF	<65> Liu, J.; Liu, H.; Zhang, W.; Wu, Q.; Liu, W.; Liu, Y.; Pan, D.;
	Xu, J.; Gu, J.: N-acetylglucosaminyltransferase V confers hepatoma
	cells with resistance to anoikis through EGFR/PAK1 activation.
	Glycobiology (2013) 23, 1097-1109. {Pubmed:23811795}
RF	<66> Abdel Rahman, A.; Ryczko, M.; Nakano, M.; Pawling, J.; Rodrigues,
	T.; Johswich, A.; Taniguchi, N.; Dennis, J.: Golgi N-glycan branching
	N-acetylglucosaminyltransferases I, V and VI promote nutrient uptake
	and metabolism. Glycobiology (2015) 25, 225-240. {Pubmed:25395405}
RF	<67> Dong, Z.; Zuber, C.; Pierce, M.; Stanley, P.; Roth, J.: Reduction
	in Golgi apparatus dimension in the absence of a residential protein,
	N-acetylglucosaminyltransferase V. Histochem. Cell Biol. (2014) 141,
	153-164. {Pubmed:24078077}

ACTIVATING_COMPOUND
AC	#3,4# NaCl (#4# stabilizes and enhances activity, 0.2 M <8>; #3# up to
	0.2 M, increase in enzyme activity <45>) <8,45>
AC	#4# Triton X-100 (#4# activation, 1.0-1.5% <8>) <8>
AC	#4# Immunoglobulin G (#4# activation and stabilization, 0.5 mg/ml <8>)
	<8>
AC	#4# glycerol (#4# activation and stabilization, 20% <8>) <8>

KI_VALUE
KI	#4# 0.141
	{N-Acetyl-D-glucosaminyl-1,2-alpha-6-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)8-COOCH3}  <8>
KI	#5# 0.014
	{N-Acetyl-D-glucosaminyl-1,2-alpha-4-O-methyl-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3}  <6>
KI	#5# 0.063
	{N-Acetyl-D-glucosaminyl-1,2-alpha-6-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3}  <6,7>
KI	#5# 0.06-0.077
	{N-Acetyl-D-glucosaminyl-1,2-alpha-6-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3}  <5>

KI_VALUE
KI	#4# 0.141
	{N-Acetyl-D-glucosaminyl-1,2-alpha-6-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)8-COOCH3}  <8>
KI	#5# 0.014
	{N-Acetyl-D-glucosaminyl-1,2-alpha-4-O-methyl-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3}  <6>
KI	#5# 0.063
	{N-Acetyl-D-glucosaminyl-1,2-alpha-6-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3}  <6,7>
KI	#5# 0.06-0.077
	{N-Acetyl-D-glucosaminyl-1,2-alpha-6-deoxy-mannosyl-1
	6-beta-D-glucosyl-O-(CH2)7-CH3}  <5>

EXPRESSION
EXP	#2,3# up (#3# increased expression after anti-CD3 stimulation <48>; #2#
	the expression of GnT-V is quite low in normal liver tissue but is
	increased under conditions of chronic hepatitis and liver regeneration
	<54>) <48,54>
EXP	#3# down (#3# decreased expression after exogenous addition
	alltrans-retinoic acid <50>; #3# during interferon-gamma-induced
	inflammation, the level of GnT-V in THP-1 monocytes are significantly
	decreased <58>) <50,58>
EXP	#3# more (#3# high GnT-V expression correlated with FIGO surgical
	stage, strong immunostaining in mucinous adendocarcinoma <51>; #3#
	overexpressed in malignant tumors <46>; #3# selective knockdown of
	GnT-Va expression, inhibition of ligand-induced downregulation of the
	epidermal growth factor receptor and intracellular signaling by
	inhibiting receptor endocytosis <44>) <44,46,51>

///
ID	2.4.1.244
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Drosophila melanogaster   <2,5,9>
PR	#2# Drosophila sp. (in: Insecta)   <5,6>
PR	#3# Homo sapiens   <3,7,8>
PR	#4# Homo sapiens Q76KP1 Swissprot <1,10>
PR	#4# Homo sapiens Q76KP1 UniProt <1,10>
PR	#5# Homo sapiens Q6L9W6 SwissProt <4,11>
PR	#5# Homo sapiens Q6L9W6 UniProt <4,11>
PR	#6# Drosophila melanogaster Q7KN92 SwissProt <2>

RECOMMENDED_NAME
RN	N-acetyl-beta-glucosaminyl-glycoprotein
	4-beta-N-acetylgalactosaminyltransferase


SYSTEMATIC_NAME
SN	UDP-N-acetyl-D-galactosamine:N-acetyl-beta-D-glucosaminyl-group
	4-beta-N-acetylgalactosaminyltransferase 


SYNONYMS
SY	#1# beta4GalNAcTB <2,9>
SY	#1# beta 1,4-N-acetylgalactosaminyltransferase-A <5>
SY	#1,2# beta4GalNAcT <5>
SY	#2# beta1,4-N-acetylgalactosaminyltransferase <5>
SY	#3# N,N'-diacetyllactosediamine synthase <3>
SY	#3# beta1,4-N-acetylgalactosaminyltransferase II <7>
SY	#3# beta4GalNAcT-II <7>
SY	#3,5# beta1,4-N-acetylgalactosaminyltransferase III <4,8>
SY	#3,5# beta4GalNAc-T3 <3,4,8>
SY	#4# N-acetyl-beta-glucosaminyl-glycoprotein
	4-beta-N-acetylgalactosaminyltransferase 1 <1>
SY	#4# beta1,4-N-acetylgalactosaminyltransferases <10>
SY	#4,5# beta4GalNAc-T4 <1,4,10>
SY	#5# beta1,4-N-acetylgalactosaminyltransferase-III <4>
SY	#5# beta1,4-N-acetylgalactosaminyltransferase IV <4>
SY	#5# N-acetyl-beta-glucosaminyl-glycoprotein
	4-beta-N-acetylgalactosaminyltransferase 2 <4>
SY	#5# B4GALNT3 (#5# gene name <11>) <11>
SY	#6# beta4GalNAcTA <2>

REACTION
RE	UDP-N-acetyl-alpha-D-galactosamine + N-acetyl-beta-D-glucosaminyl group
	= UDP +
	N-acetyl-beta-D-galactosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl group

SOURCE_TISSUE
ST	#1,2# larva (#2# beta4GalNAcT mRNA is expressed throughout the life
	cycle of the fly, i.e., from the embryo stage. In the larval stage,
	mRNA is expressed to a greater extent in the eye disc and larval brain
	than in the wing disc and leg disc <5>) <5,9>
ST	#2# embryo (#2# beta4GalNAcT mRNA is expressed throughout the life
	cycle of the fly, i.e., from the embryo stage. In the larval stage,
	mRNA is expressed to a greater extent in the eye disc and larval brain
	than in the wing disc and leg disc <5>) <5>
ST	#2# muscle (#2# beta4Gal-NAcTA has at least three distinct,
	tissue-specific roles in neurons and muscles. Substrates are present in
	both neural and muscle cells that require glycosylation by
	beta4GalNAcTA for normal function <6>) <6>
ST	#2# neuron (#2# beta4Gal-NAcTA has at least three distinct,
	tissue-specific roles in neurons and muscles. Substrates are present in
	both neural and muscle cells that require glycosylation by
	beta4GalNAcTA for normal function <6>; #2# highly expressed in the
	developmental and adult neuronal tissues <5>) <5,6>
ST	#3# colonic cancer cell (#3# enhanced expression in primary colon
	tumors <8>) <7,8>
ST	#3,5# colon (#5# mainly expressed in <11>; #5# highly expressed in <4>)
	<4,7,11>
ST	#3,5# gastric mucosa <3,11>
ST	#5# stomach (#5# mainly expressed in <11>; #5# highly expressed in <4>)
	<4,11>
ST	#5# testis (#5# mainly expressed in <11>; #5# highly expressed in <4>)
	<4,11>
ST	#5# HT-29 cell <11>
ST	#5# SW-480 cell <11>
ST	#5# epithelial cell (#5# high enzyme expression level in epithelial
	cells of gastric mucosa <11>) <11>
ST	#5# HCT-116 cell <11>
ST	#5# HCT-15 cell <11>
ST	#5# colon cancer cell (#5# primary, B4GALNT3 expression in different
	stage of colorectal tumors, overview <11>) <11>

LOCALIZATION
LO	#1# endoplasmic reticulum <9>
LO	#1,3# Golgi apparatus (#3# apical Golgi localization. The supra-nuclear
	expression of the enzyme is essential for the formation of
	GalNAC-beta-(1,4)-GlcNAc on the surface of mucous cells <3>) <3,9>

NATURAL_SUBSTRATE_PRODUCT
NSP	#1,5,6# more = ? (#5# the enzyme could transfer GalNAc residues,
	producing N,N-diacetylgalactosediamine structures at least in N-glycans
	and probably in both N- and O-glycans <4>; #6# flies mutant for
	beta4GalNAcTA are viable and fertile but display behavioral phenotypes
	suggestive of essential roles for GalNAc-beta1,4-GlcNAc containing
	glycoconjugates in neuronal and/or muscular function <2>; #1# flies
	mutant for beta4GalNAcTB are viable and display no evident
	morphological or behavioral phenotypes <2>) {} <2,4>
NSP	#2# UDP-N-acetyl-D-galactosamine + N-acetyl-beta-D-glucosaminyl-R group
	= UDP +
	N-acetyl-beta-D-galactosaminyl-(1,4)-N-acetyl-beta-D-glucosaminyl group
	(#2# beta4GalNAcTA contributs to the synthesis of the
	GalNAcbeta1,4GlcNA structure in vivo and may play a role in the
	physiological or neuronal development of Drosophila <5>) <5>
NSP	#2# UDP-N-acetyl-D-galactosamine + N-acetyl-beta-D-glucosaminyl-R group
	= UDP +
	N-acetyl-beta-D-galactosaminyl-(1,4)-N-acetyl-beta-D-glucosaminyl-R
	group (#2# beta4Gal-NAcTA has at least three distinct, tissue-specific
	roles in neurons and muscles. Substrates are present in both neural and
	muscle cells that require glycosylation by beta4GalNAcTA for normal
	function <6>) <6>

SUBSTRATE_PRODUCT
SP	#1# UDP-GalNAc +
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1
	2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1
	6)]-GlcNAc-2-pyridylaminoside = UDP +
	GalNAc-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1
	4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-[Fuc-alpha-(1
	6)]-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside <5>
SP	#1# UDP-GalNAc + GlcNAc-beta-(1,3)Fuc-dansyl = UDP +
	GalNAc-beta-(1,4)-GlcNAc-beta-(1,3)Fuc-dansyl <5>
SP	#1# UDP-GalNAc + GlcNAc-p-nitrophenyl = ? <9>
SP	#1,3,4# UDP-GalNAc + GlcNAc-beta-(1,3)-GalNAc-alpha-p-nitrophenyl = UDP
	+ GalNAc-beta-(1,4)-GlcNAc-beta-(1,3)-GalNAc-alpha-p-nitrophenyl (#4#
	20.0% of the activity with GlcNAcbeta-O-benzyl <1>) <1,5,7,8>
SP	#1,4,5,6# more = ? (#5# the enzyme could transfer GalNAc residues,
	producing N,N-diacetylgalactosediamine structures at least in N-glycans
	and probably in both N- and O-glycans <4>; #5# the most efficient
	acceptor substrate in the N-glycans examined is a non-fucosylated
	bi-antennary one. The enzyme shows no activity towards
	chondroitin-related acceptors containing GlcUA as their non-reducing
	termini <4>; #6# flies mutant for beta4GalNAcTA are viable and fertile
	but display behavioral phenotypes suggestive of essential roles for
	GalNAc-beta1,4-GlcNAc containing glycoconjugates in neuronal and/or
	muscular function <2>; #1# flies mutant for beta4GalNAcTB are viable
	and display no evident morphological or behavioral phenotypes <2>; #1#
	no activity with GalNac <5>; #4# the enzyme mediates the
	protein-specific addition of beta1,4-linked GalNAc to core 2 O-linked
	structures both in vivo and in vitro <10>; #5# enzyme B4GALNT3
	primarily modifies N-glycans of epithelial growth factor receptor,
	EGFR, in LacdiNAc by Wisteria floribunda agglutinin pull down assays
	<11>) {} <2,4,5,10,11>
SP	#2# UDP-N-acetyl-D-galactosamine + N-acetyl-beta-D-glucosaminyl-R group
	= UDP +
	N-acetyl-beta-D-galactosaminyl-(1,4)-N-acetyl-beta-D-glucosaminyl group
	(#2# beta4GalNAcTA contributs to the synthesis of the
	GalNAcbeta1,4GlcNA structure in vivo and may play a role in the
	physiological or neuronal development of Drosophila <5>) <5>
SP	#2# UDP-N-acetyl-D-galactosamine + N-acetyl-beta-D-glucosaminyl-R group
	= UDP +
	N-acetyl-beta-D-galactosaminyl-(1,4)-N-acetyl-beta-D-glucosaminyl-R
	group (#2# beta4Gal-NAcTA has at least three distinct, tissue-specific
	roles in neurons and muscles. Substrates are present in both neural and
	muscle cells that require glycosylation by beta4GalNAcTA for normal
	function <6>) <6>
SP	#2# UDP-N-acetyl-D-galactosamine +
	GlcNAcbeta1,2Manalpha1,6[GlcNAcbeta1,2Manalpha1,3]Manbeta1,4GlcNAcbeta1
	4GlcNAc-aminopyridine = ? <5>
SP	#2# UDP-N-acetyl-D-galactosamine +
	GlcNAcbeta1,2Manalpha1,6[GlcNAcbeta1,4[GlcNAcbeta1,2]Manalpha1
	3]Manbeta1,4GlcNAcbeta1,4GlcNAc-aminopyridine = ? <5>
SP	#2# UDP-N-acetyl-D-galactosamine + GlcNAcbeta1,3Fuc-dansyl = ? (#2#
	GalNAc is efficiently transferred toward N-glycans, O-glycans, and the
	arthro-series glycosphingolipids <5>) <5>
SP	#4# UDP-GalNAc + GlcNAc-beta-(1,6)-GalNAc-alpha-p-nitrophenyl = UDP +
	GalNAc-beta-(1,4)-GlcNAc-beta-(1,6)-GalNAc-alpha-p-nitrophenyl (#4#
	190.7% of the activity with GlcNAcbeta-O-benzyl <1>) <1>
SP	#4# UDP-GalNAc +
	GlcNAc-beta-(1,6)[Gal-beta-(1,3)]GalNAc-alpha-p-nitrophenyl = UDP +
	GalNAc-beta-(1,4)-GlcNAc-beta-(1,6)[Gal-beta-(1
	3)]GalNAc-alpha-p-nitrophenyl (#4# 15.2% of the activity with
	GlcNAcbeta-O-benzyl <1>) <1>
SP	#4,5# UDP-GalNAc +
	Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1
	2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1
	4)-GlcNAc-2-pyridylaminoside = UDP +
	Gal-beta-(1,4)-GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1
	6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1
	4)-GlcNAc-2-pyridylaminoside (#4# 26.2% of the activity with
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside <1>; #5#
	45% of the activity with
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside <4>) <1,4>
SP	#4,5# UDP-GalNAc +
	Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1
	2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1
	6)]-GlcNAc-2-pyridylaminoside = UDP +
	GalNAc-beta(1,4)-Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1
	6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1
	4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside (#4# 26.7% of the
	activity with
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside <1>; #5#
	51.7% of the activity with
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside <4>) <1,4>
SP	#4,5# UDP-GalNAc +
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1
	2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1
	4)-GlcNAc-2-pyridylaminoside = UDP +
	GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1
	4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1
	4)-GlcNAc-2-pyridylaminoside (#4# 16.2% of the activity with
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside <1>; #5#
	21.6% of the activity with
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside <4>) <1,4>
SP	#4,5# UDP-GalNAc +
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1
	2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1
	6)]-GlcNAc-2-pyridylaminoside = UDP +
	GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1
	4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-[Fuc-alpha-(1
	6)]-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside (#4# 3.4% of the
	activity with
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside <1>; #5#
	5% of the activity with
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside <4>) <1,4>
SP	#4,5# UDP-GalNAc +
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside = UDP +
	GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1
	2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1
	4)-GlcNAc-2-pyridylaminoside <1,4>
SP	#4,5# UDP-GalNAc +
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1
	6)]-GlcNAc-2-pyridylaminoside = UDP +
	GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1
	2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1
	4)-GlcNAc-2-pyridylaminoside (#4# 76.8% of the activity with
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside <1>; #5#
	87.1% of the activity with
	GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1
	3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside <4>) <1,4>
SP	#4,5# UDP-GalNAc + GlcNAcbeta-O-benzyl = UDP +
	GalNAc-beta-(1,4)-GlcNAcbeta-O-benzyl <1,4>
SP	#5# UDP-N-acetyl-alpha-D-galactosamine + N-acetyl-beta-D-glucosamine =
	UDP + N-acetyl-beta-D-galactosaminyl-(1->4)-N-acetyl-beta-D-glucosamine
	(#5# enzyme B4GALNT3 transfers N-acetylgalactosamine (GalNAc) to the
	non-reducing N-acetylglucosamine (GlcNAc) to form GalNAcbeta1-4GlcNAc
	(LacdiNAc) in an in vitro enzymatic assay <11>) {} <11>
SP	#5# UDP-N-acetyl-alpha-D-galactosamine + N-acetyl-beta-D-glucosaminyl
	group = UDP +
	N-acetyl-beta-D-galactosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl
	group <11>

ACTIVATING_COMPOUND
AC	#1# beta4Gal-NAcTB pilot protein (#1# generates a functionally active
	beta4GalNAcTB, in the absence of beta4Gal-NAcTB pilot protein inactive
	beta4GalNAcTB is trapped in the endoplasmic reticulum <9>) <9>

INHIBITORS
IN	#3# more (#3# beta4GalNAcT-II acts as a negative regulator of
	carbohydrate determinant sialyl Lewis x expression in colon cancer <7>)
	<7>

APPLICATION
AP	#3# more (#3# GalNAC-beta-(1,4)-GlcNAc and beta4GalNAc-T3 are novel
	differentiation markers of surface mucous cells in the gastric mucosa
	<3>) <3>

ENGINEERING
EN	#5# more (#5# B4GALNT3 overexpression enhances colon cancer cell
	malignant phenotypes in vitro and in vivo. Knockdown of B4GALNT3 using
	small interfering (si) RNAs in colon cancer cell lines (HCT116, SW480,
	HCT15, and HT29 cells) decrease sphere formation and the expression of
	stem cell markers, OCT4 and. NANOG. B4GALNT3 knockdown suppresses
	EGF-induced phosphorylation of epithelial growth factor receptor, EGFR,
	and its downstream signaling molecules <11>) <11>

CLONED
CL	#1# (expressed in sf21 cells) <5>
CL	#1# (full-length cDNA is cloned into vectors for expression in cultured
	Drosophila S2) <2>
CL	#1# (expressed in S2 cells) <9>
CL	#3# (expressed in HCT-116 cells) <8>
CL	#3# (expressed in LS-174T cells) <7>
CL	#4# (the putative catalytic domain of beta4GalNAc-T4 is expressed as a
	secreted protein fused with a FLAG peptide in HEK293T cells) <1>
CL	#4# (expressed in in HEK-293T cells) <10>
CL	#5# (truncated form of the human enzyme is expressed in HEK293T cells
	as a soluble protein) <4>
CL	#5# (gene B4GALNT3) <11>
CL	#6# (full-length cDNA is cloned into vectors for expression in cultured
	Drosophila S2) <2>

PURIFICATION
PU	#1# (anti-FLAG M1 affinity gel filtration) <5>
PU	#4# <1>
PU	#5# <4>

REFERENCE
RF	<1> Gotoh, M.; Sato, T.; Kiyohara, K.; Kameyama, A.; Kikuchi, N.; Kwon,
	Y.D.; Ishizuka, Y.; Iwai, T.; Nakanishi, H.; Narimatsu, H.: Molecular
	cloning and characterization of
	beta1,4-N-acetylgalactosaminyltransferases IV synthesizing
	N,N'-diacetyllactosediamine. FEBS Lett. (2004) 562, 134-140.
	{Pubmed:15044014}
RF	<2> Haines, N.; Irvine, K.D.: Functional analysis of Drosophila
	beta1,4-N-acetylgalactosaminyltransferases. Glycobiology (2005) 15,
	335-346. {Pubmed:15563714}
RF	<3> Ikehara, Y.; Sato, T.; Nakamura, S.; Gotoh, M.; Ikehara, S.K.;
	Kiyohara, K.; Aoki, C.; Iwai, T.; Nakanishi, H.; Hirabayashi, J.;
	Tatematsu, M.; Narimatsu, H.: Apical Golgi localization of
	N,N'-diacetyllactosediamine synthase, beta4GalNAc-T3, is responsible
	for LacdiNAc expression on gastric mucosa. Glycobiology (2006) 16,
	777-785. {Pubmed:16728562}
RF	<4> Sato, T.; Gotoh, M.; Kiyohara, K.; Kameyama, A.; Kubota, T.;
	Kikuchi, N.; Ishizuka, Y.; Iwasaki, H.; Togayachi, A.; Kudo, T.;
	Ohkura, T.; Nakanishi, H.; Narimatsu, H.: Molecular cloning and
	characterization of a novel human
	beta1,4-N-acetylgalactosaminyltransferase, beta4GalNAc-T3, responsible
	for the synthesis of N,N'-diacetyllactosediamine, GalNAc beta1-4GlcNAc.
	J. Biol. Chem. (2003) 278, 47534-47544. {Pubmed:12966086}
RF	<5> Sasaki, N.; Yoshida, H.; Fuwa, T.J.; Kinoshita-Toyoda, A.; Toyoda,
	H.; Hirabayashi, Y.; Ishida, H.; Ueda, R.; Nishihara, S.: Drosophila
	beta1,4-N-acetylgalactosaminyltransferase-A synthesizes the LacdiNAc
	structures on several glycoproteins and glycosphingolipids. Biochem.
	Biophys. Res. Commun. (2007) 354, 522-527. {Pubmed:17239818}
RF	<6> Haines, N.; Stewart, B.A.: Functional roles for
	beta1,4-N-acetylgalactosaminyltransferase-A in Drosophila larval
	neurons and muscles. Genetics (2007) 175, 671-679. {Pubmed:17151241}
RF	<7> Malagolini, N.; Santini, D.; Chiricolo, M.; DallOlio, F.:
	Biosynthesis and expression of the Sda and sialyl Lewis x antigens in
	normal and cancer colon. Glycobiology (2007) 17, 688-697.
	{Pubmed:17395692}
RF	<8> Huang, J.; Liang, J.T.; Huang, H.C.; Shen, T.L.; Chen, H.Y.; Lin,
	N.Y.; Che, M.I.; Lin, W.C.; Huang, M.C.:
	Beta1,4-N-acetylgalactosaminyltransferase III enhances malignant
	phenotypes of colon cancer cells. Mol. Cancer Res. (2007) 5, 543-552.
	{Pubmed:17579116}
RF	<9> Johswich, A.; Kraft, B.; Wuhrer, M.; Berger, M.; Deelder, A.M.;
	Hokke, C.H.; Gerardy-Schahn, R.; Bakker, H.: Golgi targeting of
	Drosophila melanogaster beta4GalNAcTB requires a DHHC protein
	family-related protein as a pilot. J. Cell Biol. (2009) 184, 173-183.
	{Pubmed:19139268}
RF	<10> Fiete, D.; Beranek, M.; Baenziger, J.U.: Peptide-specific transfer
	of N-acetylgalactosamine to O-linked glycans by the
	glycosyltransferases beta1,4-N-acetylgalactosaminyl transferase 3
	(beta4GalNAc-T3) and beta4GalNAc-T4. J. Biol. Chem. (2012) 287,
	29204-29212. {Pubmed:22722940}
RF	<11> Che, M.I.; Huang, J.; Hung, J.S.; Lin, Y.C.; Huang, M.J.; Lai,
	H.S.; Hsu, W.M.; Liang, J.T.; Huang, M.C.:
	beta1,4-N-acetylgalactosaminyltransferase III modulates cancer stemness
	through EGFR signaling pathway in colon cancer cells. Oncotarget (2014)
	5, 3673-3684. {Pubmed:25003232}

ACTIVATING_COMPOUND
AC	#1# beta4Gal-NAcTB pilot protein (#1# generates a functionally active
	beta4GalNAcTB, in the absence of beta4Gal-NAcTB pilot protein inactive
	beta4GalNAcTB is trapped in the endoplasmic reticulum <9>) <9>

EXPRESSION
EXP	#5# up (#5# expression of B4GALNT3 is regulated in colonospheres <11>)
	<11>

///
ID	2.4.1.38
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Drosophila melanogaster   <91>
PR	#2# Mus musculus   <5,8,9,10,12,18,35,48,51,68,70,110,119>
PR	#3# Homo sapiens   (#3# isozyme C4H1-1 <20>)
	<14,15,19,20,29,30,39,43,46,49,54,56,57,63,66,69,71,72,74,75,78,79,81
	82,85,86,87,88,89,91,95,97,98,100,105,106,107,109,110,111,113,114,117
	118>
PR	#4# Rattus norvegicus  
	<1,6,7,21,22,24,25,26,31,37,40,43,44,45,60,92,94,96,101,108,112,115,116>
PR	#5# Sus scrofa   <32,41>
PR	#6# Bos taurus   (#6# enzyme precursor <3>)
	<1,2,3,11,13,16,17,23,27,28,33,34,36,38,42,47,50,53,55,56,58,59,61,62
	65,67,71,77,81,83,99,103>
PR	#7# Ovis aries   <4>
PR	#8# Neisseria gonorrhoeae   <64>
PR	#9# Neisseria meningitidis   <64,90>
PR	#10# Helicobacter pylori   <90>
PR	#11# Equus caballus   <104>
PR	#12# Danio rerio   <76>
PR	#13# Notamacropus eugenii   (#13# gene SUS4 <73>) <73>
PR	#14# Cricetulus griseus Q99PC2 SwissProt <84>
PR	#15# Homo sapiens P15291 SwissProt <80,102,123>
PR	#15# Homo sapiens P15291 UniProt <80,102,123>
PR	#16# Rattus norvegicus P80225 UniProt <96>
PR	#17# Leishmania donovani A9XBL4 UniProt <93>
PR	#18# Homo sapiens O60909 UniProt <99>
PR	#19# Homo sapiens Q9UBV7 UniProt <120,121>
PR	#20# Bos taurus P08037 UniProt <122>
PR	#21# Homo sapiens O43286  <52>
PR	#22# Danio rerio C1KH59 UniProt <123>
PR	#23# Gallus gallus Q92074 UniProt <123>

RECOMMENDED_NAME
RN	beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase


SYSTEMATIC_NAME
SN	UDP-galactose:N-acetyl-beta-D-glucosaminylglycopeptide
	4-beta-galactosyltransferase


SYNONYMS
SY	 galactosyltransferase, uridine diphosphogalactose-acetylglucosamine
SY	 acetyllactosamine synthetase
SY	 lactosamine synthase
SY	 lactosamine synthetase
SY	 lactose synthetase A protein
SY	 N-acetyllactosamine synthetase
SY	 UDP-galactose N-acetylglucosamine beta-4-galactosyltransferase
SY	 UDP-galactose-acetylglucosamine galactosyltransferase
SY	 UDP-galactose-N-acetylglucosamine beta-1,4-galactosyltransferase
SY	 UDP-galactose-N-acetylglucosamine galactosyltransferase
SY	 uridine diphosphogalactose-acetylglucosamine galactosyltransferase
SY	 UDP-Gal:N-acetylglucosamine beta1-4-galactosyltransferase
SY	 beta1-4GalT
SY	 beta1,4-GT
SY	 NAL synthetase
SY	 UDP-beta-1,4-galactosyltransferase
SY	 Gal-T
SY	 UDP-galactose:N-acetylglucosaminide beta1-4-galactosyltransferase
SY	 UDPgalactose:N-acetylglucosaminyl(beta1-4)galactosyltransferase
SY	 beta-N-acetylglucosaminide beta1-4-galactosyltransferase
SY	 UDPgalactose-N-acetylglucosamine beta-D-galactosyltransferase
SY	 EC 2.4.1.98
SY	 beta-N-acetyl-beta1-4-galactosyltransferase
SY	 UDPgalactose-glycoprotein galactosyltransferase
SY	 UDPgalactose:N-acetyl-beta-D-glucosaminylglycopeptide
	beta-1,4-galactosyltransferase
SY	 glycoprotein 4-beta-galactosyl-transferase
SY	 glycoprotein beta-galactosyltransferase
SY	 thyroid galactosyltransferase
SY	 thyroid glycoprotein beta-galactosyltransferase
SY	 uridine diphosphogalactose-glycoprotein galactosyltransferase
SY	#1,3,6,15# beta4Gal-T1 <74,80,91,103>
SY	#1,3,6,9,10,11# beta-1,4-galactosyltransferase <83,90,91,104,118>
SY	#10# HP0826 <90>
SY	#12# beta4GalT1 <76>
SY	#13# 4betaGalT <73>
SY	#14# beta(1,4)-GT <84>
SY	#15# beta1-4-galactosyltransferase <102>
SY	#15# beta1,4-galactosyltransferase-I <80>
SY	#15# beta1-4GalT1 <102>
SY	#15,22,23# beta1,4-GalT1 <123>
SY	#16# beta-1,4 galactosyltransferase I <96>
SY	#17# N-acetylglucosamine beta1,4 galactosyltransferase <93>
SY	#19# beta4GalT7 <121>
SY	#19# beta-1,4-GalT7 <120>
SY	#2# beta4-GalT-V <70>
SY	#2# betaGT <68>
SY	#2# beta4-GalT-I <70>
SY	#2# beta4-GalT-II <70>
SY	#2# beta4-GalT-III <70>
SY	#2# beta4-GalT-IV <70>
SY	#2# beta-1,4-GalT6 (#2# isoform <119>) <119>
SY	#2# beta-1,4-GalT5 (#2# isoform <119>) <119>
SY	#2,3# beta1,4-galactosyltransferase <68,69,79,86,88,119>
SY	#2,3# beta 1, 4-GalT-I <110>
SY	#2,3,4# beta-1,4-galactosyltransferase I
	<108,110,111,112,113,114,115,116>
SY	#3# beta1,4-galactosyltransferase-1 <82>
SY	#3# beta1,4GT1 <66,85,97,117>
SY	#3# GalT I <69>
SY	#3# UDP-N-acetylgalactosamine:polypeptide
	N-acetylgalactosaminyltransferase 2 <86>
SY	#3# GalNAcT2 <86>
SY	#3# beta1,4-GT 1 <72>
SY	#3# GalT1 <82>
SY	#3# betaGALT1 <82>
SY	#3# beta-1,4-galactosyltransferase IV <75>
SY	#3# beta-1,4-GT-IV <75>
SY	#3# beta1,4-galactosyltransferase V <78,105>
SY	#3# GalT V <78>
SY	#3# betaGalT-1 <79>
SY	#3# beta 1,4-galactosyltransferase 1 <85,106>
SY	#3# beta 1,4GalT V <89,105>
SY	#3# betaGalT <87>
SY	#3# beta(1,4)-GalT <87>
SY	#3# beta1,4-galactosyltransferase II <95>
SY	#3# beta1,4GalT II <95>
SY	#3# galactosyltransferase 7 <98>
SY	#3# beta1,4-GalT7 <98>
SY	#3# beta-1,4-galactosyltransferase 1 <100>
SY	#3# UDP-Gal:betaGlcNAc beta-1,4-galactosyltransferase, polypeptide 1
	<100>
SY	#3# beta 1,4-GalT-I <111>
SY	#3# beta4GalT-II <114>
SY	#3# GalTI <107>
SY	#3# beta1,4-galactosyltransferase1 <109>
SY	#3,14# beta(1,4)-galactosyltransferase <84,87>
SY	#3,15,17,22,23# GALT <86,88,93,123>
SY	#3,15,22,23# beta1,4-galactosyltransferase 1 <66,72,117,123>
SY	#3,19# beta1,4-galactosyltransferase 7 <98,120,121>
SY	#3,20# B4GALT1 <100,106,109,122>
SY	#3,4,6# beta-1,4-galactosyltransferase-I <81,94,101,103,107>
SY	#3,4,6,9,10,13,16# More (#3,6,13# cf. EC 2.4.1.90 <73,82,83>; #6# cf.
	EC 2.4.1.90, the enzyme belongs to the CAZY family 7 of inverting
	glycosyltransferases <77>; #10# HP0826 belongs to the carbohydrate
	active enzyme family GT25 of inverting glycosyltransferases <90>; #9#
	LgtB belongs to the carbohydrate active enzyme family GT25 of inverting
	glycosyltransferases <90>; #4,16# the enzyme belongs to the family of
	beta-1,4-galactosyltransferases, beta-1,4-GalTs <96>)
	<73,77,82,83,90,96>
SY	#3,6# Gal-T1 <81>
SY	#3,6# beta-1,4-GalT <83,118>
SY	#3,6,12,20# beta1,4-galactosyltransferase I <71,76,97,122>
SY	#4# beta-1,4 galactosyltransferase V <96>
SY	#4# beta-1,4-GalT V <96>
SY	#4# beta-1,4-GalT-I <94,101,112,116>
SY	#4,11,16# GalTase <96,104>
SY	#4,16# beta-1,4-GalT I <96,115>
SY	#6# alpha-1,4-galactosyltransferase I <67>
SY	#6# (alpha4Gal-T1) <67>
SY	#6# beta1,4-Gal-transferase T1 <77>
SY	#6,18# beta4GalT <77,99>
SY	#6,18# beta4 Gal-transferase <99>
SY	#9# LgtB <90>

REACTION
RE	UDP-alpha-D-galactose + N-acetyl-beta-D-glucosaminylglycopeptide = UDP
	+ beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminylglycopeptide
	(#6# mechanism <33>; #2# the sequences of cDNA isolated from mammary
	and F9 cell lines are identical, thus indicating that EC 2.4.1.38 and
	EC 2.4.1.90 are non-distinguishable <8>; #3# functional role of Trp310
	residue located in the small loop near the active site of the enzyme
	<79>; #3,6# reaction mechanism and structural changes <81>; #3#
	reaction mechanism, structure-function relationship, upon binding of
	metal ion and sugar-nucleotide, the flexible loops undergo a marked
	conformational change, from an open to a closed conformation.
	Conformational change simultaneously creates at the C-terminal region
	of the flexible loop an oligosaccharide acceptor binding site that did
	not exist before. The loop acts as a lid covering the bound donor
	substrate. After completion of the transfer of the glycosyl unit to the
	acceptor, the saccharide product is ejected and the loop reverts to its
	native conformation to release the remaining nucleotide moiety <91>)

REACTION_TYPE
RT	hexosyl group transfer

SOURCE_TISSUE
ST	#11# spermatozoon <104>
ST	#11,12# oocyte <76,104>
ST	#12# embryo (#12# the enzyme is maternally loaded and expressed
	throughout development, overview <76>) <76>
ST	#14# CHO cell <84>
ST	#15# U-937 cell <102>
ST	#17# promastigote <93>
ST	#18# A-549 cell <99>
ST	#18# NCI-H292 cell <99>
ST	#18# lung epithelial cell <99>
ST	#2# duodenum <68>
ST	#2# gut (#2# in conventional mice, the beta1,4-galactosyltransferase
	gene expression rapidly increases to adult levels by the fourth
	postnatal week. In germ-free mice, gene expression remains at initial
	low levels and is rapidly induced on reintroduction of luminal microbes
	of the adult gut but not of microbes characteristic of the suckling
	gut. Essential role for microbes in the ontogeny of
	beta1,4-galactosyltransferase <68>) <68>
ST	#2# jejunum <68>
ST	#2# spermatogonium (#2# during differentiation from spermatogonia to
	pachytene spermatocytes the amount of UDP beta1,4-galactosyltransferase
	mRNA is reduced to barley detectable levels <12>) <12>
ST	#2# mastocytoma cell <5>
ST	#2# ileum <68>
ST	#2# uterine endometrium (#2# beta1, 4-GalT-I iss highly expressed in
	endometrium during implantation window <110>) <110>
ST	#2# BALB/3T12-3 cell <35>
ST	#2# F9 cell <8,9,51>
ST	#2# C-127 cell <10>
ST	#2,3# colon <68,75>
ST	#2,4# brain <7,119>
ST	#2,4# testis (#2# during differentiation from spermatogonia to
	pachytene spermatocytes the amount of UDO beta1,4-galactosyltransferase
	mRNA is reduced to barley detectable levels <12>; #2# beta4-GalT-IV is
	only expressed at low levels in 1-week-old mouse testes <70>; #2#
	expression remains relatively low at each stage of development <70>;
	#2# the transcript of beta4-GalT-II increases during development, and
	persists at the highest level in adult mouse testis <70>; #2#
	transcript of beta4-GalT-I is expressed at a significant level in 1 to
	2-week-old testis and after this stage the level decreases to barely
	detectable levels <70>) <12,51,70,94>
ST	#2,4,6# liver (#4# fetal <43>)
	<1,6,17,21,22,25,26,31,37,40,43,45,68,92,94>
ST	#3# HeLa cell (#3# expression of extremely high levels of mRNA <19>)
	<14,19,20,86,95,100,109>
ST	#3# MCF-7 cell <106>
ST	#3# hepatoma cell <66,97>
ST	#3# cartilage (#3# expression of beta1,4-GalT-I increases in the
	cartilage and synovial tissue of osteoarthritis patients compared with
	healthy controls <113>) <113>
ST	#3# skin fibroblast <30>
ST	#3# plasma <39>
ST	#3# keratinocyte <91>
ST	#3# lung cancer cell <91>
ST	#3# amniotic fluid <43>
ST	#3# colonic cancer cell (#3# of patients with colorectal cancer 48%
	have down-regulated expression of beta-1,4-GT-IV in the tumor tissue,
	while 28% of patients exhibit elevated beta-1,4-GT-IV levels, the
	patient group with tumor beta-1,4-GT-IV overexpression strongly
	predicts for tumor metastasis, overview <75>) <75>
ST	#3# glioma cell <89,105>
ST	#3# MRK-nu-1 cell <52>
ST	#3# U-87MG cell (#3# glioma cell line <78>) <78,89>
ST	#3# U-251 cell (#3# glioma cell line <78>) <78,89>
ST	#3# PG-BE1 cell (#3# highly metastatic lung cancer cells, elevated
	levels of beta1,4-galactosyltransferase I as compared to its less
	metastatic partner PGLH7 cells. Essential role for the transcription
	activator E1AF in the activation of human GalTI gene in highly
	metastatic lung cancer cells <69>) <69>
ST	#3# PG-LH7 cell <69>
ST	#3# NCI-H1299 cell <95>
ST	#3# SHG-44 cell (#3# glioma cell line <78>) <78,89>
ST	#3# SMMC-7721 cell <97,117>
ST	#3# monocyte-derived dendritic cell <107>
ST	#3# inflammatory cell <111>
ST	#3# RL95-2 cell <110>
ST	#3# RHEK-1 cell <91>
ST	#3,4# placenta <14,43,71>
ST	#3,4# serum <1,29,31,44,45>
ST	#3,4# synovial tissue (#3# expression of beta1,4-GalT-I increases in
	the cartilage and synovial tissue of osteoarthritis patients compared
	with healthy controls <113>) <108,111,113>
ST	#3,6# milk <15,16,17,23,33,34,36,42,46,47,57,63,83,99>
ST	#4# kidney <37,94>
ST	#4# heart <94>
ST	#4# spleen <94>
ST	#4# cerebral cortex <94>
ST	#4# lung (#4# fetal <43>) <43,94>
ST	#4# hepatocyte <92>
ST	#4# intestine (#4# regional distribution <24>) <24>
ST	#4# intestinal mucosa (#4# ileal-colonic <24>) <24>
ST	#4# epididymis (#4# very high enzyme concentration in Golgi apparatus
	of epididymal duct epithelium from initial segment to intermediate
	caput, although much lower amounts of enzyme are in efferent ducts,
	distal caput, corpus and cauda. Even in the initial segment and caput
	epididymis, only low levels of soluble enzyme form are detected in the
	fluid <60>) <60>
ST	#4# lymph node <94>
ST	#4# macrophage (#4# high expression level <94>) <94>
ST	#4# neutrophil (#4# high expression level <94>) <94>
ST	#4# hippocampus <94>
ST	#4# Schwann cell <101,115,116>
ST	#4# endothelial cell (#4# high expression level <94>) <94>
ST	#4# RSC96 cell <101>
ST	#4,16# astrocyte (#4,16# primary <96>) <96,112>
ST	#5# thyroid gland <32>
ST	#5# mesenteric lymph node <41>
ST	#6# thymus <3>
ST	#6# MDBK cell (#6# ATCC No. CCL22 <11>) <11>
ST	#6# cornea <36>
ST	#6# colostrum <28,33,50>
ST	#6# sperm (#6# anterior head of sperm head <38>) <38>
ST	#6,7,13# mammary gland (#13# specific enzyme expression and regulation
	during the lactation cycle, overview <73>) <4,13,73>

LOCALIZATION
LO	#2,3,4# Golgi membrane (#3# beta4Gal-T1 is a trans-Golgi
	glycosyltransferase, Glyco-T, with a type II membrane protein topology,
	a short N-terminal cytoplasmic domain, a membrane-spanning region, as
	well as a stem and a C-terminal catalytic domain facing the
	trans-Golgi-lumen <91>) <7,18,25,37,91,92>
LO	#2,3,4,5,6,20# membrane (#2# plasma membrane enriched fraction <35>;
	#4# the enzyme from kidney appears to be an intrinsic membrane protein
	<37>; #6# N-terminal hydrophobic segment serves as the membrane anchor,
	the C-terminal region is oriented within the lumen of the Golgi
	membranes <17>; #3# trans-membrane protein <91>)
	<17,22,27,32,35,37,40,41,45,59,60,88,91,101,122>
LO	#2,3,4,5,6,7,14,17,20# Golgi apparatus (#6# short and long enzyme form
	are resident trans-Golgi proteins, the NH2-terminal segment contains
	the cytoplasmic and transmembrane domains <27>; #3# cisternal space of
	the Golgi apparatus being distributed from cis to trans <86>)
	<1,4,6,7,10,17,18,19,21,25,26,27,32,37,59,84,85,86,92,93,101,122>
LO	#2,4,5# microsome <5,21,31,32,40>
LO	#3# cytoplasm (#3# localized in the cytoplasm near nucleus and
	cytomembrane <107>) <107>
LO	#3# more (#3# subcellular distribution, Golgi-to-endoplasmic reticulum
	exchange kinetics, approximately 90:10 Golgi-to-ER distribution,
	two-compartment model for Golgi glycosyltransferase cycling, overview
	<86>) <86>
LO	#3# cell surface <66,85>
LO	#3# Golgi vesicle <66>
LO	#3# trans-Golgi network <100>
LO	#3# Golgi complex <106>
LO	#3,14# endoplasmic reticulum <84,86>
LO	#3,16# plasma membrane (#16# beta-1,4-GalT I is a type II
	membrane-bound glycoprotein which occurs on the plasma membrane of
	different types of cells where it serves as a cell surface adhesion
	molecule <96>) <96,106>
LO	#3,4,5,6# soluble (#4# enzyme exists as a soluble and a membrane-bound
	form <60>) <16,21,31,36,39,41,42,43,44,45,46,60,98>
LO	#6# extracellular <83>

NATURAL_SUBSTRATE_PRODUCT
NSP	#12# UDP-galactose + laminin = UDP + beta-1,4-D-galactosyl-laminin <76>
NSP	#2,3,15,19,20,22,23# UDP-alpha-D-galactose +
	N-acetyl-beta-D-glucosaminylglycopeptide = UDP +
	beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminylglycopeptide
	<117,118,119,120,122,123>
NSP	#2,3,4,6# UDPgalactose + N-acetylglucosaminyl at the non-reducing ends
	of protein-bound oligosaccharides = ? (#6# the enzyme facilitates sperm
	binding to the oocyte zona pellucida <38>; #6# enzyme participates in
	the biosynthesis of the oligosaccharide structures of glycoproteins and
	glycolipids <17>; #2# the enzyme is involved in the biosynthesis of a
	variety of carbohydrate structures in glycoproteins and glycolipids
	<51>; #3# the enzyme may be involved in the synthesis of
	poly-N-acetyllactosamine, lacto-N-neotetraose and probably
	lacto-N-neotetraosylceramide in addition to the formation of the
	Galbeta1-4GlcNAc group of glycoprotein sugar chains and lactose <49>;
	#4# the soluble enzyme form from the luminal fluid of the epididymis is
	suggested to play a role on sperm maturation <60>; #6# enzyme functions
	in the coordinate biosynthesis of complex oligosaccharides, proposed to
	function in intercellular recognition and/or adhesion <27>; #4# the
	enzyme may be involved in the synthesis of plasma glycoproteins by the
	liver during secretion, and may possibly be required for secretion of
	these proteins <6>; #2# biosynthesis of carbohydrate moieties of
	glycoproteins and glycolipids, role in intercellular recognition and
	adhesion <10>; #3# main enzyme responsible for the transfer of
	galactose residues from UDPgalactose into terminal N-acetylglucosamine
	residues of complex-type oligosaccharides in newly synthesized
	glycoproteins in the Golgi apparatus. Deficiency of
	UDP-galactose:N-acetylglucosamine beta-1,4-galactosyltransferase I
	causes the congenital disorder of glycosylation type IId, a severe
	neurologic disease characterized by a hydrocephalus, myopathy and
	blood-clotting defects <54>; #6# biosynthesis of keratan sulfate-like
	polysaccharides <36>) <6,10,11,17,26,27,36,38,49,51,54,60>
NSP	#3,4,9,10,13,14,16# more = ? (#3# enzyme activity might be involved in
	apoptotic pathway in hepatocarcinoma cells <66>; #3# decreasing the
	expression of GalT V in glioma cells promotes apoptosis, inhibits the
	invasion and migration and the ability of tumor formation in vivo, and
	reduces the activation of AKT, the enzyme functions as a glioma growth
	activator, overview, contribution of GalT V in the activation of AKT
	and MAPK kinase, contribution of serum or EGF in the transcription
	regulation of the GalT V gene, overview <78>; #3# downregulation of the
	enzyme inhibits CDK11(p58)-mediated apoptosis induced by cycloheximide,
	while ectopically expressed beta1,4-GT 1 increases CDK11p58-mediated
	apoptosis <72>; #3# the cell surface enzyme promotes apoptosis by
	inhibiting the epidermal growth factor receptor pathway via inhibition
	of the autophosphorylation of epidermal growth factor receptor
	especially at Try 1068, mechanism, overview <85>; #13# the enzyme is
	involved in regulation of carbohydrate composition of milk during
	lactation, endocrine enzyme regulation, overview <73>; #14# the enzyme
	is part of the endoplasmic reticulum and Golgi glycosylation network,
	glycosyltransferase metabolism, overview <84>; #3# tumor
	beta-1,4-galactosyltransferase IV overexpression is closely associated
	with colorectal cancer metastasis and poor prognosis, relationships
	between tumor beta-1,4-GT-IV overexpression and clinicopathologic
	characteristics, overview <75>; #3# beta 1,4GalT V galactosylates the
	beta1,6-GlcNAc branch of N-glycans at the cell surface and of secreted
	glycoproteins, and functions as a positive regulator in glioma
	development, overview. As2O3-induced gioma cell apoptosis mechanism
	involves beta 1,4GalT V inhibition, overview <89>; #3#
	beta-1,4-galactosylransferase participates in the synthesis of
	Galbeta1-4-GlcNac disaccharide unit of glycoconjugates, overview <91>;
	#16# beta-1,4-GalT I is a type II membrane-bound glycoprotein, which
	occurs the plasma membrane of different types of cells where it serves
	as a cell surface adhesion molecule mediating various cell-cell and
	cell-matrix interactions such as sperm-egg binding, cell spreading,
	migration, and neurite outgrowth <96>; #4# beta-1,4-GalT-I plays a key
	role in the synthesis of selectin ligands such as sialy Lewis, sLex,
	and sulfated sLex, overview. beta-1,4-GalT-I may play an important role
	in the inflammation reaction <94>; #10# HP0826 is the
	beta-1,4-galactosyltransferase involved in the biosynthesis of the
	lipopolysaccharide O-chain backbone of Helicobacter pylori <90>; #9#
	LgtB is the beta-1,4-galactosyltransferase involved in the biosynthesis
	of the lipopolysaccharide O-chain backbone of Helicobacter pylori <90>;
	#3# the specific inhibitors of the phosphatidylinositol 3-kinase
	LY294002 and wortmannin up-regulate beta1,4-galactosyltransferase I and
	thus sensitize SMMC-7721 human hepatocarcinoma cells to
	cycloheximide-induced apoptosis, overview <97>; #3# beta4Gal-T1
	participates in the synthesis of Galbeta1-4-GlcNac disaccharide unit of
	glycoconjugates <91>) {} <66,72,73,75,78,84,85,89,90,91,94,96,97>
NSP	#3,4,9,10,13,14,16# more = ? (#3# enzyme activity might be involved in
	apoptotic pathway in hepatocarcinoma cells <66>; #3# decreasing the
	expression of GalT V in glioma cells promotes apoptosis, inhibits the
	invasion and migration and the ability of tumor formation in vivo, and
	reduces the activation of AKT, the enzyme functions as a glioma growth
	activator, overview, contribution of GalT V in the activation of AKT
	and MAPK kinase, contribution of serum or EGF in the transcription
	regulation of the GalT V gene, overview <78>; #3# downregulation of the
	enzyme inhibits CDK11(p58)-mediated apoptosis induced by cycloheximide,
	while ectopically expressed beta1,4-GT 1 increases CDK11p58-mediated
	apoptosis <72>; #3# the cell surface enzyme promotes apoptosis by
	inhibiting the epidermal growth factor receptor pathway via inhibition
	of the autophosphorylation of epidermal growth factor receptor
	especially at Try 1068, mechanism, overview <85>; #13# the enzyme is
	involved in regulation of carbohydrate composition of milk during
	lactation, endocrine enzyme regulation, overview <73>; #14# the enzyme
	is part of the endoplasmic reticulum and Golgi glycosylation network,
	glycosyltransferase metabolism, overview <84>; #3# tumor
	beta-1,4-galactosyltransferase IV overexpression is closely associated
	with colorectal cancer metastasis and poor prognosis, relationships
	between tumor beta-1,4-GT-IV overexpression and clinicopathologic
	characteristics, overview <75>; #3# beta 1,4GalT V galactosylates the
	beta1,6-GlcNAc branch of N-glycans at the cell surface and of secreted
	glycoproteins, and functions as a positive regulator in glioma
	development, overview. As2O3-induced gioma cell apoptosis mechanism
	involves beta 1,4GalT V inhibition, overview <89>; #3#
	beta-1,4-galactosylransferase participates in the synthesis of
	Galbeta1-4-GlcNac disaccharide unit of glycoconjugates, overview <91>;
	#16# beta-1,4-GalT I is a type II membrane-bound glycoprotein, which
	occurs the plasma membrane of different types of cells where it serves
	as a cell surface adhesion molecule mediating various cell-cell and
	cell-matrix interactions such as sperm-egg binding, cell spreading,
	migration, and neurite outgrowth <96>; #4# beta-1,4-GalT-I plays a key
	role in the synthesis of selectin ligands such as sialy Lewis, sLex,
	and sulfated sLex, overview. beta-1,4-GalT-I may play an important role
	in the inflammation reaction <94>; #10# HP0826 is the
	beta-1,4-galactosyltransferase involved in the biosynthesis of the
	lipopolysaccharide O-chain backbone of Helicobacter pylori <90>; #9#
	LgtB is the beta-1,4-galactosyltransferase involved in the biosynthesis
	of the lipopolysaccharide O-chain backbone of Helicobacter pylori <90>;
	#3# the specific inhibitors of the phosphatidylinositol 3-kinase
	LY294002 and wortmannin up-regulate beta1,4-galactosyltransferase I and
	thus sensitize SMMC-7721 human hepatocarcinoma cells to
	cycloheximide-induced apoptosis, overview <97>; #3# beta4Gal-T1
	participates in the synthesis of Galbeta1-4-GlcNac disaccharide unit of
	glycoconjugates <91>) {} <66,72,73,75,78,84,85,89,90,91,94,96,97>
NSP	#3,6,14,15# UDP-galactose + N-acetyl-beta-D-glucosaminylglycopeptide =
	UDP + beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminylglycopeptide
	(#3# the enzyme effectively galactosylates the GlcNAcbeta1,6Man arm of
	the highly branched N-glycans that are characteristic of glioma,
	overview <78>; #15# the enzyme transfers galactose from UDP-galactose
	to N-acetylglucosamine residues of the branched N-linked
	oligosaccharide chains of glycoproteins <80>)
	<74,78,79,80,81,82,83,84,85,86>

SUBSTRATE_PRODUCT
SP	#1,3,4,6,9,10,13,14,15,16# more = ? (#6# regioselectivity towards
	specific C(4)glucose OH group in the complex protopanaxadiol glycoside
	ginsenoside Rb1 <50>; #6# enzyme also catalyzes unusual galactosyl
	transfer to the 3-OH position of L-sugars <62>; #6# enzyme also
	catalyzes transfer of glucose from UDPglucose to N-acetylglucosamine
	<47>; #3# enzyme activity might be involved in apoptotic pathway in
	hepatocarcinoma cells <66>; #3# decreasing the expression of GalT V in
	glioma cells promotes apoptosis, inhibits the invasion and migration
	and the ability of tumor formation in vivo, and reduces the activation
	of AKT, the enzyme functions as a glioma growth activator, overview,
	contribution of GalT V in the activation of AKT and MAPK kinase,
	contribution of serum or EGF in the transcription regulation of the
	GalT V gene, overview <78>; #3# downregulation of the enzyme inhibits
	CDK11(p58)-mediated apoptosis induced by cycloheximide, while
	ectopically expressed beta1,4-GT 1 increases CDK11p58-mediated
	apoptosis <72>; #3# the cell surface enzyme promotes apoptosis by
	inhibiting the epidermal growth factor receptor pathway via inhibition
	of the autophosphorylation of epidermal growth factor receptor
	especially at Try 1068, mechanism, overview <85>; #13# the enzyme is
	involved in regulation of carbohydrate composition of milk during
	lactation, endocrine enzyme regulation, overview <73>; #14# the enzyme
	is part of the endoplasmic reticulum and Golgi glycosylation network,
	glycosyltransferase metabolism, overview <84>; #3# tumor
	beta-1,4-galactosyltransferase IV overexpression is closely associated
	with colorectal cancer metastasis and poor prognosis, relationships
	between tumor beta-1,4-GT-IV overexpression and clinicopathologic
	characteristics, overview <75>; #3# beta-1,4-GTs are a family of
	glycosyltransferases responsible for biosynthesizing
	N-acetyllactosamine by the transfer of a galactose from UDP-galactose
	to the terminal N-acetylgluosamine of acceptor sugars in glycoproteins
	or glycolipids with a beta-1,4-linkage <75>; #15# complex
	penta-antennary N-glycan structure, detailed substrate binding
	structure analysis of the wild-type and mutant M340H enzymes, overview
	<80>; #6# substrate specificity in presence or absence of
	alpha-lactalbumin, overview, the specifier protein alpha-lactalbumin,
	which interacts with beta-1,4-GalT forming the lactose synthase
	complex, EC 2.4.1.2 and changing the substrate specificity to the
	reaction of EC 2.4.1.90, alpha-lactalbumin is not necessary when the
	acceptors are different glucopyranosides and, in some cases, it can
	even have an inhibitory effect, e.g. in reaction with the complex
	glucosides ginsenoside Rg1 and colchicoside, overview, in absence of
	alpha-lactalbumin, the enzyme is not active with glucose as acceptor
	<83>; #3# substrate specificity of wild-type and mutant Y289L enzymes,
	overview <74>; #6# the enzyme catalyzes the transfer of Gal from
	UDP-Gal to GlcNAc-terminating acceptors with inversion of configuration
	of the glycosidic linkage, in presence of beta-lactalbumin, the enzyme
	changes its specificity to become lactose synthase, EC 2.4.1.22, and
	transfers Gal to glucose to synthesize lactose, substrate specificity,
	e.g. with GlcNAc-terminating O-glycopeptides, no activity with
	N-trimethylacetyl-GlcN, N,N-dimethyl-GlcN, N-isopropyl-GlcN, and
	N-(4-MeOBn)GlcN, overview <77>; #3# beta 1,4GalT V galactosylates the
	beta1,6-GlcNAc branch of N-glycans at the cell surface and of secreted
	glycoproteins, and functions as a positive regulator in glioma
	development, overview. As2O3-induced gioma cell apoptosis mechanism
	involves beta 1,4GalT V inhibition, overview <89>; #3#
	beta-1,4-galactosylransferase participates in the synthesis of
	Galbeta1-4-GlcNac disaccharide unit of glycoconjugates, overview <91>;
	#16# beta-1,4-GalT I is a type II membrane-bound glycoprotein, which
	occurs the plasma membrane of different types of cells where it serves
	as a cell surface adhesion molecule mediating various cell-cell and
	cell-matrix interactions such as sperm-egg binding, cell spreading,
	migration, and neurite outgrowth <96>; #4# beta-1,4-GalT-I plays a key
	role in the synthesis of selectin ligands such as sialy Lewis, sLex,
	and sulfated sLex, overview. beta-1,4-GalT-I may play an important role
	in the inflammation reaction <94>; #10# HP0826 is the
	beta-1,4-galactosyltransferase involved in the biosynthesis of the
	lipopolysaccharide O-chain backbone of Helicobacter pylori <90>; #9#
	LgtB is the beta-1,4-galactosyltransferase involved in the biosynthesis
	of the lipopolysaccharide O-chain backbone of Helicobacter pylori <90>;
	#3# the specific inhibitors of the phosphatidylinositol 3-kinase
	LY294002 and wortmannin up-regulate beta1,4-galactosyltransferase I and
	thus sensitize SMMC-7721 human hepatocarcinoma cells to
	cycloheximide-induced apoptosis, overview <97>; #1# an enzyme
	orthologue involved in the synthesis of glycoproteins and glycolipids,
	the sugar donor specificity of the enzyme toward galactose is
	determined by the Ile residue at position 289 in the binding pocket.
	The two proteins beta4Gal-T1 and alpha-lactalbukin crystallize together
	as a complex only in the presence of either donor substrate or acceptor
	Glc or GlcNAc to form lactose synthase. The specificity of the sugar
	donor is generally determined by a few residues in the sugar-nucleotide
	binding pocket. The conformational change in beta4Gal-T1 also creates
	the binding site for a mammary gland-specific protein,
	alpha-lactalbumin, which changes the acceptor specificity of the enzyme
	toward glucose to synthesize lactose during lactation <91>; #10# HP0826
	exhibits a pronounced acceptor promiscuity with the most striking
	result being the successful transfer of Gal to the 4-SH of
	pNP-4-S-beta-GlcNAc <90>; #3# beta4Gal-T1 participates in the synthesis
	of Galbeta1-4-GlcNac disaccharide unit of glycoconjugates <91>; #4#
	beta-1,4-GalT-I transfers galactose from UDP-galactose donors to
	terminal N-acetylglucosamine of carbohydrate chains in beta-1,4-linkage
	to form a Galbeta1->4GlcNAc structure <101>; #3# UDP-mannose and
	UDP-N-acetyl galactosamine are no substrates for soluble beta1,4-GalT7
	<98>) {}
	<47,50,62,66,72,73,74,75,77,78,80,83,84,85,89,90,91,94,96,97,98,101>
SP	#1,3,4,6,9,10,13,14,15,16# more = ? (#6# regioselectivity towards
	specific C(4)glucose OH group in the complex protopanaxadiol glycoside
	ginsenoside Rb1 <50>; #6# enzyme also catalyzes unusual galactosyl
	transfer to the 3-OH position of L-sugars <62>; #6# enzyme also
	catalyzes transfer of glucose from UDPglucose to N-acetylglucosamine
	<47>; #3# enzyme activity might be involved in apoptotic pathway in
	hepatocarcinoma cells <66>; #3# decreasing the expression of GalT V in
	glioma cells promotes apoptosis, inhibits the invasion and migration
	and the ability of tumor formation in vivo, and reduces the activation
	of AKT, the enzyme functions as a glioma growth activator, overview,
	contribution of GalT V in the activation of AKT and MAPK kinase,
	contribution of serum or EGF in the transcription regulation of the
	GalT V gene, overview <78>; #3# downregulation of the enzyme inhibits
	CDK11(p58)-mediated apoptosis induced by cycloheximide, while
	ectopically expressed beta1,4-GT 1 increases CDK11p58-mediated
	apoptosis <72>; #3# the cell surface enzyme promotes apoptosis by
	inhibiting the epidermal growth factor receptor pathway via inhibition
	of the autophosphorylation of epidermal growth factor receptor
	especially at Try 1068, mechanism, overview <85>; #13# the enzyme is
	involved in regulation of carbohydrate composition of milk during
	lactation, endocrine enzyme regulation, overview <73>; #14# the enzyme
	is part of the endoplasmic reticulum and Golgi glycosylation network,
	glycosyltransferase metabolism, overview <84>; #3# tumor
	beta-1,4-galactosyltransferase IV overexpression is closely associated
	with colorectal cancer metastasis and poor prognosis, relationships
	between tumor beta-1,4-GT-IV overexpression and clinicopathologic
	characteristics, overview <75>; #3# beta-1,4-GTs are a family of
	glycosyltransferases responsible for biosynthesizing
	N-acetyllactosamine by the transfer of a galactose from UDP-galactose
	to the terminal N-acetylgluosamine of acceptor sugars in glycoproteins
	or glycolipids with a beta-1,4-linkage <75>; #15# complex
	penta-antennary N-glycan structure, detailed substrate binding
	structure analysis of the wild-type and mutant M340H enzymes, overview
	<80>; #6# substrate specificity in presence or absence of
	alpha-lactalbumin, overview, the specifier protein alpha-lactalbumin,
	which interacts with beta-1,4-GalT forming the lactose synthase
	complex, EC 2.4.1.2 and changing the substrate specificity to the
	reaction of EC 2.4.1.90, alpha-lactalbumin is not necessary when the
	acceptors are different glucopyranosides and, in some cases, it can
	even have an inhibitory effect, e.g. in reaction with the complex
	glucosides ginsenoside Rg1 and colchicoside, overview, in absence of
	alpha-lactalbumin, the enzyme is not active with glucose as acceptor
	<83>; #3# substrate specificity of wild-type and mutant Y289L enzymes,
	overview <74>; #6# the enzyme catalyzes the transfer of Gal from
	UDP-Gal to GlcNAc-terminating acceptors with inversion of configuration
	of the glycosidic linkage, in presence of beta-lactalbumin, the enzyme
	changes its specificity to become lactose synthase, EC 2.4.1.22, and
	transfers Gal to glucose to synthesize lactose, substrate specificity,
	e.g. with GlcNAc-terminating O-glycopeptides, no activity with
	N-trimethylacetyl-GlcN, N,N-dimethyl-GlcN, N-isopropyl-GlcN, and
	N-(4-MeOBn)GlcN, overview <77>; #3# beta 1,4GalT V galactosylates the
	beta1,6-GlcNAc branch of N-glycans at the cell surface and of secreted
	glycoproteins, and functions as a positive regulator in glioma
	development, overview. As2O3-induced gioma cell apoptosis mechanism
	involves beta 1,4GalT V inhibition, overview <89>; #3#
	beta-1,4-galactosylransferase participates in the synthesis of
	Galbeta1-4-GlcNac disaccharide unit of glycoconjugates, overview <91>;
	#16# beta-1,4-GalT I is a type II membrane-bound glycoprotein, which
	occurs the plasma membrane of different types of cells where it serves
	as a cell surface adhesion molecule mediating various cell-cell and
	cell-matrix interactions such as sperm-egg binding, cell spreading,
	migration, and neurite outgrowth <96>; #4# beta-1,4-GalT-I plays a key
	role in the synthesis of selectin ligands such as sialy Lewis, sLex,
	and sulfated sLex, overview. beta-1,4-GalT-I may play an important role
	in the inflammation reaction <94>; #10# HP0826 is the
	beta-1,4-galactosyltransferase involved in the biosynthesis of the
	lipopolysaccharide O-chain backbone of Helicobacter pylori <90>; #9#
	LgtB is the beta-1,4-galactosyltransferase involved in the biosynthesis
	of the lipopolysaccharide O-chain backbone of Helicobacter pylori <90>;
	#3# the specific inhibitors of the phosphatidylinositol 3-kinase
	LY294002 and wortmannin up-regulate beta1,4-galactosyltransferase I and
	thus sensitize SMMC-7721 human hepatocarcinoma cells to
	cycloheximide-induced apoptosis, overview <97>; #1# an enzyme
	orthologue involved in the synthesis of glycoproteins and glycolipids,
	the sugar donor specificity of the enzyme toward galactose is
	determined by the Ile residue at position 289 in the binding pocket.
	The two proteins beta4Gal-T1 and alpha-lactalbukin crystallize together
	as a complex only in the presence of either donor substrate or acceptor
	Glc or GlcNAc to form lactose synthase. The specificity of the sugar
	donor is generally determined by a few residues in the sugar-nucleotide
	binding pocket. The conformational change in beta4Gal-T1 also creates
	the binding site for a mammary gland-specific protein,
	alpha-lactalbumin, which changes the acceptor specificity of the enzyme
	toward glucose to synthesize lactose during lactation <91>; #10# HP0826
	exhibits a pronounced acceptor promiscuity with the most striking
	result being the successful transfer of Gal to the 4-SH of
	pNP-4-S-beta-GlcNAc <90>; #3# beta4Gal-T1 participates in the synthesis
	of Galbeta1-4-GlcNac disaccharide unit of glycoconjugates <91>; #4#
	beta-1,4-GalT-I transfers galactose from UDP-galactose donors to
	terminal N-acetylglucosamine of carbohydrate chains in beta-1,4-linkage
	to form a Galbeta1->4GlcNAc structure <101>; #3# UDP-mannose and
	UDP-N-acetyl galactosamine are no substrates for soluble beta1,4-GalT7
	<98>) {}
	<47,50,62,66,72,73,74,75,77,78,80,83,84,85,89,90,91,94,96,97,98,101>
SP	#10# UDP-Gal + 4-nitrophenyl
	2-acetamido-2-deoxy-4-thio-beta-D-glucopyranoside = UDP +
	Gal-beta-S-1,4-GlcNAcpNP (#10# HP0826 catalyzes the synthesis of the
	thiodisaccharide Gal-beta-S-1,4-GlcNAcpNP as well as
	Gal-beta-1,4-Man-pNP with total regio- and stereoselectivity, overview
	<90>) <90>
SP	#10# UDP-Gal + 4-nitrophenyl-2-acetamido-2-deoxy-beta-D-glucopyranoside
	= UDP + ? <90>
SP	#10,17# UDP-galactose + p-nitrophenyl-beta-D-N-acetylglucosaminide = ?
	{} <90,93>
SP	#10,17# UDP-galactose + p-nitrophenyl-beta-D-N-acetylglucosaminide = ?
	<90,93>
SP	#12# UDP-galactose + laminin = UDP + beta-1,4-D-galactosyl-laminin <76>
SP	#13# UDP-galactose + lactose = UDP + beta-D-galactosyl-lactose <73>
SP	#15# UDP-galactose + chitotriose = ? (#15#
	GlcNAcbeta1,4-GlcNAcbeta1,4-GlcNAc <80>) <80>
SP	#15# UDP-galactose + GlcNAcbeta1,2-Manalpha1,3-Manbeta-OR = ? (#15# an
	N-linked biantennary oligosaccharide chain, one antenna is attached to
	the 3-hydroxyl-(1,2-1,3-arm) group of mannose, which is beta-1,4-linked
	to an N-linked chitobiose, attached to the aspargine residue of a
	protein <80>) <80>
SP	#15# UDP-galactose + GlcNAcbeta1,2-Manalpha1,6
	(GlcNAcbeta1,2-Manalpha1,3)Man = ? <80>
SP	#15# UDP-galactose + GlcNAcbeta1,2-Manalpha1,6-Manbeta-OR = ? (#15# an
	N-linked biantennary oligosaccharide chain, one antenna is attached to
	the 3-hydroxyl-(1,2-1,6-arm) group of mannose, which is beta-1,4-linked
	to an N-linked chitobiose, attached to the aspargine residue of a
	protein <80>) <80>
SP	#15# UDP-galactose + GlcNAcbeta1,4-Manalpha1,3-Manbeta-OR = ? (#15# an
	N-linked biantennary oligosaccharide chain, one antenna is attached to
	the 3-hydroxyl-(1,4-1,3-arm) group of mannose, which is beta-1,4-linked
	to an N-linked chitobiose, attached to the aspargine residue of a
	protein <80>) <80>
SP	#15# UDP-galactose + N-acetyl-beta-D-glucosamine = UDP +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <80>
SP	#15# UDP-galactose +
	N-acetyl-beta-D-glucosaminyl-1,4-N-acetyl-beta-D-glucosamine = UDP +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1
	4-N-acetyl-beta-D-glucosamine <80>
SP	#15# UDP-galactose + Glc-NAcbeta1-3Galbeta-O-naphthalenemethanol = ?
	<102>
SP	#18# UDP-galactose + TTTVTP-(GlcNAcbeta1-6[Galbeta1-3]GalNAcalpha1-)TG
	= UDP + TTTVTP-(Galbeta-1-4GlcNAcbeta1-6[Galbeta1-3]GalNAcalpha1-)TG
	(#18# pH 7.0, 0.2 mM, 2% activity in A549 cells, 14% activity in H292
	cells relative to benzyl 2-(acetylamino)-2-deoxy-beta-D-glucopyranoside
	<99>) <99>
SP	#19# UDP-alpha-D-galactose + 4-methylumbelliferyl-beta-D-xylopyranoside
	= ? <121>
SP	#2# UDPgalactose + asialo-agalacto-transferrin = ? (#2# transfer of
	galactose to N-acetylglucosamine residues of Asn-linked sugar chains of
	glycoproteins in a beta1-4linkage <8>) <8>
SP	#2# UDPgalactose + asialogalactofetuin = ? <51>
SP	#2,3,15,19,20,22,23# UDP-alpha-D-galactose +
	N-acetyl-beta-D-glucosaminylglycopeptide = UDP +
	beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminylglycopeptide
	<117,118,119,120,122,123>
SP	#2,3,4,5,6# UDPgalactose + N-acetylglucosamine = UDP +
	N-acetyllactosamine (#3# 7% of the activity with GlcNAcbeta-S-pNP <52>)
	<1,5,6,7,8,18,22,23,28,29,31,32,33,34,35,36,41,42,43,45,47,51,52,55,56
	57,61,62,63>
SP	#2,3,4,5,6# UDPgalactose + N-acetylglucosamine = UDP +
	N-acetyllactosamine (#3# 7% of the activity with GlcNAcbeta-S-pNP <52>)
	{}
	<1,5,6,7,8,18,22,23,28,29,31,32,33,34,35,36,41,42,43,45,47,51,52,55,56
	57,61,62,63>
SP	#2,3,4,6# UDPgalactose + glucose = lactose + UDP (#2,3,4,6# in presence
	of alpha-lactalbumin <5,8,29,31,35,36,39,40,45,47,55,62,63>; #3# enzyme
	has no lactose synthase activity in presence of alpha-lactalbumin <52>)
	<5,8,29,31,35,36,39,40,45,47,52,55,62,63>
SP	#2,3,4,6# UDPgalactose + glucose = lactose + UDP (#2,3,4,6# in presence
	of alpha-lactalbumin <5,8,29,31,35,36,39,40,45,47,55,62,63>; #3# enzyme
	has no lactose synthase activity in presence of alpha-lactalbumin <52>)
	{} <5,8,29,31,35,36,39,40,45,47,52,55,62,63>
SP	#2,3,4,6# UDPgalactose + N-acetylglucosaminyl at the non-reducing ends
	of protein-bound oligosaccharides = ? (#6# the enzyme facilitates sperm
	binding to the oocyte zona pellucida <38>; #6# enzyme participates in
	the biosynthesis of the oligosaccharide structures of glycoproteins and
	glycolipids <17>; #2# the enzyme is involved in the biosynthesis of a
	variety of carbohydrate structures in glycoproteins and glycolipids
	<51>; #3# the enzyme may be involved in the synthesis of
	poly-N-acetyllactosamine, lacto-N-neotetraose and probably
	lacto-N-neotetraosylceramide in addition to the formation of the
	Galbeta1-4GlcNAc group of glycoprotein sugar chains and lactose <49>;
	#4# the soluble enzyme form from the luminal fluid of the epididymis is
	suggested to play a role on sperm maturation <60>; #6# enzyme functions
	in the coordinate biosynthesis of complex oligosaccharides, proposed to
	function in intercellular recognition and/or adhesion <27>; #4# the
	enzyme may be involved in the synthesis of plasma glycoproteins by the
	liver during secretion, and may possibly be required for secretion of
	these proteins <6>; #2# biosynthesis of carbohydrate moieties of
	glycoproteins and glycolipids, role in intercellular recognition and
	adhesion <10>; #3# main enzyme responsible for the transfer of
	galactose residues from UDPgalactose into terminal N-acetylglucosamine
	residues of complex-type oligosaccharides in newly synthesized
	glycoproteins in the Golgi apparatus. Deficiency of
	UDP-galactose:N-acetylglucosamine beta-1,4-galactosyltransferase I
	causes the congenital disorder of glycosylation type IId, a severe
	neurologic disease characterized by a hydrocephalus, myopathy and
	blood-clotting defects <54>; #6# biosynthesis of keratan sulfate-like
	polysaccharides <36>) <6,10,11,17,26,27,36,38,49,51,54,60>
SP	#3# UDPgalactose + UDPglucose = UDP + lactose <57>
SP	#3# UDPgalactose +
	GlcNAcbeta1-6(GlcNAcbeta1-2)Manalpha1-3Manbeta1-O(CH2)8COOCH2-mNP = UDP
	+ Galbeta1-4
	GlcNAcbeta1-6(GlcNAcbeta1-2)Manalpha1-3Manbeta1-O(CH2)8COOCH2-mNP <52>
SP	#3# UDPgalactose + GlcNAcbeta-S-p-NP = UDP + Galbeta1-4
	GlcNAcbeta-S-p-NP <52>
SP	#3# UDPgalactose + asialo agalacto alpha1 acid glycoprotein = ? <29>
SP	#3# UDPgalactose + alpha1-acid glycoprotein = ? <39>
SP	#3# UDPgalactose + agalacto-poly-N-acetyllactosamine = ? <49>
SP	#3# UDPgalactose + lacto-N-triose II = ? <49>
SP	#3# UDPgalactose + lacto-N-triaosylceramide = ? <49>
SP	#3# UDP-galactose + N-acetyl-beta-D-glucosaminylglycopeptide = UDP +
	beta-D-galactosyl-(1-4)-N-acetyl-beta-D-glucosaminylglycopeptide (#3#
	for the binding of GlcNAc in the monosaccharide binding site of
	beta4Gal-T1, there is a hydrophobic N-acetyl group-binding pocket
	formed by residues Arg359, Phe360, and Ile363 from the ?-helix region
	in the closed conformation of the long loop, the sugar donor
	specificity of beta4Gal-T1 toward galactose is determined by the Tyr
	residue at position 289 in the binding pocket. The two proteins
	beta4Gal-T1 and alpha-lactalbukin crystallize together as a complex
	only in the presence of either donor substrate or acceptor Glc or
	GlcNAc to form lactose synthase. The specificity of the sugar donor is
	generally determined by a few residues in the sugar-nucleotide binding
	pocket. The conformational change in beta4Gal-T1 also creates the
	binding site for a mammary gland-specific protein, alpha-lactalbumin,
	which changes the acceptor specificity of the enzyme toward glucose to
	synthesize lactose during lactation <91>) <91>
SP	#3# UDP-galactose + 4-methylumbelliferyl beta-D-xylopyranoside = UDP +
	? <98>
SP	#3# UDP-galactose + 4-nitrophenyl beta-D-xylopyranoside = UDP +
	beta-D-galactopyranosyl-1,4-xylopyranosyl-1-O-4-nitrophenol <98>
SP	#3# UDP-glucose + 4-methylumbelliferyl beta-D-xylopyranoside = UDP +
	4-O-beta-D-galactosyl-beta-D-glucose (#3# 1.5% activity with
	UDO-glucose compared to UDP-galactose <98>) <98>
SP	#3# UDP-glucuronic acid + 4-methylumbelliferyl beta-D-xylopyranoside =
	UDP + ? <98>
SP	#3# UDP-N-acetyl-alpha-D-glucosamine + 4-methylumbelliferyl
	beta-D-xylopyranoside = UDP + ? <98>
SP	#3# UDP-xylose + 4-methylumbelliferyl beta-D-xylopyranoside = UDP + ?
	<98>
SP	#3,4,5# UDPgalactose + ovalbumin = ? <24,29,30,41,44>
SP	#3,4,5# UDPgalactose + degalactosylated fetuin = UDP + fetuin
	containing beta-1,4-galactose linkages <32,39,43,45>
SP	#3,6,11,14,15# UDP-galactose + N-acetyl-beta-D-glucosaminylglycopeptide
	= UDP + beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminylglycopeptide
	(#3# the enzyme effectively galactosylates the GlcNAcbeta1,6Man arm of
	the highly branched N-glycans that are characteristic of glioma,
	overview <78>; #15# the enzyme transfers galactose from UDP-galactose
	to N-acetylglucosamine residues of the branched N-linked
	oligosaccharide chains of glycoproteins <80>; #3,6# catalytic cycle:
	Mn2+ binds first before UDP-Gal, two flexible loops, a long and a short
	loop, change their conformation from open to closed <81>; #3# residue
	Y285 alone is responsible for determination of enzyme substrate
	specificity, overview, active site structure, overview <82>; #3#
	UDP-Gal-Mn2+ substrate binding structure, overview <79>; #3# 100%
	activity with UDP-galactose <98>)
	<74,78,79,80,81,82,83,84,85,86,98,103,104>
SP	#3,6,13# UDP-galactose + N-acetylglucosamine = UDP +
	N-acetyllactosamine <73,75,77,83>
SP	#4# UDPgalactose + ovomucoid = UDP + ovomucoid with beta-1,4-bound
	galactose <21>
SP	#4# UDPgalactose +
	N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1
	6-(N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1,3-)mannosyl-beta-1
	4-N-acetylglucosaminyl-beta-1,4-(fucosyl-alpha-1
	6-)N-acetylglucosaminyl-asparagine = UDP +
	galactosyl-beta-1,4-N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1
	6-(galactosyl-beta-1,4-N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1
	3-)mannosyl-beta-1,4-N-acetylglucosaminyl-beta-1,4-(fucosyl-alpha-1
	6-)N-acetylglucosaminyl-asparagine |#4# galactose is transferred much
	faster to the N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1,3-branch
	than to the N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1,6-branch
	<26>| <26>
SP	#5# UDPgalactose + immunoglobulin heavy chain = ? <41>
SP	#5# UDPgalactose + fetuin = ? <41>
SP	#5,6# UDPgalactose + p-nitrophenyl 2-acetamido-2-deoxy-beta-glucoside =
	? (#6# 67% of the activity with N-acetylglucosamine <36>) <36,41>
SP	#5,6# UDPgalactose + N-acetyl-beta-D-glucosaminyl-glycopeptide = UDP +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminylglycopeptide (#5#
	glycopeptide prepared from porcine IgG immunoglobulin <41>; #6#
	glycoproteins containing terminal nonreducing N-acetylglucosaminyl
	units <36>) <36,41>
SP	#6# UDPgalactose + chitobiose = ? <61>
SP	#6# UDPgalactose + chitotriose = ? <61>
SP	#6# UDPgalactose + agalactokeratan = ? (#6# agalactokeratan from bovine
	cornea and nasal septum, at 5% and 13% of the activity with
	N-acetylglucosamine <36>) <36>
SP	#6# UDP-galactose + methyl 2-acetamido-2-deoxy-beta-D-glucoside = UDP +
	beta-D-galactosyl-1
	4-beta-1-O-methyl-2-deoxy-2-acetylamido-beta-D-glucopyranoside (#6# 76%
	of the activity with N-acetylglucosamine <36>) <36>
SP	#6# UDP-galactose + methyl 2-bromo-acetamido-2-deoxy-beta-D-glucoside =
	UDP +
	beta-D-galactosyl-1
	4-1-O-methyl-2-bromo-acetamido-2-deoxy-beta-D-glucoside (#6# 75% of the
	activity with N-acetylglucosamine <36>) <36>
SP	#6# UDPgalactose +
	2-acetamido-N-(L-aspart-4-oyl)-1,2-dideoxy-beta-glucoside = ? (#6# 65%
	of the activity with N-acetylglucosamine <36>) <36>
SP	#6# UDP-galactose + methyl 2-deoxy-2-benzamido-beta-D-glucoside = UDP +
	beta-D-galactosyl-1,4-1-O-methyl-2-deoxy-2-benzamido-beta-D-glucoside
	(#6# 16% of the activity with N-acetylglucosamine <36>) <36>
SP	#6# UDPgalactose + tri-N-acetylchitotriose = ? (#6# 64% of the activity
	with N-acetylglucosamine <36>) <36>
SP	#6# UDPgalactose + di-acetylchitobiose = ? (#6# 54% of the activity
	with N-acetylglucosamine <36>) <36>
SP	#6# UDPgalactose + agalacto-ovomucoid = ? (#6# 65% of the activity with
	N-acetylglucosamine <36>) <36>
SP	#6# UDPgalactose + asialo-agalacto-alpha1-glycoprotein = ? (#6# 42% of
	the activity with N-acetylglucosamine <36>) <36>
SP	#6# UDPgalactose + N-acetylglucosaminyl-beta-1,3-galactose = UDP +
	galactosyl-beta-1,4-N-acetylglucosaminyl-beta-1,3-galactose <28>
SP	#6# UDPgalactose + N-acetylglucosaminyl-beta-1,6-galactose = UDP +
	galactosyl-beta-1,4-N-acetylglucosaminyl-beta-1,6-galactose <28>
SP	#6# UDPgalactose +
	N-acetylglucosaminyl-beta-1,3-(N-acetylglucosaminyl-beta-1,6-)galactose
	= UDP +
	galactosyl-beta-1,4-N-acetylglucosaminyl-beta-1
	3-(N-acetylglucosaminyl-beta-1,6-)galactose <28>
SP	#6# UDPgalactose +
	N-acetylglucosaminyl-beta-1,3-(galactosyl-beta-1
	4-N-acetylglucosaminyl-beta-1,6-)galactose = UDP +
	galactosyl-beta-1,4-N-acetylglucosaminyl-beta-1,3-(galactosyl-beta-1
	4-N-acetylglucosaminyl-beta-1,6-)galactose <28>
SP	#6# UDP-GalNAc + GlcNAc = ? (#6# at high concentrations of
	alpha-lactalbumin <62>; #6# transfer of GalNAc is only 1% of galactose
	transfer in wild type enzyme. Mutant enzyme Y289L exhibits nearly 100%
	of the galactose transferase activity <55>) <55,62>
SP	#6# UDPgalactose + N-acetamido-3-deoxy-D-glucose = ? <62>
SP	#6# UDPgalactose + 3-acetamido-3-deoxy-D-xylose = ? <62>
SP	#6# UDP-galactose + N-acetylglucosamine = UDP +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <67>
SP	#6# UDP-glucose + N-acetylglucosamine = UDP +
	beta-D-glucosyl-1,4-N-acetyl-beta-D-glucosamine (#6# reaction with 0.3%
	efficiency. R228K mutation results in a 15-fold higher
	glucosyltransferase activity, which is further enhanced by
	alpha-lactalbumin to nearly 25% of the galactosyltransferase activity
	of the wild type <67>) <67>
SP	#6# UDP-galactose + 3-deoxy-3-fluoro-GlcNAcbeta-Bn = UDP +
	Galbeta(1-4)3-deoxy-3-fluoro-GlcNAcbeta-Bn <77>
SP	#6# UDP-galactose + 6-deoxy-GlcNAcbeta-Bn = UDP +
	Galbeta(1-4)6-deoxy-GlcNAcbeta-Bn (#6# low activity <77>) <77>
SP	#6# UDP-galactose + 6-thio-GlcNAcbeta-Bn = UDP +
	Galbeta(1-4)6-thio-GlcNAcbeta-Bn (#6# low activity <77>) <77>
SP	#6# UDP-galactose + colchicoside = UDP +
	beta-D-galactosyl-1,4-colchicoside <83>
SP	#6# UDP-galactose + ginsenoside Rg1 = UDP +
	beta-D-galactosyl-1,4-ginsenoside Rg1 <83>
SP	#6# UDP-galactose + GlcNAcbeta-Bn = UDP + Galbeta(1-4)GlcNAcbeta-Bn <77>
SP	#6# UDP-galactose + N-4-toluenesulfonyl-GlcN = UDP +
	Galbeta(1-4)N-4-toluenesulfonyl-GlcN <77>
SP	#6# UDP-galactose + N-butyryl-GlcNbeta-Bn = UDP +
	Galbeta(1-4)N-butyryl-GlcNbeta-Bn <77>
SP	#6# UDP-galactose + N-methanesulfonyl-GlcN = UDP +
	Galbeta(1-4)N-methanesulfonyl-GlcN <77>
SP	#6# UDP-galactose + N-trifluoroacetyl-GlcN = UDP +
	Galbeta(1-4)N-trifluoroacetyl-GlcN <77>
SP	#6# UDP-galactose + T(GlcNAcbeta3GalNAcbeta)TTVTPTPTG = ? <77>
SP	#6# UDP-galactose + T(GlcNAcbeta6GalNAcbeta)TTVTPTPTG = ? <77>
SP	#6# UDP-galactose + T(GlcNAcbeta6[GlcNAcbeta3]GalNAcbeta)TTVTPTPTG = ?
	<77>
SP	#6# UDP-galactose + TT(GlcNAcbeta3GalNAcbeta)TVTPTPTG = ? <77>
SP	#6# UDP-galactose + TT(GlcNAcbeta6GalNAcbeta)TVTPTPTG = ? <77>
SP	#6# UDP-galactose + TT(GlcNAcbeta6[GlcNAcbeta3]GalNAcbeta)TVTPTPTG = ?
	<77>
SP	#6# UDP-galactose + TTTV (GlcNAcbeta3GalNAcbeta)TPTPTG = ? <77>
SP	#6# UDP-galactose + TTTV(GlcNAcbeta6GalNAcbeta)TPTPTG = ? <77>
SP	#6# UDP-galactose + TTTV(GlcNAcbeta6[GlcNAcbeta3]GalNAcbeta)TPTPTG = ?
	<77>
SP	#6# UDP-galactose + TTTVTP(GlcNAcbeta3GalNAcbeta)TPTG = ? <77>
SP	#6# UDP-galactose + TTTVTP(GlcNAcbeta6GalNAcbeta)TPTG = ? <77>
SP	#6# UDP-galactose + TTTVTPTP(GlcNAcbeta3GalNAcbeta)TG = ? <77>
SP	#6# UDP-galactose + TTTVTPTP(GlcNAcbeta6[GlcNAcbeta3]GalNAcbeta)TG = ?
	<77>
SP	#6# UDP-galactose +
	T-(GlcNAcbeta-1-6[Galbeta1-3]GalNAcalpha1-)TTVTPTPTG = UDP +
	T-(Galbeta1-4GlcNAcbeta-1-6[Galbeta1-3]GalNAcalpha1-)TTVTPTPTG (#6# pH
	7.0, 0.5 mM, 40% activity <99>) <99>
SP	#6# UDP-galactose +
	TT-(GlcNAcbeta-1-6[Galbeta1-3]GalNAcalpha1-)TVTP(GGA)TPTG = UDP +
	TT-(Galbeta1-4GlcNAcbeta-1-6[Galbeta1-3]GalNAcalpha1-)TVTP(GGA)TPTG
	(#6# pH 7.0, 0.5 mM, 25% activity <99>) <99>
SP	#6# UDP-galactose +
	TT-(GlcNAcbeta-1-6[Galbeta1-3]GalNAcalpha1-)TVTPTPTG = UDP +
	TT-(Galbeta1-4GlcNAcbeta-1-6[Galbeta1-3]GalNAcalpha1-)TVTPTPTG (#6# pH
	7.0, 0.5 mM, 30% activity <99>; #6# pH 7.0, 0.5 mM, 35% activity <99>)
	<99>
SP	#6# UDP-galactose +
	TTTVTP-(GlcNAcbeta-1-6[Galbeta1-3]GalNAcalpha1-)TPTG = UDP +
	TTTVTP-(Galbeta1-4GlcNAcbeta-1-6[Galbeta1-3]GalNAcalpha1-)TPTG (#6# pH
	7.0, 0.5 mM, 20% activity <99>) <99>
SP	#6,18# UDP-galactose + benzyl
	2-(acetylamino)-2-deoxy-beta-D-glucopyranoside = UDP + benzyl
	2-(acetylamino)-2-deoxy-4-O-beta-D-galactopyranosyl-beta-D
	glucopyranoside (#18# pH 7.0 <99>; #6# pH 7.0, 0.5 mM, 100% activity
	<99>) <99>
SP	#9,10# UDP-Gal + 4-nitrophenyl beta-D-mannopyranoside = UDP +
	Gal-beta-1,4-Man-pNP (#10# HP0826 catalyzes the synthesis of the
	thiodisaccharide Gal-beta-S-1,4-GlcNAcpNP as well as
	Gal-beta-1,4-Man-pNP with total regio- and stereoselectivity, overview
	<90>; #9# LgtB catalyzes the synthesis of Gal-beta-1,4-Man-pNP,
	overview <90>) <90>

TURNOVER_NUMBER
TN	#15# 3.3 {chitotriose}  <80>
TN	#15# 3.6 {N-acetyl-beta-D-glucosamine}  <80>
TN	#15# 1.9 {GlcNAcbeta1,2-Manalpha1,6-Manbeta-OR}  <80>
TN	#15# 3.35 {GlcNAcbeta1,4-Manalpha1,3-Manbeta-OR}  <80>
TN	#15# 2.47 {GlcNAcbeta1,2-Manalpha1,3-Manbeta-OR}  <80>
TN	#15# 4.82
	{N-acetyl-beta-D-glucosaminyl-1,4-N-acetyl-beta-D-glucosamine}  <80>
TN	#15# 1.74 {GlcNAcbeta1,2-Manalpha1,6 (GlcNAcbeta1,2-Manalpha1,3)Man} 
	<80>
TN	#15# 4.81 {chitotriose}  <80>
TN	#19# 0.5 {UDP-alpha-D-galactose}  (#19# mutant enzyme Y196F, at pH 7.0
	and 37°C <121>) <121>
TN	#19# 0.5 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme Y196F, at pH 7.0 and 37°C <121>) <121>
TN	#19# 0.82 {UDP-alpha-D-galactose}  (#19# mutant enzyme R270K, at pH 7.0
	and 37°C <121>) <121>
TN	#19# 0.82 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme R270K, at pH 7.0 and 37°C <121>) <121>
TN	#19# 0.77 {UDP-alpha-D-galactose}  (#19# mutant enzyme R270A, at pH 7.0
	and 37°C <121>) <121>
TN	#19# 0.77 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme R270A, at pH 7.0 and 37°C <121>) <121>
TN	#19# 1.35 {UDP-alpha-D-galactose}  (#19# mutant enzyme R226K, at pH 7.0
	and 37°C <121>) <121>
TN	#19# 1.35 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme R226K, at pH 7.0 and 37°C <121>) <121>
TN	#19# 1.2 {UDP-alpha-D-galactose}  (#19# mutant enzyme Y199F, at pH 7.0
	and 37°C <121>) <121>
TN	#19# 1.2 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme Y199F, at pH 7.0 and 37°C <121>) <121>
TN	#19# 1.51 {UDP-alpha-D-galactose}  (#19# recombinant wild type enzyme,
	at pH 7.0 and 37°C <121>) <121>
TN	#19# 1.51 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19#
	recombinant wild type enzyme, at pH 7.0 and 37°C <121>) <121>
TN	#19# 1.93 {UDP-alpha-D-galactose}  (#19# mutant enzyme H195A, at pH 7.0
	and 37°C <121>) <121>
TN	#19# 1.93 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme H195A, at pH 7.0 and 37°C <121>) <121>
TN	#19# 0.89 {UDP-alpha-D-galactose}  (#19# mutant enzyme R226A, at pH 7.0
	and 37°C <121>) <121>
TN	#19# 0.89 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme R226A, at pH 7.0 and 37°C <121>) <121>
TN	#19# 1.49 {UDP-alpha-D-galactose}  (#19# mutant enzyme H195R, at pH 7.0
	and 37°C <121>) <121>
TN	#19# 1.49 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme H195R, at pH 7.0 and 37°C <121>) <121>
TN	#19# 1.62 {UDP-alpha-D-galactose}  (#19# mutant enzyme H195Q, at pH 7.0
	and 37°C <121>) <121>
TN	#19# 1.62 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme H195Q, at pH 7.0 and 37°C <121>) <121>
TN	#3# 0.01 {UDP-xylose}  (#3# purified maltose-binding
	protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH 7.0) containing
	10 mM MnCl2, at 37°C <98>) <98>
TN	#3# 1.13 {4-methylumbelliferyl beta-D-xylopyranoside}  (#3# purified
	maltose-binding protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH
	7.0) containing 10 mM MnCl2, at 37°C <98>) <98>
TN	#3# 0.02 {UDP-glucose}  (#3# purified maltose-binding
	protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH 7.0) containing
	10 mM MnCl2, at 37°C <98>) <98>
TN	#3# 1.14 {UDP-galactose}  (#3# Km above 0.003 mM, purified
	maltose-binding protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH
	7.0) containing 10 mM MnCl2, at 37°C <98>) <98>
TN	#3# 0.003 {UDP-glucuronic acid}  (#3# Km above 0.003 mM, purified
	maltose-binding protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH
	7.0) containing 10 mM MnCl2, at 37°C <98>) <98>
TN	#3# 0.003 {UDP-N-acetyl-beta-D-glucosamine}  (#3# Km above 0.003 mM,
	purified maltose-binding protein-beta1,4-GalT7, in 100 mM cacodylate
	buffer (pH 7.0) containing 10 mM MnCl2, at 37°C <98>) <98>
TN	#3# 1.52 {4-nitrophenyl beta-D-xylopyranoside}  (#3# purified
	maltose-binding protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH
	7.0) containing 10 mM MnCl2, at 37°C <98>) <98>
TN	#6# -999 {more}  (#6# turnover number for UDPglucose in absence of
	alpha-lactalbumin is 3.48 and 14.8 in presence of alpha-lactalbumin
	<47>) <47,55>
TN	#6# 0.52 {UDP-galactose}  (#6# cosubstrate: N-acetylglucosamine,
	without alpha-lactalbumin, mutant enzyme R228K <67>) <67>
TN	#6# 0.52 {N-acetylglucosamine}  (#6# cosubstrate: UDP-galactose,
	without alpha-lactalbumin, mutant enzyme R228K <67>) <67>
TN	#6# 0.17 {UDP-glucose}  (#6# cosubstrate: N-acetylglucosamine, without
	alpha-lactalbumin, mutant enzyme R228K <67>) <67>
TN	#6# 0.17 {N-acetylglucosamine}  (#6# cosubstrate: UDP-glucose, without
	alpha-lactalbumin, mutant enzyme R228K <67>) <67>
TN	#6# 14 {UDP-galactose}  (#6# cosubstrate: N-acetylglucosamine, without
	alpha-lactalbumin, wild-type enzyme <67>) <67>
TN	#6# 14 {N-acetylglucosamine}  (#6# cosubstrate: UDP-galactose, without
	alpha-lactalbumin, wild-type enzyme <67>) <67>
TN	#6# 0.06 {UDP-glucose}  (#6# cosubstrate: N-acetylglucosamine, without
	alpha-lactalbumin, wild-type enzyme <67>) <67>
TN	#6# 0.06 {N-acetylglucosamine}  (#6# cosubstrate: UDP-glucose, without
	alpha-lactalbumin, wild-type enzyme <67>) <67>
TN	#6# 0.96 {UDP-glucose}  (#6# cosubstrate: N-acetylglucosamine, in
	presence of alpha-lactalbumin, mutant enzyme R228K <67>) <67>
TN	#6# 0.96 {N-acetylglucosamine}  (#6# cosubstrate: UDP-glucose, in
	presence of alpha-lactalbumin, mutant enzyme R228K <67>) <67>
TN	#6# 0.25 {UDP-glucose}  (#6# cosubstrate: N-acetylglucosamine, in
	presence of alpha-lactalbumin, wild-type enzyme <67>) <67>
TN	#6# 0.25 {N-acetylglucosamine}  (#6# cosubstrate: UDP-glucose, in
	presence of alpha-lactalbumin, wild-type enzyme <67>) <67>
TN	#6# 0.33 {UDP-galactose}  (#6# cosubstrate: N-acetylglucosamine, in
	presence of alpha-lactalbumin, mutant enzyme R228K <67>) <67>
TN	#6# 0.33 {N-acetylglucosamine}  (#6# cosubstrate: UDP-galactose, in
	presence of alpha-lactalbumin, mutant enzyme R228K <67>) <67>

KM_VALUE
KM	#1,3,6,9,10,15# -999 {more}  (#6,9,10# kinetics <77,90>; #3# effects of
	cationic polypeptides <30>; #3# Km-value for ovalbumin for the
	N-deglycosylated recombinant enzyme is 6 mg/ml, and 15 mg/ml for th
	recombinant enzyme <63>; #15# kinetics, implications of the
	oligosaccharide structures on the kinetic parameters, overview <80>;
	#3# kinetics, mutant enzyme, overview <74>) <30,63,74,77,80,90,91>
KM	#10# 0.27 {UDP-Gal}  (#10# pH 7.2 <90>) <90>
KM	#10# 0.79 {pNP-beta-GlcNAc}  (#10# pH 7.2 <90>) <90>
KM	#15# 0.06 {GlcNAcbeta1,2-Manalpha1,6-Manbeta-OR}  <80>
KM	#15# 0.6 {GlcNAcbeta1,2-Manalpha1,3-Manbeta-OR}  <80>
KM	#15# 0.01 {N-acetyl-beta-D-glucosamine}  <80>
KM	#15# 0.01 {Glc-NAcbeta1-3Galbeta-O-naphthalenemethanol}  <102>
KM	#15# 0.71 {GlcNAcbeta1,4-Manalpha1,3-Manbeta-OR}  <80>
KM	#15# 1.59
	{N-acetyl-beta-D-glucosaminyl-1,4-N-acetyl-beta-D-glucosamine}  <80>
KM	#15# 0.96 {chitotriose}  <80>
KM	#15# 1.23 {GlcNAcbeta1,2-Manalpha1,6 (GlcNAcbeta1,2-Manalpha1,3)Man} 
	<80>
KM	#19# 0.55 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme H195Q, at pH 7.0 and 37°C <121>) <121>
KM	#19# 0.6 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme R270A, at pH 7.0 and 37°C <121>) <121>
KM	#19# 0.4 {UDP-alpha-D-galactose}  (#19# mutant enzyme H195A, at pH 7.0
	and 37°C <121>) <121>
KM	#19# 0.37 {UDP-alpha-D-galactose}  (#19# mutant enzyme R270K, at pH 7.0
	and 37°C <121>) <121>
KM	#19# 0.22 {UDP-alpha-D-galactose}  (#19# recombinant wild type enzyme,
	at pH 7.0 and 37°C <121>) <121>
KM	#19# 0.29 {UDP-alpha-D-galactose}  (#19# mutant enzyme R226K, at pH 7.0
	and 37°C <121>) <121>
KM	#19# 0.32 {UDP-alpha-D-galactose}  (#19# mutant enzyme H195R, at pH 7.0
	and 37°C <121>; #19# mutant enzyme Y199F, at pH 7.0 and 37°C <121>)
	<121>
KM	#19# 0.54 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme R270K, at pH 7.0 and 37°C <121>) <121>
KM	#19# 0.33 {UDP-alpha-D-galactose}  (#19# mutant enzyme H195Q, at pH 7.0
	and 37°C <121>) <121>
KM	#19# 0.35 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme H195R, at pH 7.0 and 37°C <121>; #19# recombinant wild type
	enzyme, at pH 7.0 and 37°C <121>) <121>
KM	#19# 0.59 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme Y199F, at pH 7.0 and 37°C <121>) <121>
KM	#19# 0.34 {UDP-alpha-D-galactose}  (#19# mutant enzyme R226A, at pH 7.0
	and 37°C <121>; #19# mutant enzyme Y196F, at pH 7.0 and 37°C <121>)
	<121>
KM	#19# 0.27 {UDP-alpha-D-galactose}  (#19# mutant enzyme R270A, at pH 7.0
	and 37°C <121>) <121>
KM	#19# 0.44 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme R226A, at pH 7.0 and 37°C <121>) <121>
KM	#19# 0.46 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme R226K, at pH 7.0 and 37°C <121>) <121>
KM	#19# 1.06 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme Y196F, at pH 7.0 and 37°C <121>) <121>
KM	#19# 0.64 {4-methylumbelliferyl-beta-D-xylopyranoside}  (#19# mutant
	enzyme H195A, at pH 7.0 and 37°C <121>) <121>
KM	#2# 1 {N-acetylglucosamine}  <5>
KM	#2# 0.25 {UDPgalactose}  <5>
KM	#2# 4.6 {N-acetylglucosamine}  <35>
KM	#2# 1.6 {N-acetylglucosamine}  <51>
KM	#2# 0.056 {asialo-agalacto-transferrin}  (#2# enzyme in
	pCMGT1-transfected cells <8>) <8>
KM	#2# 0.0468 {UDPgalactose}  <51>
KM	#2# 0.0127 {UDPgalactose}  <35>
KM	#2# 0.0608 {asialogalactofetuin}  <51>
KM	#2,3# 0.024 {UDPgalactose}  (#2# enzyme in pCMGT1-transfected cells
	<8>) <8,39>
KM	#2,6# 1.9 {N-acetylglucosamine}  (#2# enzyme in pCMGT1-transfected
	cells <8>; #6# N-acetylglucosaminyl-beta-1,3-galactose <28>) <8,28>
KM	#3# 0.16 {UDP-xylose}  (#3# purified maltose-binding
	protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH 7.0) containing
	10 mM MnCl2, at 37°C <98>) <98>
KM	#3# 0.16 {4-methylumbelliferyl beta-D-xylopyranoside}  (#3# purified
	beta1,4-GalT7, in 100 mM cacodylate buffer (pH 7.0) containing 10 mM
	MnCl2, at 37°C <98>) <98>
KM	#3# 0.17 {agalacto-poly-N-acetyllactosamine}  <49>
KM	#3# 0.31 {UDP-galactose}  (#3# purified beta1,4-GalT7, in 100 mM
	cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C <98>) <98>
KM	#3# 0.21 {UDPgalactose}  (#3# reaction with glucose, recombinant enzyme
	<63>) <63>
KM	#3# 0.025 {UDPgalactose}  (#3# recombinant enzyme <49>) <49>
KM	#3# 0.2 {UDPgalactose}  (#3# reaction with glucose, wild-type enzyme
	and N-deglycosylated recombinant enzyme <63>) <63>
KM	#3# 0.2 {alpha1-Acid glycoprotein}  <39>
KM	#3# 1 {D-glucose}  (#3# recombinant enzyme <63>) <63>
KM	#3# 2 {D-glucose}  <63>
KM	#3# 0.28 {UDP-glucose}  (#3# purified maltose-binding
	protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH 7.0) containing
	10 mM MnCl2, at 37°C <98>) <98>
KM	#3# 0.19 {lacto-N-triose II}  <49>
KM	#3# 0.8 {N-acetylgalactosamine}  <29>
KM	#3# 10 {N-acetylglucosamine}  (#3# recombinant enzyme <63>) <63>
KM	#3# 10 {UDP-N-acetyl-beta-D-glucosamine}  (#3# Km above 10 mM, purified
	maltose-binding protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH
	7.0) containing 10 mM MnCl2, at 37°C <98>) <98>
KM	#3# 0.23 {UDP-galactose}  (#3# purified maltose-binding
	protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH 7.0) containing
	10 mM MnCl2, at 37°C <98>) <98>
KM	#3# 0.028 {UDPgalactose}  (#3# recombinant enzyme <20>) <20>
KM	#3# 2.5 {N-acetylglucosamine}  (#3# recombinant enzyme <49>) <49>
KM	#3# 3.3 {N-acetylglucosamine}  <63>
KM	#3# 4 {UDP-glucuronic acid}  (#3# Km above 4 mM, purified
	maltose-binding protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH
	7.0) containing 10 mM MnCl2, at 37°C <98>) <98>
KM	#3# 2.3 {N-acetylglucosamine}  <29>
KM	#3# 8.3 {N-acetylglucosamine}  (#3# recombinant N-deglycosylated enzyme
	<63>) <63>
KM	#3# 2.8 {N-acetylglucosamine}  <20>
KM	#3# 1.1 {D-glucose}  (#3# recombinant N-deglycosylated enzyme <63>) <63>
KM	#3# 0.27 {ovalbumin}  <30>
KM	#3# 0.27 {4-methylumbelliferyl beta-D-xylopyranoside}  (#3# purified
	maltose-binding protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH
	7.0) containing 10 mM MnCl2, at 37°C <98>) <98>
KM	#3# 0.091 {UDPgalactose}  (#3# recombinant enzyme <63>) <63>
KM	#3# 0.85 {4-nitrophenyl beta-D-xylopyranoside}  (#3# purified
	beta1,4-GalT7, in 100 mM cacodylate buffer (pH 7.0) containing 10 mM
	MnCl2, at 37°C <98>) <98>
KM	#3# 0.83 {lacto-N-triaosylceramide}  <49>
KM	#3# 0.0039 {N-acetylglucosamine}  <39>
KM	#3# 0.019 {UDPgalactose}  <30>
KM	#3# 0.064 {asialo-agalacto-transferrin}  (#3# recombinant enzyme <49>)
	<49>
KM	#3# 1.27 {4-nitrophenyl beta-D-xylopyranoside}  (#3# purified
	maltose-binding protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH
	7.0) containing 10 mM MnCl2, at 37°C <98>) <98>
KM	#3# 0.082 {UDPgalactose}  <20>
KM	#3# 3.6 {N-acetylglucosamine}  (#3# recombinant enzyme <20>) <20>
KM	#3# 0.143 {UDPgalactose}  (#3# recombinant N-deglycosylated enzyme
	<63>) <63>
KM	#3# 0.106 {UDPgalactose}  <63>
KM	#3# 0.00491 {UDP-Gal}  <79>
KM	#4# 0.0125 {UDPgalactose}  <45>
KM	#4# 0.03 {UDPgalactose}  <24>
KM	#4# 0.065 {UDPgalactose}  (#4# enzyme from liver <1>) <1>
KM	#4# 0.43
	{N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1,6-(galactosyl-beta-1
	4-N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1,3-)mannosyl-beta-1
	4-N-acetylglucosaminyl-beta-1,4-(fucosyl-alpha-1
	6-)N-acetylglucosaminyl-asparagine}  <26>
KM	#4# 0.33 {N-acetylglucosamine}  (#4# enzyme from liver <1>) <1>
KM	#4# 0.13
	{N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1
	6-(N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1,3-)mannosyl-beta-1
	4-N-acetylglucosaminyl-beta-1,4-(fucosyl-alpha-1
	6-)N-acetylglucosaminyl-asparagine}  <26>
KM	#4# 1.49 {N-acetylglucosamine}  <1>
KM	#4# 0.052 {UDPgalactose}  (#4# enzyme from serum <1>) <1>
KM	#4# 0.0108 {UDPgalactose}  <40>
KM	#4# 0.0118 {UDPgalactose}  (#4# enzyme from liver microsomal membrane
	<31>) <31>
KM	#4# 0.0295 {UDPgalactose}  <44>
KM	#4# 0.01205 {UDPgalactose}  (#4# enzyme from serum <31>) <31>
KM	#4# 6.28
	{galactosyl-beta-1,4-N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1
	6-(N-acetylglucosaminyl-beta-1,2-mannosyl-alpha-1,3-)mannosyl-beta-1
	4-N-acetylglucosaminyl-beta-1,4-(fucosyl-alpha-1
	6-)N-acetylglucosaminyl-asparagine}  <26>
KM	#5# 0.02 {IgG immunoglobulin heavy chain}  <41>
KM	#5# 0.022 {UDPgalactose}  <41>
KM	#5# 0.029 {fetuin}  <41>
KM	#5# 0.25 {glycopeptide prepared from porcine IgG immunoglobulin}  <41>
KM	#5# 0.08 {UDPgalactose}  <32>
KM	#5# 4 {N-acetylglucosamine}  <32>
KM	#5# 5.8 {N-acetylglucosamine}  <41>
KM	#5# 0.66 {p-nitrophenyl 2-acetamido-2-deoxy-beta-glucoside}  <41>
KM	#5# 0.054 {ovalbumin}  <41>
KM	#6# 0.5 {N-acetylglucosamine}  <1>
KM	#6# 0.009 {N-acetylglucosamine}  (#6# cosubstrate: UDP-glucose, without
	alpha-lactalbumin, mutant enzyme R228K <67>) <67>
KM	#6# 0.0025 {N-acetylglucosamine}  (#6# cosubstrate: UDP-glucose, in
	presence of alpha-lactalbumin, wild-type enzyme <67>) <67>
KM	#6# 0.0007 {N-acetylglucosamine}  (#6# cosubstrate: UDP-galactose, in
	presence of alpha-lactalbumin, mutant enzyme R228K <67>) <67>
KM	#6# 0.011 {N-acetylglucosamine}  (#6# cosubstrate: UDP-galactose,
	without alpha-lactalbumin, mutant enzyme R228K <67>; #6# cosubstrate:
	UDP-galactose, without alpha-lactalbumin, wild-type enzyme <67>) <67>
KM	#6# 1.5 {N-acetylglucosaminyl-beta-1,6-galactose}  (#6#
	N-acetylglucosaminyl-beta-1,3-(N-acetylglucosaminyl-beta-1,6-)galactose
	<28>) <28>
KM	#6# 0.055 {UDPgalactose}  <36>
KM	#6# 0.0013 {N-acetylglucosamine}  (#6# cosubstrate: UDP-glucose, in
	presence of alpha-lactalbumin, mutant enzyme R228K <67>) <67>
KM	#6# 2.8 {agalactokeratan}  <36>
KM	#6# 0.031 {UDP-glucose}  (#6# cosubstrate: N-acetylglucosamine, in
	presence of alpha-lactalbumin, wild-type enzyme <67>) <67>
KM	#6# 0.091 {UDP-glucose}  (#6# cosubstrate: N-acetylglucosamine, without
	alpha-lactalbumin, mutant enzyme R228K <67>) <67>
KM	#6# 40 {N-acetylglucosamine}  <36>
KM	#6# 0.074 {N-acetylglucosamine}  (#6# cosubstrate: UDP-glucose, without
	alpha-lactalbumin, wild-type enzyme <67>) <67>
KM	#6# 0.093 {UDP-galactose}  (#6# cosubstrate: N-acetylglucosamine,
	without alpha-lactalbumin, wild-type enzyme <67>) <67>
KM	#6# 3.4
	{N-acetylglucosaminyl-beta-1,3-(galactosyl-beta-1
	4-N-acetylglucosaminyl-beta-1,6-)galactose}  <28>
KM	#6# 0.044 {UDP-glucose}  (#6# cosubstrate: N-acetylglucosamine, in
	presence of alpha-lactalbumin, mutant enzyme R228K <67>) <67>
KM	#6# 0.087 {UDP-galactose}  (#6# cosubstrate: N-acetylglucosamine,
	without alpha-lactalbumin, mutant enzyme R228K <67>) <67>
KM	#6# 0.043 {UDPgalactose}  <1>
KM	#6# 8.2 {N-acetylglucosamine}  <28>
KM	#6# 0.0105 {UDP-galactose}  (#6# cosubstrate: N-acetylglucosamine, in
	presence of alpha-lactalbumin, mutant enzyme R228K <67>) <67>
KM	#6# 21 {D-glucose}  <36>
KM	#6# 0.148 {UDP-glucose}  (#6# cosubstrate: N-acetylglucosamine, without
	alpha-lactalbumin, wild-type enzyme <67>) <67>

PH_OPTIMUM
PHO	#10# 7.2 <90>
PHO	#2# 8.2 <5>
PHO	#2# 5 <51>
PHO	#3# 8 (#3# assay at <74>) <74>
PHO	#3# 7.5 (#3# reaction with N-acetylglucosamine and UDPgalactose,
	reaction with alpha1-acid glycoprotein and UDPgalactose <39>) <39>
PHO	#3,4# 6.5 (#3# assay at <79>) <21,31,40,79>
PHO	#3,4,5# 6.8 <41,43,45>
PHO	#3,6,18# 7 (#6,18# assay at <77,99>) <52,77,99>
PHO	#4# 6 (#4# in Tris-maleate buffer <44>) <44>
PHO	#5# 6.4-7.6 <32>
PHO	#6# 7.5-10.5 <36>
PHO	#6,13# 7.4 (#6,13# assay at <73,83>) <73,83>
PHO	#8,9# 6.5-7 <64>

PH_RANGE
PHR	#2# 5-9.3 (#2# pH 5.0: about 60% of maximal activity, pH 9.3: about 45%
	of maximal activity <5>) <5>
PHR	#4# 5.5-8 (#4# less than 50% of maximal activity above and below <40>)
	<40>

SPECIFIC_ACTIVITY
SA	#10# 160.0 (#10# purified recombinant enzyme <90>) <90>
SA	#3# 6.9 (#3# N-deglycosylated recombinant enzyme <63>) <63>
SA	#3# 0.535 <39>
SA	#3# 8.4 (#3# recombinant enzyme <63>) <63>
SA	#3# 4.7 <20>
SA	#4# 19.8 <22>
SA	#4# 0.029 <37>
SA	#4# 0.07 <24>
SA	#4# 0.291 <25>
SA	#5# 0.035 <41>
SA	#5,6,12,13# -999.0 (#6# determination of beta1,4-galactosyltransferase
	enzymatic activity by capillary electrophoresis and laser-induced
	fluorescence detection, high sensitivity of product detection <58>)
	<3,32,33,58,73,76>
SA	#6# 10.7 <36>

TEMPERATURE_OPTIMUM
TO	#3# 30 (#3# assay at <74>; #3# reaction with N-acetylglucosamine and
	UDPgalactose, reaction with alpha1-acid glycoprotein and UDPgalactose
	<39>) <39,74>
TO	#3# 42 <20>
TO	#3,5,13# 37 (#3,13# assay at <73,79>; #5# activity at 37°C is faster
	than at 31°C or at 27°C <32>) <32,43,73,79>
TO	#6# 30-37 (#6# assay at <83>) <83>

TEMPERATURE_RANGE
TR	#3# 25-45 (#3# less than 50% of maximal activity above and below <43>)
	<43>

ACTIVATING_COMPOUND
AC	#2,3,4,6# alpha-lactalbumin (#6# stimulates transfer of glucose from
	UDPglucose to N-acetylglucosamine <47>; #2,3,4,6# stimulates transfer
	of galactose from UDPgalactose to N-acetylgalactosamine
	<5,8,29,31,35,36,39,40,45,47,55,62,63>; #3# modulates the enzymes
	acceptor specificity, but does not interact with the sugar
	donor-binding site of beta4Gal-T1. Instead, interacting with the
	extended sugar-binding site of the closed conformer of beta4Gal-T1 in
	the enzyme-sugar nucleotide complex, lactalbumin stabilizes the
	complex, thereby facilitating the transfer of the sugar moiety from the
	less preferred sugar nucleotides to a monosaccharide, it kinetically
	enhances the transfer of the sugar residue from the less preferred
	sugar nucleotides to a monosaccharide, GlcNAc, lactalbumin binding site
	structure of beta4Gal-T family members, overview, modulation mechanism,
	overview <91>) <5,8,29,31,35,36,39,40,45,47,55,62,63,91>
AC	#3# Protamine sulfate (#3# activation <30>) <30>
AC	#3# poly(L-Lys) (#3# activation <30>) <30>
AC	#3# poly(L-Arg) (#3# activation <30>) <30>
AC	#3,4,13,16# more (#3# the activity of GalT V promoter can be induced by
	epidermal growth factor, dominant active Ras, ERK1, JNK1, and
	constitutively active AKT <78>; #13# the enzyme regulation/stimulation
	is a complex system involving the hormones insulin, prolactine,
	hydrocortisone, triiodothyronine, and 17beta-estradiol, and also the
	extracellular matrix and the sucking stimulus <73>; #4# intraperitoneal
	administration of lipopolysaccharide, a potent inducer of systemic
	inflammation, strongly induces beta-1,4-GalT-I mRNA expression in the
	lung, heart, liver, spleen, kidney, lymph node, hippocampus, and
	testis, as well as in the cerebral cortex. In the rat lung, liver and
	testis, LPS stimulation of beta-1,4-GalT-I mRNA expression is
	time-dependent and biphasic <94>; #4,16# lipopolysaccharide stimulation
	of astrocytes induces the enzyme expression, overview <96>; #3# the
	specific inhibitors of the phosphatidylinositol 3-kinase LY294002 and
	wortmannin up-regulate beta1,4-galactosyltransferase I through
	enhancing Sp1 protein expression, and thus sensitize SMMC-7721 human
	hepatocarcinoma cells to cycloheximide-induced apoptosis, overview
	<97>) <73,78,94,96,97>
AC	#4# dipalmitoylphosphatidylcholine (#4# activation <25>) <25>
AC	#4# dioleoylphosphatidylcholine (#4# activation <25>) <25>
AC	#4# Distearoylphosphatidylcholine (#4# activation <25>) <25>
AC	#4,6# phosphatidylcholine (#4,6# activation <23,25>) <23,25>
AC	#4,6# dimyristoylphosphatidylcholine (#4,6# activation <23,25>) <23,25>
AC	#6# phosphatidylethanolamine (#6# activation <23>) <23>
AC	#6# phosphatidylglycerol (#6# activation <23>) <23>
AC	#6# lysophosphatidylcholine (#6# activation <23>) <23>
AC	#6# histone (#6# activation <23>) <23>
AC	#6# Methylphosphatidylic acid (#6# activation <23>) <23>
AC	#8,9# Triton X-100 (#8,9# 0.1-5%, 1.5fold stimulation <64>) <64>

INHIBITORS
IN	#14# ammonium (#14# enzyme activity is decreased in ammonium treated
	cell culture <84>) <84>
IN	#15# Glc-NAcbeta1-3Galbeta-O-naphthalenemethanol <102>
IN	#15# 2-naphthylmethyl
	2-acetamido-4,6-di-O-acetyl-2
	3-dideoxy-3-methoxy-beta-D-glucopyranosyl-(1,3)-2,4
	6-tri-O-acetyl-beta-D-galactopyranoside <102>
IN	#15# 2-naphthylmethyl
	2-acetamido-4,6-di-O-acetyl-2
	3-dideoxy-3-fluoro-beta-D-glucopyranosyl-(1,3)-2,4
	6-tri-O-acetyl-beta-D-galactopyranoside <102>
IN	#15# 2-naphthylmethyl
	2-acetamido-4,6-di-O-acetyl-2,3-dideoxy-beta-D-glucopyranosyl-(1,3)-2,4
	6-tri-O-acetyl-beta-Dgalactopyranoside <102>
IN	#15# 2-naphthylmethyl
	2-acetamido-3,6-di-O-acetyl-2
	4-dideoxy-4-methoxy-beta-D-glucopyranosyl-(1,3)-2,4
	6-tri-O-acetyl-beta-D-galactopyranoside <102>
IN	#15# 2-naphthylmethyl
	2-acetamido-3,6-di-O-acetyl-4-amino-2
	4-dideoxy-beta-D-glucopyranosyl-(1,3)-2,4
	6-tri-O-acetyl-beta-Dgalactopyranoside <102>
IN	#15# 2-naphthylmethyl
	2-acetamido-3,6-di-O-acetyl-4-azido-2
	4-dideoxy-beta-D-glucopyranosyl-(1,3)-2,4
	6-tri-O-acetyl-beta-Dgalactopyranoside <102>
IN	#15# 2-naphthylmethyl
	2-acetamido-3,6-di-O-acetyl-2
	4-dideoxy-4-fluoro-beta-D-glucopyranosyl-(1,3)-2,4
	6-tri-O-acetyl-beta-D-galactopyranoside <102>
IN	#15# 2-naphthylmethyl
	2-acetamido-3,6-di-O-acetyl-2,4-dideoxy-beta-D-glucopyranosyl-(1,3)-2,4
	6-tri-O-acetyl-beta-D-galactopyranoside <102>
IN	#19# 4-methylumbelliferyl 4-deoxy-4-fluoro-beta-D-xylopyranoside <121>
IN	#19# 4-methylumbelliferyl 4-deoxy-beta-D-xylopyranoside <121>
IN	#2,3,4,6# alpha-lactalbumin (#2# partially inhibits reaction with
	UDPgalactose and asialo-agalacto-transferrin <8>; #3,4,6# inhibits
	reaction with UDPgalactose and N-acetylglucosamine <1,36,57>; #2#
	inhibits N-acetyllactosamine synthesis in plasma membrane fraction
	<35>; #6# inhibits the reaction of EC 2.4.1.38 with the complex
	glucoside colchicoside <83>; #3# cellular adhesion ability of dendritic
	cells is inhibited by alpha-lactalbumin via interference with cell
	surface GalTI <107>) <1,8,31,35,36,57,83,107>
IN	#2,4,5# EDTA <8,31,32,40,45>
IN	#3# UTP <98>
IN	#3# p-hydroxymercuribenzoate <46>
IN	#3# TDP <98>
IN	#3# poly(L-Glu) <30>
IN	#3# uridine
	5'-(6-amino-(2-[(7-methyl-2
	naphthyl)methoxycarbonylmethoxy]ethoxy)acetyl-6-deoxy-alpha-D
	galactopyranosyl) diphosphate <79>
IN	#3# 5-(indol-4-yl)-uridine <118>
IN	#3# 5-[5-({[1-(1H-indol-3-yl)ethyl]amino}methyl)thiophene-2-yl]uridine
	<118>
IN	#3#
	5'-alpha-D-galactopryanosyl-diphospho-5-[5-({[1-(1H-indol-3
	yl)ethyl]amino}methyl)thiophene-2-yl]uridine <118>
IN	#3# 5'-alpha-D-galactopryanosyl-diphospho-5-(1H-indol-4-yl)-uridine
	<118>
IN	#3# 5-(5-formylthien-2-yl)-UDP-alpha-D-galactose <118>
IN	#3# 5-(5-formylthien-2-yl)-uridine <118>
IN	#3# alpha1-Acid glycoprotein (#3# above 1.4 mM with respect to acceptor
	sites <39>) <39>
IN	#3# uridine
	5'-(6-O-[10-(2-naphthyl)-3,6
	9-trioxadecanyl]-alpha-D-galactopyranosyl)diphosphate (#3# competitive
	versus UDP-Gal, blocks acceptor substrate binding by the enzyme in
	presence of Mn2+ <79>) <79>
IN	#3# uridine
	5'-(6-amino-(2-[(7-bromomethyl-2
	naphthyl)methoxycarbonylmethoxy]ethoxy)acetyl-6-deoxy-alpha-D
	galactopyranosyl) diphosphate (#3# irreversible, modifies residue
	Trp310 <79>) <79>
IN	#3,4,6,14,16# more (#6# the enzyme is totally inactivated by iodination
	with lactoperoxidase, EC 1.11.1.7. Substrates protect against
	inactivation <42>; #3# development and synthesis of mechanism-based
	inhibitors, structure analysis, overview <79>; #14# in vivo
	galactosylation and sialylation inhibition is mainly due to decreased
	gene expression of galactosyltransferase, sialyltransferase, and
	CMP-sialic acid transporter and not due to sialidase <84>; #6#
	inhibitor synthesis and potency, mechanism of inhibition, overview
	<77>; #3# As2O3 significantly decreases beta 1,4GalT V expression level
	in in glioma cells, which increases the glioma cell apoptosis induced
	by As2O3, overviewoverview <89>; #4# bis(oxalate)oxovanadium(IV),
	bis(maltolato)oxovanadium(IV), bis(kojato)oxovanadium(IV) and
	bis(2,2-bipyridine)oxovanadium(IV) act as anti-diabetic drugs affecting
	the Golgi complex morphology and the enzyme activity, overview <92>;
	#3# structural features for rational design of specific inhibitors,
	overview <91>; #3# the constitutively active Akt protein, myr-Akt,
	inhibits CHX-induced apoptosis in SMMC-7721 cells through
	downregulating beta1,4GT1 <97>; #16# TNF-alpha and its receptors affect
	the expression of beta-1,4 galactosyltransferase I mRNA by rat primary
	astrocytes, downregulation of beta-1,4-GalT I mRNA expression by
	TNF-alpha stimulation, overview <96>; #4# TNF-alpha and its receptors
	affect the expression of beta-1,4 galactosyltransferase V mRNA by rat
	primary astrocytes, overview <96>; #3# not inhibited by CDP,
	UDP-mannose, and UDP-N-acetyl-beta-D-glucosamine <98>)
	<42,77,79,84,89,91,92,96,97,98>
IN	#3,5# N-acetylglucosamine (#3# above 10 mM <39>; #5# competitively
	inhibits the transfer of galactose to glycoprotein substrates <41>)
	<39,41>
IN	#3,5,6# UDP (#6# treatment with periodate-cleaved UDP and NaCNBH3
	results in a loss of 80% of enzyme activity, which is largely prevented
	by UDP-galactose <16>; #5# competitively inhibits the transfer of
	galactose to glycoprotein substrates <41>) <16,41,98>
IN	#4# phosphatidylethanolamine <25>
IN	#4# phosphatidylglycerol <25>
IN	#4,6# phosphatidic acid <23,25>
IN	#4,8,9# Zn2+ (#8,9# complete inhibition in presence of Mn2+ <64>)
	<24,64>
IN	#5# UMP (#5# competitively inhibits the transfer of galactose to
	glycoprotein substrates <41>) <41>
IN	#5# p-nitrophenyl 2-acetamido-2-deoxy-beta-glucoside (#5# competitively
	inhibits the transfer of galactose to glycoprotein substrates <41>) <41>
IN	#6# phosphatidylserine <23>
IN	#6# N-Acetylimidazole (#6# activity is partially restored by treatment
	with hydroxylamine <42>) <42>
IN	#6# 6-thio-N-butyryl-GlcNbeta-(2-naphthyl) (#6# 19% inhibition at 1.0
	mM <77>) <77>
IN	#6# 1,6-dithio-N-butyryl-GlcNbeta-(2-naphthyl) (#6# 45% inhibition at
	1.0 mM <77>) <77>
IN	#6# N-butyryl-GlcNbeta-(2-naphthyl) (#6# 87% inhibition at 1.0 mM <77>)
	<77>
IN	#6# 1-thioGlcNAcbeta-(2-naphthyl) (#6# 91% inhibition at 1.0 mM <77>)
	<77>
IN	#6# GlcNAcbeta-(2-naphthyl) (#6# 92% inhibition at 1.0 mM <77>) <77>
IN	#6# 1-thio-N-butyryl-GlcNbeta-(2-naphthyl) (#6# uncompetitive, complete
	inhibition at 1.0 mM, 85% inhibition at 0.2 mM <77>) <77>
IN	#8,9# Cu2+ (#8,9# complete inhibition in presence of Mn2+ <64>) <64>

KI_VALUE
KI	#19# 0.06 {4-methylumbelliferyl 4-deoxy-4-fluoro-beta-D-xylopyranoside}
	 (#19# recombinant wild type enzyme, at pH 7.0 and 37°C <121>) <121>
KI	#19# 1.28 {4-methylumbelliferyl 4-deoxy-beta-D-xylopyranoside}  (#19#
	recombinant wild type enzyme, at pH 7.0 and 37°C <121>) <121>
KI	#3# 1.65 {UTP}  (#3# purified maltose-binding protein-beta1,4-GalT7, in
	100 mM cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C
	<98>) <98>
KI	#3# 0.61 {UDP}  (#3# purified maltose-binding protein-beta1,4-GalT7, in
	100 mM cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C
	<98>) <98>
KI	#3# 1.93 {TDP}  (#3# purified maltose-binding protein-beta1,4-GalT7, in
	100 mM cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C
	<98>) <98>
KI	#3# 0.0223 {uridine
	5'-(6-amino-(2-[(7-methyl-2
	naphthyl)methoxycarbonylmethoxy]ethoxy)acetyl-6-deoxy-alpha-D
	galactopyranosyl) diphosphate}  <79>
KI	#3# 0.00186 {uridine
	5'-(6-O-[10-(2-naphthyl)-3,6
	9-trioxadecanyl]-alpha-D-galactopyranosyl)diphosphate}  <79>
KI	#6# -999 {more}  (#6# inhibition kinetics <77>) <77>
KI	#6# 0.01 {1-thio-N-butyryl-GlcNbeta-(2-naphthyl)}  (#6# pH 7.0 <77>)
	<77>

METALS_IONS
ME	#2,3,4,5,6,7,8,9,10,13,19# Mn2+ (#2,3,4,5,6,7,8,9,19# required
	<4,5,8,24,30,31,32,33,34,36,39,40,43,44,45,55,64,82,91,120>; #2#
	optimal concentration is 10 mM <8>; #10# activates <90>; #3# Km: 0.4 mM
	<39>; #6# maximal activity at 4 mM <36>; #3# Km: 0.03 mM <30>; #6#
	required for activity <103>; #6# the catalytic domain of the enzyme has
	two metal binding sites, each with a distinct affinity. Site I binds
	Mn2+ with high affinity and does not bind Ca2+. Site II binds a variety
	of metal ions, including Ca2+. In the primary metal binding site the
	Mn2+ ion is coordinated to five ligands, two supplied by the phosphates
	of the sugar nucleotide and the other three by D254, H347 and M344
	<65>; #5# optimal concentration is 5-10 mM MnCl2 <32>; #6# Km for
	MnCl2: 0.34 mM <36>; #6# binding of two Mn(II) per mol of enzyme in the
	ternary enzyme-manganese-UDPgalactose complex. The affinity of the
	enzyme for manganese is much higher in the presence of UDPgalactose
	than in its absence <34>; #4# maximal activity at 3-5 mM <1>; #3# 20
	mM, stimulates <52>; #8,9# no activation in presence of Fe2+, Zn2+ and
	Cu2+ <64>; #4# 0.0025 mM required for half-maximal activity <24>; #4#
	optimal concentration 3-5 mM <1>; #3,4# optimal concentration: 12.5 mM
	<43,45>; #6# required, binds first in the catalytic cycle <81>; #3#
	required, binds first in the catalytic cycle, Met340 is involved <81>;
	#3# the catalytic domain has two flexible loops, a long and a small
	one, with the primary metal binding site being located at the
	N-terminal hinge region of the long flexible loop <91>)
	<1,4,5,8,13,24,30,31,32,33,34,36,39,40,43,44,45,52,55,64,65,73,74,77,79
	81,82,83,90,91,103,120>
ME	#2,6,8,9# Ca2+ (#2# can partially replace Mn2+ <5>; #8,9# about 50% of
	the activity with Mn2+ <64>) <5,64,81>
ME	#2,8,9# Mg2+ (#2# can partially replace Mn2+ <5>; #8,9# about 50% of
	the activity with Mn2+ <64>) <5,64>
ME	#6# Zn2+ (#6# activation at 9.2% of the activity with Mn2+ <36>) <36>
ME	#6# Co2+ (#6# activation at 14.9% of the activity with Mn2+ <36>) <36>
ME	#8,9# Fe2+ (#8# no activation <64>; #9# partial activation <64>) <64>

MOLECULAR_WEIGHT
MW	#17# 29000 (#17# SDS-PAGE <93>) <93>
MW	#2# -999 (#2# two related forms of enzyme of 399 and 386 amino acids
	are synthesized as a consequence of alternative translation initiation.
	The long enzyme form has a NH2-terminal extension of 13 amino acids
	<10>) <10>
MW	#2# 44420 (#2# long form with NH2-terminal extension of 13 amino acids,
	calculation from gene sequence <10>) <10>
MW	#2# 42960 (#2# calculation from gene sequence, short form,
	transmembrane enzyme <10>) <10>
MW	#3# 38000 (#3# x * 38000, SDS-PAGE <49>) <49>
MW	#3# 55000 (#3# 2 * 55000, SDS-PAGE <63>) <63>
MW	#3# 47000 (#3# x * 47000, deglycosylated enzyme form, SDS-PAGE <20>)
	<20>
MW	#3# 48000 (#3# x * 48000, glycosylated enzyme form <20>) <20>
MW	#3# 106000 (#3# calculation from light-scattering experiments <63>) <63>
MW	#3# 85000-90000 (#3# gel filtration <39>) <39>
MW	#3,5# 70000 (#5# gel filtration <32>; #3# purified maltose-binding
	protein-beta-1,4-GalT7 protein, SDS/PAGE <98>; #3# x * 70000, SDS-PAGE
	<117>) <32,98,117>
MW	#4# 43000 (#4# x * 43000, SDS-PAGE <45>) <45>
MW	#4# 53000 (#4# x * 53000, SDS-PAGE <21>) <21>
MW	#4# 440000 (#4# gel filtration <22>) <22>
MW	#5# 57000 (#5# sucrose density gradient centrifugation <41>) <41>
MW	#5# 74000 (#5# 1 * 74000, SDS-PAGE <32>) <32>
MW	#6# 54000 (#6# x * 54000, enzyme from milk, SDS-PAGE <33>) <33>
MW	#6# 59000 (#6# gel filtration <3>) <3>
MW	#6# 51000 (#6# x * 51000, SDS-PAGE <3>) <3>
MW	#6# 42200 (#6# x * 42200, SDS-PAGE <36>) <36>
MW	#6# 44880 (#6# unglycosylated enzyme, calculation from gene sequence
	<17>) <17>

POSTTRANSLATIONAL_MODIFICATION
PM	#3,4,6,16# glycoprotein (#3# structure of mucin-type sugar depends on
	blood group <15>) <15,20,27,63,96>

SUBUNITS
SU	#3# dimer (#3# 2 * 55000, SDS-PAGE <63>) <63>
SU	#3,4,6# ? (#4# x * 53000, SDS-PAGE <21>; #3# x * 38000, SDS-PAGE <49>;
	#3# x * 70000, SDS-PAGE <117>; #4# x * 43000, SDS-PAGE <45>; #6# x *
	51000, SDS-PAGE <3>; #6# x * 42200, SDS-PAGE <36>; #6# x * 54000,
	enzyme from milk, SDS-PAGE <33>; #3# x * 70000-80000, SDS-PAGE <39>;
	#4# x * 65000-70000, SDS-PAGE <40>; #4# x * 70000-75000, SDS-PAGE <24>;
	#3# x * 47000, deglycosylated enzyme form, SDS-PAGE <20>; #3# x *
	48000, glycosylated enzyme form <20>; #4# x * 50000-51000, SDS-PAGE
	<22>) <3,20,21,22,24,33,36,39,40,45,49,117>
SU	#3,6# More (#3# structure analysis, in vivo and invitro folding
	analysis, open and closed conformation change of the enzyme upon Mn2+
	and substrate binding, overview <81>; #6# structure analysis, open and
	closed conformation change of the enzyme upon Mn2+ and substrate
	binding, overview <81>; #3# beta4Gal-T1 is a trans-Golgi
	glycosyltransferase, Glyco-T, with a type II membrane protein topology,
	a short N-terminal cytoplasmic domain, a membrane-spanning region, as
	well as a stem and a C-terminal catalytic domain facing the
	trans-Golgi-lumen. The two proteins beta4Gal-T1 and alpha-lactalbukin
	crystallize together as a complex only in the presence of either donor
	substrate or acceptor Glc or GlcNAc to form lactose synthase <91>)
	<81,91>
SU	#5# monomer (#5# 1 * 74000, SDS-PAGE <32>; #5# 1 * 57000, SDS-PAGE
	<41>) <32,41>

APPLICATION
AP	#3# medicine (#3# GalT V might represent a target in glioma therapy
	<78>) <78>
AP	#3# pharmacology (#3# beta 1,4GalT V inhibitors enhance the therapeutic
	effect of As2O3 for malignant glioma <89>) <89>
AP	#3,6# drug development (#6# the enzyme is a target enzyme for drug
	design <77>; #3# the enzyme is a target for rational design of specific
	inhibitors <91>) <77,91>
AP	#3,6,9,10# synthesis (#3# use of transformed whole yeast cells,
	expressing the human N-acetylglucosamine
	beta-1,4-galactosyltransferase, in synthesis of N-acetyllactosamine
	<56>; #6# preparation of a series of specific derivatives of the
	complex protopanaxadiol glycoside ginsenoside Rb1 <50>; #9# the enzyme
	is useful as catalyst for quantitative synthesis of
	Gal-beta-1,4-Man-pNP, overview <90>; #10# the enzyme is useful as
	catalyst for quantitative synthesis of the thiodisaccharide
	Gal-betaS-1,4-GlcNAcpNP as well as Gal-beta-1,4-Man-pNP, overview <90>)
	<50,56,90>

ENGINEERING
EN	#1# I289Y (#1# mutation of the Drosophila beta4GalNAc-T1 converts the
	enzyme to a beta-1,4-galactosyltransferase-1, beta4Gal-T1, by reducing
	its beta4GalNAc-T1 activity by nearly 1000fold while enhancing its
	beta4Gal-T1 activity by 80fold <91>) <91>
EN	#15# M340H (#15# site-directed mutagenesis, substrate binding structure
	in comparison to the wild-type enzyme, overview <80>) <80>
EN	#19# Y196F (#19# the mutant shows reduced activity compared to the wild
	type enzyme <121>) <121>
EN	#19# R270K (#19# the mutant shows reduced activity compared to the wild
	type enzyme <121>) <121>
EN	#19# H195Q (#19# the mutant shows reduced activity compared to the wild
	type enzyme <121>) <121>
EN	#19# Y194F (#19# inactive <121>) <121>
EN	#19# R270A (#19# the mutant shows reduced activity compared to the wild
	type enzyme <121>) <121>
EN	#19# Y199A (#19# inactive <121>) <121>
EN	#19# R226A (#19# the mutant shows reduced activity compared to the wild
	type enzyme <121>) <121>
EN	#19# Y194A (#19# inactive <121>) <121>
EN	#19# Y196A (#19# inactive <121>) <121>
EN	#19# H195A (#19# the mutant shows reduced activity compared to the wild
	type enzyme <121>) <121>
EN	#19# Y199F (#19# the mutant shows reduced activity compared to the wild
	type enzyme <121>) <121>
EN	#19# R226K (#19# the mutant shows reduced activity compared to the wild
	type enzyme <121>) <121>
EN	#19# H195R (#19# the mutant shows reduced activity compared to the wild
	type enzyme <121>) <121>
EN	#3# W312C/P401C (#3# site-directed mutagenesis, the mutations
	facilitate invitro folding of the recombinantly expressed enzyme <81>)
	<81>
EN	#3# W312C/P401C/M340H (#3# site-directed mutagenesis, substrate binding
	structure in comparison to the wild-type enzyme, overview <81>) <81>
EN	#3# Y285I (#3# site-directed mutagenesis, the mutation converts the
	betaGALT1 enzyme into an equally efficient beta4GalNAc-T1, EC 2.4.1.90
	<82>) <82>
EN	#3# Y285L (#3# site-directed mutagenesis, the mutation converts the
	betaGALT1enzyme into an equally efficient beta4GalNAc-T1, EC 2.4.1.90
	<82>) <82>
EN	#3# Y268G (#3# site-directed mutagenesis, the mutant enzyme is less
	active compared to the wild-type enzyme <78>) <78>
EN	#3# Y294G (#3# site-directed mutagenesis, the mutant enzyme is less
	active compared to the wild-type enzyme <78>) <78>
EN	#3# Y268G/Y294G (#3# site-directed mutagenesis, the mutant enzyme is
	less active compared to the wild-type enzyme <78>) <78>
EN	#3# Y289L/C342T (#3# site-directed mutagenesis, the mutant is able to
	transfer GalNAc from the sugar donor UDP-GalNAc to the acceptor,
	GlcNAc, with efficiency as good as that of galactose from UDP-Gal, in
	contrast to the wild-type enzyme, mutant substrate specificity with
	different donor substrate and oligosaccharides as acceptor substrates,
	mass spectrometry product analysis, overview, the C342T mutation does
	not alter enzyme activity, but increases the enzyme stability at room
	temperature <74>) <74>
EN	#3# R228LK (#3# the mutation enhances glucosyltransferase activity
	<91>) <91>
EN	#3,6# Y289L (#6# mutation enhances GalNAc-transferase activity. Km for
	GlcNAc is incereased compared to the wild type <55>; #3# mutation of
	the beta4GalNAc-T1 converts the enzyme to a
	beta-1,4-galactosyltransferase-1, beta4Gal-T1. Substituting Tyr289 for
	Leu removes this restriction and the Tyr289Leu mutant can now transfer
	GalNAc or other Gal C2-analogues from their respective UDPderivatives,
	not normally substrates of the enzyme, to the acceptor GlcNAc with the
	same efficiency with which the wild-type enzyme transfers Gal from
	UDP-Gal, phenotype, overview <91>; #3# the mutation makes the enzyme
	equally as efficient as Gal- or GalNAc-transferase <91>) <55,91>
EN	#3,6# Y289I (#6# mutation enhances GalNAc-transferase activity. Km for
	GlcNAc is increased compared to the wild type <55>; #3# the mutation
	makes the enzyme equally as efficient as Gal- or GalNAc-transferase
	<91>) <55,91>
EN	#3,6# Y289N (#6# mutation enhances GalNAc-transferase activity. Km for
	GlcNAc is increased compared to the wild type <55>; #3# the mutation
	makes the enzyme equally as efficient as Gal- or GalNAc-transferase
	<91>) <55,91>
EN	#3,6# R228K (#6# mutant enzyme shows 16% of the wild-type
	galactosyltransferase activity, mutation results in a 15fold higher
	glucosyltransferase activity, which is further enhanced by
	alpha-lactalbumin to nearly 25% of the galactosyltransferase activity
	of the wild type. The main effect of the mutation is on the kcat of
	glucosyltransferase, which increases 3-4fold, both in the absence and
	in the presence of alpha-lactalbumin simultaneously, the kcat for the
	galactosyltransferase reaction is reduced 30fold <67>; #3# the mutation
	enhances the glucosyltransferase activity of beta4GalNAc-T1, which is
	low for the wild-type enzyme, by steric alterations, overview <91>)
	<67,91>
EN	#3,6# M344H (#6# site-directed mutagenesis, substrate binding structure
	in comparison to the wild-type enzyme, overview <81>; #3# in the
	presence of Mg2+ the mutant exhibits 25% of the catalytic activity
	compared to the wild type enzyme in the presence of Mn2+. Although the
	mutant has higher Km in the presence of Mg2+ for the substrates
	compared to the wild type enzyme in the presence of Mn2+, the catalytic
	efficiency with respect to donor and acceptor has decreased by an order
	of about 13 and 6, respectively. The turnover number of the mutant is
	only reduced to 60% <91>) <81,91>
EN	#3,6,12# more (#6# N-terminal truncated forms of the enzyme between
	residues 1-129, do not show any significant difference in the apparent
	Km-values towards N-acetylglucosamine or linear oligosaccharide
	acceptors, e.g. for chitobiose and chitotriose, or for the nucleotide
	donor UDPgalactose. The binding behaviour of N-terminal and C-terminal
	fragments of the enzyme towards the N-acetylglucosamine-agarose and
	UDP-agarose columns differ, the former binds preferentially to the
	N-acetylglucosamine-columns, while the latter binds to UDP-agarose
	columns via Mn2+ <61>; #6# mutations of Asp318 and Asp319 abolish
	enzyme activity <65>; #3# autophosporylation of epidermal growth factor
	receptor, EGFR, and phosphorylation of protein kinase B, PKB/Akt, and
	extracellular signalregulated protein kinase1/2,ERK1/2, which are
	downstream molecules of EGFR, are reduced in cell surface
	beta1,4GT1-overexpressing SMMC-7721 cells, phenotype, overview,
	knockdown of beta1,4GT1 by siRNA increases the autophosphorylation of
	EGFR at Tyr1068 <85>; #6# covalent immobilization of the enzyme in the
	absence of alpha-lactalbumin for use as biocatalyst, method evaluation,
	overview <83>; #12# knockdown of zebrafish beta-4GalT1 by two
	independent morpholino oligonucleotides results in embryos with a
	truncated anterior-posterior axis, as well as elongated somites and
	moderate defects in the patterning of the head mesenchyme, phenotype
	with the axial mesoderm of epiboly stage embryos being abnormally
	widened in beta-4GalT1 morphants, indicative of abnormal convergent
	extension, laminin isolated from beta-4GalT1 morphant embryos is poorly
	galactosylated, activity is restored by injection of wild-type enzyme
	mRNA, overview <76>; #3# RNAi-mediated knockdown of beta1,4-GT 1
	inhibits CDK11(p58)-mediated apoptosis induced by cycloheximide, while
	ectopically expressed beta1,4-GT 1 increases CDK11p58-mediated
	apoptosis, enzyme knockout also inhibits the release of cytochrome c
	from mitochondria and caspase-3 processing, mechanism of beta1,4-GT 1
	in CHX-induced apoptosis of CDK11p58-overexpressing cells, overview
	<72>; #3# beta 1,4GalT V antisense constructs interfere with beta
	1,4GalT V leading to promotion of As2O3-induced glioma cell apoptosis,
	while overexpression of beta 1,4GalT V inhibits it, overview <89>; #3#
	introduction of human betaGalT into suspension cultured tobacco cells
	results in the production of recombinant proteins with
	galactose-extended glycans and decreased contents of beta(1,2)-xylose
	and alpha(1,3)-fucose <87>; #3# expression vectors bearing the luminal
	domains of beta4GalT-II and glucuronyltransferase show in GST-pulldown
	assays that the Golgi luminal domains are sufficient for the complex to
	form <114>) <61,65,72,76,83,85,87,89,114>
EN	#6# E317Q (#6# when partially activated by Mn2+ binding to the primary
	site, can be further activated by Co2+ or inhibited by Ca2+, an effect
	that is the opposite of what is observed with the wild-type enzyme
	<65>) <65>
EN	#6# C134S (#6# complete loss of activity <61>) <61>
EN	#6# C342S (#6# 33fold increase in the apparent Km-value for
	UDPgalactose <61>) <61>
EN	#6# D254E (#6# 0.01% of the activity of the wild-type enzyme <65>) <65>
EN	#6# D254N (#6# 0.01% of the activity of the wild-type enzyme <65>) <65>
EN	#6# M344A (#6# in presence of Mn2+ retains 54.5% of wild-type enzyme
	activity, in presence of Co2+ retains 6.15% of wild-type enzyme
	activity <65>) <65>
EN	#6# M344Q (#6# in presence of Mn2+ retains 15.37% of wild-type enzyme
	activity, in presence of Co2+ retains 31.08% of wild-type enzyme
	activity <65>) <65>
EN	#6# H347E (#6# in presence of Mn2+ retains 0.1% of wild-type enzyme
	activity, in presence of Co2+ retains 0.4% of wild-type enzyme activity
	<65>) <65>
EN	#6# H347D (#6# in presence of Mn2+ retains 0.02% of wild-type enzyme
	activity, in presence of Co2+ retains 0.085% of wild-type enzyme
	activity <65>) <65>
EN	#6# H347Q (#6# in presence of Mn2+ retains 0.28% of wild-type enzyme
	activity, in presence of Co2+ retains 1.21% of wild-type enzyme
	activity <65>) <65>
EN	#6# H347N (#6# in presence of Mn2+ retains 0.07% of wild-type enzyme
	activity, in presence of Co2+ retains 0.36% of wild-type enzyme
	activity <65>) <65>
EN	#6# E317A (#6# when partially activated by Mn2+ binding to the primary
	site, can be further activated by Co2+ or inhibited by Ca2+, an effect
	that is the opposite of what is observed with the wild-type enzyme
	<65>) <65>
EN	#6# E317D (#6# when partially activated by Mn2+ binding to the primary
	site, can be further activated by Co2+ or inhibited by Ca2+, an effect
	that is the opposite of what is observed with the wild-type enzyme
	<65>) <65>
EN	#6# D320A (#6# when partially activated by Mn2+ binding to the primary
	site, can be further activated by Co2+ or inhibited by Ca2+, an effect
	that is the opposite of what is observed with the wild-type enzyme
	<65>) <65>
EN	#6# D320E (#6# when partially activated by Mn2+ binding to the primary
	site, can be further activated by Co2+ or inhibited by Ca2+, an effect
	that is the opposite of what is observed with the wild-type enzyme
	<65>) <65>
EN	#6# D320N (#6# when partially activated by Mn2+ binding to the primary
	site, can be further activated by Co2+ or inhibited by Ca2+, an effect
	that is the opposite of what is observed with the wild-type enzyme
	<65>) <65>

CLONED
CL	#2# (expression in Cos-1 cells) <8>
CL	#2# (cloning and sequencing of the full-length cDNA) <9>
CL	#2# (HeLa cells expressing the murine enzyme on their surface spread
	more rapidly on laminin substrates than do control cells) <48>
CL	#2# (histidine-tagged 46000 Da protein produced in Escherichia coli)
	<51>
CL	#2# (isolation and characterization of the genomic locus) <18>
CL	#3# (expression in Escherichia coli) <49>
CL	#3# (comparison of sequences of enzyme from placenta and HeLa cells)
	<14>
CL	#3# (recombinant enzyme is N-glycosylated) <20>
CL	#3# (enzyme fused to protein A is expressed as a soluble form in COS-7
	cells) <52>
CL	#3# (enzymatically active soluble N-deglycosylated enzyme form) <63>
CL	#3# (molecular cloning and nucleotide sequencing) <19>
CL	#3# (expression of mutant cDNA from a patient with the congenital
	disorder of glycosylation type IId leads to the synthesis of a
	truncated, inactive polypeptide, which is localized to the endoplasmic
	reticulum) <54>
CL	#3# (cloning of the 5'-region flanking the transcription start point of
	the GalT I gene) <69>
CL	#3# (stem region fused to the catalytic domain, expression in
	Escherichia coli) <71>
CL	#3# (expression in Drosophila melanogaster S2 cells) <88>
CL	#3# (DNA and amino acid sequence determination and analysis, expresion
	analysis, stable overexpression of HA-tagged GalT V in astrocytes
	C8-D30 and glioma cell lines U87 and U251, expression of mutant
	enzymes) <78>
CL	#3# (ectopic expression in SMMC-7721 hepatocarcinoma cells
	overexpressing the CDK11(p58) kinase) <72>
CL	#3# (expressed in Escherichia coli DH5alpha cells) <117>
CL	#3# (expressed in NIH-3T3 cells) <91>
CL	#3# (expression as GFP-tagged enzyme in HeLa cells) <86>
CL	#3# (expression of mutants W312C/P401C and W312C/P401C/M340H enzymes in
	Escherichia coli, the wild-type enzyme forms inclusion bodies after
	expression in Escherichia coli, overview) <81>
CL	#3# (overexpression in human hepatocarcinoma SMMC-7721 cells) <85>
CL	#3# (functional expression in suspension cultured tobacco BY2 GT6 cells
	via Agrobacterium tumefaciens strain LBA4404) <87>
CL	#3# (expressed in HeLa cells and as a fusion protein with
	maltose-binding protein in Escherichia coli BL21(DE3) cells) <98>
CL	#6# (expression in Escherichia coli) <65>
CL	#6# (expression of wild-type and mutant enzymes in Escherichia coli)
	<61>
CL	#6# (expression of short and long enzyme form in CHO-cells) <27>
CL	#6# (isolation of a cDNA clone that encodes a major portion of
	galactosyltransferase) <11>
CL	#6# (cloning and sequencing of cDNA) <13>
CL	#6# (expression in Sf9 cells. Sfbeta4GalT cell, unlike the parental Sf9
	cells, can terminally beta1,4-galactosylate gp64 during baculovirus
	infection) <53>
CL	#6# (stem region fused to the catalytic domain, expression in
	Escherichia coli) <71>
CL	#8# (expression under the control of the T7 promoter in Escherichia
	coli BL21) <64>
CL	#9# (expression under the control of the T7 promoter in Escherichia
	coli BL21) <64>
CL	#10# (expression of full-length HP0826 in Escherichia coli) <90>
CL	#12# (DNA and amino acid sequence determination and anaylsis, sequence
	comparisons) <76>
CL	#15# (expressed in Nicotiana tabacum) <123>
CL	#15# (expression of wild-type and mutant M340H enzymes in Escherichia
	coli) <80>
CL	#19# (expressed in Escherichia coli BL21(DE3) cells) <121>
CL	#20# (expressed in Sf9 insect cells) <122>
CL	#22# (expressed in Nicotiana tabacum) <123>
CL	#23# (expressed in Nicotiana tabacum) <123>

CRYSTALLIZATION
CR	#3# <91>
CR	#3# (purified recombinant M340H-Gal-T1 mutant in the open conformation
	as apo-enzyme, and its Mn2+ and Mn2+-UDP-Gal-bound complexes,
	hanging-drop vapor diffusion method using a protein solution at 10
	mg/ml concentration with a precipitant containing sodium citratebuffer,
	pH 5.5, and 10% w/v PEG-4000, the crystals of the Mn2+ complex are
	grown in the droplet containing 10 mM MnCl2, while the crystals
	containing UDP-Gal and Mn2+ are grown in the presence of 17 mM each of
	MnCl2 and UDP–Gal, X-ray diffraction structure determination and
	analysis at 1.7-2.0 A resolution) <81>
CR	#6# <55>
CR	#6# (crystal structures of the beta4galactosyltransferase catalytic
	domain and its complex with uridine diphosphogalactose) <59>
CR	#6# (crystal structure of enzyme-alpha-lactalbumin complex with
	UDP-Glc) <47>
CR	#6# (recombinant enzyme, crystal structure of lactose synthase reveals
	a large conformational change in its catalytic component, the
	beta1,4-galactosyltransferase-I) <2>
CR	#6# (catalytic domain of R228K-Gal-T1 and mouse recombinant
	alpha-lactalbumin are cocrystallized in the presence of UDP-galactose
	and MnCl2. Crystals are grown at room temperature by the hanging drop
	method. Crystal structure of R228K-Gal-T1 complexed with
	alpha-lactalbumin, UDP-galactose, and Mn2+, determined at 1.9 Å
	resolution shows that the Asp318 side chain exhibits a minor alternate
	conformation, compared to that in the wild type) <67>
CR	#6# (purified recombinant pentenary complex of bovine M344H-Gal-T1
	mutant-Mn2+-UDP-GalNAc-Glc-alpha-lactalbumin, hanging-drop vapor
	diffusion method, using 20 mg/ml of beta-M344H-Gal-T1 and 10 mg/ml of
	mouse alpha-lactalbumin in the presence of 10 mM each ofUDP-Gal and
	CaCl2, with the precipitant containing 100 mM NaCl, 100 mM Mes-NaOH
	buffer, pH 6.0, and 12.5% PEG 4000, the crystals of the complex cannot
	be obtained in the absence of CaCl2, X-ray diffraction structure
	determination and analysis at 1.9-2.0 A resolution) <81>
CR	#15# (purified wild-type and M340H mutant enzymes in complex with
	pentasaccharide GlcNAcbeta1,2-Manalpha1,6 (GlcNAcbeta1,2-Manalpha1,3)
	and trisaccharide GlcNAcbeta1,4-GlcNAcbeta1,4-GlcNAc substrates, X-ray
	diffraction structure determination and analysis at 1.9-2.0 A
	resolution) <80>
CR	#15# (mutant enzyme M340H/C338T in complex with
	Glc-NAcbeta1-3Galbeta-O-naphthalenemethanol, hanging drop vapor
	diffusion method, using MES-NaOH buffer (pH 6.0), 1.5 M ammonium
	sulfate, and 3% dioxane) <102>

PURIFICATION
PU	#2# <5,12,51>
PU	#3# <39>
PU	#3# (recombinant enzyme) <49,63>
PU	#3# (expressed in Saccharomyces cerevisiae) <20>
PU	#3# (amylose column chromatography) <98>
PU	#3# (GST Sepharose column chromatography, and gel filtration) <117>
PU	#4# <21,22,24,25,31,37,40,45>
PU	#4# (partial) <1>
PU	#5# <32,41>
PU	#6# <3,28,36>
PU	#7# <4>
PU	#8# (recombinant enzyme) <64>
PU	#9# (recombinant enzyme) <64>
PU	#17# (PNA-Sepharose column chromatography) <93>
PU	#19# (glutathione Sepharose column chromatography) <121>
PU	#20# (nickel-affinity column chromatography) <122>

RENATURED
REN	#3# (the folding efficiency of the catalytic domain is increased
	further if the protein is renatured in a buffer that has polyethylene
	glycol and L-arginine) <71>
REN	#3# (expression of HA-tagged beta 1,4GalT V) <89>
REN	#6# (the folding efficiency of the catalytic domain is increased
	further if the protein is renatured in a buffer that has polyethylene
	glycol and L-arginine) <71>

GENERAL_STABILITY
GS	#3,6# (the N-terminal stem extension enhances the in vitro folding
	efficiency of the catalytic domain by several fold, it increases the
	solubility of even the misfolded protein) <71>
GS	#4# (glycerol stabilizes during storage) <31>
GS	#4# (ammonium sulfate stabilizes during storage) <31>
GS	#4# (more than 50% loss of activity on freezing) <45>
GS	#6# (Triton X-100 essential for stability during purification) <28>

PH_STABILITY
PHS	#2# 5-9 <5>

STORAGE_STABILITY
SS	#3# (-20°C, stable for at least 2 months) <43>
SS	#3# (-20°C, stable fo at least 1 month) <20>
SS	#4# (-20°C, stable for 3 weeks) <44>
SS	#4# (-20°C, partially purified enzyme stable for several weeks,
	purified enzyme stable for 1 week) <24>
SS	#4# (-20°C, bovine serum albumin, stable for up to 60 d) <31>
SS	#4# (4°C, concentrated enzyme) <25>
SS	#4# (4°C, purified and concentrated enzyme is stable for 4 weeks) <1>
SS	#4# (4°C, more than 50% loss of activity after 1 week) <45>
SS	#5# (-20°C, 0.02 M Tris/HCl buffer, pH 7.5, stable for several months)
	<41>
SS	#6# (-20°C, 1 mg/ml bovine serum albumin) <33>
SS	#6# (4°C, immobilized, 5 weeks, stable) <83>
SS	#7# (4°C, 0.1% bovine serum albumin, stable for 3 months) <4>

TEMPERATURE_STABILITY
TS	#3# 50 (#3# 1 h, complete loss of activity <63>) <63>
TS	#3# 56 (#3# inactivation at <20>) <20>
TS	#3# 40 (#3# 4 h, 18% loss of activity <63>) <63>
TS	#4# 45 (#4# stable up to <7>) <7>

REFERENCE
RF	<1> Paquet, M.R.; Moscarello, M.A.: A kinetic comparison of partially
	purified rat liver Golgi and rat serum galactosyltransferases. Biochem.
	J. (1984) 218, 745-751. {Pubmed:6426461}
RF	<2> Ramakrishnan, B.; Qasba, P.K.: Crystal structure of lactose
	synthase reveals a large conformational change in its catalytic
	component, the beta1,4-galactosyltransferase-I. J. Mol. Biol. (2001)
	310, 205-218. {Pubmed:11419947}
RF	<3> Blanken, W.M.; van den Eijnden, D.H.: Biosynthesis of terminal Gal
	alpha (1-3)Gal beta 1-4)GlcNAc-R oligosaccharide sequences on
	glycoconjugates. Purification and acceptor specificity of a
	UDP-Gal:N-acetyllactosaminide alpha(1-3)galactosyltransferase from calf
	thymus. J. Biol. Chem. (1985) 260, 12927-12934. {Pubmed:3932335}
RF	<4> Smith, C.A.; Brew, K.: Isolation and characteristics of
	galactosyltransferase from Golgi membranes of lactating sheep mammary
	glands. J. Biol. Chem. (1977) 252, 7294-7299. {Pubmed:409717} (c)
RF	<5> Helting, T.; Erbing, B.: Galactosyltransfer in mouse mastocytoma:
	purification and properties of N-acetyllactosamine synthetase. Biochim.
	Biophys. Acta (1973) 293, 94-104. {Pubmed:4631039} (c)
RF	<6> Schachter, H.; Jabbal, I.; Hudgin, R.L.; Pinteric, L.:
	Intracellular localization of liver sugar nucleotide glycoprotein
	glycosyltransferases in a Golgi-rich fraction. J. Biol. Chem. (1970)
	245, 1090-1100. {Pubmed:4392041} (c)
RF	<7> Deshmukh, D.S.; Bear, W.D.; Soifer, D.: Isolation and
	characterization of an enriched Golgi fraction from rat brain. Biochim.
	Biophys. Acta (1978) 542, 284-295. {Pubmed:99178} (c)
RF	<8> Nakazawa, K.; Furukawa, K.; Kobata, A.; Narimatsu, H.:
	Characterization of a murine beta 1-4 galactosyltransferase expressed
	in COS-1 cells. Eur. J. Biochem. (1991) 196, 363-368. {Pubmed:1706663}
	(c)
RF	<9> Nakazawa, K.; Ando, T.; Kimura, T.; Narimatsu, H.: Cloning and
	sequencing of a full-length cDNA of mouse N-acetylglucosamine (beta
	1-4)galactosyltransferase. J. Biochem. (1988) 104, 165-168.
	{Pubmed:3141392} (c)
RF	<10> Shaper, N.L.; Hollis, G.F.; Douglas, J.G.; Kirsch, I.R.; Shaper,
	J.H.: Characterization of the full length cDNA for murine
	beta-1,4-galactosyltransferase. Novel features at the 5-end predict two
	translational start sites at two in-frame AUGs. J. Biol. Chem. (1988)
	263, 10420-10428. {Pubmed:3134348} (c)
RF	<11> Shaper, N.L.; Shaper, J.H.; Meuth, J.L.; Fox, J.L.; Chang, H.;
	Kirsch, I.R.; Hollis, G.F.: Bovine galactosyltransferase:
	identification of a clone by direct immunological screening of a cDNA
	expression library. Proc. Natl. Acad. Sci. USA (1986) 83, 1573-1577.
	{Pubmed:2419911} (c)
RF	<12> Shaper, N.L.; Wright, W.W.; Shaper, J.H.: Murine beta
	1,4-galactosyltransferase: both the amounts and structure of the mRNA
	are regulated during spermatogenesis. Proc. Natl. Acad. Sci. USA (1990)
	87, 791-795. {Pubmed:1689054} (c)
RF	<13> Narimatsu, H.; Sinha, S.; Brew, K.; Okayama, H.; Qasba, P.K.:
	Cloning and sequencing of cDNA of bovine N-acetylglucosamine (beta
	1-4)galactosyltransferase. Proc. Natl. Acad. Sci. USA (1986) 83,
	4720-4724. {Pubmed:3014508} (c)
RF	<14> Watzele, G.; Berger, E.G.: Near identity of HeLa cell
	galactosyltransferase with the human placental enzyme. Nucleic Acids
	Res. (1990) 18, 7174. {Pubmed:2124683} (c)
RF	<15> Amano, J.; Straehl, P.; Berger, E.G.; Kochibe, N.; Kobata, A.:
	Structures of mucin-type sugar chains of the galactosyltransferase
	purified from human milk. Occurrence of the ABO and Lewis blood group
	determinants. J. Biol. Chem. (1991) 266, 11461-11477. {Pubmed:1904864}
	(c)
RF	<16> Yadav, S.; Brew, K.: Identification of a region of
	UDP-galactose:N-acetylglucosamine beta 4-galactosyltransferase involved
	in UDP-galactose binding by differential labeling. J. Biol. Chem.
	(1990) 265, 14163-14169. {Pubmed:2117606} (c)
RF	<17> D'Agostaro, G.; Bendiak, B.; Tropak, M.: Cloning of cDNA encoding
	the membrane-bound form of bovine beta 1,4-galactosyltransferase. Eur.
	J. Biochem. (1989) 183, 211-217. {Pubmed:2502398} (c)
RF	<18> Hollis, G.F.; Douglas, J.G.; Shaper, N.L.; Shaper, J.H.;
	Stafford-Hollis, J.M.; Evans, R.J.; Kirsch, I.R.: Genomic structure of
	murine beta-1,4-galactosyltransferase. Biochem. Biophys. Res. Commun.
	(1989) 162, 1069-1075. {Pubmed:2504153} (c)
RF	<19> Mengle-Gaw, L.; McCoy-Haman, M.F.; Tiemeier, D.C.: Genomic
	structure and expression of human beta-1,4-galactosyltransferase.
	Biochem. Biophys. Res. Commun. (1991) 176, 1269-1276. {Pubmed:1903938}
	(c)
RF	<20> Krezdorn, C.H.; Watzele, G.; Kleene, R.B.; Ivanov, S.X.; Berger,
	E.G.: Purification and characterization of recombinant human beta 1-4
	galactosyltransferase expressed in Saccharomyces cerevisiae. Eur. J.
	Biochem. (1993) 212, 113-120. {Pubmed:8444150} (c)
RF	<21> Kawano, J.i.; Oinuma, T.; Nakayama, T.; Suganuma, T.:
	Characterization of beta 1->4 galactosyltransferase purified from rat
	liver microsomes. J. Biochem. (1992) 111, 568-572. {Pubmed:1639751} (c)
RF	<22> Bendiak, B.; Ward, L.D.; Simpson, R.J.: Proteins of the Golgi
	apparatus. Purification to homogeneity, N-terminal sequence, and
	unusually large Stokes radius of the membrane-bound form of
	UDP-galactose:N-acetylglucosamine beta 1-4galactosyltransferase from
	rat liver. Eur. J. Biochem. (1993) 216, 405-417. {Pubmed:8375379} (c)
RF	<23> Mitranic, M.M.; Moscarello, M.A.: The influence of various lipids
	on the activity of bovine milk galactosyltransferase. Can. J. Biochem.
	(1980) 58, 809-814. {Pubmed:6780165} (c)
RF	<24> Weiser, M.M.; Majumdar, S.; Wilson, J.R.; Luther, R.:
	Distribution, purification and characterization of rat intestinal
	UDPgalactose: N-acetylglucosaminyl(beta 1->4)galactosyltransferase.
	Biochim. Biophys. Acta (1987) 924, 323-331. {Pubmed:3105591} (c)
RF	<25> Clark, P.E.; Moscarello, M.A.: The modulating effects of lipids on
	purified rat liver Golgi galactosyltransferase. Biochim. Biophys. Acta
	(1986) 859, 143-150. {Pubmed:3089277} (c)
RF	<26> Paquet, M.R.; Narasimhan, S.; Schachter, H.; Moscarello, M.A.:
	Branch specificity of purified rat liver Golgi UDP-galactose:
	N-acetylglucosamine beta-1,4-galactosyltransferase. Preferential
	transfer of of galactose on the GlcNAc beta 1,2-Man alpha 1,3-branch of
	a complex biantennary Asn-linked oligosaccharide. J. Biol. Chem. (1984)
	259, 4716-4721. {Pubmed:6425277} (c)
RF	<27> Russo, R.N.; Shaper, N.L.; Taatjes, D.J.; Shaper, J.H.: Beta
	1,4-galactosyltransferase: a short NH2-terminal fragment that includes
	the cytoplasmic and transmembrane domain is sufficient for Golgi
	retention. J. Biol. Chem. (1992) 267, 9241-9247. {Pubmed:1374389} (c)
RF	<28> Blanken, W.M.; Hooghwinkel, G.J.M.; van den Eijnden, D.H.:
	Biosynthesis of blood-group I and i substances. Specificity of bovine
	colostrum beta-N-acetyl-D-glucosaminide beta 1-4 galactosyltransferase.
	Eur. J. Biochem. (1982) 127, 547-552. {Pubmed:6816588} (c)
RF	<29> Berger, E.G.; Kozdrowski, I.; Weiser, M.M.; van den Eijnden, D.H.;
	Schiphorst, W.E.C.M.: Human serum galactosyltransferase: distinction,
	separation and product identification of two galactosyltransferase
	activities. Eur. J. Biochem. (1978) 90, 213-222. {Pubmed:710425} (c)
RF	<30> Rao, G.J.S.; Chyatte, D.; Nadler, H.L.: Enhancement of
	UDPgalactose: glycoprotein galactosyltransferase in cultured human skin
	fibroblasts by cationic polypeptides. Biochim. Biophys. Acta (1978)
	541, 435-443. {Pubmed:667130}
RF	<31> Fraser, I.H.; Wadden, P.; Mookerjea, S.: Purification and
	stabilization of galactosyltransferase from serum and lysolecithin
	extracted microsomes. Can. J. Biochem. (1980) 58, 878-884.
	{Pubmed:6780167} (c)
RF	<32> Bouchilloux, S.: Purification by affinity chromatography and some
	properties of microsomal galactosyltransferase from pig thyroid.
	Biochim. Biophys. Acta (1979) 569, 135-144. {Pubmed:113033} (c)
RF	<33> Tsopanakis, A.D.; Herries, D.G.: Bovine galactosyl transferase.
	Substrate.managanese complexes and the role of manganese ions in the
	mechanism. Eur. J. Biochem. (1978) 83, 179-188. {Pubmed:203458} (c)
RF	<34> Andree, P.J.; Berliner, L.J.: Metal ion and substrate binding to
	bovine galactosyltransferase. Biochemistry (1980) 19, 929-934.
	{Pubmed:6243960} (c)
RF	<35> Cummings, R.D.; Cebula, T.A.; Roth, S.: Characterization of a
	galactosyltransferase in plasma membrane-enriched fractions from Balb/c
	3T12 cells. J. Biol. Chem. (1979) 254, 1233-1240. {Pubmed:762126} (c)
RF	<36> Christner, J.E.; Distler, J.J.; Jourdian, G.W.: Biosynthesis of
	keratan sulfate: purification and properties of a galactosyltransferase
	from bovine cornea. Arch. Biochem. Biophys. (1979) 192, 548-558.
	{Pubmed:35107} (c)
RF	<37> Fleischer, B.; Smigel, M.: Solubilization and properties of
	galactosyltransferase and sulfotransferase activities of Golgi
	membranes in Triton X-100. J. Biol. Chem. (1978) 253, 1632-1638.
	{Pubmed:627561} (c)
RF	<38> Tengowski, M.W.; Wassler, M.J.; Shur, B.D.; Schatten, G.:
	Subcellular localization of beta1,4-galactosyltransferase on bull sperm
	and its function during sperm-egg interactions. Mol. Reprod. Dev.
	(2001) 58, 236-244. {Pubmed:11139236}
RF	<39> Bella, A.; Whitehead, J.S.; Kim, Y.S.: Human plasma uridine
	diphosphate galactose-glycoprotein galactosyltransfertase.
	Purification, properties and kinetics of the enzyme-catalysed reaction.
	Biochem. J. (1977) 167, 621-628. {Pubmed:414742} (c)
RF	<40> Fraser, I.H.; Mookerjea, S.: Purification of membrane-bound
	galactosyltransferase from rat liver microsomal fractions. Biochem. J.
	(1977) 164, 541-547. {Pubmed:16743049}
RF	<41> Rao, A.K.; Garver, F.; Mendicino, J.: Biosynthesis of the
	carbohydrate units of immunoglobulins. 1. Purification and properties
	of galactosyltransferases from swine mesentary lymph nodes.
	Biochemistry (1976) 15, 5001-5009. {Pubmed:990260} (c)
RF	<42> Chandler, D.K.; Silvia, J.C.; Ebner, K.E.: Inactivation of
	galactosyltransferase by lactoperoxidase and N-acetylimidazole.
	Biochim. Biophys. Acta (1980) 616, 179-187. {Pubmed:6783077} (c)
RF	<43> Nelson, J.D.; Jato-Rodriguez, J.J.; Mookerjea, S.: The occurrence
	and properties of soluble UDP-galactose:glycoprotein
	galactosyltransferase in human amniotic fluid. Can. J. Biochem. (1974)
	52, 42-50. {Pubmed:4821070}
RF	<44> Wagner, R.R.; Cynkin, M.A.: Glycoprotein metabolism: a
	UDP-galactose-glycoprotein galactosyltransferase of rat serum. Biochem.
	Biophys. Res. Commun. (1971) 45, 57-62. {Pubmed:5139930} (c)
RF	<45> Fraser, I.H.; Mookerjea, S.: Studies on the purification and
	properties of UDP-galactose glycoprotein galactosyltransferase from rat
	liver and serum. Biochem. J. (1976) 156, 347-355. {Pubmed:821479} (c)
RF	<46> Kitchen, B.J.; Andrews, P.: Kinetic studies on the effect of
	uridine diphosphate galactose and manganous ions on the reaction
	between lactose synthetase A protein from human milk and
	p-hydroxymercuribenzoate. Biochem. J. (1974) 143, 587-590.
	{Pubmed:4218956} (c)
RF	<47> Ramakrishnan, B.; Shah, P.S.; Qasba, P.K.: alpha-Lactalbumin (LA)
	stimulates milk beta-1,4-galactosyltransferase I (beta4Gal-T1) to
	transfer glucose from UDP-glucose to N-acetylglucosamine. Crystal
	structure of beta4Gal-T1*LA complex with UDP-Glc. J. Biol. Chem. (2001)
	276, 37665-37671. {Pubmed:11485999}
RF	<48> Nguyen, T.T.M.; Hinton, D.A.; Shur, B.D.: Expressing murine
	beta1,4-galactosyltransferase in HeLa cells produces a cell surface
	galactosyltransferase-dependent phenotype. J. Biol. Chem. (1994) 269,
	28000-28009. {Pubmed:7525565}
RF	<49> Nakazawa, K.; Furukawa, K.; Narimatsu, H.; Kobata, A.: Kinetic
	study of human beta-1,4-galactosyltransferase expressed in E. coli. J.
	Biochem. (1993) 113, 747-753. {Pubmed:8370673}
RF	<50> Gebhardt, S.; Bihler, S.; Schubert-Zsilaveez, M.; Riva, S.; Monti,
	D.; Falcone, L.; Danieli, B.: Biocatalytic generation of molecular
	diversity: modification of ginsenoside Rb1 by
	beta-1,4-galactosyltransferase and Candida antarctica lipase. Helv.
	Chim. Acta (2002) 85, 1943-1959. {Pubmed:}
RF	<51> Uehara, K.; Muramatsu, T.: Molecular cloning and characterization
	of beta-1,4-galactosyltransferase expressed in mouse testis. Eur. J.
	Biochem. (1997) 244, 706-712. {Pubmed:9108238}
RF	<52> Sato, T.; Furukawa, K.; Bakker, H.; Van den Eijnden, D.H.; Van
	Die, I.: Molecular cloning of a human cDNA encoding
	beta-1,4-galactosyltransferase with 37% identity to mammalian UDP-Gal:
	GlcNAc beta-1,4-galactosyltransferase. Proc. Natl. Acad. Sci. USA
	(1998) 95, 472-477. {Pubmed:9435216} (c)
RF	<53> Hollister, J.R.; Shaper, J.H.; Jarvis, D.L.: Stable expression of
	mammalian beta1,4-galactosyltransferase extends the N-glycosylation
	pathway in insect cells. Glycobiology (1998) 8, 473-480.
	{Pubmed:9597545}
RF	<54> Hansske, B.; Thiel, C.; Lubke, T.; Hasilik, M.; Honing, S.;
	Peters, V.; Heidemann, P.H.; Hoffmann, G.F.; Berger, E.G.; Von Figura,
	K.; Korner, C.: Deficiency of UDP-galactose:N-acetylglucosamine
	beta-1,4-galactosyltransferase I causes the congenital disorder of
	glycosylation type IId. J. Clin. Invest. (2002) 109, 725-733.
	{Pubmed:11901181}
RF	<55> Ramakrishnan, B.; Qasba, P.K.: Structure-based design of beta
	1,4-galactosyltransferase I (beta4Gal-T1) with equally efficient
	N-acetylgalactosaminyltransferase activity: point mutation broadens
	beta 4Gal-T1 donor specificity. J. Biol. Chem. (2002) 277, 20833-20839.
	{Pubmed:11916963}
RF	<56> Herrmann, G.F.; Elling, L.; Krezdorn, C.H.; Kleene, R.; Berger,
	E.G.; Wandrey, C.: Use of transformed whole yeast cells expressing
	beta-1,4-galactosyltransferase for the synthesis of
	N-acetyllactosamine. Bioorg. Med. Chem. Lett. (1995) 5, 673-676.
	{Pubmed:}
RF	<57> Elling, L.; Zervosen, A.; Gallego, R.G.; Nieder, V.; Malissard,
	M.; Berger, E.G.; Vliegenthart, J.F.G.; Kamerling, J.P.:
	UDP-N-acetyl-alpha-D-glucosamine as acceptor substrate of
	beta-1,4-galactosyltransferase. Enzymatic synthesis of
	UDP-N-acetyllactosamine. Glycoconjugate J. (1999) 16, 327-336.
	{Pubmed:10619705}
RF	<58> Snow, D.M.; Shaper, J.H.; Shaper, N.L.; Hart, G.W.: Determination
	of beta1,4-galactosyltransferase enzymatic activity by capillary
	electrophoresis and laser-induced fluorescence detection. Anal.
	Biochem. (1999) 271, 36-42. {Pubmed:10361002}
RF	<59> Gastinel, L.N.; Cambillau, C.; Bourne, Y.: Crystal structures of
	the bovine beta4galactosyltransferase catalytic domain and its complex
	with uridine diphosphogalactose. EMBO J. (1999) 18, 3546-3557.
	{Pubmed:10393171}
RF	<60> Kawano, J.I.; Ide, S.; Oinuma, T.; Suganuma, T.: Regional
	distribution of beta1-4 galactosyltransferase in rat epididymis. Acta
	Histochem. Cytochem. (1997) 30, 491-495. {Pubmed:}
RF	<61> Boeggeman, E.E.; Balajai, P.V.; Qasba, P.K.: Functional domains of
	bovine beta-1,4-galactosyltransferase. Glycoconjugate J. (1995) 12,
	865-878. {Pubmed:8748165}
RF	<62> Nishida, Y.; Tamakoshi, H.; Kitagawa, Y.; Kobayashi, K.; Thiem,
	J.: A novel bovine beta-1,4-galactosyltransferase reaction to yield
	beta-D-galactopyranosyl-(1-3)-linked disaccharides from L-sugars.
	Angew. Chem. (2000) 39, 2000-2003. {Pubmed:10941010}
RF	<63> Malissard, M.; Borsig, L.; Di Marco, S.; Gruetter, M.G.; Kragl,
	U.; Wandrey, C.; Berger, E.G.: Recombinant soluble
	beta-1,4-galactosyltransferases expressed in Saccharomyces cerevisiae.
	Purification, characterization and comparison with human enzyme. Eur.
	J. Biochem. (1996) 239, 340-348. {Pubmed:8706738}
RF	<64> Park, J.E.; Lee, K.Y.; Do, S.I.; Lee, S.S.: Expression and
	characterization of beta-1,4-galactosyltransferase from Neisseria
	meningitidis and Neisseria gonorrhoeae. J. Biochem. Mol. Biol. (2002)
	35, 330-336. {Pubmed:12297017}
RF	<65> Boeggeman, E.; Qasba, P.K.: Studies on the metal binding sites in
	the catalytic domain of beta1,4-galactosyltransferase. Glycobiology
	(2002) 12, 395-407. {Pubmed:12122021}
RF	<66> Zhu, X.; Chen, S.; Yin, X.; Shen, A.; Ji, S.; Shen, Z.; Gu, J.:
	Constitutively active PKB/Akt inhibited apoptosis and down-regulated
	beta1,4-galactosyltransferase 1 in hepatocarcinoma cells. Biochem.
	Biophys. Res. Commun. (2003) 309, 279-285. {Pubmed:12951046}
RF	<67> Ramakrishnan, B.; Boeggeman, E.; Qasba, P.K.: Mutation of arginine
	228 to lysine enhances the glucosyltransferase activity of bovine
	beta-1,4-galactosyltransferase I. Biochemistry (2005) 44, 3202-3210.
	{Pubmed:15736931} (c)
RF	<68> Nanthakumar, N.N.; Dai, D.; Meng, D.; Chaudry, N.; Newburg, D.S.;
	Walker, W.A.: Regulation of intestinal ontogeny: Effect of
	glucocorticoids and luminal microbes on galactosyltransferase and
	trehalase induction in mice. Glycobiology (2005) 15, 221-232.
	{Pubmed:15483270} (c)
RF	<69> Zhu, X.; Jiang, J.; Shen, H.; Wang, H.; Zong, H.; Li, Z.; Yang,
	Y.; Niu, Z.; Liu, W.; Chen, X.; Hu, Y.; Gu, J.: Elevated
	beta1,4-galactosyltransferase I in highly metastatic human lung cancer
	cells: Identification of E1AF as important transcription activator. J.
	Biol. Chem. (2005) 280, 12503-12516. {Pubmed:15611127} (c)
RF	<70> Zhu, D.; Shen, A.; Sun, M.; Gu, J.: Distinct patterns of
	expression of the beta-1,4-galactosyltransferases during testicular
	development in the mouse. Mol. Cell. Biochem. (2003) 247, 147-153.
	{Pubmed:12841642} (c)
RF	<71> Boeggeman, E.E.; Ramakrishnan, B.; Qasba, P.K.: The N-terminal
	stem region of bovine and human beta1,4-galactosyltransferase I
	increases the in vitro folding efficiency of their catalytic domain
	from inclusion bodies. Protein Expr. Purif. (2003) 30, 219-229.
	{Pubmed:12880771} (c)
RF	<72> Li, Z.; Wang, H.; Zong, H.; Sun, Q.; Kong, X.; Jiang, J.; Gu, J.:
	Downregulation of beta1,4-galactosyltransferase 1 inhibits
	CDK11(p58)-mediated apoptosis induced by cycloheximide. Biochem.
	Biophys. Res. Commun. (2005) 327, 628-636. {Pubmed:15629159}
RF	<73> Menzies, K.K.; Nicholas, K.R.: The expression of beta-1,3
	galactosyltransferase and beta-1,4 galactosyltransferase enzymatic
	activities in the mammary gland of the tammar wallaby (Macropus
	eugenii) during early lactation. Biochim. Biophys. Acta (2007) 1770,
	115-120. {Pubmed:17049162}
RF	<74> Boeggeman, E.; Ramakrishnan, B.; Kilgore, C.; Khidekel, N.;
	Hsieh-Wilson, L.C.; Simpson, J.T.; Qasba, P.K.: Direct identification
	of nonreducing GlcNAc residues on N-glycans of glycoproteins using a
	novel chemoenzymatic method. Bioconjug. Chem. (2007) 18, 806-814.
	{Pubmed:17370997}
RF	<75> Chen, W.S.; Chang, H.Y.; Li, C.P.; Liu, J.M.; Huang, T.S.: Tumor
	beta-1,4-galactosyltransferase IV overexpression is closely associated
	with colorectal cancer metastasis and poor prognosis. Clin. Cancer Res.
	(2005) 11, 8615-8622. {Pubmed:16361545}
RF	<76> Machingo, Q.J.; Fritz, A.; Shur, B.D.: A
	beta1,4-galactosyltransferase is required for convergent extension
	movements in zebrafish. Dev. Biol. (2006) 297, 471-482.
	{Pubmed:16904099}
RF	<77> Brockhausen, I.; Benn, M.; Bhat, S.; Marone, S.; Riley, J.G.;
	Montoya-Peleaz, P.; Vlahakis, J.Z.; Paulsen, H.; Schutzbach, J.S.;
	Szarek, W.A.: UDP-Gal: GlcNAc-R beta1,4-galactosyltransferase - a
	target enzyme for drug design. Acceptor specificity and inhibition of
	the enzyme. Glycoconj. J. (2006) 23, 525-541. {Pubmed:17006644}
RF	<78> Jiang, J.; Chen, X.; Shen, J.; Wei, Y.; Wu, T.; Yang, Y.; Wang,
	H.; Zong, H.; Yang, J.; Zhang, S.; Xie, J.; Kong, X.; Liu, W.; Gu, J.:
	beta1,4-Galactosyltransferase V functions as a positive growth
	regulator in glioma. J. Biol. Chem. (2006) 281, 9482-9489.
	{Pubmed:16461357}
RF	<79> Takaya, K.; Nagahori, N.; Kurogochi, M.; Furuike, T.; Miura, N.;
	Monde, K.; Lee, Y.C.; Nishimura, S.: Rational design, synthesis, and
	characterization of novel inhibitors for human
	beta1,4-galactosyltransferase. J. Med. Chem. (2005) 48, 6054-6065.
	{Pubmed:16162007}
RF	<80> Ramasamy, V.; Ramakrishnan, B.; Boeggeman, E.; Ratner, D.M.;
	Seeberger, P.H.; Qasba, P.K.: Oligosaccharide preferences of
	beta1,4-galactosyltransferase-I: crystal structures of Met340His mutant
	of human beta1,4-galactosyltransferase-I with a pentasaccharide and
	trisaccharides of the N-glycan moiety. J. Mol. Biol. (2005) 353, 53-67.
	{Pubmed:16157350}
RF	<81> Ramakrishnan, B.; Ramasamy, V.; Qasba, P.K.: Structural snapshots
	of beta-1,4-galactosyltransferase-I along the kinetic pathway. J. Mol.
	Biol. (2006) 357, 1619-1633. {Pubmed:16497331}
RF	<82> Ramakrishnan, B.; Qasba, P.K.: Role of a single amino acid in the
	evolution of glycans of invertebrates and vertebrates. J. Mol. Biol.
	(2007) 365, 570-576. {Pubmed:17084860}
RF	<83> Pisvejcova, A.; Rossi, C.; Husakova, L.; Kren, V.; Riva, S.;
	Monti, D.: beta-1,4-Galactosyltransferase-catalyzed glycosylation of
	sugar derivatives: Modulation of the enzyme activity by
	alpha-lactalbumin, immobilization and solvent tolerance. J. Mol. Catal.
	B (2006) 39, 98-104. {Pubmed:}
RF	<84> Chen, P.; Harcum, S.W.: Effects of elevated ammonium on
	glycosylation gene expression in CHO cells. Metab. Eng. (2006) 8,
	123-132. {Pubmed:16380282}
RF	<85> Li, Z.; Zong, H.; Kong, X.; Zhang, S.; Wang, H.; Sun, Q.; Gu, J.:
	Cell surface beta 1, 4-galactosyltransferase 1 promotes apoptosis by
	inhibiting epidermal growth factor receptor pathway. Mol. Cell.
	Biochem. (2006) 291, 69-76. {Pubmed:16786197}
RF	<86> Rhee, S.W.; Starr, T.; Forsten-Williams, K.; Storrie, B.: The
	steady-state distribution of glycosyltransferases between the Golgi
	apparatus and the endoplasmic reticulum is approximately 90:10. Traffic
	(2005) 6, 978-990. {Pubmed:16190979}
RF	<87> Fujiyama, K.; Furukawa, A.; Katsura, A.; Misaki, R.; Omasa, T.;
	Seki, T.: Production of mouse monoclonal antibody with
	galactose-extended sugar chain by suspension cultured tobacco BY2 cells
	expressing human beta(1,4)-galactosyltransferase. Biochem. Biophys.
	Res. Commun. (2007) 358, 85-91. {Pubmed:17481579}
RF	<88> Chang, K.H.; Lee, J.M.; Hwang-Bo, J.; Yoo, K.H.; Sohn, B.H.; Yang,
	J.M.; Chung, I.S.: Expression of recombinant cyclooxygenase 1 in
	Drosophila melanogaster S2 cells transformed with human
	beta1,4-galactosyltransferase and Galbeta1,4-GlcNAc
	alpha2,6-sialyltransferase. Biotechnol. Lett. (2007) 29, 1803-1809.
	{Pubmed:17665137}
RF	<89> Wei, Y.; Liu, D.; Ge, Y.; Zhou, F.; Xu, J.; Chen, H.; Yun, X.; Gu,
	J.; Jiang, J.: Down-regulation of beta 1,4GalT V at protein level
	contributes to arsenic trioxide-induced glioma cell apoptosis. Cancer
	Lett. (2008) 267, 96-105. {Pubmed:18439752}
RF	<90> Namdjou, D.J.; Chen, H.M.; Vinogradov, E.; Brochu, D.; Withers,
	S.G.; Wakarchuk, W.W.: A beta-1,4-galactosyltransferase from
	Helicobacter pylori is an efficient and versatile biocatalyst
	displaying a novel activity for thioglycoside synthesis. Chembiochem
	(2008) 9, 1632-1640. {Pubmed:18491328}
RF	<91> Qasba, P.K.; Ramakrishnan, B.; Boeggeman, E.: Structure and
	function of beta-1,4-galactosyltransferase. Curr. Drug Targets (2008)
	9, 292-309. {Pubmed:18393823}
RF	<92> Dabros, W.; Kordowiak, A.: Comparison of bipyridyl, maltol and
	kojic acid action as organic vanadium ligands on activity of
	galactosyltransferase (EC 2.4.1.38), some physiological parameters and
	ultrastructure of Golgi complexes in rat hepatocytes. Folia Histochem.
	Cytobiol. (2007) 45, 239-244. {Pubmed:17951174}
RF	<93> Bhaumik, S.K.; Singh, M.; Basu, R.; Bhaumik, S.; Roychoudhury, K.;
	Naskar, K.; Roy, S.; De, T.: Virulence attenuation of a
	UDP-galactose/N-acetylglucosamine beta1,4 galactosyltransferase
	expressing Leishmania donovani promastigote. Glycoconj. J. (2008) 25,
	459-472. {Pubmed:18197475}
RF	<94> Qian, J.; Cheng, C.; Liu, H.; Chen, J.; Yan, M.; Niu, S.; Qin, J.;
	Sun, L.; Liu, L.; Gu, J.; Shen, A.: Expression of
	beta-1,4-galactosyltransferase-I in rat during inflammation.
	Inflammation (2007) 30, 59-68. {Pubmed:17372842}
RF	<95> Zhou, J.; Wei, Y.; Liu, D.; Ge, X.; Zhou, F.; Yun, X.; Jiang, J.;
	Gu, J.: Identification of beta 1,4GalT II as a target gene of
	p53-mediated HeLa cell apoptosis. J. Biochem. (2008) 143, 547-554.
	{Pubmed:18211920}
RF	<96> Yan, M.; Xia, C.; Niu, S.; Shao, X.; Cheng, C.; Zhao, J.; Shen,
	A.: The role of TNF-alpha and its receptors in the production of
	beta-1,4 galactosyltransferase I and V mRNAs by rat primary astrocytes.
	J. Mol. Neurosci. (2007) 33, 155-162. {Pubmed:17917074}
RF	<97> Shen, J.; Jiang, J.; Wei, Y.; Zhou, L.; Liu, D.; Zhou, J.; Gu, J.:
	Two specific inhibitors of the phosphatidylinositol 3-kinase LY294002
	and wortmannin up-regulate beta1,4-galactosyltransferase I and thus
	sensitize SMMC-7721 human hepatocarcinoma cells to
	cycloheximide-induced apoptosis. Mol. Cell. Biochem. (2007) 304,
	361-367. {Pubmed:17557191}
RF	<98> Daligault, F.; Rahuel-Clermont, S.; Gulberti, S.; Cung, M.T.;
	Branlant, G.; Netter, P.; Magdalou, J.; Lattard, V.: Thermodynamic
	insights into the structural basis governing the donor substrate
	recognition by human beta1,4-galactosyltransferase 7. Biochem. J.
	(2009) 418, 605-614. {Pubmed:19032152}
RF	<99> Brockhausen, I.; Dowler, T.; Paulsen, H.: Site directed
	processing: role of amino acid sequences and glycosylation of acceptor
	glycopeptides in the assembly of extended mucin type O-glycan core 2.
	Biochim. Biophys. Acta (2009) 1790, 1244-1257. {Pubmed:19524017}
RF	<100> Lee, P.L.; Kohler, J.J.; Pfeffer, S.R.: Association of
	beta-1,3-N-acetylglucosaminyltransferase 1 and
	beta-1,4-galactosyltransferase 1, trans-Golgi enzymes involved in
	coupled poly-N-acetyllactosamine synthesis. Glycobiology (2009) 19,
	655-664. {Pubmed:19261593}
RF	<101> Yang, H.; Hu, L.; Chen, J.; Zhu, J.; Tao, T.; Zhang, F.; Li, X.;
	He, X.; Shen, A.; Cheng, C.: Lipopolysaccharide induced upregulation of
	beta-1,4-galactosyltransferase-I in Schwann cell. Inflammation (2009)
	32, 279-286. {Pubmed:19548074}
RF	<102> Brown, J.R.; Yang, F.; Sinha, A.; Ramakrishnan, B.; Tor, Y.;
	Qasba, P.K.; Esko, J.D.: Deoxygenated disaccharide analogs as specific
	inhibitors of beta1-4-galactosyltransferase 1 and selectin-mediated
	tumor metastasis. J. Biol. Chem. (2009) 284, 4952-4959.
	{Pubmed:19106107}
RF	<103> Krupicka, M.; Tvaroska, I.: Hybrid quantum mechanical/molecular
	mechanical investigation of the beta-1,4-galactosyltransferase-I
	mechanism. J. Phys. Chem. B (2009) 113, 11314-11319. {Pubmed:19627105}
RF	<104> Mugnier, S.; Boittin, S.; Douet, C.; Monget, P.; Magistrini, M.;
	Goudet, G.: The involvement of beta-1,4-galactosyltransferase and
	N-acetylglucosamine residues in fertilization has been lost in the
	horse. Reprod. Biol. Endocrinol. (2008) 6, 51. {Pubmed:19014565}
RF	<105> Wei, Y.; Zhou, F.; Ge, Y.; Chen, H.; Cui, C.; Li, Q.; Liu, D.;
	Yang, Z.; Wu, G.; Sun, S.; Gu, J.; Jiang, J.:
	beta1,4-galactosyltransferase V regulates self-renewal of
	glioma-initiating cell. Biochem. Biophys. Res. Commun. (2010) 396,
	602-607. {Pubmed:20417617}
RF	<106> Choi, H.J.; Chung, T.W.; Kim, C.H.; Jeong, H.S.; Joo, M.; Youn,
	B.; Ha, K.T.: Estrogen induced beta-1,4-galactosyltransferase 1
	expression regulates proliferation of human breast cancer MCF-7 cells.
	Biochem. Biophys. Res. Commun. (2012) 426, 620-625. {Pubmed:22982306}
RF	<107> Cheng, X.; Wang, X.; Han, Y.; Wu, Y.: The expression and function
	of beta-1,4-galactosyltransferase-I in dendritic cells. Cell. Immunol.
	(2010) 266, 32-39. {Pubmed:20851383}
RF	<108> Wang, H.; Xu, D.; Tao, R.; Ni, X.; Shen, A.; Wang, Y.:
	Beta-1,4-galactosyltransferase-I in synovial tissue of collagen-induced
	rat model of rheumatoid arthritis. Clin. Exp. Med. (2011) 11, 147-154.
	{Pubmed:21161318}
RF	<109> Peanne, R.; Legrand, D.; Duvet, S.; Mir, A.M.; Matthijs, G.;
	Rohrer, J.; Foulquier, F.: Differential effects of lobe A and lobe B of
	the Conserved Oligomeric Golgi complex on the stability of
	(beta)1,4-galactosyltransferase 1 and (alpha)2,6-sialyltransferase 1.
	Glycobiology (2011) 21, 864-876. {Pubmed:21062782}
RF	<110> Zhu, F.; Shen, F.; Fan, Y.; Xie, Y.; Xia, Y.; Kong, Y.:
	Osteopontin increases the expression of beta1,
	4-galactosyltransferase-I and promotes adhesion in human RL95-2 cells.
	Glycoconj. J. (2012) 29, 347-356. {Pubmed:22847114}
RF	<111> Wang, Y.; Xu, D.; Tao, R.; Wang, H.; Wang, Q.; Shen, A.:
	beta1,4-Galactosyltransferase-I contributes to the inflammatory
	processes in synovial tissue of patients with rheumatoid arthritis.
	Inflamm. Res. (2010) 59, 1009-1018. {Pubmed:20490888}
RF	<112> Liu, X.; Cheng, C.; Shao, B.; Wu, X.; Ji, Y.; Lu, X.; Shen, A.:
	The functional interaction between CDK11p58 and
	beta-1,4-galactosyltransferase I involved in astrocyte activation
	caused by lipopolysaccharide. Inflammation (2012) 35, 1365-1377.
	{Pubmed:22527143}
RF	<113> Liu, W.; Cui, Z.; Wang, Y.; Zhu, X.; Fan, J.; Bao, G.; Qiu, J.;
	Xu, D.: Elevated expression of beta 1,4-galactosyltransferase-I in
	cartilage and synovial tissue of patients with osteoarthritis.
	Inflammation (2012) 35, 647-655. {Pubmed:21750942}
RF	<114> Kouno, T.; Kizuka, Y.; Nakagawa, N.; Yoshihara, T.; Asano, M.;
	Oka, S.: Specific enzyme complex of beta-1,4-galactosyltransferase-II
	and glucuronyltransferase-P facilitates biosynthesis of N-linked human
	natural killer-1 (HNK-1) carbohydrate. J. Biol. Chem. (2011) 286,
	31337-31346. {Pubmed:21771787}
RF	<115> Yang, H.; Yuan, Q.; Chen, Q.; Li, C.; Wu, X.; Peng, C.; Kang, L.;
	Lu, X.; Sun, H.; Zhou, Z.; Shen, A.; Cheng, C.:
	beta-1,4-galactosyltransferase I promotes tumor necrosis factor-alpha
	autocrine via the activation of MAP kinase signal pathways in Schwann
	cells. J. Mol. Neurosci. (2011) 45, 269-276. {Pubmed:21461672}
RF	<116> Yuan, Q.; Yang, H.; Cheng, C.; Li, C.; Wu, X.; Huan, W.; Sun, H.;
	Zhou, Z.; Wang, Y.; Zhao, Y.; Lu, X.; Shen, A.:
	beta-1,4-Galactosyltransferase I involved in Schwann cells
	proliferation and apoptosis induced by tumor necrosis factor-alpha via
	the activation of MAP kinases signal pathways. Mol. Cell. Biochem.
	(2012) 365, 149-158. {Pubmed:22359038}
RF	<117> Tang, W.; Weng, S.; Zhang, S.; Wu, W.; Dong, L.; Shen, X.; Zhang,
	S.; Gu, J.; Xue, R.: Direct interaction between surface
	beta1,4-galactosyltransferase 1 and epidermal growth factor receptor
	(EGFR) inhibits EGFR activation in hepatocellular carcinoma. Biochem.
	Biophys. Res. Commun. (2013) 434, 449-454. {Pubmed:23583406}
RF	<118> Jiang, J.; Kanabar, V.; Padilla, B.; Man, F.; Pitchford, S.C.;
	Page, C.P.; Wagner, G.K.: Uncharged nucleoside inhibitors of
	beta-1,4-galactosyltransferase with activity in cells. Chem. Commun.
	(Camb.) (2016) 52, 3955-3958. {Pubmed:26882174}
RF	<119> Tokuda, N.; Numata, S.; Li, X.; Nomura, T.; Takizawa, M.; Kondo,
	Y.; Yamashita, Y.; Hashimoto, N.; Kiyono, T.; Urano, T.; Furukawa, K.;
	Furukawa, K.: beta4GalT6 is involved in the synthesis of
	lactosylceramide with less intensity than beta4GalT5. Glycobiology
	(2013) 23, 1175-1183. {Pubmed:23882130}
RF	<120> Tsutsui, Y.; Ramakrishnan, B.; Qasba, P.K.: Crystal structures of
	beta-1,4-galactosyltransferase 7 enzyme reveal conformational changes
	and substrate binding. J. Biol. Chem. (2013) 288, 31963-31970.
	{Pubmed:24052259}
RF	<121> Saliba, M.; Ramalanjaona, N.; Gulberti, S.; Bertin-Jung, I.;
	Thomas, A.; Dahbi, S.; Lopin-Bon, C.; Jacquinet, J.C.; Breton, C.;
	Ouzzine, M.; Fournel-Gigleux, S.: Probing the acceptor active site
	organization of the human recombinant beta1,4-galactosyltransferase 7
	and design of xyloside-based inhibitors. J. Biol. Chem. (2015) 290,
	7658-7670. {Pubmed:25568325}
RF	<122> Geisler, C.; Mabashi-Asazuma, H.; Kuo, C.W.; Khoo, K.H.; Jarvis,
	D.L.: Engineering beta1,4-galactosyltransferase I to reduce secretion
	and enhance N-glycan elongation in insect cells. J. Biotechnol. (2015)
	193, 52-65. {Pubmed:25462875}
RF	<123> Hesselink, T.; Rouwendal, G.J.; Henquet, M.G.; Florack, D.E.;
	Helsper, J.P.; Bosch, D.: Expression of natural human beta1,4-GalT1
	variants and of non-mammalian homologues in plants leads to differences
	in galactosylation of N-glycans. Transgenic Res. (2014) 23, 717-728.
	{Pubmed:25082356}

ACTIVATING_COMPOUND
AC	#2,3,4,6# alpha-lactalbumin (#6# stimulates transfer of glucose from
	UDPglucose to N-acetylglucosamine <47>; #2,3,4,6# stimulates transfer
	of galactose from UDPgalactose to N-acetylgalactosamine
	<5,8,29,31,35,36,39,40,45,47,55,62,63>; #3# modulates the enzymes
	acceptor specificity, but does not interact with the sugar
	donor-binding site of beta4Gal-T1. Instead, interacting with the
	extended sugar-binding site of the closed conformer of beta4Gal-T1 in
	the enzyme-sugar nucleotide complex, lactalbumin stabilizes the
	complex, thereby facilitating the transfer of the sugar moiety from the
	less preferred sugar nucleotides to a monosaccharide, it kinetically
	enhances the transfer of the sugar residue from the less preferred
	sugar nucleotides to a monosaccharide, GlcNAc, lactalbumin binding site
	structure of beta4Gal-T family members, overview, modulation mechanism,
	overview <91>) <5,8,29,31,35,36,39,40,45,47,55,62,63,91>
AC	#3# Protamine sulfate (#3# activation <30>) <30>
AC	#3# poly(L-Lys) (#3# activation <30>) <30>
AC	#3# poly(L-Arg) (#3# activation <30>) <30>
AC	#3,4,13,16# more (#3# the activity of GalT V promoter can be induced by
	epidermal growth factor, dominant active Ras, ERK1, JNK1, and
	constitutively active AKT <78>; #13# the enzyme regulation/stimulation
	is a complex system involving the hormones insulin, prolactine,
	hydrocortisone, triiodothyronine, and 17beta-estradiol, and also the
	extracellular matrix and the sucking stimulus <73>; #4# intraperitoneal
	administration of lipopolysaccharide, a potent inducer of systemic
	inflammation, strongly induces beta-1,4-GalT-I mRNA expression in the
	lung, heart, liver, spleen, kidney, lymph node, hippocampus, and
	testis, as well as in the cerebral cortex. In the rat lung, liver and
	testis, LPS stimulation of beta-1,4-GalT-I mRNA expression is
	time-dependent and biphasic <94>; #4,16# lipopolysaccharide stimulation
	of astrocytes induces the enzyme expression, overview <96>; #3# the
	specific inhibitors of the phosphatidylinositol 3-kinase LY294002 and
	wortmannin up-regulate beta1,4-galactosyltransferase I through
	enhancing Sp1 protein expression, and thus sensitize SMMC-7721 human
	hepatocarcinoma cells to cycloheximide-induced apoptosis, overview
	<97>) <73,78,94,96,97>
AC	#4# dipalmitoylphosphatidylcholine (#4# activation <25>) <25>
AC	#4# dioleoylphosphatidylcholine (#4# activation <25>) <25>
AC	#4# Distearoylphosphatidylcholine (#4# activation <25>) <25>
AC	#4,6# phosphatidylcholine (#4,6# activation <23,25>) <23,25>
AC	#4,6# dimyristoylphosphatidylcholine (#4,6# activation <23,25>) <23,25>
AC	#6# phosphatidylethanolamine (#6# activation <23>) <23>
AC	#6# phosphatidylglycerol (#6# activation <23>) <23>
AC	#6# lysophosphatidylcholine (#6# activation <23>) <23>
AC	#6# histone (#6# activation <23>) <23>
AC	#6# Methylphosphatidylic acid (#6# activation <23>) <23>
AC	#8,9# Triton X-100 (#8,9# 0.1-5%, 1.5fold stimulation <64>) <64>

KI_VALUE
KI	#19# 0.06 {4-methylumbelliferyl 4-deoxy-4-fluoro-beta-D-xylopyranoside}
	 (#19# recombinant wild type enzyme, at pH 7.0 and 37°C <121>) <121>
KI	#19# 1.28 {4-methylumbelliferyl 4-deoxy-beta-D-xylopyranoside}  (#19#
	recombinant wild type enzyme, at pH 7.0 and 37°C <121>) <121>
KI	#3# 1.65 {UTP}  (#3# purified maltose-binding protein-beta1,4-GalT7, in
	100 mM cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C
	<98>) <98>
KI	#3# 0.61 {UDP}  (#3# purified maltose-binding protein-beta1,4-GalT7, in
	100 mM cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C
	<98>) <98>
KI	#3# 1.93 {TDP}  (#3# purified maltose-binding protein-beta1,4-GalT7, in
	100 mM cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C
	<98>) <98>
KI	#3# 0.0223 {uridine
	5'-(6-amino-(2-[(7-methyl-2
	naphthyl)methoxycarbonylmethoxy]ethoxy)acetyl-6-deoxy-alpha-D
	galactopyranosyl) diphosphate}  <79>
KI	#3# 0.00186 {uridine
	5'-(6-O-[10-(2-naphthyl)-3,6
	9-trioxadecanyl]-alpha-D-galactopyranosyl)diphosphate}  <79>
KI	#6# -999 {more}  (#6# inhibition kinetics <77>) <77>
KI	#6# 0.01 {1-thio-N-butyryl-GlcNbeta-(2-naphthyl)}  (#6# pH 7.0 <77>)
	<77>

IC50_VALUE
IC50	#19# 0.03 {4-methylumbelliferyl 4-deoxy-4-fluoro-beta-D-xylopyranoside}
	 (#19# recombinant wild type enzyme, at pH 7.0 and 37°C <121>) <121>
IC50	#19# 0.53 {4-methylumbelliferyl 4-deoxy-beta-D-xylopyranoside}  (#19#
	recombinant wild type enzyme, at pH 7.0 and 37°C <121>) <121>
IC50	#3# 0.012 {5-(5-formylthien-2-yl)-UDP-alpha-D-galactose}  (#3# pH and
	temperature not specified in the publication <118>) <118>
IC50	#3# 1 {5-(5-formylthien-2-yl)-uridine}  (#3# IC50 above 1.0 mM, pH and
	temperature not specified in the publication <118>) <118>

KI_VALUE
KI	#19# 0.06 {4-methylumbelliferyl 4-deoxy-4-fluoro-beta-D-xylopyranoside}
	 (#19# recombinant wild type enzyme, at pH 7.0 and 37°C <121>) <121>
KI	#19# 1.28 {4-methylumbelliferyl 4-deoxy-beta-D-xylopyranoside}  (#19#
	recombinant wild type enzyme, at pH 7.0 and 37°C <121>) <121>
KI	#3# 1.65 {UTP}  (#3# purified maltose-binding protein-beta1,4-GalT7, in
	100 mM cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C
	<98>) <98>
KI	#3# 0.61 {UDP}  (#3# purified maltose-binding protein-beta1,4-GalT7, in
	100 mM cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C
	<98>) <98>
KI	#3# 1.93 {TDP}  (#3# purified maltose-binding protein-beta1,4-GalT7, in
	100 mM cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C
	<98>) <98>
KI	#3# 0.0223 {uridine
	5'-(6-amino-(2-[(7-methyl-2
	naphthyl)methoxycarbonylmethoxy]ethoxy)acetyl-6-deoxy-alpha-D
	galactopyranosyl) diphosphate}  <79>
KI	#3# 0.00186 {uridine
	5'-(6-O-[10-(2-naphthyl)-3,6
	9-trioxadecanyl]-alpha-D-galactopyranosyl)diphosphate}  <79>
KI	#6# -999 {more}  (#6# inhibition kinetics <77>) <77>
KI	#6# 0.01 {1-thio-N-butyryl-GlcNbeta-(2-naphthyl)}  (#6# pH 7.0 <77>)
	<77>

KCAT_KM_VALUE
KKM	#19# 1.2 (#19# mutant enzyme R270A, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 1.42 (#19# mutant enzyme R270K, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 4.05 (#19# mutant enzyme Y199F, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 4.7 (#19# mutant enzyme R226K, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 1.47 (#19# mutant enzyme Y196F, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 3 (#19# mutant enzyme H195A, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 2.95 (#19# mutant enzyme H195Q, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 4.85 (#19# mutant enzyme H195A, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 2.92 (#19# mutant enzyme R226K, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 0.47 (#19# mutant enzyme Y196F, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 2.85 (#19# mutant enzyme R226A, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 4.17 (#19# recombinant wild type enzyme, at pH 7.0 and 37°C
	<121>) <121>
KKM	#19# 1.88 (#19# mutant enzyme Y199F, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 1.87 (#19# mutant enzyme R226A, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 3.07 (#19# mutant enzyme R270A, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 4.03 (#19# mutant enzyme H195R, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 7.08 (#19# recombinant wild type enzyme, at pH 7.0 and 37°C
	<121>) <121>
KKM	#19# 4.92 (#19# mutant enzyme H195Q, at pH 7.0 and 37°C <121>; #19#
	mutant enzyme H195R, at pH 7.0 and 37°C <121>) <121>
KKM	#19# 2.32 (#19# mutant enzyme R270K, at pH 7.0 and 37°C <121>) <121>
KKM	#3# 0.07 (#3# purified maltose-binding protein-beta1,4-GalT7, in 100 mM
	cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C <98>) <98>
KKM	#3# 0.065 (#3# purified maltose-binding protein-beta1,4-GalT7, in 100
	mM cacodylate buffer (pH 7.0) containing 10 mM MnCl2, at 37°C <98>)
	<98>
KKM	#3# 4.93 (#3# Km above 0.003 mM, purified maltose-binding
	protein-beta1,4-GalT7, in 100 mM cacodylate buffer (pH 7.0) containing
	10 mM MnCl2, at 37°C <98>) <98>

EXPRESSION
EXP	#2,3,4# up (#4# beta-1,4-GalT-I mRNA is significant increased 2 h after
	lipopolysaccharide stimulation with 0.001 mg/ml <101>; #3# the
	transcriptional activity and mRNA expression level of beta1,4GalT II
	are dramatically induced by p53 transcription factor in HeLa cell, in
	response to DNA damage agent adriamycin, the mRNA expression and
	promoter activity of beta1,4GalT II are significantly up-regulated
	<95>; #2# beta 1, 4-GalT-I iss highly expressed in endometrium during
	implantation window <110>; #4# CDK11p58 and beta-1,4-GalT-I are induced
	in lipopolysaccharide-challenged rat primary astrocytes in a affinis
	dose- and time-dependent manner. CDK11p58 regulates the expression of
	beta-1,4-GalT-I by interacting with it. The expression of
	beta-1,4-GalT-I increases, and astrocyte activation enhances due to the
	overexpression of CDK11p58 <112>; #3# estrogen induces
	beta-1,4-galactosyltransferase 1 expression <106>; #3# expression of
	beta1,4-GalT-I and galactose-containing glycans increases in synovial
	tissue of rheumatoid arthritis patients compared with osteoarthritis
	patients and healthy controls. Most galactose-containing glycans and
	beta1,4-GalT-I are expressed in inflammatory cells <111>; #3#
	expression of beta1,4-GalT-I increases in the cartilage and synovial
	tissue of osteoarthritis patients compared with healthy controls <113>;
	#4# mRNA and protein expression of beta1,4-GalT-I increases in synovial
	tissue of a collagen-induced rat model of rheumatoid arthritis compared
	with the normal group at 10d and 15d after collagen-induced <108>; #3#
	recombinant human osteopontin protein induces the beta 1,4-GalT-I
	up-regulation in RL95-2 cells <110>; #3# the expression level of GalTI
	and cellular adhesion ability is increased when dendritic cells
	continue to mature <107>) <95,101,106,107,108,110,111,112,113>
EXP	#3,4# down (#4# anti-TNFR1 antibody suppresses the expression of
	beta-1,4-GalT I, and TNF-alpha autocrine <115>; #3# estrogen
	antagonists ICI 182,780 and ER-a-ERE binding blocker TPBM inhibit the
	expression of estrogen-induced B4GALT1 <106>; #3# inhibition of
	MEK/ERK, PI3K/AKT and NF-kappaB suppresses recombinant human
	osteopontin-induced beta1,4-GalT-I expression <110>) <106,110,115>

///
ID	2.4.1.92
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Cricetulus griseus   <10,23>
PR	#2# Drosophila melanogaster   <22,27,28,29>
PR	#3# Mus musculus   (#3# synthetic construct <9>) <5,9,26,37,39,41,42>
PR	#4# Homo sapiens   <3,4,16,29,32,34,36,38,40>
PR	#5# Rattus norvegicus   <1,2,3,6,7,8,18,19,20>
PR	#6# Caenorhabditis elegans   <25>
PR	#7# Campylobacter jejuni   <30,35>
PR	#8# Homo sapiens Q00973 SwissProt <11,12,13,14,15,17,31,43,44>
PR	#8# Homo sapiens Q00973 UniProt <11,12,13,14,15,17,31,43,44>
PR	#9# Mus musculus Q09200 SwissProt <15,33,45>
PR	#9# Mus musculus Q09200 UniProt <15,33,45>
PR	#10# Trichoplusia ni Q6J4T9 Swissprot <24>
PR	#11# Homo sapiens Q76KP1 Swissprot <21>
PR	#12# Rattus norvegicus Q10468 SwissProt <46,47>

RECOMMENDED_NAME
RN	(N-acetylneuraminyl)-galactosylglucosylceramide
	N-acetylgalactosaminyltransferase


SYSTEMATIC_NAME
SN	UDP-N-acetyl-D-galactosamine:1-O-[O-(N-acetyl-alpha-neuraminosyl)-(2
	>3)-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl]-ceramide
	4-beta-N-acetyl-D-galactosaminyltransferase


SYNONYMS
SY	 acetylgalactosaminyltransferase, uridine
	diphosphoacetylgalactosamine-ganglioside GM3
SY	 ganglioside GM2 synthase
SY	 ganglioside GM3 acetylgalactosaminyltransferase
SY	 UDP
	acetylgalactosamine-(N-acetylneuraminyl)-D-galactosyl-D-glucosylceramide
SY	 acetylgalactosaminyltransferase
SY	 UDP-N-acetylgalactosamine GM3 N-acetylgalactosaminyltransferase
SY	 uridine
	diphosphoacetylgalactosamine-acetylneuraminylgalactosylglucosylceramide
SY	 uridine diphosphoacetylgalactosamine-hematoside
	acetylgalactosaminyltransferase
SY	 GM2/GD2-synthase
SY	 uridine diphosphoacetylgalactosamine-ganglioside GM3
	acetylgalactosaminyltransferase
SY	 UDP-N-acetylgalactosaminyltransferase I
SY	 GalNAcT
SY	#11# betaGalNAc-T4 <21>
SY	#12# GA2 synthase <47>
SY	#12#
	UDP-2-acetamido-2-deoxy-D-galactose:(N-acetylneuraminyl)-D-galactosyl-D
	glucosyl-N-acylsphingosine acetamidodeoxygalactosyl-transferase <46>
SY	#2# beta4GalNAcT <27>
SY	#2# beta4GalNAcTA <28>
SY	#2# beta 1,4-N-acetylgalactosaminyltransferase-A <27,28>
SY	#2,4# beta1,4-N-acetylgalactosaminyltransferase <29>
SY	#2,4# beta4GalNAc-T1 <29>
SY	#3# N-acetylgalactosaminyltransferase I <41>
SY	#3# GM3S <42>
SY	#3# GA2/GM2/GD2/GT2-synthase <41>
SY	#3# GM2S <42>
SY	#3# Galgt1 (#3# gene name <42>) <42>
SY	#3,4# GM3 synthase <36,37,39,40,42>
SY	#3,4# GD2/GM2 synthase <37,38,39>
SY	#3,4,8,12# GM2 synthase <34,42,44,46,47>
SY	#4# ST3Gal V <40>
SY	#4# beta4GalNAcT-II <32>
SY	#4# Sda beta-1,4-N-acetylgalactosaminyltransferase II <32>
SY	#4# beta-1,4-N-acetylgalactosyltransferase II <32>
SY	#4# GALGT <34>
SY	#4# beta-1,4-N-acetylgalactosaminyl-transferase <34>
SY	#4# GD2 synthetase <34>
SY	#7# beta-(1-4)-N-acetylgalactosaminyltransferase <30>
SY	#7# CgtA <30>
SY	#7# beta-(1->4)-N-acetylgalactosaminyltransferase <35>
SY	#7# CJL-30 <35>
SY	#8# beta-1,4 N-acetylgalactosaminyltransferase 1 (#8# UniProt <43>) <43>
SY	#8# beta-1,4-N-acetyl-galactosaminyltransferase 1 <44>
SY	#8,12# GD2 synthase <31,47>
SY	#8,9# GM2/GD2 synthase <33,43,45>

REACTION
RE	UDP-N-acetyl-alpha-D-galactosamine +
	O-(N-acetyl-alpha-neuraminyl)-(2->3)-O-beta-D-galactopyranosyl-(1->4)
	beta-D-glucopyranosyl-(1<->1)-ceramide = UDP +
	O-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1->4)-O-[N-acetyl
	alpha-neuraminyl-(2->3)]-O-beta-D-galactopyranosyl-(1->4)-beta-D
	glucopyranosyl-(1<->1)-ceramide (#5# mechanism <6>; #2,4# residue 285
	determines the donor substrate specificity of the enzyme, catalytic
	binding pocket structure, overview <29>)

REACTION_TYPE
RT	hexosyl group transfer

SOURCE_TISSUE
ST	#1# CHO-K1 cell <23>
ST	#1,11# ovary <10,21>
ST	#11# kidney (#11# fetal <21>) <21>
ST	#11# lung (#11# fetal <21>) <21>
ST	#2# muscle <28>
ST	#2# larva (#2# third instar larvae <27>) <27,28>
ST	#2,8# neuron <28,44>
ST	#3# MEF cell <42>
ST	#3# neuroepithelial cell <41>
ST	#3,5,12# liver <3,5,6,8,18,19,20,46,47>
ST	#3,5,8,11# brain (#11# adult and fetal <21>; #3# embryonic, postnatal,
	and adult brains <41>) <1,2,7,21,41,44>
ST	#4# T-lymphocyte <34>
ST	#4# MCF-7 cell <34>
ST	#4# gastric mucosa <32>
ST	#4# Hep-G2 cell <34>
ST	#4# JURKAT cell <34>
ST	#4# neuroblastoma cell line <4>
ST	#4# colonic cancer cell <32>
ST	#4# neuroblastoma cell <38>
ST	#4# gastric cancer cell <32>
ST	#4# melanoma cell line <4>
ST	#4# KATO-III cell <32>
ST	#4# SK-N-SH cell <34>
ST	#4# IMR-32 cell <34>
ST	#4# ARPE-19 cell <40>
ST	#4# ovary cancer cell <36>
ST	#4# A-2780 cell <36>
ST	#4# NCI-H82 cell <38>
ST	#4# small cell lung carcinoma cell <38>
ST	#4# NMB-7 cell <38>
ST	#4# retinal pigment epithelial cell <40>
ST	#4# NCI-H69 cell <38>
ST	#4# NB-39 cell <34>
ST	#4# NCR-EW2 cell <34>
ST	#4# SCMC-ES1 cell <34>
ST	#4# SK-RC-26B cell <34>
ST	#4# NCI-H187 cell <38>
ST	#4# NCI-H196 cell <38>
ST	#4# NCI-H345 cell <38>
ST	#4# NCI-H524 cell <38>
ST	#8# fibroblast <44>
ST	#8# adipose tissue <31>
ST	#8# bone marrow <31>
ST	#8# melanoma cell (#8# high expression level <43>) <43>
ST	#8# melanocyte <43>
ST	#8# MeWo cell <43>
ST	#8# mesenchymal stromal cell <31>
ST	#8# MSC cell <31>
ST	#8# SK-Mel-28 cell <43>
ST	#8# SK-MEL-23 cell <43>
ST	#8# SK-MEL-37 cell <43>
ST	#8,9# more (#8# not expressed on foreskin fibroblasts <31>; #9#
	ganglioside profile analyses in brain tissues, overview. Tissue
	dependent ganglioside alteration in IDUA KO mice with a total
	ganglioside increase in cortex and cerebellum, and a selective presence
	of GM3, GM2 and GD3 gangliosides in the hippocampus and hypothalamus.
	Evaluation of gene expression of ganglioside synthesis (GM3, GD3 and
	GM2/GD2 synthases) and degradation of (neuraminidase1) enzymes in the
	cerebellum and hippocampus by RT-sq-PCR. Percentage distribution of
	gangliosides in wild-type and IDUA knockout mice, overview <45>) <31,45>
ST	#9# hypothalamus <45>
ST	#9# hippocampus <45>
ST	#9# astrocyte <33>

LOCALIZATION
LO	#1,3,4,5,8,10,12# Golgi apparatus (#4# functionally coupled to GD3
	synthase <16>; #8# dimerization occurs in the ER <12>)
	<3,5,6,11,12,15,16,18,19,23,24,44,46>
LO	#12# Golgi vesicle <47>
LO	#3,5# membrane (#5# mitochondria-associated membrane, i.e. a membrane
	bridge between the endoplasmic reticulum and mitochondria <20>) <20,26>
LO	#5# microsome <2>
LO	#5# mitochondrion <2>

NATURAL_SUBSTRATE_PRODUCT
NSP	#2,4# more = ? (#2,4# during evolution, beta4Gal-T1 appears as a result
	of the single amino acid substitution of Tyr or Phe for Leu or Ile in
	the invertebrate beta4GalNAc-T1, overview <29>; #2# the enzyme
	synthesizes the LacdiNAc structures, with GalNAcbeta1,4GlcNAc, on
	several glycoproteins and glycosphingolipids, including N-glycans,
	O-glycans, and the arthro-series GSLs,
	GalNAcbeta1,4Glc-NAcbeta1,3Manbeta1,4Glcbeta1Cer, and neutral GSLs, in
	vitro and in vivo, the GalNAcbeta1,4GlcNAc, i.e. LacdiNAc or LDN,
	structure is a more common structural feature in invertebrate
	glycoconjugates when compared with the Galbeta1,4GlcNAc, i.e. LacNAc or
	LN, structure <27>) {} <27,29>
NSP	#2,4# more = ? (#2,4# during evolution, beta4Gal-T1 appears as a result
	of the single amino acid substitution of Tyr or Phe for Leu or Ile in
	the invertebrate beta4GalNAc-T1, overview <29>; #2# the enzyme
	synthesizes the LacdiNAc structures, with GalNAcbeta1,4GlcNAc, on
	several glycoproteins and glycosphingolipids, including N-glycans,
	O-glycans, and the arthro-series GSLs,
	GalNAcbeta1,4Glc-NAcbeta1,3Manbeta1,4Glcbeta1Cer, and neutral GSLs, in
	vitro and in vivo, the GalNAcbeta1,4GlcNAc, i.e. LacdiNAc or LDN,
	structure is a more common structural feature in invertebrate
	glycoconjugates when compared with the Galbeta1,4GlcNAc, i.e. LacNAc or
	LN, structure <27>) {} <27,29>
NSP	#5,8# UDP-N-acetyl-D-galactosamine +
	(N-acetylneuraminyl)-D-galactosyl-D-glucosylceramide = UDP +
	N-acetyl-D-galactosaminyl-(N-acetylneuraminyl)-D-galactosyl-D
	glucosylceramide (#8# relative glycosyltransferase levels involved in
	determining the ganglioside composition of cells <14>; #5# model for
	ganglioside biosynthesis <6>; #5# involved in biosynthesis of
	gangliosides in brain <2>) <2,6,14>
NSP	#7# UDP-N-acetyl-D-galactosamine +
	1-O-[O-(N-acetyl-alpha-neuraminosyl)-(2-3)-O-beta-D-galactopyranosyl-(1
	4)-beta-D-glucopyranosyl]-ceramide = ? (#7# ganglioside GM3 <30>) <30>
NSP	#7# UDP-N-acetyl-D-galactosamine +
	1-O-[O-(N-acetyl-alpha-neuraminosyl)-(2-3)-O-beta-D-galactopyranosyl-(1
	4)-beta-D-glucopyranosyl]-ceramide = UDP +
	1-O-[O-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1-4)-O-[N
	acetyl-alpha-neuraminosyl-(2-3)]-O-beta-D-galactopyranosyl-(1-4)-beta-D
	glucopyranosyl]-ceramide <30>
NSP	#7# UDP-N-acetyl-D-galactosamine +
	1-O-[O-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1-4)-O-[N
	acetyl-alpha-neuraminosyl-(2-3)]-O-beta-D-galactopyranosyl-(1-4)-beta-D
	glucopyranosyl]-ceramide = ? (#7# ganglioside GM2 <30>) <30>
NSP	#8# UDP-N-acetyl-alpha-D-galactosamine + ganglioside GM3 = UDP +
	ganglioside GM2 <43>

SUBSTRATE_PRODUCT
SP	#10# UDP-galactose + p-nitrophenyl-GlcNAc = UDP +
	Gal-beta(1-4)GlcNAc-p-nitrophenyl (#10# 50% of activity with
	UDP-N-acetylgalactosamine <24>) <24>
SP	#10# UDP-N-acetylgalactosamine + p-nitrophenyl-GlcNAc = UDP +
	GalNac-beta(1-4)GlcNAc-p-nitrophenyl <24>
SP	#10# UDP-N-acetylglucosamine + p-nitrophenyl-GlcNAc = UDP +
	GlcNAc-beta(1-4)GlcNAc-p-nitrophenyl (#10# 50% of activity with
	UDP-N-acetylgalactosamine <24>) <24>
SP	#11# UDP-N-acetylgalactosamine +
	GlcNAcbeta(1-3)GalNAcalpha-p-nitrophenol (core 3-p-nitrophenol) = UDP +
	GalNAcbeta(1-4)GlcNAcbeta(1-3)GalNAcalpha-p-nitrophenol (#11# 20% of
	activity compared with N-acetylglucosamine-beta-benzyl <21>) <21>
SP	#11# UDP-N-acetylgalactosamine +
	GlcNAcbeta(1-6)(Galbeta1-3)GalNAcalpha-p-nitrophenol (core
	2-p-nitrophenol) = UDP +
	GalNAcbeta(1-4)GlcNAcbeta(1-6)(Galbeta1-3)GalNAcalpha-p-nitrophenol
	(#11# 15.2% of activity compared with N-acetylglucosamine-beta-benzyl
	<21>) <21>
SP	#11# UDP-N-acetylgalactosamine +
	GlcNAcbeta(1-6)GalNAcalpha-p-nitrophenol (core 6-p-nitrophenol) = UDP +
	GalNAcbeta(1-4)GlcNAcbeta(1-6)GalNAcalpha-p-nitrophenol (#11# 190.7% of
	activity compared with N-acetylglucosamine-beta-benzyl <21>) <21>
SP	#11# UDP-N-acetylgalactosamine + N-acetylglucosamine-beta-benzyl =
	N,N'-diacetyllactosediamine + benzol |#11# formation of
	beta-1,4-linkage <21>| <21>
SP	#12# UDP-N-acetyl-alpha-D-galactosamine + ganglioside GD3 = UDP +
	ganglioside GD2 (#12# ganglioside GD3 i.e.
	1-O-[O-(N-acetyl-alpha-neuraminyl)-(2->8)-O-(N-acetyl-alpha-neuraminyl)
	(2->3)-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl]-ceramide
	<47>) <47>
SP	#12# UDP-N-acetyl-alpha-D-galactosamine + ganglioside GM3 amide = UDP +
	ganglioside GM2 amide (#12# 10% of the activity with ganglioside GM3
	<46>) <46>
SP	#12# UDP-N-acetyl-alpha-D-galactosamine + ganglioside GM3 methyl ester
	= UDP + ganglioside GM2 methyl ester (#12# 13% of the activity with
	ganglioside GM3 <46>) <46>
SP	#12# UDP-N-acetyl-alpha-D-galactosamine + ganglioside GM3 methylamide =
	UDP + ganglioside GM2 methylamide (#12# 1% of the activity with
	ganglioside GM3 <46>) <46>
SP	#12# UDP-N-acetyl-alpha-D-galactosamine + ganglioside GM3 =
	UDP-N-acetyl-alpha-D-galactosamine + ganglioside GM2 (#12# ganglioside
	GM3 i.e.
	1-O-[O-(N-acetyl-alpha-neuraminyl)-(2->3)-O-beta-D-galactopyranosyl-(1
	>4)-beta-D-glucopyranosyl]-ceramide <47>) <47>
SP	#12# UDP-N-acetyl-alpha-D-galactosamine + ganglioside lyso-GM3 = UDP +
	ganglioside lyso-GM2 (#12# 28% of the activity with ganglioside GM3
	<46>) <46>
SP	#12# UDP-N-acetyl-alpha-D-galactosamine + ganglioside N-acetyl-lyso-GM3
	= UDP + anglioside N-acetyl-lyso-GM2 (#12# 160% of the activity with
	ganglioside GM3 <46>) <46>
SP	#12# UDP-N-acetyl-alpha-D-galactosamine + ganglioside
	N-octanoyl-lyso-GM3 = UDP + ganglioside N-octanoyl-lyso-GM2 (#12# 122%
	of the activity with ganglioside GM3 <46>) <46>
SP	#12# UDP-N-acetyl-alpha-D-galactosamine + ganglioside
	N1-pyrenyl-dodecanoyl-lyso-GM3 = UDP + ganglioside
	N1-pyrenyl-dodecanoyl-lyso-GM2 (#12# 102% of the activity with
	ganglioside GM3 <46>) <46>
SP	#12# UDP-N-acetyl-alpha-D-galactosamine + lactosylceramide =
	UDP-N-acetyl-alpha-D-galactosamine + ganglioside GA2 <47>
SP	#2# UDP-GalNAc + GlcNAcbeta1,3Fuc = UDP + GalNAcbeta1,4GlcNAcbeta1,3Fuc
	(#2# DNS-labeled acceptor substrate <27>) <27>
SP	#2,3,4,5,6,7,8,10,11# more = ? (#5# acceptor specificity <18>; #5# poor
	substrate: GM2-, GM1-, GD1b- and GT1-gangliosides and various ceramides
	<2>; #5# no substrate: N-acetylglucosamine <2>; #8# overview on
	substrate specificity <15>; #3# no substrate: lactosylceramide,
	sialylparagloboside, GM1b(N-glycolylneuraminic acid),
	GD1a(N-acetylneuraminic acid), GT1b(N-acetylneuraminic acid),
	GQ1b(N-acetylneuraminic acid), GM1a(N-acetylneuraminic acid),
	GD1b(N-acetylneuraminic acid), globoside <5>; #5# no substrates are
	SM4-ganglioside, Gb3- and Gb4-ceramide <7>; #5# no substrate: blood
	type H glycoprotein, deglucosylated bovine submaxillary mucin, various
	ceramides <8>; #3# poor substrate: sialyllactose <5>; #11# enzyme shows
	similar specificities for O-and N-glykans. Efficiency of transfer
	decreases as the number of antennas increases <21>; #10# no in vitro
	transfer of substrates other than UDP-N-acetylgalactosamine to
	synthetic N-glycans <24>; #6# stable expression of enzyme in CHO-Lec8
	cells, production of complex-type N-glycans quantitatively bearing
	LacdiNAc-structures on their antennae and containing repeating
	LacdiNAc-structures <25>; #2,4# during evolution, beta4Gal-T1 appears
	as a result of the single amino acid substitution of Tyr or Phe for Leu
	or Ile in the invertebrate beta4GalNAc-T1, overview <29>; #2# the
	enzyme synthesizes the LacdiNAc structures, with GalNAcbeta1,4GlcNAc,
	on several glycoproteins and glycosphingolipids, including N-glycans,
	O-glycans, and the arthro-series GSLs,
	GalNAcbeta1,4Glc-NAcbeta1,3Manbeta1,4Glcbeta1Cer, and neutral GSLs, in
	vitro and in vivo, the GalNAcbeta1,4GlcNAc, i.e. LacdiNAc or LDN,
	structure is a more common structural feature in invertebrate
	glycoconjugates when compared with the Galbeta1,4GlcNAc, i.e. LacNAc or
	LN, structure <27>; #7# carbohydrate-protein conjugate enzyme activity
	with truncated ceramides, analogues of GM3 and GM2 gangliosides,
	compound sythesis, overview <30>; #2# no activity with donor
	UDP-galactose, the enzyme synthesizes the LacdiNAc structures, with
	GalNAcbeta1,4GlcNAc, on several glycoproteins and glycosphingolipids,
	including N-glycans, O-glycans, and the arthro-series GSLs, such as
	GalNAcbeta1,4Glc-NAcbeta1,3Manbeta1,4Glcbeta1Cer, and neutral GSLs, in
	vitro and in vivo <27>; #2# the wild-type Drosophila beta4GalNAc-T1
	enzyme binds to the mammary gland-specific protein alpha-lactalbumin
	<29>) {} <2,5,7,8,15,18,21,24,25,27,29,30>
SP	#2,3,4,5,6,7,8,10,11# more = ? (#5# acceptor specificity <18>; #5# poor
	substrate: GM2-, GM1-, GD1b- and GT1-gangliosides and various ceramides
	<2>; #5# no substrate: N-acetylglucosamine <2>; #8# overview on
	substrate specificity <15>; #3# no substrate: lactosylceramide,
	sialylparagloboside, GM1b(N-glycolylneuraminic acid),
	GD1a(N-acetylneuraminic acid), GT1b(N-acetylneuraminic acid),
	GQ1b(N-acetylneuraminic acid), GM1a(N-acetylneuraminic acid),
	GD1b(N-acetylneuraminic acid), globoside <5>; #5# no substrates are
	SM4-ganglioside, Gb3- and Gb4-ceramide <7>; #5# no substrate: blood
	type H glycoprotein, deglucosylated bovine submaxillary mucin, various
	ceramides <8>; #3# poor substrate: sialyllactose <5>; #11# enzyme shows
	similar specificities for O-and N-glykans. Efficiency of transfer
	decreases as the number of antennas increases <21>; #10# no in vitro
	transfer of substrates other than UDP-N-acetylgalactosamine to
	synthetic N-glycans <24>; #6# stable expression of enzyme in CHO-Lec8
	cells, production of complex-type N-glycans quantitatively bearing
	LacdiNAc-structures on their antennae and containing repeating
	LacdiNAc-structures <25>; #2,4# during evolution, beta4Gal-T1 appears
	as a result of the single amino acid substitution of Tyr or Phe for Leu
	or Ile in the invertebrate beta4GalNAc-T1, overview <29>; #2# the
	enzyme synthesizes the LacdiNAc structures, with GalNAcbeta1,4GlcNAc,
	on several glycoproteins and glycosphingolipids, including N-glycans,
	O-glycans, and the arthro-series GSLs,
	GalNAcbeta1,4Glc-NAcbeta1,3Manbeta1,4Glcbeta1Cer, and neutral GSLs, in
	vitro and in vivo, the GalNAcbeta1,4GlcNAc, i.e. LacdiNAc or LDN,
	structure is a more common structural feature in invertebrate
	glycoconjugates when compared with the Galbeta1,4GlcNAc, i.e. LacNAc or
	LN, structure <27>; #7# carbohydrate-protein conjugate enzyme activity
	with truncated ceramides, analogues of GM3 and GM2 gangliosides,
	compound sythesis, overview <30>; #2# no activity with donor
	UDP-galactose, the enzyme synthesizes the LacdiNAc structures, with
	GalNAcbeta1,4GlcNAc, on several glycoproteins and glycosphingolipids,
	including N-glycans, O-glycans, and the arthro-series GSLs, such as
	GalNAcbeta1,4Glc-NAcbeta1,3Manbeta1,4Glcbeta1Cer, and neutral GSLs, in
	vitro and in vivo <27>; #2# the wild-type Drosophila beta4GalNAc-T1
	enzyme binds to the mammary gland-specific protein alpha-lactalbumin
	<29>) {} <2,5,7,8,15,18,21,24,25,27,29,30>
SP	#2,3,4,5,8# UDP-N-acetyl-D-galactosamine +
	(N-acetylneuraminyl)-D-galactosyl-D-glucosylceramide = UDP +
	N-acetyl-D-galactosaminyl-(N-acetylneuraminyl)-D-galactosyl-D
	glucosylceramide (#3,5# 73%-78% as effective as
	GM3(N-glycolylneuraminic acid) <5,8>; #4,5# from human spleen or rat
	liver <3>; #5# less effective: GM3(O-acetyl-(N-glycolyl)neuraminic
	acid) <2>; #5,8# i.e. GM3(N-acetylneuraminic acid), best substrate
	<2,15>; #8# relative glycosyltransferase levels involved in determining
	the ganglioside composition of cells <14>; #5# model for ganglioside
	biosynthesis <6>; #5# involved in biosynthesis of gangliosides in brain
	<2>) |#3,5# i.e. GM2(N-acetylneuraminic acid)-ganglioside
	<2,3,5,6,7,8,18,19>| <2,3,5,6,7,8,14,15,18,19,28,32>
SP	#3# UDP-GalNAc + n-octyl-beta-D-glucopyranoside = UDP +
	GalNAcbeta(1-4)-glc-n-octyl <26>
SP	#3,4,5,8# UDP-N-acetyl-D-galactosamine + GD3-ganglioside = UDP +
	GD2-ganglioside (#3# GD3(N-glycolylneuraminic acid): 66% as effective
	as GM3(N-glycolylneuraminic acid), GD3(N-acetylneuraminic acid): 76% as
	effective as GM3(N-glycolylneuraminic acid) <5>) <5,6,15,34>
SP	#3,5# UDP-N-acetyl-D-galactosamine + GM3(N-glycolylneuraminic acid) =
	UDP + N-acetyl-D-galactosaminyl-GM3(N-glycolylneuraminic acid) <5,8>
SP	#3,5# UDP-N-acetyl-D-galactosamine + GM3(N-glycolylneuraminic
	acid)-ganglioside = UDP + GM2(N-glycolylneuraminic acid)-ganglioside
	(#3,5# best substrate <5,8>; #5# not as effective as
	GM3(N-acetylneuraminic acid) <2>) <2,5,8>
SP	#5# GM3(O-acetyl-(N-glycolyl)neuraminic acid) +
	UDP-N-acetyl-D-galactosamine = UDP +
	N-acetyl-D-galactosaminyl-GM3(O-acetyl-(N-glycolyl)neuraminic acid)
	(#5# less effective substrate <2>) {} <2>
SP	#5# UDP-N-acetyl-D-galactosamine + lactosylceramide = UDP +
	GA2-ganglioside <6>
SP	#5# UDP-N-acetyl-D-galactosamine + SM3-ganglioside = UDP +
	SM2-ganglioside (#5# best substrate, no substrates are SM4-ganglioside,
	Gb3- and Gb4-ceramide <7>) <7>
SP	#5# UDP-N-acetyl-D-galactosamine + N-acetylneuraminelactose = UDP +
	N-acetyl-D-galactosaminyl-N-acetylneuraminelactose (#5# i.e.
	sialyllactose <8>) <8>
SP	#6# human glycoprotein hormone alpha-subunit + ? = glycosylated human
	glycoprotein hormone alpha-subunit + ? {} <25>
SP	#7# UDP-N-acetyl-D-galactosamine +
	1-O-[O-(N-acetyl-alpha-neuraminosyl)-(2-3)-O-beta-D-galactopyranosyl-(1
	4)-beta-D-glucopyranosyl]-ceramide = ? (#7# ganglioside GM3 <30>) <30>
SP	#7# UDP-N-acetyl-D-galactosamine +
	1-O-[O-(N-acetyl-alpha-neuraminosyl)-(2-3)-O-beta-D-galactopyranosyl-(1
	4)-beta-D-glucopyranosyl]-ceramide = UDP +
	1-O-[O-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1-4)-O-[N
	acetyl-alpha-neuraminosyl-(2-3)]-O-beta-D-galactopyranosyl-(1-4)-beta-D
	glucopyranosyl]-ceramide <30>
SP	#7# UDP-N-acetyl-D-galactosamine +
	1-O-[O-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1-4)-O-[N
	acetyl-alpha-neuraminosyl-(2-3)]-O-beta-D-galactopyranosyl-(1-4)-beta-D
	glucopyranosyl]-ceramide = ? (#7# ganglioside GM2 <30>) <30>
SP	#7# UDP-GalNAc + 12-azidododecyl
	5-(acetylamino)-3
	5-dideoxy-beta-L-altro-non-2-ulopyranonosyl-(2->3)-beta-D
	galactopyranosyl-(1->4)-beta-D-glucopyranoside = UDP + 12-azidododecyl
	2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1->4)-[5-(acetylamino)
	3
	5-dideoxy-beta-L-altro-non-2-ulopyranonosyl-(2->3)]-beta-D
	galactopyranosyl-(1->4)-beta-D-glucopyranoside <35>
SP	#7# UDP-GalNAc + undec-10-enyl
	(5-acetamido-3
	5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic
	acid)-(2->3)-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranoside =
	UDP + undec-10-enyl
	(5-acetamido-3
	5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic
	acid)-(2->3)-[2-acetamido-2-deoxy-beta-D-galactopyranosyl-(1->4)]-beta
	D-galactopyranosyl-(1->4)-beta-D-glucopyranoside <35>
SP	#7# UDP-GalNAc + undec-10-yn-1-yl
	5-(acetylamino)-3
	5-dideoxy-beta-L-altro-non-2-ulopyranonosyl-(2->3)-beta-D
	galactopyranosyl-(1->4)-beta-D-glucopyranoside = UDP + undec-10-yn-1-yl
	2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1->4)-[5-(acetylamino)
	3
	5-dideoxy-beta-L-altro-non-2-ulopyranonosyl-(2->3)]-beta-D
	galactopyranosyl-(1->4)-beta-D-glucopyranoside <35>
SP	#8,12# UDP-N-acetyl-alpha-D-galactosamine + ganglioside GM3 = UDP +
	ganglioside GM2 (#12# ganglioside GM3 i.e.
	1-O-[O-(N-acetyl-alpha-neuraminyl)-(2->3)-O-beta-D-galactopyranosyl-(1
	>4)-beta-D-glucopyranosyl]-ceramideganglioside <46>) <43,46>

KM_VALUE
KM	#10# 0.38 {p-nitrophenyl-GlcNAc}  (#10# pH 7.0, 37°C <24>) <24>
KM	#10# 1.64 {UDP-N-acetylgalactosamine}  (#10# pH 7.0, 37°C <24>) <24>
KM	#12# 0.152 {ganglioside GD3}  (#12# pH 7.35, 37°C <47>) <47>
KM	#12# 0.385 {ganglioside GM3}  (#12# pH 7.35, 37°C <47>) <47>
KM	#3# 0.16 {GM3(N-glycolylneuraminic acid)}  <5>
KM	#3# 0.027 {GD3(N-glycolylneuraminic acid)}  <5>
KM	#3# 0.19 {UDP-GalNAc}  (#3# pH 7.3, 37°C, membrane-bound complete
	enzyme <26>) <26>
KM	#3# 0.007 {UDP-N-acetyl-D-galactosamine}  <5>
KM	#3# 0.35 {GD3(N-acetylneuraminic acid)}  <5>
KM	#3# 0.097 {UDP-GalNAc}  (#3# pH 7.3, 37°C, soluble domain <26>) <26>
KM	#3,5# -999 {more}  (#3# assay method <26>; #5# kinetic study <6>) <6,26>
KM	#5# 0.057 {UDP-N-acetyl-D-galactosamine}  <2>
KM	#5# 0.1 {GM3}  <3>
KM	#5# 0.19 {GM3}  <7>
KM	#5# 0.017 {UDP-N-acetyl-D-galactosamine}  <8>
KM	#5# 2.1 {GM3(N-acetylneuraminic acid)}  <7>
KM	#5# 0.035 {UDP-N-acetyl-D-galactosamine}  <3>
KM	#5# 0.026 {UDP-N-acetyl-D-galactosamine}  (#5# cosubstrate GM3 <7>) <7>
KM	#5# 0.0166 {GM3}  <2>
KM	#5# 0.082 {UDP-N-acetyl-D-galactosamine}  (#5# cosubstrate SM3 <7>) <7>

PH_OPTIMUM
PHO	#12# 7.35 (#12# assay at <46,47>) <46,47>
PHO	#2# 7.2-7.4 (#2# assay at <27>) <27>
PHO	#3# 7.5-7.9 <5>
PHO	#5# 7-7.5 <7>
PHO	#5# 7.2 <3>
PHO	#5# 6.8-7.2 <2>
PHO	#5# 6.7-6.9 <8>

PH_RANGE
PHR	#5# 6.2-8.5 (#5# about half-maximal activity at pH 6.2 and about 85% of
	maximal activity at pH 8.5 <7>) <7>

SPECIFIC_ACTIVITY
SA	#2# -999.0 <27>
SA	#3# 3.6 <5>
SA	#3# 53.3 (#3# pH 7.3, 37°C, soluble domain <26>) <26>
SA	#3# 4566.0 (#3# pH 7.3, 37°C, membrane-bound complete enzyme <26>) <26>
SA	#5# 0.000149 <8>
SA	#5# 0.0004 <3>

TEMPERATURE_OPTIMUM
TO	#2# 25 (#2# assay at <27>) <27>
TO	#3,5,12# 37 (#3,5,12# assay at <2,5,6,18,19,46,47>) <2,5,6,18,19,46,47>

ACTIVATING_COMPOUND
AC	#3# Endogen lipid factor <5>
AC	#3,5# Detergents (#3,5# requirement, solubilized enzyme, e.g. Triton
	X-100 <3,5,6,18,19>; #5# CF-54, Tween 80 <2>) <2,3,5,6,18,19>
AC	#3,5,12# Triton X-100 <3,5,6,18,19,47>
AC	#4# more (#4# promoter DNA methylation plays a crucial role in the
	regulation of the Sda beta4GalNAcT-II gene and Sda antigen expression
	<32>) <32>
AC	#5# Tween 80 <2>
AC	#5# cardiolipin <3>
AC	#5# Triton CF-54 <2>
AC	#5# octylglucoside (#5# activation <3,19>; #5# optimal: 0.8% <3>) <3,19>
AC	#5# Heptylthioglucoside (#5# activation <7>) <7>
AC	#5,12# phosphatidylglycerol (#5# activation, detergent-free assay
	<18,19>; #12# stimulates the activity of GM2 synthase without
	disrupting the vesicular intactness <46>) <18,19,46>

INHIBITORS
IN	#12# ganglioside GM3 (#12# competitive inhibition of GD2 synthesis
	<47>) <47>
IN	#12# ganglioside GD3 (#12# competitive inhibition of GM2 synthesis
	<47>) <47>
IN	#12# more (#12# no inhibition by ganglioside GQ1b <47>) <47>
IN	#5# EDTA <8>
IN	#5# CMP <3>
IN	#5# IMP <3>
IN	#5# UDPgalactose <8>
IN	#5# ganglioside GM1 <19>
IN	#5# ganglioside GT1b <19>
IN	#5# ganglioside GD1a <19>
IN	#5# ganglioside GM2 <19>
IN	#5# Chelex-100 <8>
IN	#5# adenosine-5'-[alpha,beta-methylene]triphosphate <3>
IN	#5# GM3 (#5# GD3 as substrate <6>) <6>
IN	#5# GD3 (#5# GM3 as substrate <6>) <6>
IN	#5# ganglioside GQ1b (#5# not in detergent-solubilized enzyme assays,
	kinetics <19>) <19>

KI_VALUE
KI	#12# 0.12 {ganglioside GM3}  (#12# inhibition of GD2 synthesis, pH
	7.35, 37°C <47>) <47>
KI	#12# 0.066 {ganglioside GD3}  (#12# inhibition of GM2 synthesis, pH
	7.35, 37°C <47>) <47>

METALS_IONS
ME	#2,3,5# Mn2+ (#3# requirement, 2.5-10 mM <5>; #5# can replace Ni2+ to
	some extent <8>) <2,3,5,7,8,27>
ME	#3,5# Mg2+ (#5# not <2,3,7,8>; #3# activation, 22% as effective as Mn2+
	<5>) <2,3,5,7,8>
ME	#3,5# Ca2+ (#5# not <2,3,7,8>; #3# activation, 27% as effective as Mn2+
	<5>) <2,3,5,7,8>
ME	#3,5# Co2+ (#5# not <8>; #5# activation, can replace Mn2+ to some
	extent <3>; #3# 62% as effective as Mn2+ <5>) <3,5,8>
ME	#3,5# Fe2+ (#5# activation, can replace Mn2+ <3>; #3# activation, can
	replace Ni2+ to some extent, 17% as effective as Mn2+ <5>) <3,5,8>
ME	#3,5# Ni2+ (#5# not <2>; #5# can replace Mn2+ to some extent <3>; #5#
	requirement, most active, 10-20 mM <8>; #3# 5% as effective as Mn2+
	<5>) <2,3,5,8>
ME	#5# more (#5# no activation by K+, Al3+ <2>; #5# no activation by Zn2+
	<7,8>; #5# no activation by Ba2+ <3>) <2,3,7,8>
ME	#5# Cu2+ (#5# activation, can replace Ni2+ to some extent <8>) <8>
ME	#5# Cd2+ (#5# activation, can replace Mn2+ to some extent <3>) <3>

MOLECULAR_WEIGHT
MW	#3# 65000 (#3# 2 * 65000, SDS-PAGE <5>) <5>
MW	#3# 60000 (#3# 2 * 60000, SDS-PAGE <26>) <26>
MW	#3,5# 120000 (#5# gel filtration <8>; #3# PAGE <26>) <8,26>
MW	#5# 64000 (#5# 2 * 64000, SDS-PAGE <8>) <8>

POSTTRANSLATIONAL_MODIFICATION
PM	#11# more (#11# protein has 3 potential N-gylcosylation sites and a
	DXH-sequence <21>) <21>
PM	#8# glycoprotein (#8# all 3 glycosylation sites occupied by glycans,
	elimination of one or several sites leads to decrease in activity up to
	90% <12>; #8# 3 N-glycosylation sites at 79,179, 274 <15>) <12,15>

SUBUNITS
SU	#1,3,4,8,11# More (#3# probably enzyme complex with sialyltransferase
	II <9>; #4# enzyme is functionally coupled to GD3 synthase <16>; #8#
	dimer formation occurs in ER, strategy to test for dimerization of
	Golgi membrane proteins <12>; #1# enzyme is homodimer with antiparallel
	orientation of catalytic domains and intersubunit disulfide bonds <10>;
	#1# forms an in vivo complex with UDP-Gal:GA2/GM2/GD2/GT2
	galactosyltransferase, complex assembles in the endoplasmic reticulum
	<23>; #11# type II transmembrane protein <21>) <9,10,12,16,21,23>
SU	#3,5# dimer (#3# 2 * 60000, SDS-PAGE <26>; #5# 2 * 64000, SDS-PAGE <8>;
	#3# 2 * 65000, SDS-PAGE <5>) <5,8,26>

APPLICATION
AP	#3,6,7# synthesis (#3# expression of enzyme both as complete
	membrane-bound enzyme and as a soluble form in the baculovirus insect
	cell expression system <26>; #6# stable expression of enzyme in
	CHO-Lec8 cells, production of complex-type N-glycans quantitatively
	bearing LacdiNAc-structures on their antennae and containing repeating
	LacdiNAc-structures <25>; #7# the immobilized enzyme might be useful in
	chemoenzymatical ceramide glycoconjugate synthesis <30>) <25,26,30>
AP	#4,8# medicine (#8# GD2 synthase is a surface marker for the
	identification of mesenchymal stromal cells <31>; #4# GD2/GM2 synthase
	mRNA is not a reliable biomarker for small cell lung cancer <38>)
	<31,38>

ENGINEERING
EN	#1,2,3,8,9# more (#3# fusion protein with green, red or yellow
	fluorescent protein, localization to ER and Golgi, probably forms
	complex with sialyl-transferase II <9>; #9# overexpression of gene
	leads to shift of ganglioside components from b-series to a-series
	<15>; #1# site directed mutations in several Cys residues reveal that
	enzyme is homodimer with antiparallel orientation of catalytic domains
	and intersubunit disulfide bonds <10>; #8# 3 different epitope-tagged
	forms of enzyme, enzyme is homodimer and has disulfide bonds, is
	localized to Golgi <11>; #8# elimination of one or several
	glycosylation sites leads to decrease in activity up to 90% <12>; #2#
	isoform betaGalNAcTA null mutants are viable and fertile, but display
	behavioral phenotypes suggesting roles of enzyme in neuronal and/or
	muscle function. Isoform betaGalNAcTB null mutants are viable and show
	no evident morphological or behavioral phenotype. Double mutants
	display only the phenotypes associated with mutation of betaGalNAcTA
	<22>; #2# enzyme activity in beta4GalNAcT RNAi flies is reduced <27>;
	#2# beta4GalNAcTA null mutant larvae show frequent backward crawling,
	reductions in nerve terminal bouton number, decreased spontaneous
	transmitter release frequency, and short, wide, hypercontracted muscles
	with low calcium content, indicating a role for this enzyme in the
	neuromuscular system <28>; #9# comparisons of relative expressions of
	ganglioside metabolism genes in wild-type and IDUA knockout mice,
	overview <45>) <9,10,11,12,13,15,22,27,28,45>
EN	#2# I285Y (#2# site-directed mutagenesis, mutation of the residue to
	the human analogue results in change of substrate specificity from a
	beta4GalNAc-T1 to a beta4Gal-T1 by reducing its
	N-acetylgalactosaminyltransferase activity by nearly 1000fold, fold,
	while enhancing its galactosyltransferase activity by 80fold, overview
	<29>) <29>
EN	#4# Y285I (#4# site-directed mutagenesis, mutation of the residue to
	the Drosophila melanogaster analogue results in change of substrate
	specificity from a beta4Gal-T1 to a beta4GalNAc-T1, overview <29>) <29>
EN	#8# D356A/D356N (#8# variation of DXD motif, activity almost completely
	lost <17>) <17>
EN	#8# D358A/D358N (#8# variation of DXD motif, activity almost completely
	lost <17>) <17>
EN	#8# V352A (#8# 167% of wild type activity <17>) <17>
EN	#8# W354A (#8# 24% of wild type activity <17>) <17>
EN	#8# D356E (#8# variation of DXD motif, weak activity <17>) <17>
EN	#8# D357N (#8# variation of DXD motif, weak activity <17>) <17>
EN	#8# D356N/D357N/D358N (#8# variation of DXD motif, activity almost
	completely lost, no alteration in nucleotide binding <17>) <17>

CLONED
CL	#2# (enzyme expression analysis in larvae, expression of the
	FLAG-tagged catalytic domain, comprisisng residues 62–403, in the
	Spodoptera frugiperda Sf21 cell baculovirus expression system) <27>
CL	#4# <4>
CL	#7# (expression in Escherichia coli strain AD202) <30>
CL	#8# (gene B4GALNT1, genotyping and linkage analysis) <44>
CL	#8# (gene B4GALNT1, quantitative enzyme expression analysis, mRNA
	expressions of glycosyltransferases by qRT-PCR in melanocytes and
	melanoma lines, overview) <43>
CL	#9# (gene B4GALNT1, semi-quantitative PCR enzyme expression analysis in
	brain tissues in wild-type and IDUA knockout mice) <45>
CL	#11# <21>

PURIFICATION
PU	#2# (recombinant FLAG-tagged catalytic domain from Spodoptera
	frugiperda Sf21 cells by anti-FLAG M1 affinity chromatography) <27>
PU	#3# <5>
PU	#5# (Triton X-100 solubilized, affinity chromatography on GM3-acid
	Sepharose) <8>

GENERAL_STABILITY
GS	#3# (glycerol, 20% v/v, stabilizes) <5>
GS	#5# (detergents stabilize) <8>

STORAGE_STABILITY
SS	#3# (-70°C, 3 months, crude) <5>
SS	#3# (4°C, purified enzyme, at least 6 days in 20% v/v glycerol, 1% w/v
	heptylthioglucoside, 1 M sucrose, 0.2 M NaCl and 1 mM EDTA in 0.03 M
	cacodylate buffer, pH 6.9) <5>
SS	#5# (-80°C, several months, crude Triton X-100 extract) <7>
SS	#5# (-80°C, stable in 20% v/v glycerol, 1% v/v Triton X-100) <8>

REFERENCE
RF	<1> Scheideler, M.A.; Dawson, G.: Direct demonstration of the
	activation of UDP-N-acetylgalactosamine:
	[GM3]N-acetylgalactosaminyltransferase by cyclic AMP. J. Neurochem.
	(1986) 46, 1639-1643. {Pubmed:2420936}
RF	<2> Dicesare, J.L.; Dain, J.A.: The enzymic synthesis of ganglioside.
	IV. UDP-N-acetylgalactosamine: (N-acetylneuraminyl)-galactosylglucosyl
	ceramide N-acetylgalactosaminyltransferase in rat brain. Biochim.
	Biophys. Acta (1971) 231, 385-393. {Pubmed:5554906}
RF	<3> Senn, H.J.; Cooper, C.; Warnke, P.C.; Wagner, M.; Decker, K.:
	Ganglioside biosynthesis in rat liver. Characterization of
	UDP-N-acetylgalactosamine - GM3 acetylgalactosaminyltransferase. Eur.
	J. Biochem. (1981) 120, 59-67. {Pubmed:6118272}
RF	<4> Nagata, Y.; Yamashiro, S.; Yodoi, J.; Lloyd, K.O.; Shiku, H.;
	Furukawa, K.: Expression cloning of beta 1,4
	N-acetylgalactosaminyltransferase cDNAs that determine the expression
	of GM2 and GD2 gangliosides [published erratum appears in J Biol Chem
	1994 Mar 4;269(9):7045]. J. Biol. Chem. (1992) 267, 12082-12089.
	{Pubmed:1601877}
RF	<5> Hashimoto, Y.; Sekine, M.; Iwasaki, K.; Suzuki, A.: Purification
	and characterization of UDP-N-acetylgalactosamine GM3/GD3
	N-acetylgalactosaminyltransferase from mouse liver. J. Biol. Chem.
	(1993) 268, 25857-25864. {Pubmed:8245020}
RF	<6> Pohlentz, G.; Klein, D.; Schwarzmann, G.; Schmitz, D.; Sandhoff,
	K.: Both GA2, GM2, and GD2 synthases and GM1b, GD1a, and GT1b synthases
	are single enzymes in Golgi vesicles from rat liver. Proc. Natl. Acad.
	Sci. USA (1988) 85, 7044-7048. {Pubmed:3140234}
RF	<7> Nagai, K.I.; Ishizuka, I.: Biosynthesis of
	monosulfogangliotriaosylceramide and GM2 by
	N-acetylgalactosaminyltransferase from rat brain. J. Biochem. (1987)
	101, 1115-1127. {Pubmed:3115968}
RF	<8> Yanagisawa, K.; Taniguchi, N.; Makita, A.: Purification and
	properties of GM2 synthase, UDP-N-acetylgalactosamine: GM3
	beta-N-acetylgalactosaminyltransferase from rat liver. Biochim.
	Biophys. Acta (1987) 919, 213-220. {Pubmed:3109491}
RF	<9> Bieberich, E.; MacKinnon, S.; Silva, J.; Li, D.D.; Tencomnao, T.;
	Irwin, L.; Kapitonov, D.; Yu, R.K.: Regulation of ganglioside
	biosynthesis by enzyme complex formation of glycosyltransferases.
	Biochemistry (2002) 41, 11479-11487. {Pubmed:12234191}
RF	<10> Li, J.; Yen, T.Y.; Allende, M.L.; Joshi, R.K.; Cai, J.; Pierce,
	W.M.; Jaskiewicz, E.; Darling, D.S.; Macher, B.A.; Young, W.W., Jr.:
	Disulfide bonds of GM2 synthase homodimers. Antiparallel orientation of
	the catalytic domains. J. Biol. Chem. (2000) 275, 41476-41486.
	{Pubmed:11018043}
RF	<11> Jaskiewicz, E.; Zhu, G.; Taatjes, D.J.; Darling, D.S.; Zwanzig,
	G.E., Jr.; Young, W.W., Jr.: Cloned
	beta1,4N-acetylgalactosaminyltransferase: subcellular localization and
	formation of disulfide bonded species. Glycoconjugate J. (1996) 13,
	213-223. {Pubmed:8737246}
RF	<12> Zhu, G.; Jaskiewicz, E.; Bassi, R.; Darling, D.S.; Young, W.W.,
	Jr.: beta1,4 N-Acetylgalactosaminyltransferase (GM2/GD2/GA2 synthase)
	forms homodimers in the endoplasmic reticulum: a strategy to test for
	dimerization of Golgi membrane proteins. Glycobiology (1997) 7,
	987-996. {Pubmed:9363441}
RF	<13> Haraguchi, M.; Yamashiro, S.; Furukawa, K.; Takamiya, K.; Shiku,
	H.; Furukawa, K.: The effects of the site-directed removal of
	N-glycosylation sites from beta-1,4-N-acetylgalactosaminyltransferase
	on its function. Biochem. J. (1995) 312, 273-280. {Pubmed:}
RF	<14> Ruan, S.; Raj, B.K.M.; Furukawa, K.; Lloyd, K.O.: Analysis of
	melanoma cells stably transfected with b1,4GalNAc transferase (GM2/GD2
	synthase) cDNA: relative glycosyltransferase levels play a dominant
	role in determining ganglioside expression. Arch. Biochem. Biophys.
	(1995) 323, 11-18. {Pubmed:7487055}
RF	<15> Furukawa, K.; Takamiya, K.; Furukawa, K.:
	beta1,4-N-acetylgalactosaminyltransferase-GM2/GD2 synthase: a key
	enzyme to control the synthesis of brain-enriched complex gangliosides.
	Biochim. Biophys. Acta (2002) 1573, 356-362. {Pubmed:12417418}
RF	<16> Daniotti, J.L.; Martina, J.A.; Giraudo, C.G.; Zurita, A.R.;
	Maccioni, H.J.F.: GM3 alpha2,8-sialyltransferase (GD3 synthase):
	protein characterization and sub-Golgi location in CHO-K1 cells. J.
	Neurochem. (2000) 74, 1711-1720. {Pubmed:10737630}
RF	<17> Li, J.; Rancour, D.M.; Allende, M.L.; Worth, C.A.; Darling, D.S.;
	Gilbert, J.B.; Menon, A.K.; Young, W.W., Jr.: The DXD motif is required
	for GM2 synthase activity but is not critical for nucleotide binding.
	Glycobiology (2001) 11, 217-229. {Pubmed:11320060}
RF	<18> Klein, D.; Pohlentz, G.; Schwarzmann, G.; Sandhoff, K.: Substrate
	specificity of GM2 and GD3 synthase of Golgi vesicles derived from rat
	liver. Eur. J. Biochem. (1987) 167, 417-424. {Pubmed:3115774}
RF	<19> Yusuf, H.K.M.; Schwarzmann, G.; Pohlentz, G.; Sandhoff, K.:
	Oligosialogangliosides inhibit GM2- and GD3-synthesis in isolated Golgi
	vesicles from rat liver. Biol. Chem. Hoppe-Seyler (1987) 368, 455-462.
	{Pubmed:3113445}
RF	<20> Ardail, D.; Popa, I.; Bodennec, J.; Louisot, P.; Schmitt, D.;
	Portoukalian, J.: The mitochondria-associated endoplasmic-reticulum
	subcompartment (MAM fraction) of rat liver contains highly active
	sphingolipid-specific glycosyltransferases. Biochem. J. (2003) 371,
	1013-1019. {Pubmed:12578562}
RF	<21> Gotoh, M.; Sato, T.; Kiyohara, K.; Kameyama, A.; Kikuchi, N.;
	Kwon, Y.D.; Ishizuka, Y.; Iwai, T.; Nakanishi, H.; Narimatsu, H.:
	Molecular cloning and characterization of
	beta1,4-N-acetylgalactosaminyltransferases IV synthesizing
	N,N'-diacetyllactosediamine. FEBS Lett. (2004) 562, 134-140.
	{Pubmed:15044014}
RF	<22> Haines, N.; Irvine, K.D.: Functional analysis of Drosophila
	beta1,4-N-acetylgalactosaminyltransferases. Glycobiology (2005) 15,
	335-346. {Pubmed:15563714}
RF	<23> Giraudo, C.G.; Maccioni, H.J.F.: Ganglioside glycosyltransferases
	organize in distinct multienzyme complexes in CHO-K1 cells. J. Biol.
	Chem. (2003) 278, 40262-40271. {Pubmed:12900410}
RF	<24> Vadaie, N.; Jarvis, D.L.: Molecular cloning and functional
	characterization of a lepidopteran insect
	beta4-N-acetylgalactosaminyltransferase with broad substrate
	specificity, a functional role in glycoprotein biosynthesis, and a
	potential functional role in glycolipid biosynthesis. J. Biol. Chem.
	(2004) 279, 33501-33518. {Pubmed:15173167}
RF	<25> Kawar, Z.S.; Haslam, S.M.; Morris, H.R.; Dell, A.; Cummings, R.D.:
	Novel poly-GalNAcbeta1-4GlcNAc (LacdiNAc) and fucosylated poly-LacdiNAc
	N-glycans from mammalian cells expressing
	beta1,4-N-acetylgalactosaminyltransferase and
	alpha1,3-fucosyltransferase. J. Biol. Chem. (2005) 280, 12810-12819.
	{Pubmed:15653684}
RF	<26> Wendeler, M.; Reilaender, H.; Hoernschemeyer, J.; Schwarzmann, G.;
	Kolter, T.; Sandhoff, K.: Recombinant ganglioside GM2
	synthase-expression in insect cells and enzyme assay. Methods Enzymol.
	(2003) 363, 476-489. {Pubmed:14579597}
RF	<27> Sasaki, N.; Yoshida, H.; Fuwa, T.J.; Kinoshita-Toyoda, A.; Toyoda,
	H.; Hirabayashi, Y.; Ishida, H.; Ueda, R.; Nishihara, S.: Drosophila
	beta1,4-N-acetylgalactosaminyltransferase-A synthesizes the LacdiNAc
	structures on several glycoproteins and glycosphingolipids. Biochem.
	Biophys. Res. Commun. (2007) 354, 522-527. {Pubmed:17239818}
RF	<28> Haines, N.; Stewart, B.A.: Functional roles for
	beta1,4-N-acetylgalactosaminyltransferase-A in Drosophila larval
	neurons and muscles. Genetics (2007) 175, 671-679. {Pubmed:17151241}
RF	<29> Ramakrishnan, B.; Qasba, P.K.: Role of a single amino acid in the
	evolution of glycans of invertebrates and vertebrates. J. Mol. Biol.
	(2007) 365, 570-576. {Pubmed:17084860}
RF	<30> Jacques, S.; Rich, J.R.; Ling, C.; Bundle, D.R.: Chemo-enzymatic
	synthesis of GM3 and GM2 gangliosides containing a truncated ceramide
	functionalized for glycoconjugate synthesis and solid phase
	applications. Org. Biomol. Chem. (2006) 4, 142-154. {Pubmed:16358009}
RF	<31> Martinez, C.; Hofmann, T.J.; Marino, R.; Dominici, M.; Horwitz,
	E.M.: Human bone marrow mesenchymal stromal cells express the neural
	ganglioside GD2: a novel surface marker for the identification of MSCs.
	Blood (2007) 109, 4245-4248. {Pubmed:17264296}
RF	<32> Wang, H.R.; Hsieh, C.Y.; Twu, Y.C.; Yu, L.C.: Expression of the
	human Sda beta-1,4-N-acetylgalactosaminyltransferase II gene is
	dependent on the promoter methylation status. Glycobiology (2008) 18,
	104-113. {Pubmed:17965433}
RF	<33> Furukawa, K.; Aixinjueluo, W.; Kasama, T.; Ohkawa, Y.; Yoshihara,
	M.; Ohmi, Y.; Tajima, O.; Suzumura, A.; Kittaka, D.; Furukawa, K.:
	Disruption of GM2/GD2 synthase gene resulted in overt expression of
	9-O-acetyl GD3 irrespective of Tis21. J. Neurochem. (2008) 105,
	1057-1066. {Pubmed:18194438}
RF	<34> Ootsuka, S.; Asami, S.; Sasaki, T.; Yoshida, Y.; Nemoto, N.;
	Shichino, H.; Chin, M.; Mugishima, H.; Suzuki, T.: Useful markers for
	detecting minimal residual disease in cases of neuroblastoma. Biol.
	Pharm. Bull. (2008) 31, 1071-1074. {Pubmed:18520032}
RF	<35> Pukin, A.; Weijers, C.; van Lagen, B.; Wechselberger, R.; Sun, B.;
	Gilbert, M.; Karwaski, M.; Florack, D.; Jacobs, B.; Tio-Gillen, A.; van
	Belkum, A.; Endtz, H.; Visser, G.; Zuilhof, H.: GM3, GM2 and GM1 mimics
	designed for biosensing: chemoenzymatic synthesis, target affinities
	and 900 MHz NMR analysis. Carbohydr. Res. (2008) 343, 636-650.
	{Pubmed:18255051}
RF	<36> Prinetti, A.; Aureli, M.; Illuzzi, G.; Prioni, S.; Nocco, V.;
	Scandroglio, F.; Gagliano, N.; Tredici, G.; Rodriguez-Menendez, V.;
	Chigorno, V.; Sonnino, S.: GM3 synthase overexpression results in
	reduced cell motility and in caveolin-1 upregulation in human ovarian
	carcinoma cells. Glycobiology (2010) 20, 62-77. {Pubmed:19759399}
RF	<37> Li, H.; Turley, S.D.; Liu, B.; Repa, J.J.; Dietschy, J.M.: GM2/GD2
	and GM3 gangliosides have no effect on cellular cholesterol pools or
	turnover in normal or NPC1 mice. J. Lipid Res. (2008) 49, 1816-1828.
	{Pubmed:18450647}
RF	<38> Chen, L.C.; Brown, A.B.; Cheung, I.Y.; Cheung, N.K.; Kris, M.G.;
	Krug, L.M.: Analysis of GD2/GM2 synthase mRNA as a biomarker for small
	cell lung cancer. Lung Cancer (2010) 67, 216-220. {Pubmed:19457569}
RF	<39> Ohmi, Y.; Tajima, O.; Ohkawa, Y.; Mori, A.; Sugiura, Y.; Furukawa,
	K.; Furukawa, K.: Gangliosides play pivotal roles in the regulation of
	complement systems and in the maintenance of integrity in nerve
	tissues. Proc. Natl. Acad. Sci. USA (2009) 106, 22405-22410.
	{Pubmed:20018737}
RF	<40> Song, N.; Kim, S.J.; Kwon, H.Y.; Son, S.W.; Kim, K.S.; Ahn, H.B.;
	Lee, Y.C.: Transcriptional activation of human GM3 synthase (hST3Gal V)
	gene by valproic acid in ARPE-19 human retinal pigment epithelial
	cells. BMB Rep. (2011) 44, 405-409. {Pubmed:21699754}
RF	<41> Suzuki, Y.; Yanagisawa, M.; Ariga, T.; Yu, R.K.: Histone
	acetylation-mediated glycosyltransferase gene regulation in mouse brain
	during development. J. Neurochem. (2011) 116, 874-880. {Pubmed:21214566}
RF	<42> Liu, Y.; Yan, S.; Wondimu, A.; Bob, D.; Weiss, M.; Sliwinski, K.;
	Villar, J.; Notario, V.; Sutherland, M.; Colberg-Poley, A.M.; Ladisch,
	S.: Ganglioside synthase knockout in oncogene-transformed fibroblasts
	depletes gangliosides and impairs tumor growth. Oncogene (2010) 29,
	3297-3306. {Pubmed:20305696}
RF	<43> Miyata, M.; Ichihara, M.; Tajima, O.; Sobue, S.; Kambe, M.;
	Sugiura, K.; Furukawa, K.; Furukawa, K.: UVB-irradiated keratinocytes
	induce melanoma-associated ganglioside GD3 synthase gene in melanocytes
	via secretion of tumor necrosis factor alpha and interleukin 6.
	Biochem. Biophys. Res. Commun. (2014) 445, 504-510. {Pubmed:24548412}
RF	<44> Harlalka, G.V.; Lehman, A.; Chioza, B.; Baple, E.L.; Maroofian,
	R.; Cross, H.; Sreekantan-Nair, A.; Priestman, D.A.; Al-Turki, S.;
	McEntagart, M.E.; Proukakis, C.; Royle, L.; Kozak, R.P.; Bastaki, L.;
	Patton, M.; Wagner, K.; Coblentz, R.; Price, J.; Mezei, M.;
	Schlade-Bartusiak, K.; Platt, F.M.; Hurle, M.E.; Crosby, A.H.:
	Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of
	ganglioside biosynthesis. Brain (2013) 136, 3618-3624. {Pubmed:24103911}
RF	<45> Kreutz, F.; dos Santos Petry, F.; Camassola, M.; Schein, V.; Guma,
	F.C.; Nardi, N.B.; Trindade, V.M.: Alterations of membrane lipids and
	in gene expression of ganglioside metabolism in different brain
	structures in a mouse model of mucopolysaccharidosis type I (MPS I).
	Gene (2013) 527, 109-114. {Pubmed:23774686}
RF	<46> Klein, D.; Pohlentz, G.; Schwarzmann, G.; Sandhoff, K.:  Substrate
	specificity of GM2 and GD3 synthase of Golgi vesicles derived from rat
	liver. Eur. J. Biochem. (1987)  167,  417-424 . {Pubmed:3115774} (     
	    )
RF	<47> Pohlentz, G.; Klein, D.; Schwarzmann, G.; Schmitz, D.; Sandhoff,
	K.:  Both GA2, GM2, and GD2 synthases and GM1b, GD1a, and GT1b
	synthases are single enzymes in Golgi vesicles from rat liver. Proc.
	Natl. Acad. Sci. USA (1988)  85,  7044-7048 . {Pubmed:3140234} (       
	  )

ACTIVATING_COMPOUND
AC	#3# Endogen lipid factor <5>
AC	#3,5# Detergents (#3,5# requirement, solubilized enzyme, e.g. Triton
	X-100 <3,5,6,18,19>; #5# CF-54, Tween 80 <2>) <2,3,5,6,18,19>
AC	#3,5,12# Triton X-100 <3,5,6,18,19,47>
AC	#4# more (#4# promoter DNA methylation plays a crucial role in the
	regulation of the Sda beta4GalNAcT-II gene and Sda antigen expression
	<32>) <32>
AC	#5# Tween 80 <2>
AC	#5# cardiolipin <3>
AC	#5# Triton CF-54 <2>
AC	#5# octylglucoside (#5# activation <3,19>; #5# optimal: 0.8% <3>) <3,19>
AC	#5# Heptylthioglucoside (#5# activation <7>) <7>
AC	#5,12# phosphatidylglycerol (#5# activation, detergent-free assay
	<18,19>; #12# stimulates the activity of GM2 synthase without
	disrupting the vesicular intactness <46>) <18,19,46>

KI_VALUE
KI	#12# 0.12 {ganglioside GM3}  (#12# inhibition of GD2 synthesis, pH
	7.35, 37°C <47>) <47>
KI	#12# 0.066 {ganglioside GD3}  (#12# inhibition of GM2 synthesis, pH
	7.35, 37°C <47>) <47>

KI_VALUE
KI	#12# 0.12 {ganglioside GM3}  (#12# inhibition of GD2 synthesis, pH
	7.35, 37°C <47>) <47>
KI	#12# 0.066 {ganglioside GD3}  (#12# inhibition of GM2 synthesis, pH
	7.35, 37°C <47>) <47>

EXPRESSION
EXP	#4,8# up (#4# the transcriptional activity of GM3 synthase induced by
	valproic acid (2.4fold by 1 mM) in ARPE-19 cells is inhibited by
	SP600125. ATF2 binding to the CREB/ATF binding site at -143 is
	essential for transcriptional activation of the enzyme in valproic
	acid-induced ARPE-19 cells <40>; #8# GM2/GD2 synthase expression is
	slightly increased in UVB-irradiated melanocytes, except for SK-MEL-28
	cells <43>) <40,43>
EXP	#8# down (#8# enzyme expression levels are reduced after UVB
	irradiation in SK-MEL-28 melanoma cells <43>) <43>
EXP	#8# more (#8# tumor necrosis factor alpha and interleukin 6 do not
	affect the enzyme expression in in melanocytes <43>) <43>

///
ID	2.4.99.1
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Gallus gallus   <4>
PR	#2# Cavia porcellus   <14>
PR	#3# Drosophila sp. (in: Insecta)   <39>
PR	#4# Homo sapiens   <8,22,37,44,56,57>
PR	#4# Mus musculus   <8,22,37,44,56,57>
PR	#5# Homo sapiens  
	<6,7,15,18,21,27,28,30,31,32,33,42,50,52,54,57,65,74,75,76,84,85>
PR	#6# Rattus norvegicus   (#6# aldo-keto reductase family 1 member C2,
	AKR1C2 <35>; #6# isoform RBCK1 <5,9,24>)
	<2,3,4,5,9,11,12,13,19,20,21,24,27,29,30,31,33,34,35,36,38,40,46,57,58
	64>
PR	#7# Bos taurus   (#7# enzyme precursor <10>) <1,2,10,15,16,17>
PR	#8# Bombyx mori   <80>
PR	#9# Photobacterium leiognathi   <48,62>
PR	#10# Canis lupus familiaris   <77>
PR	#11# Capra hircus   <15>
PR	#12# Photobacterium sp.   <43,46>
PR	#13# Oreochromis mossambicus   <5>
PR	#14# Photobacterium damselae   <25,26,45,63,79,82>
PR	#15# Rattus norvegicus P13721  <23,41,47,59,61,83>
PR	#15# Rattus norvegicus P13721 SwissProt <23,41,47,59,61,83>
PR	#15# Rattus norvegicus P13721 UniProt <23,41,47,59,61,83>
PR	#16# Homo sapiens P15907  <41,53,55,61,66,67,70,73,78,81>
PR	#16# Homo sapiens P15907 SwissProt <41,53,55,61,66,67,70,73,78,81>
PR	#16# Homo sapiens P15907 UniProt <41,53,55,61,66,67,70,73,78,81>
PR	#17# Bos taurus O18974 SwissProt <41>
PR	#18# Pan troglodytes Q701R5 SwissProt <41>
PR	#19# Mus musculus Q64685 SwissProt <41,71,72,73>
PR	#19# Mus musculus Q64685 UniProt <41,71,72,73>
PR	#20# Gallus gallus Q92182 SwissProt <41>
PR	#21# Danio rerio Q6KB61 SwissProt <41>
PR	#22# Oryzias latipes Q5K028 SwissProt <41>
PR	#23# Takifugu rubripes Q6KB62 SwissProt <41>
PR	#24# Homo sapiens Q96JF0 SwissProt <41>
PR	#25# Pan troglodytes Q701R4 SwissProt <41>
PR	#26# Bos taurus A5D7T4 SwissProt <41,60>
PR	#27# Rattus norvegicus Q701R3 SwissProt <41>
PR	#28# Gallus gallus Q701R0 SwissProt <41>
PR	#29# Xenopus tropicalis Q701R1 SwissProt <41>
PR	#30# Takifugu rubripes Q5QQ37 SwissProt <41>
PR	#31# Oryzias latipes Q5K027 SwissProt <41>
PR	#32# Drosophila pseudoobscura Q683P0 SwissProt <41>
PR	#33# Danio rerio Q701R2 SwissProt <41>
PR	#34# Drosophila melanogaster Q9GU23 SwissProt <41>
PR	#35# Drosophila yakuba Q683P1 SwissProt <41>
PR	#36# Anopheles gambiae Q683N9 SwissProt <41>
PR	#37# Photobacterium sp. A8QYL1 UniProt <49,51,86>
PR	#38# Cricetulus griseus F1SWB0 UniProt <68>
PR	#39# Helicobacter acinonychis Q17WF8 SwissProt <69>
PR	#40# Photobacterium leiognathi A8R0T5 UniProt <86>
PR	#41# Photobacterium damselae O66375 UniProt <86>

RECOMMENDED_NAME
RN	beta-galactoside alpha-(2,6)-sialyltransferase


SYSTEMATIC_NAME
SN	CMP-N-acetyl-beta-neuraminate:beta-D-galactoside
	alpha-(2->6)-N-acetylneuraminyltransferase (configuration-inverting)


SYNONYMS
SY	 sialyltransferase
SY	 sialyltransferase, cytidine
	monophosphoacetylneuraminate-lactosylceramide
SY	 CMP-acetylneuraminate-lactosylceramide-sialyltransferase
SY	 CMP-N-acetylneuraminic acid:lactosylceramide sialyltransferase
SY	 CMP-sialic acid:lactosylceramide sialyltransferase
SY	 cytidine monophosphoacetylneuraminate-lactosylceramide
	sialyltransferase
SY	 GM3-synthase
SY	 sialyltransferase, cytidine
	monophosphoacetylneuraminate-galactosylglycoprotein
SY	 cytidine monophosphoacetylneuraminate-galactosylglycoprotein
	sialyltransferase
SY	 antigens, CD75
SY	 CMP-acetylneuraminate-galactosylglycoprotein sialyltransferase
SY	 CMP-acetylneuraminate-glycoprotein sialyltransferase
SY	 CMP-N-acetylneuraminic acid-glycoprotein sialyltransferase
SY	 sialotransferase
SY	 alpha 2,6-ST
SY	 B-cell antigen CD75
SY	#10# alpha2,6 sialyltransferase <77>
SY	#10# ST-alpha2,6 <77>
SY	#10# beta-galactoside-alpha2,6 sialyltransferase <77>
SY	#12# alpha2,6-STase <43>
SY	#14# alpha2-6 sialyltransferase <82>
SY	#14# 2,6ST <82>
SY	#14# alpha2,6ST <79>
SY	#15,16# ST6Gal1 <59,66,83>
SY	#15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36#
	More
	(#15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36#
	ST6Gal I-IV subfamilies of the sialyltransferase family ST6Gal <41>)
	<41>
SY	#16# SIAT1 <67>
SY	#16# alpha2,6-sialyltransferase 1 <66>
SY	#16# beta-galactoside alpha2,6 sialyltransferase I <81>
SY	#16# beta-galactoside alpha-2,6-sialyltransferase I <78>
SY	#16,19# beta-galactoside alpha2-6-sialyltransferase-1 <73>
SY	#19# ST6Gal-1 <72>
SY	#26# beta-galactoside-alpha2,6-sialyltransferase <60>
SY	#3# SiaT <39>
SY	#37,40,41# alpha(2,6)-sialyltransferase <86>
SY	#37,40,41# alpha(2,6)-ST <86>
SY	#39# HAC1268 (#39# gene name <69>) <69>
SY	#4# beta-galactoside alpha2,6-sialyltransferase ST6Gal II <37>
SY	#4,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36#
	ST6Gal <41,44>
SY	#4,26# ST6Gal II <37,60>
SY	#4,5,6,15,16,38# ST6Gal I <36,37,38,40,47,52,53,55,57,61,68,70,85>
SY	#4,5,6,8,14,15,16,19,38,39# alpha2,6-sialyltransferase
	<44,59,63,64,65,68,69,70,71,72,74,75,80,83>
SY	#4,5,6,9,15,16# beta-galactoside alpha2,6-sialyltransferase <57,61,62>
SY	#5# GM3 synthase <42,75>
SY	#5# CMP-NeuAc:lactosylceramide alpha2,3-sialyltransferase <42>
SY	#5# Laccer sialyltransferase <75>
SY	#5# lactosylceramide alpha2,3-sialyltransferase <42>
SY	#5# alpha2,6sialyltransferase-I <50>
SY	#5# hST6Gal-I <50>
SY	#5# beta-galactoside alpha2,6-sialyltransferase I <52>
SY	#5# ST6GalI <54>
SY	#5# ST6GALNAC2 <65>
SY	#5# alpha26SAT <75>
SY	#5#
	(alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1
	3)-N-acetylgalactosaminide alpha2,6-sialyltransferase 5 <76>
SY	#5# ST6GalNAcV <76>
SY	#5# beta-galactoside alpha2,6 sialyltranferase 1 <85>
SY	#5,6# alpha2,6-ST <64,65>
SY	#5,6,16# alpha-2,6-sialyltransferase <35,47,58,67,78,84>
SY	#5,6,16,19# ST6Gal-I <58,71,73,78,81,84>
SY	#6# Galbeta1,4-GlcNAc alpha2,6 sialyltransferase <11,19>
SY	#6# alpha2,6-sialyltransferase ST6Gal I <40>
SY	#6# R-2,6-sialyltransferase <34>
SY	#6,12# alpha-(2->6)-sialyltransferase <46>
SY	#6,12# 6STase <46>
SY	#6,12,14# alpha 2,6-sialyltransferase <36,43,79>

REACTION
RE	CMP-N-acetyl-beta-neuraminate + beta-D-galactosyl-R = CMP +
	N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl-R (#7# mechanism
	<17>; #15# Val220 participates in binding the common cytidine moiety in
	substrate CMP-NeuAc and inhibitor CDP <23>)

REACTION_TYPE
RT	glycosyl group transfer

SOURCE_TISSUE
ST	#1,4,6,13,26# brain (#1,6# cerebellum excluded <4>; #4# of 11-, 15- and
	17-day embryos <37>) <4,5,37,60>
ST	#10# serum <77>
ST	#16# HeLa cell <66>
ST	#16# monocyte <73>
ST	#16# U-937 cell <73>
ST	#16# blood serum (#16# level of serum ST6Gal I in patients with chronic
	active hepatitis is significantly increased compared to that in
	patients with chronic persistent hepatitis. Serum level of ST6Gal I in
	hepatitis C patients is correlated with the activity of hepatic
	inflammation, but not with liver fibrosis <61>) <61>
ST	#16# DLD-1 cell <70>
ST	#19# macrophage <73>
ST	#2# cerebral cortex <14>
ST	#26# colon <60>
ST	#26# salivary gland (#26# low level <60>) <60>
ST	#26# mammary epithelial cell <60>
ST	#3# central nervous system (#3# expressed during embryonic development
	in a tissue- and stage-specific fashion, with elevated expression in a
	subset of cells within the central nervous system <39>) <39>
ST	#38# CHO cell <68>
ST	#4# embryo (#4# 11-day, 15-day or 17-day <37>; #4# brain of 11-, 15-
	and 17-day old embryos <37>) <37>
ST	#4# Ehrlich ascites carcinoma cell (#4# high activity in cells grown in
	tissue culture or adherent to extracellular matrices, low activity in
	cells not adherent nor grown in tissue culture <22>) <22>
ST	#4# kidney <37>
ST	#4# heart <37>
ST	#4# melanoma cell <8>
ST	#4# oviduct (#4# of pregnant mouse <37>) <37>
ST	#4# B-16 cell <8>
ST	#4,10,26# mammary gland (#4# lactating <37>; #26# low level <60>)
	<37,60,77>
ST	#4,26# skeletal muscle (#26# very low level <60>; #4# very low
	expression <37>) <37,60>
ST	#4,26# spleen (#4# very low expression <37>) <37,60>
ST	#4,26# lung (#4# very low expression <37>; #26# high level <60>) <37,60>
ST	#4,26# more (#4# ubiquitously expressed <37>; #26# is absent from
	thymus and the adipose tissue <60>) <37,60>
ST	#4,5,6# peripheral blood (#4,6# from heart and abdominal aorta <57>)
	<57>
ST	#4,5,6,15# blood plasma <57,61>
ST	#4,5,6,19# liver (#5# ST6GalI protein level is negligibly decreased in
	moderate drinkers but decreases by 30% in heavy alcohol drinkers
	compared to non-drinkers. The appearance of asialoconjugates in
	alcoholics is possibly due to the down-regulation of ST6GalI gene
	expression <54>; #4# from liver-injured model mice <57>)
	<3,6,9,11,12,13,19,20,21,24,27,29,30,31,33,34,35,37,46,54,57,72>
ST	#4,8,26# testis (#26# very low level <60>) <37,60,80>
ST	#5# K-562 cell (#5# a leukemia cell line, the enzyme is expressed
	during the induction of megakaryocytic differentiation <42>) <42>
ST	#5# placenta (#5# both mRNA expression and enzyme activity of ST6Gal I
	do not show a significant difference in the placental tissues of the
	women with preeclampsia and without preeclampsia. ST6Gal I is not
	involved in the pathogenesis of the preeclampsia <53>) <6,53>
ST	#5# platelet <7>
ST	#5# Burkitt lymphoma cell (#5# Daudi cell line <27>) <27>
ST	#5# ovarian cancer cell <75>
ST	#5# cervical epithelium <18>
ST	#5# myeloma cell line <27>
ST	#5# B-lymphocyte <65>
ST	#5# U-266 cell (#5# myeloma cell line <27>) <27>
ST	#5# Hep-3B cell (#5# BACE1 affects the alpha2,6-sialylation of proteins
	secreted from Hep-3B cells. Following BACE1 overexpression in Hep3B
	cells, the alpha2,6-sialylation of soluble secreted glycoproteins is
	significantly increased, whereas that of cell-surface glycoproteins
	remains unchanged <52>) <52>
ST	#5,7,11# colostrum <1,2,15,16,17>
ST	#6# commercial preparation <27,30,33>
ST	#6# hepatocyte <20>
ST	#6# jejunum <24>
ST	#6# hepatoma ascites cell line (#6# cultured cells isolated from the
	tumor behave as normal hepatocytes <20>; #6# no enzyme activity in
	Zaidela ascitic hepatoma, but 3.6fold reduced mRNA content of a larger
	transcript size compared to normal liver cells <20>) <20>
ST	#7# thyroid gland <10>
ST	#8# silk gland <80>
ST	#8# larva <80>
ST	#8# fat body <80>
ST	#8# midgut <80>
ST	#8# malpighian tubule <80>

LOCALIZATION
LO	#1,2,4,6,7,13,26,38# membrane (#26# is a type II membrane-bound protein
	with a short cytosolic region of 11 amino acids (M1-G11), a single
	transmembrane region of 19 amino acids (M12-F30) and a luminal domain
	of 465 amino acids (T31-A495) <60>)
	<4,5,9,10,11,12,13,14,19,22,24,60,68>
LO	#15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36#
	Golgi membrane
	(#15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36#
	the enzyme is a Golgi type II transmembrane glycosyltransferase <41>)
	<41>
LO	#16# Golgi complex (#16# exogenous and endogenous ST6Gal I in the
	perinuclear Golgi of Hep3B-ST6Gal I and control Hep3B cells <61>) <61>
LO	#19# soluble <71>
LO	#2# synaptosome <14>
LO	#3,4,6,8,16,38# Golgi apparatus (#6# membrane-bound at the luminal
	side, trans compartment <19>; #6# the STtyr isoform is transiently
	localized in the Golgi and is ultimately cleaved and secreted, whereas
	the STcys isoform is stably localized in the Golgi and is not cleaved
	and secreted. Cytosolic tail and transmembrane region of the ST6Gal I
	both play roles in Golgi localization <40>)
	<11,12,19,22,24,39,40,66,68,80,81>
LO	#5,6# microsome <6,9,13,24>
LO	#5,6,16# more (#6# enzyme is not catalytically active in the
	endoplasmic reticulum and only achieves full activity when it locates
	itself to the trans compartment of the Golgi system <19>; #5# deletion
	of the transmembrane fragment results in loss of acceptor preference
	<32>; #16# oxidative stress changes the intracellular localizations of
	ST6Gal I and BACE1, more disperse localizations <61>) <19,32,61>
LO	#5,7,11,26# cytosol (#26# has a short cytosolic region of 11 amino
	acids (M1-G11) <60>) <15,16,60>
LO	#6# endoplasmic reticulum (#6# isoform Stcys is found in both the
	endoplasmic reticulum and in Golgi <36>) <36>
LO	#6# Golgi vesicle (#6# in medial-trans regions. Isoform Stcys is found
	in both the endoplasmic reticulum and in Golgi <36>; #6# in
	medial-trans regions. Isoform STtyr is restricted to Golgi in most
	cells <36>) <36>
LO	#6# Golgi trans face <19>

NATURAL_SUBSTRATE_PRODUCT
NSP	#16,19# CMP-N-acetylneuraminate + tumor necrosis factor receptor 1 =
	CMP + alpha2,6-sialyated tumor necrosis factor receptor 1 <73>
NSP	#4,5,6,16# more = ? (#6# addition of alpha2,6-linked sialic acid to the
	Gal1,4GlcNAc sequence, the preferred ligand for galectin-1, inhibits
	recognition of this saccharide ligand by galectin-1. The enzyme
	sialylates N-glycans on CD45, a receptor tyrosine phosphatase that is a
	T cell receptor for galectin-1. ST6Gal I expression abrogates the
	reduction in CD45 tyrosine phosphatase activity that results from
	galectin1 binding. Sialylation of CD45 by the ST6Gal I also prevents
	galectin-1-induced clustering of CD45 on the T cell surface, an initial
	step in galectin-1 cell death. Regulation of glycoprotein sialylation
	may control susceptibility to cell death at specific points during T
	cell development and peripheral activation <38>; #6# the enzyme
	functions in Golgi vesicles to terminally sialylate the N-linked
	oligosaccharides of glycoproteins <36>; #4# the enzyme is responsible
	for the synthesis of 6-sialylolifosaccharides in milk <37>; #16#
	radiation exposure is found to increase the sialylation of
	glycoproteins such as integrin beta1 by inducing the expression of
	ST6Gal I, and increased protein sialylation contributed to cellular
	radiation resistance <55>; #5# soluble ST6Gal I produced by BACE1
	plays, at least in part, a role in the sialylation of soluble
	glycoproteins <52>; #4# ST6Gal I sialyltransferase knock-out mouse
	lacks the main enzyme necessary for the attachment of alpha2,6 sialic
	acid to N-linked glycoproteins on the cell surface. Even in the absence
	of detectable alpha2,6 sialic acid in the mouse respiratory tract,
	human influenza viruses can still infect these mice and grow to similar
	titers in the lung and trachea as compared to wild-type animals. The
	presence of a major alpha2,6 sialic acid on N-linked glycoproteins is
	not essential for human influenza virus infection in mice <56>) {}
	<36,37,38,52,55,56>
NSP	#4,5,6,16# more = ? (#6# addition of alpha2,6-linked sialic acid to the
	Gal1,4GlcNAc sequence, the preferred ligand for galectin-1, inhibits
	recognition of this saccharide ligand by galectin-1. The enzyme
	sialylates N-glycans on CD45, a receptor tyrosine phosphatase that is a
	T cell receptor for galectin-1. ST6Gal I expression abrogates the
	reduction in CD45 tyrosine phosphatase activity that results from
	galectin1 binding. Sialylation of CD45 by the ST6Gal I also prevents
	galectin-1-induced clustering of CD45 on the T cell surface, an initial
	step in galectin-1 cell death. Regulation of glycoprotein sialylation
	may control susceptibility to cell death at specific points during T
	cell development and peripheral activation <38>; #6# the enzyme
	functions in Golgi vesicles to terminally sialylate the N-linked
	oligosaccharides of glycoproteins <36>; #4# the enzyme is responsible
	for the synthesis of 6-sialylolifosaccharides in milk <37>; #16#
	radiation exposure is found to increase the sialylation of
	glycoproteins such as integrin beta1 by inducing the expression of
	ST6Gal I, and increased protein sialylation contributed to cellular
	radiation resistance <55>; #5# soluble ST6Gal I produced by BACE1
	plays, at least in part, a role in the sialylation of soluble
	glycoproteins <52>; #4# ST6Gal I sialyltransferase knock-out mouse
	lacks the main enzyme necessary for the attachment of alpha2,6 sialic
	acid to N-linked glycoproteins on the cell surface. Even in the absence
	of detectable alpha2,6 sialic acid in the mouse respiratory tract,
	human influenza viruses can still infect these mice and grow to similar
	titers in the lung and trachea as compared to wild-type animals. The
	presence of a major alpha2,6 sialic acid on N-linked glycoproteins is
	not essential for human influenza virus infection in mice <56>) {}
	<36,37,38,52,55,56>
NSP	#5# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	4-N-acetyl-beta-D-glucosamine <74>
NSP	#5,6,7,11# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#6,7# R: glycoprotein or glycopeptide
	<10,20>; #7# one of a group of glycosyltransferases which act to
	assemble the carbohydrate units of thyroglobulin <10>; #6# regulation
	of enzyme expression <20>; #5,7,11# final step in synthesis of
	serum-type glycoproteins <15>) <10,15,20>
NSP	#5,6,7,11# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#6,7# R: glycoprotein or glycopeptide
	<10,20>; #7# one of a group of glycosyltransferases which act to
	assemble the carbohydrate units of thyroglobulin <10>; #6# regulation
	of enzyme expression <20>; #5,7,11# final step in synthesis of
	serum-type glycoproteins <15>) {} <10,15,20>
NSP	#5,8,14,15,16,37,40,41# CMP-N-acetylneuraminate +
	beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine = CMP +
	alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta
	D-glucosamine <78,80,81,82,83,84,85,86>

SUBSTRATE_PRODUCT
SP	#1,6,13# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,4-beta-D-glucosylceramide = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	4-beta-D-glucosylceramide (#6# i.e. lactosylceramide <4>) |#1,6,13#
	i.e. ganglioside GM3 <4,5>| <4,5>
SP	#11# CMP-N-acetylneuraminate + asialo-proteose peptone = CMP + proteose
	peptone <15>
SP	#12# CMP-9''-benzamido-Neu5Ac + lactose = ? <46>
SP	#12# CMP-9''-phenylacetamido-Neu5Ac + lactose = ? <46>
SP	#12# CMP-9''-phenylhexanamido-Neu5Ac + lactose = ? <46>
SP	#12# CMP-9''-phenylpropionamido-Neu5Ac + lactose = ? <46>
SP	#12# cytidine-5'-monophospho-sialic acid + lactose = ? <46>
SP	#14# CMP-N-acetylneuraminate + methyl-beta-D-galactopyranoside = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-methylgalactopyranoside <25,26>
SP	#14# CMP-N-acetylneuraminate + fucosyllactose = CMP +
	alpha-N-acetylneuraminyl-2,6-[alpha-L-fucopyranosyl-1
	2]-beta-D-galactopyranosyl-1,4-D-glucopyranose (#14# also
	pyridylaminated <26>) <26>
SP	#14# CMP-N-acetylneuraminate + Neu5Acalpha-2,3-Galbeta-1,4-Glc = CMP +
	alpha-N-acetylneuraminyl-2,6-(Neu5Acalpha-2,3-)Galbeta-1,4-Glc (#14#
	also pyridylaminated <26>) <26>
SP	#14# CMP-N-acetylneuraminate + 4-methylumbelliferyl beta-D-lactoside =
	? <45>
SP	#14# Neu5Acalpha-4-nitrophenyl + 4-methylumbelliferyl-beta-D-lactoside
	= ? (#14# alpha2,6-trans-sialidase activity of DELTA15Pd2,6ST <63>) <63>
SP	#15# CMP-N-acetylneuraminate +
	5-(5-dimethylaminonaphthalene-1-sulfonyl-2-(2-aminoethoxy))ethyl
	beta-N-acetyllactosamine = CMP +
	5-(5-dimethylaminonaphthalene-1-sulfonyl-2-(2-aminoethoxy)) ethyl
	beta-N-acetylneuraminic acid alpha-2,6-N-acetyllactosamine <59>
SP	#15# CMP-N-acetylneuraminate +
	5-(5-dimethylaminonaphthalene-1-sulfonyl-2-(2-aminoethoxy))ethyl
	beta-lactose = CMP + ? <59>
SP	#16# CMP-N-acetylneuraminate + pyridylamine-type 2H = CMP +
	alpha2,6-sialylated blood group type 2H antigen (#16# 2% activity
	compared to pyridylaminyl-lacto-N-neotetraose <70>) <70>
SP	#16# CMP-N-acetylneuraminate + pyridylaminyl-lacto-N-neotetraose = CMP
	+ ? (#16# 100% activity <70>) <70>
SP	#16# CMP-9-fluoresceinyl-N-acetylneuraminate + asialofetuin = ? <78>
SP	#16# CMP-N-acetylneuraminate + 6'-sialyl-N-acetyl-D-lactosamine = ? <81>
SP	#16,19# CMP-N-acetylneuraminate + tumor necrosis factor receptor 1 =
	CMP + alpha2,6-sialyated tumor necrosis factor receptor 1 <73>
SP	#19# CMP-N-acetylneuraminate + Galbeta(1->3)GalNAc = CMP +
	NeuAcalpha(2->6)Galbeta(1->3)GalNAc (#19# 10% activity compared to
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <71>) <71>
SP	#19# CMP-N-acetylneuraminate + Galbeta(1->3)GlcNAc = CMP +
	NeuAcalpha(2->6)Galbeta(1->3)GlcNAc (#19# 2% activity compared to
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <71>) <71>
SP	#19# CMP-N-acetylneuraminate + lacto-N-neotetraose = CMP + ? (#19# 108%
	activity compared to beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine
	<71>) <71>
SP	#2# CMP-N-acetylneuraminate + asialo-Tamm-Horsfall glycoprotein = CMP +
	Tamm-Horsfall glycoprotein <14>
SP	#2,4,5,6,7,11# CMP-N-acetylneuraminate + asialo-fetuin = CMP + fetuin
	(#5# best substrate <18>; #4# 106% of the activity with
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <37>; #4# 21% of the
	activity with beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <37>;
	#6# recombinant isoform STcys is somewhat more active then the
	recombinant isoform STtyr <36>) <9,10,13,14,15,17,18,30,32,33,36,37>
SP	#2,4,5,6,7,11,14,15# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#5,6,7,11,14# acceptor substrate
	specificity <1,3,10,11,15,17,24,26,27,32>; #6,7# R: glycoprotein or
	glycopeptide <9,10,17,20>; #5,6,7# transfers sialic acid to terminal
	positions on N-linked glycans <2,3,6,11,12>; #2,4,5,6,7,11,14,15#
	sialic acid is linked to C-6 of the galactose residue
	<1,2,3,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28
	29,30,31,32,33>; #7# transfers sialic acid to the terminal galactose
	residue of asialo-gyloproteins and peptides <10>; #6#
	CMP-N-acetylneuraminate analogues can serve as donor substrates, i.e.
	the 5-amino-, the 5-N-pentanoylamino-, the 5-glycylamino-, and the
	5-ethoxycarbonylamino derivative and diammonium (cytidin-5-yl)
	[(3-deoxy-D-glycero-beta-D-galacto-2-nonulpyranosyl)onate] phosphate
	<29>; #6# the non-reducing terminal galactosyl residue is essential for
	activity <9>; #5,6# substrate specificity for several synthetic
	trisaccharides <21>; #7,14# strictly specific for
	CMP-N-acetylneuraminate, forms only alpha2,6-linkages <17,25,26>;
	#5,7,11# high molecular weight substrates are more efficient acceptors
	than low molecular weight substrates <10,15,18>; #6# synthetic
	disaccharides <24>; #5,6# CMP-N-acetylneuraminate analogues can serve
	as donor substrates, i.e. formyl-, trifluoroacetyl-,
	benzyloxycarbonyl-, and amino acetyl-N-neuraminates <31>; #6# donor
	substrate specificity <3,29>; #7# one of a group of
	glycosyltransferases which act to assemble the carbohydrate units of
	thyroglobulin <10>; #6# regulation of enzyme expression <20>; #5,7,11#
	final step in synthesis of serum-type glycoproteins <15>)
	<1,2,3,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28
	29,30,31,32,33>
SP	#2,4,5,6,7,11,14,15# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-R = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	4-N-acetyl-beta-D-glucosaminyl-R (#5,6,7,11,14# acceptor substrate
	specificity <1,3,10,11,15,17,24,26,27,32>; #6,7# R: glycoprotein or
	glycopeptide <9,10,17,20>; #5,6,7# transfers sialic acid to terminal
	positions on N-linked glycans <2,3,6,11,12>; #2,4,5,6,7,11,14,15#
	sialic acid is linked to C-6 of the galactose residue
	<1,2,3,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28
	29,30,31,32,33>; #7# transfers sialic acid to the terminal galactose
	residue of asialo-gyloproteins and peptides <10>; #6#
	CMP-N-acetylneuraminate analogues can serve as donor substrates, i.e.
	the 5-amino-, the 5-N-pentanoylamino-, the 5-glycylamino-, and the
	5-ethoxycarbonylamino derivative and diammonium (cytidin-5-yl)
	[(3-deoxy-D-glycero-beta-D-galacto-2-nonulpyranosyl)onate] phosphate
	<29>; #6# the non-reducing terminal galactosyl residue is essential for
	activity <9>; #5,6# substrate specificity for several synthetic
	trisaccharides <21>; #7,14# strictly specific for
	CMP-N-acetylneuraminate, forms only alpha2,6-linkages <17,25,26>;
	#5,7,11# high molecular weight substrates are more efficient acceptors
	than low molecular weight substrates <10,15,18>; #6# synthetic
	disaccharides <24>; #5,6# CMP-N-acetylneuraminate analogues can serve
	as donor substrates, i.e. formyl-, trifluoroacetyl-,
	benzyloxycarbonyl-, and amino acetyl-N-neuraminates <31>; #6# donor
	substrate specificity <3,29>; #7# one of a group of
	glycosyltransferases which act to assemble the carbohydrate units of
	thyroglobulin <10>; #6# regulation of enzyme expression <20>; #5,7,11#
	final step in synthesis of serum-type glycoproteins <15>) {}
	<1,2,3,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28
	29,30,31,32,33>
SP	#2,4,5,6,7,8,9,14,16,26,37,39# more = ? (#6# thyroglobin is no
	substrate <9>; #5# the catalytic domain can proceed with sialic acid
	transfer with increased efficiency until 80 amino acid are deleted
	<32>; #7# no activity with galactosylhydroxylysine and its derivatives,
	or galactose-containing oligosaccharides linked to Ser/Thr-glycopeptide
	of earthworm cuticle collagen <10>; #7# no transfer to terminal
	N-acetyl-D-galactosamine <10>; #7# no activity with
	beta-methyl-L-arabinopyranoside <17>; #2,6,7# no activity with
	submaxillary asialo-mucin <9,10,11,12,14>; #7# galactose-free
	glycopeptides are poor substrates <10>; #14# low activity with several
	methylated substrates, no activity with UDP-Gal, UDP-GalNAc and UDP-Glc
	as donor substrates <25>; #14# enzyme does not recognize type I
	oligosaccharides <26>; #6# very low activity with prothrombin and
	native alpha1-acid glycoprotein, no activity with transferrin,
	asialo-agalacto-alpha1-acid glycoprotein <11>; #5# no activity with
	N-acetyl-D-galactosamine or N-acetyl-D-glucosamine, and
	asialo-agalacto-fetuin, and galactose <18>; #6,7# no activity with
	antifreeze glycoprotein <11,12,17>; #7# poor substrates are the
	beta-1,3- or beta-1,6-derivatives of
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <17>; #7# no activity
	with galactose, lactose and N-acetyllactose <10>; #5# no activity with
	Lc4Cer and Lc3Cer <27>; #6# no activity with the CMP-NeuAc analogues
	disodium[(5-acetamido-3
	5-dideoxy-D-glycero-beta-D-galacto-2-nonulopyranosyl)onate]
	(methyl-beta-D-ribofuranosid-5-yl) phosphate and bis(triethylammonium)
	[(5-acetamido-3
	5-dideoxy-D-glycero-beta-D-galacto-2-nonulopyranosyl)onate]
	[(resorcin-4-yl) (1-deoxy-beta-D-ribofuranosid-5-yl)] phosphate <29>;
	#7# no activity with ovine submaxillary asialo-mucin <15,17>; #6#
	addition of alpha2,6-linked sialic acid to the Gal1,4GlcNAc sequence,
	the preferred ligand for galectin-1, inhibits recognition of this
	saccharide ligand by galectin-1. The enzyme sialylates N-glycans on
	CD45, a receptor tyrosine phosphatase that is a T cell receptor for
	galectin-1. ST6Gal I expression abrogates the reduction in CD45
	tyrosine phosphatase activity that results from galectin1 binding.
	Sialylation of CD45 by the ST6Gal I also prevents galectin-1-induced
	clustering of CD45 on the T cell surface, an initial step in galectin-1
	cell death. Regulation of glycoprotein sialylation may control
	susceptibility to cell death at specific points during T cell
	development and peripheral activation <38>; #6# the enzyme functions in
	Golgi vesicles to terminally sialylate the N-linked oligosaccharides of
	glycoproteins <36>; #4# the enzyme is responsible for the synthesis of
	6-sialylolifosaccharides in milk <37>; #4# ST6Gal II shows no activity
	towards oligosaccharides such as Galbeta1,3GalNAc, Galbeta1,3GlcNAc,
	lactose, and lacto-N-tetraose, which do not have the Galbeta1,4GlcNAc
	structure at the nonreducing end of their carbohydrate groups.
	Relatively low activity towards some glycoproteins, which are
	considered to have the Galbeta1,4GlcNAc structure at the nonreducing
	end of the carbohydrate groups <37>; #16# radiation exposure is found
	to increase the sialylation of glycoproteins such as integrin beta1 by
	inducing the expression of ST6Gal I, and increased protein sialylation
	contributed to cellular radiation resistance <55>; #5# soluble ST6Gal I
	produced by BACE1 plays, at least in part, a role in the sialylation of
	soluble glycoproteins <52>; #4# ST6Gal I sialyltransferase knock-out
	mouse lacks the main enzyme necessary for the attachment of alpha2,6
	sialic acid to N-linked glycoproteins on the cell surface. Even in the
	absence of detectable alpha2,6 sialic acid in the mouse respiratory
	tract, human influenza viruses can still infect these mice and grow to
	similar titers in the lung and trachea as compared to wild-type
	animals. The presence of a major alpha2,6 sialic acid on N-linked
	glycoproteins is not essential for human influenza virus infection in
	mice <56>; #37# no sialidase activity is detected for the
	alpha2,6-sialyltransferase <51>; #5# the enzyme transfers Neu5Ac of
	CMP-Neu5Ac to the 6-hydroxyl group on internal GalNAc on O-glycans with
	strict specificities towards the O-glycan GalNAcalpha- (Tnantigen),
	Galbeta1-3GalNAcalpha- (T-antigen) and
	Neu5Acalpha2-3Galbeta1-3GalNAcalpha- (sialyl T-antigen) structures.
	hST6GalNAc-I shows activities towards O-linked oligosaccharides
	attached to peptides of glycoproteins and weak activities towards
	synthetic non-amino acid aglycons of O-glycans hST6GalNAc-I.
	hST6GalNAc-I shows strong activities with core 2 glycans
	(Galbeta1-3GalNAcbeta[GlcNAcbeta1-6]GalNAc). Core 2 O-glycan structures
	lacking the terminal galactose such as core 6
	(GlcNAcbeta1-6GalNAcalpha-) or substituted with other monosaccharides
	such as core 4 (GlcNAcbeta1-3[GlcNAcbeta1-6]GalNAcalpha-) do not give
	any signal indicating that hST6GalNAc-I possibly also sialylated the
	terminal galactose of core 2 glycans. Relative specificities for the
	acceptors, Galbeta1-3GalNAcalphaOpNP (23%),
	Galbeta1-3[GlcNAcbeta1-6]GalNAcOalphapNP (12%),
	Galbeta1-3GalNAcOalphaThr (100%) and
	Galbeta1-3[GlcNAcbeta1-6]Galalpha2-6GalNAcOalphaThr (alpha2-6sialyl
	Tn-antigen). Relative specificities of the acceptors,
	Galbeta1-3GalNAcalphaOpNP (0%),
	Galbeta1-3[GlcNAcbeta1-6]GalNAcOalphapNP (0%),
	Galbeta1-3GalNAcOalphaThr (100%) and
	Galbeta1-3[GlcNAcbeta1-6]GalNAcalphaThr (19%) are found <50>; #14#
	DELTA15Pd2,6ST preferentially cleaves alpha2,6-linked sialic acid <63>;
	#6# human-like sialylated recombinant thyrotropin with sialic acid
	bound to galactose by both alpha2-3 and alpha2-6 linkages, similar to
	the native preparation, obtained in CHO cells modified to produce
	alpha2,6-sialyltransferase <64>; #9# neuraminidase activity is specific
	for the Neu5Acalpha2,6Gal linkage <62>; #26# the enzyme uses the
	LacdiNAc structure (GalNAcbeta1,4GlcNAc) as a better acceptor substrate
	than the type II (Galbeta1-4GlcNAc) disaccharide. The enzymes
	efficiency is improved when the acceptor substrate is provided as a
	free oligosaccharide rather than as a protein-bound oligosaccharide. No
	activity with alpha1-acidglycoprotein and Galbeta1–3GlcNAc-octyl
	<60>; #39# no activity with Gal-beta1,3-GlcNAc, T-antigen
	Gal-beta1,3-GalNAc-alpha, and NeuAc-alpha2,3-Gal-beta1,4-Glc <69>; #16#
	the enzyme cannot transfer a N-acetylneuraminate residue to
	pyridylaminyl-LNFP I, a type 1 chain derivative of the blood group H
	antigen <70>; #16# the enzyme catalyzes alpha-2,6-sialylation of
	galactose on glycoproteins <67>; #5# the enzyme catalyzes the formation
	of the terminal alpha2,6-sialic acid linkages on gangliosides <76>; #8#
	no activity towards Glcalpha-4-nitrophenyl, Galalpha-4-nitrophenyl,
	GalNAcalpha-4-nitrophenyl, Galbeta(1,3)-GalNAcbeta-4-nitrophenyl and
	GalNAcbeta(1,3)-GlcNAcbeta-4-nitrophenyl <80>; #5# no activity with
	6-sialyllactosamine <84>; #14# the enzyme exhibits a unique
	regioselectivity and is able to sialylate internal galactose residues
	in poly-LacNAc extended glycans <82>) {}
	<9,10,11,12,14,15,17,18,25,26,27,29,32,36,37,38,50,51,52,55,56,60,62,63
	64,67,69,70,76,80,82,84>
SP	#2,4,5,6,7,8,9,14,16,26,37,39# more = ? (#6# thyroglobin is no
	substrate <9>; #5# the catalytic domain can proceed with sialic acid
	transfer with increased efficiency until 80 amino acid are deleted
	<32>; #7# no activity with galactosylhydroxylysine and its derivatives,
	or galactose-containing oligosaccharides linked to Ser/Thr-glycopeptide
	of earthworm cuticle collagen <10>; #7# no transfer to terminal
	N-acetyl-D-galactosamine <10>; #7# no activity with
	beta-methyl-L-arabinopyranoside <17>; #2,6,7# no activity with
	submaxillary asialo-mucin <9,10,11,12,14>; #7# galactose-free
	glycopeptides are poor substrates <10>; #14# low activity with several
	methylated substrates, no activity with UDP-Gal, UDP-GalNAc and UDP-Glc
	as donor substrates <25>; #14# enzyme does not recognize type I
	oligosaccharides <26>; #6# very low activity with prothrombin and
	native alpha1-acid glycoprotein, no activity with transferrin,
	asialo-agalacto-alpha1-acid glycoprotein <11>; #5# no activity with
	N-acetyl-D-galactosamine or N-acetyl-D-glucosamine, and
	asialo-agalacto-fetuin, and galactose <18>; #6,7# no activity with
	antifreeze glycoprotein <11,12,17>; #7# poor substrates are the
	beta-1,3- or beta-1,6-derivatives of
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <17>; #7# no activity
	with galactose, lactose and N-acetyllactose <10>; #5# no activity with
	Lc4Cer and Lc3Cer <27>; #6# no activity with the CMP-NeuAc analogues
	disodium[(5-acetamido-3
	5-dideoxy-D-glycero-beta-D-galacto-2-nonulopyranosyl)onate]
	(methyl-beta-D-ribofuranosid-5-yl) phosphate and bis(triethylammonium)
	[(5-acetamido-3
	5-dideoxy-D-glycero-beta-D-galacto-2-nonulopyranosyl)onate]
	[(resorcin-4-yl) (1-deoxy-beta-D-ribofuranosid-5-yl)] phosphate <29>;
	#7# no activity with ovine submaxillary asialo-mucin <15,17>; #6#
	addition of alpha2,6-linked sialic acid to the Gal1,4GlcNAc sequence,
	the preferred ligand for galectin-1, inhibits recognition of this
	saccharide ligand by galectin-1. The enzyme sialylates N-glycans on
	CD45, a receptor tyrosine phosphatase that is a T cell receptor for
	galectin-1. ST6Gal I expression abrogates the reduction in CD45
	tyrosine phosphatase activity that results from galectin1 binding.
	Sialylation of CD45 by the ST6Gal I also prevents galectin-1-induced
	clustering of CD45 on the T cell surface, an initial step in galectin-1
	cell death. Regulation of glycoprotein sialylation may control
	susceptibility to cell death at specific points during T cell
	development and peripheral activation <38>; #6# the enzyme functions in
	Golgi vesicles to terminally sialylate the N-linked oligosaccharides of
	glycoproteins <36>; #4# the enzyme is responsible for the synthesis of
	6-sialylolifosaccharides in milk <37>; #4# ST6Gal II shows no activity
	towards oligosaccharides such as Galbeta1,3GalNAc, Galbeta1,3GlcNAc,
	lactose, and lacto-N-tetraose, which do not have the Galbeta1,4GlcNAc
	structure at the nonreducing end of their carbohydrate groups.
	Relatively low activity towards some glycoproteins, which are
	considered to have the Galbeta1,4GlcNAc structure at the nonreducing
	end of the carbohydrate groups <37>; #16# radiation exposure is found
	to increase the sialylation of glycoproteins such as integrin beta1 by
	inducing the expression of ST6Gal I, and increased protein sialylation
	contributed to cellular radiation resistance <55>; #5# soluble ST6Gal I
	produced by BACE1 plays, at least in part, a role in the sialylation of
	soluble glycoproteins <52>; #4# ST6Gal I sialyltransferase knock-out
	mouse lacks the main enzyme necessary for the attachment of alpha2,6
	sialic acid to N-linked glycoproteins on the cell surface. Even in the
	absence of detectable alpha2,6 sialic acid in the mouse respiratory
	tract, human influenza viruses can still infect these mice and grow to
	similar titers in the lung and trachea as compared to wild-type
	animals. The presence of a major alpha2,6 sialic acid on N-linked
	glycoproteins is not essential for human influenza virus infection in
	mice <56>; #37# no sialidase activity is detected for the
	alpha2,6-sialyltransferase <51>; #5# the enzyme transfers Neu5Ac of
	CMP-Neu5Ac to the 6-hydroxyl group on internal GalNAc on O-glycans with
	strict specificities towards the O-glycan GalNAcalpha- (Tnantigen),
	Galbeta1-3GalNAcalpha- (T-antigen) and
	Neu5Acalpha2-3Galbeta1-3GalNAcalpha- (sialyl T-antigen) structures.
	hST6GalNAc-I shows activities towards O-linked oligosaccharides
	attached to peptides of glycoproteins and weak activities towards
	synthetic non-amino acid aglycons of O-glycans hST6GalNAc-I.
	hST6GalNAc-I shows strong activities with core 2 glycans
	(Galbeta1-3GalNAcbeta[GlcNAcbeta1-6]GalNAc). Core 2 O-glycan structures
	lacking the terminal galactose such as core 6
	(GlcNAcbeta1-6GalNAcalpha-) or substituted with other monosaccharides
	such as core 4 (GlcNAcbeta1-3[GlcNAcbeta1-6]GalNAcalpha-) do not give
	any signal indicating that hST6GalNAc-I possibly also sialylated the
	terminal galactose of core 2 glycans. Relative specificities for the
	acceptors, Galbeta1-3GalNAcalphaOpNP (23%),
	Galbeta1-3[GlcNAcbeta1-6]GalNAcOalphapNP (12%),
	Galbeta1-3GalNAcOalphaThr (100%) and
	Galbeta1-3[GlcNAcbeta1-6]Galalpha2-6GalNAcOalphaThr (alpha2-6sialyl
	Tn-antigen). Relative specificities of the acceptors,
	Galbeta1-3GalNAcalphaOpNP (0%),
	Galbeta1-3[GlcNAcbeta1-6]GalNAcOalphapNP (0%),
	Galbeta1-3GalNAcOalphaThr (100%) and
	Galbeta1-3[GlcNAcbeta1-6]GalNAcalphaThr (19%) are found <50>; #14#
	DELTA15Pd2,6ST preferentially cleaves alpha2,6-linked sialic acid <63>;
	#6# human-like sialylated recombinant thyrotropin with sialic acid
	bound to galactose by both alpha2-3 and alpha2-6 linkages, similar to
	the native preparation, obtained in CHO cells modified to produce
	alpha2,6-sialyltransferase <64>; #9# neuraminidase activity is specific
	for the Neu5Acalpha2,6Gal linkage <62>; #26# the enzyme uses the
	LacdiNAc structure (GalNAcbeta1,4GlcNAc) as a better acceptor substrate
	than the type II (Galbeta1-4GlcNAc) disaccharide. The enzymes
	efficiency is improved when the acceptor substrate is provided as a
	free oligosaccharide rather than as a protein-bound oligosaccharide. No
	activity with alpha1-acidglycoprotein and Galbeta1–3GlcNAc-octyl
	<60>; #39# no activity with Gal-beta1,3-GlcNAc, T-antigen
	Gal-beta1,3-GalNAc-alpha, and NeuAc-alpha2,3-Gal-beta1,4-Glc <69>; #16#
	the enzyme cannot transfer a N-acetylneuraminate residue to
	pyridylaminyl-LNFP I, a type 1 chain derivative of the blood group H
	antigen <70>; #16# the enzyme catalyzes alpha-2,6-sialylation of
	galactose on glycoproteins <67>; #5# the enzyme catalyzes the formation
	of the terminal alpha2,6-sialic acid linkages on gangliosides <76>; #8#
	no activity towards Glcalpha-4-nitrophenyl, Galalpha-4-nitrophenyl,
	GalNAcalpha-4-nitrophenyl, Galbeta(1,3)-GalNAcbeta-4-nitrophenyl and
	GalNAcbeta(1,3)-GlcNAcbeta-4-nitrophenyl <80>; #5# no activity with
	6-sialyllactosamine <84>; #14# the enzyme exhibits a unique
	regioselectivity and is able to sialylate internal galactose residues
	in poly-LacNAc extended glycans <82>) {}
	<9,10,11,12,14,15,17,18,25,26,27,29,32,36,37,38,50,51,52,55,56,60,62,63
	64,67,69,70,76,80,82,84>
SP	#2,5,6,7,11,15# CMP-N-acetylneuraminate + asialo-orosomucoid = CMP +
	orosomucoid (#7,11# best substrate <15,17>; #6,7#
	CMP-N-acetylneuraminate can be replaced with comparable or even higher
	transfer rates by CMP-N-glycolylneuraminate,
	CMP-9-O-acetyl-N-acetylneuraminate <2>; #2,5,6,7,11,15# i.e.
	asialo-alpha1 acid glycoprotein
	<2,7,9,11,12,14,15,17,18,23,24,27,31,32>; #5# about half as effective
	as asialofetuin <18>) <2,3,7,9,11,12,14,15,16,17,18,23,24,27,31,32>
SP	#2,6,11# CMP-N-acetylneuraminate + asialo-prothrombin = CMP +
	prothrombin <11,14,15>
SP	#26# asialo-alpha1-acidglycoprotein + CMP-Neu5Ac = ? (#26#
	membrane-bound and soluble protein, 34% and 25% relative activity,
	respectively <60>) <60>
SP	#26# Galbeta(1,4)GlcNAc-octyl + CMP-Neu5Ac = ? (#26# membrane-bound and
	soluble protein, 100% relative activity <60>) <60>
SP	#26# GalNAcbeta(1,4)GlcNAc-octyl + CMP-Neu5Ac = ? (#26# membrane-bound
	and soluble protein, 312% and 346% relative activity, respectively
	<60>) <60>
SP	#3# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,3-N-acetyl-beta-D-glucosamine = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	3-N-acetyl-beta-D-glucosamine (#3# 36% of the activity with
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <39>) <39>
SP	#3# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine-R = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	4-N-acetyl-beta-D-glucosamine-R (#3# exhibits highest activity toward
	GalNAcbeta1,4GlcNAc carbohydrate structures at the non-reducing termini
	of oligosaccharides and glycoprotein glycans. Oligosaccharides are
	preferred over glycoproteins as acceptors, and no activity toward
	glycolipid acceptors is detected. Recombinant Drosophila SiaT expressed
	in cultured insect cells possesses in vivo and in vitro autosialylation
	activity toward beta-linked GalNAc termini of its own N-linked glycans
	<39>) <39>
SP	#3# CMP-N-acetylneuraminate +
	Galbeta(1-3)-GlcNAcbeta(1-3)Galbeta(1-4)Glc = CMP +
	NeuNAcalpha(2-6)-Galbeta(1-3)GlcNAcbeta(1-3)Galbeta(1-4)Glc (#3# 30% of
	the activity with beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine
	<39>) <39>
SP	#3# CMP-N-acetylneuraminate +
	Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc = CMP +
	alpha-N-acetylneuraminyl-(2-6)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1
	4)Glc (#3# 79% of the activity with
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <39>) <39>
SP	#3# CMP-N-acetylneuraminate + GalNAcbeta1,4-GlcNAc-R = CMP +
	alpha-N-acetylneuraminyl-2,6-GalNAcbeta1,4-GlcNAc-R |#3# 190% of the
	activity with beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <39>|
	<39>
SP	#3,4,5,6,7,11,14,19,38,39# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	4-N-acetyl-beta-D-glucosamine (#39# highest activity <69>; #5# poor
	substrate <18>; #7# best substrate <17>; #19# 100% activity <71>;
	#4,5,6,7,11,14# i.e. N-acetyllactosamine <11,15,17,18,22,25,26,28>;
	#5,7,11# most active disaccharide substrate <15>)
	<11,15,17,18,22,24,25,26,28,37,39,68,69,71,72,74>
SP	#37# CMP-N-acetylneuraminate + Gal-beta-1,3-GlcNAc-beta-OMe = ? (#37#
	77% of the activity with lactose <51>) <51>
SP	#37# CMP-N-acetylneuraminate + methyl-alpha-D-galactopyranoside = ?
	(#37# 2% of the activity with lactose <51>) <51>
SP	#37# CMP-N-acetylneuraminate + methyl-beta-D-galactopyranoside = ?
	(#37# 59% of the activity with lactose <51>) <51>
SP	#37# CMP-N-acetylneuraminate + N-acetyl-D-galactosamine = ? (#37# 12%
	of the activity with lactose <51>) <51>
SP	#37,40,41# CMP-N-acetylneuraminate + AA-labeled 6'-sialyllactose = ?
	<86>
SP	#37,40,41# CMP-N-acetylneuraminate + AA-labeled G2 glycan = ? <86>
SP	#4# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1
	4-beta-D-galactosyl-1,4-beta-D-glucosyl-beta1-ceramide = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	4-N-acetyl-beta-D-glucosaminyl-1,4-beta-D-galactosyl-1
	4-beta-D-glucosyl-beta1-ceramide (#4# i.e. paragloboside <8>) |#4# i.e.
	alpha-2,6-sialylparagloboside <8>| <8>
SP	#4# CMP-N-acetylneuraminate + alpha1-acid glycoprotein = CMP + ? (#4#
	20.6% of the activity with
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <37>) <37>
SP	#4# CMP-N-acetylneuraminate + asialo-alpha1-acid glycoprotein = CMP + ?
	(#4# 12.3% of the activity with
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <37>) <37>
SP	#4# CMP-N-acetylneuraminate + asialo-alpha1-acid glycoprotein = CMP +
	alpha1-acid glycoprotein (#4# 176% of the activity with
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <37>) <37>
SP	#4# CMP-N-acetylneuraminate + asialoovomucoid = CMP + ? (#4# 9.1% of
	the activity with beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine
	<37>) <37>
SP	#4# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,3-N-acetyl-beta-D-glucosaminyl-1
	3-galactosyl-beta-1,4-D-glucose = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	3-N-acetyl-beta-D-glucosaminyl-1,3-galactosyl-beta-1,4-D-glucose (#4#
	106% of the activity with
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <37>; #4# 129% of the
	activity with beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <37>)
	<37>
SP	#4# CMP-N-acetylneuraminate + lactose = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1,4-beta-D-glucose (#4#
	15.5% of the activity with
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <37>) <37>
SP	#4# CMP-N-acetylneuraminate + ovomucoid = CMP + ? (#4# 8.4% of the
	activity with beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <37>)
	<37>
SP	#4,19# CMP-N-acetylneuraminate + lacto-N-tetraose = CMP + ? (#4# 36.8%
	of the activity with beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine
	<37>; #19# 35% activity compared to
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <71>) <37,71>
SP	#4,6# CMP-N-acetylneuraminate + lacto-N-neotetraose = ? <11,22>
SP	#5# CMP-N-acetylneuraminate + pyridylamino-lactose = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	4-beta-D-glucosyl-pyridylaminoside (#5# recombinant enzyme <27>) <27>
SP	#5# CMP-N-acetylneuraminate + 4-nitrophenyl-D-galactoside = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-(4-nitro)phenol <7>
SP	#5# CMP-N-acetylneuraminate +
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosaminyl-1,2-alpha-mannosyl-1
	6-beta-mannosyl-1,4-N-acetylglucosamine = CMP +
	alpha-N-acetylneuraminyl-2,6-beta-D-galactosyl-1
	4-N-acetyl-beta-D-glucosaminyl-1,2-alpha-mannosyl-1,6-beta-mannosyl-1
	4-N-acetylglucosamine <6>
SP	#5# CMP-N-alpha-neuraminate + ganglioside nLc4Cer = ? <27>
SP	#5# CMP-N-alpha-neuraminate + pyridylaminated ganglioside nLc4Cer = ?
	<27>
SP	#5# CMP-N-alpha-neuraminate + ganglioside nLc6Cer = ? <27>
SP	#5# CMP-N-acetylneuraminate +
	Galbeta(1->4)GlcNAcbeta(1->2)Manalpha(1->6)[Galbeta(1
	>4)GlcNAcbeta(1>2)Manalpha(1->3)]Manbeta(1->4)GlcNAcbeta(1->4)GlcNAc
	pyridylamine = CMP +
	NeuAcalpha(2->6)Galbeta(1->4)GlcNAcbeta(1->2)Manalpha(1->6)[Galbeta(1
	>4)GlcNAcbeta(1>2)Manalpha(1->3)]Manbeta(1->4)GlcNAcbeta(1->4)GlcNAc
	pyridylamine <74>
SP	#5# CMP-N-acetylneuraminate +
	Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)Glcbeta(1<->1)ceramide = CMP
	+
	NeuAcalpha(2->6)Galbeta(1->4)GlcNAcbeta(1->3)Galbeta(1->4)Glcbeta(1<
	>1)ceramide <75>
SP	#5# CMP-N-acetylneuraminate + lactosamine = ? <84>
SP	#5,6# CMP-N-formylneuraminate + asialo-alpha1-acid glycoprotein = ? <31>
SP	#5,6# CMP-N-aminoacetylneuraminate + asialo-alpha1-acid glycoprotein =
	? <31>
SP	#5,6,7,11# CMP-N-acetylneuraminate + asialo-transferrin = CMP +
	transferrin (#6# poor substrate <9>) <1,9,11,15,27,32,36>
SP	#5,6,7,9,11,14,19,37# CMP-N-acetylneuraminate + lactose = CMP +
	6'-sialyllactose (#7# no activity <10>; #6,7# poor substrate <11,17>;
	#37# Asp232 might act as a catalytic base for deprotonation of the
	acceptor substrate, and His405 might act as a catalytic acid for
	protonation of the donor substrate <49>; #19# 14% activity compared to
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <71>)
	<10,11,12,15,17,25,26,48,49,51,71,79>
SP	#5,6,7,9,11,14,19,37# CMP-N-acetylneuraminate + lactose = CMP +
	6'-sialyllactose (#7# no activity <10>; #6,7# poor substrate <11,17>;
	#37# Asp232 might act as a catalytic base for deprotonation of the
	acceptor substrate, and His405 might act as a catalytic acid for
	protonation of the donor substrate <49>; #19# 14% activity compared to
	beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine <71>) {}
	<10,11,12,15,17,25,26,48,49,51,71,79>
SP	#5,7,11# CMP-N-acetylneuraminate + fetuin = ? (#11# no activity <15>;
	#7# glycopeptides <10>; #5# about 30% as effective as asialofetuin
	<18>) <10,15,17,18>
SP	#5,7,11# CMP-N-acetylneuraminate + fetuin = ? (#11# no activity <15>;
	#7# glycopeptides <10>; #5# about 30% as effective as asialofetuin
	<18>) {} <10,15,17,18>
SP	#5,8,14,15,16,37,40,41# CMP-N-acetylneuraminate +
	beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine = CMP +
	alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta
	D-glucosamine <78,80,81,82,83,84,85,86>
SP	#5,8,37,40,41# CMP-N-acetylneuraminate + asialofetuin = ? <80,84,86>
SP	#6# CMP-N-acetylneuraminate + asialo-agalacto-prothrombin = CMP +
	agalacto-prothrombin <11>
SP	#6# CMP-N-acetylneuraminate + asialo-apoceruloplasmin = CMP +
	apoceruloplasmin (#6# best substrate <9>) <9>
SP	#6# CMP-N-acetylneuraminate + asialo-chorionic gonadotropin = CMP +
	chorionic gonadotropin (#6# acceptor protein from human source <9>) <9>
SP	#6# CMP-N-acetylneuraminate + asialo-fibrinogen = CMP + fibrinogen <9>
SP	#6# CMP-9-amino-N-acetylneuraminate + asialo-alpha1-acid glycoprotein =
	? <3>
SP	#6# CMP-9-acetamido-N-acetylneuraminate + asialo-alpha1-acid
	glycoprotein = ? <3>
SP	#6# CMP-9-benzamido-N-acetylneuraminate + asialo-alpha1-acid
	glycoprotein = ? <3>
SP	#6# CMP-9-hexanoylamido-N-acetylneuraminate + asialo-alpha1-acid
	glycoprotein = ? <3>
SP	#6# CMP-9-azido-N-acetylneuraminate + asialo-alpha1-acid glycoprotein =
	? <3>
SP	#6# CMP-9-O-acetyl-N-acetylneuraminate + asialo-alpha1-acid
	glycoprotein = CMP + ? <36>
SP	#6# CMP-N-acetylneuraminate +
	(2S,3S,4R,5R,6R)-5-acetylamino-4-hydroxy-6-methoxy-3-((2S,3R,4S,5R
	6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	2-carboxylic acid methyl ester = CMP + ? (#6# 160% of the activity with
	Galbeta(1-3)GlcNAcbeta-O-Me <35>) <35>
SP	#6# CMP-N-acetylneuraminate +
	(2S,3S,4R,5R,6R)-5-acetylamino-4-hydroxy-6-methoxy-3-((2S,3R,4S,5R
	6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	2-carboxylic acid methylamide = CMP + ? (#6# 0.2% of the activity with
	Galbeta(1-3)GlcNAcbeta-O-Me <35>) <35>
SP	#6# CMP-N-acetylneuraminate +
	(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me = CMP + ? (#6# 50% of the
	activity with Galbeta(1-3)GlcNAcbeta-O-Me <34,35>) <34,35>
SP	#6# CMP-N-acetylneuraminate + (Gal-3-O-Me)beta(1-3)GlcNAcbeta-O-Me =
	CMP + ? (#6# 80% of the activity with Galbeta(1-3)GlcNAcbeta-O-Me <35>)
	<35>
SP	#6# CMP-N-acetylneuraminate + formic acid
	(2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R
	6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro
	pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl
	ester = CMP + ? (#6# as active as Galbeta(1-3)GlcNAcbeta-O-Me <34>) <34>
SP	#6# CMP-N-acetylneuraminate + Galbeta(1-3)(GlcNAc-6-O-Me)beta-O-Me =
	CMP + ? (#6# 80% of the activity with Galbeta(1-3)GlcNAcbeta-O-Me <35>)
	<35>
SP	#6# CMP-N-acetylneuraminate + Galbeta(1-3)GlcNAcbeta-O-Me = CMP +
	NeuAcalpha(2-6)Galbeta(1-3)GlcNAcbeta-O-Me <34,35>
SP	#6# CMP-N-acetylneuraminate + methanesulfonic acid
	(2R,3S,4R,5R,6R)-5-acetylamino-4-hydroxy-6-methoxy-3-((2S,3R,4S,5R
	6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	2-ylmethyl ester = CMP + ? (#6# 90% of the activity with
	Galbeta(1-3)GlcNAcbeta-O-Me <35>) <35>
SP	#6# CMP-N-acetylneuraminate +
	N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7
	17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11
	14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide = CMP + ?
	(#6# as active as Galbeta(1-3)GlcNAcbeta-O-Me <34>) <34>
SP	#6# CMP-N-acetylneuraminate +
	N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7
	18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9
	15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide = CMP
	+ ? (#6# 110% of the activity with Galbeta(1-3)GlcNAcbeta-O-Me <34>)
	<34>
SP	#6# CMP-N-acetylneuraminate +
	N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7
	18-trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12
	15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide = CMP + ?
	(#6# 130% of the activity with Galbeta(1-3)GlcNAcbeta-O-Me <34>) <34>
SP	#6# CMP-N-acetylneuraminate +
	N-[(2R,3R,4R,5S
	6R)-4-hydroxy-6-(methanesulfonylamino-methyl)-2-methoxy-5-((2S,3R,4S,5R
	6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	3-yl]-acetamide = CMP + ? (#6# 70% of the activity with
	Galbeta(1-3)GlcNAcbeta-O-Me <35>) <35>
SP	#6# CMP-N-acetylneuraminate +
	N-[(2R,3R,4R,5S,6R)-5-((2S,3R,4S,5R,6R)-4
	5-dihydroxy-6-hydroxymethyl-3-methoxy-tetrahydro-pyran-2-yloxy)-6
	formylaminomethyl-4-hydroxy-2-methoxy-tetrahydro-pyran-3-yl]-acetamide
	= CMP + ? (#6# as active as Galbeta(1-3)GlcNAcbeta-O-Me <35>) <35>
SP	#6# CMP-N-acetylneuraminate +
	N-[(2R,3R,4R,5S,6R)-6-(acetylamino-methyl)-4-hydroxy-2-methoxy-5-((2S
	3R,4S,5R,6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	3-yl]-acetamide = CMP + ? (#6# 60% of the activity with
	Galbeta(1-3)GlcNAcbeta-O-Me <35>) <35>
SP	#6# CMP-N-acetylneuraminate +
	N-[(2R,3R,4R,5S,6R)-6-aminomethyl-4-hydroxy-2-methoxy-5-((2S,3R,4S,5R
	6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	3-yl]-acetamide = CMP + ? (#6# 50% of the activity with
	Galbeta(1-3)GlcNAcbeta-O-Me <35>) <35>
SP	#6# CMP-9''-benzamido-Neu5Ac + N-acetyllactosamine = ? <46>
SP	#6# CMP-9''-phenylacetamido-Neu5Ac + N-acetyllactosamine = ? <46>
SP	#6# CMP-9''-phenylhexanamido-Neu5Ac + N-acetyllactosamine = ? <46>
SP	#6# CMP-9''-phenylpropionamido-Neu5Ac + N-acetyllactosamine = ? <46>
SP	#6# cytidine-5'-monophospho-sialic acid + N-acetyllactosamine = ? <46>
SP	#6# cytidine 5'-monophosphate 3-(axial)-fluoro-N-acetylneuraminic acid
	+ alpha-lactose = ? (#6# [15N]Phe-labeled ST6Gal-I with a 15fold excess
	of CMP-3FNeuAc <58>) <58>
SP	#6# cytidine 5'-monophosphate
	4-O-(4-carboxy-2,2,6,6-tetramethylpiperidine-1-oxyl) +
	alpha-N-acetyllactosamine = ? <58>
SP	#6# N-acetyllactosamine
	4-O-(4-carboxy-2,2,6,6-tetramethylpiperidine-1-oxyl) = ? (#6#
	[15N]Phe-labeled ST6Gal-I with a 20fold excess of N-acetyllactosamine
	4-O-(4-carboxy-2,2,6,6-tetramethylpiperidine-1-oxyl) <58>) <58>
SP	#6,11# CMP-N-acetylneuraminate + asialo-ceruloplasmin = CMP +
	ceruloplasmin <3,9,15>
SP	#6,11# CMP-N-acetylneuraminate + asialo-thyroglobulin = CMP +
	thyroglobulin (#11# low activity <15>) <9,15>
SP	#6,37# CMP-N-acetylneuraminate + N-acetyllactosamine = ? (#37# 99% of
	the activity with lactose <51>) <47,51>
SP	#6,7# CMP-9-O-acetyl-N-acetylneuraminate + asialo-alpha1-acid
	glycoprotein = ? (#6,7# comparable or even higher transfer rates than
	with CMP-N-acetylneuraminate <2>) <2>
SP	#6,7# CMP-N-glycolylneuraminate + asialo-alpha1-acid glycoprotein = ?
	(#6,7# comparable or even higher transfer rates than with
	CMP-N-acetylneuraminate <2>) <2>
SP	#7# CMP-N-acetylneuraminate + asialo-thyroglobulin glycopeptide = CMP +
	thyroglobulin glycopeptide <10>
SP	#7# CMP-N-acetylneuraminate + asialo-immunoglobulin G = CMP +
	immunoglobulin G <17>
SP	#7# CMP-N-acetylneuraminate + asialo-immunoglobulin M = CMP +
	immunoglobulin M <17>
SP	#7,11# CMP-N-acetylneuraminate + submaxillary asialo-mucin = CMP +
	submaxillary mucin (#7# poor substrates, no activity with ovine
	acceptor <15>) <15>
SP	#8# CMP-N-acetylneuraminate +
	(Galbeta(1,4))2(GlcNAcbeta(1,2))2(Man)3(GlcNAc)2-Asn-Fmoc = ? (#8# 34.9
	activity compared to Galbeta(1,4)-GlcNAcbeta-4-nitrophenyl <80>) <80>
SP	#8# CMP-N-acetylneuraminate +
	(GalNAcbeta(1,4))2(GlcNAcbeta(1,2))2(Man)3(GlcNAc)2-Asn-Fmoc = ? (#8#
	140 activity compared to Galbeta(1,4)-GlcNAcbeta-4-nitrophenyl <80>)
	<80>
SP	#8# CMP-N-acetylneuraminate + Galbeta(1,3)-GlcNAcbeta-4-nitrophenyl = ?
	(#8# 2.5% activity compared to Galbeta(1,4)-GlcNAcbeta-4-nitrophenyl
	<80>) <80>
SP	#8# CMP-N-acetylneuraminate + Galbeta(1,4)-GlcNAcbeta-4-nitrophenyl = ?
	(#8# 100% activity <80>) <80>
SP	#8# CMP-N-acetylneuraminate + Galbeta-4-nitrophenyl = ? (#8# 26.4%
	activity compared to Galbeta(1,4)-GlcNAcbeta-4-nitrophenyl <80>) <80>
SP	#8# CMP-N-acetylneuraminate + GalNAcbeta(1,4)-GlcNAcbeta-4-nitrophenyl
	= ? (#8# best acceptor with 371.5% activity compared to
	Galbeta(1,4)-GlcNAcbeta-4-nitrophenyl <80>) <80>
SP	#8# CMP-N-acetylneuraminate + GalNAcbeta-4-nitrophenyl = ? (#8# 120.4%
	activity compared to Galbeta(1,4)-GlcNAcbeta-4-nitrophenyl <80>) <80>
SP	#9# CMP-Neu5Ac + lactose = CMP + Neu5Acalpha(2-6)Lac (#9#
	alpha2,6-sialyltransferase activity <62>) <62>
SP	#9# CMP-Neu5Ac + methyl-beta-D-galactopyranoside = CMP +
	Neu5Acalpha(2-6)Gal-alpha-methyl (#9# alpha2,6-sialyltransferase
	activity <62>) <62>
SP	#9# CMP-Neu5Ac + N-acetyllactosamine = CMP + Neu5Acalpha(2-6)LacNAc
	(#9# alpha2,6-sialyltransferase activity <62>) <62>

TURNOVER_NUMBER
TN	#14# 1.1 {4-methylumbelliferyl beta-D-lactoside}  (#14# pH 8.5, 37°C,
	enzyme form DELTA112Pd2,6ST(N) <45>) <45>
TN	#14# 16.9 {CMP-N-acetylneuraminate}  (#14# mutant enzyme I411T/L433S,
	at pH 8.0 and 22°C <79>) <79>
TN	#14# 2.3 {4-methylumbelliferyl beta-D-lactoside}  (#14# pH 8.5, 37°C,
	enzyme form DELTA15Pd2,6ST(N) <45>) <45>
TN	#14# 2.7 {CMP-N-acetylneuraminate}  (#14# pH 8.5, 37°C, enzyme form
	DELTA15Pd2,6ST(N) <45>) <45>
TN	#14# 1.4 {CMP-N-acetylneuraminate}  (#14# pH 8.5, 37°C, enzyme form
	DELTA112Pd2,6ST(N) <45>) <45>
TN	#14# 110 {lactose}  (#14# mutant enzyme I411T/L433T, at pH 8.0 and
	22°C <79>) <79>
TN	#14# 4.3 {lactose}  (#14# wild type enzyme, at pH 8.0 and 22°C <79>)
	<79>
TN	#14# 10.9 {CMP-N-acetylneuraminate}  (#14# mutant enzyme I411T, at pH
	8.0 and 22°C <79>) <79>
TN	#14# 10.7 {CMP-N-acetylneuraminate}  (#14# mutant enzyme L433T, at pH
	8.0 and 22°C <79>) <79>
TN	#14# 85 {lactose}  (#14# mutant enzyme L433S, at pH 8.0 and 22°C <79>)
	<79>
TN	#14# 102 {lactose}  (#14# mutant enzyme I411T/L433S, at pH 8.0 and
	22°C <79>) <79>
TN	#14# 0.883 {Neu5Acalpha-4-nitrophenyl}  (#14# alpha2,6-trans-sialidase
	activity of DELTA15Pd2,6ST <63>) <63>
TN	#14# 25.4 {lactose}  (#14# mutant enzyme I411T, at pH 8.0 and 22°C
	<79>) <79>
TN	#14# 18.8 {CMP-N-acetylneuraminate}  (#14# mutant enzyme I411T/L433T,
	at pH 8.0 and 22°C <79>) <79>
TN	#14# 20.3 {CMP-N-acetylneuraminate}  (#14# mutant enzyme L433S, at pH
	8.0 and 22°C <79>) <79>
TN	#14# 4.32 {CMP-N-acetylneuraminate}  (#14# wild type enzyme, at pH 8.0
	and 22°C <79>) <79>
TN	#14# 76.5 {lactose}  (#14# mutant enzyme L433T, at pH 8.0 and 22°C
	<79>) <79>
TN	#15# 0.1 {CMP-N-acetylneuraminate}  (#15# mutant enzyme Q232A, at pH
	6.5 and 37°C <83>) <83>
TN	#15# 0.19 {CMP-N-acetylneuraminate}  (#15# mutant enzyme F208A, at pH
	6.5 and 37°C <83>) <83>
TN	#15# 0.64 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme Q354A, at pH 6.5 and 37°C <83>) <83>
TN	#15# 0.05 {CMP-N-acetylneuraminate}  (#15# mutant enzyme D271A, at pH
	6.5 and 37°C <83>; #15# mutant enzyme Y272A, at pH 6.5 and 37°C <83>)
	<83>
TN	#15# 0.59 {CMP-N-acetylneuraminate}  (#15# recombinant wild type enzyme
	from 293-F cells, at pH 6.5 and 37°C <83>) <83>
TN	#15# 0.69 {CMP-N-acetylneuraminate}  (#15# mutant enzyme K355A, at pH
	6.5 and 37°C <83>) <83>
TN	#15# 1.13
	{5-(5-dimethylaminonaphthalene-1-sulfonyl-2-(2-aminoethoxy))ethyl
	beta-N-acetyllactosamine}  <59>
TN	#15# 0.07 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme Y272A, at pH 6.5 and 37°C <83>) <83>
TN	#15# 0.35 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	recombinant wild type enzyme from HEK-293 cells, at pH 6.5 and 37°C
	<83>) <83>
TN	#15# 0.14 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme Q232A, at pH 6.5 and 37°C <83>) <83>
TN	#15# 0.39 {CMP-N-acetylneuraminate}  (#15# mutant enzyme Y119F, at pH
	6.5 and 37°C <83>) <83>
TN	#15# 0.39 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme K355A, at pH 6.5 and 37°C <83>) <83>
TN	#15# 0.42 {CMP-N-acetylneuraminate}  (#15# mutant enzyme Q354A, at pH
	6.5 and 37°C <83>) <83>
TN	#15# 0.67 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	recombinant wild type enzyme from 293-F cells, at pH 6.5 and 37°C
	<83>) <83>
TN	#15# 0.43 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme F208A, at pH 6.5 and 37°C <83>) <83>
TN	#15# 0.31 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme Y119F, at pH 6.5 and 37°C <83>) <83>
TN	#15# 0.09 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme D271A, at pH 6.5 and 37°C <83>) <83>
TN	#15# 0.49 {CMP-N-acetylneuraminate}  (#15# recombinant wild type enzyme
	from HEK-293 cells, at pH 6.5 and 37°C <83>) <83>
TN	#15# 0.087
	{5-(5-dimethylaminonaphthalene-1-sulfonyl-2-(2-aminoethoxy))ethyl
	beta-lactose}  <59>

KM_VALUE
KM	#11# 0.3 {CMP-N-acetylneuraminate}  (#11# with N-acetyllactosamine
	<15>) <15>
KM	#11# 0.08 {CMP-N-acetylneuraminate}  (#11# with lactose <15>) <15>
KM	#12# 0.11 {CMP-9''-benzamido-Neu5Ac}  (#12# pH 5.0, 37°C <46>) <46>
KM	#12# 0.11 {CMP-9''-phenylpropionamido-Neu5Ac}  (#12# pH 5.0, 37°C
	<46>) <46>
KM	#12# 0.14 {cytidine-5'-monophospho-sialic acid}  (#12# pH 5.0, 37°C
	<46>) <46>
KM	#12# 1.8 {lactose}  (#12# pH 5.0, 37°C, cosubstrate:
	CMP-9-benzamido-Neu5Ac <46>) <46>
KM	#12# 2.5 {lactose}  (#12# pH 5.0, 37°C, cosubstrate:
	CMP-9-phenylacetamido-Neu5Ac <46>; #12# pH 5.0, 37°C, cosubstrate:
	CMP-phenylhexanamido-Neu5Ac <46>) <46>
KM	#12# 0.34 {CMP-9''-phenylacetamido-Neu5Ac}  (#12# pH 5.0, 37°C <46>)
	<46>
KM	#12# 0.53 {CMP-9''-phenylhexanamido-Neu5Ac}  (#12# pH 5.0, 37°C <46>)
	<46>
KM	#12# 2.6 {lactose}  (#12# pH 5.0, 37°C, cosubstrate:
	CMP-phenylpropionamido-Neu5Ac <46>) <46>
KM	#12# 3.6 {lactose}  (#12# pH 5.0, 37°C, cosubstrate:
	cytidine-5-monophospho-sialic acid <46>) <46>
KM	#14# 0.6 {4-methylumbelliferyl beta-D-lactoside}  (#14# pH 8.5, 37°C,
	enzyme form DELTA112Pd2,6ST(N) <45>) <45>
KM	#14# 0.9 {CMP-N-acetylneuraminate}  (#14# pH 8.5, 37°C, enzyme form
	DELTA112Pd2,6ST(N) <45>; #14# pH 8.5, 37°C, enzyme form
	DELTA15Pd2,6ST(N) <45>) <45>
KM	#14# 0.8 {4-methylumbelliferyl beta-D-lactoside}  (#14# pH 8.5, 37°C,
	enzyme form DELTA15Pd2,6ST(N) <45>) <45>
KM	#14# 0.32 {CMP-N-acetylneuraminate}  <25>
KM	#14# 62 {lactose}  (#14# mutant enzyme I411T/L433T, at pH 8.0 and 22°C
	<79>) <79>
KM	#14# 53 {Neu5Acalpha-4-nitrophenyl}  (#14# alpha2,6-trans-sialidase
	activity of DELTA15Pd2,6ST <63>) <63>
KM	#14# 10.7 {CMP-N-acetylneuraminate}  (#14# mutant enzyme I411T/L433S,
	at pH 8.0 and 22°C <79>) <79>
KM	#14# 6.06 {CMP-N-acetylneuraminate}  (#14# mutant enzyme I411T, at pH
	8.0 and 22°C <79>) <79>
KM	#14# 8.1 {Neu5Acalpha-2,3-Galbeta-1,4-Glc}  <26>
KM	#14# 27.3 {lactose}  (#14# mutant enzyme I411T, at pH 8.0 and 22°C
	<79>) <79>
KM	#14# 3.37 {CMP-N-acetylneuraminate}  (#14# mutant enzyme I411T/L433T,
	at pH 8.0 and 22°C <79>) <79>
KM	#14# 2.27 {CMP-N-acetylneuraminate}  (#14# mutant enzyme L433T, at pH
	8.0 and 22°C <79>) <79>
KM	#14# 13.6 {fucosyl-alpha-1,2-D-galactosyl-beta-1,4-D-glucose}  <26>
KM	#14# 8.15 {CMP-N-acetylneuraminate}  (#14# mutant enzyme L433S, at pH
	8.0 and 22°C <79>) <79>
KM	#14# 174 {methyl-beta-D-galactopyranoside}  <25>
KM	#14# 59.7 {lactose}  (#14# mutant enzyme L433S, at pH 8.0 and 22°C
	<79>) <79>
KM	#14# 8.95 {N-acetyllactosaminide}  <25>
KM	#14# 6.82 {lactose}  <25>
KM	#14# 61.1 {lactose}  (#14# mutant enzyme L433T, at pH 8.0 and 22°C
	<79>) <79>
KM	#14# 5.87 {CMP-N-acetylneuraminate}  (#14# wild type enzyme, at pH 8.0
	and 22°C <79>) <79>
KM	#14# 7.62 {lactose}  (#14# wild type enzyme, at pH 8.0 and 22°C <79>)
	<79>
KM	#14# 75.7 {lactose}  (#14# mutant enzyme I411T/L433S, at pH 8.0 and
	22°C <79>) <79>
KM	#15# 0.095 {CMP-N-acetylneuraminate}  (#15# mutant enzyme K355A, at pH
	6.5 and 37°C <83>) <83>
KM	#15# 0.133 {CMP-N-acetylneuraminate}  (#15# mutant enzyme Q232A, at pH
	6.5 and 37°C <83>) <83>
KM	#15# 0.078 {CMP-N-acetylneuraminate}  (#15# mutant enzyme Y119F, at pH
	6.5 and 37°C <83>) <83>
KM	#15# 0.4 {CMP-N-acetylneuraminate}  (#15# mutant enzyme F208A, at pH
	6.5 and 37°C <83>) <83>
KM	#15# 1 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme F208A, at pH 6.5 and 37°C <83>) <83>
KM	#15# 0.22 {CMP-N-acetylneuraminate}  (#15# mutant enzyme Y272A, at pH
	6.5 and 37°C <83>) <83>
KM	#15# 1.4 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	recombinant wild type enzyme from HEK-293 cells, at pH 6.5 and 37°C
	<83>) <83>
KM	#15# 1.8 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme Q354A, at pH 6.5 and 37°C <83>; #15# mutant enzyme
	Y119F, at pH 6.5 and 37°C <83>; #15# recombinant wild type enzyme from
	293-F cells, at pH 6.5 and 37°C <83>) <83>
KM	#15# 0.33 {asialo-alpha1-acid glycoprotein}  (#15# wild-type enzyme
	<23>) <23>
KM	#15# 2.8
	{5-(5-dimethylaminonaphthalene-1-sulfonyl-2-(2-aminoethoxy))ethyl
	beta-lactose}  <59>
KM	#15# 1.1 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme K355A, at pH 6.5 and 37°C <83>) <83>
KM	#15# 3.5 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme Y272A, at pH 6.5 and 37°C <83>) <83>
KM	#15# 0.093 {CMP-N-acetylneuraminate}  (#15# recombinant wild type
	enzyme from HEK-293 cells, at pH 6.5 and 37°C <83>) <83>
KM	#15# 2.6 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme Q232A, at pH 6.5 and 37°C <83>) <83>
KM	#15# 0.092 {CMP-N-acetylneuraminate}  (#15# recombinant wild type
	enzyme from 293-F cells, at pH 6.5 and 37°C <83>) <83>
KM	#15# 0.92
	{5-(5-dimethylaminonaphthalene-1-sulfonyl-2-(2-aminoethoxy))ethyl
	beta-N-acetyllactosamine}  <59>
KM	#15# 6.5 {beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine}  (#15#
	mutant enzyme D271A, at pH 6.5 and 37°C <83>) <83>
KM	#15# 0.365 {CMP-N-acetylneuraminate}  (#15# mutant enzyme D271A, at pH
	6.5 and 37°C <83>) <83>
KM	#15,16# 0.1 {CMP-N-acetylneuraminate}  (#16# apparent value,
	recombinant enzyme, using pyridylamine-type 2H as cosubstrate, in 50 mM
	MES-NaOH buffer (pH 6.0), 1 mM MnCl2, at 37°C <70>; #15# mutant enzyme
	Q354A, at pH 6.5 and 37°C <83>) <70,83>
KM	#16# 0.11 {CMP-N-acetylneuraminate}  (#16# apparent value, recombinant
	enzyme, using pyridylaminyl-lacto-N-neotetraose as cosubstrate, in 50
	mM MES-NaOH buffer (pH 6.0), 1 mM MnCl2, at 37°C <70>) <70>
KM	#16# 0.9 {pyridylaminyl-lacto-N-neotetraose}  (#16# recombinant enzyme,
	in 50 mM MES-NaOH buffer (pH 6.0), 1 mM MnCl2, at 37°C <70>) <70>
KM	#16# 3.5 {pyridylamine-type 2H}  (#16# recombinant enzyme, in 50 mM
	MES-NaOH buffer (pH 6.0), 1 mM MnCl2, at 37°C <70>) <70>
KM	#2# 0.003 {CMP-N-acetylneuraminate}  <14>
KM	#2# 0.035 {asialo-fetuin}  <14>
KM	#2,3,5,6,7,11# -999 {more}  (#2,6# kinetic data <11,14>; #7# kinetic
	mechanism <17>; #5# several recombinant truncated mutants <32>; #5,6#
	kinetics, several synthetic trisaccharides used as substrates <21>; #6#
	Km-values for synthetic CMP-N-acetylneuraminate analogues <29>)
	<11,14,15,17,21,27,29,32,39>
KM	#26# 1.09 {GalNAcbeta(1,4)GlcNAc-octyl}  (#26# membrane-bound protein,
	at 37°C <60>) <60>
KM	#26# 0.97 {GalNAcbeta(1,4)GlcNAc-octyl}  (#26# soluble protein, at
	37°C <60>) <60>
KM	#26# 2.04 {Galbeta(1,4)GlcNAc-octyl}  (#26# soluble protein, at 37°C
	<60>) <60>
KM	#26# 2.12 {Galbeta(1,4)GlcNAc-octyl}  (#26# membrane-bound protein, at
	37°C <60>) <60>
KM	#3# 1.4 {Galbeta(1-4)GlcNAc}  (#3# non-reducing terminus of
	asialofetuin glycans <39>) <39>
KM	#37# 0.0047 {AA-labeled G2 glycan}  (#37# at pH 8.0 and 30°C <86>) <86>
KM	#37# 31 {lactose}  <51>
KM	#37# 99 {methyl-beta-D-galactopyranoside}  <51>
KM	#4# 1.25 {beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine}  <37>
KM	#40# 0.0278 {AA-labeled G2 glycan}  (#40# at pH 8.0 and 30°C <86>) <86>
KM	#41# 0.0361 {AA-labeled G2 glycan}  (#41# at pH 8.0 and 30°C <86>) <86>
KM	#5# 0.16 {asialo-transferrin}  (#5# recombinant enzyme <27>) <27>
KM	#5# 1.3 {pyridylamino-N-acetyllactosamine}  (#5# recombinant enzyme
	<27>) <27>
KM	#5# 0.2 {asialo-alpha1-acid glycoprotein}  (#5# recombinant enzyme
	<27>) <27>
KM	#5# 0.28 {asialo-alpha1-acid glycoprotein}  (#5# recombinant enzyme
	<27>) <27>
KM	#5# 1.5 {pyridylamino-nLc4Cer}  (#5# recombinant enzyme <27>) <27>
KM	#5# 2.3 {N-acetyllactosamine}  (#5# recombinant enzyme <28>) <28>
KM	#5# 0.91 {nLc4Cer}  (#5# recombinant enzyme <27>) <27>
KM	#5# 0.0064 {asialo-fetuin}  (#5# expressed as concentration of terminal
	galactosyl residues <18>) <18>
KM	#5# 0.0205 {CMP-N-acetylneuraminate}  <18>
KM	#5# 0.555 {CMP-N-acetylneuraminate}  (#5# recombinant enzyme <33>) <33>
KM	#5# 102 {pyridylamino-lactose}  (#5# recombinant enzyme <27>) <27>
KM	#5,6# 0.15 {CMP-N-acetylneuraminate}  (#5# recombinant enzyme <28>)
	<4,28>
KM	#5,6,15# 0.05 {CMP-N-acetylneuraminate}  (#15# wild-type enzyme <23>;
	#6,15# with asialo-alpha1-acid glycoprotein <3,23>) <3,23,27>
KM	#6# 0.03 {CMP-9-benzamido-N-acetylneuraminate}  <3>
KM	#6# 0.05 {CMP-9''-phenylacetamido-Neu5Ac}  (#6# pH 5.0, 37°C <46>) <46>
KM	#6# 0.147 {asialo-alpha1-acid glycoprotein}  <36>
KM	#6# 0.21 {asialo-transferrin}  <11>
KM	#6# 1.7 {Galbeta(1-3)GlcNAcbeta-O-Me}  (#6# pH 6.5, 37°C <34>) <34,35>
KM	#6# 0.078 {asialo-ceruloplasmin}  (#6# expressed as concentration of
	acceptor sites <9>) <9>
KM	#6# 1
	{N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7
	18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9
	15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide}  (#6#
	pH 6.5, 37°C <34>) <34>
KM	#6# 2 {N-acetyllactosamine}  (#6# pH 5.0, 37°C, cosubstrate:
	CMP-9-phenylacetamido-Neu5Ac <46>) <46>
KM	#6# 0.12 {cytidine-5'-monophospho-sialic acid}  (#6# pH 5.0, 37°C
	<46>) <46>
KM	#6# 0.12 {CMP-9-acetamido-N-acetylneuraminate}  <3>
KM	#6# 0.14 {CMP-N-acetylneuraminate}  (#6# with stimulation by the
	natural cytosolic crat colon factor <24>) <24>
KM	#6# 0.14 {asialo-alpha1-acid glycoprotein}  <11>
KM	#6# 0.8
	{N-[(2R,3R,4R,5S
	6R)-4-Hydroxy-6-(methanesulfonylamino-methyl)-2-methoxy-5-((2S,3R,4S,5R
	6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	3-yl]-acetamide}  <35>
KM	#6# 1.4
	{N-[(2R,3R,4R,5S,6R)-6-(Acetylamino-methyl)-4-hydroxy-2-methoxy-5-((2S
	3R,4S,5R,6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	3-yl]-acetamide}  <35>
KM	#6# 2.4
	{(2S,3S,4R,5R,6R)-5-Acetylamino-4-hydroxy-6-methoxy-3-((2S,3R,4S,5R
	6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	2-carboxylic acid methylamide}  <35>
KM	#6# 3.1
	{N-[(2R,3R,4R,5S,6R)-5-((2S,3R,4S,5R,6R)-4
	5-Dihydroxy-6-hydroxymethyl-3-methoxy-tetrahydro-pyran-2-yloxy)-6
	formylaminomethyl-4-hydroxy-2-methoxy-tetrahydro-pyran-3-yl]-acetamide}
	 <35>
KM	#6# 10 {N-acetyllactosamine}  (#6# pH 5.0, 37°C, cosubstrate:
	CMP-9-phenylpropionamido-Neu5Ac <46>) <46>
KM	#6# 0.23 {asialo-alpha1-acid glycoprotein}  (#6# with stimulation by
	the natural cytosolic crat colon factor <24>) <24>
KM	#6# 3.3 {Formic acid
	(2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R
	6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro
	pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl
	ester}  (#6# pH 6.5, 37°C <34>) <34>
KM	#6# 4.3 {N-acetyllactosamine}  (#6# pH 5.0, 37°C, cosubstrate:
	cytidine-5-monophospho-sialic acid <46>) <46>
KM	#6# 4.3 {Galbeta(1-3)(GlcNAc-6-O-Me)beta-O-Me}  <35>
KM	#6# 0.7 {Methanesulfonic acid
	(2R,3S,4R,5R,6R)-5-acetylamino-4-hydroxy-6-methoxy-3-((2S,3R,4S,5R
	6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	2-ylmethyl ester}  <35>
KM	#6# 0.046 {CMP-N-acetylneuraminate}  <29>
KM	#6# 5.8
	{N-[(2R,3R,4R,5S,6R)-6-Aminomethyl-4-hydroxy-2-methoxy-5-((2S,3R,4S,5R
	6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	3-yl]-acetamide}  <35>
KM	#6# 0.035 {CMP-N-acetylneuraminate}  <30>
KM	#6# 6.8 {N-acetyllactosamine}  (#6# pH 5.0, 37°C, cosubstrate:
	CMP-9-benzamido-Neu5Ac <46>) <46>
KM	#6# 0.38 {CMP-N-acetylneuraminate}  <33>
KM	#6# 1.1
	{N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7
	18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12
	15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide}  (#6# pH
	6.5, 37°C <34>) <34>
KM	#6# 1.1
	{(2S,3S,4R,5R,6R)-5-Acetylamino-4-hydroxy-6-methoxy-3-((2S,3R,4S,5R
	6R)-3,4
	5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran
	2-carboxylic acid methyl ester}  <35>
KM	#6# 0.0053 {CMP-N-acetylneuraminate}  <11>
KM	#6# 0.016 {CMP-N-acetylneuraminate}  <11>
KM	#6# 4.1 {(Gal-3-O-Me)beta(1-3)GlcNAcbeta-O-Me}  <35>
KM	#6# 0.53 {asialo-alpha1-acid glycoprotein}  (#6# without stimulation by
	the natural cytosolic crat colon factor <24>) <24>
KM	#6# 0.047 {CMP-N-acetylneuraminate}  <9>
KM	#6# 0.163 {asialo-alpha1-acid glycoprotein}  <36>
KM	#6# 0.051 {CMP-9''-benzamido-Neu5Ac}  (#6# pH 5.0, 37°C <46>) <46>
KM	#6# 1.67 {lacto-N-neotetraose}  <11>
KM	#6# 5.2 {N-acetyllactosamine}  (#6# pH 5.0, 37°C, cosubstrate:
	CMP-9-phenylhexanamido-Neu5Ac <46>) <46>
KM	#6# 0.098 {CMP-9''-phenylhexanamido-Neu5Ac}  (#6# pH 5.0, 37°C <46>)
	<46>
KM	#6# 11.2 {(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me}  (#6# pH 6.5,
	37°C <34>) <34,35>
KM	#6# 11.6
	{N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7
	17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11
	14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide}  (#6# pH
	6.5, 37°C <34>) <34>
KM	#6# 0.72 {CMP-9-amino-N-acetylneuraminate}  <3>
KM	#6# 1.62 {N-acetyllactosamine}  <11>
KM	#6# 0.165 {CMP-9''-phenylpropionamido-Neu5Ac}  (#6# pH 5.0, 37°C <46>)
	<46>
KM	#6# 129 {lactose}  <11>
KM	#6,8# 0.24 {CMP-N-acetylneuraminate}  (#6# without stimulation by the
	natural cytosolic crat colon factor <24>; #8# wild type enzyme, at pH
	6.0 and 37°C <80>) <24,80>
KM	#7# 0.59 {asialo-thyroglobulin glycopeptides}  <10>
KM	#7# 12 {N-acetyllactosamine}  <17>
KM	#7# 0.27 {CMP-N-acetylneuraminate}  <10>
KM	#8# 35.7 {Galbeta(1,4)-GlcNAcbeta-4-nitrophenyl}  (#8# mutant enzyme
	N284Q, at pH 6.0 and 37°C <80>) <80>
KM	#8# 1.18 {CMP-N-acetylneuraminate}  (#8# mutant enzyme N284Q, at pH 6.0
	and 37°C <80>) <80>
KM	#8# 2.02 {CMP-N-acetylneuraminate}  (#8# mutant enzyme N284A, at pH 6.0
	and 37°C <80>) <80>
KM	#8# 40.2 {Galbeta(1,4)-GlcNAcbeta-4-nitrophenyl}  (#8# wild type
	enzyme, at pH 6.0 and 37°C <80>) <80>
KM	#8# 52.8 {Galbeta(1,4)-GlcNAcbeta-4-nitrophenyl}  (#8# mutant enzyme
	N284A, at pH 6.0 and 37°C <80>) <80>
KM	#9# 0.3 {CMP-Neu5Ac}  (#9# alpha2,6-sialyltransferase activity of the
	truncated recombinant enzyme <62>) <62>
KM	#9# 15.4 {N-acetyllactosamine}  (#9# alpha2,6-sialyltransferase
	activity of the truncated recombinant enzyme <62>) <62>
KM	#9# 17.2 {lactose}  (#9# alpha2,6-sialyltransferase activity of the
	truncated recombinant enzyme <62>) <62>

PH_OPTIMUM
PHO	#11# 6.4-7.2 (#11# broad, optimal buffer concentration: 0.05-0.15 M,
	decreasing activity above 0.15 M <15>) <15>
PHO	#14# -999 (#14# pI: 4.6 <25>) <25>
PHO	#14# 5 <25>
PHO	#14# 5.8 (#14# alpha2,6-sialidase and alpha2,6-trans-sialidase
	activities of DELTA15Pd2,6ST in MES buffer <63>) <63>
PHO	#2# 6.3 <14>
PHO	#3,6# 6-6.5 (#6# 2-(N-morpholino)ethane sulfonic acid buffer <9>) <9,39>
PHO	#37# 5-5.5 <51>
PHO	#4,5,6,7# 6.5 (#4,5,6,7# assay at <2,21,22,30,33>) <2,21,22,30,33>
PHO	#5,7,15,39# 6 (#5# broad <18>; #15# assay at <23>; #15# purified enzyme
	<59>) <10,18,23,59,69>
PHO	#6# 7.5 (#6# Tris-HCl buffer <9>) <9>
PHO	#6# 6.8 (#6# assay at <24>) <24>
PHO	#8,9# 8 <48,80>
PHO	#9# 5-6 (#9# pH 5: alpha2,6-sialyltransferase activity of the truncated
	recombinant enzyme, pH 6: neuraminidase activity of the truncated
	recombinant enzyme <62>) <62>

PH_RANGE
PHR	#11# 5.4-8 (#11# about half-maximal activity at pH 5.4 and 8, goat
	<15>) <15>
PHR	#14# 7.5-10 (#14# pH-profile of truncated enzyme forms
	DELTA15Pd2,6ST(N) and DELTA112Pd2,6ST(N). Similar to the
	DELTA15Pd2,6ST(N), the shorter DELTA112Pd2,6ST(N) is active in a wide
	pH range of 7.5-10.0 <45>) <45>
PHR	#3# 5-7.5 (#3# about 40% of maximal activity at pH 5.0 and at pH 7.5
	<39>) <39>
PHR	#5# 5.2-7.4 (#5# about half-maximal activity at pH 5.2 and 7.4 <18>)
	<18>
PHR	#6# 5-9.7 (#6# about 65% of maximal activity at pH 5 and about
	half-maximal activity at pH 9.7 <9>) <9>
PHR	#7# 5-9.2 (#7# about half-maximal activity at pH 5 and 9.2 <10>) <10>
PHR	#8# 6-9 <80>

SPECIFIC_ACTIVITY
SA	#11# 0.0035 (#11# partially purified enzyme <15>) <15>
SA	#15# 2.6 (#15# 159fold purified enzyme <59>) <59>
SA	#15# 0.016 (#15# crude enzyme <59>) <59>
SA	#37# 113.0 <51>
SA	#4# 8e-07 (#4# Ehrlich ascite carcinoma cells, adherent or from tissue
	culture <22>) <22>
SA	#4,5,6,7# -999.0 (#6# kinetics <3>; #5,6# assay method development,
	biosensor-based method using immobilized Sambucus nigra agglutinin
	<30>; #6# activity of stimulated and unstimulated enzyme with different
	substrates <24>) <3,8,9,10,11,21,24,30,31>
SA	#5# 1.6 (#5# purified, recombinant from Sf9 insect cells <33>) <33>
SA	#6# 0.00083 (#6# partially purified enzyme <9>) <9>
SA	#6# 8.2 (#6# purified enzyme <12>) <12>
SA	#6# 2.2e-07 (#6# hepatocyte <20>) <20>
SA	#7# 0.0009 (#7# partially purified enzyme <15>) <15>
SA	#7# 26.0 (#7# purified enzyme <16>) <16>
SA	#9# 0.103 (#9# neuraminidase activity of the truncated recombinant
	enzyme <62>) <62>
SA	#9# 82.9 (#9# alpha2,6-sialyltransferase activity of the 15.2fold
	purified truncated recombinant enzyme <62>) <62>
SA	#9,14# 5.5 (#14# purified enzyme <25>; #9# crude extract,
	alpha2,6-sialyltransferase activity of the truncated recombinant enzyme
	<62>) <25,62>

TEMPERATURE_OPTIMUM
TO	#37# 25-30 <51>
TO	#4,5,6,7,11,15# 37 (#4,5,6,7,11,15# assay at
	<1,2,3,6,7,9,10,11,12,15,16,17,18,21,22,23,24,28,30,33>; #15# purified
	enzyme <59>) <1,2,3,6,7,9,10,11,12,15,16,17,18,21,22,23,24,28,30,33,59>
TO	#5# 28 <18>
TO	#8,14# 30 <25,80>
TO	#9# 35 (#9# alpha2,6-sialyltransferase activity and neuraminidase
	activity of the truncated recombinant enzyme <62>) <62>

TEMPERATURE_RANGE
TR	#3# 25-37 (#3# activity at 25°C is about 75% of the activity at 100°C
	<39>) <39>
TR	#8# 25-35 <80>

ACTIVATING_COMPOUND
AC	#14,37,40,41# CMP (#14# cytidine 5-monophosphate, the product of
	sialyltransferase reactions, is not required by the trans-sialidase
	activity of the enzyme but enhances the trans-sialidase activity
	modestly as a non-essential activator. CMP can enhance the efficiency
	of the alpha2,6-sialidase activity of DELTA15Pd2,6ST in a
	dose-dependent manner <63>) <63,86>
AC	#37,40,41# CMP-N-acetylneuraminate <86>
AC	#5,15# more (#5# the enzyme is induced by phorbol 12-myristate
	13-acetate via a PKC/ERK/CREB-dependent pathway in K562 human leukemia
	cells, the induction is inhibited by Gö6976, a specific inhibitor of
	PKC, and U0126, an inhibitor of the extracellular signal-regulated
	kinase, but not by wortmannin, overview <42>; #15# in the
	sialyltransferase activity assay, FLAG-tagged ST6Gal1 has the highest
	expression level, which is 1.8- or 4.1fold higher than that of Strep-
	or His-tagged ST6Gal1, respectively <59>) <42,59>
AC	#5,6# Triton X-100 (#5# activation <18>) <18,21,24,30>
AC	#5,6# Triton CF-54/Tween 80 (#6# activation <12>) <12,27>
AC	#6# natural factor from rat colon (#6# stimulation is decreased by CTP,
	no activation at 0.75 mM CTP <24>; #6# partially purified <24>; #6#
	specific, 4fold stimulation by decreasing the Km value for the
	substrates and increasing Vmax, present in the cytosol, temperature
	dependent, protease sensitive, independent of metal ions or detergent,
	unaffceted by monosaccharides <24>; #6# may also be present in rat
	brain and kidney <24>) <24>
AC	#6# deoxycholate (#6# 9fold stimulation at 0.25%, inhibition at 0.5%
	<9>) <9>
AC	#6,7,8# EDTA (#6# activation <9>; #7# no activation <10>; #8# 138%
	activity at 10 mM <80>) <9,10,80>

INHIBITORS
IN	#2# Hg2+ <14>
IN	#2# Ba2+ <14>
IN	#2# Pb2+ <14>
IN	#2,3,5# Cu2+ (#5# weak <18>) <14,18,39>
IN	#3# Co2+ <39>
IN	#3# Ni2+ <39>
IN	#37,40,41# cytidine <86>
IN	#37,40,41# Alkaline phosphatase <86>
IN	#5# UTP (#5# 0.25 mM, inhibition decreases at higher concentrations
	<18>) <18>
IN	#5,39# Mn2+ (#5# above 10 mM <18>; #39# about 75% activity in the
	presence of 10 mM Mn2+ <69>) <18,69>
IN	#5,6# CMP (#5# competitive, less effective than CDP or CTP <18>; #6# is
	an efficient competitive inhibitor <58>) <18,58>
IN	#5,6,11,39# more (#5# no inhibition by N-ethylmaleimide <18>; #39# not
	inhibited by EDTA <69>; #6# inhibitory capacity of several synthetic
	trisaccharides <21>; #11# not affected by versenate <15>; #6# no
	inhibition by linoleic acid or linolenic acid <9>) <9,15,18,21,69>
IN	#5,6,14,15,16# CDP (#15# competitive <23>; #15# wild-type enzyme and
	mutant V220A <23>; #6# Mn2+ restores activity <11>; #14# at a
	concentration of 1 mM inhibits both sialidase and trans-sialidase
	activities of DELTA15Pd2,6ST <63>) <11,18,23,63,78>
IN	#5,6,7# EDTA (#5,6# weak <11,18>; #7# no inhibition <10>) <10,11,18>
IN	#5,6,8,14,16# CTP (#8# complete inhibition at 10 mM <80>; #6# also
	decreases the stimulation by the natural cytosolic rat colon factor
	<24>; #14# at a concentration of 1 mM inhibits both sialidase and
	trans-sialidase activities of DELTA15Pd2,6ST <63>) <11,18,24,63,78,80>
IN	#6# CMP-4-O-[2,2,6,6-tetramethylpiperidine-1-oxyl] <47>
IN	#6# CMP-4-O-[4-carboxy-2,2,6,6-tetramethylpiperidinine-1-oxyl] <47>
IN	#6# Endogenous acidic peptide (#6# heat-stable, amino acid composition
	<4>) <4>
IN	#6# Aflatoxins (#6# aflatoxins B1, B2a, G1, slightly by aflatoxins B2
	and G2, inhibition is probably due to membrane disruption through
	binding of the aflatoxins and change in enzyme conformation <13>) <13>
IN	#6# long chain fatty acids (#6# oleic acid, stearic acid, less
	efficient: palmitic acid, lauric acid, capric acid, caprylic acid or
	caproic acid, no inhibition by linoleic acid or linolenic acid <9>) <9>
IN	#6# deoxycholate (#6# 9fold stimulation at 0.25%, inactivation at 0.5%
	<9>) <9>
IN	#6# glycanase (#6# inactivation due to deglycosylation of the enzyme,
	best in methanol or ethanol <19>) <19>
IN	#6# endo F (#6# inactivation due to deglycosylation of the enzyme, best
	in methanol or ethanol, less efficient than glycanase <19>) <19>
IN	#6# cycloheximide (#6# reduces the enzyme expression 3fold in normal
	hepatocytes and 16 to 17fold in Zaidela ascitic hepatoma, but not in
	cells isolated from the tumor and cultured for 48 h <20>) <20>
IN	#7# PCMB (#7# weak <10>) <10>
IN	#7# N-acetyllactosamine (#7# with asialo-alpha1 acid glycoprotein as
	substrate <17>) <17>

KI_VALUE
KI	#15# 0.016 {CDP}  (#15# mutant V220A <23>) <23>
KI	#15# 0.0047 {CDP}  (#15# wild-type enzyme <23>) <23>
KI	#2# -999 {more}  <14>
KI	#5# 0.18 {CMP}  <18>
KI	#6# 0.79 {CMP-4-O-[4-carboxy-2,2,6,6-tetramethylpiperidinine-1-oxyl]} 
	(#6# pH 6.5, 37°C <47>) <47>
KI	#6# 4.07 {CMP-4-O-[2,2,6,6-tetramethylpiperidine-1-oxyl]}  (#6# pH 6.5,
	37°C <47>) <47>

METALS_IONS
ME	#15# MnCl2 <59>
ME	#2,5,6,7,8,11,14# more (#2,5,6,7,11# no metal ion requirement
	<9,10,11,14,15>; #14# a metal ion is not required for the activity
	<45>; #8# the enzyme does not require ions for activity <80>)
	<9,10,11,14,15,18,45,80>
ME	#39# Mg2+ (#39# about 120% activity in the presence of 10 mM Mg2+ <69>)
	<69>
ME	#5,6,7,11# MgCl2 (#5,7,11# no stimulation <10,15>; #6# slight
	stimulation at 5 mM <9>) <9,10,15>
ME	#9# NaCl (#9# alpha2,6-sialyltransferase activity is increased
	approximately 40% in the presence of 300-800 mM <62>) <62>

MOLECULAR_WEIGHT
MW	#12# 59000 (#12# gel filtration <43>) <43>
MW	#12,16# 55000 (#12# x * 55000, SDS-PAGE <43>; #16# x * 55000, the
	enzyme shows two bands at 55000 and 57000 Da, SDS-PAGE <70>) <43,70>
MW	#14# 61000 (#14# 1 * 61000, SDS-PAGE <25>) <25>
MW	#14# 64000 (#14# gel filtration <25>) <25>
MW	#16# 38000 <78>
MW	#16# 57000 (#16# x * 57000, the enzyme shows two bands at 55000 and
	57000 Da, SDS-PAGE <70>) <70>
MW	#16,19# 50000 (#16,19# x * 50000, SDS-PAGE <73>) <73>
MW	#19# 70000 (#19# 1 * 70000, SDS-PAGE <71>) <71>
MW	#37# 56732 (#37# x * 56732, MALDI-TOF <51>) <51>
MW	#4# 60122 (#4# x * 60122, calculation from nucleotide sequence <37>)
	<37>
MW	#5,15# 40000 (#15# 1 * 40000, SDS-PAGE <59>; #5# x * 40000, SDS-PAGE
	<84>) <59,84>
MW	#6# 40500 (#6# 1 * 40500, SDS-PAGE under reducing conditions <12>) <12>
MW	#7# 80000 (#7# high molecular weight form, gel filtration, two enzyme
	forms differing in molecular weight when submitted to gel filtration,
	the smaller one is probably a degradation product of the larger one
	<16>) <16>
MW	#7# 56000 (#7# 1 * 56000, high molecular weight form, SDS-PAGE under
	reducing conditions <16>) <16>
MW	#7# 44000 (#7# 1 * 44000, low molecular weight form, SDS-PAGE under
	reducing conditions <16>) <16>
MW	#7# 41500 (#7# 1 * 41500, low molecular weight form, SDS-PAGE under
	non-reducing conditions <16>) <16>
MW	#7# 57900 (#7# high molecular weight form, sedimentation equilibrium
	centrifugation, two enzyme forms differing in molecular weight when
	submitted to gel filtration, the smaller one is probably a degradation
	product of the larger one <16>) <16>
MW	#7# 53500 (#7# 1 * 53500, high molecular weight form, SDS-PAGE under
	non-reducing conditions <16>) <16>
MW	#7# 42900 (#7# low molecular weight form, sedimentation equilibrium
	centrifugation, two enzyme forms differing in molecular weight when
	submitted to gel filtration, the smaller one is probably a degradation
	product of the larger one <16>) <16>
MW	#7,38# 45000 (#7# low molecular weight form, gel filtration, two enzyme
	forms differing in molecular weight when submitted to gel filtration,
	the smaller one is probably a degradation product of the larger one
	<16>; #38# x * 45000, SDS-PAGE <68>) <16,68>
MW	#8# 42000 (#8# x * 42000, SDS-PAGE <80>) <80>
MW	#8# 53100 (#8# x * 53100, calculated from amino acid sequence <80>) <80>

POSTTRANSLATIONAL_MODIFICATION
PM	#3# sialoprotein (#3# recombinant Drosophila SiaT expressed in cultured
	insect cells possesses in vivo and in vitro autosialylation activity
	toward beta-linked GalNAc termini of its own N-linked glycans <39>) <39>
PM	#5,6,19# glycoprotein (#5# 2times N-glycosylated <28>; #6# contains at
	least 2 N-linked carbohydate chains of the complex type <19>; #6#
	catalytic activity of the enzyme depends on the presence of
	oligosaccharide chains <19>; #19# the enzyme has two N-glycosylation
	sites <71>) <19,28,71>
PM	#6# more (#6# deglycosylation of the enzyme is much more efficient in
	presence of methanol or ethanol <19>) <19>

SUBUNITS
SU	#15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36#
	More
	(#15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36#
	the enzymes contain four conserved peptide motifs: L/large, S/small,
	motif III, and motif VS/very small <41>) <41>
SU	#4,5,8,12,16,19,37,38# ? (#8# x * 42000, SDS-PAGE <80>; #16,19# x *
	50000, SDS-PAGE <73>; #38# x * 45000, SDS-PAGE <68>; #12# x * 55000,
	SDS-PAGE <43>; #5# x * 40000, SDS-PAGE <84>; #4# x * 60122, calculation
	from nucleotide sequence <37>; #37# x * 56732, MALDI-TOF <51>; #8# x *
	53100, calculated from amino acid sequence <80>; #16# x * 55000, the
	enzyme shows two bands at 55000 and 57000 Da, SDS-PAGE <70>; #16# x *
	57000, the enzyme shows two bands at 55000 and 57000 Da, SDS-PAGE <70>;
	#16# x * 38000, truncated enzyme DELTA89, SDS-PAGE <78>)
	<37,43,51,68,70,73,78,80,84>
SU	#6# oligomer (#6# STcys oligomerization is a secondary event resulting
	from its concentration in the Golgi via mechanisms independently
	mediated by its cytosolic tail and transmembrane region <40>) <40>
SU	#6,7,14,15,19# monomer (#15# 1 * 40000, SDS-PAGE <59>; #14# 1 * 61000,
	SDS-PAGE <25>; #19# 1 * 70000, SDS-PAGE <71>; #7# 1 * 44000, low
	molecular weight form, SDS-PAGE under reducing conditions <16>; #6# 1 *
	40500, SDS-PAGE under reducing conditions <12>; #7# 1 * 53500, high
	molecular weight form, SDS-PAGE under non-reducing conditions <16>; #7#
	1 * 41500, low molecular weight form, SDS-PAGE under non-reducing
	conditions <16>; #7# 1 * 56000, high molecular weight form, SDS-PAGE
	under reducing conditions <16>) <12,16,25,59,71>

PI_VALUE
PI	#15# 6.3 (#15# isoelectric focusing <59>) <59>

APPLICATION
AP	#4,5,6,16# medicine (#16# protein sialylation might be a target to
	overcome radioresistance in radiation therapie <55>; #4,5,6# two kinds
	of sandwich enzyme-linked immunosorbent assay (ELISA) systems are very
	useful tools for measuring plasma ST6Gal I, which represents a
	potential biomarker for diagnosing hepatic diseases <57>) <55,57>
AP	#5# biotechnology (#5# recombinant enzyme may be used for in vitro
	synthesis of oligosaccharides <28>) <28>
AP	#5,6,9,12,14# synthesis (#5# recombinant enzyme may be used for in
	vitro synthesis of oligosaccharides <28>; #5,6# enzyme can be exploited
	as biocatalyst in the synthesis of interesting non-natural compounds,
	especially in view of chemical, regiospecific sialylation,
	chemo-enzymatic synthesis of modified carbohydrate ligands, and their
	suitability as probes for studying molecular recognition phenomena
	<21>; #9# because this enzyme is most active at basic pH,
	sialyltransferase obtained from Photobacterium leiognathi JT-SHIZ-145
	is a promising tool for the efficient production of sialosides and the
	modification of glycoconjugates <48>; #12# the Photobacterium
	sialyltransferase can be used in the synthesis of sialoside analogues
	having a large substituent at the 9-position of Neu5Ac <46>; #14#
	application of the alpha2,6-trans-sialidase activity of DELTA15Pd2,6ST
	in the synthesis of sialosides <63>; #9# the enzyme may be a powerful
	tool for the synthesis of sialosides and the modification of
	sialyl-glycoconjugates <62>) <21,28,46,48,62,63>

ENGINEERING
EN	#14# S142A (#14# the mutant exhibits 38% of wild type activity <79>)
	<79>
EN	#14# N157A (#14# the mutant exhibits 32% of wild type activity <79>)
	<79>
EN	#14# R136A (#14# the mutant exhibits 10% of wild type activity <79>)
	<79>
EN	#14# L112A (#14# the mutant exhibits 61% of wild type activity <79>)
	<79>
EN	#14# K135A (#14# the mutant exhibits 8% of wild type activity <79>) <79>
EN	#14# W347A (#14# the mutant exhibits 16% of wild type activity <79>)
	<79>
EN	#14# T344A (#14# the mutant exhibits 38% of wild type activity <79>)
	<79>
EN	#14# L433S (#14# the mutant exhibits 3fold enhancement of the enzymes
	specific activity compared with the wild type enzyme <79>) <79>
EN	#14# L433T (#14# the mutant exhibits 3fold enhancement of the enzymes
	specific activity compared with the wild type enzyme <79>) <79>
EN	#14# I411T/L433T (#14# the mutant exhibits 5fold enhancement of the
	enzymes specific activity compared with the wild type enzyme <79>) <79>
EN	#14# I411A (#14# the mutant exhibits 169% of wild type activity <79>)
	<79>
EN	#14# L433A (#14# the mutant exhibits 114% of wild type activity <79>)
	<79>
EN	#15# T224A (#15# site-directed mutagenesis, mutant of the conserved
	sialyl-motif contained by all members of the sialyltransferase family,
	1.3fold increased Km for CMP-NeuAc, only slightly altered Km for the
	acceptor substrate <23>) <23>
EN	#15# D219A (#15# site-directed mutagenesis, mutant of the conserved
	sialyl-motif contained by all members of the sialyltransferase family,
	10.8fold increased Km for CMP-NeuAc, only slightly altered Km for the
	acceptor substrate <23>) <23>
EN	#15# V184A (#15# site-directed mutagenesis, mutant of the conserved
	sialyl-motif contained by all members of the sialyltransferase family,
	6.8fold increased Km for CMP-NeuAc, only slightly altered Km for the
	acceptor substrate <23>) <23>
EN	#15# L190A (#15# site-directed mutagenesis, mutant of the conserved
	sialyl-motif contained by all members of the sialyltransferase family,
	11.9fold increased Km for CMP-NeuAc, only slightly altered Km for the
	acceptor substrate <23>) <23>
EN	#15# V220A (#15# site-directed mutagenesis, mutant of the conserved
	sialyl-motif contained by all members of the sialyltransferase family,
	6.0fold increased Km for CMP-NeuAc, only slightly altered Km for the
	acceptor substrate <23>) <23>
EN	#15# G221A (#15# site-directed mutagenesis, mutant of the conserved
	sialyl-motif contained by all members of the sialyltransferase family,
	1.6fold increased Km for CMP-NeuAc, only slightly altered Km for the
	acceptor substrate <23>) <23>
EN	#15# K223A (#15# site-directed mutagenesis, mutant of the conserved
	sialyl-motif contained by all members of the sialyltransferase family,
	6.6fold increased Km for CMP-NeuAc, only slightly altered Km for the
	acceptor substrate <23>) <23>
EN	#15# T225A (#15# site-directed mutagenesis, mutant of the conserved
	sialyl-motif contained by all members of the sialyltransferase family,
	3.2fold increased Km for CMP-NeuAc, only slightly altered Km for the
	acceptor substrate <23>) <23>
EN	#15# D271A (#15# the mutant shows strongly reduced activity compared to
	the wild type enzyme <83>) <83>
EN	#15# Y272A (#15# the mutant shows strongly reduced activity compared to
	the wild type enzyme <83>) <83>
EN	#15# H367A (#15# inactive <83>) <83>
EN	#15# Y366A (#15# inactive <83>) <83>
EN	#15# Y119F (#15# the mutant shows reduced activity compared to the wild
	type enzyme <83>) <83>
EN	#15# N230A (#15# inactive <83>) <83>
EN	#15# C350A/C361A (#15# inactive <83>) <83>
EN	#15# F208A (#15# the mutant shows strongly reduced activity compared to
	the wild type enzyme <83>) <83>
EN	#15# Q232A (#15# the mutant shows strongly reduced activity compared to
	the wild type enzyme <83>) <83>
EN	#15# Q354A (#15# the mutant shows reduced activity compared to the wild
	type enzyme <83>) <83>
EN	#15# K355A (#15# the mutant shows increased activity compared to the
	wild type enzyme <83>) <83>
EN	#19# C139S (#19# the mutant has almost the same activity (94%) and
	specificity as those of native enzyme <71>) <71>
EN	#19# C350A (#19# no activity <71>) <71>
EN	#19# C181S (#19# no activity <71>) <71>
EN	#19# C139A (#19# the mutant has almost the same activity (98%) and
	specificity as those of native enzyme <71>) <71>
EN	#19# C350S (#19# no activity <71>) <71>
EN	#5,14,16# more (#5# construction of a chimeric enzyme with the
	N-terminal membrane portion of the rat core 2
	beta1,6-GlcNAc-transferase, amino acid residues 1-52, and the residues
	1-70 of the human alpha2,6-sialyltransferase, also FLAG-tagged,
	functional expression in CHO-K1 cells, broader acceptor substrate
	specificity than the wild-type <32>; #14# cloned as N- and C-His-tagged
	fusion proteins with different lengths (16-497 aa or 113-497 aa).
	Expression and activity assays indicate that the N-terminal 112 amino
	acid residues of the protein are not required for its
	alpha2,6-sialyltransferase activity. Among four truncated forms tested,
	N-His-tagged ELTA15Pd2,6ST(N) containing 16-497 amino acid residues has
	the highest expression level. Similar to the DELTA15Pd2,6ST(N), the
	shorter DELTA112Pd2,6ST(N) is active in a wide pH range of 7.5-10.0
	<45>; #16# the DELTA108 mutant enzyme shows only sialyl transferase
	activity with specificity for mono-sialylation and a Km value for
	6-sialyl-N-acetyl-D-lactosamine of 84 mM while the DELTA89 mutant show
	a Km value for 6-sialyl-N-acetyl-D-lactosamine of 8.3 mM <81>; #5# the
	truncated enzyme DELTA108 is active as alpha2,6-sialyltransferase and
	CMP-N-acetylneuraminate hydrolase <84>) <32,45,81,84>
EN	#8# N284A (#8# the mutant shows reduced activity compared to the wild
	type enzyme <80>) <80>
EN	#8# N284Q (#8# the mutant shows reduced activity compared to the wild
	type enzyme <80>) <80>

CLONED
CL	#3# (a full-length Drosophila SiaT protein with a C-terminal HA tag is
	transiently expressed in Drosophila S2 cells. A fraction of SiaT-HA
	protein expressed in S2 cell culture is secreted into the cell medium
	in soluble form) <39>
CL	#4# (expression in COS-7 cells) <37>
CL	#4# (ST6Gal I FLAG-pcDNA construct transiently transfected into COS-7
	cells) <57>
CL	#5# (functional expression in Saccharomyces cerevisiae) <21>
CL	#5# (DNA sequence determination, expression of various truncated forms
	lacking the transmembrane fragment as FLAG-tagged proteins, the
	chimeric mutant, and the membrane-bound enzyme form in CHO-K1 cells)
	<32>
CL	#5# (high level functional expression in Spodoptera frugiperda Sf9
	insect cells via baculovirus infection using a vector that fuses the
	enzyme to the mouse IgM signal peptide and the IgG binding domain of
	the Staphylococcus aureus protein A at the N-terminus for secretion of
	the recombinant protein into the culture medium) <33>
CL	#5# (DNA sequence determination, functional overexpression of full
	length cDNA and fragment of residues 113-1227, the latter fused to
	staphylococcal protein A, in COS-1 cells) <27>
CL	#5# (expression in Pichia pastoris, entry in the secretory pathway,
	i.e. excretion of the soluble enzyme to the medium, by usage of the
	N-terminal signal sequence of Saccharomyces cerevisiae alpha-factor, no
	hyperglycosylation) <28,32>
CL	#5# (expression analysis) <42>
CL	#5# (ST6Gal I FLAG-pcDNA construct transiently transfected into COS-7
	cells) <57>
CL	#5# (expressed in Nicotiana tabacum suspension-cultured BY-2 cells) <74>
CL	#5# (expressed in U-373MG cells) <76>
CL	#5# (expressed in Pichia pastoris strain KM71H) <84>
CL	#6# (expression in COS cells) <40>
CL	#6# (enzyme expression analysis in Zaidela ascitic hepatoma cell lines
	and normal liver cells) <20>
CL	#6# (expression of the ST6Gal I enzyme in a galectin-1-sensitive murine
	T cell line) <38>
CL	#6# (isoform STcys expressed in CHO cells or in HeLa cells) <36>
CL	#6# (isoform STtyr expressed in CHO cells or in HeLa cells) <36>
CL	#6# (a CHO clone displaying a high rat alpha2,6-ST activity
	co-transfected with dicistronic mRNA expression vectors
	pEDdc-alpha-hTSH and pEAdc-beta-hTSH in a ratio of 1:5) <64>
CL	#6# (ST6Gal I FLAG-pcDNA construct transiently transfected into COS-7
	cells) <57>
CL	#8# (expressed in Sf9 insect cells) <80>
CL	#9# (expressed in Escherichia coli) <48>
CL	#9# (expression cassettes of the full-length form in pLST-FL and of the
	truncated form (N-terminal Lys2 to Ala15 deletion) in pLST-DELTAN
	expressed in Escherichia coli) <62>
CL	#12# (the putative mature form of JT-ISH-224 alpha2,6-sialyltransferase
	is overproduced in Escherichia coli) <43>
CL	#14# (cloned as N- and C- His-tagged fusion proteins with different
	lengths (16-497 aa or 113-497 aa). Expression and activity assays
	indicate that the N-terminal 112 amino acid residues of the protein are
	not required for its alpha2,6-sialyltransferase activity but affect the
	solubility of the recombinant protein expressed in Escherichia coli)
	<45>
CL	#14# (expressed in Escherichia coli BW25113 (DE3) cells) <79>
CL	#15# (expression of wild-type and mutants in COS-1 cells) <23>
CL	#15# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#15# (ST6Gal1 cloned as N-terminal His-, Strep- and FLAG-tagged fusion
	proteins. FLAG-tagged recombinant ST6Gal1 expressed in fifth instar
	silkworm larval hemolymph using recombinant both cysteine protease- and
	chitinase-deficient Bombyx mori nucleopolyhedrovirus (BmNPV-CP--Chi-)
	bacmid) <59>
CL	#15# (expressed in HEK-293 and 293-F cells) <83>
CL	#16# (expressed in COS-1 cells) <70>
CL	#16# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#16# (overexpression of ST6Gal I in SW480 colon cancer cells that
	initially show a low level of ST6Gal I expression increases the
	sialylation of integrin beta1 and also increases the stability of the
	protein) <55>
CL	#16# (expressed in Vero cells) <67>
CL	#16# (Hep3B cells stably expressing human BACE1-myc or ST6Gal I) <61>
CL	#16# (the truncated DELTA89 and DELTA108 variants of the recombinant
	human enzyme are expressed in human embryonic kidney cells) <81>
CL	#16# (the truncated enzyme DELTA89 is expressed in HEK cells) <78>
CL	#17# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#18# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#19# (expressed in COS-7 cells) <71>
CL	#19# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#20# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#21# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#22# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#23# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#24# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#25# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#26# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#26# (two pFlag-bST6Gal II vector constructions separately transfected
	in COS-1 cells for expression of either membrane-bound or soluble
	active forms of ST6Gal II) <60>
CL	#27# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#28# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#29# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#30# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#31# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#32# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#33# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#34# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#35# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#36# (DNA and amino acid sequence analysis, detailed phylogenetic
	analysis of the ST6GalNAc family and the four subfamilies,
	sialyltransferases show a common genetic origin, by successive
	duplications of an ancestral gene, followed by divergent evolution,
	overview) <41>
CL	#37# (expression in Escherichia coli) <51>
CL	#37# (expressed in Escherichia coli BL21 cells) <86>
CL	#38# (expressed in Escherichia coli Rosetta (DE3)pLysS cells) <68>
CL	#39# (expressed in Escherichia coli strain AD202) <69>
CL	#40# (expressed in Escherichia coli BL21 cells) <86>
CL	#41# (expressed in Escherichia coli BL21 cells) <86>

CRYSTALLIZATION
CR	#12# (hanging-drop vapour-diffusion method at 20°C. The crystal
	belongs to space group P3(1)2(1) or P3(2)2(1), with unit-cell
	parameters a = b = 90.29, c = 204.33 A. X-ray diffraction data are
	collected to 2.5 A resolution) <43>
CR	#15# (microbatch method, using 100 mM Tris, pH 9, 40% (w/v) PEG 1000,
	and 100 mM lithium bromide) <83>
CR	#16# (sitting drop vapor diffusion, method truncated enzyme DELTA89 in
	complex with CMP using 0.1 M HEPES-NaOH pH 7.0, 20% (w/v) PEG 550 MME,
	0.01 MCaCl2, 0.01 MMgCl2, or in complex with cytidine and phosphate
	using 0.1 M MES-NaOH pH 5.8, 20% (w/v) PEG 2000 MME, 0.01 M CaCl2, 0.01
	M MgCl2) <78>
CR	#37# (single crystals are grown by the hanging-drop vapor diffusion
	method at 20°C. Crystal structure of DELTA16psp26ST, the N-terminal
	truncated form of alpha2,6-sialyltransferase from Photobacterium sp.
	JT-ISH-224, complexed with a donor productCMPand an acceptor substrate
	lactose) <49>

PURIFICATION
PU	#2# (partial) <14>
PU	#3# <39>
PU	#5# (partial, solubilized with Triton X-100) <7>
PU	#5# (recombinant from cell culture medium after expression in insect
	cells) <33>
PU	#5# (recombinant from COS-1 cells) <27>
PU	#6# (partial) <9,24>
PU	#6# (homogenized, centrifuged, resuspended in 140 mM-cacodylate/HCl
	buffer pH 6.8) <4>
PU	#6# (homogenized, centrifuged, resuspended in 25 mM-cacodylate buffer
	pH 6.5 containing 0.15% Triton X-100, 75 mM NaCl and 10 mM MnCl2) <5>
PU	#6# (further purification of commercial rat liver enzyme) <27>
PU	#6# (CDP-hexanolamine-agarose affinity chromatography) <12>
PU	#6# (isoform STcys) <36>
PU	#6# (isoform STtyr) <36>
PU	#6# (soluble ST6Gal I-FLAG purified from conditioned media on affinity
	gel) <57>
PU	#7# (partial) <10,15>
PU	#7# (CDP-hexanolamine-agarose affinity chromatography) <16>
PU	#7# (solubilized by ultrasonic treatment) <10>
PU	#8# (Co2+ affinity column chromatography, and gel filtration) <80>
PU	#9# (N-terminal truncated form, by gel filtration, 15.2fold, with a
	yield of 53.2%) <62>
PU	#11# (partial) <15>
PU	#12# <43>
PU	#13# (homogenized, centrifuged, resuspended in 25 mM-cacodylate buffer
	pH 6.5 containing 0.15% Triton X-100, 75 mM NaCl and 10 mM MnCl2) <5>
PU	#14# <25>
PU	#14# (truncated enzyme forms) <45>
PU	#14# (Ni-NTA column chromatography) <79>
PU	#15# (Ni-NTA column chromatography and Superdex-75 gel filtration) <83>
PU	#15# (FLAG-tagged recombinant ST6Gal1 purified by precipitation with
	ammonium sulphate followed by affinity chromatography, with a recovery
	yield of 64%, 159fold) <59>
PU	#16# (protein G Sepharose column chromatography) <70>
PU	#16# (S-Sepharose column chromatography, heparin Sepharose column
	chromatography, and Superdex 75 gel filtration) <78>
PU	#19# (IgG Sepharose column chromatography) <71>
PU	#37# (Ni-NTA column chromatography) <86>
PU	#38# (Ni-Sepharose column chromatography) <68>
PU	#39# (amylose column chromatography) <69>
PU	#40# (Ni-NTA column chromatography) <86>
PU	#41# (Ni-NTA column chromatography) <86>

GENERAL_STABILITY
GS	#5# (fractionation on Ultrogel AcA34 decreases activity, bovine serum
	albumin restores) <7>
GS	#5# (freeze-thawing, crude preparation, stable to) <18>
GS	#5# (glycerol, 20%, v/v, stabilizes) <7>
GS	#6# (high NaCl concentrations stabilize during storage) <12>
GS	#7# (stable to lyophilization) <10>
GS	#7# (high protein concentrations stabilize) <16>
GS	#7# (glycerol, 50%, stabilizes during storage) <16>
GS	#7# (use of plastic containers instead of glass stabilizes) <16>

ORGANIC_SOLVENT_STABILITY
OSS	#6# Methanol (#6# stable at 10%, 37°C <19>) <19>

PH_STABILITY
PHS	#15# 5-9 (#15# purified enzyme is relatively stable over a wide range
	of pH <59>) <59>
PHS	#6# 6 (#6# full stability for at least 1 year <12>) <12>
PHS	#6# 5.3 (#6# and below, storage stability decreases with t1/2: about 3
	months <12>) <12>
PHS	#7# 5.2-5.5 (#7# most stable <16>) <16>

STORAGE_STABILITY
SS	#14# (-80°C, 20 mM sodium cacodylate, pH 5.0, stable at least 3
	months) <25>
SS	#5# (-20°C, crude enzyme preparation, at least 3 months) <18>
SS	#5# (4°C, partially purified enzyme preparation in 20% glycerol, v/v,
	at least 1 week) <7>
SS	#6# (3°C, microsomal fraction, 2 weeks) <9>
SS	#6# (-20°C, in 50% glycerol, 35 mM cacodylate, pH 6, 0.45 M NaCl,
	0.08% Triton CF-54, at least 1 year) <12>
SS	#7# (frozen, crude, solubilized enzyme preparation, several months) <10>
SS	#7# (-20°C, in 50% glycerol, 12 mM cacodylate, pH 5.3, 2 months) <16>
SS	#7,11# (0-4°C, partially purified enzyme preparation, 2-4 weeks) <15>

TEMPERATURE_STABILITY
TS	#14# 55 (#14# 5 min, 5% remaining activity <25>) <25>
TS	#14# 40 (#14# 5 min, 80% remaining activity <25>) <25>
TS	#15# 20 (#15# purified enzyme is stable below 20°C but is rapidly
	inactivated at temperatures above 20°C <59>) <59>
TS	#6# 67 (#6# 30 s, 90% loss of activity <11>) <11>
TS	#7# 100 (#7# 5 min, complete inactivation <10>) <10>
TS	#8# 0-30 (#8# the enzyme is stable below 30°C for 1 h but shows
	significantly decreased activities at higher temperatures <80>) <80>

REFERENCE
RF	<1> Beyer, T.A.; Rearick, J.I.; Paulson, J.C.; Prieels, J.P.; Sadler,
	J.E.; Hill, R.L.: Biosynthesis of mammalian glycoproteins.
	Glycosylation pathways in the synthesis of the nonreducing terminal
	sequences. J. Biol. Chem. (1979) 254, 12531-12541. {Pubmed:500730}
RF	<2> Higa, H.H.; Paulson, J.C.: Sialylation of glycoprotein
	oligosaccharides with N-acetyl-, N-glycolyl-, and
	N-O-diacetylneuraminic acids. J. Biol. Chem. (1985) 260, 8838-8849.
	{Pubmed:4019457}
RF	<3> Gross, H.J.; Rose, U.; Krause, J.M.; Paulson, J.C.; Schmid, K.;
	Feeney, R.E.; Brossmer, R.: Transfer of synthetic sialic acid analogues
	to N- and O-linked glycoprotein glycans using four different mammalian
	sialyltransferases. Biochemistry (1989) 28, 7386-7392. {Pubmed:2510824}
RF	<4> Albarracin, I.; Lassaga, F.E.; Caputto, R.: Purification and
	characterization of an endogenous inhibitor of the sialyltransferase
	CMP-N-acetylneuraminate: lactosylceramide alpha
	2,6-N-acetylneuraminyltransferase (EC 2.4.99.-). Biochem. J. (1988)
	254, 559-565. {Pubmed:2460092}
RF	<5> Freischutz, B.; Saito, M.; Rahmann, H.; Yu, R.K.: Activities of
	five different sialyltransferases in fish and rat brains. J. Neurochem.
	(1994) 62, 1965-1973. {Pubmed:8158143}
RF	<6> Nemansky, M.; Schiphorst, W.E.C.M.; Koeleman, C.A.M.; Van den
	Eijnden, D.H.: Human liver and human placenta both contain
	CMP-NeuAc:Gal beta 1-->4GlcNAc-R alpha 2-->3- as well as alpha
	2-->6-sialyltransferase activity. FEBS Lett. (1992) 312, 31-36.
	{Pubmed:1426235}
RF	<7> Bauvois, B.; Montreuil, J.; Verbert, A.: Characterization of a
	sialyl alpha 2-3 transferase and a sialyl alpha 2-6 transferase from
	human platelets occurring in the sialylation of the N-glycosylproteins.
	Biochim. Biophys. Acta (1984) 788, 234-240. {Pubmed:6743668}
RF	<8> Tsuchiya, K.; Suzuki, Y.; Mabuchi, K.; Suzuki, T.; Hirabayashi, Y.;
	Sakiyama, H.: Characterization of sialyltransferase of B16 melanoma
	cells involved in the formation of melanoma-associated antigen GM3. J.
	Clin. Biochem. Nutr. (1993) 14, 141-149. {Pubmed:}
RF	<9> Hickman, J.; Ashwell, G.; Morell, A.G.; Van den Hamer, C.J.A.;
	Scheinberg, I.H.: Physical and chemical studies on ceruloplasmin. 8.
	Preparation of N-acetylneuraminic acid-1-14C-labeled ceruloplasmin. J.
	Biol. Chem. (1970) 245, 759-766. {Pubmed:4313609}
RF	<10> Spiro, M.J.; Spiro, R.G.: Glycoprotein biosynthesis: studies on
	thyroglobulin. Thyroid sialyltransferase. J. Biol. Chem. (1968) 243,
	6520-6528. {Pubmed:5726897}
RF	<11> Weinstein, J.; de Souza-e-Silva, U.; Paulson, J.C.: Sialylation of
	glycoprotein oligosaccharides N-linked to asparagine. Enzymatic
	characterization of a Gal beta 1-3(4)GlcNAc alpha 2-3 sialyltransferase
	and a Gal beta 1-4GlcNAc alpha 2-6 sialyltransferase from rat liver. J.
	Biol. Chem. (1982) 257, 13845-13853. {Pubmed:7142180}
RF	<12> Weinstein, J.; de Souza-e-Silva, U.; Paulson, J.C.: Purification
	of a Gal beta 1-4GlcNAc alpha 2-6 sialyltransferase and a Gal beta
	1-3(4)GlcNAc alpha 2-3 sialyltransferase to homogeneity from rat liver.
	J. Biol. Chem. (1982) 257, 13835-13844. {Pubmed:7142179}
RF	<13> Bernacki, R.J.; Gurtoo, H.L.: Differential inhibition of rat liver
	sialyltransferase(s) by various aflatoxins and their metabolites. Res.
	Commun. Chem. Pathol. Pharmacol. (1975) 10, 681-692. {Pubmed:50614}
RF	<14> Bosmann, H.B.: Synthesis of glycoproteins in brain:
	identification, purification and properties of a synaptosomal sialyl
	transferase utilizing endogenous and exogenous acceptors. J. Neurochem.
	(1973) 20, 1037-1049. {Pubmed:4633303}
RF	<15> Bartholomew, B.A.; Jourdian, G.W.; Roseman, S.: The sialic acids.
	XV. Transfer of sialic acid to glycoproteins by a sialyltransferase
	from colostrum. J. Biol. Chem. (1973) 248, 5751-5762. {Pubmed:4723915}
RF	<16> Paulson, J.C.; Beranek, W.E.; Hill, R.L.: Purification of a
	sialyltransferase from bovine colostrum by affinity chromatography on
	CDP-agarose. J. Biol. Chem. (1977) 252, 2356-2362. {Pubmed:849932}
RF	<17> Paulson, J.C.; Rearick, J.I.; Hill, R.L.: Enzymatic properties of
	beta-D-galactoside alpha2 leads to 6 sialytransferase from bovine
	colostrum. J. Biol. Chem. (1977) 252, 2363-2371. {Pubmed:849933}
RF	<18> Scudder, P.R.; Chantler, E.N.: Glycosyltransferases of the human
	cervical epithelium. II. Characterization of a CMP-N-acetylneuraminate:
	galactosyl-glycoprotein sialyltransferase. Biochim. Biophys. Acta
	(1981) 660, 136-141. {Pubmed:6168292}
RF	<19> Fast, D.G.; Jamieson, J.C.; McCaffrey, G.: The role of the
	carbohydrate chains of Gal beta-1,4-GlcNAc alpha 2,6-sialyltransferase
	for enzyme activity. Biochim. Biophys. Acta (1993) 1202, 325-330.
	{Pubmed:8399396}
RF	<20> Jain, N.; Sudhakar, C.; Das, M.R.: Regulation of expression of
	beta-galactoside alpha 2,6-sialyltransferase in a rat tumor, Zajdela
	ascitic hepatoma. FEBS Lett. (1993) 317, 147-151. {Pubmed:8428623}
RF	<21> Van Dorst, J.A.L.M.; Tikkanen, J.M.; Krezdorn, C.H.; Streiff,
	M.B.; Berger, E.G.; Van Kuik, J.A.; Kamerling, J.P.; Vliegenthart,
	J.F.G.: Exploring the substrate specificities of alpha-2,6- and
	alpha-2,3-sialyltransferases using synthetic acceptor analogs. Eur. J.
	Biochem. (1996) 242, 674-681. {Pubmed:9022696}
RF	<22> Shigeta, S.; Winter, H.C.; Goldstein, I.J.: alpha-(2->3)- and
	alpha-(2->6)-Sialyltransferase activities present in three variants of
	Ehrlich tumor cells: identification of the products derived from
	N-acetyllactosamine and beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->O)-Bn.
	Carbohydr. Res. (1994) 264, 111-121. {Pubmed:8001013}
RF	<23> Datta, A.K.; Paulson, J.C.: The sialyltransferase 'sialylmotif'
	participates in binding the donor substrate CMP-NeuAc. J. Biol. Chem.
	(1995) 270, 1497-1500. {Pubmed:7829476}
RF	<24> Nagpurkar, A.; Hunt, D.; Mookerjea, S.: Specific stimulation of
	alpha 2-6 sialyltransferase activity by a novel cytosolic factor from
	rat colon. Int. J. Biochem. Cell Biol. (1996) 28, 1337-1348.
	{Pubmed:9022292}
RF	<25> Yamamoto, T.; Nakashizuka, M.; Kodama, H.; Kajihara, Y.; Terada,
	I.: Purification and characterization of a marine bacterial
	beta-galactoside alpha 2,6-sialyltransferase from Photobacterium
	damsela JT0160. J. Biochem. (1996) 120, 104-110. {Pubmed:8864851}
RF	<26> Kajihara, Y.; Yamamoto, T.; Nagae, H.; Nakashizuka, M.;
	Sakakibara, T.; Terada, I.: A novel alpha-2,6-sialyltransferase:
	transfer of sialic acid to fucosyl and sialyl trisaccharides. J. Org.
	Chem. (1996) 61, 8632-8635. {Pubmed:}
RF	<27> Nakamura, M.; Tsunoda, A.; Yanagisawa, K.; Furukawa, Y.; Kikuchi,
	J.; Iwase, S.; Sakai, T.; Larson, G.; Saito, M.:
	CMP-NeuAc:Galbeta1->4GlcNAc alpha2->6sialyltransferase catalyzes NeuAc
	transfer to glycolipids. J. Lipid Res. (1997) 38, 1795-1806.
	{Pubmed:9323589}
RF	<28> Malissard, M.; Zeng, S.; Berger, E.G.: Expression of functional
	soluble forms of human beta-1,4-galactosyltransferase I,
	alpha-2,6-sialyltransferase, and alpha-1, 3-fucosyltransferase VI in
	the methylotrophic yeast Pichia pastoris. Biochem. Biophys. Res.
	Commun. (2000) 267, 169-173. {Pubmed:10623593}
RF	<29> Dufner, G.; Schworer, R.; Muller, B.; Schmidt, R.R.: Base- and
	sugar-modified cytidine monophosphate N-acetylneuraminic acid
	(CMP-Neu5Ac) analogues - synthesis and studies with
	alpha(2-6)-sialyltransferase from rat liver. Eur. J. Org. Chem. (2000)
	8, 1467-1482. {Pubmed:}
RF	<30> Halliday, J.A.W.; Franks, A.H.; Ramsdale, T.E.; Martin, R.;
	Palant, E.: A rapid, semi-automated method for detection of
	Galbeta1-4GlcNAc alpha2,6-sialyltransferase (EC 2.4.99.1) activity
	using the lectin Sambucus nigra agglutinin. Glycobiology (2001) 11,
	557-564. {Pubmed:11447135}
RF	<31> Gross, H.J.; Brossmer, R.: Enzymic transfer of sialic acids
	modified at C-5 employing four different sialyltransferases.
	Glycoconjugate J. (1995) 12, 739-746. {Pubmed:8748149}
RF	<32> Legaigneur, P.; Breton, C.; El Battari, A.; Guillemot, J.C.; Auge,
	C.; Malissard, M.; Berger, E.G.; Ronin, C.: Exploring the acceptor
	substrate recognition of the human beta-galactoside alpha
	2,6-sialyltransferase. J. Biol. Chem. (2001) 276, 21608-21617.
	{Pubmed:11279145}
RF	<33> Kim, H.G.; Yang, S.M.; Lee, Y.C.; Do, S.I.; Chung, I.S.; Yang,
	J.M.: High-level expression of human glycosyltransferases in insect
	cells as biochemically active form. Biochem. Biophys. Res. Commun.
	(2003) 305, 488-493. {Pubmed:12763019}
RF	<34> Galan, M.C.; Venot, A.P.; Boons, G.J.: Glycosyltransferase
	activity can be modulated by small conformational changes of acceptor
	substrates. Biochemistry (2003) 42, 8522-8529. {Pubmed:12859199} (c)
RF	<35> Galan, M.C.; Dodson, C.S.; Venot, A.P.; Boons, G.J.:
	Glycosyltransferase activity can be selectively modulated by chemical
	modifications of acceptor substrates. Bioorg. Med. Chem. Lett. (2004)
	14, 2205-2208. {Pubmed:15081009} (c)
RF	<36> Chen, T.L.; Chen, C.; Bergeron, N.Q.; Close, B.E.; Bohrer, T.J.;
	Vertel, B.M.; Colley, K.J.: The two rat alpha 2,6-sialyltransferase
	(ST6Gal I) isoforms: evaluation of catalytic activity and intra-Golgi
	localization. Glycobiology (2003) 13, 109-117. {Pubmed:12626411} (c)
RF	<37> Takashima, S.; Tsuji, S.; Tsujimoto, M.: Comparison of the
	enzymatic properties of mouse beta-galactoside
	alpha2,6-sialyltransferases, ST6Gal I and II. J. Biochem. (2003) 134,
	287-296. {Pubmed:12966079} (c)
RF	<38> Amano, M.; Galvan, M.; He, J.; Baum, L.G.: The ST6Gal I
	sialyltransferase selectively modifies N-glycans on CD45 to negatively
	regulate galectin-1-induced CD45 clustering, phosphatase modulation,
	and T cell death. J. Biol. Chem. (2003) 278, 7469-7475.
	{Pubmed:12499376} (c)
RF	<39> Koles, K.; Irvine, K.D.; Panin, V.M.: Functional characterization
	of Drosophila sialyltransferase. J. Biol. Chem. (2004) 279, 4346-4357.
	{Pubmed:14612445} (c)
RF	<40> Fenteany, F.H.; Colley, K.J.: Multiple signals are required for
	alpha2,6-sialyltransferase (ST6Gal I) oligomerization and Golgi
	localization. J. Biol. Chem. (2005) 280, 5423-5429. {Pubmed:15582997}
	(c)
RF	<41> Harduin-Lepers, A.; Mollicone, R.; Delannoy, P.; Oriol, R.: The
	animal sialyltransferases and sialyltransferase-related genes: a
	phylogenetic approach. Glycobiology (2005) 15, 805-817.
	{Pubmed:15843597}
RF	<42> Choi, H.J.; Park, Y.G.; Kim, C.H.: Lactosylceramide
	alpha2,3-sialyltransferase is induced via a PKC/ERK/CREB-dependent
	pathway in K562 human leukemia cells. Mol. Cell (2007) 23, 138-144.
	{Pubmed:17464189}
RF	<43> Okino, N.; Kakuta, Y.; Kajiwara, H.; Ichikawa, M.; Takakura, Y.;
	Ito, M.; Yamamoto, T.: Purification, crystallization and preliminary
	crystallographic characterization of the alpha 2,6-sialyltransferase
	from Photobacterium sp. JT-ISH-224. Acta Crystallogr. Sect. F (2007)
	F63, 662-664. {Pubmed:17671362}
RF	<44> Takashima, S.: Characterization of mouse sialyltransferase genes:
	their evolution and diversity. Biosci. Biotechnol. Biochem. (2008) 72,
	1155-1167. {Pubmed:18460788} (review)
RF	<45> Sun, M.; Li, Y.; Chokhawala, H.A.; Henning, R.; Chen, X.:
	N-Terminal 112 amino acid residues are not required for the
	sialyltransferase activity of Photobacterium damsela
	alpha2,6-sialyltransferase. Biotechnol. Lett. (2008) 30, 671-676.
	{Pubmed:17989925}
RF	<46> Kajihara, Y.; Kamitani, T.; Sato, R.; Kamei, N.; Miyazaki, T.;
	Okamoto, R.; Sakakibara, T.; Tsuji, T.; Yamamoto, T.: Synthesis of
	CMP-9-modified-sialic acids as donor substrate analogues for mammalian
	and bacterial sialyltransferases. Carbohydr. Res. (2007) 342,
	1680-1688. {Pubmed:17572399}
RF	<47> Liu, S.; Venot, A.; Meng, L.; Tian, F.; Moremen, K.W.; Boons, G.;
	Prestegard, J.H.: Spin-labeled analogs of CMP-NeuAc as NMR probes of
	the alpha -2,6-sialyltransferase ST6Gal I. Chem. Biol. (2007) 14,
	409-418. {Pubmed:17462576}
RF	<48> Yamamoto, T.; Hamada, Y.; Ichikawa, M.; Kajiwara, H.; Mine, T.;
	Tsukamoto, H.; Takakura, Y.: A beta-galactoside
	alpha2,6-sialyltransferase produced by a marine bacterium,
	Photobacterium leiognathi JT-SHIZ-145, is active at pH 8. Glycobiology
	(2007) 17, 1167-1174. {Pubmed:17704107}
RF	<49> Kakuta, Y.; Okino, N.; Kajiwara, H.; Ichikawa, M.; Takakura, Y.;
	Ito, M.; Yamamoto, T.: Crystal structure of Vibrionaceae Photobacterium
	sp. JT-ISH-224 alpha2,6-sialyltransferase in a ternary complex with
	donor product CMP and acceptor substrate lactose: catalytic mechanism
	and substrate recognition. Glycobiology (2008) 18, 66-73.
	{Pubmed:17962295}
RF	<50> Blixt, O.; Allin, K.; Bohorov, O.; Liu, X.; Andersson-Sand, H.;
	Hoffmann, J.; Razi, N.: Glycan microarrays for screening
	sialyltransferase specificities. Glycoconj. J. (2008) 25, 59-68.
	{Pubmed:17914671} (review)
RF	<51> Tsukamoto, H.; Takakura, Y.; Mine, T.; Yamamoto, T.:
	Photobacterium sp. JT-ISH-224 produces two sialyltransferases,
	alpha-/beta-galactoside alpha2,3-sialyltransferase and beta-galactoside
	alpha2,6-sialyltransferase. J. Biochem. (2008) 143, 187-197.
	{Pubmed:17984122}
RF	<52> Sugimoto, I.; Futakawa, S.; Oka, R.; Ogawa, K.; Marth, J.D.;
	Miyoshi, E.; Taniguchi, N.; Hashimoto, Y.; Kitazume, S.:
	beta-Galactoside alpha2,6-sialyltransferase I cleavage by BACE1
	enhances the sialylation of soluble glycoproteins. A novel regulatory
	mechanism for alpha2,6-sialylation. J. Biol. Chem. (2007) 282,
	34896-34903. {Pubmed:17897958}
RF	<53> Wang, P.H.; Lee, W.L.; Yang, Y.H.; Chen, Y.J.; Tsai, Y.C.; Yuan,
	C.C.: alpha 2,6-Sialyltransferase I expression in the placenta of
	patients with preeclampsia. J. Chin. Med. Assoc. (2007) 70, 152-158.
	{Pubmed:17475596}
RF	<54> Gong, M.; Garige, M.; Hirsch, K.; Lakshman, M.R.: Liver Galbeta
	1,4GlcNAc alpha 2,6-sialyltransferase is down-regulated in human
	alcoholics: possible cause for the appearance of asialoconjugates.
	Metab. Clin. Exp. (2007) 56, 1241-1247. {Pubmed:17697868}
RF	<55> Lee, M.; Lee, H.J.; Bae, S.; Lee, Y.S.: Protein sialylation by
	sialyltransferase involves radiation resistance. Mol. Cancer Res.
	(2008) 6, 1316-1325. {Pubmed:18708363}
RF	<56> Glaser, L.; Conenello, G.; Paulson, J.; Palese, P.: Effective
	replication of human influenza viruses in mice lacking a major alpha2,6
	sialyltransferase. Virus Res. (2007) 126, 9-18. {Pubmed:17313986}
RF	<57> Futakawa, S.; Kitazume, S.; Oka, R.; Ogawa, K.; Hagiwara, Y.;
	Kinoshita, A.; Miyashita, K.; Hashimoto, Y.: Development of sandwich
	enzyme-linked immunosorbent assay systems for plasma beta-galactoside
	alpha2,6-sialyltransferase, a possible hepatic disease biomarker. Anal.
	Chim. Acta (2009) 631, 116-120. {Pubmed:19046688}
RF	<58> Liu, S.; Meng, L.; Moremen, K.W.; Prestegard, J.H.: Nuclear
	magnetic resonance structural characterization of substrates bound to
	the alpha-2,6-sialyltransferase, ST6Gal-I. Biochemistry (2009) 48,
	11211-11219. {Pubmed:19845399}
RF	<59> Ogata, M.; Nakajima, M.; Kato, T.; Obara, T.; Yagi, H.; Kato, K.;
	Usui, T.; Park, E.Y.: Synthesis of sialoglycopolypeptide for
	potentially blocking influenza virus infection using a rat
	alpha2,6-sialyltransferase expressed in BmNPV bacmid-injected silkworm
	larvae. BMC Biotechnol. (2009) 9, 54. {Pubmed:19500344}
RF	<60> Laporte, B.; Gonzalez-Hilarion, S.; Maftah, A.; Petit, J.M.: The
	second bovine beta-galactoside-alpha2,6-sialyltransferase (ST6Gal II):
	genomic organization and stimulation of its in vitro expression by IL-6
	in bovine mammary epithelial cells. Glycobiology (2009) 19, 1082-1093.
	{Pubmed:19617256}
RF	<61> Kitazume, S.; Oka, R.; Ogawa, K.; Futakawa, S.; Hagiwara, Y.;
	Takikawa, H.; Kato, M.; Kasahara, A.; Miyoshi, E.; Taniguchi, N.;
	Hashimoto, Y.: Molecular insights into beta-galactoside
	alpha2,6-sialyltransferase secretion in vivo. Glycobiology (2009) 19,
	479-487. {Pubmed:19150807}
RF	<62> Mine, T.; Katayama, S.; Kajiwara, H.; Tsunashima, M.; Tsukamoto,
	H.; Takakura, Y.; Yamamoto, T.: An alpha2,6-sialyltransferase cloned
	from Photobacterium leiognathi strain JT-SHIZ-119 shows both
	sialyltransferase and neuraminidase activity. Glycobiology (2010) 20,
	158-165. {Pubmed:19797322}
RF	<63> Cheng, J.; Huang, S.; Yu, H.; Li, Y.; Lau, K.; Chen, X.:
	Trans-sialidase activity of Photobacterium damsela
	alpha2,6-sialyltransferase and its application in the synthesis of
	sialosides. Glycobiology (2010) 20, 260-268. {Pubmed:19880425}
RF	<64> Damiani, R.; Oliveira, J.E.; Vorauer-Uhl, K.; Peroni, C.N.;
	Vianna, E.G.; Bartolini, P.; Ribela, M.T.: Stable expression of a
	human-like sialylated recombinant thyrotropin in a Chinese hamster
	ovary cell line expressing alpha2,6-sialyltransferase. Protein Expr.
	Purif. (2009) 67, 7-14. {Pubmed:19366632}
RF	<65> Ding, J.X.; Xu, L.X.; Zhu, L.; Lv, J.C.; Zhao, M.H.; Zhang, H.;
	Wang, H.Y.: Activity of alpha2,6-sialyltransferase and its gene
	expression in peripheral B lymphocytes in patients with IgA
	nephropathy. Scand. J. Immunol. (2009) 69, 174-180. {Pubmed:19170967}
RF	<66> Peanne, R.; Legrand, D.; Duvet, S.; Mir, A.M.; Matthijs, G.;
	Rohrer, J.; Foulquier, F.: Differential effects of lobe A and lobe B of
	the Conserved Oligomeric Golgi complex on the stability of
	(beta)1,4-galactosyltransferase 1 and (alpha)2,6-sialyltransferase 1.
	Glycobiology (2011) 21, 864-876. {Pubmed:21062782}
RF	<67> Li, N.; Qi, Y.; Zhang, F.Y.; Yu, X.H.; Wu, Y.G.; Chen, Y.; Jiang,
	C.L.; Kong, W.: Overexpression of alpha-2,6 sialyltransferase
	stimulates propagation of human influenza viruses in Vero cells. Acta
	Virol. (2011) 55, 147-153. {Pubmed:21692563}
RF	<68> Onitsuka, M.; Kim, W.D.; Ozaki, H.; Kawaguchi, A.; Honda, K.;
	Kajiura, H.; Fujiyama, K.; Asano, R.; Kumagai, I.; Ohtake, H.; Omasa,
	T.: Enhancement of sialylation on humanized IgG-like bispecific
	antibody by overexpression of alpha2,6-sialyltransferase derived from
	Chinese hamster ovary cells. Appl. Microbiol. Biotechnol. (2012) 94,
	69-80. {Pubmed:22205442}
RF	<69> Schur, M.J.; Lameignere, E.; Strynadka, N.C.; Wakarchuk, W.W.:
	Characterization of alpha2,3- and alpha2,6-sialyltransferases from
	Helicobacter acinonychis. Glycobiology (2012) 22, 997-1006.
	{Pubmed:22504533}
RF	<70> Korekane, H.; Matsumoto, A.; Ota, F.; Hasegawa, T.; Misonou, Y.;
	Shida, K.; Miyamoto, Y.; Taniguchi, N.: Involvement of ST6Gal I in the
	biosynthesis of a unique human colon cancer biomarker candidate,
	alpha2,6-sialylated blood group type 2H (ST2H) antigen. J. Biochem.
	(2010) 148, 359-370. {Pubmed:20656882}
RF	<71> Hirano, Y.; Suzuki, T.; Matsumoto, T.; Ishihara, Y.; Takaki, Y.;
	Kono, M.; Dohmae, N.; Tsuji, S.: Disulphide linkage in mouse ST6Gal-I:
	determination of linkage positions and mutant analysis. J. Biochem.
	(2012) 151, 197-203. {Pubmed:22039275}
RF	<72> Jones, M.B.; Nasirikenari, M.; Feng, L.; Migliore, M.T.; Choi,
	K.S.; Kazim, L.; Lau, J.T.: Role for hepatic and circulatory ST6Gal-1
	sialyltransferase in regulating myelopoiesis. J. Biol. Chem. (2010)
	285, 25009-25017. {Pubmed:20529847}
RF	<73> Liu, Z.; Swindall, A.F.; Kesterson, R.A.; Schoeb, T.R.; Bullard,
	D.C.; Bellis, S.L.: ST6Gal-I regulates macrophage apoptosis via
	alpha2-6 sialylation of the TNFR1 death receptor. J. Biol. Chem. (2011)
	286, 39654-39662. {Pubmed:21930713}
RF	<74> Kajiura, H.; Misaki, R.; Fujiyama, K.; Seki, T.: Stable
	coexpression of two human sialylation enzymes in plant
	suspension-cultured tobacco cells. J. Biosci. Bioeng. (2011) 111,
	471-477. {Pubmed:21220208}
RF	<75> Tanaka, K.; Mikami, M.; Aoki, D.; Kiguchi, K.; Ishiwata, I.;
	Iwamori, M.: Expression of alpha2,6-sialic acid-containing and
	Lewis-active glycolipids in several types of human ovarian carcinomas.
	Oncol. Lett. (2010) 1, 1061-1066. {Pubmed:22870113}
RF	<76> Kroes, R.A.; He, H.; Emmett, M.R.; Nilsson, C.L.; Leach, F.E.;
	Amster, I.J.; Marshall, A.G.; Moskal, J.R.: Overexpression of
	ST6GalNAcV, a ganglioside-specific alpha2,6-sialyltransferase, inhibits
	glioma growth in vivo. Proc. Natl. Acad. Sci. USA (2010) 107,
	12646-12651. {Pubmed:20616019}
RF	<77> Paltrinieri, S.; Rossi, G.; Meregalli, A.; Stefanello, D.; Pecile,
	A.; Moretti, P.; Rondena, M.: Sialic acid and sialyltransferase
	activity in serum and tissues of dogs with mammary tumors. Vet. Pathol.
	(2012) 49, 669-681. {Pubmed:21427240}
RF	<78> Kuhn, B.; Benz, J.; Greif, M.; Engel, A.M.; Sobek, H.; Rudolph,
	M.G.: The structure of human alpha-2,6-sialyltransferase reveals the
	binding mode of complex glycans. Acta Crystallogr. Sect. D (2013) 69,
	1826-1838. {Pubmed:23999306}
RF	<79> Choi, Y.H.; Kim, J.H.; Park, J.H.; Lee, N.; Kim, D.H.; Jang, K.S.;
	Park, I.H.; Kim, B.G.: Protein engineering of
	alpha2,3/2,6-sialyltransferase to improve the yield and productivity of
	in vitro sialyllactose synthesis. Glycobiology (2014) 24, 159-169.
	{Pubmed:24142961}
RF	<80> Kajiura, H.; Hamaguchi, Y.; Mizushima, H.; Misaki, R.; Fujiyama,
	K.: Sialylation potentials of the silkworm, Bombyx mori; B. mori
	possesses an active alpha2,6-sialyltransferase. Glycobiology (2015) 25,
	1441-1453. {Pubmed:26306633}
RF	<81> Luley-Goedl, C.; Schmoelzer, K.; Thomann, M.; Malik, S.; Greif,
	M.; Ribitsch, D.; Jung, C.; Sobek, H.; Engel, A.; Mueller, R.; Schwab,
	H.; Nidetzky, B.: Two N-terminally truncated variants of human
	beta-galactoside alpha2,6 sialyltransferase I with distinct properties
	for invitro protein glycosylation. Glycobiology (2016) 26, 1097-1106.
	{Pubmed:27102286}
RF	<82> Nycholat, C.M.; Peng, W.; McBride, R.; Antonopoulos, A.; de Vries,
	R.P.; Polonskaya, Z.; Finn, M.G.; Dell, A.; Haslam, S.M.; Paulson,
	J.C.: Synthesis of biologically active N- and O-linked glycans with
	multisialylated poly-N-acetyllactosamine extensions using P. damsela
	alpha2-6 sialyltransferase. J. Am. Chem. Soc. (2013) 135, 18280-18283.
	{Pubmed:24256304}
RF	<83> Meng, L.; Forouhar, F.; Thieker, D.; Gao, Z.; Ramiah, A.; Moniz,
	H.; Xiang, Y.; Seetharaman, J.; Milaninia, S.; Su, M.; Bridger, R.;
	Veillon, L.; Azadi, P.; Kornhaber, G.; Wells, L.; Montelione, G.T.;
	Woods, R.J.; Tong, L.; Moremen, K.W.: Enzymatic basis for N-glycan
	sialylation: structure of rat alpha2,6-sialyltransferase (ST6GAL1)
	reveals conserved and unique features for glycan sialylation. J. Biol.
	Chem. (2013) 288, 34680-34698. {Pubmed:24155237}
RF	<84> Ribitsch, D.; Zitzenbacher, S.; Augustin, P.; Schmoelzer, K.;
	Czabany, T.; Luley-Goedl, C.; Thomann, M.; Jung, C.; Sobek, H.;
	Mueller, R.; Nidetzky, B.; Schwab, H.: High-quality production of human
	alpha-2,6-sialyltransferase in Pichia pastoris requires control over
	N-terminal truncations by host-inherent protease activities. Microb.
	Cell Fact. (2014) 13, 138. {Pubmed:25365915}
RF	<85> Lu, J.; Gu, J.: Significance of beta-galactoside alpha2,6
	sialyltranferase 1 in cancers. Molecules (2015) 20, 7509-7527.
	{Pubmed:25919275}
RF	<86> Kang, J.Y.; Lim, S.J.; Kwon, O.; Lee, S.G.; Kim, H.H.; Oh, D.B.:
	Enhanced bacterial alpha(2,6)-sialyltransferase reaction through an
	inhibition of its inherent sialidase activity by dephosphorylation of
	cytidine-5'-monophosphate. PLoS ONE (2015) 10, e0133739.
	{Pubmed:26231036}

ACTIVATING_COMPOUND
AC	#14,37,40,41# CMP (#14# cytidine 5-monophosphate, the product of
	sialyltransferase reactions, is not required by the trans-sialidase
	activity of the enzyme but enhances the trans-sialidase activity
	modestly as a non-essential activator. CMP can enhance the efficiency
	of the alpha2,6-sialidase activity of DELTA15Pd2,6ST in a
	dose-dependent manner <63>) <63,86>
AC	#37,40,41# CMP-N-acetylneuraminate <86>
AC	#5,15# more (#5# the enzyme is induced by phorbol 12-myristate
	13-acetate via a PKC/ERK/CREB-dependent pathway in K562 human leukemia
	cells, the induction is inhibited by Gö6976, a specific inhibitor of
	PKC, and U0126, an inhibitor of the extracellular signal-regulated
	kinase, but not by wortmannin, overview <42>; #15# in the
	sialyltransferase activity assay, FLAG-tagged ST6Gal1 has the highest
	expression level, which is 1.8- or 4.1fold higher than that of Strep-
	or His-tagged ST6Gal1, respectively <59>) <42,59>
AC	#5,6# Triton X-100 (#5# activation <18>) <18,21,24,30>
AC	#5,6# Triton CF-54/Tween 80 (#6# activation <12>) <12,27>
AC	#6# natural factor from rat colon (#6# stimulation is decreased by CTP,
	no activation at 0.75 mM CTP <24>; #6# partially purified <24>; #6#
	specific, 4fold stimulation by decreasing the Km value for the
	substrates and increasing Vmax, present in the cytosol, temperature
	dependent, protease sensitive, independent of metal ions or detergent,
	unaffceted by monosaccharides <24>; #6# may also be present in rat
	brain and kidney <24>) <24>
AC	#6# deoxycholate (#6# 9fold stimulation at 0.25%, inhibition at 0.5%
	<9>) <9>
AC	#6,7,8# EDTA (#6# activation <9>; #7# no activation <10>; #8# 138%
	activity at 10 mM <80>) <9,10,80>

KI_VALUE
KI	#15# 0.016 {CDP}  (#15# mutant V220A <23>) <23>
KI	#15# 0.0047 {CDP}  (#15# wild-type enzyme <23>) <23>
KI	#2# -999 {more}  <14>
KI	#5# 0.18 {CMP}  <18>
KI	#6# 0.79 {CMP-4-O-[4-carboxy-2,2,6,6-tetramethylpiperidinine-1-oxyl]} 
	(#6# pH 6.5, 37°C <47>) <47>
KI	#6# 4.07 {CMP-4-O-[2,2,6,6-tetramethylpiperidine-1-oxyl]}  (#6# pH 6.5,
	37°C <47>) <47>

IC50_VALUE
IC50	#6# 1.7 {CMP-4-O-[4-carboxy-2,2,6,6-tetramethylpiperidinine-1-oxyl]} 
	(#6# pH 6.5, 37°C <47>) <47>
IC50	#6# 8.7 {CMP-4-O-[2,2,6,6-tetramethylpiperidine-1-oxyl]}  (#6# pH 6.5,
	37°C <47>) <47>

KI_VALUE
KI	#15# 0.016 {CDP}  (#15# mutant V220A <23>) <23>
KI	#15# 0.0047 {CDP}  (#15# wild-type enzyme <23>) <23>
KI	#2# -999 {more}  <14>
KI	#5# 0.18 {CMP}  <18>
KI	#6# 0.79 {CMP-4-O-[4-carboxy-2,2,6,6-tetramethylpiperidinine-1-oxyl]} 
	(#6# pH 6.5, 37°C <47>) <47>
KI	#6# 4.07 {CMP-4-O-[2,2,6,6-tetramethylpiperidine-1-oxyl]}  (#6# pH 6.5,
	37°C <47>) <47>

PI_VALUE
PI	#15# 6.3 (#15# isoelectric focusing <59>) <59>

KCAT_KM_VALUE
KKM	#14# 5.6 (#14# mutant enzyme I411T/L433T, at pH 8.0 and 22°C <79>) <79>
KKM	#14# 0.93 (#14# mutant enzyme I411T, at pH 8.0 and 22°C <79>) <79>
KKM	#14# 1.8 (#14# mutant enzyme I411T, at pH 8.0 and 22°C <79>) <79>
KKM	#14# 0.74 (#14# wild type enzyme, at pH 8.0 and 22°C <79>) <79>
KKM	#14# 0.016 (#14# alpha2,6-trans-sialidase activity of DELTA15Pd2,6ST
	<63>) <63>
KKM	#14# 4.7 (#14# mutant enzyme L433T, at pH 8.0 and 22°C <79>) <79>
KKM	#14# 1.35 (#14# mutant enzyme I411T/L433S, at pH 8.0 and 22°C <79>)
	<79>
KKM	#14# 1.58 (#14# mutant enzyme I411T/L433S, at pH 8.0 and 22°C <79>)
	<79>
KKM	#14# 0.58 (#14# wild type enzyme, at pH 8.0 and 22°C <79>) <79>
KKM	#14# 1.26 (#14# mutant enzyme L433T, at pH 8.0 and 22°C <79>) <79>
KKM	#14# 1.43 (#14# mutant enzyme L433S, at pH 8.0 and 22°C <79>) <79>
KKM	#14# 1.78 (#14# mutant enzyme I411T/L433T, at pH 8.0 and 22°C <79>)
	<79>
KKM	#14# 2.61 (#14# mutant enzyme L433S, at pH 8.0 and 22°C <79>) <79>
KKM	#15# 0.05 (#15# mutant enzyme Q232A, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 0.031 <59>
KKM	#15# 0.44 (#15# mutant enzyme F208A, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 0.01 (#15# mutant enzyme D271A, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 5.27 (#15# recombinant wild type enzyme from HEK-293 cells, at pH
	6.5 and 37°C <83>) <83>
KKM	#15# 5 (#15# mutant enzyme Y119F, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 0.13 (#15# mutant enzyme D271A, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 0.17 (#15# mutant enzyme Y119F, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 7.3 (#15# mutant enzyme K355A, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 0.02 (#15# mutant enzyme Y272A, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 1.23 <59>
KKM	#15# 0.25 (#15# recombinant wild type enzyme from HEK-293 cells, at pH
	6.5 and 37°C <83>) <83>
KKM	#15# 0.36 (#15# mutant enzyme K355A, at pH 6.5 and 37°C <83>; #15#
	mutant enzyme Q354A, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 0.23 (#15# mutant enzyme Y272A, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 0.37 (#15# recombinant wild type enzyme from 293-F cells, at pH
	6.5 and 37°C <83>) <83>
KKM	#15# 0.47 (#15# mutant enzyme F208A, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 4.17 (#15# mutant enzyme Q354A, at pH 6.5 and 37°C <83>) <83>
KKM	#15# 6.45 (#15# recombinant wild type enzyme from 293-F cells, at pH
	6.5 and 37°C <83>) <83>

EXPRESSION
EXP	#10# more (#10# enzyme activity has little variation in dogs with
	metastatic tumors <77>) <77>
EXP	#4,5,15,16,26# up (#5# alpha2,6-ST activity in B lymphocytes is
	correlated positively with the level of alpha2,6-sialic acid in serum
	IgA1 in patients and controls <65>; #4# carbon tetrachloride
	administration significantly increases the level of plasma ST6Gal I as
	evidenced from significant increases in plasma aspartate
	aminotransferase (AST) and alanine aminotransferase (ALT) as hepatitis
	markers <57>; #15# level of plasma ST6Gal I is increased in two
	different types of liver injury models: in zone 1 hepatocyte-injured
	rats, the level of plasma ST6Gal I is increased together with acute
	phase reactions. Meanwhile, in zone 3 hepatocyte-injured rats, ST6Gal I
	secretion is most likely triggered by oxidative stress <61>; #26#
	ST6Gal II gene is upregulated in cells stimulated by interleukin-6,
	whereas interleukin-1 and TNFalpha treatments have no effect on the
	expression of ST6Gal II. Inflammatory response induced by interleukin-6
	treatment provokes an overexpression of ST6Gal II at 24 h and 48 h of
	treatment, its expression level in the treated cells is 2.5- and
	5.6fold higher than in the control, respectively <60>; #16# the enzyme
	is up-regulated in human colon cancer <70>; #5# the enzyme expression
	is increased in cancer of colon, breast, cervix, choriocarcinomas,
	acute myeloid leukemias, liver, and brain <85>) <57,60,61,65,70,85>
EXP	#5# down (#5# expression of ST6GALNAC2 in B peripheral lymphocytes is
	significantly lower in patients with IgA nephropathy than that in
	normal controls <65>) <65>

///
ID	2.4.99.3
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Gallus gallus   <22>
PR	#2# Mus musculus   <8>
PR	#3# Homo sapiens   <6,13,16,17,18,19,20,21,22,24>
PR	#4# Rattus norvegicus   <2>
PR	#5# Sus scrofa   <1,2,3,4,5,7,10>
PR	#6# Bos taurus   <2,5>
PR	#7# Ovis aries   <2,4,9,11>
PR	#8# Oncorhynchus mykiss   (#8# Escherichia coli K12 <12>) <12>
PR	#9# Homo sapiens Q9UJ37 SwissProt <14>
PR	#10# Homo sapiens Q9NSC7 SwissProt <15>
PR	#11# Homo sapiens A0A024R8M1 UniProt <23>

RECOMMENDED_NAME
RN	alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase


SYSTEMATIC_NAME
SN	CMP-N-acetylneuraminate:glycano-1
	3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein
	alpha-2,6-N-acetylneuraminyltransferase


SYNONYMS
SY	 sialyltransferase, cytidine
	monophosphoacetylneuraminate-alpha-acetylgalactosaminide alpha2-->6-
SY	 mucin sialyltransferase
SY	 alpha-N-acetylgalactosaminylprotein alpha2-->6 sialyltransferase
SY	 sialyltransferase 7A <Swissprot>
SY	 CMP-N-acetylneuraminate:alpha-N-acetylgalactosaminide alpha2-->6
	sialyltransferase
SY	 CMP-NeuAc:galactoside (alpha2-6)-sialyltransferase
SY	 CMP-sialic
	acid:alpha-N-acetylgalactosaminide(R-->Galbeta1-->3GalNAcalpha1-->O
	Ser/Thr) alpha2-->6 sialyltransferase
SY	 CMP-Neu5Ac:GalNAc alpha2,6-sialyltransferase
SY	 alpha-2,6-ST
SY	 ST6GalNAc-I
SY	#1,3# sialyltransferase <22>
SY	#1,3# ST6GalNAcI <22,24>
SY	#1,3# ST6 <22>
SY	#11# ST6GalNAc-II <23>
SY	#11# alpha2,6-sialyltransferase II <23>
SY	#3# CMPNeu5Ac:GalNAalpha2,6-sialyltransferase <18>
SY	#3# CMP-Neu5Ac: RGalNAcalpha1-O-Ser/Thralpha2,6-sialyltransferase <18>
SY	#3# ST6GalNAc I <18>
SY	#3# alpha2,6-sialyltransferase <24>
SY	#3# ST6Gal-I <19>
SY	#9# STM (#9# i.e. human ST6GalNAc-II <14>) <14>

REACTION
RE	CMP-N-acetylneuraminate +
	glycano-(1->3)-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	glycano-[(2->6)-alpha-N-acetylneuraminyl]-(N-acetyl-D-galactosaminyl)
	glycoprotein (#5# mechanism <1>)

REACTION_TYPE
RT	glycosyl group transfer

SOURCE_TISSUE
ST	#10# HT-29-MTX cell (#10# colon cancer cells, hST6GalNAc-I <15>) <15>
ST	#2# liver <8>
ST	#3# K-562 cell (#3# hematopoietic cell line, high ST6GalNAc-I
	expression <16>) <16>
ST	#3# blood platelet <6>
ST	#3# lymphocyte (#3# sialylated histo-blood group carbohydrate CD175 is
	present in all hematopoietic cell lines and native lymphocytes
	examined. CD175 and sialylated CD175 are preferentially expressed on
	erythroblastic leukemia cell lines. Presence of sialylated CD175 is
	consistent with the expression of the gene encoding
	alpha2,6-sialyltransferase ST6GalNAc-1 <20>) <20>
ST	#3# colorectal adenocarcinoma cell (#3# ST6GalNAc-II <13>) <13>
ST	#3# hematopoietic cell (#3# malignant hematopoietic cell. Sialylated
	histo-blood group carbohydrate CD175 is present in all hematopoietic
	cell lines and native lymphocytes examined. CD175 and sialylated CD175
	are preferentially expressed on erythroblastic leukemia cell lines.
	Presence of sialylated CD175 is consistent with the expression of the
	gene encoding alpha2,6-sialyltransferase ST6GalNAc-1 <20>) <20>
ST	#3# SW-480 cell (#3# human colon carcinoma cells, recombinant
	ST6GalNAc-II <13>) <13>
ST	#3# LS174T cell (#3# human colon cancer cell line, recombinant
	ST6GalNAc-II <13>) <13>
ST	#3,9,10# more (#3# ratio of ST6GalNAc-II expression in colorectal tumor
	cells versus normal mucosa cells is 1.47 <13>; #9# STM tissue
	distribution, SIATL1 gene encoding STM is widely expressed in normal
	human tissues, as well as in normal breast and prostate epithelial
	cells, but significantly down-regulated or absent in corresponding
	tumor cell lines, STM gene is down-regulated in T-47D, BT-474 and
	MDA-MB-435 breast tumor cell lines as compared to normal mammary
	epithelial cell strains, only RNA traces in other tumor cell lines
	tested, e.g. MDA-231, MDA-468 and MCF-7, only MDA-MB-361 metastatic
	tumor cell line expresses STM mRNA levels as high as in 76N <14>; #10#
	no expression of hST6GalNAc-I in MDA-MB-231, BT-20, MCF-7 and T47-D
	cells <15>; #3# low expression of ST6GalNAc-I in gastric carcinoma cell
	lines MKN45, KATO-III, GP202 and GP220, correlating with very low or
	absent detection of the Sialyl-Tn antigen <16>) <13,14,15,16>
ST	#4,5,6,7# submaxillary gland <1,2,3,4,5,7,9,10,11>
ST	#8# ovary <12>
ST	#8# egg (#8# unfertilized mature eggs <12>) <12>
ST	#9# mammary epithelium (#9# normal human mammary epithelial cell
	strains 70N, 76N and 81N, STM RNA expression is highest in 76N,
	followed by 81N and 70N <14>) <14>

LOCALIZATION
LO	#2# mitochondrial outer membrane <8>
LO	#3,8# soluble (#8# in ovaries 96% of sialyltransferase activity is
	found in the Golgi-derived immature cortical vesicles or as soluble
	enzyme released from the cortical vesicles <12>) <12,17>
LO	#5# membrane (#5# bound to <3>) <1,3,7>
LO	#5,7# microsome <4,9>
LO	#8# Golgi membrane (#8# less than 4% of sialyltransferase activity
	<12>) <12>
LO	#8# Golgi vesicle (#8# in ovaries 96% of sialyltransferase activity is
	found in the Golgi-derived immature cortical vesicles or as soluble
	enzyme released from the cortical vesicles <12>) <12>

NATURAL_SUBSTRATE_PRODUCT
NSP	#3# CMP-N-acetylneuraminate + protein MUC1-MFP6 = ? (#3# recombinant
	protein substrate expressed in MDA-MB-231 breast cancer cells,
	glycoprofiling, overview <18>) <18>
NSP	#3,11# more = ? (#3# the enzyme participates in the core O-glycan
	biosynthesis, overview <18>; #3# sialylation of Gal-deficient
	asialo-immunoglobulin A1 myeloma protein by the enzyme generates
	sialylated immunoglobulin A1 that mimics the Gal-deficient
	immunoglobulin A1 glycoforms in patients with IgA nephropathy,
	characterized by alpha2,6-sialylated galactose-deficient
	N-acetylgalactosamine. The enzyme adds three to six N-acetylneuraminic
	acid residues to synthetic hinge region peptides with three to seven
	N-acetylgalactosamine residues, with at least one N-acetylgalactosamine
	remaining without N-acetylneuraminic acid <24>; #11# the enzyme can
	sialylate GalNAc of galactose-deficient immunoglobulin A1 <23>) {}
	<18,23,24>
NSP	#3,11# more = ? (#3# the enzyme participates in the core O-glycan
	biosynthesis, overview <18>; #3# sialylation of Gal-deficient
	asialo-immunoglobulin A1 myeloma protein by the enzyme generates
	sialylated immunoglobulin A1 that mimics the Gal-deficient
	immunoglobulin A1 glycoforms in patients with IgA nephropathy,
	characterized by alpha2,6-sialylated galactose-deficient
	N-acetylgalactosamine. The enzyme adds three to six N-acetylneuraminic
	acid residues to synthetic hinge region peptides with three to seven
	N-acetylgalactosamine residues, with at least one N-acetylgalactosamine
	remaining without N-acetylneuraminic acid <24>; #11# the enzyme can
	sialylate GalNAc of galactose-deficient immunoglobulin A1 <23>) {}
	<18,23,24>
NSP	#3,5,6,7,8,9,10# CMP-N-acetylneuraminate +
	glycano-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	glycano-(2
	6-alpha-N-acetylneuraminyl)-(N-acetyl-D-galactosaminyl)-glycoprotein
	(#9# STM catalyzes the synthesis of O-glycans, SIATL1 gene encoding STM
	is widely expressed in normal human tissues, as well as in normal
	breast and prostate epithelial cells, but significantly down-regulated
	or absent in corresponding tumor cell lines <14>; #8# required for
	synthesis of polySia side chains in trout egg polysialoglycoproteins,
	developmental expression pattern of enzyme in cortical vesicles during
	oogenesis, activity increases during oogenesis <12>; #5,7# pathway of
	biosynthesis of glycans present in mucins <4>; #3# ST6GalNAc-II
	expression is significantly increased in colorectal carcinomas in cases
	with metastases to lymph nodes along the vascular trunk, involved in
	biosynthesis of the TF glycotype <13>; #10# hST6GalNAc-I catalyzes the
	key step in the biosynthesis of Sialyl-Tn antigen,
	Neu5Acalpha(2-6)GalNAcalpha1-O-Ser/Thr <15>; #7# involved in the
	sialylation of submaxillary gland mucin in vivo <9>; #5# involved in
	the biosynthesis of oligosaccharide sequences of glycoproteins <3>;
	#5,6# one of the last steps of the biosynthesis of oligosaccharides of
	glycoproteins <5>; #5,6,7# the relative preference of enzyme for a
	monosaccharide versus a substituted GalNAc may play a role in
	regulation of chain length during mucin synthesis <2>; #5# involved in
	biosynthesis of O-linked oligosaccharide chains of glycoproteins <1,7>;
	#7# last step in the synthesis of ovine submaxillary mucin, catalyzes
	the chain-terminating process in oligosaccharide synthesis of
	glycoproteins, may well be involved in the process of secretion <11>;
	#3# ST6GalNAc-I is responsible for the synthesis of Sialyl-Tn antigen,
	Neu5Acalpha(2-6)GalNAc, synthesis of Sialyl-Tn structures in mucin
	O-glycosylation stops further processing and elongation of the
	carbohydrate chain <16>) {} <1,2,3,4,5,7,9,11,12,13,14,15,16>

SUBSTRATE_PRODUCT
SP	#10# CMP-N-acetylneuraminate + GTTPSPVPT[GalNAc]TSTTSAP = CMP +
	GTTPSPVPT[Neu5Acalpha(2-6)GalNAc]TSTTSAP (#10# hexadecaglycopeptide
	acceptor, corresponding to the MUC5AC tandem repeat sequence
	substituted by a GalNAc residue on Thr-9, hST6GalNAc-I <15>) <15>
SP	#11# CMP-N-acetylneuraminate + VPSTPPTPSPSTPPTPSPSCCHPR-GalNAc = CMP +
	? <23>
SP	#2,3,4,5,6,7,8,9,10# CMP-N-acetylneuraminate +
	R-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	R-(2
	6-alpha-N-acetylneuraminyl)-(N-acetyl-D-galactosaminyl)-glycoprotein
	(#5,7,8,9# acceptor substrate specificity <1,3,4,12,14>; #5,6,7#
	preference of enzyme for a monosaccharide versus a disaccharide
	acceptor <2>; #5,6# CMP-N-glycolylneuraminate has the same efficiency
	as CMP-N-acetylneuraminate, CMP-9-O-acetyl-N-acetylneuraminate has much
	lower efficiency than CMP-N-acetylneuraminate <5>; #7# mucin-type
	acceptors <9>; #10# hST6GalNAc-I transfers a sialic acid residue in
	alpha2,6-linkage to GalNAc-O-Ser/Thr, substrate specificity of
	hST6GalNAc-I and -II <15>; #5# antifreeze glycoprotein is the best
	substrate <1>; #5# sialyl-2,3-antifreeze glycoprotein, better than
	native form <3>; #5# antifreeze glycoprotein from antarctic fish <3>;
	#3# asialo-orosomucoid <6>; #8# native and
	asialo-polysialoglycoprotein, acceptor carbohydrate unit:
	Galbeta(1-3)GalNAcalpha(1-O)-Ser/Thr, but not GalNAc1 to O-Ser/Thr
	<12>; #7# erythrocyte hemagglutination inhibitor, milk glycopeptide
	<11>; #5,6,7,8# CMP-N-glycolylneuraminate can replace
	CMP-N-acetylneuraminate <5,11,12>; #5# R: H or a beta-galactoside <1>;
	#2,3,4,5,6,7,9# asialo-fetuin <1,2,6,8,10,11,13,14>; #7# bovine
	submaxillary asialo-mucin <11>; #5# transfers sialic acid to the core
	region of O-linked glycans <10>; #5,7# specific for
	alpha-N-acetylgalactosamine attached through alpha-glycosidic linkage
	to threonine or serine in polypeptide chain <1,11>; #5,7# porcine
	submaxillary asialo-mucin <1,4,11>; #3# ST6GalNAc-II demands an
	acceptor with a protein backbone <13>; #7# native submaxillary mucin,
	less effective than asialo-mucin <11>; #5# CMP-9-acetamidoneuraminate,
	CMP-9-benzamidoneuraminate and CMP-9-hexanoylamidoneuraminate are less
	effective, CMP-9-azido-N-acetylneuraminate can replace
	CMP-N-acetylneuraminate with asialofetuin or antifreeze glycoprotein as
	acceptor, CMP-9-aminoacetylneuraminate only with asialofetuin as
	acceptor <10>; #9# Galbeta(1-3)GalNAc-O-Ser/Thr or
	Neu5Acalpha(2-3)Galbeta(1-3)GalNAc-O-Ser/Thr acceptor specificity <14>;
	#7,9# native fetuin <11,14>; #5,6# antifreeze glycoprotein <1,5,10>;
	#5,6,7# ovine submaxillary asialo-mucin, with simple O-linked
	GalNAcalpha-Thr/Ser <1,2,3,4,5,11>; #5,7# absolute requirement for
	protein as the aglycon <4>) <1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16>
SP	#2,3,4,5,6,7,8,9,10# CMP-N-acetylneuraminate +
	R-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	R-(2
	6-alpha-N-acetylneuraminyl)-(N-acetyl-D-galactosaminyl)-glycoprotein
	(#5,7,8,9# acceptor substrate specificity <1,3,4,12,14>; #5,6,7#
	preference of enzyme for a monosaccharide versus a disaccharide
	acceptor <2>; #5,6# CMP-N-glycolylneuraminate has the same efficiency
	as CMP-N-acetylneuraminate, CMP-9-O-acetyl-N-acetylneuraminate has much
	lower efficiency than CMP-N-acetylneuraminate <5>; #7# mucin-type
	acceptors <9>; #10# hST6GalNAc-I transfers a sialic acid residue in
	alpha2,6-linkage to GalNAc-O-Ser/Thr, substrate specificity of
	hST6GalNAc-I and -II <15>; #5# antifreeze glycoprotein is the best
	substrate <1>; #5# sialyl-2,3-antifreeze glycoprotein, better than
	native form <3>; #5# antifreeze glycoprotein from antarctic fish <3>;
	#3# asialo-orosomucoid <6>; #8# native and
	asialo-polysialoglycoprotein, acceptor carbohydrate unit:
	Galbeta(1-3)GalNAcalpha(1-O)-Ser/Thr, but not GalNAc1 to O-Ser/Thr
	<12>; #7# erythrocyte hemagglutination inhibitor, milk glycopeptide
	<11>; #5,6,7,8# CMP-N-glycolylneuraminate can replace
	CMP-N-acetylneuraminate <5,11,12>; #5# R: H or a beta-galactoside <1>;
	#2,3,4,5,6,7,9# asialo-fetuin <1,2,6,8,10,11,13,14>; #7# bovine
	submaxillary asialo-mucin <11>; #5# transfers sialic acid to the core
	region of O-linked glycans <10>; #5,7# specific for
	alpha-N-acetylgalactosamine attached through alpha-glycosidic linkage
	to threonine or serine in polypeptide chain <1,11>; #5,7# porcine
	submaxillary asialo-mucin <1,4,11>; #3# ST6GalNAc-II demands an
	acceptor with a protein backbone <13>; #7# native submaxillary mucin,
	less effective than asialo-mucin <11>; #5# CMP-9-acetamidoneuraminate,
	CMP-9-benzamidoneuraminate and CMP-9-hexanoylamidoneuraminate are less
	effective, CMP-9-azido-N-acetylneuraminate can replace
	CMP-N-acetylneuraminate with asialofetuin or antifreeze glycoprotein as
	acceptor, CMP-9-aminoacetylneuraminate only with asialofetuin as
	acceptor <10>; #9# Galbeta(1-3)GalNAc-O-Ser/Thr or
	Neu5Acalpha(2-3)Galbeta(1-3)GalNAc-O-Ser/Thr acceptor specificity <14>;
	#7,9# native fetuin <11,14>; #5,6# antifreeze glycoprotein <1,5,10>;
	#5,6,7# ovine submaxillary asialo-mucin, with simple O-linked
	GalNAcalpha-Thr/Ser <1,2,3,4,5,11>; #5,7# absolute requirement for
	protein as the aglycon <4>) {r} <1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16>
SP	#2,3,4,5,6,7,8,9,10# CMP-N-acetylneuraminate +
	R-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	R-(2
	6-alpha-N-acetylneuraminyl)-(N-acetyl-D-galactosaminyl)-glycoprotein
	(#5,7,8,9# acceptor substrate specificity <1,3,4,12,14>; #5,6,7#
	preference of enzyme for a monosaccharide versus a disaccharide
	acceptor <2>; #5,6# CMP-N-glycolylneuraminate has the same efficiency
	as CMP-N-acetylneuraminate, CMP-9-O-acetyl-N-acetylneuraminate has much
	lower efficiency than CMP-N-acetylneuraminate <5>; #7# mucin-type
	acceptors <9>; #10# hST6GalNAc-I transfers a sialic acid residue in
	alpha2,6-linkage to GalNAc-O-Ser/Thr, substrate specificity of
	hST6GalNAc-I and -II <15>; #5# antifreeze glycoprotein is the best
	substrate <1>; #5# sialyl-2,3-antifreeze glycoprotein, better than
	native form <3>; #5# antifreeze glycoprotein from antarctic fish <3>;
	#3# asialo-orosomucoid <6>; #8# native and
	asialo-polysialoglycoprotein, acceptor carbohydrate unit:
	Galbeta(1-3)GalNAcalpha(1-O)-Ser/Thr, but not GalNAc1 to O-Ser/Thr
	<12>; #7# erythrocyte hemagglutination inhibitor, milk glycopeptide
	<11>; #5,6,7,8# CMP-N-glycolylneuraminate can replace
	CMP-N-acetylneuraminate <5,11,12>; #5# R: H or a beta-galactoside <1>;
	#2,3,4,5,6,7,9# asialo-fetuin <1,2,6,8,10,11,13,14>; #7# bovine
	submaxillary asialo-mucin <11>; #5# transfers sialic acid to the core
	region of O-linked glycans <10>; #5,7# specific for
	alpha-N-acetylgalactosamine attached through alpha-glycosidic linkage
	to threonine or serine in polypeptide chain <1,11>; #5,7# porcine
	submaxillary asialo-mucin <1,4,11>; #3# ST6GalNAc-II demands an
	acceptor with a protein backbone <13>; #7# native submaxillary mucin,
	less effective than asialo-mucin <11>; #5# CMP-9-acetamidoneuraminate,
	CMP-9-benzamidoneuraminate and CMP-9-hexanoylamidoneuraminate are less
	effective, CMP-9-azido-N-acetylneuraminate can replace
	CMP-N-acetylneuraminate with asialofetuin or antifreeze glycoprotein as
	acceptor, CMP-9-aminoacetylneuraminate only with asialofetuin as
	acceptor <10>; #9# Galbeta(1-3)GalNAc-O-Ser/Thr or
	Neu5Acalpha(2-3)Galbeta(1-3)GalNAc-O-Ser/Thr acceptor specificity <14>;
	#7,9# native fetuin <11,14>; #5,6# antifreeze glycoprotein <1,5,10>;
	#5,6,7# ovine submaxillary asialo-mucin, with simple O-linked
	GalNAcalpha-Thr/Ser <1,2,3,4,5,11>; #5,7# absolute requirement for
	protein as the aglycon <4>) {ir}
	<1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16>
SP	#2,3,4,5,6,7,9# CMP-N-acetylneuraminate + asialo-fetuin = CMP + fetuin
	(#5# good substrate <1>; #4,5,6,7# formation of
	Galbeta(1-3)(NeuAcalpha(2-6))GalNAc <2>; #3# ST6GalNAc-II <13>; #9#
	STM, i.e. hST6GalNAc-II, more effective than native fetuin <14>)
	<1,2,6,8,11,13,14>
SP	#2,3,5,7# CMP-N-acetylneuraminate + Galbeta(1-3)GalNAc-R = CMP +
	Galbeta(1-3)(NeuAcalpha(2-6))GalNAc-R (#3# R: protein, formation of TF
	Sia6Core-1, Galbeta(1-3)(NeuAcalpha(2,6))GalNAc-R, or of TF
	DiSiaCore-1, NeuAcalpha(2-3)Galbeta(1-3)(NeuAcalpha(2,6))GalNAc-R, by
	the sialyltransferase ST6GalNAc-II <13>; #2# R: p-nitrophenol <8>;
	#5,7# R: protein, but not p-nitrophenol <4,9>) <4,8,9,13>
SP	#3# CMP-N-acetylneuraminate + asialo-orosomucoid = CMP + orosomucoid <6>
SP	#3# CMP-N-acetylneuraminate + p-nitrophenyl-beta-D-galactoside = CMP +
	alpha-sialosyl-(2-6)-p-nitrophenyl-beta-D-galactoside <6>
SP	#3# CMP-Neu5Ac + asialofetuin = CMP + ? <17>
SP	#3# CMP-Neu5Ac + fetuin = CMP + ? (#3# isoform ST6GalNAc-I, 84% of
	reactivity with asialofetuin, isoform ST6GalNAc-II, 88% of reactivity
	with asialofetuin <17>) <17>
SP	#3# CMP-Neu5Ac + HIV 120gp (17-mer) = CMP + ? (#3# isoform ST6GalNAc-I,
	34% of reactivity with asialofetuin, isoform ST6GalNAc-II, 38% of
	reactivity with asialofetuin <17>) <17>
SP	#3# CMP-Neu5Ac + HIV 120gp (21-mer) = CMP + ? (#3# isoform ST6GalNAc-I,
	62% of reactivity with asialofetuin, isoform ST6GalNAc-II, 58% of
	reactivity with asialofetuin <17>) <17>
SP	#3# CMP-N-acetylneuraminate + protein MUC1-MFP6 = ? (#3# recombinant
	protein substrate expressed in MDA-MB-231 breast cancer cells,
	glycoprofiling, overview <18>; #3# recombinant protein substrate,
	glycoprofiling, overview <18>) <18>
SP	#3# CMP-sialic acid-PEG4-biotin + desialyated bovine serum albumin = ?
	(#3# bacterially produced ST6 is active and capable of catalyzing the
	transfer of sialic acid onto a desialylated O-glycoprotein, bovine
	submaxillary mucin <22>) <22>
SP	#3,4,5,6,7,9,11# more = ? (#5,7# no acceptor:
	beta-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenol <4,9>; #5#
	no donor: CMP-9-amino-acetylneuraminate <10>; #5# no acceptor: human
	asialo-transferrin <3>; #7# no acceptors: asialo-collacalia mucoid,
	asialo-proteose peptone, asialo-prothrombin, asialo-thyroglobulin,
	asialo-transferrin, asialo-chondromucoprotein fractions from cartilage,
	human blood group substance A or B, various sugars <11>; #5,6,7# no
	acceptor: lactose <2,11>; #9# STM contains 2 catalytic domains, the
	L-sialylmotif, aa 148-194, and S-sialylmotif, aa 303-324, no acceptors:
	asialo-BSM, alpha1 acid glycoprotein, glycosphingolipids <14>; #5,7# no
	acceptor: N-acetyl-D-galactosaminyl-p-nitrophenol <4>; #4# very poor
	acceptor: ovine submaxillary asialo-mucin <2>; #3# no acceptor: TF-PAA,
	i.e. Galbeta(1-3)GalNAc conjugated to
	poly[N-(2-hydroxyethyl)acrylamide] <13>; #5# no acceptors:
	glycoproteins with Asn-linked oligosaccharides, glycosides, mono- and
	oligosaccharides <1>; #3# enzyme transfers sialic acid to O-linked
	oligosaccharide of glycoprotein, isoform ST6GalNAc-I prefers sialyl Tn
	antigen, i.e. Neu5Acalpha2-6GalNAc-O-Ser/Thr, isoform ST6GalNAc-II
	prefers T antigen as substrate <17>; #3# the enzyme participates in the
	core O-glycan biosynthesis, overview <18>; #3# the enzyme transfers a
	sialic acid residue in alpha-2,6-linkage to the GalNAcalpha1-O-Ser/Thr
	structure <18>; #3# human ST6Gal-I demonstrates acceptor specificity
	towards various terminal LacNAc (type 2) structures including several
	glycoproteins containing these terminal structures. Significant
	activities towards GalNAcbeta1-4GlcNAc, i.e.LacDiNAc and
	GlcNAcbeta1-4GlcNAcbeta1-4GlcNAc, i.e. chitotriose structures are found
	and less activities with fucosides Fucalpha1-2Galbeta1-4GlcNAc. The
	enzyme also accepts chitobiose structures as
	(GlcNAcbeta1-2Manalpha)2
	3-Manbeta1-4GlcNAcbeta1-4GlcNAcbeta1-Gly-L-Glu-L-Asn. In addition,
	hST6Gal-I sialylates sulfated lactose and H-type 2 glycans <19>; #3#
	sialylation of Gal-deficient asialo-immunoglobulin A1 myeloma protein
	by the enzyme generates sialylated immunoglobulin A1 that mimics the
	Gal-deficient immunoglobulin A1 glycoforms in patients with IgA
	nephropathy, characterized by alpha2,6-sialylated galactose-deficient
	N-acetylgalactosamine. The enzyme adds three to six N-acetylneuraminic
	acid residues to synthetic hinge region peptides with three to seven
	N-acetylgalactosamine residues, with at least one N-acetylgalactosamine
	remaining without N-acetylneuraminic acid <24>; #11# the enzyme can
	sialylate GalNAc of galactose-deficient immunoglobulin A1 <23>) {}
	<1,2,3,4,9,10,11,13,14,17,18,19,23,24>
SP	#3,4,5,6,7,9,11# more = ? (#5,7# no acceptor:
	beta-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenol <4,9>; #5#
	no donor: CMP-9-amino-acetylneuraminate <10>; #5# no acceptor: human
	asialo-transferrin <3>; #7# no acceptors: asialo-collacalia mucoid,
	asialo-proteose peptone, asialo-prothrombin, asialo-thyroglobulin,
	asialo-transferrin, asialo-chondromucoprotein fractions from cartilage,
	human blood group substance A or B, various sugars <11>; #5,6,7# no
	acceptor: lactose <2,11>; #9# STM contains 2 catalytic domains, the
	L-sialylmotif, aa 148-194, and S-sialylmotif, aa 303-324, no acceptors:
	asialo-BSM, alpha1 acid glycoprotein, glycosphingolipids <14>; #5,7# no
	acceptor: N-acetyl-D-galactosaminyl-p-nitrophenol <4>; #4# very poor
	acceptor: ovine submaxillary asialo-mucin <2>; #3# no acceptor: TF-PAA,
	i.e. Galbeta(1-3)GalNAc conjugated to
	poly[N-(2-hydroxyethyl)acrylamide] <13>; #5# no acceptors:
	glycoproteins with Asn-linked oligosaccharides, glycosides, mono- and
	oligosaccharides <1>; #3# enzyme transfers sialic acid to O-linked
	oligosaccharide of glycoprotein, isoform ST6GalNAc-I prefers sialyl Tn
	antigen, i.e. Neu5Acalpha2-6GalNAc-O-Ser/Thr, isoform ST6GalNAc-II
	prefers T antigen as substrate <17>; #3# the enzyme participates in the
	core O-glycan biosynthesis, overview <18>; #3# the enzyme transfers a
	sialic acid residue in alpha-2,6-linkage to the GalNAcalpha1-O-Ser/Thr
	structure <18>; #3# human ST6Gal-I demonstrates acceptor specificity
	towards various terminal LacNAc (type 2) structures including several
	glycoproteins containing these terminal structures. Significant
	activities towards GalNAcbeta1-4GlcNAc, i.e.LacDiNAc and
	GlcNAcbeta1-4GlcNAcbeta1-4GlcNAc, i.e. chitotriose structures are found
	and less activities with fucosides Fucalpha1-2Galbeta1-4GlcNAc. The
	enzyme also accepts chitobiose structures as
	(GlcNAcbeta1-2Manalpha)2
	3-Manbeta1-4GlcNAcbeta1-4GlcNAcbeta1-Gly-L-Glu-L-Asn. In addition,
	hST6Gal-I sialylates sulfated lactose and H-type 2 glycans <19>; #3#
	sialylation of Gal-deficient asialo-immunoglobulin A1 myeloma protein
	by the enzyme generates sialylated immunoglobulin A1 that mimics the
	Gal-deficient immunoglobulin A1 glycoforms in patients with IgA
	nephropathy, characterized by alpha2,6-sialylated galactose-deficient
	N-acetylgalactosamine. The enzyme adds three to six N-acetylneuraminic
	acid residues to synthetic hinge region peptides with three to seven
	N-acetylgalactosamine residues, with at least one N-acetylgalactosamine
	remaining without N-acetylneuraminic acid <24>; #11# the enzyme can
	sialylate GalNAc of galactose-deficient immunoglobulin A1 <23>) {}
	<1,2,3,4,9,10,11,13,14,17,18,19,23,24>
SP	#3,5,6,7,8,9,10# CMP-N-acetylneuraminate +
	glycano-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	glycano-(2
	6-alpha-N-acetylneuraminyl)-(N-acetyl-D-galactosaminyl)-glycoprotein
	(#9# STM catalyzes the synthesis of O-glycans, SIATL1 gene encoding STM
	is widely expressed in normal human tissues, as well as in normal
	breast and prostate epithelial cells, but significantly down-regulated
	or absent in corresponding tumor cell lines <14>; #8# required for
	synthesis of polySia side chains in trout egg polysialoglycoproteins,
	developmental expression pattern of enzyme in cortical vesicles during
	oogenesis, activity increases during oogenesis <12>; #5,7# pathway of
	biosynthesis of glycans present in mucins <4>; #3# ST6GalNAc-II
	expression is significantly increased in colorectal carcinomas in cases
	with metastases to lymph nodes along the vascular trunk, involved in
	biosynthesis of the TF glycotype <13>; #10# hST6GalNAc-I catalyzes the
	key step in the biosynthesis of Sialyl-Tn antigen,
	Neu5Acalpha(2-6)GalNAcalpha1-O-Ser/Thr <15>; #7# involved in the
	sialylation of submaxillary gland mucin in vivo <9>; #5# involved in
	the biosynthesis of oligosaccharide sequences of glycoproteins <3>;
	#5,6# one of the last steps of the biosynthesis of oligosaccharides of
	glycoproteins <5>; #5,6,7# the relative preference of enzyme for a
	monosaccharide versus a substituted GalNAc may play a role in
	regulation of chain length during mucin synthesis <2>; #5# involved in
	biosynthesis of O-linked oligosaccharide chains of glycoproteins <1,7>;
	#7# last step in the synthesis of ovine submaxillary mucin, catalyzes
	the chain-terminating process in oligosaccharide synthesis of
	glycoproteins, may well be involved in the process of secretion <11>;
	#3# ST6GalNAc-I is responsible for the synthesis of Sialyl-Tn antigen,
	Neu5Acalpha(2-6)GalNAc, synthesis of Sialyl-Tn structures in mucin
	O-glycosylation stops further processing and elongation of the
	carbohydrate chain <16>) {} <1,2,3,4,5,7,9,11,12,13,14,15,16>
SP	#3,5,7# CMP-N-acetylneuraminate + NeuAcalpha(2-3)Galbeta(1-3)GalNAc-R =
	CMP + NeuAcalpha(2-3)Galbeta(1-3)(NeuAcalpha(2-6))GalNAc-R (#3# R:
	protein, formation of TF Sia6Core-1,
	Galbeta(1-3)(NeuAcalpha(2,6))GalNAc-R, or of TF DiSiaCore-1,
	NeuAcalpha(2-3)Galbeta(1-3)(NeuAcalpha(2,6))GalNAc-R, by the
	sialyltransferase ST6GalNAc-II <13>; #5,7# R: protein, also
	p-nitrophenol, but with very low activity possibly due to another
	factor present in the fraction <4>) <4,13>
SP	#3,5,7# CMP-N-acetylneuraminate + GalNAc-R = CMP +
	NeuAcalpha(2-6)GalNAc-R (#5,7# R: protein, but not p-nitrophenol <4>;
	#3# formation of the TF-related blood group antigen sialosyl-Tn,
	NeuAcalpha(2-6)GalNAc-R, by the sialyltransferase ST6GalNAc-I <13>;
	#3,7# R: protein <9,13>) <4,9,13>
SP	#4# CMP-N-acetylneuraminate + lactose = CMP + 6'-sialyllactose (#4#
	poor acceptor <2>) <2>
SP	#5# CMP-9-acetamidoneuraminate +
	R-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	R-(2,6-9-acetamidoneuraminyl)-(N-acetyl-D-galactosaminyl)-glycoprotein
	(#5# less effective than CMP-N-acetylneuraminate <10>) <10>
SP	#5# CMP-9-benzamidoneuraminate +
	R-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	R-(2,6-9-benzamidoneuraminyl)-(N-acetyl-D-galactosaminyl)-glycoprotein
	(#5# less effective than CMP-N-acetylneuraminate <10>) <10>
SP	#5# CMP-9-hexanoylamidoneuraminate +
	R-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	R-(2
	6-9-hexanoylamidoneuraminyl)-(N-acetyl-D-galactosaminyl)-glycoprotein
	(#5# less effective than CMP-N-acetylneuraminate <10>) <10>
SP	#5# CMP-9-azido-N-acetylneuraminate +
	R-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	R-(2
	6-9-azido-N-acetylneuraminyl)-(N-acetyl-D-galactosaminyl)-glycoprotein
	(#5# CMP-9-azido-N-acetylneuraminate can replace
	CMP-N-acetylneuraminate with asialofetuin or antifreeze glycoprotein as
	acceptor <10>) <10>
SP	#5# CMP-9-aminoacetylneuraminate +
	R-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	R-(2
	6-9-aminoacetylneuraminyl)-(N-acetyl-D-galactosaminyl)-glycoprotein
	(#5# CMP-9-aminoacetylneuraminate can replace CMP-N-acetylneuraminate
	only with asialofetuin as acceptor <10>) <10>
SP	#5,6# CMP-N-acetylneuraminate + antifreeze glycoprotein = ? (#5# from
	antarctic fish <3>; #5# antifreeze glycoprotein 8, best acceptor <1>)
	<1,3,5>
SP	#5,6# CMP-N-acetylneuraminate + antifreeze glycoprotein = ? (#5# from
	antarctic fish <3>; #5# antifreeze glycoprotein 8, best acceptor <1>)
	{r} <1,3,5>
SP	#5,6# CMP-9-O-acetyl-N-acetylneuraminate +
	R-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	R-(2
	6-9-O-acetyl-N-acetylneuraminyl)-(N-acetyl-D-galactosaminyl)
	glycoprotein (#5,6# poor donor, 10% as effective as
	CMP-N-acetylneuraminate <5>) <5>
SP	#5,6,7# CMP-N-acetylneuraminate + submaxillary asialo-mucin = CMP +
	submaxillary mucin (#7# bovine submaxillary asialo-mucin <11>; #5,7#
	porcine submaxillary asialo-mucin <4,11>; #5,6# ovine submaxillary
	asialo-mucin, with simple O-linked GalNAcalpha-Thr/Ser <5>; #5# ovine
	and porcine submaxillary asialo-mucin are good acceptors <1>; #5,6,7#
	ovine submaxillary asialo-mucin <2,9>; #7# ovine submaxillary
	asialo-mucin is the most effective acceptor <11>) |#5,6,7# linkage
	formed is NeuAc(2-6)GalNAcalpha(1-)O-Thr/Ser <1,5,11>; #5,6,7#
	formation of NeuAcalpha(2-6)GalNAc <2>| {ir} <1,2,4,5,9,11>
SP	#5,6,7# CMP-N-acetylneuraminate + submaxillary asialo-mucin = CMP +
	submaxillary mucin (#7# bovine submaxillary asialo-mucin <11>; #5,7#
	porcine submaxillary asialo-mucin <4,11>; #5,6# ovine submaxillary
	asialo-mucin, with simple O-linked GalNAcalpha-Thr/Ser <5>; #5# ovine
	and porcine submaxillary asialo-mucin are good acceptors <1>; #5,6,7#
	ovine submaxillary asialo-mucin <2,9>; #7# ovine submaxillary
	asialo-mucin is the most effective acceptor <11>) |#5,6,7# linkage
	formed is NeuAc(2-6)GalNAcalpha(1-)O-Thr/Ser <1,5,11>; #5,6,7#
	formation of NeuAcalpha(2-6)GalNAc <2>| <1,2,4,5,9,11>
SP	#5,6,7,8# CMP-N-glycolylneuraminate +
	R-1,3-(N-acetyl-alpha-D-galactosaminyl)-glycoprotein = CMP +
	R-(2
	6-alpha-N-glycolylneuraminyl)-(N-acetyl-D-galactosaminyl)-glycoprotein
	(#5,6# CMP-N-glycolylneuraminate can replace CMP-N-acetylneuraminate
	with the same efficiency <5>) <5,11,12>
SP	#7# CMP-N-acetylneuraminate + asialo-milk glycopeptide = CMP + milk
	glycopeptide <11>
SP	#7# CMP-N-acetylneuraminate + erythrocyte hemagglutination inhibitor =
	? <11>
SP	#7,9# CMP-N-acetylneuraminate + native fetuin = ? (#9# STM, i.e.
	hST6GalNAc-II, 83% as effective as asialo-fetuin <14>) <11,14>
SP	#8# CMP-N-acetylneuraminate + asialo-polysialoglycoprotein = CMP +
	alpha-sialosyl-(2-6)-asialo-polysialoglycoprotein (#8# from egg, Sia
	residue is alpha-2,6-linked to the proximal GalNAc residue in
	asialo-polysialoglycoprotein, acceptor carbohydrate unit:
	Galbeta(1-3)GalNAcalpha(1-O)-Ser/Thr, but not GalNAc1 to O-Ser/Thr
	<12>) <12>
SP	#8# CMP-N-acetylneuraminate + native polysialoglycoprotein = ? (#8#
	from egg, almost identical amount of Neu5Ac is incorporated into native
	and asialo-polysialoglycoprotein acceptor, acceptor carbohydrate unit:
	Galbeta(1-3)GalNAcalpha(1-O)-Ser/Thr, but not GalNAc1 to O-Ser/Thr
	<12>) <12>

KM_VALUE
KM	#4# 2.2 {CMP-N-acetylneuraminate}  <2>
KM	#5# 0.1 {CMP-9-O-acetyl-N-acetylneuraminate}  (#5# 37°C <5>) <5>
KM	#5# 2.8 {CMP-N-acetylneuraminate}  <2>
KM	#5# 0.66 {CMP-N-acetylneuraminate}  (#5# pH 6.5, 37°C, ovine
	submaxillary asialo-mucin as acceptor <1>) <1>
KM	#5# 0.27 {CMP-N-acetylneuraminate}  (#5# 37°C <5>) <5>
KM	#5# 0.52 {CMP-N-acetylneuraminate}  (#5# pH 6.5, 37°C, antifreeze
	glycoprotein 8 as acceptor <1>) <1>
KM	#5# 0.52 {CMP-N-glycolylneuraminate}  (#5# 37°C <5>) <5>
KM	#5# 1.02 {Antifreeze glycoprotein}  (#5# antifreeze glycoprotein 8, pH
	6.5, 37°C <1>) <1>
KM	#5# 2.93 {submaxillary asialo-mucin}  (#5# ovine, pH 6.5, 37°C <1>) <1>
KM	#6# 0.21 {CMP-N-glycolylneuraminate}  (#6# 37°C <5>) <5>
KM	#6# 0.15 {CMP-N-acetylneuraminate}  (#6# 37°C <5>) <5>
KM	#6# 0.08 {CMP-9-O-acetyl-N-acetylneuraminate}  (#6# 37°C <5>) <5>
KM	#6# 4.7 {submaxillary asialo-mucin}  (#6# ovine,
	CMP-N-acetylneuraminate as donor, 37°C <5>) <5>
KM	#6# 2.7 {CMP-N-acetylneuraminate}  <2>
KM	#7# 1.9 {submaxillary asialo-mucin}  (#7# ovine, calculated in terms of
	N-acetylgalactosamine acceptor sites, 37°C <11>) <11>
KM	#7# 1.1 {CMP-N-acetylneuraminate}  <2>
KM	#7# 0.57 {CMP-N-acetylneuraminate}  (#7# 37°C <11>) <11>

PH_OPTIMUM
PHO	#3# 7.6 <6>
PHO	#4# 7.5 (#4# acceptor: asialo-fetuin <2>) <2>
PHO	#5# 6-6.5 <7>
PHO	#5# 5.9 (#5# acceptor: asialo-fetuin <2>) <2>
PHO	#6,7# 7.1 (#6,7# acceptor: asialo-fetuin <2>) <2>
PHO	#7# 6-6.1 (#7# with cacodylate-acetate buffer <11>) <11>
PHO	#8# 6-7 (#8# acceptor: asialo-polysialoglycoprotein <12>) <12>

PH_RANGE
PHR	#3# 6.2-8.5 (#3# about half-maximal activity at pH 6.2 and 8.5 <6>) <6>

SPECIFIC_ACTIVITY
SA	#4,5,6,7# 0.0003 (#4,5,6,7# crude extract, acceptor asialo-fetuin, pH
	7.1, 37°C <2>) <2>
SA	#5# 44.6 <1>
SA	#6# 28.3 (#6# 37°C <5>) <5>
SA	#6,7# 0.00435 (#6# 37°C <5>) <5,11>

TEMPERATURE_OPTIMUM
TO	#2# 25 (#2# broad <8>) <8>
TO	#3,4,5,6,7,9,10# 37 (#3,4,5,6,7,9,10# assay at
	<1,2,3,4,5,6,9,11,13,14,15>; #3# optimal activity at <6>)
	<1,2,3,4,5,6,9,11,13,14,15>
TO	#8# 22 (#8# assay at <12>) <12>

TEMPERATURE_RANGE
TR	#2# 17-38 (#2# about half-maximal activity at 17°C and 38°C <8>) <8>
TR	#3# 20-40 (#3# about half-maximal activity at 20°C and 40°C <6>) <6>

ACTIVATING_COMPOUND
AC	#1# more (#1# ST6 activity yield produced in Sf9 insect cells is higher
	as compared to bacterial cells <22>) <22>

INHIBITORS
IN	#2# PCMB (#2# weak <8>) <8>
IN	#3# dithioerythritol <6>
IN	#3,7# Ca2+ (#7# CaCl2, at 0.004 M: 30% inhibition, at 0.016 M: 60%
	inhibition <11>) <6,11>
IN	#5# CTP (#5# strong <7>; #5# competitive to CMP-NeuAc <1>) <1,7>
IN	#5# CMP (#5# less effective than CTP <7>) <7>
IN	#5# CDP (#5# less effective than CTP <7>) <7>
IN	#5# Antifreeze glycoprotein (#5# competitive to ovine submaxillary
	asialo-mucin, non-competitive to CMP-NeuAc <1>) <1>
IN	#5# Triton X-100 (#5# above critical micelle concentration of 0.016%,
	15% inhibition, reversible <1>) <1>
IN	#5,7# more (#5,7# not inhibited by EDTA <1,11>; #5,7# not inhibited by
	Mg2+ <1,11>; #7# not inhibited by native ovine submaxillary mucin <11>;
	#5# not inhibited by Zn2+, Mn2+ <1>) <1,11>

KI_VALUE
KI	#5# 0.92 {Antifreeze glycoprotein}  (#5# pH 6.5, 37°C <1>) <1>

METALS_IONS
ME	#3,5,7# more (#5# no metal ion requirement, e.g. Mn2+, Mg2+ or Zn2+
	<1>; #3# activity decreases with increasing divalent cation
	concentration <6>; #7# no divalent metal cation requirement <11>)
	<1,6,11>

MOLECULAR_WEIGHT
MW	#11# 54000 (#11# x * 54000, SDS-PAGE <23>) <23>
MW	#3# 65000 (#3# ST6, Western blotting <22>; #3# x * 65000, isoform
	ST6GalNAc-I, x * 39000, isoform ST6GalNAc-II, SDS-PAGE <17>) <17,22>
MW	#3# 104000 (#3# maltose-binding protein-ST6, Western blotting <22>) <22>
MW	#3# 39000 (#3# x * 65000, isoform ST6GalNAc-I, x * 39000, isoform
	ST6GalNAc-II, SDS-PAGE <17>) <17>
MW	#5# 160000 (#5# x * 160000, enzyme consists of several electrophoretic
	forms, 160 kDa: largest one, SDS-PAGE <1>) <1>
MW	#5# 100000-172000 (#5# enzyme exists in several active molecular weight
	forms from 100000-172000, gel filtration or PAGE <1>) <1>
MW	#6# 120000 (#6# x * 120000, SDS-PAGE <5>) <5>
MW	#9# 42000 (#9# x * 42000, predicted from the amino acid sequence <14>)
	<14>

POSTTRANSLATIONAL_MODIFICATION
PM	#3,9# more (#9# amino acid sequence of STM has a potential site for
	casein kinase II phosphorylation and 3 consensus motifs for
	N-glycosylation at positions Asn-85, Asn-130 and Asn-161 <14>; #3# no
	proteolytic cleavage at N-terminus of both isoform ST6GalNAc-I and
	ST6GalNAc-II <17>) <14,17>

SUBUNITS
SU	#3,5,6,9,11# ? (#11# x * 54000, SDS-PAGE <23>; #6# x * 120000, SDS-PAGE
	<5>; #5# x * 160000, enzyme consists of several electrophoretic forms,
	160 kDa: largest one, SDS-PAGE <1>; #9# x * 42000, predicted from the
	amino acid sequence <14>; #3# x * 65000, isoform ST6GalNAc-I, x *
	39000, isoform ST6GalNAc-II, SDS-PAGE <17>) <1,5,14,17,23>

APPLICATION
AP	#3# medicine (#3# St6GalNAc-II expression provides a prognostic factor
	for patient survival in human colorectal carcinomas, overexpression is
	related to poor patient survival <13>; #3# patients with IgA
	nephropathy display an aberrant glycosylation of IgA. EBV-immortalized
	IgA1-producing cells from these patients indicate a decrease in
	beta1,3-glucosyltransferase activity and an increase in
	N-acetylgalactosamine-specific alpha2,6-sialyltransferase activity,
	with concomitant increase in alpha2,6-sialyltransferase gene
	expression. EBV-immortalized cells from patients with lupus nephritis
	and healthy individuals do not produce IgA with the defective
	galactosylation pattern <21>; #3# sialylated histo-blood group
	carbohydrate CD175 is present in all hematopoietic cell lines and
	native lymphocytes examined. CD175 and sialylated CD175 are
	preferentially expressed on erythroblastic leukemia cell lines.
	Presence of sialylated CD175 is consistent with the expression of the
	gene encoding alpha2,6-sialyltransferase ST6GalNAc-1 <20>) <13,20,21>
AP	#3# synthesis (#3# use of glycan microarrays for high-throughput
	acceptor specificity screening of recombinant sialyltransferases. Donor
	substrate is cytidine 5-monophospho-N-acteylneuraminate, which has been
	biotinylated at position 9. human alpha2,6sialyltransferase-I also
	sialylates chitobiose structures including N-glycans <19>) <19>
AP	#3# biotechnology (#3# Escherichia coli system may be used as a
	starting point for the evolution of sialyltransferases with better
	expression characteristics or altered donor/acceptor specificities
	<22>) <22>

CLONED
CL	#1# (expressed in Sf9 insect cells) <22>
CL	#3# (ST6GalNAc-II cDNA is cloned, LS147T and SW-480 human colorectal
	carcinoma cells are transfected with human ST6GalNAc-II cDNA leading to
	an increased cell surface expression of Thomsen-Friedenreich-related
	blood group antigen TF, which depends in SW-480 cells on the ratio of
	core 2 beta-1,6-N-acetylglucosaminyltransferase and ST6GalNAc-II) <13>
CL	#3# (stable transfection of the breast cancer cell line MDA-MB-231 with
	ST6GalNAc I cDNA induces sialyl-Tn antigen expression, modifications of
	the O-glycosylation pattern of a MUC1-related recombinant protein
	secreted by MDA-MB-231 sialyl-Tn positive cells occurs, sialyl-Tn
	expression and concomitant changes in the overall O-glycan profiles
	induce a decrease of adhesion and an increase of migration of
	MDA-MB-231, overview) <18>
CL	#3# (overexpression in baculovirus system) <19>
CL	#3# (a codon-optimized gene encoding the catalytic domain of ST6 (amino
	acids Lys36-end) cloned into pTrc99a downstream from the tac promoter,
	FLAG tag and an octahistidine tag fused at the N- and C-termini,
	respectively. Catalytic domain of ST6 cloned into the high-copy number
	plasmid pCWin2MBP, which expresses an N-terminal fusion of ST6 with the
	Escherichia coli maltose-binding protein under the control of a dual
	tac promoter. Expression of soluble ST6 in a variety of Escherichia
	coli strains with oxidizing cytoplasm. Fusion of the ST6 enzyme to
	maltose-binding protein expressed in Origami 2 cells) <22>
CL	#3# (expressed in Sf9 insect cells or HEK-293T cells) <24>
CL	#9# (SIATL1 gene encoding STM is mapped to the long arm of chromosome
	17 at q23-qter, full-length cDNA from normal human mammary epithelial
	cell strain 76N is cloned, sequenced and encodes a protein of 374 amino
	acids, expression in COS-7 cells) <14>
CL	#10# (cDNA encoding the full-length hST6GalNAc-I from HT-29-MTX cells
	is cloned, stable transfection of MDA-MB-231 breast cancer cells
	expressing enzyme induces the expression of sialyl-Tn antigen at the
	cell surface associated with morphological changes, decreased growth
	and increased migration of the cells) <15>
CL	#11# (expressed in HEK-293 cells) <23>

PURIFICATION
PU	#1# <22>
PU	#3# (recombinant ST6GalNAc-II, immobilized metal-affinity
	chromatography) <13>
PU	#5# <5>
PU	#5# (partial) <7>
PU	#5# (solubilized with Triton X-100, CDP-agarose affinity
	chromatography, 117000fold) <1>
PU	#6# (solubilized with Triton X-100, CDP-agarose affinity
	chromatography, 4500fold) <5>
PU	#7# (partial, 44fold) <11>
PU	#11# (Ni-NTA agarose column chromatography) <23>

GENERAL_STABILITY
GS	#5# (50 mM NaCl stabilizes during purification) <1>
GS	#5# (glycerol, 50% w/v, stabilizes during storage) <1>
GS	#5# (glycerol, 25% w/v, stabilizes during purification) <3>
GS	#5,7# (bovine serum albumin, 1 mg/ml, stabilizes purified enzyme) <4>

PH_STABILITY
PHS	#5# 6-6.5 (#5# maximal stability <7>) <7>

STORAGE_STABILITY
SS	#5# (4°C, partially purified, at least 6 months) <7>
SS	#6# (-20°C, 10 mM sodium cacodylate, pH 6.5, 50 mM NaCl, 50% glycerol,
	0.02% NaN3, at least 6 months, stable) <5>
SS	#7# (frozen, crude preparation, at least 2 months, stable) <11>

TEMPERATURE_STABILITY
TS	#3# 4 (#3# t1/2: about 60 min <6>) <6>

REFERENCE
RF	<1> Sadler, J.E.; Rearick, J.I.; Hill, R.L.: Purification to
	homogeneity and enzymatic characterization of an
	alpha-N-acetylgalactosaminide alpha 2 leads to 6 sialyltransferase from
	porcine submaxillary glands. J. Biol. Chem. (1979) 254, 5934-5941.
	{Pubmed:447688}
RF	<2> Sherblom, A.P.; Bourassa, C.R.: Specificity of submaxillary gland
	sialyltransferases. Biochim. Biophys. Acta (1983) 761, 94-102.
	{Pubmed:6639963}
RF	<3> Beyer, T.A.; Rearick, J.I.; Paulson, J.C.; Prieels, J.P.; Sadler,
	J.E.; Hill, R.L.: Biosynthesis of mammalian glycoproteins.
	Glycosylation pathways in the synthesis of the nonreducing terminal
	sequences. J. Biol. Chem. (1979) 254, 12531-12541. {Pubmed:500730}
RF	<4> Bergh, M.L.E.; van den Eijnden, D.H.: Aglycon specificity of fetal
	calf liver and ovine and porcine submaxillary gland
	alpha-N-acetylgalactosaminide alpha 2 leads to 6 sialyltransferase.
	Eur. J. Biochem. (1983) 136, 113-118. {Pubmed:6617653}
RF	<5> Higa, H.H.; Paulson, J.C.: Sialylation of glycoprotein
	oligosaccharides with N-acetyl-, N-glycolyl-, and
	N-O-diacetylneuraminic acids. J. Biol. Chem. (1985) 260, 8838-8849.
	{Pubmed:4019457}
RF	<6> Bauvois, B.; Cacan, R.; Fournet, B.; Caen, J.; Montreuil, J.;
	Verbert, A.: Discrimination between activity of (alpha
	2-3)-sialyltransferase and (alpha 2-6)-sialyltransferase in human
	platelets using p-nitrophenyl-beta-D-galactoside as acceptor. Eur. J.
	Biochem. (1982) 121, 567-572. {Pubmed:7035171}
RF	<7> Sadler, J.E.; Rearick, J.I.; Paulson, J.C.; Hill, R.L.:
	Purification to homogeneity of a beta-galactoside alpha2 leads to 3
	sialyltransferase and partial purification of an
	alpha-N-acetylgalactosaminide alpha2 leads to 6 sialyltransferase from
	porcine submaxillary glands. J. Biol. Chem. (1979) 254, 4434-4443.
	{Pubmed:438196}
RF	<8> Gasnier, F.; Baubichon-Cortay, H.; Louisot, P.; Gateau-Roesch, O.:
	Sialylation processes in mitochondria: evidence for two distinct
	sialyltransferases located in the outer membrane. J. Biochem. (1991)
	110, 702-707. {Pubmed:1723730}
RF	<9> Bergh, M.L.E.; Koppen, P.L.; Van den Eijnden, D.H.: Specificity of
	ovine submaxillary-gland sialyltransferases. Application of
	high-pressure liquid chromatography in the identification of
	sialo-oligosaccharide products. Biochem. J. (1982) 201, 411-415.
	{Pubmed:7082299}
RF	<10> Gross, H.J.; Rose, U.; Krause, J.M.; Paulson, J.C.; Schmid, K.;
	Feeney, R.E.; Brossmer, R.: Transfer of synthetic sialic acid analogues
	to N- and O-linked glycoprotein glycans using four different mammalian
	sialyltransferases. Biochemistry (1989) 28, 7386-7392. {Pubmed:2510824}
RF	<11> Carlson, D.M.; McGuire, E.J.; Jourdian, G.W.; Roseman, S.: The
	sialic acids. XVI. Isolation of a mucin sialyltransferase from sheep
	submaxillary gland. J. Biol. Chem. (1973) 248, 5763-5773.
	{Pubmed:4723916}
RF	<12> Kitazume, S.; Kitajima, K.; Inoue, S.; Inoue, Y.; Troy, F.A.2nd.:
	Developmental expression of trout egg polysialoglycoproteins and the
	prerequisite alpha2,6-, and alpha2,8-sialyl and
	alpha2,8-polysialyltransferase activities required for their synthesis
	during oogenesis. J. Biol. Chem. (1994) 269, 10330-10340.
	{Pubmed:8144614}
RF	<13> Schneider, F.; Kemmner, W.; Haensch, W.; Franke, G.; Gretschel,
	S.; Karsten, U.; Schlag, P.M.: Overexpression of sialyltransferase
	CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-sialyltransferase is related
	to poor patient survival in human colorectal carcinomas. Cancer Res.
	(2001) 61, 4605-4611. {Pubmed:11389097}
RF	<14> Sotiropoulou, G.; Kono, M.; Anisowicz, A.; Stenman, G.; Tsuji, S.;
	Sager, R.: Identification and functional characterization of a human
	GalNAc alpha2,6-sialyltransferase with altered expression in breast
	cancer. Mol. Med. (2002) 8, 42-55. {Pubmed:11984005}
RF	<15> Julien, S.; Krzewinski-Recchi, M.A.; Harduin-Lepers, A.; Gouyer,
	V.; Huet, G.; Le Bourhis, X.; Delannoy, P.: Expression of sialyl-Tn
	antigen in breast cancer cells transfected with the human
	CMP-Neu5Ac:GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA.
	Glycoconjugate J. (2001) 18, 883-893. {Pubmed:}
RF	<16> Marcos, N.T.; Cruz, A.; Silva, F.; Almeida, R.; David, L.; Mandel,
	U.; Clausen, H.; von Mensdorff-Pouilly, S.; Reis, C.A.: Polypeptide
	GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I
	expression in gastric carcinoma cell lines. J. Histochem. Cytochem.
	(2003) 51, 761-771. {Pubmed:12754287}
RF	<17> Marcos, N.T.; Pinho, S.; Grandela, C.; Cruz, A.; Samyn-Petit, B.;
	Harduin-Lepers, A.; Almeida, R.; Silva, F.; Morais, V.; Costa, J.;
	Kihlberg, J.; Clausen, H.; Reis, C.A.: Role of the human ST6GalNAc-I
	and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn
	antigen. Cancer Res. (2004) 64, 7050-7057. {Pubmed:15466199}
RF	<18> Julien, S.; Adriaenssens, E.; Ottenberg, K.; Furlan, A.; Courtand,
	G.; Vercoutter-Edouart, A.S.; Hanisch, F.G.; Delannoy, P.; Le Bourhis,
	X.: ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly
	modifies their O-glycosylation pattern and enhances their
	tumourigenicity. Glycobiology (2006) 16, 54-64. {Pubmed:16135558}
RF	<19> Blixt, O.; Allin, K.; Bohorov, O.; Liu, X.; Andersson-Sand, H.;
	Hoffmann, J.; Razi, N.: Glycan microarrays for screening
	sialyltransferase specificities. Glycoconj. J. (2008) 25, 59-68.
	{Pubmed:17914671} (review)
RF	<20> Cao, Y.; Merling, A.; Karsten, U.; Goletz, S.; Punzel, M.; Kraft,
	R.; Butschak, G.; Schwartz-Albiez, R.: Expression of CD175 (Tn), CD175s
	(sialosyl-Tn) and CD176 (Thomsen-Friedenreich antigen) on malignant
	human hematopoietic cells. Int. J. Cancer (2008) 123, 89-99.
	{Pubmed:18398838}
RF	<21> Suzuki, H.; Moldoveanu, Z.; Hall, S.; Brown, R.; Vu, H.L.; Novak,
	L.; Julian, B.A.; Tomana, M.; Wyatt, R.J.; Edberg, J.C.; Alarcon, G.S.;
	Kimberly, R.P.; Tomino, Y.; Mestecky, J.; Novak, J.: IgA1-secreting
	cell lines from patients with IgA nephropathy produce aberrantly
	glycosylated IgA1. J. Clin. Invest. (2008) 118, 629-639.
	{Pubmed:18172551}
RF	<22> Skretas, G.; Carroll, S.; DeFrees, S.; Schwartz, M.F.; Johnson,
	K.F.; Georgiou, G.: Expression of active human sialyltransferase
	ST6GalNAcI in Escherichia coli. Microb. Cell Fact. (2009) 8, 50.
	{Pubmed:19788761}
RF	<23> Stuchlova Horynova, M.; Vrablikova, A.; Stewart, T.J.; Takahashi,
	K.; Czernekova, L.; Yamada, K.; Suzuki, H.; Julian, B.A.; Renfrow,
	M.B.; Novak, J.; Raska, M.: N-acetylgalactosaminide
	alpha2,6-sialyltransferase II is a candidate enzyme for sialylation of
	galactose-deficient IgA1, the key autoantigen in IgA nephropathy.
	Nephrol. Dial. Transplant. (2015) 30, 234-238. {Pubmed:25281698}
RF	<24> Takahashi, K.; Raska, M.; Horynova, M.; Hall, S.; Poulsen, K.;
	Kilian, M.; Hiki, Y.; Yuzawa, Y.; Moldoveanu, Z.; Julian, B.; Renfrow,
	M.; Novak, J.: Enzymatic sialylation of IgA1 O-glycans: Implications
	for studies of IgA nephropathy. PLoS ONE (2014) 9, e99026.
	{Pubmed:24918438}

ACTIVATING_COMPOUND
AC	#1# more (#1# ST6 activity yield produced in Sf9 insect cells is higher
	as compared to bacterial cells <22>) <22>

KI_VALUE
KI	#5# 0.92 {Antifreeze glycoprotein}  (#5# pH 6.5, 37°C <1>) <1>

KI_VALUE
KI	#5# 0.92 {Antifreeze glycoprotein}  (#5# pH 6.5, 37°C <1>) <1>

EXPRESSION
EXP	#3# up (#3# while wild-type Escherichia coli strain DHB4 produces very
	small amounts of soluble ST6, engineered strains of Escherichia coli
	(strains SMG96, FA113, MJF277.2, and DR611), which possess certain
	types of oxidative cytoplasm or which co-express specific molecular
	chaperones (DnaK/DnaJ, GroEL/GroES, and Skp), can result in significant
	yields of ST6. DR611 cells are able to produce dramatically increased
	amounts of soluble ST6. Fusion of the ST6 enzyme to maltose-binding
	protein results in a marked increase in the amount of soluble ST6 in
	Origami 2 cells, as well as in the DR611 strain <22>) <22>

///
ID	2.4.99.4
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Mus musculus   <6>
PR	#2# Homo sapiens   <1,3,4,10>
PR	#3# Rattus norvegicus   <11>
PR	#4# Pasteurella multocida   <2>
PR	#5# Rattus norvegicus Q11205 SwissProt <5>
PR	#6# Sus scrofa Q02745 SwissProt <7,8,9>

RECOMMENDED_NAME
RN	beta-galactoside alpha-2,3-sialyltransferase


SYSTEMATIC_NAME
SN	CMP-N-acetylneuraminate:beta-D-galactoside
	alpha-(2->3)-N-acetylneuraminyl-transferase


SYNONYMS
SY	 alpha2-->3 sialyltransferase
SY	 alpha 2,3-ST <Swissprot>
SY	 alpha3-SA-T
SY	 galbeta1,3galNAcalpha2,3-sialyltransferase
SY	 beta-galactoside alpha-2,3-sialyltransferase <Swissprot>
SY	 beta-D-Gal-(1-3)-D-GalNAc alpha-(2-3)-sialyltransferase
SY	 CMP-N-acetylneuraminate:beta-D-galactoside alpha2-3 sialyltransferase
SY	 CMP-Neu5Ac:Glbeta1-3GalNAc alpha2,3-sialyltransferase
SY	 CMP-NeuAc:galactoside(alpha2-3)-sialyltransferase
SY	 CMP-SA:Galbeta3GalNAc-R alpha3-sialyltransferase
SY	 CMP-sialic acid:Galbeta1-3GalNAc-R alpha3-sialyltransferase
SY	 Gal-NAc6S <Swissprot>
SY	 Gal-beta-1,3-GalNAc-alpha-2,3-sialyltransferase <Swissprot>
SY	 Galbeta1,3GalNAc alpha2,3-sialyltransferase
SY	 NeuAc alpha-2,3-sialyltransferase
SY	 sialyltransferase, cytidine
	monophosphoacetylneuraminate-beta-galactoside alpha2-->3-
SY	 SIATFL <Swissprot>
SY	 ST3Gal I
SY	 ST3GalA.1 <Swissprot>
SY	 ST3GalIA <Swissprot>
SY	 ST3O <Swissprot>
SY	#2# ST3Gal III (#2# isoform <3>) <1,3>
SY	#2# alpha3SA-T <10>
SY	#2# alpha-2,3-sialyltransferase <3>
SY	#2# beta-galactoside a-2,3-sialyltransferase <1>
SY	#2# St3gal <4>
SY	#2# beta-galactoside alpha2,3-sialyltransferase <4>
SY	#2# CMP-SA:Gal63GalNAc-R alpha3-sialyltransferase (SA to Gal) <10>
SY	#4# ST1 <2>
SY	#4# alpha2-3-sialyltransferase 1 (#4# multifunctional enzyme which has
	alpha2-6-sialyltransferase, alpha2-3-sialidase, and
	alpha2-3-trans-sialidase activities in addition to its major
	alpha2-3-sialyltransferase activity <2>) <2>
SY	#5# ST3Gal-II <5>
SY	#6# beta-D-galactoside alpha2->3 sialyltransferase <8>

REACTION
RE	CMP-N-acetylneuraminate +
	beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R = CMP +
	alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-alpha
	D-galactosaminyl-R

REACTION_TYPE
RT	glycosyl group transfer

SOURCE_TISSUE
ST	#1# Ehrlich ascites carcinoma cell <6>
ST	#2# lymphocyte (#2# T-lymphocytes, Epstein-Barr virus immortalized
	B-lymphocytes <10>) <10>
ST	#2# SKOV-3 cell (#2# expresses little ST3Gal III protein <1>) <1>
ST	#2# Capan-1 cell <3>
ST	#2# MDA-Panc-28 cell <3>
ST	#3# liver <11>
ST	#6# submandibular gland <7,8,9>

LOCALIZATION
LO	#1,6# Golgi apparatus <6,9>
LO	#6# membrane <7>

NATURAL_SUBSTRATE_PRODUCT
NSP	#2# CMP-N-acetylneuraminate +
	beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R = CMP +
	alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-alpha
	D-galactosaminyl-R (#2# the enzyme is involved in O-linked
	glycosylation pathway for synthesis of core 1 and core 2
	oligosaccharides <10>) <10>
NSP	#6# CMP-N-acetyl-beta-neuraminate + [antifreeze
	glycoprotein]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L-serine =
	CMP + [antifreeze
	glycoprotein]-(O-3-(alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha-D
	GalNAc-(1->)))-L-serine (#6# the enzyme specifically modifies
	glycoproteins and glycolipids which contain the sequence
	beta-D-Gal-(1->3)-beta-D-GalNAc to form the sequence
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc <8>) <8>
NSP	#6# CMP-N-acetyl-beta-neuraminate + [antifreeze
	glycoprotein]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L
	threonine = CMP + [antifreeze
	glycoprotein]-(O-3-(alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha-D
	GalNAc-(1->)))-L-threonine (#6# the enzyme specifically modifies
	glycoproteins and glycolipids which contain the sequence
	beta-D-Gal-(1->3)-beta-D-GalNAc to form the sequence
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc <8>) <8>
NSP	#6# CMP-N-acetyl-beta-neuraminate +
	[asialoglycoprotein]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L
	serine = CMP +
	[asialoglycoprotein]-(O-3-(alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha
	D-GalNAc-(1->)))-L-serine <8>
NSP	#6# CMP-N-acetyl-beta-neuraminate +
	[asialoglycoprotein]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L
	threonine = CMP +
	[asialoglycoprotein]-(O-3-(alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha
	D-GalNAc-(1->)))-L-threonine (#6# the enzyme specifically modifies
	glycoproteins and glycolipids which contain the sequence
	beta-D-Gal-(1->3)-beta-D-GalNAc to form the sequence
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc <8>) <8>

SUBSTRATE_PRODUCT
SP	#1# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-Gal-(1->3)-alpha-D-GalNAc = CMP + benzyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha-D-GalNAc <6>
SP	#2# CMP-N-acetylneuraminate +
	beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R = CMP +
	alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-alpha
	D-galactosaminyl-R (#2# the enzyme is involved in O-linked
	glycosylation pathway for synthesis of core 1 and core 2
	oligosaccharides <10>) <10>
SP	#2# CMP-N-acetylneuraminate + 4-nitrophenyl
	beta-D-Gal-(1->3)-alpha-D-GalNAc = CMP + 4-nitrophenyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha-D-GalNAc <10>
SP	#3# CMP-N-acetyl-beta-neuraminate + octyl
	beta-D-Gal-(1->3)-alpha-D-GalNAc = CMP + octyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha-D-GalNAc <11>
SP	#4# CMP-N-acetylneuraminate + 4-methylumbelliferyl
	4-O-beta-D-galactosyl-beta-D-glucoside = CMP + 4-methylumbelliferyl
	alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D
	glucoside (#4# best substrate, about 37% conversion <2>) {} <2>
SP	#4# CMP-N-acetylneuraminate + lactose = CMP +
	NeuAcalpha(2->3)Galbeta(1->4)Glc <2>
SP	#5# CMP +
	3-O-[alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha-D-GalNAc]-L-tyrosyl
	[protein] = CMP-N-acetyl-beta-neuraminate +
	3-O-[beta-D-Gal-(1->3)-alpha-D-GalNAc]-L-tyrosyl-[protein] (#5# the
	enzyme synthesizes CMP-NeuAc by transferring NeuAc from the
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha-D-GalNAc-unit of O-glycans
	<5>) {r} <5>
SP	#6# more = ? (#6# with glycoprotein and ganglioside acceptors the
	substrate specificity is strict, with the sequence
	beta-D-Gal-(1->3)-alpha-D-GalNAc serving as the exclusive acceptor. The
	enzyme has an equilibrium random order mechanism <8>) {} <8>
SP	#6# CMP-N-acetyl-beta-neuraminate + [antifreeze
	glycoprotein]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L-serine =
	CMP + [antifreeze
	glycoprotein]-(O-3-(alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha-D
	GalNAc-(1->)))-L-serine (#6# the enzyme specifically modifies
	glycoproteins and glycolipids which contain the sequence
	beta-D-Gal-(1->3)-beta-D-GalNAc to form the sequence
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc <8>) <8>
SP	#6# CMP-N-acetyl-beta-neuraminate + [antifreeze
	glycoprotein]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L
	threonine = CMP + [antifreeze
	glycoprotein]-(O-3-(alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha-D
	GalNAc-(1->)))-L-threonine (#6# the enzyme specifically modifies
	glycoproteins and glycolipids which contain the sequence
	beta-D-Gal-(1->3)-beta-D-GalNAc to form the sequence
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc <8>) <8>
SP	#6# CMP-N-acetyl-beta-neuraminate +
	[asialoglycoprotein]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L
	serine = CMP +
	[asialoglycoprotein]-(O-3-(alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha
	D-GalNAc-(1->)))-L-serine <8>
SP	#6# CMP-N-acetyl-beta-neuraminate +
	[asialoglycoprotein]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L
	threonine = CMP +
	[asialoglycoprotein]-(O-3-(alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha
	D-GalNAc-(1->)))-L-threonine (#6# the enzyme specifically modifies
	glycoproteins and glycolipids which contain the sequence
	beta-D-Gal-(1->3)-beta-D-GalNAc to form the sequence
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc <8>) <8>
SP	#6# CMP-N-acetyl-beta-neuraminate + [porcine submaxillary
	asialo-mucin]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L-serine =
	CMP + [porcine submaxillary
	asialo-mucin]-(O-3-(alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha-D
	GalNAc-(1->)))-L-serine <7>
SP	#6# CMP-N-acetyl-beta-neuraminate + [porcine submaxillary
	asialo-mucin]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L
	threonine = CMP + [porcine submaxillary
	asialo-mucin]-(O-3-(alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-alpha-D
	GalNAc-(1->)))-L-threonine <7>
SP	#6# CMP-N-acetylneuraminate + beta-D-Gal-(1->3)-beta-D-GalNAc = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc (#6# best acceptor
	substrate <8>) <8>

TURNOVER_NUMBER
TN	#4# 2-8 {4-methylumbelliferyl 4-O-beta-D-galactosyl-beta-D-glucoside} 
	(#4# mutant enzyme E271F, in Tris-HCl buffer (100 mM, pH 8.5), at 37°C
	<2>) <2>
TN	#4# 17 {4-methylumbelliferyl 4-O-beta-D-galactosyl-beta-D-glucoside} 
	(#4# mutant enzyme E271F/R313Y, in Tris-HCl buffer (100 mM, pH 8.5), at
	37°C <2>) <2>
TN	#4# 19 {CMP-N-acetylneuraminate}  (#4# mutant enzyme R313Y, in Tris-HCl
	buffer (100 mM, pH 8.5), at 37°C <2>) <2>
TN	#4# 19 {4-methylumbelliferyl 4-O-beta-D-galactosyl-beta-D-glucoside} 
	(#4# mutant enzyme R313Y, in Tris-HCl buffer (100 mM, pH 8.5), at 37°C
	<2>) <2>
TN	#4# 26 {CMP-N-acetylneuraminate}  (#4# mutant enzyme E271F, in Tris-HCl
	buffer (100 mM, pH 8.5), at 37°C <2>) <2>
TN	#4# 47 {4-methylumbelliferyl 4-O-beta-D-galactosyl-beta-D-glucoside} 
	(#4# wild type enzyme, in Tris-HCl buffer (100 mM, pH 8.5), at 37°C
	<2>) <2>
TN	#4# 23 {CMP-N-acetylneuraminate}  (#4# mutant enzyme E271F/R313Y, in
	Tris-HCl buffer (100 mM, pH 8.5), at 37°C <2>) <2>
TN	#4# 32 {CMP-N-acetylneuraminate}  (#4# wild type enzyme, in Tris-HCl
	buffer (100 mM, pH 8.5), at 37°C <2>) <2>

KM_VALUE
KM	#4# 0.18 {CMP-N-acetylneuraminate}  (#4# mutant enzyme E271F, in
	Tris-HCl buffer (100 mM, pH 8.5), at 37°C <2>) <2>
KM	#4# 0.67 {4-methylumbelliferyl 4-O-beta-D-galactosyl-beta-D-glucoside} 
	(#4# mutant enzyme R313Y, in Tris-HCl buffer (100 mM, pH 8.5), at 37°C
	<2>) <2>
KM	#4# 1.4 {4-methylumbelliferyl 4-O-beta-D-galactosyl-beta-D-glucoside} 
	(#4# wild type enzyme, in Tris-HCl buffer (100 mM, pH 8.5), at 37°C
	<2>) <2>
KM	#4# 0.54 {4-methylumbelliferyl 4-O-beta-D-galactosyl-beta-D-glucoside} 
	(#4# mutant enzyme E271F/R313Y, in Tris-HCl buffer (100 mM, pH 8.5), at
	37°C <2>) <2>
KM	#4# 0.62 {CMP-N-acetylneuraminate}  (#4# mutant enzyme R313Y, in
	Tris-HCl buffer (100 mM, pH 8.5), at 37°C <2>) <2>
KM	#4# 0.34 {CMP-N-acetylneuraminate}  (#4# mutant enzyme E271F/R313Y, in
	Tris-HCl buffer (100 mM, pH 8.5), at 37°C <2>) <2>
KM	#4# 0.71 {4-methylumbelliferyl 4-O-beta-D-galactosyl-beta-D-glucoside} 
	(#4# mutant enzyme E271F, in Tris-HCl buffer (100 mM, pH 8.5), at 37°C
	<2>) <2>
KM	#4# 0.44 {CMP-N-acetylneuraminate}  (#4# wild type enzyme, in Tris-HCl
	buffer (100 mM, pH 8.5), at 37°C <2>) <2>
KM	#6# 0.21 {beta-D-Gal-(1->3)-beta-D-GalNAc}  (#6# pH 6.5, 37°C, enzyme
	form B <8>) <8>
KM	#6# 0.2 {beta-D-Gal-(1->3)-beta-D-GalNAc}  (#6# pH 6.5, 37°C, enzyme
	form A <8>) <8>
KM	#6# 0.35 {[antifreeze
	glycoprotein]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L
	threonine}  (#6# pH 6.5, 37°C, enzyme form A <8>) <8>
KM	#6# 0.39 {[antifreeze
	glycoprotein]-(O-3-(beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->)))-L
	threonine}  (#6# pH 6.5, 37°C, enzyme form B <8>) <8>

PH_OPTIMUM
PHO	#2# 7 (#2# assay at <10>) <10>
PHO	#5# 4.8-6.4 (#5# formation of CMP-N-acetyl-beta-neuraminate from CMP
	<5>) <5>
PHO	#5# 5.2-7.2 (#5# direct sialylation using CMP-N-acetyl-beta-neuraminate
	<5>) <5>
PHO	#6# 6.5 (#6# assay at <8>) <8>

PH_RANGE
PHR	#4# 6-10 <2>

TEMPERATURE_OPTIMUM
TO	#6# 37 (#6# assay at <8>) <8>

ACTIVATING_COMPOUND
AC	#6# phospholipid/octylglucoside liposomes (#6# incorporation into
	phospholipid/octylglucoside liposomes activates enzyme form A <9>) <9>
AC	#6# lysophosphatidylcholine (#6# C16-18 acyl derivatives of
	lysophosphatidylcholine stimulate the activity of enzyme form A more
	extensively than the C14 acyl derivative, and the C12 acyl derivative
	is without effect on enzyme form A <9>) <9>
AC	#6# Triton X-100 (#6# stimulates activity of enzyme form A. Enzyme form
	B is fully active in absence of detergents. Detergents stimulate the
	activity of enzyme form A by lowering the KD and KM of
	CMP-N-acetylneuraminate and increasing the Vmax of the reaction <9>) <9>

INHIBITORS
IN	#2# more (#2# overexpression of N-acetylglucosaminyltransferase III
	significantly inhibits alpha2,3-sialylation <4>) <4>
IN	#5# Sodium citrate (#5# direct sialylation using
	CMP-N-acetyl-beta-neuraminate <5>) <5>
IN	#6# CMP (#6# less effective than CTP <7>) <7>
IN	#6# CDP (#6# less effective than CTP <7>) <7>
IN	#6# lysophosphatidylserine (#6# inhibition of enzyme form A <9>) <9>
IN	#6# lysophosphatidylglycerol (#6# inhibition of enzyme form A and B
	<9>) <9>
IN	#6# octyl-D-glucoside (#6# inhibition of enzyme form A and B <9>) <9>
IN	#6# CTP (#6# most potent inhibitor among cytidine nucleotides <7>) <7>

KI_VALUE
KI	#6# 0.00022 {CTP}  (#6# pH and temperature not specified in the
	publication <7>) <7>

MOLECULAR_WEIGHT
MW	#6# 50000 (#6# gel filtration, enzyme form A and B <7>; #6# gel
	filtrazion, enzyme form A and B <8>) <7,8>
MW	#6# 44000 (#6# enzyme form B <9>) <9>
MW	#6# 49000 (#6# enzyme form A <9>) <9>

APPLICATION
AP	#2# drug development (#2# ST3Gal III can serve as a therapeutic target
	of taxol therapy <1>) <1>
AP	#3,5# synthesis (#3# chemoenzymatic synthesis of sialylated
	oligosaccharides for their evaluation in a polysialyltransferase assay
	<11>; #5# the enzyme can be exploited for the enzymatic synthesis of
	diverse sialyl products <5>) <5,11>

ENGINEERING
EN	#4# E271F/R313Y (#4# the mutations do not affect
	alpha2-3-sialyltransferase activity <2>) <2>
EN	#4# E271F (#4# the mutation does not affect alpha2-3-sialyltransferase
	activity <2>) <2>
EN	#4# R313Y (#4# the mutation does not affect alpha2-3-sialyltransferase
	activity <2>) <2>

CLONED
CL	#2# (full-length ST3Gal III DNA fragment subcloned into the pEF6/V5-His
	TOPO expression vector. SKOV-3 cells transfected with ST3Gal III-EF6)
	<1>
CL	#4# (expressed in Escherichia coli BL21 (DE3) cells) <2>

PURIFICATION
PU	#4# (Ni2+-NTA column chromatography) <2>
PU	#6# <7,9>
PU	#6# (purification of enzyme form A and B) <8>

STORAGE_STABILITY
SS	#6# (-20°C, 50% (w/v) glycerol, 6 months, no loss of activity) <7>

REFERENCE
RF	<1> Huang, S.; Day, T.W.; Choi, M.R.; Safa, A.R.: Human
	beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated
	Taxol-induced apoptosis in ovarian cancer cells by downregulating
	caspase-8 activity. Mol. Cell. Biochem. (2009) 331, 81-88.
	{Pubmed:19415457}
RF	<2> Sugiarto, G.; Lau, K.; Li, Y.; Khedri, Z.; Yu, H.; Le, D.T.; Chen,
	X.: Decreasing the sialidase activity of multifunctional Pasteurella
	multocida alpha2-3-sialyltransferase 1 (PmST1) by site-directed
	mutagenesis. Mol. Biosyst. (2011) 7, 3021-3027. {Pubmed:21858283}
RF	<3> Perez-Garay, M.; Arteta, B.; Pages, L.; de Llorens, R.; de Bolos,
	C.; Vidal-Vanaclocha, F.; Peracaula, R.: alpha2,3-Sialyltransferase
	ST3Gal III modulates pancreatic cancer cell motility and adhesion in
	vitro and enhances its metastatic potential in vivo. PLoS ONE (2010) 5,
	e12524. {Pubmed:20824144}
RF	<4> Lu, J.; Isaji, T.; Im, S.; Fukuda, T.; Kameyama, A.; Gu, J.:
	Expression of N-acetylglucosaminyltransferase III suppresses
	alpha2,3-sialylation, and its distinctive functions in cell migration
	are attributed to alpha2,6-sialylation levels. J. Biol. Chem. (2016)
	291, 5708-5720. {Pubmed:26801611}
RF	<5> Chandrasekaran, E.V.; Xue, J.; Xia, J.; Locke, R.D.; Matta, K.L.;
	Neelamegham, S.:  Reversible sialylation	 synthesis of cytidine
	5-monophospho-N-acetylneuraminic acid from cytidine 5-monophosphate
	with alpha2,3-sialyl O-glycan-, glycolipid-, and macromolecule-based
	donors yields diverse sialylated products. Biochemistry (2008)  47, 
	320-330 . {Pubmed:18067323} (          )
RF	<6> Shigeta, S.; Winter, H.C.; Goldstein, I.J.:  alpha-(2->3)- and
	alpha-(2->6)-Sialyltransferase activities present in three variants of
	Ehrlich tumor cells	 identification of the products derived from
	N-acetyllactosamine and beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->O)-Bn.
	Carbohydr. Res. (1994)  264,  111-121 . {Pubmed:8001013} (          )
RF	<7> Sadler, J.E.; Rearick, J.I.; Paulson, J.C.; Hill, R.L.: 
	Purification to homogeneity of a beta-galactoside alpha2 leads to 3
	sialyltransferase and partial purification of an
	alpha-N-acetylgalactosaminide alpha2 leads to 6 sialyltransferase from
	porcine submaxillary glands. J. Biol. Chem. (1979)  254,  4434-4443 .
	{Pubmed:438196} (          )
RF	<8> Rearick, J.I.; Sadler, J.E.; Paulson, J.C.; Hill, R.L.:  Enzymatic
	characterization of beta D-galactoside alpha2 leads to 3
	sialyltransferase from porcine submaxillary gland. J. Biol. Chem.
	(1979)  254,  4444-4451 . {Pubmed:438198} (          )
RF	<9> Westcott, K.R.; Hill, R.L.:  Reconstitution of a porcine
	submaxillary gland beta-D-galactoside alpha 2-3 sialyltransferase into
	liposomes. J. Biol. Chem. (1985)  260,  13116-13121 . {Pubmed:4055734}
	(          )
RF	<10> Higgins, E.A.; Siminovitch, K.A.; Zhuang, D.; Brockhausen, I.;
	Dennis, J.W.:  Aberrant O-linked oligosaccharide biosynthesis in
	lymphocytes and platelets from patients with the Wiskott-Aldrich
	syndrome. J. Biol. Chem. (1991)  266,  6280-6290 . {Pubmed:2007580} (  
	       )
RF	<11> Sengupta, P.; Misra, A.K.; Suzuki, M.; Fukuda, M.; Hindsgaul, O.: 
	Chemoenzymatic synthesis of sialylated oligosaccharides for their
	evaluation in a polysialyltransferase assay. Tetrahedron Lett. (2003) 
	44,  6037-6042 . {Pubmed:} (          )

ACTIVATING_COMPOUND
AC	#6# phospholipid/octylglucoside liposomes (#6# incorporation into
	phospholipid/octylglucoside liposomes activates enzyme form A <9>) <9>
AC	#6# lysophosphatidylcholine (#6# C16-18 acyl derivatives of
	lysophosphatidylcholine stimulate the activity of enzyme form A more
	extensively than the C14 acyl derivative, and the C12 acyl derivative
	is without effect on enzyme form A <9>) <9>
AC	#6# Triton X-100 (#6# stimulates activity of enzyme form A. Enzyme form
	B is fully active in absence of detergents. Detergents stimulate the
	activity of enzyme form A by lowering the KD and KM of
	CMP-N-acetylneuraminate and increasing the Vmax of the reaction <9>) <9>

KI_VALUE
KI	#6# 0.00022 {CTP}  (#6# pH and temperature not specified in the
	publication <7>) <7>

KI_VALUE
KI	#6# 0.00022 {CTP}  (#6# pH and temperature not specified in the
	publication <7>) <7>

KCAT_KM_VALUE
KKM	#4# 30 (#4# mutant enzyme R313Y, in Tris-HCl buffer (100 mM, pH 8.5),
	at 37°C <2>) <2>
KKM	#4# 28 (#4# mutant enzyme R313Y, in Tris-HCl buffer (100 mM, pH 8.5),
	at 37°C <2>) <2>
KKM	#4# 69 (#4# mutant enzyme E271F/R313Y, in Tris-HCl buffer (100 mM, pH
	8.5), at 37°C <2>) <2>
KKM	#4# 140 (#4# mutant enzyme E271F, in Tris-HCl buffer (100 mM, pH 8.5),
	at 37°C <2>) <2>
KKM	#4# 32 (#4# mutant enzyme E271F/R313Y, in Tris-HCl buffer (100 mM, pH
	8.5), at 37°C <2>) <2>
KKM	#4# 39 (#4# mutant enzyme E271F, in Tris-HCl buffer (100 mM, pH 8.5),
	at 37°C <2>) <2>
KKM	#4# 34 (#4# wild type enzyme, in Tris-HCl buffer (100 mM, pH 8.5), at
	37°C <2>) <2>
KKM	#4# 73 (#4# wild type enzyme, in Tris-HCl buffer (100 mM, pH 8.5), at
	37°C <2>) <2>

EXPRESSION
EXP	#2# up (#2# taxol treatment upregulates ST3Gal III expression and
	forces expression of ST3Gal III attenuated taxol induced apoptosis.
	Taxol induces the expression of ST3Gal III by a post-transcriptional
	mechanism in SKOV-3 ovarian cancer cells <1>) <1>

///
ID	2.4.99.6
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Gallus gallus   <20,21>
PR	#2# Mus musculus   <2>
PR	#3# Homo sapiens   <4,6,11,16,20>
PR	#4# Rattus norvegicus   <5,7,8,10>
PR	#5# Bos taurus   <20>
PR	#6# Rattus norvegicus Q02734 SwissProt <24>
PR	#7# Mus musculus P97325 SwissProt <14,25,26>
PR	#8# myxoma virus Q9YJT3 UniProt <12>
PR	#9# Homo sapiens Q9Y2A9 SwissProt <27>
PR	#10# Photobacterium sp. JT-ISH-224 A8QYL0 SwissProt <19>
PR	#11# Photobacterium phosphoreum A5LHX0 UniProt <22>
PR	#12# Homo sapiens Q11206 SwissProt <3,15>
PR	#13# Mus musculus Q91Y74 SwissProt <9,14,25,26>
PR	#14# Pasteurella multocida Q15KI8 UniProt <1>
PR	#15# Helicobacter bizzozeronii   <17>
PR	#16# Homo sapiens Q11203 SwissProt <3>
PR	#17# Helicobacter acinonychis Q17WF9 SwissProt <13>
PR	#18# Vibrio sp. JT-FAJ-16 A8R0Y0 UniProt <18>
PR	#19# Gallus gallus A0A1D5NU03 UniProt <23>
PR	#20# Gallus gallus F1NQP1 UniProt <23>

RECOMMENDED_NAME
RN	N-acetyllactosaminide alpha-2,3-sialyltransferase


SYSTEMATIC_NAME
SN	CMP-N-acetyl-beta-neuraminate:beta-D-galactosyl-(1->4)-N-acetyl-btea-D
	glucosaminyl-R (2->3)-N-acetyl-alpha-neuraminyltransferase
	(configuration-inverting)


SYNONYMS
SY	 sialyltransferase
SY	 cytidine monophosphoacetylneuraminate-neolactotetraosylceramide
	sialyltransferase
SY	 sialyltransferase 3
SY	 SAT-3
SY	 sialyltransferase, cytidine
	monophosphoacetylneuraminate-beta-galactosyl(1-->4)acetylglucosaminide
	alpha2-->3-
SY	 cytidine
	monophosphoacetylneuraminate-beta-galactosyl(1-->4)acetylglucosaminide
	alpha2-->3-sialyltransferase
SY	 alpha2-->3 sialyltransferase
SY	 Gal beta-1,3(4) GlcNAc alpha-2,3 sialyltransferase
SY	 N-acetyllactosaminide alpha-2,3-sialyltransferase
SY	 ST3N
SY	#1,3,5# Galbeta(1->4)GlcNAc-R alpha(2->3)sialyltransferase <20>
SY	#12,13# ST3Gal IV <14,15,26>
SY	#12,13# ST3Gal-IV <3,9>
SY	#13# ST3Gal VI <25>
SY	#14# PmST1 <1>
SY	#15# GT-42 sialyltransferase <17>
SY	#15# Hb-ST2 <17>
SY	#16# ST3Gal-III <3>
SY	#17# HAC1267 <13>
SY	#19# ST3Gal3 <23>
SY	#20# St3gal6 <23>
SY	#3# Galbeta1->4GlcNAc-R alpha2->3-sialyltransferase <11>
SY	#3# CMP-NeuAc:Gal beta 1-4GlcNAc-R alpha(2-3)-sialyltransferase <16>
SY	#4# alpha2,3(N)ST <5>
SY	#4# alpha2,3(O)ST <5>
SY	#4# alpha2,3(N) sialyltransferase <5>
SY	#4# alpha2,3(O) sialyltransferase <5>
SY	#7,9# ST3Gal III <14,25,26,27>

REACTION
RE	CMP-N-acetylneuraminate +
	beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D
	galactosyl-(1->4)-D-glucosyl-(1<->1)-ceramide = CMP +
	alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta
	D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucosyl-(1<->1)
	ceramide
RE	CMP-N-acetyl-beta-neuraminate +
	beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-R = CMP +
	N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta
	D-glucosaminyl-R

REACTION_TYPE
RT	glycosyl group transfer

SOURCE_TISSUE
ST	#1,7,13# brain (#1# embryonic <20>; #1# 7- to 12-day old embryonic
	chicken brain <21>; #13# restricted expression: moderate in several
	thalamic nuclei and cerebellar Purkinje cell layer <25>; #7# widespread
	expression: high in olfactory bulb, hippocampal formation, red nuclei,
	pontine nuclei, and cerebellar Purkinje cell layer <25>) <14,20,21,25>
ST	#12# pancreas (#12# normal pancreas has around 40% less quantity of
	ST3Gal IV transcript compared to the positive tumour cell lines. The
	level of the ST3Gal III transcripts can not be associated with the
	degree of differentiation of the tumours from which the cell lines are
	derived <15>) <15>
ST	#12# adenocarcinoma cell (#12# Capan-1 cell, Panc-1 cell, MDAPanc-3
	cell, Capan-1 cell. The level of the ST3Gal III transcripts can not be
	associated with the degree of differentiation of the tumours from which
	the cell lines are derived <15>) <15>
ST	#12# PANC-1 cell <15>
ST	#12# MDA-Panc-3 cell <15>
ST	#13# lung <9>
ST	#13# salivary gland <9>
ST	#13,20# small intestine <9,23>
ST	#20# oviduct (#20# the expression level of ST3Gal6 in the magnum of the
	oviduct is almost a half that in the liver <23>) <23>
ST	#3# placenta <11,16,20>
ST	#3# blood platelet <6>
ST	#3# lymphocyte (#3# from peripheral blood mononuclear cells, enzyme
	level stimulated by phytohemagglutinin <4>) <4>
ST	#3,4,5,7,13,19,20# liver (#5# fetal, calf <20>; #19# expression of
	chicken ST3Gal3 is generally low in all the organs tested, although a
	certain level of expression is observed with ST3Gal3 in the liver <23>)
	<8,11,14,20,23>
ST	#4# commercial preparation (#4# recombinant enzyme expressed in
	Spodoptera frugiperda cells <7>) <5,7>
ST	#7# testis (#7# weak expression <14>) <14>
ST	#7# olfactory bulb (#7# high expression <25>) <25>
ST	#7# hippocampus (#7# high expression <25>) <25>
ST	#7,13# heart <14>
ST	#7,13# spleen <14>
ST	#7,13# colon <9,14>
ST	#7,13# thymus (#7# weak expression <14>) <14>
ST	#7,13,20# kidney <14,23>
ST	#9# MDA-Panc-28 cell <27>
ST	#9,12# Capan-1 cell <15,27>

LOCALIZATION
LO	#1,3,19,20# Golgi membrane <4,21,23>
LO	#13# Golgi apparatus <9>

SUBSTRATE_PRODUCT
SP	#1# CMP-N-acetyl-beta-neuraminate +
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<
	>1)-ceramide = CMP + ganglioside LM1 (#1# i.e.
	neolactotetraosylceramide <21>) <21>
SP	#1,3,5# CMP-N-acetyl-beta-neuraminate + beta-D-Gal-(1->4)-alpha-D-Glc =
	CMP + alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-alpha-D-Glc (#1,3,5# i.e.
	lactose <20>) <20>
SP	#1,3,5# CMP-N-acetyl-beta-neuraminate +
	beta-D-Gal-(1->4)-beta-D-GlcNAc-R = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-R (#1,3,5#
	asialo-alpha1-acid glycoprotein <20>; #3# the enzyme prefers type 2
	chain (Gal beta 1-4GlcNAc) over type 1 chain (Gal beta 1-3GlcNAc)
	acceptors. Oligosaccharides and glycopeptides are better acceptor
	substrates than glycoproteins. Of the branched oligosaccharides, those
	with a bisected N-acetylglucosamine (GlcNAc) structure appear to be
	poorer substrates, while triantennary structures containing a
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->4)-alpha-Man-(1->3)-beta-D-Man
	branch are preferred <16>) <16,20>
SP	#1,3,5,6,7,10,11,13,18# CMP-N-acetyl-beta-neuraminate +
	beta-D-Gal-(1->4)-beta-D-GlcNAc = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc (#1,3,5# i.e.
	N-acetyllactosamine <20>; #11# 103% of the activity with
	beta-D-Gal-(1->4)-beta-D-Glc, truncated recombinant enzyme <22>; #18#
	127% of the activity with beta-D-Gal-(1->4)-beta-D-Glc, recombinant
	enzyme <18>; #10# 96% of the activity with
	beta-D-Gal-(1->4)-beta-D-Glc, recombinant enzyme <19>; #13# relative
	Vmax is 2:5:1 for beta-D-Gal-(1->3)-beta-D-GlcNAc,
	beta-D-Gal-(1->4)-beta-D-GlcNAc and beta-D-Gal-(1->3)-beta-D-GalNAc,
	respectively <14>; #7# relative Vmax is 4:2:1 for
	beta-D-Gal-(1->3)-beta-D-GlcNAc, beta-D-Gal-(1->4)-beta-D-GlcNAc and
	beta-D-Gal-(1->3)-beta-D-GalNAc as substrate, respectively <14>; #6#
	the recombinant enzyme transfers sialyl residues to
	beta-D-Gal-(1->3)-beta-D-GlcNAc as well as to
	beta-D-Gal-(1->4)-beta-D-GlcNAc partial structures in gangliosides
	<24>) <14,18,19,20,22,24>
SP	#10,11,18# CMP-N-acetyl-beta-neuraminate + beta-D-Gal-(1->4)-beta-D-Glc
	= CMP + alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc <18,19,22>
SP	#10,18# CMP-N-acetyl-beta-neuraminate + beta-D-N-acetylgalactosamine =
	CMP + alpha-Neu5Ac-(2->3)-beta-D-GalNAc (#18# 58% of the activity with
	beta-D-Gal-(1->4)-beta-D-Glc, recombinant enzyme <18>; #10# 76% of the
	activity with beta-D-Gal-(1->4)-beta-D-Glc, recombinant enzyme <19>)
	<18,19>
SP	#10,18# CMP-N-acetyl-beta-neuraminate + methyl
	beta-D-Gal-(1->3)-beta-D-GlcNAc = CMP + methyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc (#18# 124% of the
	activity with beta-D-Gal-(1->4)-beta-D-Glc, recombinant enzyme <18>;
	#10# 192% of the activity with beta-D-Gal-(1->4)-beta-D-Glc,
	recombinant enzyme <19>) <18,19>
SP	#10,18# CMP-N-acetyl-beta-neuraminate + methyl beta-D-galactopyranoside
	= CMP + methyl alpha-Neu5Ac-(2->3)-beta-D-galactopyranoside (#18# 114%
	of the activity with beta-D-Gal-(1->4)-beta-D-Glc, recombinant enzyme
	<18>; #10# 343% of the activity with beta-D-Gal-(1->4)-beta-D-Glc,
	recombinant enzyme <19>) <18,19>
SP	#11# CMP-N-acetyl-beta-neuraminate + beta-D-mannopyranoside = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Man (#11# 43% of the activity with
	beta-D-Gal-(1->4)-beta-D-Glc, truncated recombinant enzyme <22>) <22>
SP	#11# CMP-N-acetyl-beta-neuraminate + methyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc = CMP + methyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc (#11# 129% of the
	activity with beta-D-Gal-(1->4)-beta-D-Glc, truncated recombinant
	enzyme <22>) <22>
SP	#11# CMP-N-acetyl-beta-neuraminate + methyl beta-D-galactopyranoside =
	CMP + methyl alpha-Neu5Ac-(2->3)-beta-D-Gal (#11# 251% of the activity
	with beta-D-Gal-(1->4)-beta-D-Glc, truncated recombinant enzyme <22>)
	<22>
SP	#11# CMP-N-acetyl-beta-neuraminate + methyl beta-D-glucopyranoside =
	CMP + methyl alpha-Neu5Ac-(2->3)-beta-D-Glc (#11# 33% of the activity
	with beta-D-Gal-(1->4)-beta-D-Glc, truncated recombinant enzyme <22>)
	<22>
SP	#11,18# CMP-N-acetyl-beta-neuraminate + beta-D-N-acetylglucosamine =
	CMP + alpha-Neu5Ac-(2->3)-beta-D-GlcNAc (#11# 40% of the activity with
	beta-D-Gal-(1->4)-beta-D-Glc, truncated recombinant enzyme <22>; #18#
	55% of the activity with beta-D-Gal-(1->4)-beta-D-Glc, recombinant
	enzyme <18>) <18,22>
SP	#11,18# CMP-N-acetyl-beta-neuraminate + methyl beta-D-mannopyranoside =
	CMP + methyl alpha-Neu5Ac-(2->3)-beta-D-Man (#18# 57% of the activity
	with beta-D-Gal-(1->4)-beta-D-Glc, recombinant enzyme <18>; #11# 63% of
	the activity with beta-D-Gal-(1->4)-beta-D-Glc, truncated recombinant
	enzyme <22>) <18,22>
SP	#12# CMP-N-acetyl-beta-neuraminate +
	beta-D-Gal-(1->4)-beta-D-GlcNAc-[protein] = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-[protein] <15>
SP	#12,16# CMP-N-acetyl-beta-neuraminate + 4-nitrophenyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc
	= CMP + 4-nitrophenyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal
	(1->4)-beta-D-GlcNAc (#16# conversion at 15.2% compared to activity
	with benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[4-deoxy-4-fluoro-beta-D-Gal-(1
	>3)]-beta-D-GalNAc <3>; #12# conversion at 20.87% compared to activity
	with benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[4-deoxy-4-fluoro-beta-D-Gal-(1
	>3)]-beta-D-GalNAc <3>) <3>
SP	#12,16# CMP-N-acetyl-beta-neuraminate + 4-nitrophenyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal = CMP + 4-nitrophenyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal
	(#16# conversion at 16.8% compared to activity with benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[4-deoxy-4-fluoro-beta-D-Gal-(1
	>3)]-beta-D-GalNAc <3>; #12# conversion at 79.5% compared to activity
	with benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[4-deoxy-4-fluoro-beta-D-Gal-(1
	>3)]-beta-D-GalNAc <3>) <3>
SP	#12,16# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-(4-O-Me)Gal-(1->4)-beta-D-GlcNAc = CMP + benzyl
	alpha-Neu5Ac-(2->3)-beta-D-(4-O-Me)Gal-(1->4)-beta-D-GlcNAc (#16#
	conversion at 15.6% compared to activity with benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[4-deoxy-4-fluoro-beta-D-Gal-(1
	>3)]-beta-D-GalNAc <3>; #12# conversion at 66.97% compared to activity
	with benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[4-deoxy-4-fluoro-beta-D-Gal-(1
	>3)]-beta-D-GalNAc <3>) <3>
SP	#12,16# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[4-deoxy-4-fluoro-beta-D-Gal-(1
	>3)]-beta-D-GalNAc = CMP + benzyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[4-deoxy-4
	fluoro-beta-D-Gal-(1->3)]-beta-D-GalNAc <3>
SP	#13# CMP-N-acetyl-beta-neuraminate + beta-D-Gal-(1->3)-beta-D-GlcNAc =
	CMP + alpha-Neu5Ac-(2->3)-beta-D-Glc-(1->3)-beta-D-GalNAc (#13#
	relative Vmax is 2:5:1 for beta-D-Gal-(1->3)-beta-D-GlcNAc,
	beta-D-Gal-(1->4)-beta-D-GlcNAc and beta-D-Gal-(1->3)-beta-D-GalNAc,
	respectively <14>) <14>
SP	#14# CMP-N-acetyl-beta-neuraminate + 4-methylumbelliferyl
	beta-lactoside = CMP + alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc
	<1>
SP	#14# CMP-N-acetyl-beta-neuraminate + 4-methylumbelliferyl beta-Lewis x
	= CMP + 4-methylumbelliferyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D
	GlcNAc <1>
SP	#14# CMP-N-acetyl-beta-neuraminate +
	beta-D-Gal-(1->4)-[alpha-D-Fuc-(1->3)]-beta-D-GlcNAc-[protein] = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-D-Fuc-(1->3)]-beta-D
	GlcNAc-[protein] (#14# i.e. Lewis x epitope <1>) <1>
SP	#15# CMP-N-acetyl-beta-neuraminate + beta-D-Gal-(1->4)-beta-D-GlcNAc =
	CMP + alpha-NeuAc-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNA (#15# i.e.
	N-acetyllactosamine. Sialyltransferase Hb-ST2 shows monofunctional
	alpha2,3-sialyltransferase activity with a strong preference for
	N-acetyllactosamine over lactose and very low levels of activity on
	3-linked Gal. No 2,8-sialyltransferase activity <17>) <17>
SP	#15# CMP-N-acetyl-beta-neuraminate + FCHASE
	beta-D-Gal-(1->4)-beta-D-GlcNAc = CMP + FCHASE
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc <17>
SP	#17# CMP-N-acetylneuraminate + beta-D-Gal-(1->3)-beta-D-GlcNAc = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GlcNAc (#17# about 25% of
	the activity with beta-D-Gal-(1->4)-beta-D-GlcNAc <13>) <13>
SP	#17# CMP-N-acetylneuraminate + beta-D-Gal-(1->4)-beta-D-Glc = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc (#17# about 10% of the
	activity with beta-D-Gal-(1->4)-beta-D-GlcNAc <13>) <13>
SP	#18# CMP-N-acetyl-beta-neuraminate + methyl beta-D-glucopyranoside =
	CMP + methyl alpha-Neu5Ac-(2->3)-beta-D-glucopyranoside (#18# 52% of
	the activity with beta-D-Gal-(1->4)-beta-D-Glc, recombinant enzyme
	<18>) <18>
SP	#19# CMP-N-acetyl-beta-neuraminate + beta-D-Gal-(1->3)-beta-D-GlcNAc =
	CMP + alphaNeuAc-(2->3)-beta-D-Gal-(1->3)-beta-D-GlcNA (#19# activity
	with beta-D-Gal-(1->3)-beta-D-GlcNAc is higher than activity with
	beta-D-Gal-(1->4)-beta-D-GlcNAc <23>) <23>
SP	#19# CMP-N-acetyl-beta-neuraminate + beta-D-Gal-(1->4)-beta-D-GlcNAc =
	CMP + alphaNeuAc-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNA (#19# activity
	with beta-D-Gal-(1->3)-beta-D-GlcNAc is higher than activity with
	beta-D-Gal-(1->4)-beta-D-GlcNAc <23>) <23>
SP	#20# CMP-N-acetyl-beta-neuraminate + beta-D-Gal-(1->3)-beta-GlcNAc =
	CMP + alphaNeuAc-(2->3)-beta-D-Gal-(1->3)-beta-D-GlcNA (#20# activity
	with beta-D-Gal-(1->4)-beta-D-GlcNAc is higher than activity with
	beta-D-Gal-(1->3)-beta-D-GlcNAc <23>) <23>
SP	#20# CMP-N-acetyl-beta-neuraminate + beta-D-Gal-(1->4)-beta-D-GlcNAc =
	CMP + alphaNeuAc-(2->3)-beta-Gal-(1->4)-beta-GlcNA (#20# activity with
	beta-D-Gal-(1->4)-beta-D-GlcNAc is higher than activity with
	beta-Gal-(1->3)-beta-GlcNAc <23>) <23>
SP	#3# CMP-N-acetyl-beta-neuraminate +
	beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-ceramide = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-ceramide (#3#
	i.e. lactosylceramide <4>) <4>
SP	#3# CMP-N-acetyl-beta-neuraminate +
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)-beta-D-Man-(1
	>4)-beta-D-GlNAc = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man
	(1->6)-beta-D-Man-(1->4)-beta-D-GlNAc <11>
SP	#3,8# CMP-N-acetylneuraminate + beta-D-Gal-(1->4)-beta-D-GalNAc-R = CMP
	+ alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GalNAc-R (#3,8# type II
	disaccharides are preferred substrates <6,12>) <6,12>
SP	#4# CMP-N-acetyl-beta-neuraminate + 4-methylumbelliferyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc = CMP + 4-methylumbelliferyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc <8>
SP	#4# CMP-N-acetyl-beta-neuraminate + ally
	beta-D-Gal-(1->4)-beta-D-GlcNAc = CMP + allyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc (#4# alpha2,3(N)
	sialyltransferase. 4.7.2% of the activity compared to benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc, alpha2,3(O) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-(3-F)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]-alpha-D
	GalNAc = CMP + benzyl
	alpha-Neu5Ac-(2->3)-beta-D-(3-F)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D
	Gal-(1->3)]-alpha-D-GalNAc (#4# 7.2% of the activity compared to mucin
	core 2-based compound benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-(3-O-Me)Gal-(1->3)-alpha
	D-GalNAc, alpha2,3(N) sialyltransferase. 102.9% of the activity
	compared to mucin core 2-based compound benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc, alpha2,3(O) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc = CMP + benzy
	alpha-Neu5Ac-(2->3)-beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)
	[beta-D-Gal-(1->3)]-alpha-D-GalNAc (#4# 4.5% of the activity compared
	to mucin core 2-based compound benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-(3-O-Me)Gal-(1->3)-alpha
	D-GalNAc, alpha2,3(N) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc = CMP + benzyl
	alpha-Neu5Ac-(2->3)-beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)
	[beta-D-Gal-(1->3)]-alpha-D-GalNAc (#4# alpha2,3(O) sialyltransferase.
	50.8% of the activity compared to ally beta-D-Gal-(1->4)-beta-D-GlcNAc,
	alpha2,3(N) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-(4-O-Me)Gal-beta-D-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1
	>3)]-alpha-D-GalNAc = CMP + benzyl
	alpha-Neu5Ac-(2->3)-beta-D-(4-O-Me)Gal-beta-D-(1->4)-beta-D-GlcNAc-(1
	>6)-[beta-D-Gal-(1->3)]-alpha-D-GalNAc (#4# 99.8% of the activity
	compared to mucin core 2-based compound benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-(3-O-Me)Gal-(1->3)-alpha
	D-GalNAc, alpha2,3(N) sialyltransferase. 103% of the activity compared
	to mucin core 2-based compound benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc, alpha2,3(O) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-(4-O-Me)Gal-beta-D-(1->3)-alpha
	D-GalNAc = CMP + benzyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-(4-O-Me)Gal
	beta-D-(1->3)-alpha-D-GalNAc (#4# 100.6% of the activity compared to
	mucin core 2-based compound benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-(3-O-Me)Gal-(1->3)-alpha
	D-GalNAc, alpha2,3(N) sialyltransferase. 101.3% of the activity
	compared to mucin core 2-based compound benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc, alpha2,3(O) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-(3-F)Gal-(1->3)-alpha-D
	GalNAc = CMP + benzyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-(3
	F)Gal-(1->3)-alpha-D-GalNAc (#4# 96.9% of the activity compared to
	mucin core 2-based compound benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-(3-O-Me)Gal-(1->3)-alpha
	D-GalNAc, alpha2,3(N) sialyltransferase. 77.2% of the activity compared
	to mucin core 2-based compound benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc, alpha2,3(O) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-(3-O-Me)Gal-(1->3)-alpha
	D-GalNAc = CMP + benzyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-(3-O
	Me)Gal-(1->3)-alpha-D-GalNAc (#4# 49.6% of the activity compared to
	mucin core 2-based compound benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc, alpha2,3(N) sialyltransferase <5>; #4# 95.3% of the
	activity compared to ally beta-D-Gal-(1->4)-beta-D-GlcNAc, alpha2,3(N)
	sialyltransferase. 49.6% of the activity compared to benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc, alpha2,3(O) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]-alpha-GalNAc
	= CMP + benzyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal
	(1->3)]-alpha-GalNAc (#4# 101% of the activity compared to ally
	beta-D-Gal-(1->4)-beta-D-GlcNAc, alpha2,3(N) sialyltransferase. 94.4%
	of the activity compared to benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc, alpha2,3(O) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate + benzyl
	beta-D-Gal-(1->4)-[alpha-D-Fuc-(1->3)]-beta-D-GlcNAc-(1->6)-[alpha
	NeuAc-(2->3)-beta-D-Gal-(1->3)]-alpha-D-GalNAc = CMP + benzyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-D-Fuc-(1->3)]-beta-D
	GlcNAc-(1->6)-[alpha-NeuAc-(2->3)-beta-D-Gal-(1->3)]-alpha-D-GalNAc
	(#4# 27.1% of the activity compared to ally
	beta-D-Gal-(1->4)-beta-D-GlcNAc, alpha2,3(N) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate +
	beta-D-(2-O-Me)Gal-(1->4)-beta-D-GlcNAc = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-(2-O-Me)Gal-(1->4)-beta-D-GlcNAc (#4# 60% of
	the activity compared to ally beta-D-Gal-(1->4)-beta-D-GlcNAc,
	alpha2,3(N) sialyltransferase. 0.2% of the activity compared to benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc, alpha2,3(O) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate +
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-Gal-(1->3)-alpha-D-GalNAc
	R = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-Gal
	(1->3)-alpha-D-GalNAc-R <10>
SP	#4# CMP-N-acetyl-beta-neuraminate + beta-D-Gal-(1->4)-N-GlcNAc-R = CMP
	+ alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-N-GlcNAc-R {} <10>
SP	#4# CMP-N-acetyl-beta-neuraminate + methyl
	beta-D-Gal-(1->4)-beta-D-(6-O-sulfo)GlcNAc-(1->6)-[alphaNeu5Ac-(2->3)
	beta-D-Gal-(1->3)]-alpha-GalNAc = CMP + methyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-(6-O-sulfo)GlcNAc-(1->6)
	[alphaNeu5Ac-(2->3)-beta-D-Gal-(1->3)]-alpha-GalNAc (#4# 50.8% of the
	activity compared to ally beta-D-Gal-(1->4)-beta-D-GlcNAc, alpha2,3(N)
	sialyltransferase <5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate + methyl
	beta-D-Gal-(1->4)-beta-D-(6-O-sulfo)GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc = CMP + methyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-(6-O-sulfo)GlcNAc-(1->6)
	[beta-D-Gal-(1->3)]-alpha-D-GalNAc (#4# 28.1% of the activity compared
	to ally beta-D-Gal-(1->4)-beta-D-GlcNAc, alpha2,3(N) sialyltransferase
	<5>) <5>
SP	#4# CMP-N-acetyl-beta-neuraminate + methyl
	beta-D-Gal-(1->4)-[alpha-D-Fuc-(1->3)]-beta-D-GlcNAc-(1->6)-[beta-D-Gal
	(1->3)]-alpha-D-GalNAc = CMP + methyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-D-Fuc-(1->3)]-beta-D
	GlcNAc-(1->6)-[beta-D-Gal-(1->3)]-alpha-D-GalNAc (#4# 19% of the
	activity compared to ally beta-D-Gal-(1->4)-beta-D-GlcNAc, alpha2,3(N)
	sialyltransferase. 133.4% of the activity compared to benzyl
	beta-D-(3-O-Me)Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]
	alpha-D-GalNAc, alpha2,3(O) sialyltransferase <5>) <5>
SP	#4# CMP-N-acetylneuraminate + beta-D-Gal-(1->4)-beta-D-Glc-R = CMP +
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-R (#4# artificial
	glycopolypeptides carrying beta-D-Gal-(1->4)-beta-D-GlcNAc and
	beta-D-Gal-(1->4)-beta-D-Glc are further converted to
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc and
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc sialyloligosaccharides
	<7>) <7>
SP	#4,8,13# CMP-N-acetylneuraminate + beta-D-Gal-(1->4)-beta-D-GlcNAc-R =
	CMP + alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-R (#8# broad
	substrate specificity, the viral enzyme utilizes disaccharides type
	I-III and also fucosylated Lewis a and Lewis x <12>; #4# artificial
	glycopolypeptides carrying beta-D-Gal-(1->4)-beta-D-GlcNAc and
	beta-D-Gal-(1->4)-beta-D-Glc are further converted to
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc and
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc sialyloligosaccharides
	<7>; #13# the alpha-2,3-sialyltransferase ST3Gal-IV can sialylate the
	type II glycan chains (beta-D-Gal-(1->4)-beta-D-GlcNAc) that are part
	of the glycan linkages of sialyl Lewis X <9>) <7,9,12>
SP	#8# CMP-N-acetyl-beta-neuraminate + 8-methoxy-8-oxooctyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc = CMP + 8-methoxy-8-oxooctyl
	alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc <12>
SP	#8,17# CMP-N-acetylneuraminate + beta-D-Gal-(1->4)-beta-D-GlcNAc = CMP
	+ alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc (#8# i.e.
	N-acetyllactosamine <12>) <12,13>

TURNOVER_NUMBER
TN	#14# 0.55 {CMP-N-acetyl-beta-neuraminate}  (#14# wild type enzyme,
	using 4-methylumbelliferyl beta-Lewis x as cosubstrate, in Tris-HCl
	buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 2.1 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme H311A, in
	Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 21 {4-methylumbelliferyl beta-lactoside}  (#14# mutant enzyme
	M144H, in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 21 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144H,
	using 4-methylumbelliferyl beta-lactoside as cosubstrate, in Tris-HCl
	buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 22 {4-methylumbelliferyl beta-lactoside}  (#14# mutant enzyme
	M144D, in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 27 {CMP-N-acetyl-beta-neuraminate}  (#14# wild type enzyme, in
	Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 0.59 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144D,
	using 4-methylumbelliferyl beta-Lewis x as cosubstrate, in Tris-HCl
	buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 4 {4-methylumbelliferyl beta-Lewis x}  (#14# mutant enzyme M144D,
	in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 6.5 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144D, in
	Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 1.9 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144D,
	using 4-methylumbelliferyl beta-lactoside as cosubstrate, in Tris-HCl
	buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 0.025 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme D141A,
	in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 47 {4-methylumbelliferyl beta-lactoside}  (#14# wild type enzyme,
	in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 6.7 {4-methylumbelliferyl beta-Lewis x}  (#14# wild type enzyme,
	in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 32 {CMP-N-acetyl-beta-neuraminate}  (#14# wild type enzyme, using
	4-methylumbelliferyl beta-lactoside as cosubstrate, in Tris-HCl buffer
	(200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 8.4 {4-methylumbelliferyl beta-Lewis x}  (#14# mutant enzyme
	M144H, in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 0.93 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144H,
	using 4-methylumbelliferyl beta-Lewis x as cosubstrate, in Tris-HCl
	buffer (200 mM, pH 8.5), at 37°C <1>) <1>
TN	#14# 71 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144H, in
	Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>

KM_VALUE
KM	#1# 0.5
	{beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc
	(1<->1)-ceramide}  (#1# pH 6.4, 37°C <21>) <21>
KM	#10# 31 {beta-D-Gal-(1->4)-beta-D-Glc}  (#10# pH 6.0, 30°C <19>) <19>
KM	#10# 99 {methyl beta-D-galactopyranoside}  (#10# pH 6.0, 30°C <19>)
	<19>
KM	#11# 0.05 {CMP-N-acetyl-beta-neuraminate}  (#11# pH 6.0, 25°C <22>)
	<22>
KM	#11# 1.7 {beta-D-Gal-(1->4)-beta-D-Glc}  (#11# pH 6.0, 25°C <22>) <22>
KM	#11# 2.5 {beta-D-Gal-(1->4)-beta-D-GlcNAc}  (#11# pH 6.0, 25°C <22>)
	<22>
KM	#12# 0.14 {4-nitrophenyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal}  (#12# pH and
	temperature not specified in the publication <3>) <3>
KM	#13# 0.22 {beta-D-Gal-(1->4)-beta-D-GlcNAc}  (#13# pH 6.4, 37°C <14>)
	<14>
KM	#13# 0.75 {beta-D-Gal-(1->3)-beta-D-GlcNAc}  (#13# pH 6.4, 37°C <14>)
	<14>
KM	#14# 0.3 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144D,
	using 4-methylumbelliferyl beta-lactoside as cosubstrate, in Tris-HCl
	buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 0.4 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144H,
	using 4-methylumbelliferyl beta-Lewis x as cosubstrate, in Tris-HCl
	buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 1.4 {4-methylumbelliferyl beta-lactoside}  (#14# wild type enzyme,
	in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 1.4 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme D141A, in
	Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 1.8 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme H311A, in
	Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 1.5 {CMP-N-acetyl-beta-neuraminate}  (#14# wild type enzyme, in
	Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 0.81 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144H,
	using 4-methylumbelliferyl beta-lactoside as cosubstrate, in Tris-HCl
	buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 0.39 {CMP-N-acetyl-beta-neuraminate}  (#14# wild type enzyme,
	using 4-methylumbelliferyl beta-Lewis x as cosubstrate, in Tris-HCl
	buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 2.1 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144D,
	using 4-methylumbelliferyl beta-Lewis x as cosubstrate, in Tris-HCl
	buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 12 {4-methylumbelliferyl beta-lactoside}  (#14# mutant enzyme
	M144D, in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 17 {4-methylumbelliferyl beta-Lewis x}  (#14# wild type enzyme, in
	Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 0.44 {CMP-N-acetyl-beta-neuraminate}  (#14# wild type enzyme,
	using 4-methylumbelliferyl beta-lactoside as cosubstrate, in Tris-HCl
	buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 13 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144H, in
	Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 13 {4-methylumbelliferyl beta-Lewis x}  (#14# mutant enzyme M144D,
	in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 0.79 {4-methylumbelliferyl beta-lactoside}  (#14# mutant enzyme
	M144H, in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 7.3 {CMP-N-acetyl-beta-neuraminate}  (#14# mutant enzyme M144D, in
	Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#14# 8.1 {4-methylumbelliferyl beta-Lewis x}  (#14# mutant enzyme
	M144H, in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KM	#15# 0.1085 {FCHASE beta-D-Gal-(1->4)-beta-D-GlcNAc}  (#15# pH and
	temperature not specified in the publication <17>) <17>
KM	#15# 0.1255 {CMP-N-acetyl-beta-neuraminate}  (#15# pH and temperature
	not specified in the publication <17>) <17>
KM	#16# 0.83 {4-nitrophenyl
	beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal}  (#16# pH and
	temperature not specified in the publication <3>) <3>
KM	#6# 0.08761 {beta-D-Gal-(1->4)-beta-D-GlcNAc}  (#6# pH and temperature
	not specified in the publication <24>) <24>
KM	#7# 3 {beta-D-Gal-(1->4)-beta-D-GlcNAc}  (#7# pH 6.4, 37°C <14>) <14>
KM	#8# 0.11 {8-methoxy-8-oxooctyl beta-D-Gal-(1->4)-beta-D-GlcNAc}  (#8#
	pH and temperature not specified in the publication <12>) <12>

PH_OPTIMUM
PHO	#1,3,5# 6.8 (#1,3,5# assay at <20>) <20>
PHO	#10,11# 5-5.5 (#11# native enzyme and the full-length recombinant
	enzyme <22>) <19,22>
PHO	#11# 5.5-6 (#11# truncated recombinant enzyme <22>) <22>
PHO	#18# 5.5 <18>
PHO	#19,20# 6.9 (#19,20# assay at <23>) <23>
PHO	#4# 6 (#4# assay at <5>) <5>
PHO	#7,13# 6.4 <14>

PH_RANGE
PHR	#11# 5-11 (#11# active between pH 5.0 and pH 11.0, native enzyme and
	recombinant enzyme <22>) <22>
PHR	#18# 5-9 (#18# pH 5: about 40% of maximal activity, pH 9: about 60% of
	maximal actzivity <18>) <18>

SPECIFIC_ACTIVITY
SA	#10# 113.0 (#10# pH 6.0, 30°C <19>) <19>

TEMPERATURE_OPTIMUM
TO	#1,3,4,5,19,20# 37 (#1,3,4,5,19,20# assay at <5,11,20,23>) <5,11,20,23>
TO	#10,11# 25-30 (#11# truncated recombinant enzyme <22>) <19,22>
TO	#11# 20-25 (#11# native enzyme and the full-length recombinant enzyme
	<22>) <22>
TO	#18# 20 <18>

TEMPERATURE_RANGE
TR	#18# 10-30 (#18# 10°C: 65% of maximal activity, 30°C: 80% of maximal
	activity <18>) <18>

ACTIVATING_COMPOUND
AC	#1# Triton X-100 <21>
AC	#1# Triton CF-54 <21>
AC	#1# Triton CF-54/X-100 <21>

INHIBITORS
IN	#1# 5'-CMP <21>

METALS_IONS
ME	#11,18# NaCl (#18# in presence of 500-700 mM NaCl 2fold increase in
	activity <18>; #11# native and recombinant enzymes are twice as active
	in the presence of NaCl at 500, 750, and 1000 mM as in the absence of
	NaCl <22>) <18,22>
ME	#3# Mg2+ <4>

MOLECULAR_WEIGHT
MW	#10# 56732 (#10# MALDI-TOF <19>) <19>
MW	#11# 40000 (#11# SDS-PAGE <22>) <22>
MW	#11# 45026 (#11# MALDI-TOF MS analysis <22>) <22>
MW	#15# 80000 (#15# x * 80000, fusion protein, SDS-PAGE <17>) <17>
MW	#18# 43921 (#18# MALDI-TOF of truncated enzyme with N-terminal Lys2 to
	Cys22 deletion <18>) <18>

SUBUNITS
SU	#10,11,15,18# ? (#11# x * 40000, SDS-PAGE <22>; #18# x * 43921,
	MALDI-TOF of truncated enzyme with N-terminal Lys2 to Cys22 deletion
	<18>; #10# x * 56732, MALDI-TOF <19>; #15# x * 80000, fusion protein,
	SDS-PAGE <17>) <17,18,19,22>

APPLICATION
AP	#2# medicine (#2# the enzyme is a drug target for modulating leukocyte
	trafficking in human disorders, including autoimmune diseases and
	cancer <2>) <2>
AP	#4# synthesis (#4# chemical-enzymatic synthesis of sialyl-Lewis
	x-containing hexasaccharides found on O-linked glycoproteins, process
	involves several enzymes of the pathway <10>; #4# enzymatic synthesis
	of 4-methylumbelliferyl derivatives of N-acetyllactosaminide and sialyl
	N-acetyllactosaminides from 4-methylumbelliferyl
	N-acetyl-beta-D-glucosaminide by beta-galactosidase and
	sialyltransferase. The fluorescent synthesized compounds are useful for
	the assay of neuraminidase, sialyltransferase, and fucosyltransferase
	<8>; #4# the enzyme is useful for chemoenzymatic synthesis of
	artificial glycopolypeptides containing multivalent
	sialyloligosaccharides with a gamma-polyglutamic acid backbone. These
	sialyloligosaccharides are effective in inhibition of infections of
	cells by influenza viruses, which bind preferentially to
	alpha2,3-linked Neu5Ac <7>) <7,8,10>

ENGINEERING
EN	#14# D141A (#14# the mutation results in 1000fold decrease in the
	efficiency of alpha2-3-sialyltransferase activity <1>) <1>
EN	#14# H311A (#14# the mutation results in 16fold decrease in the
	efficiency of alpha2-3-sialyltransferase activity <1>) <1>
EN	#14# E271F/R313Y (#14# the mutant does not efficiently sialylate
	fucose-containing oligosaccharides such as Lex <1>) <1>
EN	#14# M144D (#14# the mutant shows 20000fold decreased donor hydrolysis
	activity without significantly affecting its alpha2-3-sialylation
	activity when a poor fucose-containing acceptor substrate is used <1>)
	<1>
EN	#14# M144H (#14# the mutation results in 3fold decrease in the
	efficiency of alpha2-3-sialyltransferase activity <1>) <1>

CLONED
CL	#6# (expression from baculovirus infected Sf9 insect cells ) <24>
CL	#7# (expressed in COS-7 cells as a recombinant enzyme fused with
	protein A) <14>
CL	#10# (expression in Escherichia coli) <19>
CL	#11# (expression of full-length and truncated protein in Escherichia
	coli) <22>
CL	#12# (expressed in Chinese hamster ovary (CHO) and human embryonic
	kidney (HEK293T) cells with a C-terminal human Fc and His-tag) <3>
CL	#13# (expressed in COS-7 cells as a recombinant enzyme fused with
	protein A) <14>
CL	#15# (expressed in Escherichia coli AD202 cells) <17>
CL	#16# (expressed in Chinese hamster ovary (CHO) and human embryonic
	kidney (HEK293T) cells with a C-terminal human Fc and His-tag) <3>
CL	#18# (expression in Escherichia coli, N-terminally truncated form) <18>
CL	#19# <23>
CL	#20# <23>

PURIFICATION
PU	#1# (partial, using centrifugation in a sucrose gradient) <21>
PU	#3# <6>
PU	#8# <12>
PU	#11# <22>
PU	#12# <3>
PU	#14# <1>
PU	#15# <17>
PU	#16# <3>
PU	#18# (recombinant truncated enzyme) <18>

STORAGE_STABILITY
SS	#15# (-70°C, purified enzyme, over 50 days, isoform ST2 remains
	stable) <17>
SS	#3# (4°C, partially purified enzyme preparation in 20% (v/v) glycerol,
	at least 1 week) <6>
SS	#4# (-20°C, 3 months, retains full activity) <5>

REFERENCE
RF	<1> Sugiarto, G.; Lau, K.; Qu, J.; Li, Y.; Lim, S.; Mu, S.; Ames, J.B.;
	Fisher, A.J.; Chen, X.:  A sialyltransferase mutant with decreased
	donor hydrolysis and reduced sialidase activities for directly
	sialylating Lewisx. ACS Chem. Biol. (2012)  7,  1232-1240 .
	{Pubmed:22583967} (          )
RF	<2> Sperandio, M.:  The expanding role of alpha2-3 sialylation for
	leukocyte trafficking in vivo. Ann. N. Y. Acad. Sci. (2012)  1253, 
	201-205 . {Pubmed:22257379} (          )
RF	<3> Gupta, R.; Matta, K.L.; Neelamegham, S.:  A systematic analysis of
	acceptor specificity and reaction kinetics of five human
	alpha(2,3)sialyltransferases	 Product inhibition studies illustrate
	reaction mechanism for ST3Gal-I. Biochem. Biophys. Res. Commun. (2016) 
	469,  606-612 . {Pubmed:26692484} (          )
RF	<4> Basu, S.K.; Whisler, R.L.; Yates, A.J.:  Effects of lectin
	activation on sialyltransferase activities in human lymphocytes.
	Biochemistry (1986)  25,  2577-2581 . {Pubmed:3718965} (          )
RF	<5> Chandrasekaran, E.V.; Xue, J.; Xia, J.; Chawda, R.; Piskorz, C.;
	Locke, R.D.; Neelamegham, S.; Matta, K.L.:  Analysis of the specificity
	of sialyltransferases toward mucin core 2, globo, and related
	structures. Identification of the sialylation sequence and the effects
	of sulfate, fucose, methyl, and fluoro substituents of the carbohydrate
	chain in the biosynthesis of selectin and siglec ligands, and novel
	sialylation by cloned alpha2,3(O)sialyltransferase. Biochemistry (2005)
	 44,  15619-15635 . {Pubmed:16300412} (          )
RF	<6> Bauvois, B.; Montreuil, J.; Verbert, A.:  Characterization of a
	sialyl alpha 2-3 transferase and a sialyl alpha 2-6 transferase from
	human platelets occurring in the sialylation of the N-glycosylproteins.
	Biochim. Biophys. Acta (1984)  788,  234-240 . {Pubmed:6743668} (      
	   )
RF	<7> Ogata, M.; Murata, T.; Murakami, K.; Suzuki, T.; Hidari, K.I.;
	Suzuki, Y.; Usui, T.:  Chemoenzymatic synthesis of artificial
	glycopolypeptides containing multivalent sialyloligosaccharides with a
	gamma-polyglutamic acid backbone and their effect on inhibition of
	infection by influenza viruses. Bioorg. Med. Chem. (2007)  15, 
	1383-1393 . {Pubmed:17129732} (          )
RF	<8> Zeng, X.; Sun, Y.; Uzawa, H.:  Efficient enzymatic synthesis of
	4-methylumbelliferyl N-acetyllactosaminide and 4-methylumbelliferyl
	sialyl N-acetyllactosaminides employing beta-D-galactosidase and
	sialyltransferases. Biotechnol. Lett. (2005)  27,  1461-1465 .
	{Pubmed:16231217} (          )
RF	<9> Yang, W.H.; Nussbaum, C.; Grewal, P.K.; Marth, J.D.; Sperandio, M.:
	 Coordinated roles of ST3Gal-VI and ST3Gal-IV sialyltransferases in the
	synthesis of selectin ligands. Blood (2012)  120,  1015-1026 .
	{Pubmed:22700726} (          )
RF	<10> Oehrlein, R.; Hindsgaul, O.; Palcic, M.M.:  Use of the
	core-2-N-acetylglucosaminyltransferase in the chemical-enzymic
	synthesis of a sialyl-LeX-containing hexasaccharide found on O-linked
	glycoproteins. Carbohydr. Res. (1993)  244,  149-159 . {Pubmed:8101768}
	(          )
RF	<11> Nemansky, M.; Schiphorst, W.E.C.M.; Koeleman, C.A.M.; Van den
	Eijnden, D.H.:  Human liver and human placenta both contain
	CMP-NeuAc	Gal beta 1->4GlcNAc-R alpha 2->3- as well as alpha
	2->6-sialyltransferase activity. FEBS Lett. (1992)  312,  31-36 .
	{Pubmed:1426235} (          )
RF	<12> Sujino, K.; Jackson, R.J.; Chan, N.W.C.; Tsuji, S.; Palcic, M.M.: 
	A novel viral alpha2,3-sialyltransferase (v-ST3Gal I)	 transfer of
	sialic acid to fucosylated acceptors. Glycobiology (2000)  10,  313-320
	. {Pubmed:10704530} (          )
RF	<13> Schur, M.J.; Lameignere, E.; Strynadka, N.C.; Wakarchuk, W.W.: 
	Characterization of alpha2,3- and alpha2,6-sialyltransferases from
	Helicobacter acinonychis. Glycobiology (2012)  22,  997-1006 .
	{Pubmed:22504533} (          )
RF	<14> Kono, M.; Ohyama, Y.; Lee, Y.C.; Hamamoto, T.; Kojima, N.; Tsuji,
	S.:  Mouse beta-galactoside alpha2,3-sialyltransferases	 comparison of
	in vitro substrate specificities and tissue specific expression.
	Glycobiology (1997)  7,  469-479 . {Pubmed:9184827} (          )
RF	<15> Peracaula, R.; Tabares, G.; Lopez-Ferrer, A.; Brossmer, R.; de
	Bolos, C.; de Llorens, R.:  Role of sialyltransferases involved in the
	biosynthesis of Lewis antigens in human pancreatic tumour cells.
	Glycoconj. J. (2005)  22,  135-144 . {Pubmed:16133834} (          )
RF	<16> Nemansky, M.; Van den Eijnden, D.H.:  Enzymic characterization of
	CMP-NeuAc	Gal-beta-1,4GlcNAc-R alpha(2,3)-sialyltransferase from human
	placenta. Glycoconjugate J. (1993)  10,  99-108 . {Pubmed:8395270} (   
	      )
RF	<17> Kondadi, P.K.; Rossi, M.; Twelkmeyer, B.; Schur, M.J.; Li, J.;
	Schott, T.; Paulin, L.; Auvinen, P.; Haenninen, M.L.; Schweda, E.K.;
	Wakarchuk, W.:  Identification and characterization of a
	lipopolysaccharide alpha,2,3-sialyltransferase from the human pathogen
	Helicobacter bizzozeronii. J. Bacteriol. (2012)  194,  2540-2550 .
	{Pubmed:22408169} (          )
RF	<18> Takakura, Y.; Tsukamoto, H.; Yamamoto, T.:  Molecular cloning,
	expression and properties of an alpha/beta-galactoside
	alpha2,3-sialyltransferase from Vibrio sp. JT-FAJ-16. J. Biochem.
	(2007)  142,  403-412 . {Pubmed:17673486} (          )
RF	<19> Tsukamoto, H.; Takakura, Y.; Mine, T.; Yamamoto, T.: 
	Photobacterium sp. JT-ISH-224 produces two sialyltransferases,
	alpha-/beta-galactoside alpha2,3-sialyltransferase and beta-galactoside
	alpha2,6-sialyltransferase. J. Biochem. (2008)  143,  187-197 .
	{Pubmed:17984122} (          )
RF	<20> Van den Eijnden, D.H.; Schiphorst, W.E.C.M.:  Detection of
	beta-galactosyl(1->4)N-acetylglucosaminide
	alpha(2->3)-sialyltransferase activity in fetal calf liver and other
	tissues. J. Biol. Chem. (1981)  256,  3159-3162 . {Pubmed:7204397} (   
	      )
RF	<21> Basu, M.; Basu, S.; Stoffyn, A.; Stoffyn, P.:  Biosynthesis in
	vitro of sialyl(alpha 2-3)neolactotetraosylceramide by a
	sialyltransferase from embryonic chicken brain. J. Biol. Chem. (1982) 
	257,  12765-12769 . {Pubmed:7130178} (          )
RF	<22> Tsukamoto, H.; Takakura, Y.; Yamamoto, T.:  Purification, cloning,
	and expression of an alpha/beta-galactoside alpha-2,3-sialyltransferase
	from a luminous marine bacterium, Photobacterium phosphoreum. J. Biol.
	Chem. (2007)  282,  29794-29802 . {Pubmed:17702755} (          )
RF	<23> Kojima, Y.; Mizutani, A.; Okuzaki, Y.; Nishijima, K.; Kaneoka, H.;
	Sasamoto, T.; Miyake, K.; Iijima, S.:  Analyses of chicken
	sialyltransferases related to N-glycosylation. J. Biosci. Bioeng.
	(2015)  119,  623-628 . {Pubmed:25499752} (          )
RF	<24> Schwardt, O.; Gao, G.P.; Visekruna, T.; Rabbani, S.; Gassmann, E.;
	Ernst, B.:  Substrate specificity and preparative use of recombinant
	rat ST3Gal III. J. Carbohydr. Chem. (2004)  23,  1-26 . {Pubmed:} (    
	     )
RF	<25> Matsuhashi, H.; Horii, Y.; Kato, K.:  Region-specific and
	epileptogenic-dependent expression of six subtypes of
	alpha2,3-sialyltransferase in the adult mouse brain. J. Neurochem.
	(2003)  84,  53-66 . {Pubmed:12485401} (          )
RF	<26> Petit, D.; Teppa, E.; Mir, A.M.; Vicogne, D.; Thisse, C.; Thisse,
	B.; Filloux, C.; Harduin-Lepers, A.:  Integrative view of
	alpha2,3-sialyltransferases (ST3Gal) molecular and functional evolution
	in deuterostomes	 significance of lineage-specific losses. Mol. Biol.
	Evol. (2015)  32,  906-927 . {Pubmed:25534026} (          )
RF	<27> Perez-Garay, M.; Arteta, B.; Pages, L.; de Llorens, R.; de Bolos,
	C.; Vidal-Vanaclocha, F.; Peracaula, R.:  alpha2,3-Sialyltransferase
	ST3Gal III modulates pancreatic cancer cell motility and adhesion in
	vitro and enhances its metastatic potential in vivo. PLoS ONE (2010) 
	5,  e12524 . {Pubmed:20824144} (          )

ACTIVATING_COMPOUND
AC	#1# Triton X-100 <21>
AC	#1# Triton CF-54 <21>
AC	#1# Triton CF-54/X-100 <21>

KCAT_KM_VALUE
KKM	#14# 1.1 (#14# mutant enzyme H311A, in Tris-HCl buffer (200 mM, pH
	8.5), at 37°C <1>) <1>
KKM	#14# 0.018 (#14# mutant enzyme D141A, in Tris-HCl buffer (200 mM, pH
	8.5), at 37°C <1>) <1>
KKM	#14# 1.4 (#14# wild type enzyme, using 4-methylumbelliferyl beta-Lewis
	x as cosubstrate, in Tris-HCl buffer (200 mM, pH 8.5), at 37°C <1>) <1>
KKM	#14# 5.5 (#14# mutant enzyme M144H, in Tris-HCl buffer (200 mM, pH
	8.5), at 37°C <1>) <1>
KKM	#14# 0.89 (#14# mutant enzyme M144D, in Tris-HCl buffer (200 mM, pH
	8.5), at 37°C <1>) <1>
KKM	#14# 0.28 (#14# mutant enzyme M144D, using 4-methylumbelliferyl
	beta-Lewis x as cosubstrate, in Tris-HCl buffer (200 mM, pH 8.5), at
	37°C <1>) <1>
KKM	#14# 18 (#14# wild type enzyme, in Tris-HCl buffer (200 mM, pH 8.5), at
	37°C <1>) <1>
KKM	#14# 34 (#14# wild type enzyme, in Tris-HCl buffer (200 mM, pH 8.5), at
	37°C <1>) <1>
KKM	#14# 6.1 (#14# mutant enzyme M144D, using 4-methylumbelliferyl
	beta-lactoside as cosubstrate, in Tris-HCl buffer (200 mM, pH 8.5), at
	37°C <1>) <1>
KKM	#14# 1 (#14# mutant enzyme M144H, in Tris-HCl buffer (200 mM, pH 8.5),
	at 37°C <1>) <1>
KKM	#14# 2.2 (#14# mutant enzyme M144H, using 4-methylumbelliferyl
	beta-Lewis x as cosubstrate, in Tris-HCl buffer (200 mM, pH 8.5), at
	37°C <1>) <1>
KKM	#14# 0.32 (#14# mutant enzyme M144D, in Tris-HCl buffer (200 mM, pH
	8.5), at 37°C <1>) <1>
KKM	#14# 0.38 (#14# wild type enzyme, in Tris-HCl buffer (200 mM, pH 8.5),
	at 37°C <1>) <1>
KKM	#14# 1.9 (#14# mutant enzyme M144D, in Tris-HCl buffer (200 mM, pH
	8.5), at 37°C <1>) <1>
KKM	#14# 27 (#14# mutant enzyme M144H, in Tris-HCl buffer (200 mM, pH 8.5),
	at 37°C <1>) <1>
KKM	#14# 27 (#14# mutant enzyme M144H, using 4-methylumbelliferyl
	beta-lactoside as cosubstrate, in Tris-HCl buffer (200 mM, pH 8.5), at
	37°C <1>) <1>
KKM	#14# 73 (#14# wild type enzyme, using 4-methylumbelliferyl
	beta-lactoside as cosubstrate, in Tris-HCl buffer (200 mM, pH 8.5), at
	37°C <1>) <1>

EXPRESSION
EXP	#13# up (#13# the number of ST3Gal IV-expressing neurons in the
	anterior thalamic nuclei increases from 2% to 21% in a time-dependent
	manner during epileptogenesis <25>) <25>

///
ID	2.4.99.7
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Mus musculus   <6>
PR	#2# Homo sapiens   <2,8,9,11,12>
PR	#3# Rattus norvegicus   <4,5>
PR	#4# Bos taurus   (#4# enzyme precursor <1,3>) <1,3>
PR	#5# Ovis aries   (#5# adh, fragment <3>) <3>
PR	#6# Homo sapiens Q8NDV1 SwissProt <9,10>
PR	#7# Homo sapiens Q969X2 SwissProt <9,10>
PR	#8# Homo sapiens Q9H4F1  <7,10>
PR	#8# Homo sapiens Q9H4F1 SwissProt <7,10>
PR	#9# Homo sapiens Q9BVH7 SwissProt <10>
PR	#10# Danio rerio Q704S4 SwissProt <10>
PR	#11# Danio rerio Q5NDG1 SwissProt <10>
PR	#12# Danio rerio Q6ZXY7 SwissProt <10>
PR	#13# Danio rerio Q6ZXX8 SwissProt <10>

RECOMMENDED_NAME
RN	alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1
	3-N-acetylgalactosaminide 6-alpha-sialyltransferase


SYSTEMATIC_NAME
SN	CMP-N-acetylneuraminate:N-acetyl-alpha-neuraminyl-(2->3)-beta-D
	galactosyl-(1->3)- N-acetyl-D-galactosaminide
	galactosamine-6-alpha-N-acetylneuraminyltransferase


SYNONYMS
SY	 sialyltransferase
SY	 sialyltransferase, cytidine
	monophosphoacetylneuraminate-(alpha-N-acetylneuraminyl-2
	3-beta-galactosyl-1,3)-N-acetylgalactosaminide-alpha-2
	6-sialyltransferase
SY	 NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc-alpha-2,6-sialyltransferase
	<Swissprot>
SY	 sialyltransferase 3C <Swissprot>
SY	 sialyltransferase 7D <Swissprot>
SY	#2# ST6GalNAc-III <12>
SY	#2# ST6GalNAc-IV <12>
SY	#2,6,10# ST6GalNAc III <9,10,11>
SY	#6,7,8,9,10,11,12,13# More (#6,7,8,9,10,11,12,13# the enzyme belongs to
	the ST6GalNAc family <10>) <10>
SY	#7,13# ST6GalNAc VI <9,10>
SY	#8,11# ST6GalNAc IV <10>
SY	#9,12# ST6GalNAc V <10>

REACTION
RE	CMP-N-acetylneuraminate +
	N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-D
	galactosaminyl-R = CMP +
	N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->3)-[N-acetyl
	alpha-neuraminyl-(2->6)]-N-acetyl-D-galactosaminyl-R

REACTION_TYPE
RT	glycosyl group transfer

SOURCE_TISSUE
ST	#2# skeletal muscle (#2# constitutive expression of ST6GalNac IV gene
	<7>) <7>
ST	#2# T-lymphocyte <2>
ST	#2# thymus (#2# constitutive expression of ST6GalNac IV gene <7>) <7>
ST	#2# platelet <2>
ST	#2# B-cell (#2# Epstein-Barr virus transformed cell line <2>) <2>
ST	#2# OS-RC-2 cell <9>
ST	#2# Caki-1 cell <9>
ST	#2# SK-RC-45 cell <9>
ST	#2# VMRC-RCW cell <9>
ST	#2# VMRC-RCZ cell <9>
ST	#2# TUHR-10TKB cell <9>
ST	#2# TUHR-14TKB cell <9>
ST	#2# RCC-10RGB cell <9>
ST	#2# TUHR-4TKB cell <9>
ST	#2,3,6,7# brain (#2# constitutive expression of ST6GalNac IV gene <7>;
	#3# activity is 4 times lower in adult than in embryonic brain <5>; #6#
	expression of ST6GalNAc III <9>; #7# expression of ST6GalNAc VI <9>)
	<4,5,7,9,11>
ST	#2,4,7# liver (#4# fetal <1>; #2# constitutive expression of ST6GalNac
	IV gene <7>; #7# expression of ST6GalNAc VI <9>) <1,3,7,9>
ST	#2,6,7# kidney (#2# constitutive expression of ST6GalNac IV gene <7>;
	#6# in proximal tubule epithelial cells, expression of ST6GalNAc III
	<9>; #7# in proximal tubule epithelial cells, expression of ST6GalNAc
	VI <9>; #2# isoform ST6GalNAc-VI and disialylgalactosylgloboside are
	found in proximal tubule epithelial cells in normal kidney tissues <9>)
	<7,9,11>
ST	#2,6,7# more (#6# ST6GalNAc III tissue expression pattern, in situ
	hybridization, overview <9>; #7# ST6GalNAc VI tissue expression
	pattern, ST6GalNAc VI is downregulated in renal cancer cell lines and
	cancer tissues, in situ hybridization, overview <9>; #2# tissue
	distribution of isozyme expression <11>) <9,11>
ST	#2,7# placenta (#2# constitutive expression of ST6GalNac IV gene <7>;
	#7# expression of ST6GalNAc VI <9>) <7,9>
ST	#2,7# heart (#2# constitutive expression of STGalNac IV gene <7>; #7#
	expression of ST6GalNAc VI <9>) <7,9>
ST	#2,7# spleen (#2# constitutive expression of ST6GalNac IV gene <7>; #7#
	expression of ST6GalNAc VI <9>) <7,9>
ST	#2,7# lung (#2# constitutive expression of ST6GalNac IV gene <7>; #7#
	expression of ST6GalNAc VI <9>) <7,9>
ST	#2,7# small intestine (#2# constitutive expression of ST6GalNac IV gene
	<7>; #7# expression of ST6GalNAc VI <9>) <7,9>
ST	#2,7# colon (#2# constitutive expression of ST6GalNac IV gene <7>; #7#
	expression of ST6GalNAc VI <9>) <7,9>
ST	#2,7# Moroff cell (#7# renal cancer cell line, expression of ST6GalNAc
	VI <9>) <9>
ST	#2,7# SK-RC 1 cell (#7# renal cancer cell line, expression of ST6GalNAc
	VI <9>) <9>
ST	#2,7# SK-RC 6 cell (#7# renal cancer cell line, expression of ST6GalNAc
	VI <9>) <9>
ST	#2,7# SK-RC 7 cell (#7# renal cancer cell line, expression of ST6GalNAc
	VI <9>) <9>
ST	#2,7# SK-RC 17 cell (#7# renal cancer cell line, expression of
	ST6GalNAc VI <9>) <9>
ST	#2,7# SK-RC 29 cell (#7# renal cancer cell line, expression of
	ST6GalNAc VI <9>) <9>
ST	#2,7# SK-RC 35 cell (#7# renal cancer cell line, expression of
	ST6GalNAc VI <9>) <9>
ST	#2,7# SK-RC 39 cell (#7# renal cancer cell line, expression of
	ST6GalNAc VI <9>) <9>
ST	#2,7# SK-RC 44 cell (#7# renal cancer cell line, expression of
	ST6GalNAc VI <9>) <9>
ST	#2,7# SK-RC 99 cell (#7# renal cancer cell line, expression of
	ST6GalNAc VI <9>) <9>
ST	#5# submaxillary gland <3>
ST	#7# stomach (#7# expression of ST6GalNAc VI <9>) <9>
ST	#7# muscle (#7# expression of ST6GalNAc VI <9>) <9>
ST	#7# testis (#7# expression of ST6GalNAc VI <9>) <9>
ST	#7# epithelial cell (#7# expression of ST6GalNAc VI <9>) <9>
ST	#7# SK-RC 45 cell (#7# renal cancer cell line, expression of ST6GalNAc
	VI <9>) <9>

LOCALIZATION
LO	#2,3,4,5# microsome <1,2,3,4>
LO	#2,3,4,5,6,7# membrane (#2# type II membrane protein <11>) <2,3,4,9,11>
LO	#6,7,8,9,10,11,12,13# Golgi membrane (#6,7,8,9,10,11,12,13# the enzyme
	is a Golgi type II transmembrane glycosyltransferase <10>) <10>

NATURAL_SUBSTRATE_PRODUCT
NSP	#2# more = ? (#2# enzyme is responsible for synthesis of disialyl Lewis
	a structures in colon tissues, but not for synthesis of alpha-series
	gangliosides, model of pathway for synthesis of disialyl
	lactoetraosylceramides and disialyl Lewis a structures <8>) {} <8>
NSP	#2# CMP-N-acetylneuraminate + NeuAc-alpha-(2->3)-Gal-beta-(1->3)-GalNAc
	= ? <12>
NSP	#2,4,5# CMP-N-acetylneuraminate +
	alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1
	3-N-acetyl-D-galactosaminyl-R = CMP +
	alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1
	3-(N-acetylneuraminyl-2,6)-N-acetyl-D-galactosaminyl-R (#2,4,5# pathway
	in glycoprotein biosynthesis <1,2,3>) {} <1,2,3>
NSP	#6,7# CMP-NAC + monosialylgalactosylgloboside = CMP +
	disialylgalactosylgloboside (#6,7# the enzyme is responsible for the
	synthesis of disialylgalactosylgloboside from
	monosialylgalactosylgloboside in normal and malignant kidney cells, the
	reaction suppressed during the malignant transformation of the proximal
	tubules as a maturation arrest of glycosylation, overview <9>) <9>

SUBSTRATE_PRODUCT
SP	#2# more = ? (#2# enzyme is responsible for synthesis of disialyl Lewis
	a structures in colon tissues, but not for synthesis of alpha-series
	gangliosides, model of pathway for synthesis of disialyl
	lactoetraosylceramides and disialyl Lewis a structures <8>; #2#
	substrate specificity, no activity with GA1, GA2, GM1, GM2, GD3, GT1b,
	GQ1b, and Lc4, overview <11>) {} <8,11>
SP	#2# CMP-N-acetylneuraminate + fetuin = ? (#2# acceptor structures:
	Neu5Acalpha2-3Galbeta1-3GalNacalpha1-O-Ser/Thr,
	Neu5Acalpha2-3Galbeta1-3[Neu5Acalpha2-6]GalNacalpha1-O-Ser/Thr and
	Neu5Acalpha2-6(3)Galbeta1-4GlcNac-R <7>) <7>
SP	#2# CMP-N-acetylneuraminate + alpha1-acid glycoprotein = ? (#2#
	acceptor structur: Neu5Acalpha2-6Galbeta1-4GlcNac-R, 8.7% of activity
	with fetuin <7>) <7>
SP	#2# CMP-N-acetylneuraminate +
	Neu5Acalpha2-3Galbeta1-4GlcNac-alpha1-O-benzyl = ? (#2# 224% of
	activity with fetuin <7>) <7>
SP	#2# CMP-N-acetylneuraminate + GlcNac-alpha1-O-benzyl = ? (#2# 7.6% of
	activity with fetuin <7>) <7>
SP	#2# CMP-N-acetylneuraminate + Neu5Acalpha2-3Galbeta1-3GalNac = ? (#2#
	60.3% of activity with fetuin <7>) <7>
SP	#2# CMP-N-acetylneuraminate + GM1b = CMP + ? <8>
SP	#2# CMP-N-acetylneuraminate + sialyl lactoetraosylceramide = CMP + ?
	|#2# product are disialyl Lewis a structures <8>| <8>
SP	#2# CMP-Neu5Ac + fetuin = ? (#2# ST6GalNAc III also shows activity with
	O-glycans, but not N-glycans, in fetuin <11>) <11>
SP	#2# CMP-Neu5Ac + Galbeta1,3GlcNAcbeta1,3Galbeta1,4Glcbeta1-Cer = ? <11>
SP	#2# CMP-Neu5Ac + Galbeta1,4GlcNAcbeta1,3Galbeta1,4Glcbeta1-Cer = ? {}
	<11>
SP	#2# CMP-Neu5Ac + GM1b = ? (#2# i.e.
	NeuAcalpha2,3Galbeta1,3GalNAcbeta1,4Galbeta1,4Glcbeta1-Cer, best
	substrate <11>) <11>
SP	#2# CMP-N-acetylneuraminate + monosialylgalactosylgloboside = CMP +
	disialylgalactosylgloboside (#2# isoforms ST6GalNAc III and ST6GalNAc
	VI generate disialylgalactosylgloboside from
	monosialylgalactosylgloboside with Vmax/Km values of 1.91 and 4.16
	respectively <9>) <9>
SP	#2# CMP-N-acetylneuraminate + NeuAc-alpha-(2->3)-Gal-beta-(1->3)-GalNAc
	= ? <12>
SP	#2,3,4,5# CMP-N-acetylneuraminate +
	N-alpha-acetylneuraminyl-2,3-beta-D-galactosyl-1
	3-N-acetyl-D-galactosaminyl-R = CMP +
	alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1
	3-(N-acetylneuraminyl-2,6)-N-acetyl-D-galactosaminyl-R (#4# no
	substrates are beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R or
	N-acetylgalactosylaminyl-R <1>; #4,5# attaches sialic acid in
	alpha-2,6-linkage to N-acetylgalactosamine only when present in the
	structure of
	alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1
	3-N-acetylgalactosaminyl-R <3>; #4# R can be a protein or p-nitrophenol
	<1>; #4# substrates are sialylated antifreeze glycoprotein as well as
	N-acetyl-D-galactosamine or
	beta-galactosyl-1,3-N-acetyl-D-galactosamine side chains from ovine
	submaxillary asialomucin or porcine submaxillary asialo/afucomucin
	respectively <3>) <1,2,3,4>
SP	#2,4,5# CMP-N-acetylneuraminate +
	alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1
	3-N-acetyl-D-galactosaminyl-R = CMP +
	alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1
	3-(N-acetylneuraminyl-2,6)-N-acetyl-D-galactosaminyl-R (#2,4,5# pathway
	in glycoprotein biosynthesis <1,2,3>) {} <1,2,3>
SP	#6,7# CMP-NAC + monosialylgalactosylgloboside = CMP +
	disialylgalactosylgloboside (#6,7# the enzyme is responsible for the
	synthesis of disialylgalactosylgloboside from
	monosialylgalactosylgloboside in normal and malignant kidney cells, the
	reaction suppressed during the malignant transformation of the proximal
	tubules as a maturation arrest of glycosylation, overview <9>) <9>
SP	#6,7# CMP-NeuAc + glycoprotein = ? <9>
SP	#6,7# CMP-NeuAc + glycosphingolipid = ? <9>

KM_VALUE
KM	#2# 0.07 {CMP-N-acetylneuraminate}  <7>
KM	#2# 0.9 {sialyl lactoetraosylceramide}  (#2# isoform ST6GalNAc V, pH
	6.0, 37°C <8>) <8>
KM	#2# 0.33 {GM1b}  (#2# isoform ST6GalNAc VI, pH 6.0, 37°C <8>) <8>
KM	#2# 0.56 {GM1b}  (#2# isoform ST6GalNAc V, pH 6.0, 37°C <8>) <8>
KM	#2# 1.1 {Neu5Acalpha2-3Galbeta1-3GalNac}  <7>
KM	#2# 0.46 {sialyl lactoetraosylceramide}  (#2# isoform ST6GalNAc VI, pH
	6.0, 37°C <8>) <8>
KM	#2# 2.21 {Neu5Acalpha2-3Galbeta1-3GalNacalpha-O-benzyl}  <7>

PH_OPTIMUM
PHO	#2,3,6,7# 6 (#2,6,7# assay at <9,11>) <5,9,11>

TEMPERATURE_OPTIMUM
TO	#2,4,6,7# 37 (#2,4,6,7# assay at <1,9,11>) <1,9,11>
TO	#3# 28 <5>

INHIBITORS
IN	#3# CMP (#3# 50 mM, strong inhibition <4>) <4>
IN	#3# N-bromosuccinimide (#3# 5 mM, 98% inhibition <4>) <4>
IN	#3# Mersalyl acid (#3# 0.025 mM, 50% inhibition <4>) <4>
IN	#3# 6,6'-dithiodinicotinic acid carboxypyridine disulfide (#3# IC50:
	0.028 mM <4>) <4>
IN	#3# p-chloromercuribenzoic acid (#3# 0.036 mM, 50% inhibition, 0.1 mM,
	97% inhibition <4>) <4>
IN	#3# 5,5'-dithiobis-(2-nitrobenzoic acid) (#3# 0.01 mM, 50% inhibition,
	0.1 mM, 97% inhibition <4>) <4>
IN	#3# N-ethylmaleimide (#3# 0.014 mM, 50% non-competitive inhibition,
	almost complete protection with 0.05 mM CMP-N-acetylneuraminate <4>) <4>

METALS_IONS
ME	#2,6,7# Mg2+ <9,11>

MOLECULAR_WEIGHT
MW	#2# 34900 (#2# x * 34900, deduced from nucleotide sequence <7>) <7>

SUBUNITS
SU	#2# ? (#2# x * 34900, deduced from nucleotide sequence <7>) <7>
SU	#2# More (#2# two transmembrane isozymes, short and long enzyme form of
	305 and 240 amino acids, respectively, the long form shows a short
	cytoplasmic transmembrane domain of sixteen amino acids and a catalytic
	domain of 280 amino acids, both isozymes contain the sialyl motif L and
	sialyl motif S, overview <11>) <11>

APPLICATION
AP	#2# medicine (#2# the expression profiles of isoform ST6GalNAc VI among
	20 renal cancer cell lines correlates clearly with those of
	disialylgalactosylgloboside, suggesting that the sialyltransferase
	involved in the synthesis of disialylgalactosylgloboside in the kidney
	is ST6GalNAc-VI. ST6GalNAc-VI and disialylgalactosylgloboside are found
	in proximal tubule epithelial cells in normal kidney tissues, while
	they are downregulated in renal cancer cell lines and cancer tissues
	<9>) <9>

CLONED
CL	#1# (ST6GalNac III and IV genes) <6>
CL	#2# (expression of ST6GalNac IV in COS-7 cells) <7>
CL	#2# (short and long enzyme form of 305 and 240 amino acids,
	respectively, DNA and amino acid sequence determination and analysis,
	alternative usage of the second exon seems to generate these two
	transcripts, expression analysis, sequence comparisons, overview,
	expression of soluble fusion enzyme, a truncated form of ST6GalNAc III
	lacking 21 amino acids from the NH2 terminus) <11>
CL	#6# (co-expression of ST6GalNAc VI and ST6GalNAc III with
	disialylgalactosylgloboside in Caki-1 cells) <9>
CL	#6# (phylogenetic analysis, sequence comparison and sialylmotif regions
	analysis, overview) <10>
CL	#7# (co-expression of ST6GalNAc VI and ST6GalNAc III with
	disialylgalactosylgloboside in Caki-1 cells) <9>
CL	#7# (phylogenetic analysis, sequence comparison and sialylmotif regions
	analysis, overview) <10>
CL	#8# (phylogenetic analysis, sequence comparison and sialylmotif regions
	analysis, overview) <10>
CL	#9# (phylogenetic analysis, sequence comparison and sialylmotif regions
	analysis, overview) <10>
CL	#10# (phylogenetic analysis, sequence comparison and sialylmotif
	regions analysis, overview) <10>
CL	#11# (phylogenetic analysis, sequence comparison and sialylmotif
	regions analysis, overview) <10>
CL	#12# (phylogenetic analysis, sequence comparison and sialylmotif
	regions analysis, overview) <10>
CL	#13# (phylogenetic analysis, sequence comparison and sialylmotif
	regions analysis, overview) <10>

REFERENCE
RF	<1> Bergh, M.L.E.; van den Eijnden, D.H.: Aglycon specificity of fetal
	calf liver and ovine and porcine submaxillary gland
	alpha-N-acetylgalactosaminide alpha 2 leads to 6 sialyltransferase.
	Eur. J. Biochem. (1983) 136, 113-118. {Pubmed:6617653}
RF	<2> Higgins, E.A.; Siminovitch, K.A.; Zhuang, D.; Brockhausen, I.;
	Dennis, J.W.: Aberrant O-linked oligosaccharide biosynthesis in
	lymphocytes and platelets from patients with the Wiskott-Aldrich
	syndrome. J. Biol. Chem. (1991) 266, 6280-6290. {Pubmed:2007580} (c)
RF	<3> Bergh, M.L.E.; Hooghwinkel, G.J.M.; Van den Eijnden, D.H.:
	Biosynthesis of the O-glycosidically linked oligosaccharide chains of
	fetuin. Indications for an alpha-N-acetylgalactosaminide alpha 2 leads
	to 6 sialyltransferase with a narrow acceptor specificity in fetal calf
	liver. J. Biol. Chem. (1983) 258, 7430-7436. {Pubmed:6190802}
RF	<4> Baubichon-Cortay, H.; Broquet, P.; George, P.; Louisot, P.:
	Different reactivity of two brain sialyltransferases towards sulfhydryl
	reagents. Evidence for a thiol group involved in the nucleotide-sugar
	binding site of the NeuAc alpha 2-3Gal beta 1-3GalNAc
	alpha(2-6)sialyltransferase. Glycoconjugate J. (1989) 6, 115-127.
	{Pubmed:2485232}
RF	<5> Dall'olio, F.: Sialyltransferases of developing rat brain.
	Glycoconjugate J. (1990) 7, 301-310. {Pubmed:1726633}
RF	<6> Takashima, S.; Kurosawa, N.; Tachida, Y.; Inoue, M.; Tsuji, S.:
	Comparative analysis of the genomic structures and promoter activities
	of mouse Siaa2,3Galb1,3GalNAc GalNAca2,6-sialyltransferase genes
	(ST6GalNAc III and IV): characterization of their Sp1 binding sites. J.
	Biochem. (2000) 127, 399-409. {Pubmed:10731711}
RF	<7> Harduin-Lepers, A.; Stokes, D.C.; Steelant, W.F.A.; Samyn-Petit,
	B.; Krzewinski-Recchi, M.A.; Vallejo-Ruiz, V.; Zanetta, J.P.; Auge, C.;
	Delannoy, P.: Cloning, expression and gene organization of a human
	Neu5Aca2-3Galb1-3GalNAc a2,6-sialyltransferase: hST6GalNAc IV. Biochem.
	J. (2000) 352, 37-48. {Pubmed:11062056}
RF	<8> Tsuchida, A.; Okajima, T.; Furukawa, K.; Ando, T.; Ishida, H.;
	Yoshida, A.; Nakamura, Y.; Kannagi, R.; Kiso, M.: Synthesis of disialyl
	Lewis a (Le(a)) structure in colon cancer cell lines by a
	sialyltransferase, ST6GalNAc VI, responsible for the synthesis of
	alpha-series gangliosides. J. Biol. Chem. (2003) 278, 22787-22794.
	{Pubmed:12668675}
RF	<9> Senda, M.; Ito, A.; Tsuchida, A.; Hagiwara, T.; Kaneda, T.;
	Nakamura, Y.; Kasama, K.; Kiso, M.; Yoshikawa, K.; Katagiri, Y.; Ono,
	Y.; Ogiso, M.; Urano, T.; Furukawa, K.; Oshima, S.; Furukawa, K.:
	Identification and expression of a sialyltransferase responsible for
	the synthesis of disialylgalactosylgloboside in normal and malignant
	kidney cells: downregulation of ST6GalNAc VI in renal cancers. Biochem.
	J. (2007) 402, 459-470. {Pubmed:17123352}
RF	<10> Harduin-Lepers, A.; Mollicone, R.; Delannoy, P.; Oriol, R.: The
	animal sialyltransferases and sialyltransferase-related genes: a
	phylogenetic approach. Glycobiology (2005) 15, 21G. {Pubmed:}
RF	<11> Tsuchida, A.; Ogiso, M.; Nakamura, Y.; Kiso, M.; Furukawa, K.;
	Furukawa, K.: Molecular cloning and expression of human ST6GalNAc III:
	restricted tissue distribution and substrate specificity. J. Biochem.
	(2005) 138, 237-243. {Pubmed:16169874}
RF	<12> Wang, L.; Liu, Y.; Wu, L.; Sun, X.L.: Sialyltransferase inhibition
	and recent advances. Biochim. Biophys. Acta (2016) 1864, 143-153.
	{Pubmed:26192491}

IC50_VALUE
IC50	#3# 0.028 {6,6'-dithiodinicotinic acid carboxypyridine disulfide}  (#3#
	IC50: 0.028 mM <4>) <4>

///
ID	3.2.1.114
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Drosophila melanogaster   <11,25,36,40,49,50,51,63>
PR	#2# Mus musculus   <16,21,25,43,44>
PR	#3# Homo sapiens   <5,16,20,25,27,34,35,39,41,42,49,53,56,58,60,62>
PR	#4# Rattus norvegicus   <1,2,3,9,12,13,14,15,16,19,20,25,26,47,64>
PR	#5# Bombyx mori   <22>
PR	#6# Canis lupus familiaris   <6,10,18>
PR	#7# Xenopus laevis   <22>
PR	#8# Vigna radiata   (#8# fragment CYP153A8 <8,10,17,18,22>)
	<8,10,17,18,22>
PR	#9# Aspergillus fischeri   <57>
PR	#10# Aspergillus phoenicis   <4,7,33>
PR	#11# Spodoptera frugiperda   <22,23,28,29>
PR	#12# Thermotoga maritima   <30>
PR	#13# Canavalia ensiformis   <49>
PR	#14# Ginkgo biloba   <31,32>
PR	#15# plant   <9>
PR	#16# Mamestra brassicae   <22>
PR	#17# Drosophila melanogaster Q24451 
	<21,24,38,45,46,48,49,50,51,52,54,61>
PR	#17# Drosophila melanogaster Q24451 SwissProt
	<21,24,38,45,46,48,49,50,51,52,54,61>
PR	#17# Drosophila melanogaster Q24451 UniProt
	<21,24,38,45,46,48,49,50,51,52,54,61>
PR	#18# Mus musculus P27046 SwissProt <20>
PR	#19# Arabidopsis thaliana Q9LFR0 SwissProt <37>
PR	#20# Aspergillus fumigatus Q5I5K3 UniProt <55>
PR	#21# Streptococcus pyogenes Q99YP5 UniProt <59>

RECOMMENDED_NAME
RN	mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase


SYSTEMATIC_NAME
SN	(1->3)-(1->6)-mannosyl-oligosaccharide alpha-D-mannohydrolase
	(configuration-retaining)


SYNONYMS
SY	 alpha-D-mannosidase II
SY	 GlcNAc transferase I-dependent alpha1,3[alpha1,6]mannosidase
SY	 alpha1-3,6-mannosidase
SY	 MAN IIx
SY	 mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase
SY	 mannosidase, exo-1,3-1,6-alpha-
SY	 exo-1,3-1,6-alpha-mannosidase
SY	 alpha-mannosidase III
SY	 ManIII
SY	#1# GH38 Golgi alpha-mannosidase II <40>
SY	#1# mannose-trimming enzyme <50>
SY	#1# mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase II <50>
SY	#1,17# dGMII <48,49>
SY	#1,2,3,12,21# More (#1,2,3# member of glycosyl hydrolase family 38
	<11,24,25>; #12# the enzyme belongs to the glycoside hydrolase family
	38 <30>; #3# Bt3991 belongs to the glycosyl hydrolase family 92, GH92
	<58>; #21# the enzyme belongs to the family GH38 of alpha-mannosidases
	<59>) <11,24,25,30,58,59>
SY	#1,2,3,13# alpha-mannosidase II <43,44,49,53>
SY	#1,3,17,19# GmII <21,24,34,36,37,38,40,45,46,50,51,54,61,63>
SY	#1,3,4,17,19# Golgi alpha-mannosidase II
	<34,36,37,38,39,40,41,45,46,48,50,51,54,56,60,61,62,63,64>
SY	#10# 1,6-alpha-D-mannosidase <33>
SY	#10# 1,3(1,6)-alpha-D-mannosidase <33>
SY	#12# TM1851 <30>
SY	#13# jack bean alpha-mannosidase <49>
SY	#17# glycoside hydrolase <48>
SY	#17# Drosophila GMII <48>
SY	#17,21# alpha-mannosidase <48,59>
SY	#2# MII <43,44>
SY	#2,3# Golgi mannosidase IIx (#2,3# close homolog to Golgi mannosidase
	II with different substrate specificity <25>) <25>
SY	#2,3# alpha-mannosidase IIx (#3# homolog to alpha-mannosidase II with
	different substrate specificity <27>) <27,43,44>
SY	#20# class IIC alpha-mannosidase <55>
SY	#20# Afams1 <55>
SY	#21# alpha-1,3 mannosidase <59>
SY	#21# GH38 alpha-mannosidase II <59>
SY	#21# GH38 enzyme <59>
SY	#21# SpGH38 <59>
SY	#3# neutral alpha-mannosidase <42>
SY	#3# class II alpha-D-mannosidase <35>
SY	#3# NAM <42>
SY	#3# ManII <39>
SY	#3# human type II alpha-mannosidase <49>
SY	#3# alpha-1,3-mannosidase <58>
SY	#3# Bt3991 <58>
SY	#4# mannosidase II <47>
SY	#4# Man II <47>
SY	#4# MAN2A1 <64>
SY	#9,12# class II alpha-mannosidase <30,57>

REACTION
RE	Man5GlcNAc3-[protein] + 2 H2O = Man3GlcNAc3-[protein] + 2
	alpha-D-mannopyranose (#1# catalytic mechanism <11,24>; #17# the
	conformational change of the bound mannoside to a high-energy B2,5
	conformation is facilitated by steric hindrance from, and the formation
	of strong hydrogen bonds to, resiude D204 <51>; #21# reaction mechanism
	via glycosyl-enzyme intermediate, overview <59>)

REACTION_TYPE
RT	hydrolysis
RT	hydrolysis of O-glycosyl bond
RT	hydrolysis of N-glycosyl bond

SOURCE_TISSUE
ST	#10# mycelium (#10# freeze-dried mixture of mycelium and its culture
	medium, commercially available as Morushin <4,7>) <4,7>
ST	#11# SF-21 cell (#11# baculovirus-infected IPLB-SF-21AE cells <23>) <23>
ST	#14# seed <31,32>
ST	#17# SCHNEIDER-2 cell <48>
ST	#2,17# embryo <21,43,44>
ST	#2,18# NIH-3T3 cell (#2# BALB/clone A31 <16>) <16,20>
ST	#2,3,4,7# liver (#4# rat <16,20,25>; #7# frog <22>)
	<1,2,3,9,12,13,14,15,16,19,20,22,25,35>
ST	#3# HeLa cell (#3# alpha-mannosidase IIx <27>) <16,27>
ST	#3# fibroblast <42>
ST	#3# commercial preparation <58>
ST	#3# gut <58>
ST	#3# MCF-7 cell <53>
ST	#3# hepatoma cell <5>
ST	#3# Hep-G2 cell <20>
ST	#3# JURKAT cell <53>
ST	#3# colonic adenocarcinoma cell <5>
ST	#3# A-549 cell <53>
ST	#3# MDA-MB-231 cell <53>
ST	#3# PC-3 cell <53>
ST	#3# U-266 cell <53>
ST	#3# glioblastoma cell line (#3# LNZ 308 <49>) <49>
ST	#3# BT-474 cell <53>
ST	#3# U-87MG cell <53>
ST	#3# HEK-293T cell (#3# mutant HEK293T cell line called Lec36, which
	displays sensitivity to ricin that lies between the parental HEK 293T
	cells, in which the secreted and membrane-expressed proteins are
	dominated by complex-type glycosylation, and 293S Lec1 cells, which
	produce only oligomannose-type N-linked glycans. Lec36 cells are
	dominated by hybrid-type glycosylation. Wild-type and mutant enzyme
	expression analysis, overview <56>) <41,56>
ST	#3# SK-BR-3 cell <53>
ST	#3# endothelial cell line (#3# HCEC <49>) <49>
ST	#3# LN-18 cell <49>
ST	#4# cerebral cortex <64>
ST	#4# cerebellum <64>
ST	#4# brain (#4# the enzyme is lowly expressed in the molecular layer of
	the cerebral cortex and hippocampal layers, and highly expressed in
	other areas of the brain <64>) <64>
ST	#4# more (#4# tissue distribution of Man II mRNA <20>) <20>
ST	#4# hepatocyte (#4# fetal <47>) <47>
ST	#4# testis (#4# in the Golgi apparatus of Sertoli and Leydig cells
	<26>) <26>
ST	#4# Sertoli cell (#4# in the Golgi apparatus <26>) <26>
ST	#4# epididymis (#4# clear cells in all epdididymal regions, not in
	principal cells <26>) <26>
ST	#4# hippocampus <64>
ST	#4# Leydig cell (#4# in the Golgi apparatus <26>) <26>
ST	#4# NRK cell (#4# normal kidney cells <19>) <19>
ST	#6# MDCK cell (#6# influenza virus-infected <6,10,18>) <6,10,18>
ST	#8# seedling <8,10,17,18,22>

LOCALIZATION
LO	#1,2,3,4,11,13,17,19# Golgi apparatus (#11# alpha-mannosidase III <28>;
	#1# Golgi alpha-mannosidase II <36>; #19# Golgi alpha-mannosidase II,
	the enzyme has a transmembrane domain and a cytoplasmic tail sufficient
	for localisation of the enzyme to the Golgi complex, retention by
	lumenal sequences is not involved, retention mechanism <37>)
	<11,16,25,28,36,37,47,48,49,50,51,52,53,54,56,62,63,64>
LO	#11# extracellular (#11# at least 3 forms of alpha-mannosidase III, the
	smallest form accumulates in the extracellular fraction <28>) <28>
LO	#2,5,17,19# membrane (#5# membrane-bound, predominantly in the
	microsomal pellet <22>; #2,17# type II transmembrane protein with short
	cytoplasmic tail, single transmembrane domain and large hydrophilic
	C-terminal domain <21>; #19# Golgi alpha-mannosidase II is a type II
	membrane protein <37>) <21,22,37>
LO	#21# intracellular (#21# SpGH38 may be intracellular, absence of any
	classical signal peptide <59>) <59>
LO	#3# lysosome <35>
LO	#3,12# cytosol (#3# granularly distributed <42>) <30,42>
LO	#3,20# more (#3# absent from the endoplasmic reticulum, lysosomes, and
	autophagosomes <42>; #20# AfAms1 contains no cleavable signal sequence
	or transmembrane domain <55>) <42,55>
LO	#3,4,11,18# Golgi membrane (#4# liver <16>; #4# integral membrane
	protein, hydrophilic catalytic domain is anchored to the lumenal face
	of Golgi membranes through an NH2-terminal hydrophobic
	membrane-anchoring domain <1>; #18# type II transmembrane protein with
	short cytoplasmic tail, single transmembrane domain and large
	C-terminal catalytic domain <20>; #4# topology study: integral membrane
	protein with lumenal orientation, hydrophilic catalytic domain is bound
	to an integral hydrophobic membrane anchoring domain through a
	proteolytically sensitive linkage <15>; #3# type II membrane protein,
	alpha-mannosidase II and IIx <27>; #4# type II transmembrane enzyme,
	subcompartmental localization, mainly over medial saccules of the Golgi
	stack <26>; #11# alpha-mannosidase III, integral membrane glycoprotein
	with type II topology <29>) <1,2,3,12,13,14,15,16,19,20,23,26,27,29>
LO	#3,4,5,8# microsome (#5# predominantly, membrane-bound <22>)
	<5,8,17,19,22>
LO	#4# cytoplasm (#4# hepatocytes cultured in dexamethason-supplemented
	medium <47>) <47>
LO	#4# specific granule (#4# hepatocytes cultured in colchicine-containing
	medium <47>) <47>

NATURAL_SUBSTRATE_PRODUCT
NSP	#1# 4-methylumbelliferyl alpha-D-mannopyranoside + H2O = ? <50>
NSP	#1,2,3,4,6,8,11,12,14,17,18,19,21# more = ? (#4# involved in
	asparagine-linked oligosaccharide processing <15>; #4# required in the
	maturation of asparagine-linked oligosaccharides in the Golgi complex
	<16>; #4# biosynthesis of complex-type N-linked oligosaccharides of
	glycoproteins <2>; #11# alpha-mannosidase III probably provides an
	alternate N-glycan processing pathway in Sf-9 cells <29>; #4# function
	in Golgi membranes: presumably glycopolymer metabolism <3>; #3,4,18#
	Man II catalyzes the final hydrolytic step in the N-glycan maturation
	pathway acting as the committed step in the conversion of high mannose
	to complex type structures <20>; #2,3# involved in trimming reactions
	in N-glycan maturation in the Golgi complex <25>; #1,4,6,8,11#
	asparagine-linked glycoprotein biosynthesis <10,13,23,24>; #11# study
	of biosynthesis and processing of alpha-mannosidase III <28>; #14# Co2+
	regulates the substrate specificity, overview <32>; #19# Golgi
	alpha-mannosidase II is a key enzyme in the formation of complex
	N-glycans in plants <37>; #12# the exo-type cytosolic class II enzyme
	cleaves off alpha-1,2-, alpha-1,3-, and alpha-1,6-mannose residues
	<30>; #2# MII and alpha-mannosidase IIx function in N-glycan processing
	in a similar manner <44>; #3# Bt1769, Bt3858 and Bt3991 are
	alpha-1,3-mannosidases that display particularly high activity against
	alpha-1,3-mannobiose <58>; #17# GMII is involved in the creation of
	glycoproteins that contain complex carbohydrates. It is responsible for
	the formation of the core trimannose structure to which all complex
	carbohydrates are appended. It catalyses the hydrolysis of an
	alpha(1,6)- and an alpha(1,3)-linked mannose from GlcNAc-Man5-GlcNAc2
	to form GlcNAc-Man3-GlcNAc2-Asn-X <54>; #21# higher eukaryotic GH38
	alpha-mannosides play a key role in the modification and
	diversification of hybrid N-glycans, processes with strong cellular
	links to cancer and autoimmune disease <59>) {}
	<2,3,10,13,15,16,20,23,24,25,28,29,30,32,37,44,54,58,59>
NSP	#1,2,3,4,6,8,11,12,14,17,18,19,21# more = ? (#4# involved in
	asparagine-linked oligosaccharide processing <15>; #4# required in the
	maturation of asparagine-linked oligosaccharides in the Golgi complex
	<16>; #4# biosynthesis of complex-type N-linked oligosaccharides of
	glycoproteins <2>; #11# alpha-mannosidase III probably provides an
	alternate N-glycan processing pathway in Sf-9 cells <29>; #4# function
	in Golgi membranes: presumably glycopolymer metabolism <3>; #3,4,18#
	Man II catalyzes the final hydrolytic step in the N-glycan maturation
	pathway acting as the committed step in the conversion of high mannose
	to complex type structures <20>; #2,3# involved in trimming reactions
	in N-glycan maturation in the Golgi complex <25>; #1,4,6,8,11#
	asparagine-linked glycoprotein biosynthesis <10,13,23,24>; #11# study
	of biosynthesis and processing of alpha-mannosidase III <28>; #14# Co2+
	regulates the substrate specificity, overview <32>; #19# Golgi
	alpha-mannosidase II is a key enzyme in the formation of complex
	N-glycans in plants <37>; #12# the exo-type cytosolic class II enzyme
	cleaves off alpha-1,2-, alpha-1,3-, and alpha-1,6-mannose residues
	<30>; #2# MII and alpha-mannosidase IIx function in N-glycan processing
	in a similar manner <44>; #3# Bt1769, Bt3858 and Bt3991 are
	alpha-1,3-mannosidases that display particularly high activity against
	alpha-1,3-mannobiose <58>; #17# GMII is involved in the creation of
	glycoproteins that contain complex carbohydrates. It is responsible for
	the formation of the core trimannose structure to which all complex
	carbohydrates are appended. It catalyses the hydrolysis of an
	alpha(1,6)- and an alpha(1,3)-linked mannose from GlcNAc-Man5-GlcNAc2
	to form GlcNAc-Man3-GlcNAc2-Asn-X <54>; #21# higher eukaryotic GH38
	alpha-mannosides play a key role in the modification and
	diversification of hybrid N-glycans, processes with strong cellular
	links to cancer and autoimmune disease <59>) {}
	<2,3,10,13,15,16,20,23,24,25,28,29,30,32,37,44,54,58,59>
NSP	#1,3,4#
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1
	3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + 2 H2O =
	Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc + 2 alpha-D-mannose (#3# alpha-mannosidase II, biosynthesis of
	N-glycans <27>; #4# involved in N-glycan maturation, acts after GlcNAc
	transferase I to remove 2 mannose residues to form
	GlcNAc(Man)3(GlcNAc)2 prior to extension into complex N-glycans <26>;
	#1# N-glycosylation pathway <11>) <11,26,27>
NSP	#1,3,4#
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1
	3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + 2 H2O =
	Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc + 2 alpha-D-mannose (#3# alpha-mannosidase II, biosynthesis of
	N-glycans <27>; #4# involved in N-glycan maturation, acts after GlcNAc
	transferase I to remove 2 mannose residues to form
	GlcNAc(Man)3(GlcNAc)2 prior to extension into complex N-glycans <26>;
	#1# N-glycosylation pathway <11>) {} <11,26,27>
NSP	#17# GlcNAcMan5GlcNAc2 + H2O = ? + alpha-D-mannose <61>
NSP	#19#
	Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-1-Asn + H2O =
	Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc-1-Asn + alpha-D-mannose (#19# physiological substrate,
	conversion by sequential removal of two alpha1,6-linked and
	alpha1,3-linked mannose residues from the alpha-1,6-branch of the
	substrate <37>) <37>
NSP	#21# high mannose N-glycan + H2O = ? <59>
NSP	#3#
	Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(Manalpha(1-2)Manalpha(1
	3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + 2 H2O =
	Manalpha(1-6)(Manalpha(1-2)Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc + 2 alpha-D-mannose (#3# alpha-mannosidase IIx, M6Gn2 is the
	primary target in vivo, integral part of N-glycan biosynthesis <27>)
	<27>
NSP	#3# 3-O-alpha-D-mannopyranosyl-alpha-D-mannopyranose + H2O =
	alpha-D-mannopyranose <58>
NSP	#3# Man5GlcNAc2 + H2O = Man3GlcNAc2 + 2 alpha-D-mannopyranose <58>
NSP	#4,8# GlcNAc(Man)5GlcNAc + 2 H2O = GlcNAc(Man)3GlcNAc + 2
	alpha-D-mannose (#4,8# natural substrate, involved in the processing of
	N-linked oligosaccharides <1,18>) <1,18>

SUBSTRATE_PRODUCT
SP	#1# 5-fluoro-beta-L-gulosyl fluoride + H2O = ? (#1# acts as slow
	substrate with a rate-limiting deglycosylation step, wild-type and
	D341N mutant GMII <24>) <24>
SP	#1# 2-deoxy-2-fluoro-alpha-D-mannosyl fluoride = ? (#1# wild-type and
	D341N mutant GMII, acts as very slow substrate of the mutant enzyme
	with a rate-limiting deglycosylation step <24>) <24>
SP	#1# 4-methylumbelliferyl alpha-D-mannoside + H2O = 4-methylumbelliferol
	+ alpha-D-mannose <36>
SP	#1# 4-methylumbelliferyl alpha-D-mannopyranoside + H2O = ? <50>
SP	#1# 2,4-dinitrophenyl alpha-D-mannopyranoside + H2O = ? <51>
SP	#1# 4-nitrophenyl-alpha-D-mannopyranoside + H2O = 4-nitrophenol +
	alpha-D-mannose (#1# 30 min, 20°C <49>) <49>
SP	#1,2,3,4,5,6,8,10,11,12,14,17,18,19,21# more = ? (#14,19# substrate
	specificity, overview <31,37>; #4,18# domain structure <1,20>; #5,11#
	not: (Man)5(GlcNAc)2 <22,23>; #8# not: Glc3(Man)9GlcNAc <8,17>; #10#
	not: 4-nitrophenyl alpha-mannoside <4,7>; #10# not:
	D-Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(GlcNAcbeta(1
	4))[GlcNAcbeta(1-4)(GlcNAcbeta(1-2))Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc,
	GlcNAcbeta(1-2)Manalpha(1-3)(Manalpha(1-6))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc,
	GlcNAcbeta(1-4)Manalpha(1-3)(Manalpha(1-6))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc, all sodium borate reduced <4>; #1# enzyme/active site
	structure and substrate binding, catalytic mechanism <24>; #4,8# not:
	(Man)9GlcNAc <8,13,17>; #10# not:
	Manalpha(1-6)(R-Manalpha(1-3))Manbeta(1-4)GlcNAc <7>; #4# not:
	GlcNAc(Man)3GlcNAc <13>; #4,8# not: (Man)5GlcNAc <2,8,13,17>; #10#
	substrate specificity, hydrolysis mechanism of branched
	oligosaccharides <4>; #11# alpha-mannosidase III hydrolyzes
	(Man)5-9(GlcNAc)2, not: GlcNAc(Man)5(GlcNAc)2 <28,29>; #4# involved in
	asparagine-linked oligosaccharide processing <15>; #4# required in the
	maturation of asparagine-linked oligosaccharides in the Golgi complex
	<16>; #4# biosynthesis of complex-type N-linked oligosaccharides of
	glycoproteins <2>; #11# alpha-mannosidase III probably provides an
	alternate N-glycan processing pathway in Sf-9 cells <29>; #4# function
	in Golgi membranes: presumably glycopolymer metabolism <3>; #3,4,18#
	Man II catalyzes the final hydrolytic step in the N-glycan maturation
	pathway acting as the committed step in the conversion of high mannose
	to complex type structures <20>; #2,3# involved in trimming reactions
	in N-glycan maturation in the Golgi complex <25>; #1,4,6,8,11#
	asparagine-linked glycoprotein biosynthesis <10,13,23,24>; #11# study
	of biosynthesis and processing of alpha-mannosidase III <28>; #14# Co2+
	regulates the substrate specificity, overview <32>; #19# Golgi
	alpha-mannosidase II is a key enzyme in the formation of complex
	N-glycans in plants <37>; #12# the exo-type cytosolic class II enzyme
	cleaves off alpha-1,2-, alpha-1,3-, and alpha-1,6-mannose residues
	<30>; #14# in vitro hydrolysis of high-mannose type N-glycans, removal
	of terminal alpha-1,2-mannose residues, substrate specificity and
	isomeric substrate/product structures, overview <32>; #2# MII and
	alpha-mannosidase IIx function in N-glycan processing in a similar
	manner <44>; #3# co-expression of
	beta1,4-N-acetylglucosaminyltransferase III-ManIII and ManII, or of
	beta1,4-N-acetylglucosaminyltransferase III and ManII leads to the
	formation of bisected non-fucosylated glycans of the complex type <39>;
	#2# MII and alpha-mannosidase IIx function in N-glycan processing in a
	similar manner. Alpha-mannosidase IIx shows no reactivity to
	high-mannose-type carbohydrates <44>; #17# about 80-fold preference of
	isoform GMII for the cleavage of substrates containing a nonreducing
	beta-(1,2)-linked GlcNAc group <51>; #3# Bt1769, Bt3858 and Bt3991 are
	alpha-1,3-mannosidases that display particularly high activity against
	alpha-1,3-mannobiose <58>; #17# GMII is involved in the creation of
	glycoproteins that contain complex carbohydrates. It is responsible for
	the formation of the core trimannose structure to which all complex
	carbohydrates are appended. It catalyses the hydrolysis of an
	alpha(1,6)- and an alpha(1,3)-linked mannose from GlcNAc-Man5-GlcNAc2
	to form GlcNAc-Man3-GlcNAc2-Asn-X <54>; #21# higher eukaryotic GH38
	alpha-mannosides play a key role in the modification and
	diversification of hybrid N-glycans, processes with strong cellular
	links to cancer and autoimmune disease <59>; #3#
	alpha-1,3-mannosidases, Bt3858 and Bt1769, convert Man4GlcNAc2 to
	Man3GlcNAc2, but do not attack Man5GlcNAc2, indicat­ing that these
	enzymes cannot tolerate alpha-1,6-Man side chains <58>; #21# SpGH38 is
	an alpha-mannosidase with specificity for alpha-1,3 mannosidic
	linkages, active site structure, overview <59>; #17# the cleavage
	mechanism involves formation of a covalent glycosyl-enzyme intermediate
	and results in net retention of configuration <54>) {}
	<1,2,3,4,7,8,10,13,15,16,17,20,22,23,24,25,28,29,30,31,32,37,39,44,51
	54,58,59>
SP	#1,2,3,4,5,6,8,10,11,12,14,17,18,19,21# more = ? (#14,19# substrate
	specificity, overview <31,37>; #4,18# domain structure <1,20>; #5,11#
	not: (Man)5(GlcNAc)2 <22,23>; #8# not: Glc3(Man)9GlcNAc <8,17>; #10#
	not: 4-nitrophenyl alpha-mannoside <4,7>; #10# not:
	D-Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(GlcNAcbeta(1
	4))[GlcNAcbeta(1-4)(GlcNAcbeta(1-2))Manalpha(1-3)]Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc,
	GlcNAcbeta(1-2)Manalpha(1-3)(Manalpha(1-6))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc,
	GlcNAcbeta(1-4)Manalpha(1-3)(Manalpha(1-6))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc, all sodium borate reduced <4>; #1# enzyme/active site
	structure and substrate binding, catalytic mechanism <24>; #4,8# not:
	(Man)9GlcNAc <8,13,17>; #10# not:
	Manalpha(1-6)(R-Manalpha(1-3))Manbeta(1-4)GlcNAc <7>; #4# not:
	GlcNAc(Man)3GlcNAc <13>; #4,8# not: (Man)5GlcNAc <2,8,13,17>; #10#
	substrate specificity, hydrolysis mechanism of branched
	oligosaccharides <4>; #11# alpha-mannosidase III hydrolyzes
	(Man)5-9(GlcNAc)2, not: GlcNAc(Man)5(GlcNAc)2 <28,29>; #4# involved in
	asparagine-linked oligosaccharide processing <15>; #4# required in the
	maturation of asparagine-linked oligosaccharides in the Golgi complex
	<16>; #4# biosynthesis of complex-type N-linked oligosaccharides of
	glycoproteins <2>; #11# alpha-mannosidase III probably provides an
	alternate N-glycan processing pathway in Sf-9 cells <29>; #4# function
	in Golgi membranes: presumably glycopolymer metabolism <3>; #3,4,18#
	Man II catalyzes the final hydrolytic step in the N-glycan maturation
	pathway acting as the committed step in the conversion of high mannose
	to complex type structures <20>; #2,3# involved in trimming reactions
	in N-glycan maturation in the Golgi complex <25>; #1,4,6,8,11#
	asparagine-linked glycoprotein biosynthesis <10,13,23,24>; #11# study
	of biosynthesis and processing of alpha-mannosidase III <28>; #14# Co2+
	regulates the substrate specificity, overview <32>; #19# Golgi
	alpha-mannosidase II is a key enzyme in the formation of complex
	N-glycans in plants <37>; #12# the exo-type cytosolic class II enzyme
	cleaves off alpha-1,2-, alpha-1,3-, and alpha-1,6-mannose residues
	<30>; #14# in vitro hydrolysis of high-mannose type N-glycans, removal
	of terminal alpha-1,2-mannose residues, substrate specificity and
	isomeric substrate/product structures, overview <32>; #2# MII and
	alpha-mannosidase IIx function in N-glycan processing in a similar
	manner <44>; #3# co-expression of
	beta1,4-N-acetylglucosaminyltransferase III-ManIII and ManII, or of
	beta1,4-N-acetylglucosaminyltransferase III and ManII leads to the
	formation of bisected non-fucosylated glycans of the complex type <39>;
	#2# MII and alpha-mannosidase IIx function in N-glycan processing in a
	similar manner. Alpha-mannosidase IIx shows no reactivity to
	high-mannose-type carbohydrates <44>; #17# about 80-fold preference of
	isoform GMII for the cleavage of substrates containing a nonreducing
	beta-(1,2)-linked GlcNAc group <51>; #3# Bt1769, Bt3858 and Bt3991 are
	alpha-1,3-mannosidases that display particularly high activity against
	alpha-1,3-mannobiose <58>; #17# GMII is involved in the creation of
	glycoproteins that contain complex carbohydrates. It is responsible for
	the formation of the core trimannose structure to which all complex
	carbohydrates are appended. It catalyses the hydrolysis of an
	alpha(1,6)- and an alpha(1,3)-linked mannose from GlcNAc-Man5-GlcNAc2
	to form GlcNAc-Man3-GlcNAc2-Asn-X <54>; #21# higher eukaryotic GH38
	alpha-mannosides play a key role in the modification and
	diversification of hybrid N-glycans, processes with strong cellular
	links to cancer and autoimmune disease <59>; #3#
	alpha-1,3-mannosidases, Bt3858 and Bt1769, convert Man4GlcNAc2 to
	Man3GlcNAc2, but do not attack Man5GlcNAc2, indicat­ing that these
	enzymes cannot tolerate alpha-1,6-Man side chains <58>; #21# SpGH38 is
	an alpha-mannosidase with specificity for alpha-1,3 mannosidic
	linkages, active site structure, overview <59>; #17# the cleavage
	mechanism involves formation of a covalent glycosyl-enzyme intermediate
	and results in net retention of configuration <54>) {}
	<1,2,3,4,7,8,10,13,15,16,17,20,22,23,24,25,28,29,30,31,32,37,39,44,51
	54,58,59>
SP	#1,2,3,4,8,18# 4-methylumbelliferyl alpha-D-mannoside + H2O =
	4-methylumbelliferone + alpha-D-mannose (#3# catalytic domain of
	alpha-mannosidase IIx <27>) <15,16,17,20,27,49,51>
SP	#1,2,3,4,8,18# 4-methylumbelliferyl alpha-D-mannoside + H2O =
	4-methylumbelliferone + alpha-D-mannose (#3# catalytic domain of
	alpha-mannosidase IIx <27>) {} <15,16,17,20,27,49,51>
SP	#1,3,4,11#
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1
	3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + 2 H2O =
	Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc + 2 alpha-D-mannose (#3# alpha-mannosidase II <27>; #4# acts
	after GlcNAc transferase I to remove the alpha-1,3- and
	alpha-1,6-linked mannose residue <26>; #4# non-reduced and NaBH4
	reduced substrate, removes the alpha-1,3- and alpha-1,6-mannosyl
	residues with preference for the alpha-1,6-linked mannose residue on
	the alpha-1,6-linked mannose arm, via GlcNAc(Man)4(GlcNAc)2 <12>; #3#
	alpha-mannosidase II, biosynthesis of N-glycans <27>; #4# involved in
	N-glycan maturation, acts after GlcNAc transferase I to remove 2
	mannose residues to form GlcNAc(Man)3(GlcNAc)2 prior to extension into
	complex N-glycans <26>; #1# N-glycosylation pathway <11>)
	<11,12,23,26,27>
SP	#1,3,4,11#
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1
	3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + 2 H2O =
	Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc + 2 alpha-D-mannose (#3# alpha-mannosidase II <27>; #4# acts
	after GlcNAc transferase I to remove the alpha-1,3- and
	alpha-1,6-linked mannose residue <26>; #4# non-reduced and NaBH4
	reduced substrate, removes the alpha-1,3- and alpha-1,6-mannosyl
	residues with preference for the alpha-1,6-linked mannose residue on
	the alpha-1,6-linked mannose arm, via GlcNAc(Man)4(GlcNAc)2 <12>; #3#
	alpha-mannosidase II, biosynthesis of N-glycans <27>; #4# involved in
	N-glycan maturation, acts after GlcNAc transferase I to remove 2
	mannose residues to form GlcNAc(Man)3(GlcNAc)2 prior to extension into
	complex N-glycans <26>; #1# N-glycosylation pathway <11>) {}
	<11,12,23,26,27>
SP	#1,3,4,5,6,8,11,19# 4-nitrophenyl alpha-D-mannoside + H2O =
	4-nitrophenol + alpha-D-mannose (#4# rat <25>; #11# alpha-mannosidase
	III <29>; #4# rate at 23.5% of GlcNAc(Man)5GlcNAc hydrolysis <2>; #3#
	alpha-mannosidase IIx <27>)
	<1,2,3,11,13,14,15,17,18,19,22,23,25,27,29,37,42,46>
SP	#1,4# 2,4-dinitrophenyl alpha-D-mannoside + H2O = 2,4-dinitrophenol +
	alpha-D-mannose <24,64>
SP	#10# p-nitrophenyl-alpha-D-mannopyranoside + H2O = p-nitrophenol +
	alpha-D-mannopyranose <33>
SP	#10# D-Manalpha(1-3)Manbeta(1-4)GlcNAc + H2O = D-Manbeta(1-4)GlcNAc +
	alpha-D-mannose (#10# NaBH4 reduced, good substrate <4,7>) |#10# NaBH4
	reduced <4>| <4,7>
SP	#10# R-Manalpha(1-6)(Manalpha(1-3))Manbeta(1-4)GlcNAc + H2O = ? <7>
SP	#10# D-Manalpha(1-6)Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + H2O =
	D-Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + alpha-D-mannose (#10# NaBH4
	reduced, at lower rate than Manalpha(1-3)Manbeta(1-4)GlcNAc hydrolysis
	<4>) |#10# NaBH4 reduced <4>| <4>
SP	#10# D-Manalpha(1-2)Manalpha(1-3)Manbeta(1-4)GlcNAc + H2O = ? (#10#
	NaBH4 reduced, poor substrate <4,7>) <4,7>
SP	#10# Manalpha(1-6)(Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc +
	H2O = Manalpha(1-6)Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + alpha-D-mannose
	(#10# NaBH4 reduced, cleaves the Manalpha(1-6)Man linkage only after
	its Manalpha(1-3) residue is removed <4>) |#10# NaBH4 reduced, no
	product: Manalpha(1-3)Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc <4>| {} <4,7>
SP	#10# Manalpha(1-6)(Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc +
	H2O = Manalpha(1-6)Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + alpha-D-mannose
	(#10# NaBH4 reduced, cleaves the Manalpha(1-6)Man linkage only after
	its Manalpha(1-3) residue is removed <4>) |#10# NaBH4 reduced, no
	product: Manalpha(1-3)Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc <4>| <4,7>
SP	#10#
	Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(Manalpha(1-3))Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc + H2O =
	Manalpha(1-6)(Manalpha(1-3))D-Manalpha(1-6)Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc + alpha-D-mannose (#10# NaBH4 reduced <4>) |#10# NaBH4 reduced
	<4>| <4>
SP	#10#
	GlcNAcbeta(1-2)Manalpha(1-6)(Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc + H2O = ? (#10# NaBH4 reduced, hydrolysis at equal rate as
	Manalpha(1-6)(Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc,
	galactosyl and sialyl-galactosyl derivatives are substrates, too <4>)
	<4>
SP	#10#
	GlcNAcbeta(1-6)(GlcNAcbeta(1-2))Manalpha(1-6)(Manalpha(1-3))Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc + H2O = ? (#10# NaBH4 reduced, rate at 50% of
	Manalpha(1-6)(Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc
	hydrolysis <4>) <4>
SP	#10# alpha-D-Man-(1,6)-D-Man + H2O = alpha-D-mannopyranose <33>
SP	#10# alpha-D-Manp-(1,3)-D-Manp + H2O = alpha-D-mannopyranose <33>
SP	#10# alpha-D-Manp-(1,6)-D-Manp + H2O = alpha-D-mannopyranose <33>
SP	#10# baker's yeast mannan + H2O = ? <33>
SP	#11# pyridylaminated (Man)5(GlcNAc)2 + H2O = pyridylaminated
	(Man)3(GlcNAc)2 + alpha-D-mannose (#11# via a (Man)4(GlcNAc)2
	intermediate <29>; #11# alpha-mannosidase III <28,29>) <28,29>
SP	#13# 4-nitrophenyl-alpha-D-mannopyranoside + H2O = 4-nitrophenol +
	alpha-D-mannopyranose (#13# 30 min, 37°C <49>) <49>
SP	#14# 4-nitrophenyl-alpha-D-mannoside + H2O = 4-nitrophenol +
	alpha-D-mannose <31,32>
SP	#14#
	Manalpha(1-3)Manalpha(1-6)(Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc-pyridylaminoside + H2O =
	Manalpha(1-6)(Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc
	pyridylaminoside + alpha-D-mannose <31,32>
SP	#14# Manalpha(1-3)Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside +
	H2O = Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside +
	alpha-D-mannose <31,32>
SP	#14#
	Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(Manalpha(1-3))Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside + H2O =
	Manalpha(1-3)Manalpha(1-6)(Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc-pyridylaminoside + alpha-D-mannose <31,32>
SP	#14#
	Manalpha(1-6)(Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc
	pyridylaminoside + H2O =
	Manalpha(1-3)Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside +
	alpha-D-mannose <31,32>
SP	#17# 2,4-dinitrophenyl-alpha-D-mannopyranoside + H2O =
	2,4-dinitrophenol + D-mannose <51>
SP	#17# 2,5-dinitrophenyl-alpha-D-mannopyranoside + H2O =
	2,4-dinitrophenol + D-mannose <48>
SP	#17# 2,5-dinitrophenyl-alpha-D-mannopyranoside + H2O =
	2,5-dinitrophenol + alpha-D-mannose (#17# pH 5.6, room temperature
	<48>) <48>
SP	#17#
	2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->2)-alpha-D
	mannopyranosyl-(1->3)-[alpha-D-mannopyranosyl-(1->3)-alpha-D
	mannopyranosyl-(1->6)]-beta-D-mannopyranosyl-(1->4)-2-(acetylamino)-2
	deoxy-alpha-D-glucopyranose + H2O =
	2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->2)-alpha-D
	mannopyranosyl-(1->3)-[alpha-D-mannopyranosyl-(1->6)]-beta-D
	mannopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-alpha-D-glucopyranose +
	D-mannose {ir} <52>
SP	#17#
	2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->2)-alpha-D
	mannopyranosyl-(1->3)-[alpha-D-mannopyranosyl-(1->3)-[alpha-D
	mannopyranosyl-(1->6)]-alpha-D-mannopyranosyl-(1->6)]-beta-D
	mannopyranosyl-(1->4)-2-(acetylamino)-2-deoxy-alpha-D-glucopyranose +
	H2O =
	2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1->2)-alpha-D
	mannopyranosyl-(1->3)-[alpha-D-mannopyranosyl-(1->3)-alpha-D
	mannopyranosyl-(1->6)]-beta-D-mannopyranosyl-(1->4)-2-(acetylamino)-2
	deoxy-alpha-D-glucopyranose + D-mannose {ir} <52>
SP	#17# GlcNAcMan5GlcNAc2 + H2O = ? + alpha-D-mannose <61>
SP	#19#
	Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-1-Asn + H2O =
	Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc-1-Asn + alpha-D-mannose (#19# physiological substrate,
	conversion by sequential removal of two alpha1,6-linked and
	alpha1,3-linked mannose residues from the alpha-1,6-branch of the
	substrate <37>; #19# conversion by sequential removal of two
	alpha1,6-linked and alpha1,3-linked mannose residues from the
	alpha-1,6-branch of the substrate <37>) <37>
SP	#19#
	Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))(Xylbeta(1-4))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-1-Asn + H2O =
	Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))(Xylbeta(1-4))Manbeta(1
	4)GlcNAcbeta(1-4)GlcNAc-1-Asn + alpha-D-mannose <37>
SP	#19#
	Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-pyridylaminoside + H2O =
	Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc-pyridylaminoside + alpha-D-mannose <37>
SP	#2# GlcNAc(Man)5GlcNAc2 + H2O = GlcNAc(Man)3GlcNAc2 + D-mannose (#2#
	alpha-mannosidase IIx protein <44>) <43,44>
SP	#2,3,4#
	D-Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + H2O =
	D-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc + alpha-D-mannose (#3# alpha-mannosidase II <27>) <2,25,27>
SP	#21# high mannose N-glycan + H2O = ? <59>
SP	#21# 2,4-dinitrophenyl alpha-D-mannopyranoside + H2O =
	2,4-dinitrophenol + alpha-D-mannopyranose <59>
SP	#3# ovalbumin + H2O = ? <58>
SP	#3#
	D-Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-Asn + H2O =
	D-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc-Asn + alpha-D-mannose (#3# i.e. glycopeptide III, derived from
	ovalbumin, no hydrolysis of the innermost alpha-1,6-linked or the
	alpha-1,2-linked mannose <5>) |#3# i.e. glycopeptide II <5>| <5>
SP	#3#
	Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(Manalpha(1-2)Manalpha(1
	3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + 2 H2O =
	Manalpha(1-6)(Manalpha(1-2)Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc + 2 alpha-D-mannose (#3# recombinant alpha-mannosidase IIx,
	expressed in CHO cells, hydrolyzes 2 peripheral Manapha(1-6) and
	Manalpha(1-3) residues <27>; #3# alpha-mannosidase IIx, M6Gn2 is the
	primary target in vivo, integral part of N-glycan biosynthesis <27>)
	<27>
SP	#3# GlcNAcMan5GlcNAc2 + H2O = ? <34>
SP	#3# (Man)9GlcNAc + H2O = (Man)5GlcNAc + D-mannose (#3# hydrolysis to
	(Man)5GlcNAc in the presence of Fe2+, Co2+, and Mn2+. Without
	activating cations the main reaction product is (Man)8GlcNAc <42>) <42>
SP	#3# 4-methyl-umbelliferyl-alpha-D-mannopyranoside + H2O =
	4-methyl-umbelliferone + alpha-D-mannopyranose (#3# 30 min, 37°C <49>)
	<49>
SP	#3# Man5GlcNAc2 + H2O = Man3GlcNAc2 + 2 alpha-D-mannopyranose (#3# the
	alpha-1,3-mannosidase Bt3991, while unable to hydrolyze Man9GlcNAc2,
	converts Man5GlcNAc2 into Man3GlcNAc2 hydrolyzing the distal
	alpha-1,6-mannosidic linkage in high-mannose N-glycans. The
	alpha-1,3-mannosidic linkages in N-glycans are available to the enzyme
	once the terminal alpha-1,2-linked mannosyl residues are removed  <58>)
	<58>
SP	#3# 3-O-alpha-D-mannopyranosyl-alpha-D-mannopyranose + H2O = 2
	alpha-D-mannopyranose (#3# Bt3991 displays particularly high activity
	against alpha-1,3-mannobiose <58>) <58>
SP	#3# yeast mannan + H2O = ? <58>
SP	#3,21# 3-O-alpha-D-mannopyranosyl-alpha-D-mannopyranose + H2O =
	alpha-D-mannopyranose (#21# the enzyme is only active with the
	alpha-1,3-linked disaccharide <59>) <58,59>
SP	#3,9,21# 4-nitrophenyl alpha-D-mannopyranoside + H2O = 4-nitrophenol +
	alpha-D-mannopyranose <57,58,59,60>
SP	#4# (Man)9GlcNAc + H2O = ? (#4# rate at 6.4% of GlcNAc(Man)5GlcNAc
	hydrolysis <2>) <2>
SP	#4# (Man)8GlcNAc + H2O = ? (#4# rate at 5% of GlcNAc(Man)5GlcNAc
	hydrolysis <2>) <2>
SP	#4# (Man)7GlcNAc + H2O = ? (#4# rate at 3% of GlcNAc(Man)5GlcNAc
	hydrolysis <2>) <2>
SP	#4# (Man)6GlcNAc + H2O = ? (#4# rate at 2% of GlcNAc(Man)5GlcNAc
	hydrolysis <2>) <2>
SP	#4#
	Manalpha(1-6)[Manalpha(1-3)]Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1
	3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-Asn + H2O =
	Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc-Asn + alpha-D-mannose (#4# processing of asparagine-linked
	oligosaccharides by alpha-D-mannosidase dependent on the prior action
	of UDP-GlcNAc:alpha-D-mannoside beta2-N-acetylglucosaminyltransferase
	I, removes 2 mannosyl residues, via GlcNAc(Man)4(GlcNAc)2Asn <12>) <12>
SP	#4,6,8# GlcNAc(Man)5GlcNAc + 2 H2O = GlcNAc(Man)3GlcNAc + 2
	alpha-D-mannose (#4# preferred substrate <2>; #8# strict substrate
	specificity <8>; #4# removes the exposed alpha-1,3- and
	alpha-1,6-mannosyl residues <13>; #8# excellent substrate, removes the
	alpha-1,3- and alpha-1,6-mannosyl residues with preference for the
	alpha-1,6-linkage <17>; #4,8# natural substrate, involved in the
	processing of N-linked oligosaccharides <1,18>) |#8# final product, via
	GlcNAc(Man)4GlcNAc <8,17>; #8# product structure:
	GlcNAcManalpha(1-3)(Manalpha(1-6))ManbetaGlcNAc <17>|
	<1,2,8,9,10,13,17,18>
SP	#5,7,8,11,16# pyridylaminated
	D-Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc + H2O = pyridylaminated
	D-Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1-3))Manbeta(1-4)GlcNAcbeta(1
	4)GlcNAc + alpha-D-mannose (#5,7,8# via the intermediate product
	GlcNAc(Man)4(GlcNAc)2, the alpha-1,6-linked mannosyl residue is removed
	first, then the 1,3-linked <22>; #5# dependent on the prior action of
	N-acetylglucosaminyl transferase I on (Man)5(GlcNAc)2 <22>) <22>
SP	#8# (Man)3GlcNAc + H2O = ? (#8# poor substrate <8,17>) <8,17>
SP	#9,21# 4-methylumbelliferyl alpha-D-mannopyranoside + H2O =
	4-methylumbelliferol + alpha-D-mannopyranose <57,59>

TURNOVER_NUMBER
TN	#1# 0.048 {2,4-dinitrophenyl alpha-D-mannoside}  (#1# pH 5.6, 37°C,
	D341N mutant GMII <24>) <24>
TN	#1# 8.6 {2,4-dinitrophenyl alpha-D-mannoside}  (#1# pH 5.6, 37°C,
	wild-type GMII <24>) <24>
TN	#1# 0.0051 {5-fluoro-beta-L-gulosyl fluoride}  (#1# pH 5.6, 37°C,
	wild-type GMII <24>) <24>
TN	#21# 6.4 {3-O-alpha-D-mannopyranosyl-alpha-D-mannopyranose}  (#21# pH
	6.8, 37°C, recombinant enzyme <59>) <59>
TN	#21# 0.03 {4-methylumbelliferyl alpha-D-mannopyranoside}  (#21# pH 6.8,
	37°C, recombinant enzyme <59>) <59>
TN	#3# 4.67 {3-O-alpha-D-mannopyranosyl-alpha-D-mannopyranose}  (#3# pH
	7.0, 37°C, Bt3991 <58>) <58>
TN	#3# 0.0025 {4-nitrophenyl alpha-D-mannopyranoside}  (#3# pH 7.0, 37°C,
	Bt3991 <58>) <58>

KM_VALUE
KM	#1# 0.05 {2,4-dinitrophenyl alpha-D-mannoside}  (#1# pH 5.6, 37°C,
	D341N mutant GMII <24>) <24>
KM	#1# 0.2 {5-fluoro-beta-L-gulosyl fluoride}  (#1# pH 5.6, 37°C,
	wild-type GMII <24>) <24>
KM	#1# 25 {2-deoxy-2-fluoro-alpha-D-mannosyl fluoride}  (#1# pH 5.6,
	37°C, above, wild-type GMII <24>) <24>
KM	#1# 5.5 {2,4-dinitrophenyl alpha-D-mannoside}  (#1# pH 5.6, 37°C,
	wild-type GMII <24>) <24>
KM	#10# 14 {alpha-D-Man-(1,6)-D-Man}  <33>
KM	#10# 1.25
	{Manalpha(1,6)(Manalpha(1,3))Manbeta(1,4)GlcNAcbeta(1,4)GlcNAc}  (#10#
	NaBH4 reduced <4,7>; #10# pH 5, 37°C <4>) <4,7>
KM	#21# 3.6 {4-methylumbelliferyl alpha-D-mannopyranoside}  (#21# pH 6.8,
	37°C, recombinant enzyme <59>) <59>
KM	#21# 27 {3-O-alpha-D-mannopyranosyl-alpha-D-mannopyranose}  (#21# pH
	6.8, 37°C, recombinant enzyme <59>) <59>
KM	#3# 0.55 {4-methylumbelliferyl-alpha-D-mannopyranoside}  (#3# extracted
	from endothelial cells HCEC <49>) <49>
KM	#3# 0.2
	{D-Manalpha(1-6)(Manalpha(1-3))Manalpha(1-6)(GlcNAcbeta(1-2)Manalpha(1
	3))Manbeta(1-4)GlcNAcbeta(1-4)GlcNAc-Asn}  (#3# i.e. glycopeptide III
	<5>) <5>
KM	#3# 0.65 {4-methylumbelliferyl-alpha-D-mannopyranoside}  (#3# extracted
	from human glioblastoma cells LNZ308 <49>) <49>
KM	#3# 9 {3-O-alpha-D-mannopyranosyl-alpha-D-mannopyranose}  (#3# pH 7.0,
	37°C, Bt3991 <58>) <58>
KM	#3# 2.7 {4-nitrophenyl alpha-D-mannopyranoside}  (#3# pH 7.0, 37°C,
	Bt3991 <58>) <58>
KM	#3# 1.065 {4-methylumbelliferyl-alpha-D-mannopyranoside}  (#3#
	extracted from human glioblastoma cells LN18 <49>) <49>
KM	#4# 40 {4-nitrophenyl alpha-D-mannoside}  (#4# intact 124 kDa Man II
	and chymotrypsin-cleaved 110 kDa catalytic subunit <1>) <1>
KM	#4# 30 {4-nitrophenyl alpha-D-mannoside}  <3>

PH_OPTIMUM
PHO	#1# 5.6 (#1# assay at <24>) <24>
PHO	#1,17# 5.75 (#17# assay at <54>; #1# in MES buffer <38>) <38,54>
PHO	#1,4,19# 5.8 (#19# assay at <37>; #4# (Man)8GlcNAc as substrate <2>)
	<2,11,37>
PHO	#10,14# 5 <4,7,31,32>
PHO	#11# 6.5-6.7 <29>
PHO	#21# 6.8 (#21# assay at <59>) <59>
PHO	#3# 6.5 <58>
PHO	#3,11# -999 (#11# neutral pH-optimum <28>; #3# optimal pH is between
	6.25 and 6.75 <42>) <28,42>
PHO	#3,4,18# 5.5 (#4# assay at <13,14>; #4# 4-nitrophenyl alpha-D-mannoside
	hydrolysis <2>; #3# recombinant alpha-mannosidase IIx <27>; #18#
	endogenous enzyme in 3T3 cells and recombinant enzyme expressed in COS
	cells <20>) <2,3,13,14,20,27>
PHO	#5,9# 6-6.5 <22,57>
PHO	#8# 5.8-6.4 <8>
PHO	#8,11# 6 (#11# non-reduced GlcNAc(Man)5(GlcNAc)2 hydrolysis <23>)
	<17,23>

PH_RANGE
PHR	#1# 3.8-9 (#1# 30 min <50>) <50>
PHR	#10# 4-4.5 <33>
PHR	#10# 3.5-6 (#10# pH 3.5: more than 70% of maximal activity, pH 6: about
	half-maximal activity <4>) <4>
PHR	#11# 5.5-6.7 (#11# alpha-mannosidase III activity is negligible at pH
	5.5, increases at pH 5.7-5.9, decreases at pH 6.1 and rises to a
	plateau at pH 6.5-6.7 <29>) <29>
PHR	#3# 4.25-8 <42>
PHR	#4# 4.2-6 (#4# pH 4.2: about half-maximal activity, pH 6: about 80% of
	maximal activity <3>) <3>
PHR	#8# 4.8-7 (#8# about half-maximal activity at pH 4.8 and 7 <17>) <17>

SPECIFIC_ACTIVITY
SA	#10# 38000.0 <4,7>
SA	#12# 4.2 (#12# purified recombinant TM1851 <30>) <30>
SA	#14# 5.4 (#14# purified native enzyme <31>) <31>
SA	#19# 6.38 (#19# purified recombinant GMII expressed in insect cells,
	substrate 4-nitrophenyl alpha-mannoside <37>) <37>
SA	#4# 3.1 (#4# pH 5.5, 37°C <3>) <3>
SA	#4# 6.75 (#4# intact 124 kDa Man II <1>) <1>
SA	#4# 1.425 (#4# 4-nitrophenyl alpha-D-mannoside as substrate <2>) <2>
SA	#4# 7.03 (#4# chymotrypsin-cleaved soluble 110 kDa catalytic subunit
	<1>) <1>
SA	#4,8,11,18# -999.0 <8,13,17,20,23>

TEMPERATURE_OPTIMUM
TO	#1# 20 <49>
TO	#1,2,3,4,5,8,10,11,13,14,16,19,21# 37 (#1,2,3,4,5,8,10,11,14,16,19,21#
	assay at <2,3,4,5,7,8,11,12,13,14,16,19,22,23,24,27,29,31,32,37,58,59>)
	<2,3,4,5,7,8,11,12,13,14,16,19,22,23,24,27,29,31,32,37,38,49,58,59>
TO	#10# 60 <33>
TO	#17# 25 (#17# assay at <54>) <54>
TO	#9# 30 (#9# assay at <57>) <57>

TEMPERATURE_RANGE
TR	#14# 4-8.5 (#14# low activity at neutral pH <31>) <31>

ACTIVATING_COMPOUND
AC	#3,4# more (#4# not activated by glucose, galactose, AMP, ADP, GMP,
	GDP, GTP, CDP, CTP, UMP, UDP, UTP, cAMP, cGMP <3>; #3# no effect with
	EDTA <42>) <3,42>
AC	#4# dithiothreitol (#4# activation <3>) <3>
AC	#4# 2-mercaptoethanol (#4# activation <3>) <3>
AC	#4# bovine serum albumin (#4# 0.125 mg/l, 35% activation <3>) <3>
AC	#4# fucose (#4# 250 mM, 15-20% activation <3>) <3>
AC	#4# ATP (#4# 1 mM, 27% activation <3>) <3>
AC	#4# CMP (#4# 1 mM, 25% activation <3>) <3>
AC	#5,8# Triton X-100 (#8# activation, 0.15-0.2% <8>; #8# 25-30%
	activation, 0.05% <17>; #5# omission results in 40% decrease of
	activity <22>) <8,17,22>

INHIBITORS
IN	#1# salacinol <38,45>
IN	#1# ghavamiol <38>
IN	#1# N-benzyl-mannostatin <36>
IN	#1# 1-deoxyamino-cyclopentitetrol <36>
IN	#1#
	(2R,3R,4S)-2-([[(1S)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol <45>
IN	#1#
	(2R,3R,4S
	5R)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-5-methylpyrrolidine
	3,4-diol <45>
IN	#1# 8-epi-lentiginosine <46>
IN	#1# (1R,2S,3R,4R,5R)-5-aminocyclopentane-1,2,3,4-tetraol <50>
IN	#1# seleno-salacinol <38>
IN	#1# diastereomer of salacinol <38>
IN	#1# diastereomer of seleno-salacinol <38>
IN	#1# (2R,3R,4R,5R)-2-(hydroxymethyl)piperidine-3,4,5-triol <45>
IN	#1# (2R,3R,4R,5R)-5-amino-2-(hydroxymethyl)piperidine-3,4-diol <45>
IN	#1#
	(2R,3R,4S,5S)-6-amino-2-(hydroxymethyl)-2,3,4,5-tetrahydropyridine-3,4
	5-triol <45>
IN	#1#
	(2R,3S,4S)-1-[(2S,3S)-2,4-dihydroxy-3-(sulfooxy)butyl]-3
	4-dihydroxy-2-(hydroxymethyl)tetrahydrothiophenium <45>
IN	#1# (3R,4R)-4-aminopyrrolidin-3-ol <45>
IN	#1#
	(5R,6R,7S,8R)-5-methyl-1,5,6,7,8,8a-hexahydrotetrazolo[1,5-a]pyridine-6
	7,8-triol <45>
IN	#1#
	(5R,6R,7S,8S)-5-(hydroxymethyl)-1,5,6,7,8,8a-hexahydroimidazo[1
	2-a]pyridine-6,7,8-triol <45>
IN	#1# 5-thio-alpha-D-mannopyranosylamine <45>
IN	#1# N-[(R)-amino(phenyl)methyl]-5-thio-alpha-D-mannopyranosylamine <45>
IN	#1# 1-deoxyaminocyclopentitetrol (#1# poor inhibitor <50>; #1#
	structural basis of the inhibition of Golgi alpha-mannosidase II and
	the role of the thiomethyl moiety in ligand-protein interactions,
	overview <36>) <36,50>
IN	#1# di-epi-swainsonine (#1# weak inhibitor <46>) <46>
IN	#1# 5-fluoro-beta-L-gulosyl fluoride (#1# reversible, wild-type and
	D341N mutant GMII, inhibits only at low assay temperatures, acts as
	slow substrate at 37°C <24>) <24>
IN	#1# 2-deoxy-2-fluoro-alpha-D-mannosyl fluoride (#1# reversible, D341N
	mutant GMII <24>) <24>
IN	#1# N-benzyl mannostatin A (#1# structural basis of the inhibition of
	Golgi alpha-mannosidase II and the role of the thiomethyl moiety in
	ligand-protein interactions, overview <36>) <36>
IN	#1# (1R,2S,8aS)-1,2-dihydroxyoctahydrothieno[1,2-a]thiopyranium
	chloride (#1# good inhibitor, lacks a hydroxyl group at C-5, more than
	140fold better inhibitor of GMII than di-epi-swainsonine <46>) <46>
IN	#1# (1S,2R,6R,7R,8S,8aS)-octahydroindolizine-1,2,6,7,8-pentol (#1# most
	active <45>) <45>
IN	#1# (2R,3S,4R)-2-[(1R)-1-hydroxyethyl]pyrrolidine-3,4-diol (#1# most
	active <45>) <45>
IN	#1,14,17# kifunensine (#14# complete inhibition at 0.5 mM <31>; #1#
	weak, mode of binding <11>) <11,31,45,48>
IN	#1,17# deoxymannojirimycin <48,63>
IN	#1,17#
	(2R,3R,4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol <45,49>
IN	#1,17# noeuromycin <40,48>
IN	#1,17# (1R,2R,3R,4S,5R)-4-amino-5-methoxycyclopentane-1,2,3-triol <50>
IN	#1,17# mannostatin B (#1# strong inhibitor, reversible, competitive
	<50>) <50>
IN	#1,2,3,4,5,8,11,13,17,18,19,21# swainsonine (#1,4,8# very strong
	<11,13,17,18>; #4# i.e.
	(1S,2R,8R,8aR)-1,2,8-trihydroxyoctahydroindolizidine <13>; #8# i.e.
	(1S,2R,8R,8aR)-trihydroxyindolizidine <17>; #3# inhibits both
	alpha-mannosidase II and IIx, the latter is less sensitive <27>; #4#
	kinetics, in vivo and in vitro, partially reversible depending on
	inhibitor concentration <14>; #5# 30 nM, 85% inhibition <22>; #11#
	alpha-mannosidase III, IC50: 10 nM <29>; #1# mode of binding <11>; #4#
	200 nM, 50% inhibition <13,14>; #11# 20 nM, 50% inhibition <23>; #19#
	50% inhibition of recombinant GMII at 18 nM <37>; #3# potent inhibition
	at 1 mM, 100% inhibition of the activity of the liver lysosomal
	fraction at pH 4.0, 95% at pH 6.5 <35>; #21# binding structure,
	overview <59>; #3# disrupts enzyme activity, whereby inducing a novel
	class of hybrid-type glycosylation containing a partially processed
	mannose moiety <41>; #1# most active <45>; #1,3,13# competitve
	inhibitor <49>; #17# most powerful inhibitor <61>)
	<1,8,9,11,13,14,17,18,20,22,23,24,25,27,29,35,37,38,41,45,46,48,49,51
	53,54,56,59,60,61,63,64>
IN	#1,3# mannostatin <34,49,51>
IN	#1,3,11,14# 1-deoxymannojirimycin (#14# complete inhibition at 0.5 mM
	<31>; #11# 0.4 mM, 50% inhibition <23>; #1# more inhibitory than
	kifunensine, mode of binding <11>; #3# 61% inhibition of the activity
	of the liver lysosomal fraction at pH 4.0, 37% at pH 6.5, at 1 mM <35>)
	<11,23,31,35>
IN	#1,3,13#
	(2S,3R,4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol <49>
IN	#1,3,13#
	(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one (#1,13# competitive inhibitor <49>) <49>
IN	#1,3,13#
	(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one (#1,3,13# competitve inhibitor <49>) <49>
IN	#1,3,4,5,6,8,10,11,17,19# more (#4,8,10,11# not inhibited by EDTA
	<2,3,4,17,23>; #5# not inhibited by Ca2+ <22>; #4# not inhibited by
	chelating agents, 0.1 mM 1,10-phenanthroline, 1 mM 2,2-dipyridyl, 250
	mM glucose, 250 mM galactose <3>; #4,5,8# not inhibited by Mn2+, Mg2+
	<3,17,22>; #4,6,8# not inhibited by N-acetylmannostatin A <9,18>; #8#
	not inhibited by castanospermine, deoxynojirimycin <8>; #4,8# not
	inhibited by Co2+, Zn2+ <2,17>; #4# not inhibited by Tris-maleate
	<2,16>; #8# not inhibited by deoxymannojirimycin <8,17>; #8# not
	inhibited by EGTA, 6-epicastanospermine, 2-episwainsonine, a
	trisaccharide of mannose residues linked in alpha-1,2-linkages, a
	tetrasaccharide of mannose with the nonreducing mannose linked in
	alpha-1,3-linkage to an alpha-1,2-linked trisaccharide of mannose <17>;
	#11# effect of tunicamycin and castanospermine on the production of the
	3 forms of alpha-mannosidase III <28>; #4# not inhibited by Tris-Cl,
	iodoacetamide, alpha-methylmannoside <2>; #19# no inhibition of
	recombinant GMII by EDTA <37>; #1# simulations of ligand/inhibitor
	binding <36>; #17# inhibitor synthesis, overview <54>; #3# inhibitor
	design and synthesis, and cytototxic effect in vivo, overview.
	2-[(Benzylamino)methyl]pyrrolidine-3,4-diol derivatives as
	alpha-mannosidase inhibitors and with antitumor activities against
	hematological and solid malignancies <53>; #3# not inhibited by
	alpha-D-mannose <60>) <2,3,4,8,9,16,17,18,22,23,28,36,37,53,54,60>
IN	#1,3,4,6,8,17# Mannostatin A (#4,6,8# cyclopentanol structure
	containing thiomethyl and amino functional groups, in vivo and in vitro
	<9,10,18>; #8# very potent inhibitor, competitive, IC50: about 10 nM
	with 4-nitrophenyl alpha-D-mannoside as substrate, about 90 nM with
	GlcNAc(Man)5GlcNAc as substrate, equally potent as swainsonine <18>;
	#8# potent inhibitor, equally effective as D-mannonolactam amidrazone
	<10>; #1# structural basis of the inhibition of Golgi alpha-mannosidase
	II and the role of the thiomethyl moiety in ligand-protein
	interactions, overview <36>; #1# strong inhibitor, reversible,
	competitive <50>) <9,10,18,36,46,50,60>
IN	#10# Mn2+ <33>
IN	#11,14# Zn2+ (#14# 9% inhibition at 1 mM <31>; #11# 10 mM: 40%
	inhibition, 2.5 mM: no inhibition <23>; #11# alpha-mannosidase III
	<29>) <23,29,31>
IN	#17#
	(3R,4R,5R)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one <49>
IN	#17#
	(3R,4R,5R)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one <49>
IN	#17# (1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol <49>
IN	#17# glucoimidazole <48>
IN	#17# mannoimidazole <48,61>
IN	#17# gluco-hydroxyiminolactam <48,61>
IN	#17# N-octyl-6-epi-valienamine <48>
IN	#17#
	[[(3S,4S,5R,6R)-3,4
	5-trihydroxy-6-(hydroxymethyl)piperidin-2-ylidene]amino]
	N-(4-chlorophenyl)carbamate <48>
IN	#17#
	1-phenyl-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone <54>
IN	#17#
	1-(4-methylphenyl)-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone <54>
IN	#17#
	1-(4-tert-butylphenyl)-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone <54>
IN	#17# (1R,2R,3S,4R,5R)-5-aminocyclopentane-1,2,3,4-tetrol <50>
IN	#17# (3S,4S,5R,6R,E)-3,4,5-trihydroxy-6-(hydroxymethyl)piperidin-2-one
	O-4-chlorophenylcarbamoyl oxime <48>
IN	#17#
	1-(4-tert-butylphenyl)-2-[(1S,2R,5S,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone <54>
IN	#17#
	(1S,2R,5S,8R,8aR)-5-[2-(4-tert-butylphenyl)ethyl]octahydroindolizine-1
	2,8-triol <54>
IN	#17#
	(1S,2R,5R,8R,8aR)-5-[2-(4-tert-butylphenyl)ethyl]octahydroindolizine-1
	2,8-triol <54>
IN	#2,3,4,6,8# 1,4-Dideoxy-1,4-imino-D-mannitol (#8# much less effective
	than swainsonine <17>) <6,8,9,17,25>
IN	#3# 8,8a-di-epi-swainsonine <35>
IN	#3# 8a-epi-swainsonine <35>
IN	#3#
	(2S,3R
	4S)-2-[([(1R)-2-[(4-bromophenyl)(hydroxy)methoxy]-1
	phenylethyl]amino)methyl]pyrrolidine-3,4-diol <49>
IN	#3#
	(3R,4R
	5S)-5-[([(1R)-2-[(4-bromophenyl)(hydroxy)methoxy]-1
	phenylethyl]amino)methyl]-3,4-dihydroxy-1-methylpyrrolidin-2-one <49>
IN	#3#
	(3R,4R
	5S)-5-[([(1R)-2-[(4-bromophenyl)(hydroxy)methoxy]-1
	phenylethyl]amino)methyl]-3,4-dihydroxypyrrolidin-2-one <49>
IN	#3# meso-aminocyclopentitretrol <34>
IN	#3#
	(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-benzylamino)cyclopentane <34>
IN	#3#
	(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-fluoro-benzyl)amino)cyclopentane <34>
IN	#3#
	(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-chloro-benzyl)amino)cyclopentane <34>
IN	#3#
	(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-bromo-benzyl)amino)cyclopentane <34>
IN	#3#
	(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-methoxy-benzyl)amino)cyclopentane <34>
IN	#3# (1R,2R,3R,4S,5S)-1,2,3,4-tetrahydroxy-5-(N-benzylamino)cyclopentane
	<34>
IN	#3#
	(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-fluoro-benzyl)amino)cyclopentane <34>
IN	#3#
	(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-chloro-benzyl)amino)cyclopentane <34>
IN	#3#
	(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-bromo-benzyl)amino)cyclopentane <34>
IN	#3#
	(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-methoxy-benzyl)amino)cyclopentane <34>
IN	#3# (1R,2R,3R,4S,5S)-1,2,3,4-tetrahydroxy-5-(N-(p-allyl ester
	benzyl)amino)cyclopentane <34>
IN	#3# (RS)-2-phenylethyl alpha-D-mannopyranosyl sulfoxide <60>
IN	#3# benzyl alpha-D-mannopyranosyl sulfone <60>
IN	#3# 2-phenylethyl alpha-D-mannopyranosyl sulfone <60>
IN	#3#
	(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-allyl-ester-benzyl)amino)cyclopentane <34>
IN	#3#
	(2R,3R,4S)-2[[((1R)-1-[1
	1'-biphenyl]-4-yl-2-hydroxyethyl)amino]-methyl]pyrrolidine-3,4-diol <53>
IN	#3#
	(2R,3R
	4S)-2[[((1R)-2-hydroxy-1-[4-(2-thienyl)phenyl]ethyl)
	amino]methyl]pyrrolidine-3,4-diol <53>
IN	#3#
	(2R,3R
	4S)-2[[((1R)-2-hydroxy-1-[4-(prop-2-enyloxy)phenyl]-ethyl)amino]methyl]
	pyrrolidine-3,4-diol <53>
IN	#3#
	(2R,3R
	4S)-2[[((1R)-2-hydroxy-1-(4
	(phenylmethoxy)phenyl)ethyl)amino]methyl]pyrrolidine-3,4-diol <53>
IN	#3#
	(2R,3R
	4S)-2[([(1R)-2-hydroxy-1-(4-methoxyphenyl)ethyl]amino)
	methyl]pyrrolidine-3,4-diol <53>
IN	#3# (1R,6R,7R,8S)-7,8-dihydroxy-5-thia-1-thioniabicyclo[4.3.0]nonane
	chloride (#3# synthetic inhibitor, selective and potent inhibition at 1
	mM, 97% inhibition of the activity of the liver lysosomal fraction at
	pH 4.0, 100% at pH 6.5 <35>) <35>
IN	#3#
	(2R,3R,4S)-2-[[((1R)-2-hydroxy-1-[4'-(trifluoromethyl)-[1
	1'-biphenyl]-4-yl]ethyl)amino] methyl]pyrrolidine-3,4-diol (#3#
	inhibits the proliferation of primary cells and cell lines of different
	origins, irrespective of Bcl-2 expression levels, inducing a G2/Mcell
	cycle arrest and by modification of genes involved in cell cycle
	progression and survival, IC50 in vivo and cytotoxic effects in
	different cell lines, overview <53>) <53>
IN	#3,4,5,8,10,11,14,19# Cu2+ (#4,11# strong <2,3,23>; #10# 1 mM, 50%
	inhibition <4>; #14# complete inhibition at 1 mM <31>; #4# 1 mM, 91-93%
	inhibition <2>; #11# 0.1 mM, 90% inhibition of GlcNAc(Man)5(GlcNAc)2
	hydrolysis, 0.01 mM, 50% inhibition of 4-nitrophenyl alpha-D-mannoside
	hydrolysis <23>; #5# 20 mM, 90% inhibition <22>; #8# 0.2 mM CuCl2, 75%
	inhibition <17>; #19# over 97% inhibition of the recombinant GMII at 1
	mM <37>; #3# completely inhibits <42>) <2,3,4,8,16,17,22,23,31,37,42>
IN	#4# p-Chloromercuriphenylsulfonate (#4# 1 mM, 80% inhibition <3>) <2,3>
IN	#4# Fe2+ (#4# strong <2,3>; #4# 1 mM, 70-76% inhibition <2>) <2,3>
IN	#4# mannose (#4# 250 mM, 30% inhibition <3>) <3>
IN	#4# Fe3+ (#4# less potent inhibitor than Fe2+ and Cu2+, 1 mM, 24-30%
	inhibition <2>) <2>
IN	#5,10,11,14# EDTA (#10# 10 mM <33>; #14# 26% inhibition at 1 mM <31>;
	#5# 20 mM, 20% inhibition <22>; #11# alpha-mannosidase III, 1 mM, 90%
	inhibition of 4-nitrophenyl alpha-D-mannoside hydrolysis, 5 mM,
	complete inhibition of (Man)5(GlcNAc)2-PA hydrolysis <29>) <22,29,31,33>
IN	#6,8# D-mannonolactam amidrazone (#6,8# broad spectrum mannosidase
	inhibitor, strong <10>; #8# equally as effective as mannostatin A,
	IC50: 90-100 nM <10>; #6# IC50: 400 nM <10>) <10>
IN	#8# alpha-1,6-linked trisaccharide of mannose (#8# 1.5 mM, 40%
	inhibition <17>) <17>
IN	#9# guanidinium hydrochloride (#9# the enzyme loses 54% and 70% of the
	original activity in 0.5 M and 1.0 M guanidinium hydrochloride,
	respectively. Irreversible denaturation at higher concentration of 6 M
	of guanidinium hydrochloride, kinetics, overview. The protein almost
	completely unfolds in 4.0 M guanidinium hydrochloride <57>) <57>

KI_VALUE
KI	#1# -999 {more}  (#1# although too weak for full Ki analyses with the
	amounts of material available, all analogues with salacinol-like
	stereochemistry at positions 2 and 3 proved to be weak inhibitors of
	the enzyme with IC50 values of approximately 7.5 mM <38>) <38>
KI	#1# 0.001
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  <49>
KI	#1# 0.0003 {(1R,2S,3R,4R,5R)-5-aminocyclopentane-1,2,3,4-tetraol}  <50>
KI	#1# 0.6 {5-fluoro-beta-L-gulosyl fluoride}  (#1# pH 5.6, 37°C, D341N
	mutant GMII <24>) <24>
KI	#1# 0.067
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  <49>
KI	#1# 0.022
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  <49>
KI	#1# 7.5 {2-deoxy-2-fluoro-alpha-D-mannosyl fluoride}  (#1# pH 5.6,
	37°C, D341N mutant GMII <24>) <24>
KI	#1# 5.2 {kifunensine}  (#1# pH 5.75, 37°C <11>) <11>
KI	#1# 0.265 {1-deoxyaminocyclopentitetrol}  <36,50>
KI	#1# 0.265 {1-deoxyamino-cyclopentitetrol}  <36>
KI	#1# 0.0000105 {swainsonine}  (#1# pH 5.75, 37°C <11>) <11>
KI	#1# 0.000249 {N-benzyl mannostatin A}  <36>
KI	#1# 0.000249 {N-benzyl-mannostatin}  <36>
KI	#1,17# 0.00002 {swainsonine}  (#17# pH 5.6 <48>) <48,49>
KI	#1,17# 0.00015 {mannostatin B}  <50>
KI	#1,17# 0.000036 {Mannostatin A}  <36,50>
KI	#1,17# 0.000076
	{(1R,2R,3R,4S,5R)-4-amino-5-methoxycyclopentane-1,2,3-triol}  <50>
KI	#13# 0.004
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  <49>
KI	#13# 0.000155 {swainsonine}  <49>
KI	#13# 0.000135
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  <49>
KI	#13# 0.000206
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  <49>
KI	#17# 0.07 {gluco-hydroxyiminolactam}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.4 {1-deoxymannojirimycin}  <48>
KI	#17# 0.4 {deoxymannojirimycin}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.02 {noeuromycin}  (#17# pH 5.6 <48>) <48>
KI	#17# 5 {kifunensine}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.001
	{(3R,4R,5R)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#17# 20C, pH 6.8 <49>) <49>
KI	#17# 0.003 {swainsonine}  (#17# pH 5.75, 25°C <54>) <54>
KI	#17# 0.0003 {(1R,2R,3S,4R,5R)-5-aminocyclopentane-1,2,3,4-tetrol}  <50>
KI	#17# 0.002 {mannoimidazole}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.017 {N-octyl-6-epi-valienamine}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.0027
	{1-(4-methylphenyl)-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
KI	#17# 0.0027
	{1-(4-tert-butylphenyl)-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
KI	#17# 0.067
	{(2R,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#17# 20C, pH 6.8 <49>) <49>
KI	#17# 0.022
	{(3R,4R,5R)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  (#17# 20C, pH 6.8 <49>) <49>
KI	#17# 0.52
	{[[(3S,4S,5R,6R)-3,4
	5-trihydroxy-6-(hydroxymethyl)piperidin-2-ylidene]amino]
	N-(4-chlorophenyl)carbamate}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.52
	{(3S,4S,5R,6R,E)-3,4,5-trihydroxy-6-(hydroxymethyl)piperidin-2-one
	O-4-chlorophenylcarbamoyl oxime}  <48>
KI	#17# 0.013 {glucoimidazole}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.0028
	{1-phenyl-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
KI	#17# 0.00002 {(1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol}  (#17#
	20C, pH 6.8 <49>) <49>
KI	#21# 0.018 {swainsonine}  <59>
KI	#3# 0.02 {8,8a-di-epi-swainsonine}  (#3# liver lysosomal fraction <35>)
	<35>
KI	#3# 0.006
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-fluoro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.01
	{(1R,2R,3R,4S,5S)-1,2,3,4-tetrahydroxy-5-(N-benzylamino)cyclopentane} 
	(#3# reaction volume containing 4-methylumbelliferyl
	alpha-D-mannopyranoside, sodium acetate pH 5.6 and ZnCl at 37°C <34>)
	<34>
KI	#3# 0.0066
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-methoxy-benzyl)amino)cyclopentane}  (#3#
	reaction volume containing 4-methylumbelliferyl
	alpha-D-mannopyranoside, sodium acetate pH 5.6 and ZnCl at 37°C <34>)
	<34>
KI	#3# 0.00067
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#3# extracted from endothelial cells HCEC
	<49>) <49>
KI	#3# 50 {meso-aminocyclopentitretrol}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.0032
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#3# extracted from human glioblastoma cells
	LN18 <49>) <49>
KI	#3# 0.75 {1-deoxymannojirimycin}  (#3# pH 5.5, liver lysosomal fraction
	<35>) <35>
KI	#3# 0.75 {8a-epi-swainsonine}  (#3# liver lysosomal fraction <35>) <35>
KI	#3# 0.0044 {(1R,2R,3R,4S,5S)-1,2,3,4-tetrahydroxy-5-(N-(p-allyl ester
	benzyl)amino)cyclopentane}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.0076
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-bromo-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.0081
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-chloro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00053
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-fluoro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00091
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-chloro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00052
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-methoxy-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00021 {mannostatin}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.00051
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-bromo-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00055
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#3# extracted from human glioblastoma cells
	LNZ308 <49>) <49>
KI	#3# 0.0233
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#3# extracted from endothelial cells HCEC <49>) <49>
KI	#3# 0.00088
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-benzylamino)cyclopentane}  (#3# reaction volume
	containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate
	pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00322
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3,4-trihydroxy-5-(N-(p-allyl ester
	benzyl)amino)cyclopentane}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.0415
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#3# extracted from human glioblastoma cells LNZ308 <49>) <49>
KI	#3# 0.0325
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#3# extracted from human glioblastoma cells LN18 <49>) <49>

METALS_IONS
ME	#1,4,17,19,21# Zn2+ (#4# activation <2,3>; #17# contains zinc <61>;
	#21# involved in catalysis <59>; #1# active site coordination to Zn2+
	<11,24,25>; #17# crystallization data <52>; #19# the recombinant GMII
	contains zinc in a stoichiometric amount <37>; #1# di-epi-swainsonine
	has only a single hydroxyl group at C-8 interacting with the zinc ion
	of the enzyme <46>; #1# GMII contains a Zn atom which forms contacts
	with substrate analogues, stabilizes catalytic intermediates, and other
	inhibitors observed in the active site <40>; #1# is involved in the
	catalytic activity of the enzyme and in the strong binding of
	inhibitors <45>; #1# contains one zinc atom <63>)
	<2,3,11,24,25,37,40,45,46,48,52,54,59,61,63>
ME	#10,14# Ca2+ (#10# 1 mM <33>; #10# strongly activates, 1 mM, 13fold
	<4,7>; #14# 7% activation at 1 mM <31>) <4,7,31,33>
ME	#11# Ni2+ (#11# alpha-mannosidase III, little activation <29>) <29>
ME	#12# Cd2+ (#12# preferred divalent cation <30>) <30>
ME	#3,11# Mn2+ (#11# alpha-mannosidase III, activates to a lesser extend
	than Co2+ <29>) <29,42>
ME	#3,14# Fe2+ (#14# 14% activation at 1 mM <31>; #3# is more activated by
	Fe2+ than Co2+ <42>) <31,42>
ME	#3,4,11,12,14# Co2+ (#4,11# activation <2,3,29>; #11# alpha-mannosidase
	III, cobalt-dependent <28,29>; #12# preferred divalent cation <30>;
	#14# 120% activation at 1 mM, not essential <31>; #14# activates,
	responsible for regulation of substrate specificity <32>)
	<2,3,28,29,30,31,32,42>
ME	#3,4,5,8,10,11,14,19# more (#5,8,11# no metal ion requirement
	<17,22,23>; #5,8,11# not activated by Ca2+ <17,22,23>; #4# not
	activated by Na+ <3>; #8,10,11# not activated by Zn2+ <4,17,23>; #8,11#
	not activated by Co2+ <17,23>; #11# not activated by Sr2+ <23>; #10#
	not activated by Ba2+ <4>; #4,5,8,10,11# not activated by Mg2+, Mn2+
	<3,4,17,22,23>; #10# does not need Ca2+ or any other metal cofactor of
	those tested <33>; #19# no effect on recombinant GMII through Ca2+,
	Co2+, Mn2+, Ni2+, and Zn2+ <37>; #14# the enzyme is not affected by
	Mn2+ <31>; #3# no effect with Zn2+, Ca2+, and Mg2+ <42>)
	<3,4,17,22,23,31,33,37,42>

MOLECULAR_WEIGHT
MW	#1# 120500 (#1# x * 120500, D341N mutant GMII <24>) <24>
MW	#10# 97000 (#10# SDS-PAGE <33>) <33>
MW	#10# 81000 (#10# native-PAGE <33>) <33>
MW	#10# 74000 (#10# SDS-PAGE <33>) <33>
MW	#11# 150000 (#11# x * 150000, intact glutathione S-transferase-tagged
	secreted form of SfManIII, SDS-PAGE <29>) <29>
MW	#11# 240000 (#11# PAGE under nonreducing conditions <23>) <23>
MW	#11,14# 120000 (#11# 2 * 120000, SDS-PAGE <23>; #14# x * 120000,
	SDS-PAGE <32>; #14# 3 * 120000, SDS-PAGE <31>) <23,31,32>
MW	#14# 340000 (#14# gel filtration <31>) <31>
MW	#17# 127000 (#17# x * 127000, predicted from the amino acid sequence
	<21>) <21>
MW	#18# 131000 (#18# x * 131000, predicted from the amino acid sequence
	<20>) <20>
MW	#2,4,20# 124000 (#4# 2 * 124000, intact enzyme, SDS-PAGE <1>; #2,4# x *
	124000, intact subunit, SDS-PAGE <15,16>; #20# x * 124000 <55>)
	<1,15,16,55>
MW	#3# 112000 (#3# 4 * 112000, SDS-PAGE <42>) <42>
MW	#3# 468000 (#3# gel filtration <42>) <42>
MW	#4# 230000 (#4# chymotrypsin-cleaved 110 kDa catalytic subunit, gel
	filtration <1>) <1>
MW	#4# 285000 (#4# intact enzyme, gel filtration <1>) <1>
MW	#4# 14000 (#4# x * 110000 + x * 14000, 110 kDa proteolytically
	resistant, hydrophilic catalytic domain and 14 kDa hydrophobic membrane
	anchoring domain, generated by mild chymotrypsin digest, SDS-PAGE <15>)
	<15>
MW	#4# 295000 (#4# tetrameric form, gel filtration <3>) <3>
MW	#4,10# 110000 (#4# sucrose density gradient centrifugation <3>; #10#
	native-PAGE <33>; #4# 2 * 110000, chymotrypsin-cleaved catalytic
	subunit, SDS-PAGE <1>; #4# x * 110000 + x * 14000, 110 kDa
	proteolytically resistant, hydrophilic catalytic domain and 14 kDa
	hydrophobic membrane anchoring domain, generated by mild chymotrypsin
	digest, SDS-PAGE <15>) <1,3,15,33>
MW	#4,8# 128000 (#4# 2 * 128000, SDS-PAGE <19>; #8# x * 128000, SDS-PAGE
	<8>) <8,19>
MW	#8# 125000 (#8# x * 125000, SDS-PAGE <17>) <17>

POSTTRANSLATIONAL_MODIFICATION
PM	#11# proteolytic modification (#11# a subpopulation of Golgi
	alpha-mannosidase III appears to be proteolytically cleaved and is
	secreted in enzymically active form <28>) <28>
PM	#2# lipoprotein (#2# [3H]palmitate can be incorporated into enzyme,
	glycosylation is not required for fatty acid attachment <16>) <16>
PM	#2,3# phosphoprotein (#3# phosphate is present as serine phosphate
	<16>) <16>
PM	#2,3,11# more (#11# study of biosynthesis and processing of
	alpha-mannosidase III <28>; #2,3# study of posttanslational
	modifications, sulfate is attached to N-linked oligosaccharide, no
	proteolytic modification <16>) <16,28>
PM	#2,3,4,8,11,14,18,19# glycoprotein (#11# integral membrane glycoprotein
	<29>; #3# addition of O- and asparagine-linked oligosaccharides <16>;
	#2# addition of asparagine-linked oligosaccharides, not O-glycosylated
	<16>; #4# presumably <3>; #11# alpha-mannosidase III is initially
	synthesized as a high-mannose glycoprotein precursor, its N-glycans are
	trimmed as it is transported to the Golgi apparatus, N-glycosylation is
	required for the production of active enzyme <28>; #8# presumably an
	N-linked glycoprotein with high-mannose chains <17>; #14#
	N-glycosylation, the sugar chain of the enzyme is recognized by
	concanavalin A, no digestion by endoglycosidase H, glycan type is
	deduced as GlcNAc2Man3Xyl1Fuc1GlcNAc2, bianntenary plant complex type
	N-glycans <31>; #19# recombinant secreted His-tagged soluble enzyme
	from culture medium of Spodoptera frugiperda Sf21 insect cells is
	N-glycosylated ans sensitive to PNGaseF <37>) <1,3,16,17,20,28,29,31,37>

SUBUNITS
SU	#1,2,3,4,8,11,14,17,18,20# ? (#8# x * 125000, SDS-PAGE <17>; #14# x *
	120000, SDS-PAGE <32>; #1# x * 120500, D341N mutant GMII <24>; #11# x *
	150000, intact glutathione S-transferase-tagged secreted form of
	SfManIII, SDS-PAGE <29>; #4# x * 110000 + x * 14000, 110 kDa
	proteolytically resistant, hydrophilic catalytic domain and 14 kDa
	hydrophobic membrane anchoring domain, generated by mild chymotrypsin
	digest, SDS-PAGE <15>; #2,4# x * 124000, intact subunit, SDS-PAGE
	<15,16>; #3# x * 134000-136000, MW after posttranslational
	modification, initial synthesis product of 124 kDa, SDS-PAGE <16>; #18#
	x * 131000, predicted from the amino acid sequence <20>; #17# x *
	127000, predicted from the amino acid sequence <21>; #8# x * 128000,
	SDS-PAGE <8>; #20# x * 124000 <55>) <8,15,16,17,20,21,24,29,32,55>
SU	#14# trimer (#14# 3 * 120000, SDS-PAGE <31>) <31>
SU	#19,21# More (#19# the enzyme has a transmembrane domain and a
	cytoplasmic tail sufficient for localisation of the enzyme to the Golgi
	complex, retention by lumenal sequences is not involved <37>; #21#
	structure comparisons, overview <59>) <37,59>
SU	#3,4# tetramer (#3# 4 * 112000, SDS-PAGE <42>; #4# 4 * 75000-80000,
	enzyme exists also in a relatively stable 150 kDa dimeric form,
	SDS-PAGE <3>) <3,42>
SU	#4,11# dimer (#11# 2 * 120000, SDS-PAGE <23>; #4# 2 * 124000, intact
	enzyme, SDS-PAGE <1>; #4# 2 * 110000, chymotrypsin-cleaved catalytic
	subunit, SDS-PAGE <1>; #4,11# disulfide-linked homodimer <1,19,23>; #4#
	2 * 128000, SDS-PAGE <19>) <1,19,23>

PI_VALUE
PI	#10# 4.8 (#10# for the second isoform of the enzyme, isoelectric
	focusing <33>) <33>
PI	#10# 4.3 (#10# for the first isoform of the enzyme, isoelectric
	focusing <33>) <33>
PI	#10# 4.6 (#10# method not mentioned <33>) <33>
PI	#4# 5.8 (#4# pH 3 to 10 gradient, isoelectric focusing <3>) <3>

APPLICATION
AP	#1,17# drug development (#1# development of specific inhibitors of GMII
	that can lead to novel anti-metastatic or anti-inflammatory compounds
	<40>; #17# the enzyme Golgi alpha-mannosidase II is a promising target
	for intervention in the glycosylation process <54>) <40,54>
AP	#1,2,3# medicine (#2,3# enzyme deficiency causes congenital
	dyserythropoietic anemia with splenomegaly and various additional
	abnormalities and complications <25>; #3# reduced expression of Man II
	in the autosomal genetic HEMPAS disease, i.e. hereditary erythroblastic
	multinuclearity associated with positive acidified serum <20,25>; #2#
	alpha-mannosidase IIx is an isozyme of MII. Either MII or
	alpha-mannosidase IIx can biochemically compensate for the deficiency
	of the other in vivo, and either of two is required for late embryonic
	and early postnatal development <44>; #1# promising target for drug
	development in anti-tumor therapies, ability of seven available docking
	programs to predict the binding mode and binding affinity of
	alpha-mannosidase II inhibitors <45>) <20,25,44,45>
AP	#3# biotechnology (#3# the Lec36 cell line will be useful for
	expressing therapeutic glycoproteins with hybrid-type glycans and as a
	sensitive host for detecting mutations in human MAN2A1 causing type II
	congenital dyserythropoietic anemia <56>) <56>

ENGINEERING
EN	#1,17# D341N (#1# mutant with removed acid/base catalyst, 2fold lower
	Km and 200fold kcat values compared with the wild-type enzyme <24>; #1#
	acid-base mutant, residual mannosidase activity <51>; #17# almost
	complete loss of activity. Substrate mannose is found in a distorted
	high energy B2,5 conformation, which is necessary for it to fit in the
	confined space of the binding pocket <51>) <24,51>
EN	#1,17# D204A (#17# almost complete loss of activity. Residue D204 is
	involved in the conformational change of the bound mannoside to a
	high-energy B2,5 conformation. In the mutant, mannose adopts the
	low-energy 4C1 conformation <51>; #1# mutant of Drosophila
	melanogaster, residual mannosidase activity <51>) <51>
EN	#2,3,19,20# more (#2# mutants without GlcNAc(Man)5(GlcNAc)2 activity,
	Golgi mannosidase II-null mice phenotype <25>; #19# construction of two
	Golgi alpha-mannosidase II knockout mutant plants, lines Salk_052443
	and Salk_141821, resulting in predominant presence of unprocessed
	N-glycans but revealing also that alternative routes for N-glycan
	processing exist in the plants, mutant substrate specificity analysis,
	overview <37>; #2# MII/alpha-mannosidase IIx double knockout mice
	synthesize no complex-type N-glycans <43>; #2# MII/alpha-mannosidase
	IIx double knockout mice, completely lack complex-type N-glycans, some
	double-nulls die between embryonic days 15.5 and 18.5, but most survive
	until shortly after birth and die of respiratory failure.
	Alpha-mannosidase IIx-null mice are mainly complex-type and also
	contain high-mannose-type but not significant levels of hybrid-type
	N-glycans. In contrast, MII-null embryos show high levels of
	hybrid-type N-glycans and reduced levels of complex-type N-glycans
	<44>; #20# construction of a knockout mutant DELTAAfams1, deletion of
	the Afams1 leads to a severe defect in conidial formation, especially
	at a higher temperature. In addition, abnormalities of polarity and
	septation are associated with the DELTAAfams1 mutant, phenotype and
	morphogenesis of the DELTAAfams1 mutant, detailed overview.
	Construction of a complemented strain by reintroduction of a wild-type
	copy of Afams1 directly into the mutated locus, under the control of
	its own promoter <55>; #3# the mutant gene MAN2A1 from strain Lec36
	harbors a point mutation in the active site in one allele and an
	in-frame deletion of 12 nucleotides in the other allele, compared to
	parent HEK293T cells, which alters the glycosylation pattern.
	Expression of the wild-type but not the mutant MAN2A1 alleles in Lec36
	cells restores processing of the 19A reporter glycoprotein to
	complex-type glycosylation, overview <56>) <25,37,43,44,55,56>
EN	#3# R60Q/R73N/L79S/E81S (#3# beta1,4-N-acetylglucosaminyltransferase
	III-ManII mutant with amino acid substitutions in the localization
	domain of ManII, is expressed in similar amounts as
	beta1,4-N-acetylglucosaminyltransferase III-ManII, yields antibody
	glycovariants featuring substantially reduced proportions of bisected
	non-fucosylated oligosaccharides compared to the non-mutated
	beta1,4-N-acetylglucosaminyltransferase III-ManII <39>) <39>
EN	#3# R73N/L79S/E81S (#3# beta1,4-N-acetylglucosaminyltransferase
	III-ManII mutant with amino acid substitutions in the localization
	domain of ManII, is expressed in similar amounts as
	beta1,4-N-acetylglucosaminyltransferase III-ManII, yields antibody
	glycovariants featuring substantially reduced proportions of bisected
	non-fucosylated oligosaccharides compared to the non-mutated
	beta1,4-N-acetylglucosaminyltransferase III-ManII <39>) <39>

CLONED
CL	#1# (expressed in S2 insect cells) <63>
CL	#2# (cDNA fragments encoding full-length enzymes subcloned into the
	pcDNA3.1 mammalian expression vector. cDNA fragments encoding soluble
	forms of enzymes subcloned into pcDNA-HSH. Full-length
	alpha-mannosidase IIx expressed in MII/alpha-mannosidase IIx
	double-null fibroblasts. Soluble recombinant alpha-mannosidase IIx
	expressed in COS cells) <44>
CL	#2# (pcDNA-HSH-MX expression vector encoding the soluble
	alpha-mannosidase IIx, transfection into Cos-1 cells) <43>
CL	#3# (isolation of partial cDNA clones, gene is located on chromosome 5)
	<20>
CL	#3# (Golgi mannosidase II gene is located on chromosome 5q21, Golgi
	mannosidase IIx on chromosome 15q25) <25>
CL	#3# (alpha-mannosidase II and IIx, expression in COS cells as protein A
	fusion, overexpression of alpha-mannosidase IIx in CHO-K1 cells) <27>
CL	#3# (expressed in HEK293 cells) <34>
CL	#3# (preparation of expression construct containing 6 x His and tobacco
	etch virus protease recognition sites in the N-terminus of NAM and
	integrated into the Pichia pastoris chromosome under inducible alcohol
	oxygenase promoter. CHO-K1 cells transfected with pNAM-EGFP) <42>
CL	#3# (expressed in Drosophila melanogaster) <60>
CL	#3# (gene MAN2A1 from mutant strain Lec36 and wild-type gene, DNA and
	amino acid sequence determination and analysis. Wild-type and mutant
	enzyme expression analysis, overview) <56>
CL	#11# (alpha-mannosidase III cDNA is cloned) <29>
CL	#12# (TM1851, expression in Escherichia coli) <30>
CL	#17# (GmII is cloned, sequenced and localized to a single site,
	85D14-18, on the right arm of chromosome 3) <21>
CL	#18# (full-length cDNA is cloned and sequenced, 8-12fold overexpression
	in COS cells) <20>
CL	#19# (GMII, DNA and amino acid sequence determination and analysis,
	expression of His-tagged functional Golgi alpha-mannosidase II as
	soluble protein, which is secreted to the culture medium, in Spodoptera
	frugiperda Sf21 insect cells using the baculovirus transfection system,
	transient expression of GFP-tagged enzyme in Nicotiana benthamiana
	plants shows localization of the recombinant enzyme to the Golgi and
	endoplasmic reticulum) <37>
CL	#20# (DNA and amino acid sequence determination and analysis) <55>
CL	#21# (gene M1 GAS SF370, DNA and amino acid sequence determination and
	analysis, cloning of the coding sequence for SpGH38 residues 1-901,
	overexpression as 3C protease cleavable N-terminal His6-tagged enzyme
	in Escherichia coli strain BL21(DE3)) <59>

CRYSTALLIZATION
CR	#1# <49,50,51>
CR	#1# (crystal structure of enzyme with bound inhibitors kifunensine,
	swainsonine and 1-deoxymannojirimycin) <11>
CR	#1# (wild-type and D341N mutant GMII, hanging drop vapor diffusion) <24>
CR	#1# (hanging drop vapor diffusion) <38>
CR	#1# (enzyme in complex with inhibitors mannostatin A, N-benzyl
	mannostatin A, and 1-deoxyaminocyclopentitetrol, crystal growth
	overnight of enzyme solved in phosphate buffered reservoir solution,
	crystals are soaked for 3-6 h in 10 mM ligand solution,
	co-crystallization in Tris buffer without phosphate washing, X-ray
	diffraction structure determination and analysis, molecular modelling
	and structure simulation, overview) <36>
CR	#1# (by hanging-drop vapor diffusion method, GMII in complex with
	inhibitors di-epi-swainsonine and 8-epi-lentiginosine, both adopt a
	3C6/E7 conformation, water molecule substructure in the active site
	plays a significant role in dictating inhibitory activity) <46>
CR	#1# (GMII complexed with inhibitors
	(2R,3R,4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol,
	(2R,3R,4S)-2-([[(1S)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol, and
	(2R,3R,4S
	5R)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-5-methylpyrrolidine
	3,4-diol, to 1.30-1.45 A resolution) <45>
CR	#12# (purified recombinant TM1851, sitting drop vapour diffusion
	method, optimal conditions: 0.001 ml of protein solution containing 5.3
	mg/ml protein in 5 mM sodium phosphate and 150 mM NaCl, pH 6.8, mixed
	with an equal volume of reservoir solution containing 4% w/v PEG 6000,
	50 mM sodium phosphate, pH 6.0, and 0.5 M NaCl, 1 day at 25°C, X-ray
	diffraction structure determination and preliminary analysis at 2.9 A
	resolution) <30>
CR	#17# <48>
CR	#17# (in complex with inhibitor mannostatin A and its derivatives. The
	interaction with the backbone carbonyl of residue R876 is crucial to
	the high potency of the inhibitor and enhanced by the hydrophobic
	interaction between the thiomethyl group and an aromatic pocket vivinal
	to the cleavage site) <50>
CR	#17# (in complex with inhibitors
	(3R,4R,5R)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one and
	(3R,4R,5R)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one, to 1.08 A and 1.74 A resolution, respectively)
	<49>
CR	#17# (in complex with inhibitors mannoimidazole, glucoimidazole,
	N-octyl-6-epi-valienamine, gluco-hydroxyiminolactam, and
	[[(3S,4S,5R,6R)-3,4
	5-trihydroxy-6-(hydroxymethyl)piperidin-2-ylidene]amino]
	N-(4-chlorophenyl)carbamate) <48>
CR	#17# (in complex with natural substrate GlcNAcMan5GlcNAc2 and with
	oligosaccharide Man5. The natural substrate binds in a large groove on
	the surface of the enzyme. This groove contains the site of the
	nucleophile D204, acid/base catalyst D341, and zinc ion. substrate
	binding does not induce any noticeable conformational change. the
	larger active site cleft contains three sugar-binding subsites) <52>
CR	#17# (mutants D204A and D341N in complex with
	2,4-dinitrophenyl-alpha-D-mannopyranoside and in complex with
	oligosaccharides containing an alpha-(1,6)-or alpha-(1,3)-linked
	1-thio-alpha-mannoside) <51>
CR	#17# (enzyme with bound unhibitors, X-ray diffraction structure
	determination and analysis) <54>
CR	#21# (purified recombinent enzyme free or in complex with the inhibitor
	swainsonine, sitting drop vapour diffusion method, mixing of 12 mg/ml
	protein in 100 mM Tris, pH 8.5, 1.5 M (NH4)2SO4 and 12% v/v glycerol,
	with reservoir solution, containing 3% v/v glycerol, 54% v/v Tacsimate,
	pH 7.0, and 2% v/v PEG 6000, also acting as the cryo-protectant,
	crystals of the swainsonine complex form are obtained by soaking SpGH38
	crystals for ,16 h in mother liquor supplemented with 2 mM swainsonine,
	X-ray diffraction structure determination and analysis at 1.9 A and 2.6
	A resolution, respectively) <59>

PURIFICATION
PU	#1# <46,49,51>
PU	#1# (method not mentioned) <36>
PU	#2# (soluble alpha-mannosidase IIx protein purified by a nickel
	affinity column) <43>
PU	#3# <34>
PU	#3# (partial) <5>
PU	#3# (recombinant protein A fusion of alpha-mannosidase II and IIx,
	expressed in COS cells) <27>
PU	#3# (ammonium sulfate fractionation of recombinant enzyme followed by
	two cobalt chelating chromatography steps) <42>
PU	#4# <13,14,15,16>
PU	#4# (20fold) <2>
PU	#4# (intact 124 kDa Man II and chymotrypsin-cleaved soluble 110 kDa
	catalytic subunit) <1>
PU	#4# (97fold) <3>
PU	#8# <8,10>
PU	#8# (1200fold) <17>
PU	#10# (1000fold) <4>
PU	#10# (anion-exchange chromatography, chromatofocusing chromatography,
	gel filtration) <33>
PU	#11# (glutathione S-transferase-tagged secreted form of SfManIII) <29>
PU	#11# (353fold) <23>
PU	#12# (recombinant TM1851 from Escherichia coli by ion exchange and
	hydroxyapatite chromatography, and gel filtration) <30>
PU	#14# (native enzyme 600fold from mature seeds to homogeneity by
	ammonium sulfate fractionation, ion exchange and hydrophobic
	interaction chromatography, and gel filtration, and another 2 steps of
	ion exchange chromatography and gel filtration) <31>
PU	#14# (native enzyme from mature seeds to homogeneity by ammonium
	sulfate fractionation, ion exchange and hydrophobic interaction
	chromatography, and gel filtration) <32>
PU	#19# (recombinant secreted His-tagged soluble enzyme from culture
	medium of Spodoptera frugiperda Sf21 insect cells by nickel affinity
	chromatography) <37>
PU	#21# (recombinant His6-tagged enzyme from Escherichia coli strain
	BL21(DE3) by nickel affinity chromatography and gel filtration) <59>

GENERAL_STABILITY
GS	#11# (freezing inactivates column-bound glutathione
	S-transferase-tagged secreted form of SfManIII) <29>
GS	#4# (stable to repeated freeze-thawing cycles) <3>
GS	#4# (requires presence of detergent, 0.1% Triton X-100, to maintain
	enzyme in soluble form) <3>
GS	#4# (4-nitrophenyl alpha-D-mannoside stabilizes) <3>
GS	#4# (enzyme retains full activity after incubation with chymotrypsin or
	other proteases that cleave the enzyme into catalytic and
	membrane-anchoring domains, a decrease in activity occurs with a
	corresponding cleavage of the catalytic subunit to a MW 105000 species)
	<15>
GS	#4# (ultrafiltration, even in the presence of PMSF at 0°C, results in
	a slow conversion of the intact enzyme to the 110 kDa degradation
	product, the catalytic domain, which itself is extremely stable) <1>
GS	#4# (freezing and thawing greatly enhances the rate of cleavage of the
	intact enzyme) <1>
GS	#8# (glycerol stabilizes) <8,17>
GS	#9# (unfolding and denaturation in 6 M guanidinium hydrochloride, the
	protein almost completely unfolds in 4.0 M guanidinium hydrochloride,
	overview) <57>

PH_STABILITY
PHS	#4# 4-6 (#4# unstable at 37°C, no activity below pH 4 <3>) <3>
PHS	#4# 8 (#4# 1 h, at 37°C, stable <2>) <2>
PHS	#4# 7-9 (#4# stable at 37°C <3>) <3>
PHS	#4# 4 (#4# 1 h, at 37°C, inactivation, 1 mM ZnCl2 partially stabilizes
	<2>) <2>
PHS	#4,8# 6 (#8# below, high loss of activity within 1 week <17>; #4# 1 h,
	at 37°C, 30% loss of activity <2>) <2,17>
PHS	#8# 6.5 (#8# below, loss of activity <8>) <8>
PHS	#9# -999 (#9# pH dependent denaturation, kinetics, overview <57>) <57>
PHS	#9# 5-7 (#9# the enzyme is most stable, inactivation below pH 5.0 and
	above pH 8.0 is irreversible <57>) <57>

STORAGE_STABILITY
SS	#10# (-20°C or 4°C, 4 months, less than 5% loss of activity) <4>
SS	#10# (-20°C or 4°C, 10 mM sodium acetate buffer, pH 5, with or
	without CaCl2, 4 months, stable) <7>
SS	#11# (4°C, column-bound glutathione S-transferase-tagged secreted form
	of SfManIII, at least 1 week, stable) <29>
SS	#4# (5°C or frozen, 0.1 M potassium phosphate buffer, pH 7.2, Triton
	X-100, 30 days, 20% loss of activity) <3>
SS	#4# (2-4°C, 10 mM potassium phosphate buffer, pH 7.2, 1% Triton X-100,
	4 weeks, 20% loss of activity) <2>
SS	#4# (frozen, at least 2 months, stable) <3>
SS	#4# (4°C, intact enzyme, several weeks, stable) <1>
SS	#8# (0-4°C, 10 mM HEPES buffer, pH 7.2, 10% glycerol, several days,
	stable) <17>
SS	#8# (0-4°C, 10 mM HEPES buffer, pH 7.1, 0.1% Triton X-100, 0.5 mM
	PMSF, 0.2 mM dithiothreitol, 10% glycerol, at least 2 weeks, stable) <8>
SS	#8# (frozen, 10 mM HEPES buffer, pH 7.1, 0.1% Triton X-100, 0.5 mM
	PMSF, 0.2 mM dithiothreitol, 10% glycerol, at least 2 months, stable)
	<17>

TEMPERATURE_STABILITY
TS	#4# 37 (#4# stable at pH 7-9, unstable at acidic pH-values, Zn2+
	stabilizes <3>; #4# 24 h, in 100 mM sodium acetate buffer, pH 5.8,
	30-50% loss of activity <2>) <2,3>
TS	#4# 50 (#4# 3 h, about 30% loss of activity, 4-nitrophenyl
	alpha-D-mannoside or (Man)9GlcNAc as substrate <2>) <2>
TS	#4# 40 (#4# and below, 15 min stable, rapid inactivation above, Zn2+ or
	0.125 mg/l bovine serum albumin stabilizes <3>) <3>
TS	#9# 30-90 (#9# activity is reduced by 8% at 50°C while positive
	ellipticity at 190-195 nm is almost same in the temperature range of
	35-50°C. The activity is not affected in this range. At 60°C, 18% and
	at 70°C and above, 25% loss in the alpha-helical content of the
	protein occurs with significant decrease in the positive ellipticity,
	the protein does not completely unfold at 90°C <57>) <57>

REFERENCE
RF	<1> Moremen, K.W.; Touster, O.; Robbins, P.W.: Novel purification of
	the catalytic domain of golgi alpha-mannosidase II. Characterization
	and comparison with the intact enzyme. J. Biol. Chem. (1991) 266,
	16876-16885. {Pubmed:1885615} (c)
RF	<2> Tulsiani, D.R.P.; Hubbard, S.C.; Robbins, P.W.; Touster, O.:
	alpha-D-Mannosidases of rat liver Golgi membranes. Mannosidase II is
	the GlcNAcMAN5-cleaving enzyme in glycoprotein biosynthesis and
	mannosidases Ia and IB are the enzymes converting Man9 precursors to
	Man5 intermediates. J. Biol. Chem. (1982) 257, 3660-3668.
	{Pubmed:7061502} (c)
RF	<3> Tulsiani, D.R.P.; Opheim, D.J.; Touster, O.: Purification and
	characterization of alpha-D-mannosidase from rat liver golgi membranes.
	J. Biol. Chem. (1977) 252, 3227-3233. {Pubmed:863880} (c)
RF	<4> Amano, J.; Kobata, A.: Purification and characterization of a novel
	alpha-mannosidase from Aspergillus saitoi. J. Biochem. (1986) 99,
	1645-1654. {Pubmed:3745139} (c)
RF	<5> Chandrasekaran, E.V.; Savila, M.; Nixon, D.; Mendicino, J.:
	Purification and properties of
	alpha-D-mannose:beta-1,2-N-acetylglucosaminyl-transferases and
	alpha-D-mannosidases from human adenocarcinoma. Cancer Res. (1984) 44,
	4059-4068. {Pubmed:6234987}
RF	<6> Palamarczyk, G.; Mitchell, M.; Smith, P.W.; Fleet, G.W.; Elbein,
	A.D.: 1,4-Dideoxy-1,4-imino-D-mannitol inhibits glycoprotein processing
	and mannosidase. Arch. Biochem. Biophys. (1985) 243, 35-45.
	{Pubmed:4062306}
RF	<7> Kobata, A.; Amano, J.: alpha-Mannosidases I and II from Aspergillus
	saitoi. Methods Enzymol. (1987) 138, 779-785. {Pubmed:3600352} (review)
RF	<8> Kaushal, G.P.; Elbein, A.D.: Glycoprotein processing enzymes of
	plants. Methods Enzymol. (1989) 179, 452-475. {Pubmed:2560127} (review)
RF	<9> Elbein, A.D.: Glycosidase inhibitors: inhibitors of N-linked
	oligosaccharide processing. FASEB J. (1991) 5, 3055-3063.
	{Pubmed:1743438} (review)
RF	<10> Pan, Y.T.; Kaushal, G.P.; Papandreou, G.; Ganem, B.; Elbein, A.D.:
	D-Mannonolactam amidrazone. A new mannosidase inhibitor that also
	inhibits the endoplasmic reticulum or cytoplasmic alpha-mannosidase. J.
	Biol. Chem. (1992) 267, 8313-8318. {Pubmed:1569086}
RF	<11> Shah, N.; Kuntz, D.A.; Rose, D.R.: Comparison of kifunensine and
	1-deoxymannojirimycin binding to class I and II alpha-mannosidases
	demonstrates different saccharide distortions in inverting and
	retaining catalytic mechanisms. Biochemistry (2003) 42, 13812-13816.
	{Pubmed:14636047}
RF	<12> Harpaz, N.; Schachter, H.: Control of glycoprotein synthesis.
	Processing of asparagine-linked oligosaccharides by one or more rat
	liver Golgi alpha-D-mannosidases dependent on the prior action of
	UDP-N-acetylglucosamine: alpha-D-mannoside beta
	2-N-acetylglucosaminyltransferase I. J. Biol. Chem. (1980) 255,
	4894-4902. {Pubmed:6445359}
RF	<13> Tulsiani, D.R.P.; Harris, T.M.; Touster, O.: Swainsonine inhibits
	the biosynthesis of complex glycoproteins by inhibition of Golgi
	mannosidase II. J. Biol. Chem. (1982) 257, 7936-7939. {Pubmed:6806288}
RF	<14> Tulsiani, D.R.P.; Broquist, H.P.; Touster, O.: Marked differences
	in the swainsonine inhibition of rat liver lysosomal
	alpha-D-mannosidase, rat liver Golgi mannosidase II, and jack bean
	alpha-D-mannosidase. Arch. Biochem. Biophys. (1985) 236, 427-434.
	{Pubmed:3917650}
RF	<15> Moremen, K.W.; Touster, O.: Topology of mannosidase II in rat
	liver Golgi membranes and release of the catalytic domain by selective
	proteolysis. J. Biol. Chem. (1986) 261, 10945-10951. {Pubmed:3733740}
RF	<16> Moremen, K.W.; Touster, O.: Biosynthesis and modification of Golgi
	mannosidase II in HeLa and 3T3 cells. J. Biol. Chem. (1985) 260,
	6654-6662. {Pubmed:3922977}
RF	<17> Kaushal, G.P.; Szumilo, T.; Pastuszak, I.; Elbein, A.D.:
	Purification to homogeneity and properties of mannosidase II from mung
	bean seedlings. Biochemistry (1990) 29, 2168-2176. {Pubmed:2139344}
RF	<18> Tropea, J.E.; Kaushal, G.P.; Pastuszak, I.; Mitchell, M.; Aoyagi,
	T.; Molyneux, R.J.; Elbein, A.D.: Mannostatin A, a new
	glycoprotein-processing inhibitor. Biochemistry (1990) 29, 10062-10069.
	{Pubmed:2271638}
RF	<19> Baron, M.D.; Garoff, H.: Mannosidase II and the 135-kDa
	Golgi-specific antigen recognized monoclonal antibody 53FC3 are the
	same dimeric protein. J. Biol. Chem. (1990) 265, 19928-19931.
	{Pubmed:2246269}
RF	<20> Moremen, K.W.; Robbins, P.W.: Isolation, characterization, and
	expression of cDNAs encoding murine alpha-mannosidase II, a Golgi
	enzyme that controls conversion of high mannose to complex N-glycans.
	J. Cell Biol. (1991) 115, 1521-1534. {Pubmed:1757461}
RF	<21> Foster, J.M.; Yudkin, B.; Lockyer, A.E.; Roberts, D.B.: Cloning
	and sequence analysis of GmII, a Drosophila melanogaster homologue of
	the cDNA encoding murine Golgi alpha-mannosidase II. Gene (1995) 154,
	183-186. {Pubmed:7890162}
RF	<22> Altmann, F.; März, L.: Processing of asparagine-linked
	oligosaccharides in insect cells: evidence for alpha-mannosidase II.
	Glycoconj. J. (1995) 12, 150-155. {Pubmed:7620332}
RF	<23> Ren, J.; Castellino, F.J.; Bretthauer, R.K.: Purification and
	properties of alpha-mannosidase II from Golgi-like membranes of
	baculovirus-infected Spodoptera frugiperda (IPLB-SF-21AE) cells.
	Biochem. J. (1997) 324, 951-956. {Pubmed:9210421}
RF	<24> Numao, S.; Kuntz, D.A.; Withers, S.G.; Rose, D.R.: Insights into
	the mechanism of Drosophila melanogaster Golgi alpha-mannosidase II
	through the structural analysis of covalent reaction intermediates. J.
	Biol. Chem. (2003) 278, 48074-48083. {Pubmed:12960159}
RF	<25> Moremen, K.W.: Golgi alpha-mannosidase II deficiency in vertebrate
	systems: implications for asparagine-linked oligosaccharide processing
	in mammals. Biochim. Biophys. Acta (2002) 1573, 225-235.
	{Pubmed:12417404} (review)
RF	<26> Igdoura, S.A.; Herscovics, A.; Lal, A.; Moremen, K.W.; Morales,
	C.R.; Hermo, L.: alpha-Mannosidases involved in N-glycan processing
	show cell specificity and distinct subcompartmentalization within the
	Golgi apparatus of cells in the testis and epididymis. Eur. J. Cell
	Biol. (1999) 78, 441-452. {Pubmed:10472797}
RF	<27> Oh-Eda, M.; Nakagawa, H.; Akama, T.O.; Lowitz, K.; Misago, M.;
	Moremen, K.W.; Fukuda, M.N.: Overexpression of the Golgi-localized
	enzyme alpha-mannosidase IIx in Chinese hamster ovary cells results in
	the conversion of hexamannosyl-N-acetylchitobiose to
	tetramannosyl-N-acetylchitobiose in the N-glycan-processing pathway.
	Eur. J. Biochem. (2001) 268, 1280-1288. {Pubmed:11231279}
RF	<28> Francis, B.R.; Paquin, L.; Weinkauf, C.; Jarvis, D.L.:
	Biosynthesis and processing of Spodoptera frugiperda alpha-mannosidase
	III. Glycobiology (2002) 12, 369-377. {Pubmed:12107079} (a)
RF	<29> Kawar, Z.; Karaveg, K.; Moremen, K.W.; Jarvis, D.L.: Insect cells
	encode a class II alpha-mannosidase with unique properties. J. Biol.
	Chem. (2001) 276, 16335-16340. {Pubmed:11279010}
RF	<30> Nakajima, M.; Fushinobu, S.; Imamura, H.; Shoun, H.; Wakagi, T.:
	Crystallization and preliminary X-ray analysis of cytosolic
	alpha-mannosidase from Thermotoga maritima. Acta Crystallogr. Sect. F
	(2006) 62, 104-105. {Pubmed:16511275}
RF	<31> Woo, K.K.; Miyazaki, M.; Hara, S.; Kimura, M.; Kimura, Y.:
	Purification and characterization of a co(II)-sensitive
	alpha-mannosidase from Ginkgo biloba seeds. Biosci. Biotechnol.
	Biochem. (2004) 68, 2547-2556. {Pubmed:15618626}
RF	<32> Woo, K.K.; Kimura, Y.: Regulation of substrate specificity of
	plant alpha-mannosidase by cobalt ion: in vitro hydrolysis of
	high-mannose type N-glycans by Co2+-activated Ginkgo alpha-mannosidase.
	Biosci. Biotechnol. Biochem. (2005) 69, 1111-1119. {Pubmed:15973042}
RF	<33> Athanasopoulos, V.I.; Niranjan, K.; Rastall, R.A.: The production,
	purification and characterization of two novel alpha-D-mannosidases
	from Aspergillus phoenicis. Carbohydr. Res. (2005) 340, 609-617.
	{Pubmed:15721331}
RF	<34> Li, B.; Kawatkar, S.P.; George, S.; Strachan, H.; Woods, R.J.;
	Siriwardena, A.; Moremen, K.W.; Boons, G.J.: Inhibition of Golgi
	mannosidase II with mannostatin A analogues: synthesis, biological
	evaluation, and structure-activity relationship studies. Chembiochem
	(2004) 5, 1220-1227. {Pubmed:15368573}
RF	<35> Siriwardena, A.; Strachan, H.; El-Daher, S.; Way, G.; Winchester,
	B.; Glushka, J.; Moremen, K.; Boons, G.: Potent and selective
	inhibition of class II alpha-D-mannosidase activity by a bicyclic
	sulfonium salt. ChemBioChem (2005) 6, 845-848. {Pubmed:15800866}
RF	<36> Kawatkar, S.P.; Kuntz, D.A.; Woods, R.J.; Rose, D.R.; Boons, G.J.:
	Structural basis of the inhibition of Golgi alpha-mannosidase II by
	mannostatin A and the role of the thiomethyl moiety in ligand-protein
	interactions. J. Am. Chem. Soc. (2006) 128, 8310-8319. {Pubmed:16787095}
RF	<37> Strasser, R.; Schoberer, J.; Jin, C.; Gloessl, J.; Mach, L.;
	Steinkellner, H.: Molecular cloning and characterization of Arabidopsis
	thaliana Golgi alpha-mannosidase II, a key enzyme in the formation of
	complex N-glycans in plants. Plant J. (2006) 45, 789-803.
	{Pubmed:16460512}
RF	<38> Kuntz, D.A.; Ghavami, A.; Johnston, B.D.; Pinto, B.M.; Rose, D.R.:
	Crystallographic analysis of the interactions of Drosophila
	melanogaster Golgi alpha-mannosidase II with the naturally occurring
	glycomimetic salacinol and its analogues. Tetrahedron Asymmetry (2005)
	16, 25-32. {Pubmed:}
RF	<39> Ferrara, C.; Bruenker, P.; Suter, T.; Moser, S.; Puentener, U.;
	Umana, P.: Modulation of therapeutic antibody effector functions by
	glycosylation engineering: influence of Golgi enzyme localization
	domain and co-expression of heterologous
	beta1,4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase
	II. Biotechnol. Bioeng. (2006) 93, 851-861. {Pubmed:16435400}
RF	<40> Kuntz, D.A.; Liu, H.; Bols, M.; Rose, D.R.: The role of the active
	site Zn in the catalytic mechanism of the GH38 Golgi alpha -mannosidase
	II: implications from noeuromycin inhibition. Biocatal. Biotransform.
	(2006) 24, 55-61. {Pubmed:}
RF	<41> Crispin, M.; Aricescu, A.R.; Chang, V.T.; Jones, E.Y.; Stuart,
	D.I.; Dwek, R.A.; Davis, S.J.; Harvey, D.J.: Disruption of
	alpha-mannosidase processing induces non-canonical hybrid-type
	glycosylation. FEBS Lett. (2007) 581, 1963-1968. {Pubmed:17466984}
RF	<42> Kuokkanen, E.; Smith, W.; Maekinen, M.; Tuominen, H.; Puhka, M.;
	Jokitalo, E.; Duvet, S.; Berg, T.; Heikinheimo, P.: Characterization
	and subcellular localization of human neutral class II
	alpha-mannosidase cytosolic enzymes/free
	oligosaccharides/glycosidehydrolase family 38/M2C1/N-glycosylation.
	Glycobiology (2007) 17, 1084-1093. {Pubmed:17681998}
RF	<43> Akama, T.O.; Fukuda, M.N.: N-Glycan structure analysis using
	lectins and an alpha-mannosidase activity assay. Methods Enzymol.
	(2006) 416, 304-314. {Pubmed:17113875}
RF	<44> Akama, T.O.; Nakagawa, H.; Wong, N.K.; Sutton-Smith, M.; Dell, A.;
	Morris, H.R.; Nakayama, J.; Nishimura, S.; Pai, A.; Moremen, K.W.;
	Marth, J.D.; Fukuda, M.N.: Essential and mutually compensatory roles of
	{alpha}-mannosidase II and {alpha}-mannosidase IIx in N-glycan
	processing in vivo in mice. Proc. Natl. Acad. Sci. USA (2006) 103,
	8983-8988. {Pubmed:16754854}
RF	<45> Englebienne, P.; Fiaux, H.; Kuntz, D.A.; Corbeil, C.R.;
	Gerber-Lemaire, S.; Rose, D.R.; Moitessier, N.: Evaluation of docking
	programs for predicting binding of Golgi alpha-mannosidase II
	inhibitors: a comparison with crystallography. Proteins (2007) 69,
	160-176. {Pubmed:17557336}
RF	<46> Kumar, N.S.; Kuntz, D.A.; Wen, X.; Pinto, B.M.; Rose, D.R.:
	Binding of sulfonium-ion analogues of di-epi-swainsonine and
	8-epi-lentiginosine to Drosophila Golgi alpha-mannosidase II: The role
	of water in inhibitor binding. Proteins (2008) 71, 1484-1496.
	{Pubmed:18076078}
RF	<47> Chida, K.; Taguchi, M.: Change in localization of alkaline
	phosphatase and mannosidase II by colchicine treatment of primary
	cultures of fetal rat hepatocytes. Acta Histochem. Cytochem. (2008) 41,
	1-5. {Pubmed:18320021}
RF	<48> Kuntz, D.A.; Tarling, C.A.; Withers, S.G.; Rose, D.R.: Structural
	analysis of Golgi alpha-mannosidase II inhibitors identified from a
	focused glycosidase inhibitor screen. Biochemistry (2008) 47,
	10058-10068. {Pubmed:18759458}
RF	<49> Fiaux, H.; Kuntz, D.A.; Hoffman, D.; Janzer, R.C.; Gerber-Lemaire,
	S.; Rose, D.R.; Juillerat-Jeanneret, L.: Functionalized pyrrolidine
	inhibitors of human type II alpha-mannosidases as anti-cancer agents:
	optimizing the fit to the active site. Bioorg. Med. Chem. (2008) 16,
	7337-7346. {Pubmed:18599296}
RF	<50> Kuntz, D.A.; Zhong, W.; Guo, J.; Rose, D.R.; Boons, G.J.: The
	molecular basis of inhibition of Golgi alpha-mannosidase II by
	mannostatin A. ChemBioChem (2009) 10, 268-277. {Pubmed:19101978}
RF	<51> Zhong, W.; Kuntz, D.A.; Ember, B.; Singh, H.; Moremen, K.W.; Rose,
	D.R.; Boons, G.J.: Probing the substrate specificity of Golgi
	alpha-mannosidase II by use of synthetic oligosaccharides and a
	catalytic nucleophile mutant. J. Am. Chem. Soc. (2008) 130, 8975-8983.
	{Pubmed:18558690}
RF	<52> Shah, N.; Kuntz, D.A.; Rose, D.R.: Golgi alpha-mannosidase II
	cleaves two sugars sequentially in the same catalytic site. Proc. Natl.
	Acad. Sci. USA (2008) 105, 9570-9575. {Pubmed:18599462}
RF	<53> Bello, C.; Cea, M.; Bello, G.D.; Garuti, A.; Rocco, I.; Cirmena,
	G.; Moran, E.; Nahimana, A.; Duchosal, M.A.; Fruscione, F.; Pronzato,
	P.; Grossi, F.; Patrone, F.; Ballestrero, A.; Dupuis, M.; Sordat, B.;
	Nencioni, A.; Vogel, P.: Novel
	2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as
	alpha-mannosidase inhibitors and with antitumor activities against
	hematological and solid malignancies. Bioorg. Med. Chem. (2010) 18,
	3320-3334. {Pubmed:20346684}
RF	<54> Kuntz, D.A.; Nakayama, S.; Shea, K.; Hori, H.; Uto, Y.; Nagasawa,
	H.; Rose, D.R.: Structural investigation of the binding of
	5-substituted swainsonine analogues to Golgi alpha-mannosidase II.
	ChemBioChem (2010) 11, 673-680. {Pubmed:20209559}
RF	<55> Li, Y.; Fang, W.; Zhang, L.; Ouyang, H.; Zhou, H.; Luo, Y.; Jin,
	C.: Class IIC alpha-mannosidase AfAms1 is required for morphogenesis
	and cellular function in Aspergillus fumigatus. Glycobiology (2009) 19,
	624-632. {Pubmed:19240271}
RF	<56> Crispin, M.; Chang, V.T.; Harvey, D.J.; Dwek, R.A.; Evans, E.J.;
	Stuart, D.I.; Jones, E.Y.; Lord, J.M.; Spooner, R.A.; Davis, S.J.: A
	human embryonic kidney 293T cell line mutated at the Golgi
	alpha-mannosidase II locus. J. Biol. Chem. (2009) 284, 21684-21695.
	{Pubmed:19465480}
RF	<57> Shashidhara, K.S.; Gaikwad, S.M.: Conformational and functional
	transitions in class II alpha-mannosidase from Aspergillus fischeri. J.
	Fluoresc. (2010) 20, 827-836. {Pubmed:20204683}
RF	<58> Zhu, Y.; Suits, M.D.; Thompson, A.J.; Chavan, S.; Dinev, Z.;
	Dumon, C.; Smith, N.; Moremen, K.W.; Xiang, Y.; Siriwardena, A.;
	Williams, S.J.; Gilbert, H.J.; Davies, G.J.: Mechanistic insights into
	a Ca2+-dependent family of alpha-mannosidases in a human gut symbiont.
	Nat. Chem. Biol. (2010) 6, 125-132. {Pubmed:20081828}
RF	<59> Suits, M.D.; Zhu, Y.; Taylor, E.J.; Walton, J.; Zechel, D.L.;
	Gilbert, H.J.; Davies, G.J.: Structure and kinetic investigation of
	Streptococcus pyogenes family GH38 alpha-mannosidase. PLoS ONE (2010)
	5, e9006. {Pubmed:20140249}
RF	<60> Polakova, M.; Sestak, S.; Lattova, E.; Petrus, L.; Mucha, J.;
	Tvaroska, I.; Kona, J.: alpha-D-mannose derivatives as models designed
	for selective inhibition of Golgi alpha-mannosidase II. Eur. J. Med.
	Chem. (2011) 46, 944-952. {Pubmed:21295890}
RF	<61> Petersen, L.; Ardevol, A.; Rovira, C.; Reilly, P.J.: Molecular
	mechanism of the glycosylation step catalyzed by Golgi
	alpha-mannosidase II: a QM/MM metadynamics investigation. J. Am. Chem.
	Soc. (2010) 132, 8291-8300. {Pubmed:20504027}
RF	<62> Cheng, T.; Chan, T.; Tsou, E.; Chang, S.; Yun, W.; Yang, P.; Wu,
	Y.; Cheng, W.: From natural product-inspired pyrrolidine scaffolds to
	the development of new human Golgi alpha-mannosidase II inhibitors.
	Chemistry (2013) 8, 2600-2604. {Pubmed:}
RF	<63> Rose, D.R.: Structure, mechanism and inhibition of Golgi
	alpha-mannosidase II. Curr. Opin. Struct. Biol. (2012) 22, 558-562.
	{Pubmed:22819743}
RF	<64> Lu, H.; Wang, S.S.; Wang, W.L.; Zhang, L.; Zhao, B.Y.: Effect of
	swainsonine in Oxytropis kansuensis on Golgi alpha-mannosidase II
	expression in the brain tissues of Sprague-Dawley rats. J. Agric. Food
	Chem. (2014) 62, 7407-7412. {Pubmed:24741992}

ACTIVATING_COMPOUND
AC	#3,4# more (#4# not activated by glucose, galactose, AMP, ADP, GMP,
	GDP, GTP, CDP, CTP, UMP, UDP, UTP, cAMP, cGMP <3>; #3# no effect with
	EDTA <42>) <3,42>
AC	#4# dithiothreitol (#4# activation <3>) <3>
AC	#4# 2-mercaptoethanol (#4# activation <3>) <3>
AC	#4# bovine serum albumin (#4# 0.125 mg/l, 35% activation <3>) <3>
AC	#4# fucose (#4# 250 mM, 15-20% activation <3>) <3>
AC	#4# ATP (#4# 1 mM, 27% activation <3>) <3>
AC	#4# CMP (#4# 1 mM, 25% activation <3>) <3>
AC	#5,8# Triton X-100 (#8# activation, 0.15-0.2% <8>; #8# 25-30%
	activation, 0.05% <17>; #5# omission results in 40% decrease of
	activity <22>) <8,17,22>

KI_VALUE
KI	#1# -999 {more}  (#1# although too weak for full Ki analyses with the
	amounts of material available, all analogues with salacinol-like
	stereochemistry at positions 2 and 3 proved to be weak inhibitors of
	the enzyme with IC50 values of approximately 7.5 mM <38>) <38>
KI	#1# 0.001
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  <49>
KI	#1# 0.0003 {(1R,2S,3R,4R,5R)-5-aminocyclopentane-1,2,3,4-tetraol}  <50>
KI	#1# 0.6 {5-fluoro-beta-L-gulosyl fluoride}  (#1# pH 5.6, 37°C, D341N
	mutant GMII <24>) <24>
KI	#1# 0.067
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  <49>
KI	#1# 0.022
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  <49>
KI	#1# 7.5 {2-deoxy-2-fluoro-alpha-D-mannosyl fluoride}  (#1# pH 5.6,
	37°C, D341N mutant GMII <24>) <24>
KI	#1# 5.2 {kifunensine}  (#1# pH 5.75, 37°C <11>) <11>
KI	#1# 0.265 {1-deoxyaminocyclopentitetrol}  <36,50>
KI	#1# 0.265 {1-deoxyamino-cyclopentitetrol}  <36>
KI	#1# 0.0000105 {swainsonine}  (#1# pH 5.75, 37°C <11>) <11>
KI	#1# 0.000249 {N-benzyl mannostatin A}  <36>
KI	#1# 0.000249 {N-benzyl-mannostatin}  <36>
KI	#1,17# 0.00002 {swainsonine}  (#17# pH 5.6 <48>) <48,49>
KI	#1,17# 0.00015 {mannostatin B}  <50>
KI	#1,17# 0.000036 {Mannostatin A}  <36,50>
KI	#1,17# 0.000076
	{(1R,2R,3R,4S,5R)-4-amino-5-methoxycyclopentane-1,2,3-triol}  <50>
KI	#13# 0.004
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  <49>
KI	#13# 0.000155 {swainsonine}  <49>
KI	#13# 0.000135
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  <49>
KI	#13# 0.000206
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  <49>
KI	#17# 0.07 {gluco-hydroxyiminolactam}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.4 {1-deoxymannojirimycin}  <48>
KI	#17# 0.4 {deoxymannojirimycin}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.02 {noeuromycin}  (#17# pH 5.6 <48>) <48>
KI	#17# 5 {kifunensine}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.001
	{(3R,4R,5R)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#17# 20C, pH 6.8 <49>) <49>
KI	#17# 0.003 {swainsonine}  (#17# pH 5.75, 25°C <54>) <54>
KI	#17# 0.0003 {(1R,2R,3S,4R,5R)-5-aminocyclopentane-1,2,3,4-tetrol}  <50>
KI	#17# 0.002 {mannoimidazole}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.017 {N-octyl-6-epi-valienamine}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.0027
	{1-(4-methylphenyl)-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
KI	#17# 0.0027
	{1-(4-tert-butylphenyl)-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
KI	#17# 0.067
	{(2R,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#17# 20C, pH 6.8 <49>) <49>
KI	#17# 0.022
	{(3R,4R,5R)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  (#17# 20C, pH 6.8 <49>) <49>
KI	#17# 0.52
	{[[(3S,4S,5R,6R)-3,4
	5-trihydroxy-6-(hydroxymethyl)piperidin-2-ylidene]amino]
	N-(4-chlorophenyl)carbamate}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.52
	{(3S,4S,5R,6R,E)-3,4,5-trihydroxy-6-(hydroxymethyl)piperidin-2-one
	O-4-chlorophenylcarbamoyl oxime}  <48>
KI	#17# 0.013 {glucoimidazole}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.0028
	{1-phenyl-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
KI	#17# 0.00002 {(1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol}  (#17#
	20C, pH 6.8 <49>) <49>
KI	#21# 0.018 {swainsonine}  <59>
KI	#3# 0.02 {8,8a-di-epi-swainsonine}  (#3# liver lysosomal fraction <35>)
	<35>
KI	#3# 0.006
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-fluoro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.01
	{(1R,2R,3R,4S,5S)-1,2,3,4-tetrahydroxy-5-(N-benzylamino)cyclopentane} 
	(#3# reaction volume containing 4-methylumbelliferyl
	alpha-D-mannopyranoside, sodium acetate pH 5.6 and ZnCl at 37°C <34>)
	<34>
KI	#3# 0.0066
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-methoxy-benzyl)amino)cyclopentane}  (#3#
	reaction volume containing 4-methylumbelliferyl
	alpha-D-mannopyranoside, sodium acetate pH 5.6 and ZnCl at 37°C <34>)
	<34>
KI	#3# 0.00067
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#3# extracted from endothelial cells HCEC
	<49>) <49>
KI	#3# 50 {meso-aminocyclopentitretrol}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.0032
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#3# extracted from human glioblastoma cells
	LN18 <49>) <49>
KI	#3# 0.75 {1-deoxymannojirimycin}  (#3# pH 5.5, liver lysosomal fraction
	<35>) <35>
KI	#3# 0.75 {8a-epi-swainsonine}  (#3# liver lysosomal fraction <35>) <35>
KI	#3# 0.0044 {(1R,2R,3R,4S,5S)-1,2,3,4-tetrahydroxy-5-(N-(p-allyl ester
	benzyl)amino)cyclopentane}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.0076
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-bromo-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.0081
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-chloro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00053
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-fluoro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00091
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-chloro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00052
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-methoxy-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00021 {mannostatin}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.00051
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-bromo-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00055
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#3# extracted from human glioblastoma cells
	LNZ308 <49>) <49>
KI	#3# 0.0233
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#3# extracted from endothelial cells HCEC <49>) <49>
KI	#3# 0.00088
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-benzylamino)cyclopentane}  (#3# reaction volume
	containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate
	pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00322
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3,4-trihydroxy-5-(N-(p-allyl ester
	benzyl)amino)cyclopentane}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.0415
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#3# extracted from human glioblastoma cells LNZ308 <49>) <49>
KI	#3# 0.0325
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#3# extracted from human glioblastoma cells LN18 <49>) <49>

IC50_VALUE
IC50	#1# 0.014 {8-epi-lentiginosine}  <46>
IC50	#1# 2 {di-epi-swainsonine}  <46>
IC50	#1# 0.000017 {swainsonine}  <45>
IC50	#1# 1
	{(2R,3R,4S
	5R)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-5-methylpyrrolidine
	3,4-diol}  <45>
IC50	#1# 0.8
	{(2R,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  <45>
IC50	#1# 0.72
	{(2R,3R
	4S)-2-([[(1S)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  <45>
IC50	#17# 0.00003
	{1-phenyl-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
IC50	#17# 0.000037 {swainsonine}  (#17# pH 5.75, 25°C <54>) <54>
IC50	#17# 0.000029
	{1-(4-methylphenyl)-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
IC50	#17# 0.000029
	{1-(4-tert-butylphenyl)-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
IC50	#17# 0.000044
	{(1S,2R,5S,8R,8aR)-5-[2-(4-tert-butylphenyl)ethyl]octahydroindolizine-1
	2,8-triol}  (#17# pH 5.75, 25°C <54>) <54>
IC50	#17# 0.00025
	{1-(4-tert-butylphenyl)-2-[(1S,2R,5S,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
IC50	#17# 0.00025
	{(1S,2R,5R,8R,8aR)-5-[2-(4-tert-butylphenyl)ethyl]octahydroindolizine-1
	2,8-triol}  (#17# pH 5.75, 25°C <54>) <54>
IC50	#3# 0.0005
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#3# extracted from endothelial cells HCEC
	<49>; #3# extracted from human glioblastoma cells LNZ308 <49>) <49>
IC50	#3# 0.002
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#3# extracted from human glioblastoma cells
	LN18 <49>) <49>
IC50	#3# 1.5 {2-phenylethyl alpha-D-mannopyranosyl sulfone}  (#3# in 50 mM
	sodium acetate buffer pH 5.8, at 37°C <60>) <60>
IC50	#3# 0.025
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#3# extracted from endothelial cells HCEC <49>) <49>
IC50	#3# 0.0075
	{(3R,4R
	5S)-5-[([(1R)-2-[(4-bromophenyl)(hydroxy)methoxy]-1
	phenylethyl]amino)methyl]-3,4-dihydroxy-1-methylpyrrolidin-2-one}  (#3#
	extracted from human glioblastoma cells LNZ308 <49>) <49>
IC50	#3# 0.000005 {swainsonine}  (#3# in 50 mM sodium acetate buffer pH 5.8,
	at 37°C <60>) <60>
IC50	#3# 2 {benzyl alpha-D-mannopyranosyl sulfone}  (#3# in 50 mM sodium
	acetate buffer pH 5.8, at 37°C <60>) <60>
IC50	#3# 0.05
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#3# extracted from human glioblastoma cells LN18 <49>; #3#
	extracted from human glioblastoma cells LNZ308 <49>) <49>
IC50	#3# 0.05
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  (#3# extracted from human glioblastoma cells LNZ308 <49>) <49>
IC50	#3# 0.00013 {Mannostatin A}  (#3# in 50 mM sodium acetate buffer pH
	5.8, at 37°C <60>) <60>
IC50	#3# 0.00002 {swainsonine}  (#3# extracted from human glioblastoma cells
	LNZ308 <49>) <49>
IC50	#3# 0.15
	{(3R,4R
	5S)-5-[([(1R)-2-[(4-bromophenyl)(hydroxy)methoxy]-1
	phenylethyl]amino)methyl]-3,4-dihydroxypyrrolidin-2-one}  (#3#
	extracted from human glioblastoma cells LNZ308 <49>) <49>
IC50	#3# 0.2
	{(2S,3R
	4S)-2-[([(1R)-2-[(4-bromophenyl)(hydroxy)methoxy]-1
	phenylethyl]amino)methyl]pyrrolidine-3,4-diol}  (#3# extracted from
	human glioblastoma cells LN18 <49>) <49>
IC50	#3# 0.35
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  (#3# extracted from human glioblastoma cells LN18 <49>) <49>
IC50	#3# 0.075
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  (#3# extracted from endothelial cells HCEC <49>) <49>
IC50	#3# 0.075
	{(2S,3R
	4S)-2-[([(1R)-2-[(4-bromophenyl)(hydroxy)methoxy]-1
	phenylethyl]amino)methyl]pyrrolidine-3,4-diol}  (#3# extracted from
	endothelial cells HCEC <49>; #3# extracted from human glioblastoma
	cells LNZ308 <49>) <49>
IC50	#3# 0.075
	{(3R,4R
	5S)-5-[([(1R)-2-[(4-bromophenyl)(hydroxy)methoxy]-1
	phenylethyl]amino)methyl]-3,4-dihydroxy-1-methylpyrrolidin-2-one}  (#3#
	extracted from human glioblastoma cells LN18 <49>) <49>
IC50	#3# 0.075
	{(3R,4R
	5S)-5-[([(1R)-2-[(4-bromophenyl)(hydroxy)methoxy]-1
	phenylethyl]amino)methyl]-3,4-dihydroxypyrrolidin-2-one}  (#3#
	extracted from endothelial cells HCEC <49>) <49>
IC50	#3# 0.00005 {swainsonine}  (#3# extracted from human glioblastoma cells
	LN18 <49>) <49>
IC50	#3# 2.5 {(RS)-2-phenylethyl alpha-D-mannopyranosyl sulfoxide}  (#3# in
	50 mM sodium acetate buffer pH 5.8, at 37°C <60>) <60>
IC50	#3# 0.00075
	{(3R,4R
	5S)-5-[([(1R)-2-[(4-bromophenyl)(hydroxy)methoxy]-1
	phenylethyl]amino)methyl]-3,4-dihydroxy-1-methylpyrrolidin-2-one}  (#3#
	extracted from endothelial cells HCEC <49>) <49>
IC50	#3# 0.75
	{(3R,4R
	5S)-5-[([(1R)-2-[(4-bromophenyl)(hydroxy)methoxy]-1
	phenylethyl]amino)methyl]-3,4-dihydroxypyrrolidin-2-one}  (#3#
	extracted from human glioblastoma cells LN18 <49>) <49>
IC50	#3,11# 0.00001 {swainsonine}  (#11# alpha-mannosidase III, IC50: 10 nM
	<29>; #3# extracted from endothelial cells HCEC <49>) <29>
IC50	#3,11# 0.00001 {swainsonine}  (#11# alpha-mannosidase III, IC50: 10 nM
	<29>; #3# extracted from endothelial cells HCEC <49>) <49>
IC50	#6# 0.0004 {D-mannonolactam amidrazone}  (#6# IC50: 400 nM <10>) <10>
IC50	#8# 0.00001 {Mannostatin A}  (#8# very potent inhibitor, competitive,
	IC50: about 10 nM with 4-nitrophenyl alpha-D-mannoside as substrate,
	about 90 nM with GlcNAc(Man)5GlcNAc as substrate, equally potent as
	swainsonine <18>) <18>
IC50	#8# 0.00009-0.0001 {D-mannonolactam amidrazone}  (#8# equally as
	effective as mannostatin A, IC50: 90-100 nM <10>) <10>

KI_VALUE
KI	#1# -999 {more}  (#1# although too weak for full Ki analyses with the
	amounts of material available, all analogues with salacinol-like
	stereochemistry at positions 2 and 3 proved to be weak inhibitors of
	the enzyme with IC50 values of approximately 7.5 mM <38>) <38>
KI	#1# 0.001
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  <49>
KI	#1# 0.0003 {(1R,2S,3R,4R,5R)-5-aminocyclopentane-1,2,3,4-tetraol}  <50>
KI	#1# 0.6 {5-fluoro-beta-L-gulosyl fluoride}  (#1# pH 5.6, 37°C, D341N
	mutant GMII <24>) <24>
KI	#1# 0.067
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  <49>
KI	#1# 0.022
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  <49>
KI	#1# 7.5 {2-deoxy-2-fluoro-alpha-D-mannosyl fluoride}  (#1# pH 5.6,
	37°C, D341N mutant GMII <24>) <24>
KI	#1# 5.2 {kifunensine}  (#1# pH 5.75, 37°C <11>) <11>
KI	#1# 0.265 {1-deoxyaminocyclopentitetrol}  <36,50>
KI	#1# 0.265 {1-deoxyamino-cyclopentitetrol}  <36>
KI	#1# 0.0000105 {swainsonine}  (#1# pH 5.75, 37°C <11>) <11>
KI	#1# 0.000249 {N-benzyl mannostatin A}  <36>
KI	#1# 0.000249 {N-benzyl-mannostatin}  <36>
KI	#1,17# 0.00002 {swainsonine}  (#17# pH 5.6 <48>) <48,49>
KI	#1,17# 0.00015 {mannostatin B}  <50>
KI	#1,17# 0.000036 {Mannostatin A}  <36,50>
KI	#1,17# 0.000076
	{(1R,2R,3R,4S,5R)-4-amino-5-methoxycyclopentane-1,2,3-triol}  <50>
KI	#13# 0.004
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  <49>
KI	#13# 0.000155 {swainsonine}  <49>
KI	#13# 0.000135
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  <49>
KI	#13# 0.000206
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  <49>
KI	#17# 0.07 {gluco-hydroxyiminolactam}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.4 {1-deoxymannojirimycin}  <48>
KI	#17# 0.4 {deoxymannojirimycin}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.02 {noeuromycin}  (#17# pH 5.6 <48>) <48>
KI	#17# 5 {kifunensine}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.001
	{(3R,4R,5R)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#17# 20C, pH 6.8 <49>) <49>
KI	#17# 0.003 {swainsonine}  (#17# pH 5.75, 25°C <54>) <54>
KI	#17# 0.0003 {(1R,2R,3S,4R,5R)-5-aminocyclopentane-1,2,3,4-tetrol}  <50>
KI	#17# 0.002 {mannoimidazole}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.017 {N-octyl-6-epi-valienamine}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.0027
	{1-(4-methylphenyl)-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
KI	#17# 0.0027
	{1-(4-tert-butylphenyl)-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
KI	#17# 0.067
	{(2R,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#17# 20C, pH 6.8 <49>) <49>
KI	#17# 0.022
	{(3R,4R,5R)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidin-2
	one}  (#17# 20C, pH 6.8 <49>) <49>
KI	#17# 0.52
	{[[(3S,4S,5R,6R)-3,4
	5-trihydroxy-6-(hydroxymethyl)piperidin-2-ylidene]amino]
	N-(4-chlorophenyl)carbamate}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.52
	{(3S,4S,5R,6R,E)-3,4,5-trihydroxy-6-(hydroxymethyl)piperidin-2-one
	O-4-chlorophenylcarbamoyl oxime}  <48>
KI	#17# 0.013 {glucoimidazole}  (#17# pH 5.6 <48>) <48>
KI	#17# 0.0028
	{1-phenyl-2-[(1S,2R,5R,8R,8aR)-1,2
	8-trihydroxyoctahydroindolizin-5-yl]ethanone}  (#17# pH 5.75, 25°C
	<54>) <54>
KI	#17# 0.00002 {(1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol}  (#17#
	20C, pH 6.8 <49>) <49>
KI	#21# 0.018 {swainsonine}  <59>
KI	#3# 0.02 {8,8a-di-epi-swainsonine}  (#3# liver lysosomal fraction <35>)
	<35>
KI	#3# 0.006
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-fluoro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.01
	{(1R,2R,3R,4S,5S)-1,2,3,4-tetrahydroxy-5-(N-benzylamino)cyclopentane} 
	(#3# reaction volume containing 4-methylumbelliferyl
	alpha-D-mannopyranoside, sodium acetate pH 5.6 and ZnCl at 37°C <34>)
	<34>
KI	#3# 0.0066
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-methoxy-benzyl)amino)cyclopentane}  (#3#
	reaction volume containing 4-methylumbelliferyl
	alpha-D-mannopyranoside, sodium acetate pH 5.6 and ZnCl at 37°C <34>)
	<34>
KI	#3# 0.00067
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#3# extracted from endothelial cells HCEC
	<49>) <49>
KI	#3# 50 {meso-aminocyclopentitretrol}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.0032
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#3# extracted from human glioblastoma cells
	LN18 <49>) <49>
KI	#3# 0.75 {1-deoxymannojirimycin}  (#3# pH 5.5, liver lysosomal fraction
	<35>) <35>
KI	#3# 0.75 {8a-epi-swainsonine}  (#3# liver lysosomal fraction <35>) <35>
KI	#3# 0.0044 {(1R,2R,3R,4S,5S)-1,2,3,4-tetrahydroxy-5-(N-(p-allyl ester
	benzyl)amino)cyclopentane}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.0076
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-bromo-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.0081
	{(1R,2R,3R,4S,5S)-1,2,3
	4-tetrahydroxy-5-(N-(p-chloro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00053
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-fluoro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00091
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-chloro-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00052
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-methoxy-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00021 {mannostatin}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.00051
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-(p-bromo-benzyl)amino)cyclopentane}  (#3# reaction
	volume containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium
	acetate pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00055
	{(3R,4R,5S)-3
	4-dihydroxy-5-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)-1
	methylpyrrolidin-2-one}  (#3# extracted from human glioblastoma cells
	LNZ308 <49>) <49>
KI	#3# 0.0233
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#3# extracted from endothelial cells HCEC <49>) <49>
KI	#3# 0.00088
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3
	4-trihydroxy-5-(N-benzylamino)cyclopentane}  (#3# reaction volume
	containing 4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate
	pH 5.6 and ZnCl at 37°C <34>) <34>
KI	#3# 0.00322
	{(1R,2R,3R,4R,5S)-1-(methylthio)-2,3,4-trihydroxy-5-(N-(p-allyl ester
	benzyl)amino)cyclopentane}  (#3# reaction volume containing
	4-methylumbelliferyl alpha-D-mannopyranoside, sodium acetate pH 5.6 and
	ZnCl at 37°C <34>) <34>
KI	#3# 0.0415
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#3# extracted from human glioblastoma cells LNZ308 <49>) <49>
KI	#3# 0.0325
	{(2S,3R
	4S)-2-([[(1R)-2-hydroxy-1-phenylethyl]amino]methyl)pyrrolidine-3
	4-diol}  (#3# extracted from human glioblastoma cells LN18 <49>) <49>

PI_VALUE
PI	#10# 4.8 (#10# for the second isoform of the enzyme, isoelectric
	focusing <33>) <33>
PI	#10# 4.3 (#10# for the first isoform of the enzyme, isoelectric
	focusing <33>) <33>
PI	#10# 4.6 (#10# method not mentioned <33>) <33>
PI	#4# 5.8 (#4# pH 3 to 10 gradient, isoelectric focusing <3>) <3>

KCAT_KM_VALUE
KKM	#3# 0.0009 (#3# pH 7.0, 37°C, Bt3991 <58>) <58>
KKM	#3# 0.52 (#3# pH 7.0, 37°C, Bt3991 <58>) <58>

EXPRESSION
EXP	#4# down (#4# the expression of mRNA is inhibited in cerebral and
	cerebellar tissues by swainsonine in Oxytropis kansuensis <64>) <64>

///
ID	3.2.1.78
********************************************************************************
*                                                                              *
* Copyrighted by Dietmar Schomburg, Techn. University Braunschweig, GERMANY    *
* Distributed under the License as stated at http:/www.brenda-enzymes.org      *
*                                                                              *
********************************************************************************

PROTEIN
PR	#1# Bacillus subtilis   (#1# reference sequence for mutated Btk genes
	<9,19>; #1# D3IWE5 i.e. allele 1, D3IWE6 i.e. allele 2 <28>; #1# D3IWE6
	i.e. allele 2, enzyme additionally catalyzes the reaction of EC
	1.14.14.82 <30>) <9,19,28,30,53,58,102>
PR	#2# Geobacillus stearothermophilus   <34>
PR	#3# Aspergillus nidulans   <94>
PR	#4# Aspergillus niger   (#4# cf. EC 3.1.1.73 <6,19>)
	<6,19,23,60,64,75,76,85>
PR	#5# Glycine max   <89>
PR	#6# Byssochlamys spectabilis   <3>
PR	#7# Medicago sativa   (#7# cf. EC 3.2.1.4 <7,9,19>) <7,9,19>
PR	#8# Chlorella fusca   <13,15>
PR	#9# Bacillus sp. (in: Bacteria)   (#9# cf. EC 6.3.4.15 <17>) <17,45,63>
PR	#10# Solanum lycopersicum   (#10# orf7, isozyme oppA1 <48>) <4,48>
PR	#11# Paenibacillus polymyxa   <50>
PR	#12# Aeromonas hydrophila   (#12# cf. EC 6.3.4.10 <11>) <11>
PR	#13# Talaromyces purpureogenus   <16>
PR	#14# Helix pomatia   (#14# ATPLC5 <9,19>) <9,19>
PR	#15# Vibrio sp.   <25,33>
PR	#16# Lactuca sativa   <5,8,20,21>
PR	#17# Streptomyces sp.   <10>
PR	#18# Thermotoga neapolitana   (#18# gene nuc2 <2>) <2,32>
PR	#19# Cyamopsis tetragonoloba   (#19# mutant supA4 <19>) <19>
PR	#20# Trigonella foenum-graecum   (#20# cf. EC 3.2.1.74 <10,18>) <10,18>
PR	#21# Aspergillus fischeri   <99>
PR	#22# Aspergillus flavus   <60>
PR	#23# no activity in Escherichia coli   <44>
PR	#24# Penicillium oxalicum   <96>
PR	#25# Leucaena leucocephala   <9>
PR	#26# Mytilus edulis   <35,38>
PR	#27# Haliotis discus hannai   <55>
PR	#28# Tyromyces palustris   <12>
PR	#29# Aspergillus fumigatus   <43>
PR	#30# Rhizomucor miehei   <100>
PR	#31# Irpex lacteus   <19>
PR	#32# Orpinomyces sp.   <44>
PR	#33# Thermomyces lanuginosus   <110>
PR	#34# Athelia rolfsii   <1>
PR	#35# Talaromyces funiculosus   <3>
PR	#36# Aspergillus aculeatus   <26,68,80,93>
PR	#37# Penicillium wortmanni   <3>
PR	#38# Ruminiclostridium thermocellum   <105>
PR	#39# Alicyclobacillus acidocaldarius   <59>
PR	#40# Basidiomycota   (#40# reference sequence for mutated Btk genes
	<9>) <9>
PR	#41# Cellulomonas fimi   <42>
PR	#42# Talaromyces verruculosus   <3>
PR	#43# Caldibacillus cellulovorans   <31>
PR	#44# Gleditsia triacanthos   <9>
PR	#45# Lilium testaceum   <22>
PR	#46# Dictyoglomus thermophilum   (#46# enzyme acts as reductase
	component of toluene monooxygenase, EC 1.14.15.26  <27>) <27>
PR	#47# Caldicellulosiruptor sp.   (#47# enzyme acts as reductase
	component of xylene monooxygenase, EC 1.18.1.3 <29>) <29>
PR	#48# Lemonniera terrestris   <14>
PR	#49# Alatospora acuminata   <14>
PR	#50# Articulospora tetracladia   <14>
PR	#51# Gyoerffyella rotula   <14>
PR	#52# Gyoerffyella speciosa   <14>
PR	#53# Lemonniera aquatica   <14>
PR	#54# Aspergillus giganteus   <3>
PR	#55# Penicillium ochrochloron   <3>
PR	#56# Aspergillus luchuensis   <3>
PR	#57# Fusicoccum sp.   <3>
PR	#58# Cellvibrio japonicus   <37>
PR	#59# Coffea arabica   <40>
PR	#60# Rhodothermus marinus P49425 Swissprot <36>
PR	#61# Solanum lycopersicum Q8L5J1  (#61# orf7, isozyme oppA1 <49>)
	<24,39,49,71,77>
PR	#61# Solanum lycopersicum Q8L5J1 Swissprot (#61# orf7, isozyme oppA1
	<49>) <24,39,49,71,77>
PR	#62# Clostridium cellulovorans   <82>
PR	#63# Hypothenemus hampei   <97>
PR	#64# Sesbania virgata   <52,57>
PR	#65# Phanerochaete chrysosporium Q0PQY8 SwissProt <54>
PR	#66# Aspergillus sulphureus Q2LE69 SwissProt <56>
PR	#67# Penicillium occitanis   <72>
PR	#68# Aspergillus fumigatus Q4WBS1 UniProt <66,109>
PR	#69# Cryptopygus antarcticus B4XC07 UniProt <67,107>
PR	#70# Bacillus circulans Q49HI4 UniProt <69>
PR	#71# Bispora sp. B5LXD7 UniProt <62>
PR	#72# Vibrio sp. B5BQ69 UniProt <65>
PR	#73# Aplysia kurodai   <87>
PR	#74# Bacillus subtilis B5LX62 UniProt <73>
PR	#75# Xanthomonas campestris Q8P9S0 UniProt <74>
PR	#76# Bacillus licheniformis D0UHB3 UniProt <79>
PR	#77# Aspergillus niger B6V876 UniProt <78>
PR	#78# Arabidopsis thaliana Q9FJZ3 UniProt <91>
PR	#79# Arabidopsis thaliana Q9LZV3 UniProt <91>
PR	#80# Thermotoga petrophila A5IMX7 UniProt <81,104,106>
PR	#81# Aplysia kurodai E5RSM0 UniProt <88>
PR	#82# Bacillus subtilis O05512 UniProt <84>
PR	#83# Aspergillus nidulans Q5B7X2 UniProt <83>
PR	#84# Aspergillus nidulans Q5AZ53 UniProt <83>
PR	#85# Cellulosimicrobium sp. G3FBL1 UniProt <86>
PR	#86# Paenibacillus sp. C6KL35 UniProt <90>
PR	#87# Arabidopsis thaliana Q9M0H6 UniProt <91>
PR	#88# Hordeum vulgare Q2I011  <51>
PR	#89# Bacillus subtilis Q5PSP8  <70>
PR	#90# Aspergillus aculeatus Q00012  <41>
PR	#91# Bacillus circulans Q0IJR6  <61>
PR	#92# Mytilus edulis Q8WPJ2  <46>
PR	#93# Solanum lycopersicum Q6YM50  (#93# orf7, isozyme oppA1 <47>) <47>
PR	#94# Penicillium freii I3PML9 UniProt <101>
PR	#95# Bacillus subtilis D0UH99 UniProt <98>
PR	#96# Aspergillus niger A2R6F5 SwissProt <103>
PR	#97# Reinekea sp. KIT-YO10   <95>
PR	#98# Neurospora sitophila I4IY26 UniProt <92>
PR	#99# Thermothelomyces thermophila G2Q4H7 UniProt <108>
PR	#100# Dictyoglomus turgidum B8DZM3 UniProt <111>

RECOMMENDED_NAME
RN	mannan endo-1,4-beta-mannosidase


SYSTEMATIC_NAME
SN	4-beta-D-mannan mannanohydrolase


SYNONYMS
SY	 endo-beta-1,4-mannase
SY	 mannanase, endo-1,4-beta-
SY	 beta-mannanase B
SY	 beta-1,4-mannan 4-mannanohydrolase
SY	 beta-D-mannanase
SY	 1,4-beta-D-mannan mannanohydrolase
SY	 Endo-1,4-mannanase
SY	#1,26,29,41,80,94# endo-beta-1,4-mannanase <42,43,46,101,102,106>
SY	#10# (1,4)-beta-D-mannan mannanohydrolase <49>
SY	#10# LeMAN4a <48,49>
SY	#10# endo-beta-D-mannanase <48>
SY	#10# Man4A <77>
SY	#10,38# endo-beta-mannanase <47,105>
SY	#100# CelB <111>
SY	#100# Dtur_0671 (#100# gene name <111>) <111>
SY	#21# Man5P1 (#21# gene name <99>) <99>
SY	#24# PoMan5A <96>
SY	#24,30,63,95,96# endo-1,4-beta-mannanase <96,97,98,100,103>
SY	#26,32,36,39,83# ManA <38,44,59,83,93>
SY	#26,62# ManB <38,82>
SY	#29# Man II (#29# isozyme, minor form <43>) <43>
SY	#29# MAN I (#29# isozyme, major form <43>) <43>
SY	#3# Man5XZ3 (#3# gene name <94>) <94>
SY	#30# endo-acting beta-1,4-mannanase <100>
SY	#32# mannanase <44>
SY	#36# endo-beta-1,4,D-mannanase <93>
SY	#36# ManA/HmA <93>
SY	#38# endo-mannanase <105>
SY	#38# endo-beta-(1->4)-mannanase <105>
SY	#38# CtManf <105>
SY	#4# Man5A <64>
SY	#4,99# Man26A <85,108>
SY	#41# Man26A-50K <42>
SY	#5# Man1 <89>
SY	#61# LeMAN4 <39>
SY	#65# man5D <54>
SY	#67# ManIII <72>
SY	#68# ManF <109>
SY	#69# endo-beta-1,4-D-mannanase <107>
SY	#69# cold-adapted beta-mannanase <107>
SY	#69# CaMan <107>
SY	#69# beta-1,4-D-mannanase <107>
SY	#72# Man5C <65>
SY	#78,79# Man7 <91>
SY	#80# GH5-CBM27 <104>
SY	#80# TpMan <104,106>
SY	#80,97# endo-1,4-beta-D-mannanase <95,104>
SY	#84# ManC <83>
SY	#85# ManH <86>
SY	#86# Man26b <90>
SY	#9,10,21,74,80,96,97# Beta-mannanase <45,49,73,95,99,103,104,106>
SY	#9,87# Man5 <63,91>
SY	#96# Man <103>
SY	#96# mannan endo-1,4-beta-mannanase <103>
SY	#97# Rman <95>
SY	#98# endo-beta-D-1,4-mannanase <92>
SY	#98# CsMan5 <92>
SY	#99# em26a <108>
SY	#99# MYCTH_99077 (#99# gene name <108>) <108>

REACTION
RE	Random hydrolysis of (1->4)-beta-D-mannosidic linkages in mannans,
	galactomannans and glucomannans

REACTION_TYPE
RT	hydrolysis of O-glycosyl bond

SOURCE_TISSUE
ST	#1,4,7,14,25,40,44# commercial preparation <6,7,9,19>
ST	#1,4,7,14,25,40,44# gut <6,7,9,19>
ST	#1,4,7,9,14,16,19,28,31,64,78,79,87# endosperm
	<5,6,7,8,9,12,17,19,20,21,52,57,91>
ST	#1,6,7,13,18,31,35,37,42,54,55,56,57# culture filtrate
	<2,3,7,9,16,19,28,30,32>
ST	#1,9,29,32,65,66# culture fluid <43,44,45,54,56,58>
ST	#10,61# fruit (#61# red fruit, not during early stages of ripening
	<39>; #10# isoform Man4a is expressed in the fruit cell wall at all
	ripening stages, but it is not active during the initial green stage.
	This is not due to the presence of inhibitors of its activity, nor due
	to changes in its mRNA sequence <77>) <39,71,77>
ST	#12# culture medium <11>
ST	#26# digestive gland <46>
ST	#27,73# digestive juice <55,87>
ST	#45# bulb <22>
ST	#5# cotyledon (#5# specifically expressed in cotyledons of seedling
	<89>) <89>
ST	#5# seedling (#5# specifically expressed in cotyledons of seedling
	<89>) <51,89>
ST	#61# flower <39>
ST	#61,80,98# more (#61# not in leaf <39>; #98# solid state fermentation
	on medium containing microcrystalline cellulose <92>; #80# the
	temperature range for growth is 47-88°C with an optimum at 80°C
	<106>) <39,92,106>
ST	#64,78,79,87# radicle (#64# high degree of enzyme expression during
	germination facilitates radicle protrusion through the surrounding
	endosperm by weakeing it in the region close to the radicle tip <52>)
	<52,91>
ST	#7,10,16,59,64,78,79,87# seed (#59# germinating <40>)
	<4,5,7,8,9,19,20,21,24,40,52,57,91>

LOCALIZATION
LO	#1,3,9,21,24,33,63,65,66,77,95# extracellular (#77# recombinant enzyme
	<78>; #3,24,95# the enzyme is secreted <94,96,98>; #21# the enzyme
	contains a putative 19-residue signal peptide at the N-terminus <99>)
	<17,54,56,58,78,94,96,97,98,99,110>
LO	#10,41# cell wall (#10# main enzyme activity in the fruit <47>; #10#
	transient expression in onion epidermal cells of endo-beta-mannanase
	trancripts fused to green fluorescent protein results in the expressed
	enzyme being localized to the cell walls. This occurs initially during
	ripening in the skin and outer pericarp of the fruit, and later in the
	skin and throughout the pericarp <77>) <42,47,48,49,77>
LO	#94# more (#94# the enzyme contains a putative 18-residue signal
	peptide <101>) <101>

NATURAL_SUBSTRATE_PRODUCT
NSP	#1,2,15# locust bean gum + H2O = mannose + galactose <30,33,34>
NSP	#15# ivory nut mannan + H2O = mannobiose + mannotriose <33>
NSP	#35,37,54# guar gum + H2O = mannose + mannobiose + mannotriose |#54#
	mannobiose + mannotriose + mannotetraose <3>| {} <3>
NSP	#5,21,24,36,63,80,98# more = ? (#5# enzyme is active in hydrolyzing the
	beta-mannan-rich cell wall of soybean seeds <89>; #80# the enzyme
	catalyzes the hydrolysis of beta-1,4-mannoside linkages in various
	mannan-containing polysaccharides, such as glucomannans and
	galactomannans. Protein-ligand interactions from crystal structure
	analysis, circular dichroism spectroscopy, overview <104>; #24# the
	enzyme catalyzes the random hydrolysis of beta-1,4-mannosidic linkages
	in the main chain of mannans, glucomannans and galactomannans, main
	products are mannobiose, mannotriose, and mannopentaose <96>; #63# the
	enzyme hydrolyzes high-molecular weight polysaccharides with
	beta-1,4-glycosidic bonds <97>; #21# the enzyme is highly active
	towards galactomannan and glucomannan, and exhibits classic
	endo-activity producing a mixture of mannooligosaccharides <99>; #36#
	the enzyme is involved in release of mannooligosaccharides from spent
	coffee ground cleaving the backbone at random locations in
	galactomannan, glucomannan, galactoglucomannan and mannan <93>; #98#
	the native wild-type enzyme shows bifunctional activity as both an
	endo-glucanase and an endo-mannanase, substrate specificity, overview
	<92>) <89,92,93,96,97,99,104>
NSP	#5,21,24,36,63,80,98# more = ? (#5# enzyme is active in hydrolyzing the
	beta-mannan-rich cell wall of soybean seeds <89>; #80# the enzyme
	catalyzes the hydrolysis of beta-1,4-mannoside linkages in various
	mannan-containing polysaccharides, such as glucomannans and
	galactomannans. Protein-ligand interactions from crystal structure
	analysis, circular dichroism spectroscopy, overview <104>; #24# the
	enzyme catalyzes the random hydrolysis of beta-1,4-mannosidic linkages
	in the main chain of mannans, glucomannans and galactomannans, main
	products are mannobiose, mannotriose, and mannopentaose <96>; #63# the
	enzyme hydrolyzes high-molecular weight polysaccharides with
	beta-1,4-glycosidic bonds <97>; #21# the enzyme is highly active
	towards galactomannan and glucomannan, and exhibits classic
	endo-activity producing a mixture of mannooligosaccharides <99>; #36#
	the enzyme is involved in release of mannooligosaccharides from spent
	coffee ground cleaving the backbone at random locations in
	galactomannan, glucomannan, galactoglucomannan and mannan <93>; #98#
	the native wild-type enzyme shows bifunctional activity as both an
	endo-glucanase and an endo-mannanase, substrate specificity, overview
	<92>) {} <89,92,93,96,97,99,104>
NSP	#5,21,24,36,63,80,98# more = ? (#5# enzyme is active in hydrolyzing the
	beta-mannan-rich cell wall of soybean seeds <89>; #80# the enzyme
	catalyzes the hydrolysis of beta-1,4-mannoside linkages in various
	mannan-containing polysaccharides, such as glucomannans and
	galactomannans. Protein-ligand interactions from crystal structure
	analysis, circular dichroism spectroscopy, overview <104>; #24# the
	enzyme catalyzes the random hydrolysis of beta-1,4-mannosidic linkages
	in the main chain of mannans, glucomannans and galactomannans, main
	products are mannobiose, mannotriose, and mannopentaose <96>; #63# the
	enzyme hydrolyzes high-molecular weight polysaccharides with
	beta-1,4-glycosidic bonds <97>; #21# the enzyme is highly active
	towards galactomannan and glucomannan, and exhibits classic
	endo-activity producing a mixture of mannooligosaccharides <99>; #36#
	the enzyme is involved in release of mannooligosaccharides from spent
	coffee ground cleaving the backbone at random locations in
	galactomannan, glucomannan, galactoglucomannan and mannan <93>; #98#
	the native wild-type enzyme shows bifunctional activity as both an
	endo-glucanase and an endo-mannanase, substrate specificity, overview
	<92>) {} <89,92,93,96,97,99,104>
NSP	#8# mannan + H2O = ? <13,15>
NSP	#97# konjac glucomannan + H2O = ? <95>

SUBSTRATE_PRODUCT
SP	#1# xylan + H2O = ? (#1# poor substrate <53>) <53>
SP	#1# starch + H2O = ? (#1# poor substrate <53>) <53>
SP	#1# carboxymethyl cellulose + H2O = ? (#1# poor substrate <53>) <53>
SP	#1# mannan + H2O = mannotetraose + mannobiose + mannotriose (#1# source
	of substrate: copra <53>) <53>
SP	#1,2,15# locust bean gum + H2O = mannose + galactose <30,33,34>
SP	#1,26,36,97# ivory nut mannan + H2O = ? (#97# 46% activity compared to
	konjac glucomannan <95>) <38,41,70,95>
SP	#1,3,4,22,24,29,60,62,63,70,71,77,97# guar gum + H2O = ? (#1# 21% of
	the activity with locust bean gum <58>; #77# 18% of the activity with
	locust bean gum <78>; #4# 90% of the activity with locust bean gum
	<76>; #97# 1.7% activity compared to konjac glucomannan <95>; #3# 41.2%
	of the activity with locust bean gum <94>) |#71# 14.8% of the activity
	with locust bean gum <62>; #70# 26% of the activity with locust bean
	gum <69>| <36,43,58,60,62,69,76,78,82,94,95,96,97>
SP	#1,3,4,5,6,9,12,20,21,24,26,27,30,34,35,36,37,38,42,46,54,55,56,57,59
	60,63,65,67,70,72,73,77,80,82,83,84,85,97,98,99,100# more = ? (#4,9,12#
	not: mannobiose <6,11,17,19>; #20# transglycosylation reaction,
	Streptomyces: transfer of one mannose unit from oligosaccharides,
	fenugreek: transfer of oligomannose residues <10,18>; #59# no
	substrate: mannotriose, mannobiose, enzyme requires a minimum of four
	sugar units in substrates <40>; #26# no substrate: xylan, caroxymethyl
	cellulose, cellulose, mannan <38>; #60# requires at least five sugar
	moieties for effective catalytic activity, no substrate: yeast mannan
	<36>; #27# enzyme degrades either beta-1,4-mannan or
	beta-1,4-mannooligosaccharides to mannotriose and mannotetraose. Enzyme
	disperses the fronds of the red alga Porphyra yezoensis into cell
	masses consisting of 10-20 cells that are available for cell
	engineering <55>; #65# enzyme exhibits substantial transglycosylase
	activity <54>; #1# no substrate: carboxymethyl cellulose <58>; #72#
	enzyme has the ability to bind soluble beta-mannans <65>; #72# enzyme
	hydrolyzes homopolysaccharides such as codium mannan, Porphyra mannan,
	coffee mannan, and coconut mannan, to form mainly mannobiose and
	mannotriose in addition to minor sugars, such as mannose,
	mannotetraose, and mannopentaose <65>; #70# no substrate: soluble
	starch, methylcellulose <69>; #1# no substrates: mannobiose,
	mannotriose, mannotetraose, mannohexaose <70>; #77# negligible activity
	with starch, carboxymethyl cellulose, and alpha-cellulose <78>; #67# no
	substrate: carboxymethyl cellulose, oat spelt xylan, starch, pectin,
	4-nitrophenyl-beta-D-mannopyranoside <72>; #5# enzyme is active in
	hydrolyzing the beta-mannan-rich cell wall of soybean seeds <89>; #84#
	enzyme displays good transgycosylation activity using mannotriose,
	melezitose and isomaltotriose as acceptors <83>; #83# enzyme displays
	transglycosylation activity using only mannotriose as acceptor <83>;
	#82# no substrate: guar gum, copra meal <84>; #85# no substrate:
	mannobiose, or 4-nitrophenyl sugar derivatives <86>; #73# preferably
	degrades a linear beta-1,4-mannan from green algae Codium fragile
	producing tri- and disaccharides. no substrate: carboxymethyl
	cellulose, agarose, dextran and xylan <87>; #80# the enzyme catalyzes
	the hydrolysis of beta-1,4-mannoside linkages in various
	mannan-containing polysaccharides, such as glucomannans and
	galactomannans. Protein-ligand interactions from crystal structure
	analysis, circular dichroism spectroscopy, overview <104>; #24# the
	enzyme catalyzes the random hydrolysis of beta-1,4-mannosidic linkages
	in the main chain of mannans, glucomannans and galactomannans, main
	products are mannobiose, mannotriose, and mannopentaose <96>; #63# the
	enzyme hydrolyzes high-molecular weight polysaccharides with
	beta-1,4-glycosidic bonds <97>; #21# the enzyme is highly active
	towards galactomannan and glucomannan, and exhibits classic
	endo-activity producing a mixture of mannooligosaccharides <99>; #36#
	the enzyme is involved in release of mannooligosaccharides from spent
	coffee ground cleaving the backbone at random locations in
	galactomannan, glucomannan, galactoglucomannan and mannan <93>; #98#
	the native wild-type enzyme shows bifunctional activity as both an
	endo-glucanase and an endo-mannanase, substrate specificity, overview
	<92>; #63# main by products of the hydrolysis of both guar and locust
	bean gum are mannose and manno-oligosaccharides of different sizes
	(mannobiose, mannotriose and mannotetraose). Enzyme mode of action
	involving a transglycosylation reaction in the mechanism that allows
	the enzyme to hydrolyze this manno-oligosaccharide. No activity with
	mannobiose and mannotriose <97>; #3# no activity with beechwood xylan,
	4-nitrophenyl beta-D-glucopyranoside, 4-nitrophenyl beta-D-mannoside,
	and carboxymethyl cellulose <94>; #97# no activity with tamarind
	xyloglucan, sodium arginate, carboxymethylcellulose, low-melting point
	agarose, gellan gum, xylan, carrageenan, and laminaran <95>; #38#
	production of mannooligosaccharides from pretreated and defatted copra
	meal hydrolysis by the enzyme <105>; #98# the enzyme also show
	transglycosylation activity <92>; #21# the enzyme has no exo-activity
	and is a typical endo-acting beta-mannanase, substrate specificity,
	overview. No activity with mannobiose, beechwood xylan, barley
	beta-glucan, 4-nitrophenyl beta-D-mannoside, and carboxymethyl
	cellulose <99>; #30# the enzyme shows requirement of four mannose
	residues for hydrolysis, and is also capable of catalyzing
	transglycosylation reactions <100>; #99# no activity against barley
	beta-glucan, birchwood xylan, and low viscosity carboxymethyl cellulose
	<108>; #100# enzyme shows high endo-beta-1,4-mannanase activity versus
	various mannans, but low endo-beta-1,4 glucanase activity towards
	carboxymethylcellulose, andd negligible activity towards glucomannans
	<111>)
	<1,3,6,10,11,17,18,19,27,36,38,40,51,54,55,58,65,69,70,72,78,83,84,86
	87,89,92,93,94,95,96,97,99,100,104,105,108,111>
SP	#1,3,4,5,6,9,12,20,21,24,26,27,30,34,35,36,37,38,42,46,54,55,56,57,59
	60,63,65,67,70,72,73,77,80,82,83,84,85,97,98,99,100# more = ? (#4,9,12#
	not: mannobiose <6,11,17,19>; #20# transglycosylation reaction,
	Streptomyces: transfer of one mannose unit from oligosaccharides,
	fenugreek: transfer of oligomannose residues <10,18>; #59# no
	substrate: mannotriose, mannobiose, enzyme requires a minimum of four
	sugar units in substrates <40>; #26# no substrate: xylan, caroxymethyl
	cellulose, cellulose, mannan <38>; #60# requires at least five sugar
	moieties for effective catalytic activity, no substrate: yeast mannan
	<36>; #27# enzyme degrades either beta-1,4-mannan or
	beta-1,4-mannooligosaccharides to mannotriose and mannotetraose. Enzyme
	disperses the fronds of the red alga Porphyra yezoensis into cell
	masses consisting of 10-20 cells that are available for cell
	engineering <55>; #65# enzyme exhibits substantial transglycosylase
	activity <54>; #1# no substrate: carboxymethyl cellulose <58>; #72#
	enzyme has the ability to bind soluble beta-mannans <65>; #72# enzyme
	hydrolyzes homopolysaccharides such as codium mannan, Porphyra mannan,
	coffee mannan, and coconut mannan, to form mainly mannobiose and
	mannotriose in addition to minor sugars, such as mannose,
	mannotetraose, and mannopentaose <65>; #70# no substrate: soluble
	starch, methylcellulose <69>; #1# no substrates: mannobiose,
	mannotriose, mannotetraose, mannohexaose <70>; #77# negligible activity
	with starch, carboxymethyl cellulose, and alpha-cellulose <78>; #67# no
	substrate: carboxymethyl cellulose, oat spelt xylan, starch, pectin,
	4-nitrophenyl-beta-D-mannopyranoside <72>; #5# enzyme is active in
	hydrolyzing the beta-mannan-rich cell wall of soybean seeds <89>; #84#
	enzyme displays good transgycosylation activity using mannotriose,
	melezitose and isomaltotriose as acceptors <83>; #83# enzyme displays
	transglycosylation activity using only mannotriose as acceptor <83>;
	#82# no substrate: guar gum, copra meal <84>; #85# no substrate:
	mannobiose, or 4-nitrophenyl sugar derivatives <86>; #73# preferably
	degrades a linear beta-1,4-mannan from green algae Codium fragile
	producing tri- and disaccharides. no substrate: carboxymethyl
	cellulose, agarose, dextran and xylan <87>; #80# the enzyme catalyzes
	the hydrolysis of beta-1,4-mannoside linkages in various
	mannan-containing polysaccharides, such as glucomannans and
	galactomannans. Protein-ligand interactions from crystal structure
	analysis, circular dichroism spectroscopy, overview <104>; #24# the
	enzyme catalyzes the random hydrolysis of beta-1,4-mannosidic linkages
	in the main chain of mannans, glucomannans and galactomannans, main
	products are mannobiose, mannotriose, and mannopentaose <96>; #63# the
	enzyme hydrolyzes high-molecular weight polysaccharides with
	beta-1,4-glycosidic bonds <97>; #21# the enzyme is highly active
	towards galactomannan and glucomannan, and exhibits classic
	endo-activity producing a mixture of mannooligosaccharides <99>; #36#
	the enzyme is involved in release of mannooligosaccharides from spent
	coffee ground cleaving the backbone at random locations in
	galactomannan, glucomannan, galactoglucomannan and mannan <93>; #98#
	the native wild-type enzyme shows bifunctional activity as both an
	endo-glucanase and an endo-mannanase, substrate specificity, overview
	<92>; #63# main by products of the hydrolysis of both guar and locust
	bean gum are mannose and manno-oligosaccharides of different sizes
	(mannobiose, mannotriose and mannotetraose). Enzyme mode of action
	involving a transglycosylation reaction in the mechanism that allows
	the enzyme to hydrolyze this manno-oligosaccharide. No activity with
	mannobiose and mannotriose <97>; #3# no activity with beechwood xylan,
	4-nitrophenyl beta-D-glucopyranoside, 4-nitrophenyl beta-D-mannoside,
	and carboxymethyl cellulose <94>; #97# no activity with tamarind
	xyloglucan, sodium arginate, carboxymethylcellulose, low-melting point
	agarose, gellan gum, xylan, carrageenan, and laminaran <95>; #38#
	production of mannooligosaccharides from pretreated and defatted copra
	meal hydrolysis by the enzyme <105>; #98# the enzyme also show
	transglycosylation activity <92>; #21# the enzyme has no exo-activity
	and is a typical endo-acting beta-mannanase, substrate specificity,
	overview. No activity with mannobiose, beechwood xylan, barley
	beta-glucan, 4-nitrophenyl beta-D-mannoside, and carboxymethyl
	cellulose <99>; #30# the enzyme shows requirement of four mannose
	residues for hydrolysis, and is also capable of catalyzing
	transglycosylation reactions <100>; #99# no activity against barley
	beta-glucan, birchwood xylan, and low viscosity carboxymethyl cellulose
	<108>; #100# enzyme shows high endo-beta-1,4-mannanase activity versus
	various mannans, but low endo-beta-1,4 glucanase activity towards
	carboxymethylcellulose, andd negligible activity towards glucomannans
	<111>) {}
	<1,3,6,10,11,17,18,19,27,36,38,40,51,54,55,58,65,69,70,72,78,83,84,86
	87,89,92,93,94,95,96,97,99,100,104,105,108,111>
SP	#1,3,4,5,6,9,12,20,21,24,26,27,30,34,35,36,37,38,42,46,54,55,56,57,59
	60,63,65,67,70,72,73,77,80,82,83,84,85,97,98,99,100# more = ? (#4,9,12#
	not: mannobiose <6,11,17,19>; #20# transglycosylation reaction,
	Streptomyces: transfer of one mannose unit from oligosaccharides,
	fenugreek: transfer of oligomannose residues <10,18>; #59# no
	substrate: mannotriose, mannobiose, enzyme requires a minimum of four
	sugar units in substrates <40>; #26# no substrate: xylan, caroxymethyl
	cellulose, cellulose, mannan <38>; #60# requires at least five sugar
	moieties for effective catalytic activity, no substrate: yeast mannan
	<36>; #27# enzyme degrades either beta-1,4-mannan or
	beta-1,4-mannooligosaccharides to mannotriose and mannotetraose. Enzyme
	disperses the fronds of the red alga Porphyra yezoensis into cell
	masses consisting of 10-20 cells that are available for cell
	engineering <55>; #65# enzyme exhibits substantial transglycosylase
	activity <54>; #1# no substrate: carboxymethyl cellulose <58>; #72#
	enzyme has the ability to bind soluble beta-mannans <65>; #72# enzyme
	hydrolyzes homopolysaccharides such as codium mannan, Porphyra mannan,
	coffee mannan, and coconut mannan, to form mainly mannobiose and
	mannotriose in addition to minor sugars, such as mannose,
	mannotetraose, and mannopentaose <65>; #70# no substrate: soluble
	starch, methylcellulose <69>; #1# no substrates: mannobiose,
	mannotriose, mannotetraose, mannohexaose <70>; #77# negligible activity
	with starch, carboxymethyl cellulose, and alpha-cellulose <78>; #67# no
	substrate: carboxymethyl cellulose, oat spelt xylan, starch, pectin,
	4-nitrophenyl-beta-D-mannopyranoside <72>; #5# enzyme is active in
	hydrolyzing the beta-mannan-rich cell wall of soybean seeds <89>; #84#
	enzyme displays good transgycosylation activity using mannotriose,
	melezitose and isomaltotriose as acceptors <83>; #83# enzyme displays
	transglycosylation activity using only mannotriose as acceptor <83>;
	#82# no substrate: guar gum, copra meal <84>; #85# no substrate:
	mannobiose, or 4-nitrophenyl sugar derivatives <86>; #73# preferably
	degrades a linear beta-1,4-mannan from green algae Codium fragile
	producing tri- and disaccharides. no substrate: carboxymethyl
	cellulose, agarose, dextran and xylan <87>; #80# the enzyme catalyzes
	the hydrolysis of beta-1,4-mannoside linkages in various
	mannan-containing polysaccharides, such as glucomannans and
	galactomannans. Protein-ligand interactions from crystal structure
	analysis, circular dichroism spectroscopy, overview <104>; #24# the
	enzyme catalyzes the random hydrolysis of beta-1,4-mannosidic linkages
	in the main chain of mannans, glucomannans and galactomannans, main
	products are mannobiose, mannotriose, and mannopentaose <96>; #63# the
	enzyme hydrolyzes high-molecular weight polysaccharides with
	beta-1,4-glycosidic bonds <97>; #21# the enzyme is highly active
	towards galactomannan and glucomannan, and exhibits classic
	endo-activity producing a mixture of mannooligosaccharides <99>; #36#
	the enzyme is involved in release of mannooligosaccharides from spent
	coffee ground cleaving the backbone at random locations in
	galactomannan, glucomannan, galactoglucomannan and mannan <93>; #98#
	the native wild-type enzyme shows bifunctional activity as both an
	endo-glucanase and an endo-mannanase, substrate specificity, overview
	<92>; #63# main by products of the hydrolysis of both guar and locust
	bean gum are mannose and manno-oligosaccharides of different sizes
	(mannobiose, mannotriose and mannotetraose). Enzyme mode of action
	involving a transglycosylation reaction in the mechanism that allows
	the enzyme to hydrolyze this manno-oligosaccharide. No activity with
	mannobiose and mannotriose <97>; #3# no activity with beechwood xylan,
	4-nitrophenyl beta-D-glucopyranoside, 4-nitrophenyl beta-D-mannoside,
	and carboxymethyl cellulose <94>; #97# no activity with tamarind
	xyloglucan, sodium arginate, carboxymethylcellulose, low-melting point
	agarose, gellan gum, xylan, carrageenan, and laminaran <95>; #38#
	production of mannooligosaccharides from pretreated and defatted copra
	meal hydrolysis by the enzyme <105>; #98# the enzyme also show
	transglycosylation activity <92>; #21# the enzyme has no exo-activity
	and is a typical endo-acting beta-mannanase, substrate specificity,
	overview. No activity with mannobiose, beechwood xylan, barley
	beta-glucan, 4-nitrophenyl beta-D-mannoside, and carboxymethyl
	cellulose <99>; #30# the enzyme shows requirement of four mannose
	residues for hydrolysis, and is also capable of catalyzing
	transglycosylation reactions <100>; #99# no activity against barley
	beta-glucan, birchwood xylan, and low viscosity carboxymethyl cellulose
	<108>; #100# enzyme shows high endo-beta-1,4-mannanase activity versus
	various mannans, but low endo-beta-1,4 glucanase activity towards
	carboxymethylcellulose, andd negligible activity towards glucomannans
	<111>) {}
	<1,3,6,10,11,17,18,19,27,36,38,40,51,54,55,58,65,69,70,72,78,83,84,86
	87,89,92,93,94,95,96,97,99,100,104,105,108,111>
SP	#1,4,5,9,11,22,24,26,29,33,36,62,63,65,66,67,69,70,71,76,82,86,97#
	locust bean gum + H2O = ? (#1# enzyme is highly specific for substrate
	<58>; #97# 9.6% activity compared to konjac glucomannan <95>) |#70#
	hydrolysis products are mainly oligosaccharides plus one monosaccharide
	<69>; #76# main products are manno-oligosaccharides of 2-6 residues and
	mannose <79>; #82# products are various manno-oligosaccharides of M2-M6
	size and mannose <84>|
	<38,43,50,53,54,56,58,60,61,62,63,67,69,70,72,76,79,82,84,85,89,90,93
	95,96,97,110>
SP	#1,4,6,7,9,12,14,15,16,19,31,34,35,37,42,54,55,56,57,65# mannan + H2O =
	oligosaccharides (#12# codium, coffee <11>) |#6,35,37,42,54,55,56,57#
	dimers, trimers and other <3>| <1,3,5,8,11,17,19,25,30,33,54>
SP	#1,4,6,7,9,12,14,15,16,19,31,34,35,37,42,54,55,56,57,65# mannan + H2O =
	oligosaccharides (#12# codium, coffee <11>) |#6,35,37,42,54,55,56,57#
	dimers, trimers and other <3>| {} <1,3,5,8,11,17,19,25,30,33,54>
SP	#1,4,7,12,13,14,25,34,40,44,46,65# galactomannan + H2O = hydrolyzed
	galactomannan <1,6,7,9,11,16,19,27,54>
SP	#1,4,7,9,12,13,14,17,25,40,44# mannotetraose + H2O = mannobiose +
	mannose + mannotriose |#4,9# small amounts of mannose and mannotriose
	<6,17,19>| <6,7,9,10,11,16,17,19>
SP	#1,4,7,9,12,14,15,16,19,28,31,34,45,65# glucomannan + H2O =
	oligosaccharides |#12,28# of various size <11,12>|
	<1,5,6,8,9,11,12,17,19,20,21,22,25,54>
SP	#1,4,7,9,12,14,15,16,19,31# mannopentaose + H2O = mannose + mannobiose
	+ mannotriose + mannotetraose <5,6,7,8,11,17,19,20,21,33>
SP	#1,4,7,9,14,16,19,31,34,62# galactoglucomannan + H2O = ?
	<1,5,6,8,17,19,20,21,82>
SP	#1,9,61,71,72,76,77,82# glucomannan + H2O = ? (#1,9,71,72# from konjac
	flour <62,63,65,70>; #76# 219% of the activity with locust bean gum
	<79>) |#71# 70% of the activity with locust bean gum <62>; #9# products
	are a large amount of oligosaccharides with a degree of polymerizytion
	of 2-6 and a very small amount of monosaccharide <63>|
	<39,45,62,63,65,70,78,79,84>
SP	#10# azurine-crosslinked galactomannan + H2O = ? (#10# hydrolysis <48>)
	<48>
SP	#10# galactoglucomannan + oligosaccharide = [3H]-labelled
	polysaccharide (#10# transglucosylation <48>) <48>
SP	#10# Manbeta(1-4)Manbeta(1-4)Man + H2O = ? <48>
SP	#10,26# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man + H2O =
	Manbeta(1-4)Manbeta(1-4)Man + Manbeta(1-4)Man +
	Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man + mannose <46,49>
SP	#100# carob glucomannan + H2O = ? (#100# 13% of the activity with
	konjac glucomannan <111>) <111>
SP	#100# guar glucomannan + H2O = ? (#100# 1.4% of the activity with
	konjac glucomannan <111>) <111>
SP	#15# ivory nut mannan + H2O = mannobiose + mannotriose <33>
SP	#21# mannotriose + H2O = ? <99>
SP	#21# mannotetraose + H2O = ? <99>
SP	#21# mannopentaose + H2O = ? <99>
SP	#21# galactomannan + H2O = mannose + mannobiose + mannotriose +
	mannotetraose + galactose-linked mannotetraose + mannopentaose +
	mannohexaose (#21# different contents of glucose and mannose, overview
	<99>) |#21# product ratio overview <99>| <99>
SP	#21# guar gum + H2O = mannose + mannobiose + mannotriose +
	mannotetraose + galactose-linked mannotetraose + mannopentaose +
	mannohexaose |#21# product ratio overview <99>| <99>
SP	#21# locust bean gum + H2O = mannose + mannobiose + mannotriose +
	mannotetraose + galactose-linked mannotetraose + mannopentaose +
	mannohexaose |#21# product ratio overview <99>| <99>
SP	#21# mannohexaose + H2O = ? <99>
SP	#26# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man + H2O =
	Manbeta(1-4)Manbeta(1-4)Man + mannose + Manbeta(1-4)Man <46>
SP	#26# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man-ol + H2O =
	Manbeta(1-4)Man-ol + Manbeta(1-4)Manbeta(1-4)Man + mannose +
	Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man-ol +
	Manbeta(1-4)Man <46>
SP	#26# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man +
	H2O = Manbeta(1-4)Manbeta(1-4)Man +
	Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man +
	Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man + mannose <46>
SP	#26# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man-ol
	+ H2O = mannose +
	Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man-ol +
	Manbeta(1-4)Manbeta(1-4)Man + Manbeta(1-4)Man-ol + Manbeta(1-4)Man +
	Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man <46>
SP	#27# beta-1,4-mannan + H2O = beta-1,4-mannotriose +
	beta-1,4-mannotetraose <55>
SP	#27# glucomannan + H2O = glucosyl-mannosyl oligosaccharides (#27#
	source of substrate konjac <55>) <51,55>
SP	#27,64# galactomannan + H2O = galactosyl-mannosyl oligosaccharides
	(#64# enzyme prefers galactomannans with lower degree of
	galactosylation e.g. from carob gum <52>; #27# source of substrate
	locust bean gum <55>) <51,52,55>
SP	#29# low viscosity locust bean galactomannan + H2O = ? <43>
SP	#29# mannan A + H2O = ? <43>
SP	#3# locust bean gum + H2O = mannobiose + mannotriose + mannotetraose
	(#3# best substrate <94>) |#3# hydrolysis products are 17.2%
	mannobiose, 37.4% mannotriose, 9.9% mannotetraose, and 35.5% other
	unidentified oligosaccharides <94>| <94>
SP	#30# guar gum + H2O = mannobiose + mannotriose |#30# mannobiose,
	mannotriose, and a mixture of various mannose-linked oligosaccharides
	<100>| <100>
SP	#30,94# locust bean gum + H2O = mannobiose + mannotriose (#30# best
	substrate <100>) |#94# 52.7% mannobiose, 18.1% mannotriose and 29.2%
	other unidentifiable oligosaccharides <101>; #30# mannobiose,
	mannotriose, and a mixture of various mannose-linked oligosaccharides
	<100>| <100,101>
SP	#35,37,54# guar gum + H2O = mannose + mannobiose + mannotriose |#54#
	mannobiose + mannotriose + mannotetraose <3>| {} <3>
SP	#4# copra mannan + H2O = ? (#4# 90% of the activity with locust bean
	gum <76>) <76>
SP	#4# palm kernel cake + H2O = ? <75>
SP	#4,22# copra meal defatted with n-hexane + H2O = ? (#4,22# better
	substrate than locust bean gum and guar gum <60>) <60>
SP	#4,9,13# mannotriose + H2O = mannobiose + mannose |#13# not <16>|
	<6,16,17,19>
SP	#41# Manbeta(1-4)Manbeta(1-4)Man + H2O = mannose + Manbeta(1-4)Man <42>
SP	#41# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man + H2O = Manbeta(1-4)Man +
	Manbeta(1-4)Manbeta(1-4)Man + Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man +
	mannose <42>
SP	#41# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man + H2O = mannose +
	Manbeta(1-4)Man + Manbeta(1-4)Manbeta(1-4)Man <42>
SP	#41# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man-ol + H2O =
	D-mannitol + Manbeta(1-4)Man-ol + D-mannose +
	Manbeta(1-4)Manbeta(1-4)Man-ol +
	Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man-ol + Manbeta(1-4)Man +
	Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man-ol +
	Manbeta(1-4)Manbeta(1-4)Man <42>
SP	#41# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man +
	H2O = Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man + Manbeta(1-4)Man +
	Manbeta(1-4)Manbeta(1-4)Man + mannose +
	Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man <42>
SP	#58# 2,4-dinitrophenyl-beta-mannobioside + H2O = 2,4-dinitrophenol +
	beta-mannobiose <37>
SP	#59# mannohexaose + H2O = mannotriose |#59# main product <40>| <40>
SP	#59# mannopentaose + H2O = mannotriose + mannobiose |#59# main products
	<40>| <40>
SP	#60# carob-galactomannan + H2O = ? (#60# i.e. locust bean gum <36>) <36>
SP	#69# mannopentaose + H2O = mannose + mannotetraose <107>
SP	#73# guar gum galactomannan + H2O = ? <87>
SP	#73# tara gum galactomannan + H2O = ? <87>
SP	#73,83,84,86,97,99,100# konjac glucomannan + H2O = ? (#97# best
	substrate <95>) <83,87,90,95,108,111>
SP	#76# beta-1,4-D-mannan + H2O = ? (#76# 166% of the activity with locust
	bean gum <79>) |#76# main products are manno-oligosaccharides of 2-6
	residues and mannose <79>| <79>
SP	#77# birch wood xylan + H2O = ? (#77# 9.1% of the activity with locust
	bean gum <78>) <78>
SP	#77# locust bean gum galactomannan + H2O = mannobiose |#77# main
	product, with low amounts of mannotriose and higher
	manno-oligosaccharides <78>| <78>
SP	#77,82# 1,4-beta-D-mannan + H2O = ? <78,84>
SP	#77,99# carob galactomannan + H2O = ? <78,108>
SP	#8,61# mannan + H2O = ? <13,15,39>
SP	#83,84# guar gum glucomannan + H2O = ? <83>
SP	#83,84# locust bean gum glucomannan + H2O = ? <83>
SP	#83,84# Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man + H2O = 2
	Man-beta-1,4-Man (#83# increasing catalytic efficiency towards beta-1,4
	mannooligosaccharides with the degree of polymerisation from 4 to 6
	<83>; #84# increasing catalytic efficiency towards
	beta-1,4-mannooligosaccharides with the degree of polymerisation from 4
	to 6 <83>) |#83# 64% of product <83>; #84# 68% of product <83>| <83>
SP	#83,84# Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man + H2O =
	Man-beta-1,4-Man-beta-1,4-Man + Man-beta-1,4-Man (#83# increasing
	catalytic efficiency towards beta-1,4 mannooligosaccharides with the
	degree of polymerisation from 4 to 6 <83>; #84# increasing catalytic
	efficiency towards beta-1,4-mannooligosaccharides with the degree of
	polymerisation from 4 to 6 <83>) |#83,84# sole products <83>| <83>
SP	#83,84#
	Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man +
	H2O = Man-beta-1,4-Man + Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man
	(#83# increasing catalytic efficiency towards beta-1,4
	mannooligosaccharides with the degree of polymerisation from 4 to 6
	<83>; #84# increasing catalytic efficiency towards
	beta-1,4-mannooligosaccharides with the degree of polymerisation from 4
	to 6 <83>) |#83,84# 88% of products <83>| <83>
SP	#85# ivory nut mannan + H2O = mannotriose + mannotetraose +
	mannopentaose + mannohexaose |#85# main products, at 14%, 25%, 20%, and
	13%, respectively <86>| <86>
SP	#85# locust bean gum + H2O = mannopentaose |#85# 44%, main product
	<86>| <86>
SP	#9,36,61,74# galactomannan + H2O = ? <39,45,73,80>
SP	#98# 4-nitrophenyl beta-D-mannopyranoside + H2O = 4-nitrophenol +
	beta-D-mannopyranose <92>
SP	#98# azo-carob galactomannan + H2O = ? <92>
SP	#99# beta-mannan + H2O = ? <108>
SP	#99# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man + H2O = ? <108>
SP	#99# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man + H2O =
	Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man + mannose <108>
SP	#99# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man +
	H2O = Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man + Manbeta(1-4)Man <108>

TURNOVER_NUMBER
TN	#1# -999 {more}  (#1# turnover numbers are 61.2 per s, substrate locust
	bean gum, wild-type, 75.1 per s, konjac flour, wild-type, 11 per s,
	ivory nut mannan, wild-type, 1.97 per s, locust bean gum, mutant E167A,
	26.5 per s, locust bean gum, mutant H1A/H23A, respectively, at 37°C,
	pH 7.0 <70>) <70>
TN	#26# 0.7 {Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man}  <46>
TN	#26# 45 {Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man}  <46>
TN	#26# 99
	{Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man}  <46>
TN	#29# 1935 {low viscosity locust bean galactomannan}  (#29# isozyme MAN
	I <43>) <43>
TN	#29# 2246 {low viscosity locust bean galactomannan}  (#29# isozyme MAN
	II <43>) <43>
TN	#30# 4.77 {guar gum}  (#30# pH 7.0, 55°C, recombinant enzyme <100>)
	<100>
TN	#30# 14.9 {locust bean gum}  (#30# pH 7.0, 55°C, recombinant enzyme
	<100>) <100>
TN	#41# 0.41 {Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man}  <42>
TN	#41# 0.26 {Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man}  <42>
TN	#41# 1.17 {Manbeta(1-4)Manbeta(1-4)Man}  <42>
TN	#41# 77
	{Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man}  <42>
TN	#41# 11.64 {Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man}  <42>
TN	#41# 52.42 {Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man}  <42>
TN	#5# 25.2 {locust bean gum}  (#5# pH 5.0, 28°C <89>) <89>
TN	#63# 50.87 {guar gum}  (#63# pH 5.5, 30°C, recombinant enzyme <97>)
	<97>
TN	#76# 21000 {glucomannan}  (#76# 50°C, pH 6.0 <79>) <79>
TN	#76# 31200 {locust bean gum}  (#76# 50°C, pH 6.0 <79>) <79>
TN	#76# 18200 {beta-1,4-D-mannan}  (#76# 50°C, pH 6.0 <79>) <79>
TN	#77# 330 {locust bean gum galactomannan}  (#77# 70°C <78>) <78>
TN	#77# 292 {carob galactomannan}  (#77# 70°C <78>) <78>
TN	#77# 148 {1,4-beta-D-Mannan}  (#77# 70°C <78>) <78>
TN	#77# 215 {glucomannan}  (#77# 70°C <78>) <78>
TN	#83# 2.8 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man}  (#83# mutant
	W283S, pH 5.5, 37°C <83>) <83>
TN	#83# 67 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man}  (#83# pH 5.5,
	37°C <83>) <83>
TN	#83# 193 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man} 
	(#83# pH 5.5, 37°C <83>) <83>
TN	#83# 148 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man} 
	(#83# mutant W283S, pH 5.5, 37°C <83>) <83>
TN	#84# 117 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man} 
	(#84# mutant W283S, pH 5.5, 37°C <83>) <83>
TN	#84# 98 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man}  (#84# mutant
	W283S, pH 5.5, 37°C <83>) <83>
TN	#84# 112 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man}  (#84# wild-type,
	pH 5.5, 37°C <83>) <83>
TN	#84# 134 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man} 
	(#84# wild-type, pH 5.5, 37°C <83>) <83>

KM_VALUE
KM	#1,3,4,7,9,14,16,19,21,24,25,30,31,40,44,63,65,66,72,76,77,94,96,97#
	-999 {more}  (#9# copra beta-mannan: 2.0 mg/ml, locust bean
	beta-mannan: 3.8 mg/ml, konjak beta-mannan: 7.7 mg/ml, carob
	galactomannan: 0.9 mg/ml <17>; #97# Michaelis-Menten kinetics <95>;
	#65# apparent Km values of the mannanase for locust bean gum,
	glucomannan, glactomannan and mannan are 3, 2.3, 1.6 and 0.54 mg/ml,
	respectively <54>; #1# apparent Km values of the mannanase for locust
	bean gum, guar gum and konjac powder are 7.6, 10.5 and 27.4 mg/ml,
	respectively <53>; #66# Km value for locust bean gum at pH 2.4, 50°C
	is 0.93 mg/ml <56>; #9# Km value for konjac flour is 7.5 mg/ml, for
	locust bean gum 11.67 mg/ml <63>; #72# Km value for konjac glucomannan
	0.6 mg/ml <65>; #76# Km values are 14.9 mg/ml, 17.5 mg/ml, and 15.2
	mg/ml for glucomannan, locust bean gum and beta-D-mannan, respectively
	<79>; #77# Km values for konjac glucomannan of low viscosity, locust
	bean gum galactomannan, carob galactomannan of low viscosity, and
	1,4-beta-D-mannan from carob are 0.6 mg/ml, 2.0 mg/ml, 2.2 mg/ml and
	1.5 mg/ml, respectively <78>; #4# Km values for locust bean gum, guar
	gum, and copra mannan, are 0.11, 0.28, and 0.33 mg/ml, respectively
	<76>; #96# kinetics of recombinant chimeric enzymes, overview <103>;
	#63# Km is 2.074 mg/ml with guar gum for the recombinant enzyme at pH
	5.5 and 30°C <97>; #94# Km of the recombinant enzyme is 7.8 mg/ml for
	locust bean gum, pH 4.5, 50°C <101>; #30# Km values of the recombinant
	enzyme are 3.78 mg/ml for locust bean gum, and 7.75 mg/ml for guar gum
	<100>; #3# Km values with ocust bean gum are 0.9 mg/ml for wild-type
	enzyme, 0.8 mg/ml for mutant Man5DELTACBM, and 1.1 mg/ml for mutant
	Man5DELTACL <94>; #24# Michaelis-Menten kinetics, Km values for locust
	bean gum, konjac mannan, and guar gum are 7.6 mg/ml, 2.1 mg/ml, and 2.3
	mg/ml, respectively, pH 4.0, 80°C <96>; #21# recombinant enzyme, Km
	for locust bean gum is 0.83 ± 0.2 mg/ml, pH 4.0, 80°C <99>)
	<5,8,9,17,19,20,21,51,53,54,56,63,65,76,78,79,94,95,96,97,99,100,101
	103>
KM	#10# 9 {Manbeta(1-4)Manbeta(1-4)Man}  <48>
KM	#26# 0.5
	{Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man}  <46>
KM	#26# 1.61 {Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man}  <46>
KM	#26# 2.49 {Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man}  <46>
KM	#29# 3.07 {low viscosity locust bean galactomannan}  (#29# isozyme MAN
	I <43>) <43>
KM	#29# 3.12 {low viscosity locust bean galactomannan}  (#29# isozyme MAN
	II <43>) <43>
KM	#5,86# -999 {locust bean gum}  (#86# KM value is 3.8 mg/ml <90>; #5# KM
	value is 34.9 mg/ml, pH 5.0, 28°C <89>) <89,90>
KM	#58# 0.0014 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5, mutant
	D283H <37>) <37>
KM	#58# 0.0068 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5, mutant
	H211A <37>) <37>
KM	#58# 0.04 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5, mutant
	H143A <37>) <37>
KM	#58# 0.01 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5, mutant
	H211N <37>) <37>
KM	#58# 0.0037 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5, mutant
	H211A/D283A <37>) <37>
KM	#58# 0.0166 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5, mutant
	D283A <37>) <37>
KM	#58# 0.0205 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5, mutant
	W217A <37>) <37>
KM	#58# 0.0093 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5, wild
	type <37>) <37>
KM	#58# 0.0141 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5, mutant
	W162A <37>) <37>
KM	#58# 0.00074 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5,
	mutant Y285A <37>) <37>
KM	#58# 0.0149 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5, mutant
	W156A <37>) <37>
KM	#58# 0.00066 {2,4-dinitrophenyl-beta-mannobioside}  (#58# pH 6.5,
	mutant E212A <37>) <37>
KM	#7# 1.9 {soluble mannan}  <7,19>
KM	#83# 1.3 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man} 
	(#83# mutant W283S, pH 5.5, 37°C <83>) <83>
KM	#83# 1.8 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man} 
	(#83# pH 5.5, 37°C <83>) <83>
KM	#83# 1.6 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man}  (#83# mutant
	W283S, pH 5.5, 37°C <83>) <83>
KM	#83# 2.9 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man}  (#83# pH 5.5,
	37°C <83>) <83>
KM	#84# 0.6 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man} 
	(#84# wild-type, pH 5.5, 37°C <83>) <83>
KM	#84# 1 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man}  (#84#
	mutant W283S, pH 5.5, 37°C <83>) <83>
KM	#84# 1.8 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man}  (#84# wild-type,
	pH 5.5, 37°C <83>) <83>
KM	#84# 2.8 {Man-beta-1,4-Man-beta-1,4-Man-beta-1,4-Man}  (#84# mutant
	W283S, pH 5.5, 37°C <83>) <83>
KM	#99# -999 {carob galactomannan}  (#99# Km value 2.22 mg/ml, pH 5.0,
	60°C <108>) <108>
KM	#99,100# -999 {konjac glucomannan}  (#99# Km value 3.22 mg/ml, pH 5.0,
	60°C <108>; #100# Km value 4.7 mg/ml, pH 5.4, 70°C <111>) <108,111>

PH_OPTIMUM
PHO	#1# 6.4 <58>
PHO	#1# 5-6 <19>
PHO	#1,15# 6.5 (#1# recombinant enzyme <102>) <33,102>
PHO	#1,18# 7.1 (#18# at 91°C <32>) <30,32>
PHO	#1,30,62,72,73,75# 7 <28,65,74,82,87,100>
PHO	#1,37,41,74,82,85,99# 6 <3,42,53,73,84,86,108>
PHO	#1,4,7,9,13,14,16,19,25,31,40,44# -999 <5,6,8,9,16,17,19,20,21>
PHO	#10# 5-5.3 <48>
PHO	#14# 4.5-5.5 <19>
PHO	#15,27# 7.5 <25,55>
PHO	#18,38# 6.9 (#38# assay at <105>) <2,105>
PHO	#19,21,24,67# 4 (#21,24# recombinant enzyme <96,99>) <19,72,96,99>
PHO	#2# 5.5-7.5 <34>
PHO	#26,68# 5.2 (#68# recombinant enzyme expressed in Pichia pastoris
	<66,109>) <38,46,66,109>
PHO	#3,4,5,11,13,33,36,46,96# 5 (#36# recombinant protein <26>; #11#
	xylanase and mannanase activities of enzyme <50>; #96# recombinant
	chimeric enzymes <103>) <16,26,27,50,85,89,94,103,110>
PHO	#34# 3.3 (#34# 41.9 kDa protein <1>) <1>
PHO	#34# 2.9 (#34# 61.2 kDa protein <1>) <1>
PHO	#36# 4.8 (#36# assay at <93>) <51,93>
PHO	#36# 3.8 <68>
PHO	#4# 3.6 <6,19>
PHO	#4,36,40# 3 <6,9,19,41>
PHO	#4,9,12,63,83,84# 5.5 (#63# recombinant enzyme <97>) <11,63,76,83,97>
PHO	#60,100# 5.4 <36,111>
PHO	#64# 3.5-4.5 <52>
PHO	#65# 4-6 (#65# broad <54>) <54>
PHO	#66# 2.4 <56>
PHO	#69# 3.5 <67>
PHO	#7,29,45,68,86,94# 4.5 (#29# at 60°C <43>; #94# recombinant enzyme
	<101>; #68# recombinant enzyme expressed in Aspergillus sojae <66,109>)
	<9,22,43,66,90,101,109>
PHO	#70# 7.6 <61,69>
PHO	#71# 11.5 <62>
PHO	#76# 6-7 <79>
PHO	#77# 4.5-5 <78>
PHO	#80# 4.5-6.5 <106>
PHO	#9# 8.5 (#9# M-III, at 65°C <17>) <17>
PHO	#9# 9.5 <45>
PHO	#9,97# 9 (#9# M-I, M-II, at 60°C <17>) <17,95>
PHO	#95# 6.3 (#95# recombinant enzyme <98>) <98>

PH_RANGE
PHR	#1# 10 (#1# 44% of maximum activity <58>) <58>
PHR	#1,33# 5-8 (#33# more than 90% of maximum activity <110>; #1# more than
	70% of maximum activity <58>) <58,110>
PHR	#1,4,7,9,14,16,19,31,37# -999 <3,5,6,8,9,17,19,20,21>
PHR	#10# 3.5-6 <48>
PHR	#21# 2-9 (#21# recombinant enzyme, over 20% of maximal activity at pH
	2.0 and pH 9.0 <99>) <99>
PHR	#29# 4-5 <43>
PHR	#3,94# 4-9 (#3# activity range, wild-type enzyme, optimum at pH 5.0,
	45% of maximal activity at pH 9.0 <94>; #94# more than 77% of the
	maximal activity in the pH range of pH 4.0 to pH 7.0 <101>) <94,101>
PHR	#30# 4-10 (#30# activity range, recombinant enzyme, profile overview
	<100>) <100>
PHR	#4# 3-7 <76>
PHR	#4,6,13,35,37,42,55,56,57# 3-8 (#13# pH 3: 15% of maximal activity
	<16>) <3,16,19>
PHR	#54# 4.5-8 <3>
PHR	#63# 4-8 (#63# 95% activity at pH 5.0 and 75% activity at pH 4.0, pH
	6.0 and pH 7.0, 50% at pH 7.5 and pH 8.0 <97>) <97>
PHR	#66# 2.2-8 <56>
PHR	#69# 2.5-6 (#69# more than 50% of maximum activity <67>) <67>
PHR	#70# 6.8-8 (#70# more than 75% of maximum activity <69>) <69>
PHR	#71# 1-5.5 (#71# more than 70% of maximum activity within <62>) <62>
PHR	#73# 4-7.5 <87>
PHR	#74# 3-9 (#74# more than 60% of maximum activity <73>) <73>
PHR	#74# 8 (#74# 50% of maximum activity <73>) <73>
PHR	#81# 7.5 (#81# rapid loss of activity above, native enzyme <88>) <88>
PHR	#81# 6 (#81# rapid loss of activity above, recombinant enzyme <88>) <88>
PHR	#83,84# 4.5-7 (#83,84# more than 95% of maximum activity <83>) <83>
PHR	#86# 4-8.5 <90>
PHR	#9# 6-10 <17>
PHR	#95# 4.8-9.1 (#95# recombinant enzyme, more than 80% of the maximum
	activity at pH 4.8-7.8, the enzyme activity drops rapidly when at below
	pH 4.8 or above pH 9.1 <98>) <98>
PHR	#96# 2-7 (#96# activity range, recombinant chimeric enzymes, profiles
	overview <103>) <103>
PHR	#97# 7-9 (#97# over 80% of amximal activity <95>) <95>
PHR	#99# 5-9 (#99# more than 90% of maximum activity <108>) <108>

SPECIFIC_ACTIVITY
SA	#1# 514.0 <19>
SA	#1# 8302.0 (#1# pH 6.0, 50°C <53>) <53>
SA	#1# 928.0 (#1# pH 6.4, 50°C <58>) <58>
SA	#1# 2718.0 (#1# purified recombinant enzyme, pH 6.5, 45°C <102>) <102>
SA	#1,4,7,8,9,14,16,19,24,29,31,36# -999.0 (#29# 1638 A550/min/mg optical
	path 1cm,isozyme MAN I, OBR-LBG <43>; #29# 1763 A550/min/mg optical
	path 1cm, isozyme MAN II, OBR-LBG <43>; #29# no activity against
	4-nitrophenyl-alpha and -beta-mannopyranosides <43>; #24# 84.4 U/ml of
	recombinant enzyme in the culture supernatant of Pichia pastoris, pH
	4.0, 80°C <96>; #36# recombinant enzyme in Yarrowia lipolytica is
	produced with an activity of 183.5 U/ml and 0.23 mg protein/ml <93>)
	<5,6,8,9,13,15,17,19,20,21,43,93,96>
SA	#12# 201.0 <11>
SA	#13# 21.0 <16>
SA	#19# 125.0 <19>
SA	#21# 1703.0 (#21# purified recombinant enzyme, substrate locust bean
	gum, pH 4.0, 80°C <99>) <99>
SA	#24# 420.9 (#24# purified recombinant enzyme, locust bean gum as
	substrate, pH 4.0, 80°C <96>) <96>
SA	#27# 4.8 (#27# pH 7.0, 30°C, substrate beta-1,4-mannan <55>) <55>
SA	#27# 9.6 (#27# pH 7.0, 30°C, substrate glucomannan <55>) <55>
SA	#27# 11.48 (#27# pH 7.0, 30°C, substrate galactomannan <55>) <55>
SA	#29# 4.6 (#29# crude medium <43>) <43>
SA	#29# 317.0 (#29# isozyme MAN II, guar gum <43>) <43>
SA	#29# 190.0 (#29# isozyme MAN I, mannan A <43>) <43>
SA	#29# 627.0 (#29# isozyme MAN II, locust bean gum <43>) <43>
SA	#29# 294.0 (#29# isozyme MAN I, guar gum <43>) <43>
SA	#29# 751.0 (#29# isozyme MAN II, low viscosity locust bean
	galactomannan <43>) <43>
SA	#29# 45.7 (#29# isozyme MAN I, after 9.9fold purification with DEAE
	Sepharose chromatography <43>) <43>
SA	#29# 562.0 (#29# isozyme MAN I, locust bean gum <43>) <43>
SA	#29# 471.0 (#29# isozyme MAN I, after 102.4fold purification with
	Phenyl Sepharose chromatography <43>) <43>
SA	#29# 56.7 (#29# isozyme MAN II, after 12.3fold purification with DEAE
	Sepharose chromatography <43>) <43>
SA	#29# 225.4 (#29# isozyme MAN II, after 49fold purification with Phenyl
	Sepharose chromatography <43>) <43>
SA	#29# 663.0 (#29# isozyme MAN I, low viscosity locust bean galactomannan
	<43>) <43>
SA	#29,100# 215.0 (#29# isozyme MAN II, mannan A <43>; #100# substrate
	konjac glucomannan, pH 5.4, 70°C <111>) <43,111>
SA	#30# 10760.0 (#30# purified recombinant enzyme, pH 7.0, 55°C,
	substrate locust bean gum <100>) <100>
SA	#34# 380.0 (#34# 41.9 kDa protein <1>) <1>
SA	#34# 475.0 (#34# 61.2 kDa protein <1>) <1>
SA	#36# 64.6 (#36# pH 5.0, 50°C, recombinant protein <41>) <41>
SA	#36# 60.0 <26>
SA	#36# 264.1 (#36# pH 5.0, 50°C, native protein <41>) <41>
SA	#4# 65.0 (#4# 50°C <76>) <76>
SA	#4# 39.0 <19>
SA	#4# 1139.0 (#4# pH 5.0, 40°C <85>) <85>
SA	#41# 1.95 (#41# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man <42>) <42>
SA	#41# 1.13 (#41# Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man
	<42>) <42>
SA	#41# 3.1 (#41# Manbeta(1-4)Manbeta(1-4)Man <42>) <42>
SA	#41# 0.69 (#41#
	Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Manbeta(1-4)Man} <42>)
	<42>
SA	#59# 1400.0 (#59# ManB, 37°C, pH 5.0 <40>) <40>
SA	#62# 18.5 (#62# substrate glucomannan, pH 7.0, 40°C <82>) <82>
SA	#62# 2.2 (#62# substrate guar gum, pH 7.0, 40°C <82>) <82>
SA	#62# 12.2 (#62# substrate locust bean gum, pH 7.0, 40°C <82>) <82>
SA	#66# 366.0 (#66# pH 2.4, 50°C <56>) <56>
SA	#67# 129.3 (#67# pH 4.0, 40°C <72>) <72>
SA	#68# 350.0 <66>
SA	#69# 416.3 (#69# 30°C, pH 3.5 <67>) <67>
SA	#70# 481.5 <69>
SA	#71# 3373.0 (#71# pH 1.5, 65°C <62>) <62>
SA	#73# 27.4 (#73# pH 7.0, 30°C <87>) <87>
SA	#76# 1672.0 (#76# 50°C, pH 6.0 <79>) <79>
SA	#82# 635.0 (#82# pH 6.0, 60°C, substrate locust bean gum <84>) <84>
SA	#82# 962.0 (#82# pH 6.0, 60°C, substrate glucomannan <84>) <84>
SA	#82# 2223.0 (#82# pH 6.0, 60°C, substrate 1,4-beta-D-mannan <84>) <84>
SA	#85# 14710.0 (#85# substrate ivory nut mannan, pH 6.0, 50°C <86>) <86>
SA	#85# 8498.0 (#85# substrate locust bean gum, pH 6.0, 50°C <86>) <86>
SA	#9# 470.0 <17>
SA	#9# 5383.0 (#9# 50°C <63>) <63>
SA	#94# 47.5 (#94# purified recombinant enzyme, pH 4.5, 50°C <101>) <101>
SA	#95# 4449.0 (#95# purified recombinant enzyme, pH 6.3, 70°C <98>) <98>
SA	#96# 768.5 (#96# purified recombinant chimeric enzymes, pH 5.0, 50°C
	<103>) <103>
SA	#97# 236.0 (#97# pH 8.0, 40°C, substrate konjac glucomannan  <95>) <95>
SA	#99# 220.0 (#99# substrate carob galactomannan, pH 5.0, 60°C <108>)
	<108>
SA	#99# 182.0 (#99# substrate beta-mannan, pH 5.0, 60°C <108>) <108>
SA	#99# 312.0 (#99# substrate konjac glucomannan, pH 5.0, 60°C <108>)
	<108>

TEMPERATURE_OPTIMUM
TO	#1# 50-55 <28>
TO	#1,4,15,27,68,81# 45 (#1,81# recombinant enzyme <88,102>; #68#
	recombinant enzyme expressed in Pichia pastoris <66,109>)
	<25,55,66,85,88,102,109>
TO	#1,4,7,9,13,14,16,19,31# -999 <5,6,7,8,9,16,17,19,20,21>
TO	#1,4,9,71# 65 (#9# M-III <17>) <17,53,60,62>
TO	#1,5,9,11,36,64,66,72,74,83,84,85# 50 <41,50,52,56,58,63,65,73,83,86,89>
TO	#1,76# 50-60 (#1# for four enzyme forms <30>) <30,79>
TO	#15,26,45,62,67# 40 <22,33,46,72,82>
TO	#18# 90-92 <2,32>
TO	#3,4,21,24,36,46,77# 80 (#21,24,36# recombinant enzyme <93,96,99>)
	<6,19,27,78,93,94,96,99>
TO	#34# 74 (#34# 61.2 kDa protein <1>) <1>
TO	#34# 72 (#34# 41.9 kDa protein <1>) <1>
TO	#36# 75-80 <68>
TO	#4,30,73# 55 <76,87,100>
TO	#41,75# 37 <42,74>
TO	#6,35,37,42,54,55,56,57# 60-70 <3>
TO	#60# 85 <36>
TO	#63,69# 30 (#63# recombinant enzyme <97>; #69# cold-adapted
	beta-mannanase <107>) <67,97,107>
TO	#70# 58 <69>
TO	#80# 81-93 <106>
TO	#9,13,95,97,100# 70 (#95# recombinant enzyme <98>) <16,45,95,98,111>
TO	#9,22,29,33,36,38,65,68,82,86,94,99# 60 (#38# assay at <105>; #29# at
	pH 4.5 <43>; #94# recombinant enzyme <101>; #9# M-I, M-II <17>; #36#
	recombinant protein from Aspergillus oryzae, SDS-PAGE <26>; #68#
	recombinant enzyme expressed in Aspergillus sojae <66,109>)
	<17,26,43,54,60,61,66,84,90,101,105,108,109,110>
TO	#96# 45-55 (#96# recombinant chimeric enzymes <103>) <103>

TEMPERATURE_RANGE
TR	#1,4,7,9,10,14,16,19,31# -999 <4,5,6,8,9,17,19,20,21>
TR	#13,30,97# 30-80 (#13# 30°C: about 25% of maximal activity, 80°C:
	about 30% of maximal activity <16>; #97# activity range, profile
	overview <95>; #30# activity range, recombinant enzyme, profile
	overview <100>) <16,95,100>
TR	#21# 40-90 (#21# recombinant enzyme, over 20% of maximal activity
	within this range <99>) <99>
TR	#26# 50-55 <38>
TR	#29# 60-65 <43>
TR	#3,36# 30-90 (#36# activity range, profile overview <93>; #3# activity
	range, wild-type enzyme <94>) <93,94>
TR	#37# 30-70 <3>
TR	#4# 5-60 (#4# recombinant enzyme, more than 30% of maximum activity
	within <85>) <85>
TR	#62# 50 (#62# rapid decrease in activity above <82>) <82>
TR	#62# 20-30 (#62# more than 80% of maximum activity <82>) <82>
TR	#63# 10-50 (#63# approximately 70% between 10°C and 20°C, 60%
	activity at 40°C, 30% activity at 50°C <97>) <97>
TR	#69# 0-60 (#69# the enzyme shows 20-40% of its maximum activity at
	0-4°C and has its optimum at 30°C, about 10% of maximal activity at
	50-60°C, inactivation at 70°C, profile overview <107>) <107>
TR	#69# 0-5 (#69# 20-40% of maximum activity <67>) <67>
TR	#74# 40 (#74# about 50% of maximum activity <73>) <73>
TR	#80# 40-100 (#80# activity range, profile overview <106>) <106>
TR	#86# 35-65 <90>
TR	#86# 70 (#86# 40% of maximum activity <90>) <90>
TR	#9# 50-70 <17>
TR	#95# 40-80 (#95# recombinant enzyme, over 80% of maximal activity
	within this range <98>) <98>
TR	#96# 10-80 (#96# activity range, recombinant chimeric enzymes, profiles
	overview <103>) <103>

ACTIVATING_COMPOUND
AC	#10# NaCl (#10# 0.3 M <48>) <48>
AC	#21,27,73,75,94# 2-mercaptoethanol (#27# 1 mM, 11% increase in activity
	<55>; #75# 1 mMm, 121% of initial activity <74>; #73# 153% of initial
	activity <87>) <55,74,87,99,101>
AC	#27# Ca2+ (#27# 1 mM, 20% increase in activity <55>) <55>
AC	#3# acetone (#3# activates the wild-type enzyme and mutant Man5DELTACBM
	at 40-60% v/v, no effect on mutant Man5DELTACL <94>) <94>
AC	#3# SDS (#3# the wild-type enzyme slightly at 0.5-1.0% v/v, inhibits
	the mutant enzymes <94>) <94>
AC	#3,75# Triton X-100 (#75# 1%, 123% of initial activity <74>; #3#
	activates the wild-type enzyme slightly at 0.5% v/v, inhibits the
	mutant enzymes <94>) <74,94>
AC	#62# more (#62# an assembly of ManB with mini-CbpA, which contains a
	carbohydrate-binding module that provides proximity to insoluble
	substrates, increases the activity toward galactomannan from locust
	bean gum and guar gum 1.7- and 2.0fold over those without mini-CbpA
	<82>) <82>
AC	#73# dithiothreitol (#73# 129% of initial activity <87>) <87>
AC	#77# EDTA (#77# 236% of initial activity <78>) <78>
AC	#85# Sodium azide (#85# hydrolysis of locust bean gum is enhanced by
	approximately 1.45fold in poresence of sodium azide <86>) <86>
AC	#9# cysteine (#9# slight activation <17>) <17>

INHIBITORS
IN	#1# ethanol <102>
IN	#1# methanol <102>
IN	#1# acetone <102>
IN	#1# sodium dodecylsulfate (#1# 1 mM, 55% residual activity <53>; #1# 1
	mM, 79% residual activity <58>) <53,58>
IN	#1# n-butanol (#1# complete inhibition at 20-30% v/v <102>) <102>
IN	#1,100# Triton X-100 (#100# 0.5%, 44% residual activity <111>) <102,111>
IN	#1,100# Tween 20 (#100# 0.5%, 77% residual activity <111>) <102,111>
IN	#1,12,72,94# Pb2+ (#72# 1 mM, more than 80% inhibition <65>)
	<11,65,101,102>
IN	#1,21,27,67# Co2+ (#27# 1 mM, 50% loss of activity <55>; #67# 2.5 mM,
	42% residual activity <72>) <55,72,99,102>
IN	#1,21,73,94,100# Mg2+ (#100# 1 mM, 34% residual activity <111>; #1# 1
	mM, 53% residual activity <53>; #73# 84% residual activity <87>)
	<53,87,99,101,111>
IN	#1,21,94# Ni2+ (#1# 1 mM, 61% residual activity <53>) <53,99,101>
IN	#1,21,94,95,100# SDS (#1# complete inhibition at 0.25-1.0% w/v <102>;
	#100# 0.5%, 1% residual activity <111>) <98,99,101,102,111>
IN	#1,4,12,13,24,69,70,71,72,75,86,94,95# Hg2+ (#71# strong <62>; #4#
	complete inhibition <76>; #72# 1 mM, more than 80% inhibition <65>; #1#
	1 mM, 2% residual activity <58>; #86# 1 mM, 4% residual activity <90>;
	#75# 1 mM, 1% residual activity <74>; #70# 1 mM, 8% residual activity
	<69>; #69# 5 mM, 16.4% residual activity <67>)
	<11,16,28,58,61,62,65,67,69,74,76,90,96,98,101,102>
IN	#1,4,21,71,86,97,99,100# more (#1# not inhibitory: EDTA,
	2-mercaptoethanol <58>; #100# not inhibitory: EDTA, dithiothreitol
	<111>; #71# enzymatic activity is not significantly affected by ions
	such as Ca2+, Cr3+, Co2+, Zn2+, Na+, K+, and Mg2+ <62>; #4# not
	inhibitory: EDTA, phenyl methyl sulfonyl fluoride, 1,10-phenanthroline
	<76>; #86# not inhibtory: Mg2+, Co2+, EDTA <90>; #97# Ca2+, Mg2+, Mn2+,
	Fe2+, Ni2+, and Zn2+ have either no effect or a slightly inhibitory
	effect <95>; #21# the purified recombinant enzyme has a strong
	resistance to SDS and Ag+ and proteases pepsin and trypsin <99>; #99#
	presence of Ca2+, Na+, Mg2+, Mn2+, urea, and EDTA does not affect
	catalytic activity <108>) <58,62,76,90,95,99,108,111>
IN	#1,4,9# N-bromosuccinimide (#4# complete inhibition <76>; #1# 1 mM, 3%
	residual activity <53>) <17,53,76>
IN	#1,4,9,12,21,27,69,70,72,73,75,94,99,100# Ag+ (#4# complete inhibition
	<76>; #9# 90% inhibition <63>; #27# 1 mM, complete loss of activity
	<55>; #72# 1 mM, more than 80% inhibition <65>; #70# 1 mM, 2% residual
	activity <69>; #1# 1 mM, 3% residual activity <58>; #1# 1 mM, 54%
	residual activity <53>; #100# 1 mM, 12% residual activity <111>; #99# 5
	mM, complete loss of activity <108>; #69# 5 mM, 24.8% residual activity
	<67>; #75# 1 mM, 18% residual activity <74>; #73# 48% residual activity
	<87>) <11,17,28,53,55,58,61,63,65,67,69,74,76,87,99,101,108,111>
IN	#1,4,9,12,21,27,70,72,75,85,86,95,100# Cu2+ (#4# complete inhibition
	<76>; #27# 1 mM, 49% loss of activity <55>; #72# 1 mM, more than 80%
	inhibition <65>; #75# 1 mM, 2% residual activity <74>; #86# 1 mM, 76%
	residual activity <90>; #70# 1 mM, 12% residual activity <69>; #100# 1
	mM, 8% residual activity <111>; #9# 35-40% inhibition <63>; #85# more
	than 50% inhibtion <86>) <11,28,55,63,65,69,74,76,86,90,98,99,111>
IN	#1,5,9,69,77,86# Mn2+ (#5# 5 mM, 50% residual activity <89>; #1# 1 mM,
	22% residual activity <53>; #9# 35-40% inhibition <63>; #69# 5 mM, 32%
	residual activity <67>; #77# 35% of initial activity <78>; #86# 1 mM,
	63% residual activity <90>) <28,53,63,67,78,89,90>
IN	#1,9,21,67,85,95# EDTA (#1# 1 mM, 37% residual activity <53>; #9# 1 mM,
	33.9% residual activity <63>; #67# 2.5 mM, 77% residual activity <72>;
	#85# 5 mM, 20% residaul activity <86>) <53,63,72,86,98,99,102>
IN	#1,94# Cr3+ <28,101>
IN	#10# NaCl (#10# 1.3 M <48>) <48>
IN	#12# p-chloromercuribenzoate <11>
IN	#16# cycloheximide <5,8,20,21>
IN	#21# Li+ <99>
IN	#21,86# K+ (#86# 1 mM, 62% residual activity <90>) <90,99>
IN	#27# dithiothreitol (#27# 1 mM, 25% loss of activity <55>) <55>
IN	#27,85,95# Fe2+ (#27# 1 mM, 40% loss of activity <55>; #85# more than
	50% inhibtion <86>) <55,86,98>
IN	#4,12,21,72,75,85,95,99# Zn2+ (#72# 1 mM, more than 80% inhibition
	<65>; #75# 1 mM, 16% residual activity <74>; #4# 68% residual activity
	<76>; #85# more than 50% inhibtion <86>; #99# 5 mM, partial loss of
	activity <108>) <11,65,74,76,86,98,99,108>
IN	#63# 4-nitrophenyl-thio-beta-D-mannopyranoside <97>
IN	#64# abscisic acid (#64# presence of exogenous abscisic acid provokes a
	delay in the cellular disassembly of the endosperm and disappearance of
	endo-beta-mannanase in the tissue, resulting in delayed galactomannan
	degradation <57>) <57>
IN	#67# mannose <72>
IN	#67,86# Ca2+ (#86# 1 mM, 83% residual activity <90>; #67# 2 mM, 64%
	residual activity. Stimulating above 2.5 mM <72>) <72,90>
IN	#71,77# Sodium dodecyl sulfate (#71# strong <62>; #77# 20% of initial
	activity <78>) <61,62,78>
IN	#72,75,95# Al3+ (#72# 1 mM, more than 80% inhibition <65>; #75# 1 mM,
	31% residual activity <74>) <65,74,98>
IN	#86# 2-mercaptoethanol (#86# 1 mM, 54% residual activity <90>) <90>
IN	#9,12,21,24,67,73,75,95,100# Fe3+ (#9# 90% inhibition <63>; #75# 1 mM,
	37% residual activity <74>; #100# 1 mM, 42% residual activity <111>;
	#67# 2.5 mM, 71% residual activity <72>; #73# 30.6% residual activity
	<87>) <11,63,72,74,87,96,98,99,111>

METALS_IONS
ME	#1# Fe2+ (#1# 1 mM, 124% of initial activity <53>) <53>
ME	#1,70,94,95,99# Co2+ (#94,95# activates <98,101>; #1# 1 mM, 126% of
	initial activity <53>; #70# 1 mM, 112% of initial activity <69>; #99# 5
	mM, 123% of initial activity <108>) <53,69,98,101,108>
ME	#12,67,69,70,75# Ca2+ (#12# stimulates <11>; #70# 1 mM, 124% of initial
	activity <69>; #69# 5 mM, 228% of initial activity <67>; #75# 1 mM,
	119% of initial activity <74>; #67# 2.5 mM, 10% stimulation. Inhibition
	at 2.0 mM <72>) <11,67,69,72,74>
ME	#13,69,75# Mg2+ (#13# slight activation <16>; #69# 5 mM, 178% of
	initial activity <67>; #75# 1 mM, 118% of initial activity <74>)
	<16,67,74>
ME	#21,94,95# more (#95# Na+, Li+, NH4+, Ca2+, Mg2+ and Ba2+ have no
	effect on the recombinant mannanase activity <98>; #21# poor effects by
	Na+, Ca2+, and Mn2+ <99>; #94# poor effects by Na+, K+, Ag+, Li+, Ca2+,
	Ni2+ and EDTA at 1 mM <101>) <98,99,101>
ME	#67,69,74,77,94,99# Cu2+ (#94# activates <101>; #69# 5 mM, 151% of
	initial activity <67>; #77# 110% of initial activity <78>; #67# 2.5 mM,
	9% stimulation <72>; #74# 38% residual activity <73>; #99# 5 mM, 121%
	of initial activity <108>) <67,72,73,78,101,108>
ME	#69,74,86# Zn2+ (#86# slight stimulation <90>; #69# 5 mM, 220% of
	initial activity <67>; #74# 79% residual activity <73>) <67,73,90>
ME	#70# Li+ (#70# 1 mM, 112% of initial activity <69>) <69>
ME	#71# Fe3+ (#71# stimulation <62>) <62>
ME	#71# Ag+ (#71# stimulation <62>) <62>
ME	#71,74,94# Mn2+ (#94# activates <101>; #71# stimulation <62>; #74# 53%
	residual activity <73>) <62,73,101>
ME	#71,99# Ni2+ (#71# stimulation <62>; #99# 5 mM, 115% of initial
	activity <108>) <62,108>
ME	#74# EDTA (#74# 64% residual activity <73>) <73>
ME	#86# Pb2+ (#86# slight stimulation <90>) <90>
ME	#95# NaCl (#95# activates 150% at 100 mg/ml <98>) <98>

MOLECULAR_WEIGHT
MW	#1# 39600 (#1# x * 39600, SDS-PAGE <53>) <53>
MW	#1# 38013 (#1# x * 38013, calculated, x * 38000, SDS-PAGE, mature
	protein <58>) <58>
MW	#1,10,26,27,66# 39000 (#10# SDS-PAGE <48>; #1# SDS-PAGE, 40000 by gel
	filtration <28>; #26# method not mentioned <46>; #26# gel filtration,
	ManA and ManB <38>; #27# x * 39000, SDS-PAGE, x * 39627, calculated for
	mature protein <55>; #66# x * 41389, calculated, x * 48000, SDS-PAGE of
	glycosylated enzyme, x * 39000, SDS-PAGE of deglycosylated enzyme <56>)
	<28,38,46,48,55,56>
MW	#1,14# 37000 (#1,14# SDS-PAGE <9,19>) <9,19>
MW	#1,3,39# 38000 (#39# x * 38000, SDS-PAGE <59>; #1# x * 38013,
	calculated, x * 38000, SDS-PAGE, mature protein <58>; #3# x * 63000,
	glycosylated recombinant wild-type enzyme, SDS-PAGE, x * 58000,
	glycosylated mutant lacking the CBM1 domain, SDS-PAGE, x * 41000,
	glycosylated mutant lacking the CBM1 domain and linker region,
	SDS-PAGE, x * 60000, deglycosylated recombinant wild-type enzyme,
	SDS-PAGE, x * 55000, deglycosylated mutant lacking the CBM1 domain,
	SDS-PAGE, x * 38000, deglycosylated mutant lacking the CBM1 domain and
	linker region, SDS-PAGE <94>) <58,59,94>
MW	#1,3,7,15,76# 41000 (#7# SDS-PAGE <9,19>; #15# recombinant protein
	expressed in E. coli, SDS-PAGE <25>; #76# x * 45000, SDS-PAGE, x *
	41000, calculated <79>; #1# x * 41000, recombinant enzyme, SDS-PAGE
	<102>; #3# x * 63000, glycosylated recombinant wild-type enzyme,
	SDS-PAGE, x * 58000, glycosylated mutant lacking the CBM1 domain,
	SDS-PAGE, x * 41000, glycosylated mutant lacking the CBM1 domain and
	linker region, SDS-PAGE, x * 60000, deglycosylated recombinant
	wild-type enzyme, SDS-PAGE, x * 55000, deglycosylated mutant lacking
	the CBM1 domain, SDS-PAGE, x * 38000, deglycosylated mutant lacking the
	CBM1 domain and linker region, SDS-PAGE <94>) <9,19,25,79,94,102>
MW	#10# 38950 (#10# calculation from sequence of DNA <24>) <24>
MW	#11# 145294 (#11# x * 145294, calculated <50>) <50>
MW	#12# 24000 (#12# gel filtration <11>) <11>
MW	#13# 57000 (#13# SDS-PAGE <16>) <16>
MW	#15# 49000 (#15# SDS-PAGE <33>) <33>
MW	#15# 43100 (#15# calculation from sequence of DNA <25>) <25>
MW	#16# 46000 (#16# SDS-PAGE <5,8,20,21>) <5,8,20,21>
MW	#2# 162000 (#2# dimeric protein, SDS-PAGE <34>) <34>
MW	#2,72# 73000 (#2# 2 * 73000, SDS-PAGE <34>; #72# 1 * 76309, calculated
	including signal peptide, 1 * 73588, calculated, mature protein, 1 *
	73000, SDS-PAGE <65>) <34,65>
MW	#21# 39500 (#21# x * 39500, about, sequence calculation, x * 43000,
	recombinant glycosylated enzyme, SDS-PAGE, x * 40000, recombinant
	deglycosylated enzyme, SDS-PAGE <99>) <99>
MW	#21,30,59,94,100# 43000 (#100# gel filtration <111>; #30# x * 43000,
	recombinant enzyme, SDS-PAGE <100>; #59# x * 43000, ManB, SDS-PAGE
	<40>; #21# x * 39500, about, sequence calculation, x * 43000,
	recombinant glycosylated enzyme, SDS-PAGE, x * 40000, recombinant
	deglycosylated enzyme, SDS-PAGE <99>; #94# x * 72000, recombinant
	enzyme, SDS-PAGE, x * 43000, about, sequence calculation of the mature
	enzyme <101>) <40,51,99,100,101,111>
MW	#26# 39216 (#26# 1 * 39216, ManA, 1 * 39265, ManB, MALDI-TOF
	spectrometry <38>) <38>
MW	#26# 39265 (#26# 1 * 39216, ManA, 1 * 39265, ManB, MALDI-TOF
	spectrometry <38>) <38>
MW	#27# 39627 (#27# x * 39000, SDS-PAGE, x * 39627, calculated for mature
	protein <55>) <55>
MW	#3,18# 55000 (#3# x * 63000, glycosylated recombinant wild-type enzyme,
	SDS-PAGE, x * 58000, glycosylated mutant lacking the CBM1 domain,
	SDS-PAGE, x * 41000, glycosylated mutant lacking the CBM1 domain and
	linker region, SDS-PAGE, x * 60000, deglycosylated recombinant
	wild-type enzyme, SDS-PAGE, x * 55000, deglycosylated mutant lacking
	the CBM1 domain, SDS-PAGE, x * 38000, deglycosylated mutant lacking the
	CBM1 domain and linker region, SDS-PAGE <94>) <32,94>
MW	#3,29# 63000 (#29# isozyme MAN II, SDS-PAGE <43>; #3# x * 63000,
	glycosylated recombinant wild-type enzyme, SDS-PAGE, x * 58000,
	glycosylated mutant lacking the CBM1 domain, SDS-PAGE, x * 41000,
	glycosylated mutant lacking the CBM1 domain and linker region,
	SDS-PAGE, x * 60000, deglycosylated recombinant wild-type enzyme,
	SDS-PAGE, x * 55000, deglycosylated mutant lacking the CBM1 domain,
	SDS-PAGE, x * 38000, deglycosylated mutant lacking the CBM1 domain and
	linker region, SDS-PAGE <94>) <43,94>
MW	#3,29,68# 60000 (#29# isozyme MAN I, SDS-PAGE <43>; #68# x * 60000,
	SDS-PAGE, recombinant enzyme <66>; #3# x * 63000, glycosylated
	recombinant wild-type enzyme, SDS-PAGE, x * 58000, glycosylated mutant
	lacking the CBM1 domain, SDS-PAGE, x * 41000, glycosylated mutant
	lacking the CBM1 domain and linker region, SDS-PAGE, x * 60000,
	deglycosylated recombinant wild-type enzyme, SDS-PAGE, x * 55000,
	deglycosylated mutant lacking the CBM1 domain, SDS-PAGE, x * 38000,
	deglycosylated mutant lacking the CBM1 domain and linker region,
	SDS-PAGE <94>) <43,66,94>
MW	#3,9# 58000 (#9# M-I, SDS-PAGE <17>; #3# x * 63000, glycosylated
	recombinant wild-type enzyme, SDS-PAGE, x * 58000, glycosylated mutant
	lacking the CBM1 domain, SDS-PAGE, x * 41000, glycosylated mutant
	lacking the CBM1 domain and linker region, SDS-PAGE, x * 60000,
	deglycosylated recombinant wild-type enzyme, SDS-PAGE, x * 55000,
	deglycosylated mutant lacking the CBM1 domain, SDS-PAGE, x * 38000,
	deglycosylated mutant lacking the CBM1 domain and linker region,
	SDS-PAGE <94>) <17,94>
MW	#34# 41900 <1>
MW	#34# 61200 <1>
MW	#36,41# 50000 (#41# SDS-PAGE, a stable fragment corresponding to about
	460 residues and comprising the catalytic domain and 50 to 60 extra
	residues at the C-terminus <42>; #36# x * 50000, recombinant protein, x
	* 45000, native protein, SDS-PAGE <41>) <41,42>
MW	#4# 66000 (#4# 1 * 66000, SDS-PAGE <76>) <76>
MW	#4# 37700 (#4# x * 37700, calculated <85>) <85>
MW	#4,10,21,46,73# 40000 (#10# SDS-PAGE <49>; #73# x * 40000, SDS-PAGE
	<87>; #21# x * 39500, about, sequence calculation, x * 43000,
	recombinant glycosylated enzyme, SDS-PAGE, x * 40000, recombinant
	deglycosylated enzyme, SDS-PAGE <99>) <23,27,49,87,99>
MW	#4,18,65# 65000 (#4# PAGE <76>; #18# SDS-PAGE <2>; #65# x * 65000,
	SDS-PAGE <54>) <2,54,76>
MW	#4,36,76# 45000 (#36# recombinant protein expressed in Aspergillus
	oryzae, SDS-PAGE <26>; #36# x * 50000, recombinant protein, x * 45000,
	native protein, SDS-PAGE <41>; #76# x * 45000, SDS-PAGE, x * 41000,
	calculated <79>) <19,26,41,79>
MW	#40,77# 53000 (#40# SDS-PAGE <9>; #77# x * 53000, SDS-PAGE <78>) <9,78>
MW	#45,63,75# 33000 (#45# gel filtration <22>; #75# x * 33000, SDS-PAGE
	and calculated <74>; #63# x * 35500, recombinant His6-tagged enzyme,
	SDS-PAGE, x * 33000, about, enzyme without signal sequence, sequence
	calculation <97>) <22,74,97>
MW	#60# 113000 (#60# x * 113000, deduced from gene sequence, upon
	expression in Escherichia coli, two fragments of 45000 and 50000 Da
	<36>) <36>
MW	#61# 42400 (#61# x * 42400, deduced from gene sequence, mature protein
	<39>) <39>
MW	#63# 35500 (#63# x * 35500, recombinant His6-tagged enzyme, SDS-PAGE, x
	* 33000, about, enzyme without signal sequence, sequence calculation
	<97>) <97>
MW	#64# 36000 (#64# gel filtration <52>) <52>
MW	#64# 26000 (#64# x * 26000, SDS-PAGE <52>) <52>
MW	#66# 48000 (#66# x * 41389, calculated, x * 48000, SDS-PAGE of
	glycosylated enzyme, x * 39000, SDS-PAGE of deglycosylated enzyme <56>)
	<56>
MW	#66# 41389 (#66# x * 41389, calculated, x * 48000, SDS-PAGE of
	glycosylated enzyme, x * 39000, SDS-PAGE of deglycosylated enzyme <56>)
	<56>
MW	#67# 18000 (#67# SDS-PAGE <72>) <72>
MW	#70# 31000 (#70# x * 31000, SDS-PAGE <69>) <69>
MW	#71# 46800 (#71# x * 46800, SDS-PAGE <62>) <62>
MW	#72# 76309 (#72# 1 * 76309, calculated including signal peptide, 1 *
	73588, calculated, mature protein, 1 * 73000, SDS-PAGE <65>) <65>
MW	#72# 73588 (#72# 1 * 76309, calculated including signal peptide, 1 *
	73588, calculated, mature protein, 1 * 73000, SDS-PAGE <65>) <65>
MW	#8# 25000 (#8# gel filtration <13,15>) <13,15>
MW	#8# 27000 (#8# gel filtration <13,15>) <13,15>
MW	#8,62,72# 70000 (#8# gel filtration <13,15>; #72# gel fitlration <65>;
	#62# x * 70000, SDS-PAGE, recombinant protein including His-tag <82>)
	<13,15,65,82>
MW	#8,80,85# 44000 (#8# SDS-PAGE <13,15>; #80# x * 44000, SDS-PAGE <81>;
	#85# x * 44000, SDS-PAGE, x * 43767, calculated <86>) <13,15,81,86>
MW	#81# 39961 (#81# x * 39961, calculated <88>) <88>
MW	#83# 46644 (#83# x * 56000, SDS-PAGE, x * 46644, calculated <83>) <83>
MW	#83,84# 56000 (#84# x * 56000, SDS-PAGE, x * 43847, calculated <83>;
	#83# x * 56000, SDS-PAGE, x * 46644, calculated <83>) <83>
MW	#84# 43847 (#84# x * 56000, SDS-PAGE, x * 43847, calculated <83>) <83>
MW	#85# 43767 (#85# x * 44000, SDS-PAGE, x * 43767, calculated <86>) <86>
MW	#86# 53600 (#86# x * 53600, calculated <90>) <90>
MW	#9# 59000 (#9# M-II, SDS-PAGE <17>) <17>
MW	#9# 42000 (#9# M-III, SDS-PAGE <17>) <17>
MW	#94# 72000 (#94# x * 72000, recombinant enzyme, SDS-PAGE, x * 43000,
	about, sequence calculation of the mature enzyme <101>) <101>
MW	#97# 44300 (#97# x * 44300, SDS-PAGE <95>) <95>

POSTTRANSLATIONAL_MODIFICATION
PM	#1,3,15,21,36,59,64,66,67,77,83,84,96,98,99# glycoprotein (#67# 5%
	carbohydrate content <72>; #36# treatment with PNGaseF results in a
	shift to 41000 Da, both for native and recombinant protein <41>; #59#
	two putative N-glycosilation sites, ManB <40>; #1# carbohydrate content
	of 13.1% <53>; #66# treatment with Endo H leads to 30% loss of enzymic
	activity and a reduction in molecular weight by about 9 kDa <56>; #83#
	treatment by endoglycosidase H decreases molecular mass to 46000 Da
	<83>; #84# treatment by endoglycosidase H decreases molecular mass to
	51000 Da <83>; #96# deglycosylation by
	endo-beta-N-acetylglucosaminidase H <103>; #3# one potential
	N-glycosylation site, Asn98-Phe99-Thr100, the enzyme is deglycosylated
	by endo-beta-N-acetylglucosaminidase H. The Thr/Ser-rich linker region
	has numerous putative O-glycosylation sites <94>; #21# the enzyme
	contains two putative N-glycosylation sites and no O-glycosylation
	site, deglycosylation by endo-beta-N-acetylglucosaminidase H <99>; #98#
	the enzyme shows two different N-glycosylation sites. The first site
	Asn63 contains two linked N-acetylglucosamine residues. This
	glycosylation may have a structural role in stabilizing structural
	elements, as there are hydrogen bonds between the glucosamine residues
	and Ile67 and Leu71, which both belong to a very long loop (residues
	64-84), and Val136 located on helix 4. The other site Asn319 is not
	fully occupied, suggesting disorder or perhaps different populations of
	glycosylation <92>; #99# treatment with EndoH leads to a mass reduction
	of 7000 Da <108>) <33,40,41,52,53,56,72,78,83,92,94,99,103,108>
PM	#27,61,65,72,81,85# proteolytic modification (#61# amino acid sequence
	contains a signal peptide cleavage site between residues 21-22,
	targeting sequence for cell wall <39>; #65# sequence contains a
	secretory signal peptide <54>; #27# sequence contains a signal peptide
	of 17 amino acids <55>; #72# sequence contains a signal peptide of 26
	amino acids <65>; #81# sequence contains a N-terminal signal peptide of
	17 amino acids <88>; #85# sequence contains a N-terminal signal peptide
	of 24 amino acids <86>) <39,54,55,65,86,88>

SUBUNITS
SU	#1,3,4,11,21,27,30,36,39,59,60,61,62,63,64,65,66,68,70,71,73,75,76,77
	80,81,83,84,85,86,94,97,99# ? (#77# x * 53000, SDS-PAGE <78>; #39# x *
	38000, SDS-PAGE <59>; #68# x * 60000, SDS-PAGE <109>; #64# x * 26000,
	SDS-PAGE <52>; #65# x * 65000, SDS-PAGE <54>; #73# x * 40000, SDS-PAGE
	<87>; #70# x * 31000, SDS-PAGE <69>; #80# x * 44000, SDS-PAGE <81>;
	#30# x * 43000, recombinant enzyme, SDS-PAGE <100>; #60# x * 113000,
	deduced from gene sequence, upon expression in Escherichia coli, two
	fragments of 45000 and 50000 Da <36>; #61# x * 42400, deduced from gene
	sequence, mature protein <39>; #59# x * 43000, ManB, SDS-PAGE <40>;
	#36# x * 50000, recombinant protein, x * 45000, native protein,
	SDS-PAGE <41>; #4# x * 37700, calculated <85>; #11# x * 145294,
	calculated <50>; #1# x * 38013, calculated, x * 38000, SDS-PAGE, mature
	protein <58>; #27# x * 39000, SDS-PAGE, x * 39627, calculated for
	mature protein <55>; #1# x * 39600, SDS-PAGE <53>; #66# x * 41389,
	calculated, x * 48000, SDS-PAGE of glycosylated enzyme, x * 39000,
	SDS-PAGE of deglycosylated enzyme <56>; #71# x * 46800, SDS-PAGE <62>;
	#68# x * 60000, SDS-PAGE, recombinant enzyme <66>; #75# x * 33000,
	SDS-PAGE and calculated <74>; #76# x * 45000, SDS-PAGE, x * 41000,
	calculated <79>; #81# x * 39961, calculated <88>; #85# x * 44000,
	SDS-PAGE, x * 43767, calculated <86>; #86# x * 53600, calculated <90>;
	#84# x * 56000, SDS-PAGE, x * 43847, calculated <83>; #83# x * 56000,
	SDS-PAGE, x * 46644, calculated <83>; #62# x * 70000, SDS-PAGE,
	recombinant protein including His-tag <82>; #97# x * 44300, SDS-PAGE
	<95>; #63# x * 35500, recombinant His6-tagged enzyme, SDS-PAGE, x *
	33000, about, enzyme without signal sequence, sequence calculation
	<97>; #21# x * 39500, about, sequence calculation, x * 43000,
	recombinant glycosylated enzyme, SDS-PAGE, x * 40000, recombinant
	deglycosylated enzyme, SDS-PAGE <99>; #1# x * 41000, recombinant
	enzyme, SDS-PAGE <102>; #3# x * 63000, glycosylated recombinant
	wild-type enzyme, SDS-PAGE, x * 58000, glycosylated mutant lacking the
	CBM1 domain, SDS-PAGE, x * 41000, glycosylated mutant lacking the CBM1
	domain and linker region, SDS-PAGE, x * 60000, deglycosylated
	recombinant wild-type enzyme, SDS-PAGE, x * 55000, deglycosylated
	mutant lacking the CBM1 domain, SDS-PAGE, x * 38000, deglycosylated
	mutant lacking the CBM1 domain and linker region, SDS-PAGE <94>; #94# x
	* 72000, recombinant enzyme, SDS-PAGE, x * 43000, about, sequence
	calculation of the mature enzyme <101>; #99# x * 60000, SDS-PAGE of
	recombinant protein, x * 50605, calculated <108>)
	<36,39,40,41,50,51,52,53,54,55,56,58,59,61,62,66,69,74,78,79,81,82,83
	85,86,87,88,90,94,95,97,99,100,101,102,108,109>
SU	#2# dimer (#2# 2 * 73000, SDS-PAGE <34>) <34>
SU	#3,38,58,60,69,80,98# More (#60# C-terminal domain of 550 amino acid
	residues with homology to glycosidase family 26 <36>; #58# Trp360 is
	critical in substrate binding at -1 subsite, Tyr285 works as
	nucleophile catalyst, Trp217 and Trp162 are important for the activity
	against mannooligosaccharides but less important for activity against
	polysaccharides <37>; #69# the enzyme adopts a TIM (beta/alpha)8-barrel
	fold <107>; #98# the enzyme adopts the (beta/alpha)8-barrel fold <92>;
	#80# the enzyme shows some level of molecular flexibility in solution
	and is composed of three distinct domains, a GH5 catalytic domain (373
	amino acid residues) and a carbohydrate-binding domain (172 amino acid
	residues) connected through a linker (102 amino acid residues).
	Secondary structure, overview <106>; #3# the multimodular enzyme
	consists of a family 1 carbohydrate-binding module (CBM1), a
	Thr/Ser-rich linker region, and a catalytic domain <94>; #38# the
	three-dimensional enzyme structure contains a (beta/alpha)8 TIM barrel
	folding motif <105>; #80# the two-domain enzyme encompasses a GH5
	catalytic domain with a C-terminal CBM27 accessory domain, structure
	analysis and comparisons, overview <104>) <36,37,92,94,104,105,106,107>
SU	#4,26,72,100# monomer (#4# 1 * 66000, SDS-PAGE <76>; #26# 1 * 39216,
	ManA, 1 * 39265, ManB, MALDI-TOF spectrometry <38>; #72# 1 * 76309,
	calculated including signal peptide, 1 * 73588, calculated, mature
	protein, 1 * 73000, SDS-PAGE <65>; #100# 1 * 40000, SDS-PAGE, 1 *
	40457, calculated <111>) <38,65,76,111>

PI_VALUE
PI	#11,59# 5.5 (#11# calculated <50>; #59# chromatofocusing, 7 isomers
	<40>) <40,50>
PI	#21# 5.93 (#21# sequence calculation <99>) <99>
PI	#26# 6.9 (#26# isoelectric focusing <38>) <38>
PI	#29# 4.9-5.2 (#29# isozyme MAN I <43>) <43>
PI	#29# 4.75-4.9 (#29# isozyme MAN II <43>) <43>
PI	#61# 4.6-4.7 (#61# calculated from amino acid sequence <39>) <39>
PI	#61# 9 (#61# isoelectric focusing <39>) <39>
PI	#64# 4.5 (#64# isoelectric focusing <52>) <52>
PI	#66# 4.9 (#66# isoelectric focusing <56>) <56>
PI	#85# 4.6 (#85# calculated <86>) <86>
PI	#99# 4.4 (#99# calculated <108>) <108>
PI	#99# 3.6 (#99# isoelectric focusing <108>) <108>

APPLICATION
AP	#1,9,10# agriculture (#10# fruit ripening and seed germination <49>;
	#9# 10 U/mg enzyme can hydrolyze more than 90% of 10 mg/ml konjac flour
	at 50°C in 24 h <63>; #10# when endo-beta-mannanase activity is much
	reduced by RNAi and antisense RNA strategies, their firmness is higher
	compared to those of control fruits at the turning and orange-color
	stages, but at the red-ripe stage firmness is similar between the two
	fruit-types <77>; #1# the recombinant enzyme can be an additive in the
	feed for monogastric animals <102>) <49,63,77,102>
AP	#10,74# biotechnology (#10# bio-bleaching for kraft pulp production
	<49>; #74# optimization of mannanase gene for expression in Pichia
	pastoris by substitution of 258 nucleotides with their corresponding
	counterparts according to the codon usage in Pichia pastoris, which has
	no change on the beta-mannanase amino acid sequence. Compared to the
	activity of wild-type, the expression enzyme of the optimized
	beta-mannanase gene acquires approximately 35% more activity <73>)
	<49,73>
AP	#26# paper production (#26# cellulose degradation <46>) <46>
AP	#29# nutrition (#29# pulp production <43>) <43>
AP	#30,65# industry (#65# when used to treat softwood pulp, enzyme
	hydrolyzes mainly glucomannan and exhibits a positive effect as a
	prebleaching agent <54>; #30# the enzyme is highly useful in the
	food/feed, paper and pulp, and detergent industries <100>) <54,100>
AP	#38# medicine (#38# mixed maltooligosacchrides produced by the enzyme
	exhibit in vitro anti-tumorigenic activity on human colon cancer HT29
	cells <105>) <105>
AP	#4# pharmacology (#4# tailoring of hydrogel release profiles of
	potential interest for intestine drug delivery. The rate of hydrolysis
	of O-acetyl-galactomannan hydrogels modified with alpha-galactosidase
	increases with decreasing degree of substitution. The addition of
	alpha-mannanase significantly enhances the release of bovine serum
	albumin encapsulated in hydrogels with a degree of substitution of
	0.36, reaching a maximum of 95% released bovine serum albumin after
	eight hours compared to 60% without enzyme <64>) <64>
AP	#4,36,82# synthesis (#36# production of enzyme by expression in
	Aspergillus niger under control of the Aspergillus niger
	glyceraldehyde-3-phosphate dehydrogenase promoter gpdP and the
	Aspergillus awamori glucoamylase terminator glaAT. The glucose
	concentration and the organic nitrogen source have an effect on both
	the volumetric enzyme activity and the specific enzyme activity. The
	highest mannanase activity levels of 16596 nkat ml-1 and 574 nkat mg-1
	dcw are obtained for Aspergillus niger when cultivated in a
	process-viable medium containing corn steep liquor as the organic
	nitrogen source and high glucose concentrations <68>; #36# expression
	in Yarrowia lipolytica using beta-mannosidases own secretion signal.
	Fed batch fermentations result in a 3.9fold increase in volumetric
	enzyme activity compared with batch fermentation, and a maximum titre
	of 26,139 nkat/ml <80>; #4# production of beta-mannanase using palm
	kernel cake as substrate in solid substrate fermentation. Optimal
	conditions are incubation temperature of 32°C, initial moisture level
	of 59% and aeration rate of 0.5 l/min, resulting in a beta-mannanase
	yield of 2231.26 U/g <75>; #4# development of a fed-batch strategy for
	engineered enzyme, using high cell-density fermentation. Mannanase
	activity reaches 5069 U/ml after cultivation for 56 h in 50 l fermenter
	<85>; #82# expression in Escherichia coli based on T7 RNA polymerase
	promoter and tac promoter systems. Both Escherichia coli OmpA signal
	peptide and native Bacillus signal peptide can be used efficiently for
	secretion of recombinant protein. Enzyme can be harvested from whole
	cell lysate, periplasmic extract or culture broth 4-20 h after
	induction by IPTG <84>; #4# production of beta-mannanase from palm
	kernel cake as a substrate in solid substrate fermentation. A
	statistical model suggests that the optimal conditions for attaining
	the highest level of beta-mannanase are incubation temperature of
	32°C, initial moisture level of 59% and aeration rate of 0.5 l/min. A
	beta-mannanase yield of 2231.26 U/g is obtained under these optimal
	conditions <75>) <68,75,80,84,85>
AP	#62,99# degradation (#62# when assembled with the mini-CbpA, which
	contains a carbohydrate-binding module that provides proximity to
	insoluble substrates, a mixture of endoglucanase E and ManB at a molar
	ratio of 1:2 shows the highest synergistic effect of 2.4fold on locust
	bean gum degradation. The mixture at a ratio of 1:3 shows the highest
	synergistic effect of 2.8fold on guar gum <82>; #99# the addition of
	Man26A as a supplement to the commercial enzyme mixture Celluclast 1.5
	L and Novozyme 188 results in enhanced enzymatic hydrolysis of
	pretreated beechwood sawdust, the release of total reducing sugars and
	glucose is improved by 13 and 12%, respectively <108>) <82,108>
AP	#63# drug development (#63# the enzyme is a target for the development
	of inhibitor molecules to be used in pest control strategies to reduce
	the serious damage caused by the coffee berry borer during coffee
	cultivation <97>) <97>

ENGINEERING
EN	#1# E266A (#1# complete loss of activity <70>) <70>
EN	#1# E167A (#1# about 60% loss of catalytic efficiency <70>) <70>
EN	#1# H1A/H23A (#1# about 10% loss of catalytic efficiency <70>) <70>
EN	#11# E222A (#11# no catalytic acitivity <50>) <50>
EN	#11# E91A (#11# no catalytic acitivity <50>) <50>
EN	#3,4,10,74,75,86,96,98# more (#10# the cultivar Walter displays an
	inactive enzyme due to the absence of the C-terminal four amino acid
	residues 394-399, SerLysLeuSer. The inactive form has a lower stability
	than the active one. The loss of amino acids from the C-terminal end of
	the protein indirectly affects the conformation of the catalytic Glu318
	residue and stability of active site because of interactions between
	residues at the C-terminus and the rest of protein <71>; #75# mutant
	MG17 is catalytically inactive, mutant protein is present at wild-type
	molecular mass <74>; #74# optimization of mannanase gene for expression
	in Pichia pastoris by substitution of 258 nucleotides with their
	corresponding counterparts according to the codon usage in Pichia
	pastoris, which has no change on the beta-mannanase amino acid sequence
	<73>; #86# deletion of the CBM6 domain increases the enzyme stability
	while enabling it to retain 80% and 60% of its initial activity after
	treatment at 80°C and 90°C for 30 min <90>; #4# gene optimization
	according to the codon usage bias in Pichia pastoris and synthesis by
	splicing overlap extension PCR <85>; #96# construction of a chimeric
	enzyme of xylanase and mannanase with higher catalytic efficiency and
	improved properties, the two enzymes are fused together with twelve
	fusion types <103>; #3# generation of two truncated enzyme mutants
	lacking the family 1 carbohydrate-binding module Man5DELTACBM or the
	family 1 carbohydrate-binding module and the Thr/Ser-rich linker
	region, Man5DELTACL, respectively. The mutant enzymes show
	significantly altered secondary structures compared to the wild-type
	enzyme, overview. Removal of the family 1 carbohydrate-binding module
	alone improves the thermostability of the enzyme, but additional
	removal of the linker region results in worse thermostability. The
	mutants are less stable in presence of acetone, SDS, Triton X-100, or
	urea compared to the wild-type enzyme <94>; #98# mutagenesis of Trp271
	at the +1 subsite plays a crucial role in the enhanced
	transglycosylation activity <92>) <71,73,74,85,90,92,94,103>
EN	#58# H211A (#58# decrease of Km-value by about 30% <37>) <37>
EN	#58# D283A (#58# increase of Km-value by about 80% <37>) <37>
EN	#58# W156A (#58# increase of Km-valueby almost 80% <37>) <37>
EN	#58# W162A (#58# increase of Km-value by about 50% <37>) <37>
EN	#58# E212A (#58# dramatic decrease of Km-value <37>) <37>
EN	#58# W217A (#58# increase of Km-value by more than 100% <37>) <37>
EN	#58# D283H (#58# dramatic decrease of Km-value <37>) <37>
EN	#58# H211N (#58# dramatic decrease of Km-value <37>) <37>
EN	#58# H211N/D283H (#58# decrease of Km-value by about 50% <37>) <37>
EN	#58# Y285A (#58# dramatic decrease of Km-value <37>) <37>
EN	#58# H143A (#58# decrease of Km-value by about 50% <37>) <37>
EN	#83# S289W (#83# mutation lowers KM for mannooligosaccharides by 30-45%
	and increases transglycosylation yield by 50% compared to wild-type
	<83>) <83>
EN	#84# W283S (#84# mutation in subsite +1, mutation results in increase
	in KM value, reduction in the transglycosylation yield by 30-45% and
	decrease in activity towards mannans <83>) <83>

CLONED
CL	#1# (expression in Escherichia coli) <58>
CL	#1# (gene man5A, DNA and amino acid sequence determination and
	analysis, recombinant expression in Pichia pastoris strain GS115) <102>
CL	#3# (gene man5XZ3, sequence comparisons, cloning in Escherichia coli
	strain Trans1-T1, and recombinant expression of wild-type and mutant
	enzymes fused in frame to the DNA sequence for the Saccharomyces
	cerevisiae alpha-factor secretory signal peptide and under the control
	of the methanol-inducible alcohol oxidase promoter in Pichia pastoris
	strain GS115, induction by methanol, the proteins are secreted) <94>
CL	#4# (expression in Pichia pastoris) <85>
CL	#5# (expression in Escherichia coli) <89>
CL	#10# <24>
CL	#10# (expressed in Escherichia coli) <48>
CL	#10# (expressed in Escherichia coli strain BL21) <49>
CL	#10# (expressed in Arabidopsis thaliana transformed with Agrobacterium
	tumefaciens) <47>
CL	#11# (expression in Escherichia coli) <50>
CL	#15# (expression in Escherichia coli) <25>
CL	#21# (gene man5P1, DNA and amino acid sequence determination and
	analysis, sequence comparisons, recombinant expression of extracellular
	enzyme in Pichia pastoris strain GS115) <99>
CL	#24# (gene poman5A, recombinant expression of C-terminally His6-tagged
	extracellular enzyme in and secretion from Pichia pastoris strain
	GS115) <96>
CL	#26# (expressed in Pichia pastoris) <35,46>
CL	#30# (gene RmMan5A, DNA and amino acid sequence determination and
	analysis, sequence comparisons, expression of His-tagged enzyme in
	Escherichia coli strain BL21) <100>
CL	#32# (expressed in Saccharomyces cerevisiae and Escherichia coli) <44>
CL	#36# (expression in Aspergillus oryzae) <26>
CL	#36# (expression in Aspergillus niger) <68>
CL	#36# (expression in Yarrowia lipolytica) <80>
CL	#36# (gene manA, recombinant expression in and secretion from Yarrowia
	lipolytica) <93>
CL	#39# (expression in Escherichia coli) <59>
CL	#41# (expressed in Escherichia coli) <42>
CL	#43# <31>
CL	#46# <27>
CL	#47# <29>
CL	#59# (both ManA and ManB) <40>
CL	#60# <36>
CL	#61# <39>
CL	#62# (expression in Escherichia coli) <82>
CL	#63# (gene HhMan, DNA and amino acid sequence determination and
	analysis, sequence comparisons, recombinant expression of C-terminally
	His6-tagged extracellular enzyme in and secretion from Pichia pastoris
	strain GS115) <97>
CL	#65# (expression in Aspergillus niger) <54>
CL	#66# (expression in Pichia pastoris) <56>
CL	#68# (expression in Aspergillus sojae and Pichia pastoris) <66>
CL	#68# (expression in in Aspergillus sojae and Pichia pastoris) <109>
CL	#69# (exprression in Escherichia coli fused with thioredoxin gene) <67>
CL	#70# (expression in Escherichia coli) <69>
CL	#71# (expression in Escherichia coli) <62>
CL	#72# (expression in Escherichia coli) <65>
CL	#74# (expression in Pichia pastoris) <73>
CL	#75# (expression in Escherichia coli) <74>
CL	#76# (expression in Escherichia coli) <79>
CL	#77# (expression in Pichia pastoris) <78>
CL	#80# (expression in Escherichia coli) <81>
CL	#80# (gene Tpet_1542, recombinant expression of His-tagged full-length
	enzyme and isolated catalytic domain in Escerichia coli strain
	BL21(DE3)DELTASlyD) <104>
CL	#80# (recombinant expression of His-tagged full-length enzyme and
	catalytic domain) <106>
CL	#81# (expression in Escherichia coli) <88>
CL	#82# (expression in Escherichia coli) <84>
CL	#83# (expression in Pichia pastoris) <83>
CL	#84# (expression in Pichia pastoris) <83>
CL	#85# (expression in Escherichia coli) <86>
CL	#94# (gene man5F63, DNA and amino acid sequence determination and
	analysis, sequence comparisons, cloning in Escherichia coli strain
	Trans1-T1, overexpression in Pichia pastoris strain GS115 and secretion
	to the culture medium) <101>
CL	#95# (cloning in Escherichia coli strain JM109, functional
	overexpression in Pichia pastoris strain GS115, the enzyme is secreted)
	<98>
CL	#96# (gene An15g07760, cloning in Escherichia coli, and expression of
	recombinant chimeric xylanase/mannanase fusion enzymes in Pichia
	pastoris strain X33 using GAP promoter, secretion to the medium) <103>
CL	#98# (gene man5, DNA and amino acid sequence determination and
	analysis) <92>
CL	#99# (expression in Pichia pastoris) <108>
CL	#100# (expression in Escherichia coli) <111>
CL	#1207# (expression in Pichia pastoris and Escherichia coli) <61>

CRYSTALLIZATION
CR	#1# (to 1.45 A resolution, crystal shows a typical (beta/alpha)8
	folding type. The catalytic acid/base Glu167 and nucleophile Glu266 are
	positioned on the beta4 and beta7 strands, respectively) <70>
CR	#10# (recombinant enzyme) <48>
CR	#10# (hanging drop vapor diffusion) <49>
CR	#10# (molecular dynamic simulation of wild-type and mutant lacking the
	C-terminal amino acid residues 394-399, SerLysLeuSer. The inactive form
	has a lower stability than the active one. The loss of amino acids from
	the C-terminal end of the protein indirectly affects the conformation
	of the catalytic Glu318 residue and stability of active site because of
	interactions between residues at the C-terminus and the rest of
	protein) <71>
CR	#26# (both native protein and selenomethionyl derivative, enzyme
	expressed in Pichia pastoris) <35>
CR	#39# (native and selenomethionyl enzyme, to 1.9 and 1.99 A resolution,
	respectively) <59>
CR	#41# (hanging-drop vapor diffusion method at room temperature) <42>
CR	#58# <37>
CR	#69# (enzyme in apoform and in complex with mannopentaose, the
	precipitant solution contains 25% w/v PEG 3350, 0.1 M Tris-HCl, pH 8.5,
	X-ray diffraction structure determination and analysis, modelling) <107>
CR	#80# (crystallization of catalytic domain. Crystals from conditions
	with phosphate or citrate salts as precipitant belong to space group
	P212121, resolution to 1.4 A, while a crystal from a condition with
	ethanol as precipitant belongs to space group I212121, resolution to
	1.45 A) <81>
CR	#80# (purified recombinant His-tagged full-length enzyme and catalytic
	domain, X-ray diffraction structure determination and analysis by
	dynamic light scattering and small-angle X-ray scattering. molecular
	modelling) <106>
CR	#80# (purified recombinant isolated His-tagged catalytic domain in
	apoform and complexed with iodine, glucose, maltose, and maltose +
	gycerol, sitting drop vapor diffusion method, mixing of 0.0005 ml of 12
	mg/ml protein in 25 mM Tris-HCl, pH 7.5, with 0.0005 ml of precipitant
	solution containing 0.1 M citrate, pH 5.5, 1 M ammonium phosphate, and
	0.2 M sodium chloride, 20°C, soaking of crystals in ligand solutions,
	X-ray diffraction structure determination and analysis at 1.40-1,92 A
	resolution) <104>
CR	#98# (hanging drop vapour diffusion method, mixing of 6.5 mg/ml protein
	in 20 mM Tris-HCl, pH 7.6, with reservoir solution containing 0.1 M
	magnesium chloride, 0.1 M sodium acetate pH 4.5, 23% w/v PEG 3350,
	20°C, method optimization, X-ray diffraction structure determination
	and analysis at 1.40 A resolution, molecular replacement) <92>
CR	#99# (homology modeling of structure) <108>

PURIFICATION
PU	#1# <19,28,53>
PU	#1# (four enzyme forms) <30>
PU	#1# (from culture supernatant) <58>
PU	#1# (recombinant enzyme from Pichia pastoris strain GS115) <102>
PU	#2# <34>
PU	#3# (recombinant wild-type and mutant enzymes from Pichia pastoris
	strain GS115 culture supernatant by ultrafiltration and anion exchange
	chromatography to homogeneity) <94>
PU	#4# <76>
PU	#7# <19>
PU	#8# <13,15>
PU	#9# (M-I, M-II, M-III) <17>
PU	#10# (cation exchange chromatography) <49>
PU	#10# (salt extraction, dialysis, cation exchange chromatography) <48>
PU	#11# (recombinant protein) <50>
PU	#12# <11>
PU	#13# <16>
PU	#14# <19>
PU	#15# <33>
PU	#15# (recombinant protein expressed in Escherichia coli) <25>
PU	#16# <8,20>
PU	#18# <2>
PU	#19# <19>
PU	#21# (recombinant extracellular enzyme from Pichia pastoris strain
	GS115 culture supernatant by ultrafiltration and anion exchange
	chromatography) <99>
PU	#24# (recombinant His6-tagged extracellular enzyme from Pichia pastoris
	strain GS115 culture supernatant by nickel affinity chromatography to
	homogeneity) <96>
PU	#26# <38>
PU	#27# (from digestive fluid) <55>
PU	#29# (fast flow column chromatography) <43>
PU	#30# (recombinant His-tagged enzyme from Escherichia coli strain BL21
	by nickel affinity chromatography) <100>
PU	#31# <19>
PU	#36# (recombinant protein expressed in Aspergillus oryzae) <26>
PU	#36# (both native protein and expressed in Saccharomyces cerevisiae)
	<41>
PU	#36# (recombinant extracellular enzyme from Yarrowia lipolytica culture
	supernatant by ultrafiltration) <93>
PU	#43# (recombinant protein containing active protein domain) <31>
PU	#61# <39>
PU	#62# <82>
PU	#67# <72>
PU	#74# (recombinant enzyme) <73>
PU	#75# (recombinant enzyme) <74>
PU	#76# (recombinant enzyme) <79>
PU	#77# (recombinant enzyme) <78>
PU	#80# <81>
PU	#80# (recombinant His-tagged full-length enzyme and catalytic domain by
	nickel affinity chromatography) <106>
PU	#80# (recombinant His-tagged full-length enzyme and isolated catalytic
	domain from Escerichia coli strain BL21(DE3)DELTASlyD by nickel
	affinity chromatography, gel filtration, and ultrafiltration) <104>
PU	#94# (recombinant extracellular enzyme from Pichia pastoris strain
	GS115 culture supernatant by ultrafiltration) <101>
PU	#95# (recombinant enzyme 9.7fold from Pichia pastoris strain GS115
	culture supernatant to homogeneity by ammonium sulfate fractionation,
	dialysis, PEG 20000 fractionation, anion exchange chromatography,
	ultrafiltration, and gel filtration) <98>
PU	#96# (recombinant chimeric enzymes from Pichia pastoris strain X33
	culture supernatant by ammonium sulfate fractionation and gel
	filtration) <103>
PU	#97# (native enzyme 29.4fold by anion exchange chromatography) <95>
PU	#98# (native enzyme by ultrafiltration and anion exchange
	chromatography) <92>
PU	#99# (recombinant protein) <108>
PU	#283# (purification from seedling) <51>

RENATURED
REN	#26# (can be completely renatured after denaturation in 6 M guanidine
	hydrochloride) <38>

GENERAL_STABILITY
GS	#71# (enzyme is strongly resistant to pepsin and trypsin digestion) <62>

ORGANIC_SOLVENT_STABILITY
OSS	#37# Acetone (#37# may be used in preparations <3>) <3>

PH_STABILITY
PHS	#1# 5.5-10.1 <53>
PHS	#1,4,7,9,13,14,16,19,25,31,40,44# -999 <9,16,17,19,21>
PHS	#1,9,12,100# 5-9 (#1# purified recombinant enzyme, 50°C, 8 h, stable
	at <102>; #100# 1 h, 90% residual activity <111>) <11,63,102,111>
PHS	#13# 4.5-8 <16>
PHS	#14# 5-8 <19>
PHS	#21,67# 2-12 (#21# purified recombinant enzyme, 1 h, over 65% activity
	remaining <99>) <72,99>
PHS	#29# 4.5-8.5 <43>
PHS	#3# 3 (#3# purified recombinant wild-type enzyme, 37°C, 1 h, 50%
	activity remaining <94>) <94>
PHS	#3# 1-2 (#3# purified recombinant wild-type enzyme, 37°C, 1 h, 50%
	activity remaining <94>) <94>
PHS	#3,26,94# 4-9 (#3# purified recombinant wild-type enzyme, 37°C, 1 h,
	stable at <94>; #94# purified reocmbinant enzyme, 37°C, 1 h, without
	substrate, more than 86% of the initial activity remaning <101>)
	<38,94,101>
PHS	#30,99# 4-10 (#30# purified recombinant enzyme, 30 min, without
	substrate, over 80% activity remaining <100>; #99# 24 h, more than 88%
	residual activity <108>) <100,108>
PHS	#34# 4-5 <1>
PHS	#36# 2.5-10 (#36# recombinant protein expressed in Aspergillus oryzae
	<26>) <26>
PHS	#47# 4.5-9 <29>
PHS	#64# 5 (#64# 30°C, 24 h, 50% loss of activity <52>) <52>
PHS	#64# 7.8 (#64# 30°C, 96 h, no loss of activity <52>) <52>
PHS	#68# 3.5-8.5 <109>
PHS	#69# 7 (#69# inactivation above <67>) <67>
PHS	#7,65# 4-8 (#7# 40°C, 1 h <7,19>) <7,19,54>
PHS	#72# 6.5-10 (#72# more than 80% of original activity after 12 h
	incubation at 4°C <65>) <65>
PHS	#73# 4 (#73# 40°C, 20 min, stable <87>) <87>
PHS	#76# 6-9 (#76# after incubation at 50°C for 24 h <79>) <79>
PHS	#76# 5-12 (#76# after incubation at 50°C for 30 min <79>) <79>
PHS	#82# 2-10 (#82# 50°C, stable for 30 min <84>) <84>
PHS	#85# 5.5-9 (#85# 1 h, more than 80% residual activity <86>) <86>
PHS	#94# 11-12 (#94# purified reocmbinant enzyme, 37°C, 1 h, without
	substrate, more than 40% of the initial activity remaning <101>) <101>
PHS	#95# 5.5-7.8 (#95# purified recombinant enzyme, over 80% remaning after
	1 h <98>) <98>
PHS	#95# 6.3-7.1 (#95# purified recombinant enzyme, over 80% remaning after
	2 h <98>) <98>
PHS	#96# 2.2-11 (#96# purified recombinant chimeric enzymes display similar
	high pH stability as the wild-type mannanase with over 80% activity in
	this range, profiles overview <103>) <103>
PHS	#97# 8 (#97# purified enzyme, 30°C, 30 min, over 90% activity
	remaining <95>) <95>

STORAGE_STABILITY
SS	#10# (-20°C, MES buffer, 4 months, without loss of activity) <48>
SS	#10# (4°C, 48h, 20% residual activity) <48>
SS	#12# (dialyzed) <11>
SS	#4# (4°C, stable for 18 h, pH 4-10) <19>
SS	#6,35,37,42,54,55,56,57# (cold) <3>
SS	#66# (enzyme is stable at room temperature for at least 2 days) <56>

TEMPERATURE_STABILITY
TS	#1# 75 (#1# 30 min, 90% loss of activity <53>) <53>
TS	#1,3,4,7,9,13,14,16,19,21,31,36,80# -999 (#36# glycerol at 30-40%,
	potassium sorbate/sodium benzoate at 0.2%, and sorbitol at 30-35%
	enhances enzyme thermostability and activity, overview <93>; #3#
	removal of the family 1 carbohydrate-binding module alone improves the
	thermostability of the enzyme, but additional removal of the linker
	region results in worse thermostability <94>; #80# the CBM27 accessory
	domain is critical for thermal stability, it reduces the melting
	temperature from 100°C to 88°C <104>; #21# the glycosylation status
	of the enzyme has no effect on the thermostability <99>)
	<5,8,9,16,17,19,20,21,93,94,99,104>
TS	#1,36,46# 80 (#36# 2 min, complete loss of activity <68>; #46# no loss
	of activity over 16 h <27>; #1# 20 min, 18% residual activity, 30 min,
	complete loss of activity <58>) <27,58,68>
TS	#1,4,21,22,24,32,33,36,40,65,66,70,74,82,86,94,99# 60 (#40,65# stable
	up to <9,54>; #74# 30 min, complete loss of activity <73>; #33# 30 min,
	stable up to <110>; #1# for 1 h <9,28>; #86# half-life 12 min <90>;
	#32# rapidly inactivated at 60°C <44>; #1# 60 min, 90% residual
	activity <58>; #1# at pH 6.0, stable up to <53>; #66# half-life 50 min
	<56>; #36# 5 h, more than 50% residual activity <68>; #22# 6 h, 50%
	residual activity <60>; #4# 8 h, 50% residual activity <60>; #70# but
	no activity remains after incubation for 20 min <69>; #82# hlaf-life 4
	min <84>; #36# a combination of mannanase with 0.2% sodium benzoate and
	30% or 35% sorbitol presents the highest relative activity of about
	150% when incubated at 60°C for 4 h, the control retains 63% of the
	initial activity <93>; #21# purified recombinant enzyme, 6 h, over 80%
	activity remaining <99>; #24# purified recombinant His6-tagged enzyme,
	half-life is approximately 58 h at pH 4.0 <96>; #94# purified
	reocmbinant enzyme, pH 4.5, 30 min, complete loss of activity <101>;
	#99# half-life 14.4 h <108>)
	<9,28,44,53,54,56,58,60,61,68,69,73,84,90,93,96,99,101,108,110>
TS	#1,4,21,36,60,67,71,77,97,100# 70 (#4# stable up to <6>; #67# stable
	for 30 min <72>; #36# recombinant protein from Aspergillus oryzae <26>;
	#60# 1 h, 70% residual activity, truncated protein fragments produced
	in Escherichia coli, 1 h, 87% residual activity, protein derived from
	Rhodothermus marinus <36>; #1# 30 min, 20% residual activity <58>; #71#
	20 min, 50% residual activity <62>; #77# half-life 56 h, pH 4.0 <78>;
	#97# purified enzyme, pH 8.0, 20 min, loss of 50% activity <95>; #21#
	purified recombinant enzyme, 80% activity remaining after 1 h,
	inactivation after 2 h <99>; #100# 2 h, 50% residual activtiy <111>)
	<6,19,26,36,58,62,72,78,95,99,111>
TS	#1,4,5,7,9,14,68,70,76,82,85,94# 50 (#1,7,14# stable below <9,19>; #85#
	half-life 15 min <86>; #5# 30 min, 20% residual activity <89>; #9# pH
	6-9, 1 h, 70% residual activity <63>; #68# recombinant enzyme expressed
	in Pichia pastoris <66>; #70# retains 90% of its activity after
	incubation for 60 min <69>; #76# after incubation for 30 min, stable at
	pH 5-12. After incubation for 24 h, stable at pH 6-9. Half-life about
	80 h at pH 6.0 <79>; #82# pH 6.0, stable for 30 min, incubation without
	substrate <84>; #1# purified recombinant enzyme, pH 5.0-9.0, 8 h,
	stable at <102>; #94# purified reocmbinant enzyme, pH 4.5, 90 min, loss
	of 50% activity <101>) <9,19,23,61,63,66,69,79,84,86,89,101,102>
TS	#100# 88 (#100# melting temperature <111>) <111>
TS	#12,26,27,66,68,83,84# 40 (#12# stable up to <11>; #66# stable below
	<56>; #27# 30 min, stable <55>; #26# unstable above <38>; #68#
	recombinant enzyme expressed in Aspergillus sojae <66>; #83,84# 3 h,
	95% residual activity <83>) <11,38,55,56,66,83>
TS	#18# 91 (#18# half-life 13 h <2,32>) <2,32>
TS	#2,9,13,99# 65 (#13# stable up to <16>; #9# stable below <63>; #2#
	completely stable at <34>; #99# half-life 35.3 min <108>) <16,34,63,108>
TS	#3# 30-90 (#3# purified recombinant wild-type enzyme, pH 5.0, 1 h, more
	than 45% of maximal activity at 50-80°C and over 30% activity at 90°C
	<94>) <94>
TS	#4# 39 (#4# 4 h, stable between pH 5 and 7 <19>) <19>
TS	#4,29,30,64# 55 (#29# stable up to 55°C <43>; #64# 15 min, almost
	complete loss of activity <52>; #4# 6 h, 50% residual activity <76>;
	#30# purified recombinant enzyme, without substrate, stable up to, 90%
	activity remaning at 55°C after 30 min <100>) <43,52,76,100>
TS	#4,60,97# 90 (#4# half-life 15 min <85>; #60# 1 h, 25% residual
	activity, truncated protein fragments produced in Escherichia coli
	<36>; #97# purified enzyme, pH 8.0, 20 min, inactivation <95>)
	<36,85,95>
TS	#5,94# 37 (#5# stable up to <89>; #94# purified reocmbinant enzyme, pH
	4.5, 2 h, no loss of activity <101>) <89,101>
TS	#69,72,74# 45 (#69# half-life less than 10 min <67>; #72# stable up to,
	for at least 20 min <65>; #74# 30 min, 60% rsidual activity <73>)
	<65,67,73>
TS	#71# 40-70 (#71# more than 65% of maximum activity within <62>) <62>
TS	#73# 52 (#73# 20 min, 50% residual activity <87>) <87>
TS	#80# 85 (#80# pH 6.0, the full-length enzyme is completely stable,
	while the isolated catalytic domain starts to precipitate <106>) <106>
TS	#81# 38 (#81# 20 min, 50% residual activity, recombinant enzyme <88>)
	<88>
TS	#96# 10-80 (#96# varying residual activities of recombinant chimeric
	enzymes, overview <103>) <103>
TS	#97# 20-50 (#97# purified enzyme, pH 8.0, 20 min, stable at <95>) <95>

REFERENCE
RF	<1> Gubitz, G.M.; Hayn, M.; Sommerauer, M.; Steiner, W.:
	Mannan-degrading enzymes from Sclerotium rolfsii: characterisation and
	synergism of two endo beta-mannanases and a beta-mannosidase.
	Bioresour. Technol. (1996) 58, 127-135. {Pubmed:} (c)
RF	<2> Duffaud, G.D.; McCutchen, C.M.; Leduc, P.; Parker, K.N.; Kelly,
	R.M.: Purification and characterisation of extremely thermostable
	beta-mannanase, beta-mannosidase, and alpha-galactosidase from the
	hyperthermophilic eubacterium Thermotoga neapolitana 5068. Appl.
	Environ. Microbiol. (1997) 63, 169-177. {Pubmed:8979350} (c)
RF	<3> Reese, E.T.; Shibata, Y.: beta-Mannanases of fungi. Can. J.
	Microbiol. (1965) 11, 167-18. {Pubmed:14323029}
RF	<4> Groot, S.P.C.; Kieliszewska-Rokicka, B.; Vermeer, E.; Karsson,
	C.M.: Gibberellin-induced hydrolysis of endosperm cell walls in
	gibberellin-deficient tomato seeds prior to radicle protrusion. Planta
	(1988) 174, 500-504. {Pubmed:24221566}
RF	<5> Halmer, P.; Bewley, J.D.; Thorpe, T.A.: Enzyme to break down
	lettuce endosperm cell wall during gibberellin- and light-induced
	germination. Nature (1975) 258, 716-718. {Pubmed:}
RF	<6> Yamazaki, N.; Sinner, M.; Dietrichs, H.H.: Isolierung und
	Eigenschaften einer beta-1,4-Mannanase aus Aspergillus niger.
	Holzforschung (1976) 30, 101-109. {Pubmed:}
RF	<7> McCleary, B.V.: Prification of a beta-mannanase enzyme from lucerne
	seed by substrate affinity chromatography. Phytochemistry (1978) 17,
	651-653. {Pubmed:}
RF	<8> Halmer, P.; Bewley, J.D.: Mannanase production by the lettuce
	endosperm. Planta (1979) 144, 333-340. {Pubmed:24407322}
RF	<9> McCleary, B.V.: Modes of action of beta-mannanase enzymes of
	diverse origin on legume seed galactomannans. Phytochemistry (1979) 18,
	757-763. {Pubmed:}
RF	<10> Coulombel, C.; Clermont, S.; Foglietti, M.J.; Percheron, F.:
	Transglycosylation reactions catalysed by two beta-mannanases. Biochem.
	J. (1981) 195, 333-335. {Pubmed:7306059}
RF	<11> Araki, T.: Purification and characterization of an
	endo-beta-mannanase from Aeromonas sp. F-25. J. Fac. Agric. Kyushu
	Univ. (1983) 27, 89-98. {Pubmed:}
RF	<12> Shimizu, K.; Ishihara, M.: Isolation and characterization of
	oligosaccharides from the hydrolyzate of larch wood glucomannan with
	endo-beta-D-mannanase. Agric. Biol. Chem. (1983) 47, 949-955. {Pubmed:}
RF	<13> Loos, E.; Meindl, D.: Cell wall-lytic activity in Chlorella fusca.
	Planta (1984) 160, 357-362. {Pubmed:24258585}
RF	<14> Zemek, J.; Marvanova, L.; Kuniak, L.; Kadlecikova, B.: Hydrolytic
	enzymes in aquatic hyphomycetes. Folia Microbiol. (Praha) (1985) 30,
	363-372. {Pubmed:}
RF	<15> Loos, E.; Meindl, D.: Cell-wall-bound lytic activity in Chlorella
	fusca: function and characterization of an endo-mannanase. Planta
	(1985) 166, 557-562. {Pubmed:24241623}
RF	<16> Park, G.G.; Kusakabe, I.; Komatsu, Y.; Kobayashi, H.; Yasui, T.;
	Murakami, K.: Purification and some properties of beta-mannanase from
	Penicillium purpurogenum. Agric. Biol. Chem. (1987) 51, 2709-2716.
	{Pubmed:}
RF	<17> Akino, T.; Nakamura, N.; Horikoshi, K.: Characterization of three
	beta-mannanases of an alkalophilic Bacillus sp.. Agric. Biol. Chem.
	(1988) 52, 773-779. {Pubmed:}
RF	<18> Spyropoulos, C.G.; Reid, J.S.G.: Water stress and galactomannan
	breakdown in germinated fenugreek seeds. Stress affects the production
	and the activities in vivo of galactomannan-hydrolysing enzymes. Planta
	(1988) 174, 473-478. {Pubmed:24221562}
RF	<19> McCleary, B.V.: beta-D-Mannanase. Methods Enzymol. (1988) 160,
	596-610. {Pubmed:}
RF	<20> Dulson, J.; Bewley, J.D.: Mannanse from Lactuca sativa: Metabolic
	requirements for production and partial purification. Phytochemistry
	(1989) 28, 363-369. {Pubmed:}
RF	<21> Halmer, P.: De novo synthesis of mannanase by the endosperm of
	Lactuca sativa. Phytochemistry (1989) 28, 371-379. {Pubmed:}
RF	<22> Wozniewski, T.; Blaschek, W.; Fransz, G.: Isolation and
	characterization of an endo-beta-mannanase of Lilium testaceum bulbs.
	Phytochemistry (1992) 31, 3365-3370. {Pubmed:}
RF	<23> Ademark, P.; Carga, A.; Medve, J.; Harjunpää, V.; Drakenberg,
	T.; Tjerneld, F.; Stalbrand, H.: Softwood hemicellulose-degrading
	enzymes from Aspergillus niger: Purification and properties of a
	beta-mannase. J. Biotechnol. (1998) 63, 199-210. {Pubmed:9803534}
RF	<24> Bewley, J.D.; Burton, R.A.; Morohashi, Y.; Fincher, G.B.:
	Molecular cloning of a cDNA encoding a (1->4)-beta-mannan endohydrolase
	from the seeds of germinated tomato (Lycopersicon esculentum). Planta
	(1997) 203, 454-459. {Pubmed:9421930}
RF	<25> Tamaru, Y.; Araki, T.; Morishita, T.; Kimura, T.; Sakka, K.;
	Ohmiya, K.: Cloning, DNA sequencing, and expression of the
	beta-1,4-mannanase gene from a marine bacterium, Vibrio sp. strain
	MA-138. J. Ferment. Bioeng. (1997) 83, 201-205. {Pubmed:}
RF	<26> Christgau, S.; Kauppinen, S.; Vind, J.; Kofod, L.V.; Dalboge, H.:
	Expression cloning, purification and characterization of a
	beta-1,4-mannanase from Aspergillus aculeatus. Biochem. Mol. Biol. Int.
	(1994) 33, 917-925. {Pubmed:7987261}
RF	<27> Gibbs, M.D.; Reeves, R.A.; Sunna, A.; Bergquist, P.L.: Sequencing
	and expression of a beta-mannanase gene from the extreme thermophile
	Dictyoglomus thermophilum Rt46B.1, and characteristics of the
	recombinant enzyme. Curr. Microbiol. (1999) 39, 351-357.
	{Pubmed:10525841}
RF	<28> Zakaria, M.M.; Yamamoto, S.; Yagi, T.: Purification and
	characterization of an endo-1,4-beta-mannanase from Bacillus subtilis
	KU-1. FEMS Microbiol. Lett. (1998) 158, 25-31. {Pubmed:}
RF	<29> Gibbs, M.D.; Elinder, A.U.; Reeves, R.A.; Bergquist, P.L.:
	Sequencing, cloning and expression of a beta-1,4-mannanase gene, manA,
	from the extremely thermophilic anaerobic bacterium,
	Caldicellulosirutor Rt8B.4. FEMS Microbiol. Lett. (1996) 141, 37-43.
	{Pubmed:8764509}
RF	<30> Hossain, M.Z.; Abe, J.; Hizukuri, S.: Multiple forms of
	beta-mannanase from Bacillus sp. KK01. Enzyme Microb. Technol. (1996)
	18, 95-98. {Pubmed:}
RF	<31> Sunna, A.; Gibbs, M.D.; Chin, C.W.J.; Nelson, P.J.; Bergquist,
	P.L.: A gene encoding a novel multidomain beta-1,4-mannanase from
	Caldibacillus cellulovorans and action of the recombinant enzyme on
	kraft pulp. Appl. Environ. Microbiol. (2000) 66, 664-670.
	{Pubmed:10653733}
RF	<32> McCutchen, C.M.; Duffaud, G.D.; Leduc, P.; Petersen, A.R.H.;
	Tayal, A.; Khan, S.A.; Kelly, R.M.: Characterization of extremely
	thermostable enzymatic breakers (alpha-1,6-galactosidase and
	beta-1,4-mannanase) from the hyperthermophilic bacterium Thermotoga
	neapolitana 5068 for hydrolysis of guar gum. Biotechnol. Bioeng. (1996)
	52, 332-339. {Pubmed:18629900}
RF	<33> Tamaru, Y.; Araki, T.; Amagoi, H.; Mori, H.; Morishita, T.:
	Purification and characterization of an extracellular mannanase from a
	marine bacterium, Vibrio sp. strain MA-138. Appl. Environ. Microbiol.
	(1995) 61, 4454-4458. {Pubmed:8534110}
RF	<34> Talbot, G.; Sygusch, J.: Purification and characterization of
	themostable beta-mannanase and alpha-galactosidase from Bacillus
	stearothermophilus. Appl. Environ. Microbiol. (1990) 56, 3505-3510.
	{Pubmed:2176449}
RF	<35> Xu, B.; Munoz, I.I.; Janson, J.C.; Stahlberg, J.: Crystallization
	and X-ray analysis of native and selenomethionyl beta-mannanase Man5A
	from blue mussel, Mytilus edulis, expressed in Pichia pastoris. Acta
	Crystallogr. Sect. D (2002) 58, 542-545. {Pubmed:11856850}
RF	<36> Politz, O.; Krah, M.; Thomsen, K.K.; Borriss, R.: A highly
	thermostable endo-(1,4)-beta-mannanase from the marine bacterium
	Rhodothermus marinus. Appl. Microbiol. Biotechnol. (2000) 53, 715-721.
	{Pubmed:10919332}
RF	<37> Hogg, D.; Woo, E.J.; Bolam, D.N.; McKie, V.A.; Gilbert, H.J.;
	Pickersgill, R.W.: Crystal structure of mannanase 26A from Pseudomonas
	cellulosa and analysis of residues involved in substrate binding. J.
	Biol. Chem. (2001) 276, 31186-31192. {Pubmed:11382747}
RF	<38> Xu, B.; Hagglund, P.; Stalbrand, H.; Janson, J.C.:
	endo-beta-1,4-Mannanases from blue mussel, Mytilus edulis:
	purification, characterization, and mode of action. J. Biotechnol.
	(2002) 92, 267-277. {Pubmed:11689251}
RF	<39> Carrington, C.M.S.; Vendrell, M.; Dominguez-Puigjaner, E.:
	Characterisation of an endo-(1,4)-b-mannanase (LeMAN4) expressed in
	ripening tomato fruit. Plant Sci. (2002) 163, 599-606. {Pubmed:}
RF	<40> Marraccini, P.; Rogers, W.J.; Allard, C.; Andre, M.L.; Caillet,
	V.; Lacoste, N.; Lausanne, F.; Michaux, S.: Molecular and biochemical
	characterization of endo-beta-mannanases from germinating coffee
	(Coffea arabica) grains. Planta (2001) 213, 296-308. {Pubmed:11469596}
RF	<41> Setati, M.E.; Ademark, P.; van Zyl, W.H.; Hahn-Hagerdal, B.;
	Stalbrand, H.: Expression of the Aspergillus aculeatus
	endo-beta-1,4-mannanase encoding gene (man1) in Saccharomyces
	cerevisiae and characterization of the recombinant enzyme. Protein
	Expr. Purif. (2001) 21, 105-114. {Pubmed:11162394}
RF	<42> Le Nours, J.; Anderson, L.; Stoll, D.; Stalbrand, H.; Lo Leggio,
	L.: The structure and characterization of a modular
	endo-beta-1,4-mannanase from Cellulomonas fimi. Biochemistry (2005) 44,
	12700-12708. {Pubmed:16171384}
RF	<43> Puchart, V.; Vrsanska, M.; Svoboda, P.; Pohl, J.; Ogel, Z.B.;
	Biely, P.: Purification and characterization of two forms of
	endo-beta-1,4-mannanase from a thermotolerant fungus, Aspergillus
	fumigatus IMI 385708 (formerly Thermomyces lanuginosus IMI 158749).
	Biochim. Biophys. Acta (2004) 1674, 239-250. {Pubmed:15541293}
RF	<44> Ximenes, E.A.; Chen, H.; Kataeva, I.A.; Cotta, M.A.; Felix, C.R.;
	Ljungdahl, L.G.; Li, X.L.: A mannanase, ManA, of the polycentric
	anaerobic fungus Orpinomyces sp. strain PC-2 has carbohydrate binding
	and docking modules. Can. J. Microbiol. (2005) 51, 559-568.
	{Pubmed:16175204}
RF	<45> Ma, Y.; Xue, Y.; Dou, Y.; Xu, Z.; Tao, W.; Zhou, P.:
	Characterization and gene cloning of a novel beta-mannanase from
	alkaliphilic Bacillus sp. N16-5. Extremophiles (2004) 8, 447-454.
	{Pubmed:15316858}
RF	<46> Larsson, A.M.; Anderson, L.; Xu, B.; Munoz, I.G.; Uson, I.;
	Janson, J.C.; Stalbrand, H.; Stahlberg, J.: Three-dimensional crystal
	structure and enzymic characterization of beta-mannanase Man5A from
	blue mussel Mytilus edulis. J. Mol. Biol. (2006) 357, 1500-1510.
	{Pubmed:16487541}
RF	<47> Filichkin, S.A.; Leonard, J.M.; Monteros, A.; Liu, P.P.; Nonogaki,
	H.: A novel endo-beta-mannanase gene in tomato LeMAN5 is associated
	with anther and pollen development. Plant Physiol. (2004) 134,
	1080-1087. {Pubmed:14976239}
RF	<48> Schroeder, R.; Wegrzyn, T.F.; Sharma, N.N.; Atkinson, R.G.: LeMAN4
	endo-beta-mannanase from ripe tomato fruit can act as a mannan
	transglycosylase or hydrolase. Planta (2006) 224, 1091-1102.
	{Pubmed:16649044}
RF	<49> Bourgault, R.; Oakley, A.J.; Bewley, J.D.; Wilce, M.C.:
	Three-dimensional structure of (1,4)-beta-D-mannan mannanohydrolase
	from tomato fruit. Protein Sci. (2005) 14, 1233-1241. {Pubmed:15840830}
RF	<50> Cho, K.M.; Hong, S.Y.; Lee, S.M.; Kim, Y.H.; Kahng, G.G.; Kim, H.;
	Yun, H.D.: A cel44C-man26A gene of endophytic Paenibacillus polymyxa
	GS01 has multi-glycosyl hydrolases in two catalytic domains. Appl.
	Microbiol. Biotechnol. (2006) 73, 618-630. {Pubmed:16912849}
RF	<51> Hrmova, M.; Burton, R.A.; Biely, P.; Lahnstein, J.; Fincher, G.B.:
	Hydrolysis of (1,4)-beta-D-mannans in barley (Hordeum vulgare L.) is
	mediated by the concerted action of (1,4)-beta-D-mannan endohydrolase
	and beta-D-mannosidase. Biochem. J. (2006) 399, 77-90. {Pubmed:16771710}
RF	<52> Lisboa, C.G.; Tonini, P.P.; Tine, M.A.; Buckeridge, M.S.:
	Endo-beta -mannanase from the endosperm of seeds of Sesbania virgata
	(Cav.) Pers. (Leguminosae): purification, characterisation and its dual
	role in germination and early seedling growth. Braz. J. Plant Physiol.
	(2006) 18, 269-280. {Pubmed:}
RF	<53> Jiang, Z.; Wei, Y.; Li, D.; Li, L.; Chai, P.; Kusakabe, I.:
	High-level production, purification and characterization of a
	thermostable beta-mannanase from the newly isolated Bacillus subtilis
	WY34. Carbohydr. Polym. (2006) 66, 88-96. {Pubmed:}
RF	<54> Benech, R.; Li, X.; Patton, D.; Powlowski, J.; Storms, R.;
	Bourbonnais, R.; Paice, M.; Tsang, A.: Recombinant expression,
	characterization, and pulp prebleaching property of a Phanerochaete
	chrysosporium endo-beta -1,4-mannanase. Enzyme Microb. Technol. (2007)
	41, 740-747. {Pubmed:}
RF	<55> Ootsuka, S.; Saga, N.; Suzuki, K.; Inoue, A.; Ojima, T.: Isolation
	and cloning of an endo-beta-1,4-mannanase from Pacific abalone Haliotis
	discus hannai. J. Biotechnol. (2006) 125, 269-280. {Pubmed:16621092}
RF	<56> Chen, X.; Cao, Y.; Ding, Y.; Lu, W.; Li, D.: Cloning, functional
	expression and characterization of Aspergillus sulphureus
	beta-mannanase in Pichia pastoris. J. Biotechnol. (2007) 128, 452-461.
	{Pubmed:17194495}
RF	<57> Tonini, P.P.; Lisboa, C.G.; Freschi, L.; Mercier, H.;
	Mazzoni-Viveiros, S.C.; Buckeridge, M.S.: Effect of abscisic acid on
	galactomannan degradation and endo-beta -mannanase activity in seeds of
	Sesbania virgata (Cav.) Pers. (Leguminosae). Trees (2006) 20, 669-678.
	{Pubmed:}
RF	<58> Li, Y.N.; Meng, K.; Wang, Y.R.; Yao, B.: A beta-mannanase from
	Bacillus subtilis B36: purification, properties, sequencing, gene
	cloning and expression in Escherichia coli. Z. Naturforsch. C (2007)
	61, 840-846. {Pubmed:17294696}
RF	<59> Zhang, Y.; Gao, F.; Xue, Y.; Zeng, Y.; Peng, H.; Qi, J.; Ma, Y.:
	Crystallization and preliminary X-ray study of native and
	selenomethionyl beta-1,4-mannanase AaManA from Alicyclobacillus
	acidocaldarius Tc-12-31. Acta Crystallogr. Sect. F (2008) 64, 209-212.
	{Pubmed:18323611}
RF	<60> Kote, N.V.; Patil, A.G.; Mulimani, V.H.: Optimization of the
	production of thermostable endo-beta-1,4 mannanases from a newly
	isolated Aspergillus niger gr and Aspergillus flavus gr. Appl. Biochem.
	Biotechnol. (2009) 152, 213-223. {Pubmed:18597050}
RF	<61> Yang, P.; Li, Y.; Wang, Y.; Meng, K.; Luo, H.; Yuan, T.; Bai, Y.;
	Zhan, Z.; Yao, B.: A novel beta-mannanase with high specific activity
	from Bacillus circulans CGMCC1554: gene cloning, expression and
	enzymatic characterization. Appl. Biochem. Biotechnol. (2008) 159,
	85-94. {Pubmed:18820840}
RF	<62> Luo, H.; Wang, Y.; Wang, H.; Yang, J.; Yang, Y.; Huang, H.; Yang,
	P.; Bai, Y.; Shi, P.; Fan, Y.; Yao, B.: A novel highly acidic
	beta-mannanase from the acidophilic fungus Bispora sp. MEY-1: gene
	cloning and overexpression in Pichia pastoris. Appl. Microbiol.
	Biotechnol. (2009) 82, 453-461. {Pubmed:18998121}
RF	<63> Zhang, M.; Chen, X.L.; Zhang, Z.H.; Sun, C.Y.; Chen, L.L.; He,
	H.L.; Zhou, B.C.; Zhang, Y.Z.: Purification and functional
	characterization of endo-beta-mannanase MAN5 and its application in
	oligosaccharide production from konjac flour. Appl. Microbiol.
	Biotechnol. (2009) 83, 865-873. {Pubmed:19263048}
RF	<64> Roos, A.A.; Edlund, U.; Sjoeberg, J.; Albertsson, A.C.; Stalbrand,
	H.: Protein release from galactoglucomannan hydrogels: influence of
	substitutions and enzymatic hydrolysis by beta-mannanase.
	Biomacromolecules (2008) 9, 2104-2110. {Pubmed:18590309}
RF	<65> Tanaka, M.; Umemoto, Y.; Okamura, H.; Nakano, D.; Tamaru, Y.;
	Araki, T.: Cloning and characterization of a beta-1,4-mannanase 5C
	possessing a family 27 carbohydrate-binding module from a marine
	bacterium, Vibrio sp. strain MA-138. Biosci. Biotechnol. Biochem.
	(2009) 73, 109-116. {Pubmed:19129644}
RF	<66> Duruksu, G.; Ozturk, B.; Biely, P.; Bakir, U.; Ogel, Z.B.:
	Cloning, expression and characterization of endo-beta-1,4-mannanase
	from Aspergillus fumigatus in Aspergillus sojae and Pichia pastoris.
	Biotechnol. Prog. (2009) 25, 271-276. {Pubmed:19205049}
RF	<67> Song, J.M.; Nam, K.W.; Kang, S.G.; Kim, C.G.; Kwon, S.T.; Lee,
	Y.H.: Molecular cloning and characterization of a novel cold-active
	beta-1,4-D-mannanase from the Antarctic springtail, Cryptopygus
	antarcticus. Comp. Biochem. Physiol. B (2008) 151, 32-40.
	{Pubmed:18579426}
RF	<68> van Zyl, P.J.; Moodley, V.; Rose, S.H.; Roth, R.L.; van Zyl, W.H.:
	Production of the Aspergillus aculeatus endo-1,4-beta-mannanase in A.
	niger. J. Ind. Microbiol. Biotechnol. (2009) 36, 611-617.
	{Pubmed:19277742}
RF	<69> Li, Y.; Yang, P.; Meng, K.; Wang, Y.; Luo, H.; Wu, N.; Fan, Y.;
	Yao, B.: Gene cloning, expression, and characterization of a novel
	beta-mannanase from Bacillus circulans CGMCC 1416. J. Microbiol.
	Biotechnol. (2008) 18, 160-166. {Pubmed:18239434}
RF	<70> Yan, X.X.; An, X.M.; Gui, L.L.; Liang, D.C.: From structure to
	function: insights into the catalytic substrate specificity and
	thermostability displayed by Bacillus subtilis mannanase BCman. J. Mol.
	Biol. (2008) 379, 535-544. {Pubmed:18455734}
RF	<71> Li, J.; Bewley, J.D.; Hua, Z.; Zheng, W.; Wang, A.: Model and
	molecular dynamic simulations of active and inactive
	endo-beta-1,4-mannanase in tomato fruit. Protein J. (2008) 27, 363-370.
	{Pubmed:18769888}
RF	<72> Blibech, M.; Ghorbel, R.E.; Fakhfakh, I.; Ntarima, P.; Piens, K.;
	Bacha, A.B.; Chaabouni, S.E.: Purification and characterization of a
	low molecular weight of beta-mannanase from Penicillium occitanis Pol6.
	Appl. Biochem. Biotechnol. (2010) 160, 1227-1240. {Pubmed:19418261}
RF	<73> Qiao, J.; Rao, Z.; Dong, B.; Cao, Y.: Expression of Bacillus
	subtilis MA139 beta-mannanase in Pichia pastoris and the enzyme
	characterization. Appl. Biochem. Biotechnol. (2010) 160, 1362-1370.
	{Pubmed:19504356}
RF	<74> Hsiao, Y.M.; Liu, Y.F.; Fang, M.C.; Tseng, Y.H.: Transcriptional
	regulation and molecular characterization of the manA gene encoding the
	biofilm dispersing enzyme mannan endo-1,4-beta-mannosidase in
	Xanthomonas campestris. J. Agric. Food Chem. (2010) 58, 1653-1663.
	{Pubmed:20073482}
RF	<75> Abdeshahian, P.; Samat, N.; Hamid, A.A.; Yusoff, W.M.: Utilization
	of palm kernel cake for production of beta-mannanase by Aspergillus
	niger FTCC 5003 in solid substrate fermentation using an aerated column
	bioreactor. J. Ind. Microbiol. Biotechnol. (2010) 37, 103-109.
	{Pubmed:19937085}
RF	<76> Naganagouda, K.; Salimath, P.V.; Mulimani, V.H.: Purification and
	characterization of endo-beta-1,4 mannanase from Aspergillus niger gr
	for application in food processing industry. J. Microbiol. Biotechnol.
	(2009) 19, 1184-1190. {Pubmed:19884778}
RF	<77> Wang, A.; Li, J.; Zhang, B.; Xu, X.; Bewley, J.D.: Expression and
	location of endo-beta-mannanase during the ripening of tomato fruit,
	and the relationship between its activity and softening. J. Plant
	Physiol. (2009) 166, 1672-1684. {Pubmed:19450903}
RF	<78> Do, B.C.; Dang, T.T.; Berrin, J.G.; Haltrich, D.; To, K.A.;
	Sigoillot, J.C.; Yamabhai, M.: Cloning, expression in Pichia pastoris,
	and characterization of a thermostable GH5 mannan
	endo-1,4-beta-mannosidase from Aspergillus niger BK01. Microb. Cell
	Fact. (2009) 8, 59. {Pubmed:19912637}
RF	<79> Songsiriritthigul, C.; Buranabanyat, B.; Haltrich, D.; Yamabhai,
	M.: Efficient recombinant expression and secretion of a thermostable
	GH26 mannan endo-1,4-beta-mannosidase from Bacillus licheniformis in
	Escherichia coli. Microb. Cell Fact. (2010) 9, 20. {Pubmed:20380743}
RF	<80> Roth, R.; Moodley, V.; van Zyl, P.: Heterologous expression and
	optimized production of an Aspergillus aculeatus
	endo-1,4-beta-mannanase in Yarrowia lipolytica. Mol. Biotechnol. (2009)
	43, 112-120. {Pubmed:19507068}
RF	<81> Santos, C.R.; Squina, F.M.; Navarro, A.M.; Ruller, R.; Prade, R.;
	Murakami, M.T.: Cloning, expression, purification, crystallization and
	preliminary X-ray diffraction studies of the catalytic domain of a
	hyperthermostable endo-1,4-beta-D-mannanase from Thermotoga petrophila
	RKU-1. Acta Crystallogr. Sect. F (2010) 66, 1078-1081. {Pubmed:20823531}
RF	<82> Jeon, S.D.; Yu, K.O.; Kim, S.W.; Han, S.O.: A celluloytic complex
	from Clostridium cellulovorans consisting of mannanase B and
	endoglucanase E has synergistic effects on galactomannan degradation.
	Appl. Microbiol. Biotechnol. (2011) 90, 565-572. {Pubmed:21311881}
RF	<83> Dilokpimol, A.; Nakai, H.; Gotfredsen, C.H.; Baumann, M.J.; Nakai,
	N.; Hachem, M.A.; Svensson, B.: Recombinant production and
	characterisation of two related GH5 endo-beta-1,4-mannanases from
	Aspergillus nidulans FGSC A4 showing distinctly different
	transglycosylation capacity. Biochim. Biophys. Acta (2011) 1814,
	1720-1729. {Pubmed:21867780}
RF	<84> Yamabhai, M.; Buranabanyat, B.; Jaruseranee, N.;
	Songsiriritthigul, C.: Efficient E. coli expression systems for the
	production of recombinant beta-mannanases and other bacterial
	extracellular enzymes. Bioeng. Bugs (2011) 2, 45-49. {Pubmed:21636987}
RF	<85> Zhao, W.; Zheng, J.; Zhou, H.B.: A thermotolerant and cold-active
	mannan endo-1,4-beta-mannosidase from Aspergillus niger CBS 513.88:
	Constitutive overexpression and high-density fermentation in Pichia
	pastoris. Biores. Technol. (2011) 102, 7538-7547. {Pubmed:21632240}
RF	<86> Kim, d.o..Y.; Ham, S.J.; Lee, H.J.; Cho, H.Y.; Kim, J.H.; Kim,
	Y.J.; Shin, D.H.; Rhee, Y.H.; Son, K.H.; Park, H.Y.: Cloning and
	characterization of a modular GH5 beta-1,4-mannanase with high specific
	activity from the fibrolytic bacterium Cellulosimicrobium sp. strain
	HY-13. Biores. Technol. (2011) 102, 9185-9192. {Pubmed:21767948}
RF	<87> Zahura, U.A.; Rahman, M.M.; Inoue, A.; Tanaka, H.; Ojima, T.: An
	endo-beta-1,4-mannanase, AkMan, from the common sea hare Aplysia
	kurodai. Comp. Biochem. Physiol. B (2010) 157, 137-143.
	{Pubmed:20639136}
RF	<88> Zahura, U.A.; Rahman, M.M.; Inoue, A.; Tanaka, H.; Ojima, T.: cDNA
	cloning and bacterial expression of an endo-beta-1,4-mannanase, AkMan,
	from Aplysia kurodai. Comp. Biochem. Physiol. B (2011) 159, 227-235.
	{Pubmed:21601647}
RF	<89> Lin, J.; Pantalone, V.R.; Li, G.; Chen, F.: Molecular cloning and
	biochemical characterization of an endo-beta-mannanase gene from
	soybean for soybean meal improvement. J. Agric. Food Chem. (2011) 59,
	4622-4628. {Pubmed:21425861}
RF	<90> Fu, X.; Huang, X.; Liu, P.; Lin, L.; Wu, G.; Li, C.; Feng, C.;
	Hong, Y.: Cloning and characterization of a novel mannanase from
	Paenibacillus sp. BME-14. J. Microbiol. Biotechnol. (2010) 20, 518-524.
	{Pubmed:20372022}
RF	<91> Iglesias-Fernandez, R.; Rodriguez-Gacio, M.C.; Barrero-Sicilia,
	C.; Carbonero, P.; Matilla, A.: Three endo-beta-mannanase genes
	expressed in the micropylar endosperm and in the radicle influence
	germination of Arabidopsis thaliana seeds. Planta (2011) 233, 25-36.
	{Pubmed:20878180}
RF	<92> Goncalves, A.M.; Silva, C.S.; Madeira, T.I.; Coelho, R.; de
	Sanctis, D.; San Romao, M.V.; Bento, I.: Endo-beta-D-1,4-mannanase from
	Chrysonilia sitophila displays a novel loop arrangement for substrate
	selectivity. Acta Crystallogr. Sect. D (2012) 68, 1468-1478.
	{Pubmed:23090396}
RF	<93> Chiyanzu, I.; Brienzo, M.; Garcia-Aparicio, M.P.; Goergens, J.F.:
	Application of endo-beta-1,4,D-mannanase and cellulase for the release
	of mannooligosaccharides from steam-pretreated spent coffee ground.
	Appl. Biochem. Biotechnol. (2014) 172, 3538-3557. {Pubmed:24557953}
RF	<94> Lu, H.; Luo, H.; Shi, P.; Huang, H.; Meng, K.; Yang, P.; Yao, B.:
	A novel thermophilic endo-beta-1,4-mannanase from Aspergillus nidulans
	XZ3: functional roles of carbohydrate-binding module and Thr/Ser-rich
	linker region. Appl. Microbiol. Biotechnol. (2014) 98, 2155-2163.
	{Pubmed:23900799}
RF	<95> Hakamada, Y.; Ohkubo, Y.; Ohashi, S.: Purification and
	characterization of beta-mannanase from Reinekea sp. KIT-YO10 with
	transglycosylation activity. Biosci. Biotechnol. Biochem. (2014) 78,
	722-728. {Pubmed:25036974}
RF	<96> Liao, H.; Li, S.; Zheng, H.; Wei, Z.; Liu, D.; Raza, W.; Shen, Q.;
	Xu, Y.: A new acidophilic thermostable endo-1,4-beta-mannanase from
	Penicillium oxalicum GZ-2: cloning, characterization and functional
	expression in Pichia pastoris. BMC Biotechnol. (2014) 14, 90.
	{Pubmed:25348022}
RF	<97> Aguilera-Galvez, C.; Vasquez-Ospina, J.J.; Gutierrez-Sanchez, P.;
	Acuna-Zornosa, R.: Cloning and biochemical characterization of an
	endo-1,4-beta-mannanase from the coffee berry borer Hypothenemus
	hampei. BMC Res. Notes (2013) 6, 333. {Pubmed:23965285}
RF	<98> Li, H.; Liu, Z.; Wang, C.; Huang, S.; Zhao, M.: Secretory
	expression and characterization of a novel thermo-stable, salt-tolerant
	endo-1,4-beta-mannanase of Bacillus subtilis WD23 by Pichia pastoris.
	Eur. Food Res. Technol. (2015) 240, 671-677. {Pubmed:}
RF	<99> Yang, H.; Shi, P.; Lu, H.; Wang, H.; Luo, H.; Huang, H.; Yang, P.;
	Yao, B.: A thermophilic beta-mannanase from Neosartorya fischeri P1
	with broad pH stability and significant hydrolysis ability of various
	mannan polymers. Food Chem. (2015) 173, 283-289. {Pubmed:25466024}
RF	<100> Katrolia, P.; Yan, Q.; Zhang, P.; Zhou, P.; Yang, S.; Jiang, Z.:
	Gene cloning and enzymatic characterization of an alkali-tolerant
	endo-1,4-beta-mannanase from Rhizomucor miehei. J. Agric. Food Chem.
	(2013) 61, 394-401. {Pubmed:23252695}
RF	<101> Wang, Y.; Shi, P.; Luo, H.; Bai, Y.; Huang, H.; Yang, P.; Xiong,
	H.; Yao, B.: Cloning, over-expression and characterization of an
	alkali-tolerant endo-beta-1,4-mannanase from Penicillium freii F63. J.
	Biosci. Bioeng. (2012) 113, 710-714. {Pubmed:22382013}
RF	<102> Vu, T.T.; Quyen, D.T.; Dao, T.T.; Nguyen, S.l.e.T.: Cloning,
	high-level expression, purification, and properties of a novel
	endo-beta-1,4-mannanase from Bacillus subtilis G1 in Pichia pastoris.
	J. Microbiol. Biotechnol. (2012) 22, 331-338. {Pubmed:22450788}
RF	<103> Guo, N.; Zheng, J.; Wu, L.; Tian, J.; Zhou, H.: Engineered
	bifunctional enzymes of endo-1,4-beta-xylanase/endo-1,4-beta-mannanase
	were constructed for synergistically hydrolyzing hemicellulose. J. Mol.
	Catal. B (2013) 97, 311-318. {Pubmed:}
RF	<104> dos Santos, C.; Paiva, J.; Meza, A.; Cota, J.; Alvarez, T.;
	Ruller, R.; Prade, R.; Squina, F.; Murakami, M.: Molecular insights
	into substrate specificity and thermal stability of a bacterial
	GH5-CBM27 endo-1,4-beta-D-mannanase. J. Struct. Biol. (2012) 177,
	469-476. {Pubmed:22155669}
RF	<105> Ghosh, A.; Verma, A.K.; Tingirikari, J.R.; Shukla, R.; Goyal, A.:
	Recovery and purification of oligosaccharides from copra meal by
	recombinant endo-beta-mannanase and deciphering molecular mechanism
	involved and its role as potent therapeutic agent. Mol. Biotechnol.
	(2015) 57, 111-127. {Pubmed:25260892}
RF	<106> da Silva, V.M.; Colussi, F.; de Oliveira Neto, M.; Braz, A.S.;
	Squina, F.M.; Oliveira, C.L.; Garcia, W.: Modular hyperthermostable
	bacterial endo-beta-1,4-mannanase: molecular shape, flexibility and
	temperature-dependent conformational changes. PLoS ONE (2014) 9,
	e92996. {Pubmed:24671161}
RF	<107> Kim, M.K.; An, Y.J.; Song, J.M.; Jeong, C.S.; Kang, M.H.; Kwon,
	K.K.; Lee, Y.H.; Cha, S.S.: Structure-based investigation into the
	functional roles of the extended loop and substrate-recognition sites
	in an endo-beta-1,4-D-mannanase from the Antarctic springtail,
	Cryptopygus antarcticus. Proteins (2014) 82, 3217-3223.
	{Pubmed:25082572}
RF	<108> Katsimpouras, C.; Dimarogona, M.; Petropoulos, P.;
	Christakopoulos, P.; Topakas, E.:  A thermostable GH26
	endo-beta-mannanase from Myceliophthora thermophila capable of
	enhancing lignocellulose degradation. Appl. Microbiol. Biotechnol.
	(2016)  100,  8385-8397 . {Pubmed:27193267} (          )
RF	<109> Duruksu, G.; Ozturk, B.; Biely, P.; Bakir, U.; Ogel, Z.: 
	Cloning, expression and characterization of endo-beta-1,4-mannanase
	from Aspergillus fumigatus in Aspergillus sojae and Pichia pastoris.
	Biotechnol. Prog. (2009)  25,  271-276 . {Pubmed:19205049} (          )
RF	<110> Singh, S.; Pillay, B.; Dilsook, V.; Prior, B.A.:  Production and
	properties of hemicellulases by a Thermomyces lanuginosus strain. J.
	Appl. Microbiol. (2000)  88,  975-982 . {Pubmed:10849173} (          )
RF	<111> Fusco, F.A.; Ronca, R.; Fiorentino, G.; Pedone, E.; Contursi, P.;
	Bartolucci, S.; Limauro, D.:  Biochemical characterization of a
	thermostable endomannanase/endoglucanase from Dictyoglomus turgidum.
	Extremophiles (2018)  22,  131-140 . {Pubmed:29177717} (          )

ACTIVATING_COMPOUND
AC	#10# NaCl (#10# 0.3 M <48>) <48>
AC	#21,27,73,75,94# 2-mercaptoethanol (#27# 1 mM, 11% increase in activity
	<55>; #75# 1 mMm, 121% of initial activity <74>; #73# 153% of initial
	activity <87>) <55,74,87,99,101>
AC	#27# Ca2+ (#27# 1 mM, 20% increase in activity <55>) <55>
AC	#3# acetone (#3# activates the wild-type enzyme and mutant Man5DELTACBM
	at 40-60% v/v, no effect on mutant Man5DELTACL <94>) <94>
AC	#3# SDS (#3# the wild-type enzyme slightly at 0.5-1.0% v/v, inhibits
	the mutant enzymes <94>) <94>
AC	#3,75# Triton X-100 (#75# 1%, 123% of initial activity <74>; #3#
	activates the wild-type enzyme slightly at 0.5% v/v, inhibits the
	mutant enzymes <94>) <74,94>
AC	#62# more (#62# an assembly of ManB with mini-CbpA, which contains a
	carbohydrate-binding module that provides proximity to insoluble
	substrates, increases the activity toward galactomannan from locust
	bean gum and guar gum 1.7- and 2.0fold over those without mini-CbpA
	<82>) <82>
AC	#73# dithiothreitol (#73# 129% of initial activity <87>) <87>
AC	#77# EDTA (#77# 236% of initial activity <78>) <78>
AC	#85# Sodium azide (#85# hydrolysis of locust bean gum is enhanced by
	approximately 1.45fold in poresence of sodium azide <86>) <86>
AC	#9# cysteine (#9# slight activation <17>) <17>

PI_VALUE
PI	#11,59# 5.5 (#11# calculated <50>; #59# chromatofocusing, 7 isomers
	<40>) <40,50>
PI	#21# 5.93 (#21# sequence calculation <99>) <99>
PI	#26# 6.9 (#26# isoelectric focusing <38>) <38>
PI	#29# 4.9-5.2 (#29# isozyme MAN I <43>) <43>
PI	#29# 4.75-4.9 (#29# isozyme MAN II <43>) <43>
PI	#61# 4.6-4.7 (#61# calculated from amino acid sequence <39>) <39>
PI	#61# 9 (#61# isoelectric focusing <39>) <39>
PI	#64# 4.5 (#64# isoelectric focusing <52>) <52>
PI	#66# 4.9 (#66# isoelectric focusing <56>) <56>
PI	#85# 4.6 (#85# calculated <86>) <86>
PI	#99# 4.4 (#99# calculated <108>) <108>
PI	#99# 3.6 (#99# isoelectric focusing <108>) <108>

KCAT_KM_VALUE
KKM	#83# 23 (#83# pH 5.5, 37°C <83>) <83>
KKM	#83# 115 (#83# mutant W283S, pH 5.5, 37°C <83>) <83>
KKM	#83# 27 (#83# mutant W283S, pH 5.5, 37°C <83>) <83>
KKM	#83# 109 (#83# pH 5.5, 37°C <83>) <83>
KKM	#84# 118 (#84# mutant W283S, pH 5.5, 37°C <83>) <83>
KKM	#84# 36 (#84# mutant W283S, pH 5.5, 37°C <83>) <83>
KKM	#84# 61 (#84# wild-type, pH 5.5, 37°C <83>) <83>
KKM	#84# 215 (#84# wild-type, pH 5.5, 37°C <83>) <83>
KKM	#99# -999 (#99# kcat/Km value 8022 ml/mg/s, pH 5.0, 60°C <108>) <108>
KKM	#99# -999 (#99# kcat/Km value 8855 ml/mg/s, pH 5.0, 60°C <108>) <108>

EXPRESSION
EXP	#36,75,78,79,87# up (#75# isoform manA transcription is positively
	regulated by Clp and RpfF and induced by locust bean gum <74>;
	#78,79,87# expression upon seed imbibition <91>; #36# recombinant
	enzyme production is improved by 150% via supplementation with 0.2%
	sodium benzoate and 35% sorbitol as a preservative and stabiliser,
	respectively <93>) <74,91,93>

///
